methylphenidate has been researched along with ADDH in 3735 studies
Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.
methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.
methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This research evaluates the preventive effects of cyproheptadine on sleeping and appetite disorders induced by methylphenidate in ADHD children." | 9.30 | Preventive effect of cyproheptadine on sleep and appetite disorders induced by methylphenidate: an exploratory randomised, double-blinded, placebo-controlled clinical trial. ( Elyasi, S; Kadkhoda Mezerji, F; Mohammadpour, AH; Moharreri, F, 2019) |
| "The objective of this study was to assess the response of anxiety and depression symptoms to methylphenidate (MPH) treatment in patients with Asperger syndrome (AS) combined with attention deficit/hyperactivity disorder (ADHD)." | 9.24 | The effect of methylphenidate on anxiety and depression symptoms in patients with Asperger syndrome and comorbid attention deficit/hyperactivity disorder. ( Golubchik, P; Rapaport, M; Weizman, A, 2017) |
| "Although the nonrandomized, nonblind design limits the conclusions of our exploratory study, our findings suggest that when ADHD is comorbid with ODD and aggression MPH and risperidone are both effective on aggressive behavior, but only stimulants are effective on ADHD symptoms." | 9.24 | A Naturalistic Comparison of Methylphenidate and Risperidone Monotherapy in Drug-Naive Youth With Attention-Deficit/Hyperactivity Disorder Comorbid With Oppositional Defiant Disorder and Aggression. ( Manfredi, A; Masi, G; Milone, A; Muratori, P; Nieri, G; Pfanner, C, 2017) |
| "Thirty epilepsy patients entered a 1-month open-label methylphenidate trial after a double-blind phase." | 9.24 | Methylphenidate, cognition, and epilepsy: A 1-month open-label trial. ( Adams, J; Alipio-Jocson, V; Barry, JJ; Bartlett, V; Inoyama, K; Loring, DW; Meador, KJ; Oso, J; Sandhu, S, 2017) |
| " We examine the use of parent target problems (PTPs) in a randomized trial of methylphenidate (MPH) in children with autism spectrum disorder and symptoms of attention-deficit/hyperactivity disorder." | 9.24 | Using a Patient-Centered Outcome Measure to Test Methylphenidate Versus Placebo in Children with Autism Spectrum Disorder. ( Aman, MG; Arnold, LE; Bearss, K; Gillespie, S; McCracken, JT; McDougle, CJ; Postorino, V; Sarhangian, R; Scahill, L; Tierney, E; Vitiello, B, 2017) |
| "Both atomoxetine and methylphenidate reduced the symptoms of ADHD and anxiety." | 9.22 | Anxiety reduction on atomoxetine and methylphenidate medication in children with ADHD. ( Hrtanek, I; Kulhan, T; Marcincakova-Husarova, V; Nosalova, G; Ondrejka, I; Snircova, E, 2016) |
| " Although cumulative evidence suggests that dopamine is involved in pain processing, pain perception in ADHD subjects and the effect of dopamine agonists such as methylphenidate (MP, Ritalin) on it have rarely been studied." | 9.20 | Alterations in pain response are partially reversed by methylphenidate (Ritalin) in adults with attention deficit hyperactivity disorder (ADHD). ( Demeter, N; Eisenberg, E; Pud, D; Treister, R, 2015) |
| " However, our findings suggest the association between 5-HTTLPR polymorphism and the occurrence of tics and nail-biting as an adverse event of methylphenidate." | 9.20 | Association Between 5-HTTLPR Polymorphism and Tics after Treatment with Methylphenidate in Korean Children with Attention-Deficit/Hyperactivity Disorder. ( Cheon, KA; Kim, EJ; Park, SY, 2015) |
| "Optimal dosing of methylphenidate is practical and effective in some children with hyperkinetic disorder and intellectual disability." | 9.17 | Randomized controlled double-blind trial of optimal dose methylphenidate in children and adolescents with severe attention deficit hyperactivity disorder and intellectual disability. ( Baird, G; Bernard, S; Chadwick, O; Golaszewski, A; Jichi, F; Kelly, J; Kennedy, J; Liang, H; Riemer, K; Rodney, L; Sharma, K; Sharma, SP; Simonoff, E; Taylor, E; Walwyn, R; West, N; Whitwell, S; Wood, N, 2013) |
| " Although smoking cessation tends to result in weight increase, potentially initiating or exacerbating weight problems, adults with ADHD who are treated with osmotic release oral system methylphenidate (OROS-MPH) tend to lose weight." | 9.17 | Osmotic release oral system methylphenidate prevents weight gain during a smoking-cessation attempt in adults with ADHD. ( Heffner, JL; Lewis, DF; Winhusen, TM, 2013) |
| "To examine the relationship between attention and anxiety and the response to methylphenidate in children with attention deficit hyperactivity disorder (ADHD), a total of 57 boys, between the ages of 7-12 years, were assessed for their attention and level of anxiety." | 9.16 | Anxiety and methylphenidate in attention deficit hyperactivity disorder: a double-blind placebo-drug trial. ( Karni, A; Moshe, K; Tirosh, E, 2012) |
| "The goal of this study was to pilot a randomized controlled trial of OROS methylphenidate (OROS-MPH) to treat attention deficit hyperactivity disorder (ADHD) plus epilepsy." | 9.14 | Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. ( Biederman, J; Bourgeois, B; de Moor, C; Demaso, DR; Dodds, A; Faraone, SV; Forbes, P; Gonzalez-Heydrich, J; Hsin, O; Macmillan, C; Mrakotsky, C; Rao, S; Torres, A; Waber, D; Whitney, J, 2010) |
| " The aim of this pilot study was to investigate the impact of the combined diagnoses of developmental coordination disorder (DCD) and ADHD on HRQOL, and the effectiveness of methylphenidate (MPH) on HRQOL." | 9.13 | Effects of methylphenidate on quality of life in children with both developmental coordination disorder and ADHD. ( Flapper, BC; Schoemaker, MM, 2008) |
| "To determine whether children with attention-deficit hyperactivity disorder (ADHD) and learning disabilities respond differently to methylphenidate (MPH) compared with children with ADHD only." | 9.12 | Efficacy of methylphenidate in children with attention-deficit hyperactivity disorder and learning disabilities: a randomized crossover trial. ( Bhat, M; Grizenko, N; Joober, R; Schwartz, G; Ter-Stepanian, M, 2006) |
| "The purpose of this study was to evaluate the effectiveness and safety of methylphenidate treatment in epilepsy patients with comorbid adult attention deficit hyperactivity disorder (ADHD)." | 9.12 | Effectiveness and safety of methylphenidate in adult attention deficit hyperactivity disorder in patients with epilepsy: an open treatment trial. ( Aldenkamp, AP; van der Feltz-Cornelis, CM, 2006) |
| "To evaluate the effects of risperidone augmentation for treatment-resistant aggression in children with attention-deficit/hyperactivity disorder (ADHD)." | 9.12 | Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: a placebo-controlled pilot study. ( Armenteros, JL; Davalos, M; Lewis, JE, 2007) |
| "This study investigated the safety and efficacy of adding the atypical antipsychotic quetiapine to ongoing OROS methylphenidate treatment for adolescents with comorbid ADHD and severe aggression that were incompletely responsive to methylphenidate monotherapy." | 9.12 | Quetiapine addition in methylphenidate treatment-resistant adolescents with comorbid ADHD, conduct/oppositional-defiant disorder, and aggression: a prospective, open-label study. ( Bohnstedt, BN; Dunn, DW; Giauque, AL; Kronenberger, WG; Lafata, DE; Maxey, LE, 2007) |
| "To examine the short-term efficacy of methylphenidate in the treatment of youths with bipolar disorder (BD) and comorbid attention deficit/hyperactivity disorder (ADHD)." | 9.12 | Methylphenidate in the treatment of children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder. ( Calabrese, JR; Demeter, CA; Findling, RL; Gracious, BL; Manos, MJ; McNamara, NK; Short, EJ; Stansbrey, RJ; Whipkey, R, 2007) |
| "Our objective was to study the short-term efficacy and safety of methylphenidate in patients with the dual diagnosis of cerebral palsy and attention-deficit hyperactivity disorder (ADHD)." | 9.10 | Efficacy of methylphenidate in patients with cerebral palsy and attention-deficit hyperactivity disorder (ADHD). ( Badihi, N; Gross-Tsur, V; Manor, O; Shalev, RS, 2002) |
| "A pilot comparison of the safety and efficacy of methylphenidate (MPH) combined with clonidine, clonidine monotherapy, or MPH monotherapy in 6- to 16-year-old children diagnosed with attention deficit hyperactivity disorder (ADHD) and comorbid aggressive oppositional defiant disorder or conduct disorder was completed." | 9.09 | A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder. ( Barkley, RA; Connor, DF; Davis, HT, 2000) |
| "2 years) with autism and symptoms of attention-deficit hyperactivity disorder (ADHD) participated in a double-blind, placebo-controlled crossover study of methylphenidate (0." | 9.09 | Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. ( Handen, BL; Johnson, CR; Lubetsky, M, 2000) |
| "To study the safety and efficacy of methylphenidate in children with the dual diagnosis of epilepsy and attention deficit hyperactivity disorder (ADHD)." | 9.08 | Epilepsy and attention deficit hyperactivity disorder: is methylphenidate safe and effective? ( Gross-Tsur, V; Joseph, A; Manor, O; Shalev, RS; van der Meere, J, 1997) |
| "To study the safety and efficacy of methylphenidate in children with the dual diagnosis of epilepsy and attention deficit hyperactivity disorder (ADHD)." | 9.08 | Epilepsy and attention deficit hyperactivity disorder: is methylphenidate safe and effective? ( Gross-Tsur, V; Joseph, A; Manor, O; Shalev, RS; van der Meere, J, 1997) |
| "Children diagnosed with attention deficit disorder (ADD; n = 44), ADD plus aggression/oppositionality (ADD/O; n = 34), and as not meeting ADD criteria (NC; n = 29) received methylphenidate and placebo for 21 consecutive days each." | 9.07 | Clinical and cognitive effects of methylphenidate on children with attention deficit disorder as a function of aggression/oppositionality and age. ( Borgstedt, AD; Brumaghim, JT; Fitzpatrick, PA; Klorman, R; Strauss, J, 1994) |
| "One of the least documented "known" effects of methylphenidate in hyperactive children is the suppression of peer aggression." | 9.06 | Methylphenidate in aggressive-hyperactive boys: I. Effects on peer aggression in public school settings. ( Gadow, KD; Nolan, EE; Paolicelli, L; Sprafkin, J; Sverd, J, 1990) |
| "The effect of methylphenidate on aggression in adolescents diagnosed with both aggressive conduct disorder and attention deficit disorder with hyperactivity was assessed in nine male adolescents." | 9.06 | Effects of methylphenidate on adolescents with aggressive conduct disorder and ADDH: a preliminary report. ( Busner, J; Kaplan, SL; Kupietz, S; Segal, B; Wassermann, E, 1990) |
| "This investigation examined the relationship between methylphenidate (MPH) and the learning and recall of paired associations by children with attention deficit disorder with hyperactivity (ADDH)." | 9.06 | Attention deficit disorder with hyperactivity and methylphenidate: the effects of dose and mastery level on children's learning performance. ( DuPaul, GJ; Kelly, KL; Quinn, EP; Quinn, SO; Rapport, MD, 1989) |
| "Investigated the effect of methylphenidate (MPH) on the ability of children with Attention Deficit Disorder with Hyperactivity (ADDH) to learn both trained and untrained complex visual relationships and compared these findings to their school performance under identical dosage parameters." | 9.06 | The effects of methylphenidate on learning in children with ADDH: the stimulus equivalence paradigm. ( Rapport, MD; Vyse, SA, 1989) |
| "One of the most effective treatments for children with Attention Deficit Disorder with Hyperactivity (ADDH) has been the prescription of methylphenidate (MPH)." | 9.06 | ADDH and methylphenidate responders: effects on behavior controlled by complex reinforcement schedules. ( DuPaul, GJ; Rapport, MD; Vyse, SA, 1988) |
| "The aims of this review were to summarize the scientific evidence about the risks of using methylphenidate for ADHD in pregnancy and lactation, to present a case in which interruption of treatment after delivery and during breastfeeding was harmful and to discuss the implications of treating or not treating ADHD in pregnancy and lactation." | 8.90 | Methylphenidate use in pregnancy and lactation: a systematic review of evidence. ( Bolea-Alamanac, BM; Davies, SJ; Green, A; Maxwell, P; Verma, G, 2014) |
| "To establish the efficacy and safety of methylphenidate (MPH) treatment for attention deficit hyperactivity disorder (ADHD) in a group of children and young people with learning disability and severe epilepsy." | 8.89 | Methylphenidate treatment of attention deficit hyperactivity disorder in young people with learning disability and difficult-to-treat epilepsy: evidence of clinical benefit. ( Aylett, SE; Fosi, T; Lax-Pericall, MT; Neville, BG; Scott, RC, 2013) |
| " Little is known about whether the beneficial effect of methylphenidate is persistent in individuals with other comorbid mental disorders and epilepsy." | 8.12 | Methylphenidate and TBI in ADHD and co-occurring epilepsy and mental disorders: a self-controlled case series study. ( Chen, VC; Chen, YL; Dewey, ME; Gossop, M; Lee, CT; Yang, YH, 2022) |
| "Patients aged 5-18 years with a methylphenidate (MPH) prescription and an incident poisoning diagnosis between January 2001 and June 2020 were identified from the Hong Kong Clinical Data Analysis and Reporting System." | 8.02 | Treatment with Methylphenidate for Attention Deficit Hyperactivity Disorder (ADHD) and the Risk of All-Cause Poisoning in Children and Adolescents: A Self-Controlled Case Series Study. ( Chan, EW; Chui, CSL; Coghill, D; Gao, L; Hon, KL; Ip, P; Li, X; Lum, TYS; Man, KKC; Tse, ML; Wong, ICK; Wong, KHTW, 2021) |
| "In a multisite, randomized study (CTN-0029), a 3-month course of Osmotic-Release Oral System Methylphenidate (OROS-MPH) improved smoking cessation in a group of patients with higher baseline severity in Attention-Deficit/Hyperactivity Disorder (ADHD)." | 7.91 | Differential Posttreatment Outcomes of Methylphenidate for Smoking Cessation for Individuals With ADHD. ( Covey, LS; Hu, MC; Luo, SX; Nunes, EV; Winhusen, TM, 2019) |
| "We aimed to investigate the effectiveness and safety of methylphenidate (MPH), and especially its influence on seizures, in subjects with attention-deficit/hyperactivity disorder (ADHD) and epilepsy through a retrospective chart review of subjects treated with MPH in a clinical setting." | 7.88 | Relationship Between Aggravation of Seizures and Methylphenidate Treatment in Subjects with Attention-Deficit/Hyperactivity Disorder and Epilepsy. ( Choi, HW; Kim, HW; Ko, TS; Park, J; Shon, SH; Yum, MS, 2018) |
| " Thus, a decline in state anxiety while performing a cognitive task when taking methylphenidate would discriminate between ADHD patients and controls." | 7.85 | Methylphenidate Reduces State Anxiety During a Continuous Performance Test That Distinguishes Adult ADHD Patients From Controls. ( Aviram, S; Bloch, Y; Braw, Y; Levkovitz, Y; Mimouni Bloch, A; Nitzan, U; Segev, A, 2017) |
| "Though both lisdexamfetamine dimesylate and methylphenidate are widely used among pediatricians today for treatment of ADHD, reports of life-threatening water intoxication as a result of overdose is rare." | 7.85 | Methylphenidate Overdose Causing Secondary Polydipsia and Severe Hyponatremia in an 8-Year-Old Boy. ( Kaagaza, M; Krishna, AS; Lefevre, C; Patel, V; Wittkamp, M, 2017) |
| "We describe a case whereby a 15-year-old female with treatment-resistant obsessive-compulsive disorder (OCD) was treated with methylphenidate for co-morbid attention deficit hyperactivity disorder (ADHD)." | 7.85 | Methylphenidate in the treatment of an adolescent female with obsessive-compulsive disorder and attention deficit hyperactivity disorder: a case report. ( Dowling, N; King, J; Leow, F, 2017) |
| "This study estimated the risk of developing psychotic disorders by comparing children with ADHD to non-ADHD controls, and to examine whether methylphenidate (MPH) treatment influences the risks of psychotic disorders." | 7.81 | Attention-deficit/hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia spectrum disorders: A nationwide population-based study in Taiwan. ( Lee, SY; Lee, TL; Shyu, YC; Wang, LJ; Yang, CJ; Yang, KC; Yuan, SS, 2015) |
| " Is this also the case with methylphenidate, an amphetamine-like psychostimulant used in attention-deficit hyperactivity disorder (especially in children) and also in narcolepsy? Cases of pulmonary hypertension and heart valve disease have been reported with methylphenidate, including in children." | 7.81 | Methylphenidate: pulmonary hypertension and heart valve disease. ( , 2015) |
| "The aims of this study were to evaluate the neuropsychological characteristics of the restrictive (R) subtype according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition and the attention-deficit/hyperactivity disorder (ADHD) combined (CB) type and predominantly inattentive (PI) type subtypes and to evaluate whether methylphenidate (MPH) affects neurocognitive test battery scores according to these subtypes." | 7.80 | Effect of methylphenidate on neurocognitive test battery: an evaluation according to the diagnostic and statistical manual of mental disorders, fourth edition, subtypes. ( Ardic, UA; Durak, S; Ercan, E; Ercan, ES; Ipci, M; Yuce, D, 2014) |
| "An 11-year-old boy with attention deficit/hyperactivity disorder (ADHD) presented with visual hallucinations several years after starting methylphenidate (MPH)." | 7.77 | Methylphenidate-induced visual hallucinations. ( Curatolo, P; Giana, G; Giovinazzo, S; Porfirio, MC, 2011) |
| "There are controversial evidence in the literature on the role of comorbid anxiety disorders (ANX) in the improvement of attention-deficit/hyperactivity disorder (ADHD) symptoms with methylphenidate (MPH) treatment." | 7.75 | Response to methylphenidate in children and adolescents with ADHD: does comorbid anxiety disorders matters? ( Garcia, SP; Guimarães, J; Martinez, AL; Polanczyk, G; Rohde, LA; Zampieri, JF, 2009) |
| "A 15-year-old boy with attention-deficit hyperactivity disorder (ADHD) presented with complex visual hallucinations of rats running around and touching and smelling him soon after receiving a first low dose of methylphenidate." | 7.75 | Methylphenidate induction of complex visual hallucinations. ( Halevy, A; Shuper, A, 2009) |
| "Attention deficit hyperactivity disorder (ADHD) is prevalent in adult cocaine abusers." | 7.73 | Response to cocaine, alone and in combination with methylphenidate, in cocaine abusers with ADHD. ( Collins, SL; Evans, SM; Foltin, RW; Kleber, HD; Levin, FR, 2006) |
| "The aims of this study were to investigate fine motor skills of children with both attention-deficit-hyperactivity disorder (ADHD) and developmental coordination disorder (DCD) and those of a control group, and to examine the effects of methylphenidate on these skills." | 7.73 | Fine motor skills and effects of methylphenidate in children with attention-deficit-hyperactivity disorder and developmental coordination disorder. ( Flapper, BC; Houwen, S; Schoemaker, MM, 2006) |
| "Atomoxetine and OROS methylphenidate were successfully used concomitantly in a 10-year-old boy suffering from attention-deficit/hyperactivity disorder (ADHD) with comorbid bipolar disorder and Tourette syndrome (TS)." | 7.73 | Concomitant use of atomoxetine and OROS-methylphenidate in a 10-year-old child suffering from attention-deficit/hyperactivity disorder with comorbid bipolar disorder and Tourette syndrome. ( Benarroch, F; Gross-Tsur, V; Jaworowski, S, 2006) |
| "Attention-deficit/hyperactivity disorder (ADHD) is common among cocaine abusers seeking treatment." | 7.70 | Methylphenidate treatment for cocaine abusers with adult attention-deficit/hyperactivity disorder: a pilot study. ( Evans, SM; Kleber, HD; Levin, FR; McDowell, DM, 1998) |
| "We report a patient who developed paroxysmal kinesigenic dystonia shortly after initiation of therapy with methylphenidate for presumed attention deficit-hyperactivity disorder." | 7.69 | Paroxysmal kinesigenic dystonia after methylphenidate administration. ( Gay, CT; Ryan, SG, 1994) |
| "This case describes the beneficial effect on the binge eating component of bulimia nervosa of methylphenidate, which was prescribed to treat comorbid attention-deficit/hyperactivity disorder." | 7.69 | Efficacy of methylphenidate in bulimia nervosa comorbid with attention-deficit hyperactivity disorder: a case report. ( Moskowitz, A; Schweickert, LA; Strober, M, 1997) |
| "High and low-aggressive boys with attention deficit-hyperactivity disorder (ADHD) were compared and the effects of methylphenidate were examined on measures from three domains of aggression: (1) directly observed verbal and nonverbal aggressive behaviors exhibited in the context of a day treatment program, (2) aggressive responding when provoked during a laboratory task, and (3) social information processing patterns exhibited on tasks designed to tap the putative cognitive components of aggression." | 7.68 | Aggression in boys with attention deficit-hyperactivity disorder: methylphenidate effects on naturalistically observed aggression, response to provocation, and social information processing. ( Lang, AR; Murphy, DA; Pelham, WE, 1992) |
| "The onset, duration, and offset of pemoline action to improve cognitive performance is examined intensively in 25 prepubescent males suffering from attention-deficit disorder with hyperactivity (ADDH)." | 7.68 | Pharmacodynamics of pemoline in attention deficit disorder with hyperactivity. ( Perel, JM; Sallee, FR; Stiller, RL, 1992) |
| "Methylphenidate is widely used in the treatment of school-age children with attention deficit disorder with hyperactivity (ADDH)." | 7.67 | Sustained release methylphenidate: pharmacokinetic studies in ADDH males. ( Birmaher, B; Cooper, TB; Fried, J; Greenhill, LL; Maminski, B, 1989) |
| "High-affinity [3H]imipramine binding to platelets was investigated in 11 boys with attention deficit disorder and hyperactivity (ADDH) before and after 28 days of methylphenidate (MPH) treatment, and the results were compared to [3H]imipramine binding parameters (Kd, Bmax) of 10 age-matched normal boys." | 7.67 | Imipramine binding to platelets of children with attention deficit disorder with hyperactivity. ( Bernhout, E; Rehavi, M; Tyano, S; Weitz, R; Weizman, A, 1988) |
| "This study examined whether methylphenidate normalizes the behavior of hyperactive children (ADDH)." | 7.67 | The normalizing effects of methylphenidate on the classroom behavior of ADDH children. ( Abikoff, H; Gittelman, R, 1985) |
| "In a child with minimal brain dysfunction, we found that chorea was related to the major central effect of methylphenidate and probably to the effect of the drug on central catecholaminergic systems." | 7.66 | Methylphenidate-induced chorea: case report and pharmacologic implications. ( Klawans, HL; Nausieda, PA; Weiner, WJ, 1978) |
| " Larger studies with higher doses combined with individual dosage and longer follow-up periods are warranted." | 6.75 | Sustained release methylphenidate for the treatment of ADHD in amphetamine abusers: a pilot study. ( Beck, O; Franck, J; Jayaram-Lindström, N; Konstenius, M, 2010) |
| " We conducted a randomized crossover trial with MPH and placebo (2 weeks each) combined with aripiprazole in children and adolescents (n = 16; 8-17 years old) with JBPD and ADHD who had a significant response in manic symptoms with aripiprazole but still presented clinically significant symptoms of ADHD." | 6.74 | Methylphenidate combined with aripiprazole in children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder: a randomized crossover trial. ( Ketzer, CR; Pheula, GF; Rohde, LA; Tramontina, S; Zeni, CP, 2009) |
| " The results from the literature underline the necessity of caution and patient monitoring when risperidone dosing is modified during methylphenidate therapy." | 6.72 | Movement disorders and use of risperidone and methylphenidate: a review of case reports and an analysis of the WHO database in pharmacovigilance. ( Burden, AM; Stämpfli, D; Weiler, S, 2021) |
| "Methylphenidate (MPH) is a stimulant, FDA-approved for the treatment of ADHD, and often used for ADHD in the setting of pediatric epilepsy." | 6.72 | Methylphenidate for attention problems in epilepsy patients: Safety and efficacy. ( Adams, J; Devinsky, O; Leeman-Markowski, BA; Martin, SP; Meador, KJ, 2021) |
| "The authors explored genetic moderators of symptom reduction and side effects in methylphenidate-treated preschool-age children diagnosed with attention-deficit/hyperactivity disorder (ADHD)." | 6.72 | Pharmacogenetics of methylphenidate response in preschoolers with ADHD. ( Abikoff, H; Chuang, S; Cunningham, C; Davies, M; Ghuman, J; Greenhill, L; Kastelic, E; Kollins, S; McCRACKEN, J; McGOUGH, J; Moyzis, R; Posner, K; Riddle, M; Shigawa, S; Skrobala, A; Swanson, J; Vitiello, B; Wigal, S; Wigal, T, 2006) |
| "The safety and efficacy of treatment with antiepilepsy drugs combined with methylphenidate were determined by assessing seizure frequency, changes in ADHD symptoms, the Conners' Rating Scales, EEG differences, and side effects." | 6.71 | Use of methylphenidate for attention-deficit hyperactivity disorder in patients with epilepsy or electroencephalographic abnormalities. ( Erdemoglu, AK; Gucuyener, K; Kockar, AI; Senol, S; Serdaroglu, A; Soysal, S, 2003) |
| "This study analyzes the incidence of tics reported across five studies of children with ADHD who received methylphenidate (MPH)-based therapy as part of the clinical development program for once-daily OROS MPH (CONCERTA McNeil Consumer & Specialty Pharmaceuticals, Fort Washington, PA)." | 6.71 | Emergence of tics in children with ADHD: impact of once-daily OROS methylphenidate therapy. ( Co-Chien, H; Faraone, SV; Lynch, J; Palumbo, D; Spencer, T, 2004) |
| "Methylphenidate has short-term positive effects on children and adolescents with CD." | 6.68 | Clinical efficacy of methylphenidate in conduct disorder with and without attention deficit hyperactivity disorder. ( Abikoff, H; Ganeles, D; Klass, E; Klein, RG; Pollack, S; Seese, LM, 1997) |
| "Covert antisocial behaviors such as stealing, destroying property, and cheating carry high risk for delinquency." | 6.67 | Covert antisocial behavior in boys with attention-deficit hyperactivity disorder: external validation and effects of methylphenidate. ( Heller, T; Hinshaw, SP; McHale, JP, 1992) |
| "The impulsivity component of attention deficit disorder with hyperactivity requires regulation because its effects interfere with children's school performance and persist into adulthood." | 6.66 | Attention deficit disorder with hyperactivity: differential effects of methylphenidate on impulsivity. ( Birmingham, BK; DuPaul, GJ; Masse, G; Rapport, MD; Stoner, G, 1985) |
| "Methylphenidate is a first-line treatment for ADHD, however no previous meta-analysis has evaluated its overall efficacy for ADHD in children with comorbid intellectual disability (ID) or borderline intellectual functioning." | 6.61 | Therapeutic effects of methylphenidate for attention-deficit/hyperactivity disorder in children with borderline intellectual functioning or intellectual disability: A systematic review and meta-analysis. ( Carvalho, AF; Chen, TY; Chen, YW; Cheng, YS; Li, DJ; Lin, PY; Stubbs, B; Sun, CK; Tseng, PT; Wu, CK; Wu, MK, 2019) |
| "Children with autistic spectrum disorder (ASD) frequently present with inattention, impulsivity and hyperactivity, which are the cardinal symptoms of attention deficit hyperactivity disorder (ADHD)." | 6.55 | Methylphenidate for children and adolescents with autism spectrum disorder. ( Deckx, L; Sturman, N; van Driel, ML, 2017) |
| "Inclusion criteria were at least two epileptic seizures in the previous 6 months and a diagnosis of ADHD based on DSM-IV criteria." | 6.47 | Efficacy and safety of methylphenidate in treating ADHD symptoms in children and adolescents with uncontrolled seizures: a Brazilian sample study and literature review. ( Agertt, F; Casella, EB; Ferreira, MG; Koneski, JA, 2011) |
| "Methylphenidate (MPH) is an indirect-acting sympathomimetic drug and structurally related to amphetamine." | 5.72 | Acute myocardial infarction due to spontaneous coronary artery dissection in a 6-year-old boy with ADHD on the third day of treatment with methylphenidate. ( Becker, M; Kerst, G; Ostermayer, S; Pitzer, M; Pohlmann, U; Rascher, W; Stammschulte, T, 2022) |
| "Methylphenidate was effective and safe in treating ADHD in 76% of cases in children with DS, with few serious side effects to report." | 5.62 | Efficacy and safety of methylphenidate on attention deficit hyperactivity disorder in children with Down syndrome. ( Cieuta-Walti, C; Conte, M; Durand, S; Falquero, S; Labidi, A; Mégarbané, A; Mircher, C; Prioux, E; Ravel, A; Roche, M; Stora, S; Toulas, J, 2021) |
| "Methylphenidate (MPH) is a piperidine similar to amphetamines, and is indicated for attention deficit hyperactivity disorder." | 5.51 | Methylphenidate and stuttering. ( Azzouz, B; Claustre, G; Djerada, Z; Herlem, E; Morel, A; Trenque, A; Trenque, T, 2019) |
| "Conduct disorder was significantly higher in patients with DP, whereas ODD was significantly higher in the DESR and non-ED groups (P < 0." | 5.46 | Effect of Methylphenidate on Emotional Dysregulation in Children With Attention-Deficit/Hyperactivity Disorder + Oppositional Defiant Disorder/Conduct Disorder. ( Akyol Ardic, U; Ercan, ES; Kutlu, A, 2017) |
| "Methylphenidate was initiated in 61 patients, including 55 in whom a follow-up evaluation was available." | 5.43 | ADHD in childhood epilepsy: Clinical determinants of severity and of the response to methylphenidate. ( Arzimanoglou, A; Auvin, S; Berquin, P; Cances, C; Castelneau, P; Gaillard, S; Herbillon, V; Isnard, H; Kassai, B; Mercier, C; Nabbout, R; Napuri, S; Nguyen The Tich, S; Rheims, S; Villega, F; Villeneuve, N, 2016) |
| "Methylphenidate treatment for ADHD and CD has acute effects on these processes." | 5.43 | Acute effects of methylphenidate on impulsivity and attentional behavior among adolescents comorbid for ADHD and conduct disorder. ( Acheson, A; Dougherty, DM; Hill-Kapturczak, N; Mathias, CW; Olvera, RL; Ryan, SR, 2016) |
| "Baseline oppositional defiant disorder (ODD) and conduct disorder (CD) scores were correlated with the CGI-S score; however, no association was found between core ADHD symptom severity and the CGI-S score." | 5.40 | Effect of OROS methylphenidate on encopresis in children with attention-deficit/hyperactivity disorder. ( Bilgiç, A; Hergüner, S; Yılmaz, S, 2014) |
| "Adult Attention Deficit Disorder is increasingly diagnosed and treated." | 5.36 | Acute myocardial infarction related to methylphenidate for adult attention deficit disorder. ( Thompson, J; Thompson, JR, 2010) |
| "Methylphenidate is a potent central nervous system stimulant that exerts its effects by increasing synaptic levels of dopamine and norepinephrine." | 5.35 | A case of acute cardiomyopathy and pericarditis associated with methylphenidate. ( Dadfarmay, S; Dixon, J, 2009) |
| "Excessive daytime sleepiness due to any cause can result in various symptoms similar to those used for the diagnosis of attention deficit/hyperactivity disorder (ADHD)." | 5.35 | Sleep and daytime sleepiness in methylphenidate medicated and un-medicated children with attention-deficit/hyperactivity disorder (ADHD). ( Ashwal, J; Bentley, A; Cockcroft, K, 2009) |
| "Methylphenidate is a stimulant medication that is sometimes used as an antidepressant in bipolar adults and is frequently used in children with comorbid bipolar and attention-deficit disorder." | 5.33 | Naturalistic long-term use of methylphenidate in bipolar disorder. ( El-Mallakh, RS; Lydon, E, 2006) |
| "Gabapentin is an anticonvulsant drug released in the United States in 1993 for use as adjunctive therapy in refractory partial epilepsy." | 5.31 | Gabapentin and methylphenidate treatment of a preadolescent with attention deficit hyperactivity disorder and bipolar disorder. ( Bailey, K; Hamrin, V, 2001) |
| " This research evaluates the preventive effects of cyproheptadine on sleeping and appetite disorders induced by methylphenidate in ADHD children." | 5.30 | Preventive effect of cyproheptadine on sleep and appetite disorders induced by methylphenidate: an exploratory randomised, double-blinded, placebo-controlled clinical trial. ( Elyasi, S; Kadkhoda Mezerji, F; Mohammadpour, AH; Moharreri, F, 2019) |
| "Methylphenidate improved secondary outcomes during smoking cessation independent of baseline ADHD severity, with no evident treatment-baseline severity interaction." | 5.27 | Exploring longitudinal course and treatment-baseline severity interactions in secondary outcomes of smoking cessation treatment in individuals with attention-deficit hyperactivity disorder. ( Covey, L; Hu, MC; Levin, FR; Luo, SX; Nunes, EV; Scodes, JM; Wall, M; Winhusen, T, 2018) |
| "The objective of this study was to assess the response of anxiety and depression symptoms to methylphenidate (MPH) treatment in patients with Asperger syndrome (AS) combined with attention deficit/hyperactivity disorder (ADHD)." | 5.24 | The effect of methylphenidate on anxiety and depression symptoms in patients with Asperger syndrome and comorbid attention deficit/hyperactivity disorder. ( Golubchik, P; Rapaport, M; Weizman, A, 2017) |
| "Although the nonrandomized, nonblind design limits the conclusions of our exploratory study, our findings suggest that when ADHD is comorbid with ODD and aggression MPH and risperidone are both effective on aggressive behavior, but only stimulants are effective on ADHD symptoms." | 5.24 | A Naturalistic Comparison of Methylphenidate and Risperidone Monotherapy in Drug-Naive Youth With Attention-Deficit/Hyperactivity Disorder Comorbid With Oppositional Defiant Disorder and Aggression. ( Manfredi, A; Masi, G; Milone, A; Muratori, P; Nieri, G; Pfanner, C, 2017) |
| "Thirty epilepsy patients entered a 1-month open-label methylphenidate trial after a double-blind phase." | 5.24 | Methylphenidate, cognition, and epilepsy: A 1-month open-label trial. ( Adams, J; Alipio-Jocson, V; Barry, JJ; Bartlett, V; Inoyama, K; Loring, DW; Meador, KJ; Oso, J; Sandhu, S, 2017) |
| " We examine the use of parent target problems (PTPs) in a randomized trial of methylphenidate (MPH) in children with autism spectrum disorder and symptoms of attention-deficit/hyperactivity disorder." | 5.24 | Using a Patient-Centered Outcome Measure to Test Methylphenidate Versus Placebo in Children with Autism Spectrum Disorder. ( Aman, MG; Arnold, LE; Bearss, K; Gillespie, S; McCracken, JT; McDougle, CJ; Postorino, V; Sarhangian, R; Scahill, L; Tierney, E; Vitiello, B, 2017) |
| "Both atomoxetine and methylphenidate reduced the symptoms of ADHD and anxiety." | 5.22 | Anxiety reduction on atomoxetine and methylphenidate medication in children with ADHD. ( Hrtanek, I; Kulhan, T; Marcincakova-Husarova, V; Nosalova, G; Ondrejka, I; Snircova, E, 2016) |
| "The aim of this study was to determine the effect of methylphenidate (MPH) on creative potential in a group of children with attention deficit disorder with hyperactivity (ADHD)." | 5.22 | Medication and creativity in Attention Deficit Hyperactivity Disorder (ADHD). ( González-Carpio Hernández, G; Serrano Selva, JP, 2016) |
| "We combined neural measures from three separate procedures (two inhibitory control tasks differing in their degree of emotional salience and resting-state functional connectivity) during methylphenidate (20 mg oral, versus randomized and counterbalanced placebo) and correlated these aggregated responses with cocaine use disorder diagnosis (22 cocaine abusers, 21 controls), symptoms of attention deficit hyperactivity disorder, and working memory capacity." | 5.22 | Abnormal response to methylphenidate across multiple fMRI procedures in cocaine use disorder: feasibility study. ( Goldstein, RZ; Konova, AB; Moeller, SJ; Parvaz, MA; Tomasi, D, 2016) |
| " Although cumulative evidence suggests that dopamine is involved in pain processing, pain perception in ADHD subjects and the effect of dopamine agonists such as methylphenidate (MP, Ritalin) on it have rarely been studied." | 5.20 | Alterations in pain response are partially reversed by methylphenidate (Ritalin) in adults with attention deficit hyperactivity disorder (ADHD). ( Demeter, N; Eisenberg, E; Pud, D; Treister, R, 2015) |
| "Osmotic-release oral system methylphenidate (OROS-MPH) did not show overall benefit as an adjunct smoking cessation treatment for adult smokers with ADHD in a randomized, placebo-controlled, multicenter clinical trial." | 5.20 | Toward personalized smoking-cessation treatment: Using a predictive modeling approach to guide decisions regarding stimulant medication treatment of attention-deficit/hyperactivity disorder (ADHD) in smokers. ( Covey, LS; Hu, MC; Levin, FR; Luo, SX; Nunes, EV; Winhusen, TM, 2015) |
| " Subjects received methylphenidate following 3months of baseline, during which antiepileptic drugs (AEDs) were adjusted and epilepsy, ADHD, and quality-of-life variables were assessed." | 5.20 | Methylphenidate improves the quality of life of children and adolescents with ADHD and difficult-to-treat epilepsies. ( Bastos, F; Kieling, RR; Palmini, AL; Radziuk, AL; Rotert, R; Santos, K, 2015) |
| " However, our findings suggest the association between 5-HTTLPR polymorphism and the occurrence of tics and nail-biting as an adverse event of methylphenidate." | 5.20 | Association Between 5-HTTLPR Polymorphism and Tics after Treatment with Methylphenidate in Korean Children with Attention-Deficit/Hyperactivity Disorder. ( Cheon, KA; Kim, EJ; Park, SY, 2015) |
| " To determine (1) the serum baseline daily variations and nocturnal excretion of melatonin in ADHD subtypes and (2) the effect of chronic administration of methylphenidate, as well as the effects on symptomatology, 136 children with ADHD (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision: DSM-IV-TR criteria) were divided into subgroups using the "Children's Depression Inventory" (CDI)." | 5.19 | Methylphenidate ameliorates depressive comorbidity in ADHD children without any modification on differences in serum melatonin concentration between ADHD subtypes. ( Cubero-Millán, I; Fernández-López, L; Luna-del-Castillo, JD; Machado-Casas, I; Martínez-Serrano, S; Molina-Carballo, A; Muñoz-Hoyos, A; Ruiz-López, A; Tortosa-Pinto, P; Uberos, J, 2014) |
| "After a 3 month period in which antiepileptic drugs were adjusted, 22 patients recruited from a specialist outpatient clinic for severe epilepsy (16 males, six females; mean age 11 y 2 mo, SD 3 y 2 mo) received methylphenidate for 3 months in an open label, non-controlled trial; four with generalized or multifocal (symptomatic/cryptogenic) epilepsy, one with generalized (idiopathic) epilepsy, 17 with partial (symptomatic/cryptogenic) epilepsy; five with partial seizures only, 17 with primarily or secondarily generalized seizures)." | 5.17 | The impact of methylphenidate on seizure frequency and severity in children with attention-deficit-hyperactivity disorder and difficult-to-treat epilepsies. ( Bastos, F; Booij, L; Fernandes, BS; Palmini, A; Radziuk, AL; Rotert, R; Santos, K, 2013) |
| "Optimal dosing of methylphenidate is practical and effective in some children with hyperkinetic disorder and intellectual disability." | 5.17 | Randomized controlled double-blind trial of optimal dose methylphenidate in children and adolescents with severe attention deficit hyperactivity disorder and intellectual disability. ( Baird, G; Bernard, S; Chadwick, O; Golaszewski, A; Jichi, F; Kelly, J; Kennedy, J; Liang, H; Riemer, K; Rodney, L; Sharma, K; Sharma, SP; Simonoff, E; Taylor, E; Walwyn, R; West, N; Whitwell, S; Wood, N, 2013) |
| " Although smoking cessation tends to result in weight increase, potentially initiating or exacerbating weight problems, adults with ADHD who are treated with osmotic release oral system methylphenidate (OROS-MPH) tend to lose weight." | 5.17 | Osmotic release oral system methylphenidate prevents weight gain during a smoking-cessation attempt in adults with ADHD. ( Heffner, JL; Lewis, DF; Winhusen, TM, 2013) |
| "To examine the relationship between attention and anxiety and the response to methylphenidate in children with attention deficit hyperactivity disorder (ADHD), a total of 57 boys, between the ages of 7-12 years, were assessed for their attention and level of anxiety." | 5.16 | Anxiety and methylphenidate in attention deficit hyperactivity disorder: a double-blind placebo-drug trial. ( Karni, A; Moshe, K; Tirosh, E, 2012) |
| "While nortriptyline statistically decreased the incidence of nocturnal enuresis during the intervention, the number of enuresis events did not significantly change in the placebo group." | 5.16 | Nortriptyline for treating enuresis in ADHD--a randomized double-blind controlled clinical trial. ( Ghanizadeh, A; Haghighat, R, 2012) |
| " In a placebo-controlled trial of osmotic-release oral system methylphenidate (OROS-MPH) as augmentation treatment for smokers with attention deficit hyperactivity/impulsivity disorder (ADHD), three types of sites were selected according to their clinical research specialty (ADHD, smoking cessation, and general mental health)." | 5.15 | An exploration of site effects in a multisite trial of OROS-methylphenidate for smokers with attention deficit/hyperactivity disorder. ( Adler, L; Brigham, G; Covey, LS; Green, CA; Hu, MC; Hurt, RD; Winhusen, T, 2011) |
| " The present study evaluated if using osmotic-release oral system methylphenidate (OROS-MPH) to treat ADHD enhances response to smoking cessation treatment in smokers with ADHD." | 5.14 | Impact of attention-deficit/hyperactivity disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers: a randomized, double-blind, placebo-controlled trial. ( Adler, LA; Brigham, GS; Covey, LS; Croghan, IT; Dorer, EM; Green, CA; Leimberger, JD; Lewis, DF; Liu, DS; Somoza, EC; Weiss, RD; Winhusen, TM, 2010) |
| "The goal of this study was to pilot a randomized controlled trial of OROS methylphenidate (OROS-MPH) to treat attention deficit hyperactivity disorder (ADHD) plus epilepsy." | 5.14 | Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. ( Biederman, J; Bourgeois, B; de Moor, C; Demaso, DR; Dodds, A; Faraone, SV; Forbes, P; Gonzalez-Heydrich, J; Hsin, O; Macmillan, C; Mrakotsky, C; Rao, S; Torres, A; Waber, D; Whitney, J, 2010) |
| "There were more incidents of bradycardia in subjects treated with clonidine compared with those not treated with clonidine (17." | 5.13 | Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis. ( Bukstein, OG; Daviss, WB; Harris, P; McDERMOTT, MP; Palumbo, D; Patel, NC; Pelham, WE; Robb, AS; Sallee, FR, 2008) |
| " The aim of this pilot study was to investigate the impact of the combined diagnoses of developmental coordination disorder (DCD) and ADHD on HRQOL, and the effectiveness of methylphenidate (MPH) on HRQOL." | 5.13 | Effects of methylphenidate on quality of life in children with both developmental coordination disorder and ADHD. ( Flapper, BC; Schoemaker, MM, 2008) |
| " The data on the effects of stimulants (methylphenidate and amphetamines) in pregnancy are generally reassuring, but methylphenidate might slightly increase the rate of cardiac malformations and of spontaneous abortions, while amphetamines might slightly increase the risk for premature birth, low birth weight and other pregnancy complications." | 5.12 | The Effects of Drugs used for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) on Pregnancy Outcome and Breast-feeding: A Critical Review. ( Koren, G; Ornoy, A, 2021) |
| "To determine whether children with attention-deficit hyperactivity disorder (ADHD) and learning disabilities respond differently to methylphenidate (MPH) compared with children with ADHD only." | 5.12 | Efficacy of methylphenidate in children with attention-deficit hyperactivity disorder and learning disabilities: a randomized crossover trial. ( Bhat, M; Grizenko, N; Joober, R; Schwartz, G; Ter-Stepanian, M, 2006) |
| "The purpose of this study was to evaluate the effectiveness and safety of methylphenidate treatment in epilepsy patients with comorbid adult attention deficit hyperactivity disorder (ADHD)." | 5.12 | Effectiveness and safety of methylphenidate in adult attention deficit hyperactivity disorder in patients with epilepsy: an open treatment trial. ( Aldenkamp, AP; van der Feltz-Cornelis, CM, 2006) |
| "Methylphenidate ameliorated task-incompatible behavior, arithmetic performance, and inattention comparably in both ADHD subtypes, whereas medication reduced hyperactivity and aggression largely in children with ADHD/C." | 5.12 | Effects of methylphenidate on subtypes of attention-deficit/hyperactivity disorder. ( Borgstedt, AD; Gorman, EB; Klorman, R; Thatcher, JE, 2006) |
| "To evaluate the effects of risperidone augmentation for treatment-resistant aggression in children with attention-deficit/hyperactivity disorder (ADHD)." | 5.12 | Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: a placebo-controlled pilot study. ( Armenteros, JL; Davalos, M; Lewis, JE, 2007) |
| "This study investigated the safety and efficacy of adding the atypical antipsychotic quetiapine to ongoing OROS methylphenidate treatment for adolescents with comorbid ADHD and severe aggression that were incompletely responsive to methylphenidate monotherapy." | 5.12 | Quetiapine addition in methylphenidate treatment-resistant adolescents with comorbid ADHD, conduct/oppositional-defiant disorder, and aggression: a prospective, open-label study. ( Bohnstedt, BN; Dunn, DW; Giauque, AL; Kronenberger, WG; Lafata, DE; Maxey, LE, 2007) |
| "To examine the short-term efficacy of methylphenidate in the treatment of youths with bipolar disorder (BD) and comorbid attention deficit/hyperactivity disorder (ADHD)." | 5.12 | Methylphenidate in the treatment of children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder. ( Calabrese, JR; Demeter, CA; Findling, RL; Gracious, BL; Manos, MJ; McNamara, NK; Short, EJ; Stansbrey, RJ; Whipkey, R, 2007) |
| "We provided n-of-1 trials for osteoarthritis (OA), comparing paracetamol and ibuprofen; and attention deficit hyperactivity disorder (ADHD), comparing dexamphetamine or methylphenidate and placebo." | 5.11 | Using n-of-1 trials as a clinical tool to improve prescribing. ( Clavarino, AM; Del Mar, CB; Nikles, CJ, 2005) |
| "Our objective was to study the short-term efficacy and safety of methylphenidate in patients with the dual diagnosis of cerebral palsy and attention-deficit hyperactivity disorder (ADHD)." | 5.10 | Efficacy of methylphenidate in patients with cerebral palsy and attention-deficit hyperactivity disorder (ADHD). ( Badihi, N; Gross-Tsur, V; Manor, O; Shalev, RS, 2002) |
| "A pilot comparison of the safety and efficacy of methylphenidate (MPH) combined with clonidine, clonidine monotherapy, or MPH monotherapy in 6- to 16-year-old children diagnosed with attention deficit hyperactivity disorder (ADHD) and comorbid aggressive oppositional defiant disorder or conduct disorder was completed." | 5.09 | A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder. ( Barkley, RA; Connor, DF; Davis, HT, 2000) |
| "We describe an open trial of psychostimulants (primarily methylphenidate sustained release [SR]) added to selective serotonin reuptake inhibitors (SSRIs; primarily fluoxetine) during the course of pharmacologic treatment of men with paraphilias and paraphilia-related disorders (PRDs)." | 5.09 | Psychostimulant augmentation during treatment with selective serotonin reuptake inhibitors in men with paraphilias and paraphilia-related disorders: a case series. ( Hennen, J; Kafka, MP, 2000) |
| "2 years) with autism and symptoms of attention-deficit hyperactivity disorder (ADHD) participated in a double-blind, placebo-controlled crossover study of methylphenidate (0." | 5.09 | Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. ( Handen, BL; Johnson, CR; Lubetsky, M, 2000) |
| "The effect of methylphenidate preceded by a moderate dose of haloperidol on reaction times over the duration of a continuous performance test (CPT), was investigated in ten male children, with a DSM-III diagnosis of attention deficit disorder with hyperactivity disorder (ADDH)." | 5.08 | Does haloperidol block methylphenidate? Motivation or attention? ( Hobbes, G; Levy, F, 1996) |
| "To study the safety and efficacy of methylphenidate in children with the dual diagnosis of epilepsy and attention deficit hyperactivity disorder (ADHD)." | 5.08 | Epilepsy and attention deficit hyperactivity disorder: is methylphenidate safe and effective? ( Gross-Tsur, V; Joseph, A; Manor, O; Shalev, RS; van der Meere, J, 1997) |
| "To evaluate the hypothesis that gross body mass is functionally related to methylphenidate (MPH) response in children with attention deficit disorder/hyperactivity disorder (ADDH)." | 5.08 | Titrating methylphenidate in children with attention-deficit/hyperactivity disorder: is body mass predictive of clinical response? ( Denney, C; Rapport, MD, 1997) |
| "To study the safety and efficacy of methylphenidate in children with the dual diagnosis of epilepsy and attention deficit hyperactivity disorder (ADHD)." | 5.08 | Epilepsy and attention deficit hyperactivity disorder: is methylphenidate safe and effective? ( Gross-Tsur, V; Joseph, A; Manor, O; Shalev, RS; van der Meere, J, 1997) |
| " Levels of CSF 5-hydroxyindoleacetic acid (5-HIAA), homovanillic acid (HVA), and 3-methoxy-4-hydroxyphenylglycol (MHPG), the metabolites of serotonin, dopamine, and norepinephrine, respectively, correlated significantly with behavioral measures of aggression and impulsivity/hyperactivity." | 5.07 | Cerebrospinal fluid monoamine metabolites in boys with attention-deficit hyperactivity disorder. ( Castellanos, FX; Elia, J; Gulotta, CS; Kruesi, MJ; Mefford, IN; Potter, WZ; Rapoport, JL; Ritchie, GF, 1994) |
| " The three groups were found to be similar in mean age, gender ratio, prevalence, and pattern of associated learning disabilities, family history of psychopathology, and probability of favorable response to methylphenidate." | 5.07 | Attention deficit disorder in children: three clinical variants. ( de Quirós, GB; Kinsbourne, M; Palmer, RL; Rufo, DT, 1994) |
| "Children diagnosed with attention deficit disorder (ADD; n = 44), ADD plus aggression/oppositionality (ADD/O; n = 34), and as not meeting ADD criteria (NC; n = 29) received methylphenidate and placebo for 21 consecutive days each." | 5.07 | Clinical and cognitive effects of methylphenidate on children with attention deficit disorder as a function of aggression/oppositionality and age. ( Borgstedt, AD; Brumaghim, JT; Fitzpatrick, PA; Klorman, R; Strauss, J, 1994) |
| "One of the least documented "known" effects of methylphenidate in hyperactive children is the suppression of peer aggression." | 5.06 | Methylphenidate in aggressive-hyperactive boys: I. Effects on peer aggression in public school settings. ( Gadow, KD; Nolan, EE; Paolicelli, L; Sprafkin, J; Sverd, J, 1990) |
| "The effect of methylphenidate on aggression in adolescents diagnosed with both aggressive conduct disorder and attention deficit disorder with hyperactivity was assessed in nine male adolescents." | 5.06 | Effects of methylphenidate on adolescents with aggressive conduct disorder and ADDH: a preliminary report. ( Busner, J; Kaplan, SL; Kupietz, S; Segal, B; Wassermann, E, 1990) |
| "This investigation examined the relationship between methylphenidate (MPH) and the learning and recall of paired associations by children with attention deficit disorder with hyperactivity (ADDH)." | 5.06 | Attention deficit disorder with hyperactivity and methylphenidate: the effects of dose and mastery level on children's learning performance. ( DuPaul, GJ; Kelly, KL; Quinn, EP; Quinn, SO; Rapport, MD, 1989) |
| "Investigated the effect of methylphenidate (MPH) on the ability of children with Attention Deficit Disorder with Hyperactivity (ADDH) to learn both trained and untrained complex visual relationships and compared these findings to their school performance under identical dosage parameters." | 5.06 | The effects of methylphenidate on learning in children with ADDH: the stimulus equivalence paradigm. ( Rapport, MD; Vyse, SA, 1989) |
| "0 mg/kg of methylphenidate on the overt behavior and academic functioning of 12 children with an established diagnosis of attention deficit disorder with hyperactivity were evaluated." | 5.06 | Dose-response effects of methylphenidate on academic performance and overt behavior in hyperactive children. ( Carr, RP; Logan, GD; Schachar, RJ; Tannock, R, 1989) |
| "Fourteen children with Attention Deficit Disorder with Hyperactivity (ADD + H) were administered the psychostimulant methylphenidate in a double-blind, placebo-controlled, crossover study." | 5.06 | Methylphenidate and memory: dissociated effects in hyperactive children. ( Amara, I; Evans, RW; Gualtieri, CT, 1986) |
| "One of the most effective treatments for children with Attention Deficit Disorder with Hyperactivity (ADDH) has been the prescription of methylphenidate (MPH)." | 5.06 | ADDH and methylphenidate responders: effects on behavior controlled by complex reinforcement schedules. ( DuPaul, GJ; Rapport, MD; Vyse, SA, 1988) |
| "Sixteen children meeting diagnostic criteria for Attention Deficit Disorder with Hyperactivity (ADD-H) were tested on methylphenidate (0." | 5.06 | Short term effects of methylphenidate on the cognitive, learning and academic performance of children with attention deficit disorder in the laboratory and the classroom. ( Barr, RG; Britton, BG; Douglas, VI; O'Neill, ME, 1986) |
| "The relationship between methylphenidate (MP) oral dose and plasma concentration to social and cognitive behaviors was studied in 25 boys diagnosed as having "attention deficit disorder with hyperactivity"." | 5.05 | Methylphenidate oral dose plasma concentrations and behavioral response in children. ( Hungund, BL; Kupietz, SS; Sverg, J; Winsberg, BG; Young, NL, 1982) |
| "The purpose of this manuscript is to review the evidence generated by clinical trials of pharmaceuticals in autism spectrum disorder (ASD), describe challenges in the conduct of such trials, and discuss future directions RECENT FINDINGS: Clinical trials in ASD have produced several compounds to adequately support the pharmacological treatment of associated symptom domains: attention deficit hyperactivity disorder (methylphenidate, atomoxetine, and alpha agonists), irritability/aggression (risperidone and aripiprazole), sleep (melatonin), and weight gain associated with atypical antipsychotic use (metformin)." | 4.98 | Clinical trials in autism spectrum disorder: evidence, challenges and future directions. ( Anagnostou, E, 2018) |
| " In this article, we report and analyze a case of 52-year-old male patient with morbid obesity and attention-deficit/hyperactivity disorder (ADHD) who experienced lack of methylphenidate efficacy after Roux en-Y gastric bypass (RYGB), which was eventually resolved by using the transdermal patch instead of an oral product." | 4.95 | Impaired oral absorption of methylphenidate after Roux-en-Y gastric bypass. ( Azran, C; Dahan, A; Langguth, P, 2017) |
| "Using the keywords bupropion or Wellbutrin or Zyban or Elontril and attention deficit hyperactivity disorder or ADHD or ADDH, a preliminary search on the PubMed and Ovid databases yielded 25,455 articles published in English between January 1, 1988 and May 1, 2016." | 4.95 | A Systematic Review of the Use of Bupropion for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. ( Ng, QX, 2017) |
| "Antipsychotics, particularly risperidone, appear to be effective in reducing problem behaviors in children with intellectual disability." | 4.93 | Pharmacotherapy for mental health problems in people with intellectual disability. ( Findling, RL; Ji, NY, 2016) |
| "The aims of this review were to summarize the scientific evidence about the risks of using methylphenidate for ADHD in pregnancy and lactation, to present a case in which interruption of treatment after delivery and during breastfeeding was harmful and to discuss the implications of treating or not treating ADHD in pregnancy and lactation." | 4.90 | Methylphenidate use in pregnancy and lactation: a systematic review of evidence. ( Bolea-Alamanac, BM; Davies, SJ; Green, A; Maxwell, P; Verma, G, 2014) |
| "A comprehensive literature search was conducted through PubMed (1966-May 15, 2014) using the search terms priapism, methylphenidate, amphetamine, atomoxetine, attention-deficit disorder with hyperactivity, and pediatrics." | 4.90 | Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children. ( Bell, EA; Eiland, LS; Erramouspe, J, 2014) |
| "A systematic literature search was conducted in MEDLINE and PsycINFO in March 2012 using the MeSH terms: attention deficit disorder with hyperactivity/drug therapy; methylphenidate/therapeutic use and All Fields: Concerta; Ritalin LA; OROS and ADHD; Medikinet; Equasym XL and ADHD; long-acting methylphenidate; Diffucaps and ADHD; SODAS and methylphenidate." | 4.89 | Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies. ( Banaschewski, T; Coghill, D; Doepfner, M; Gagliano, A; Pelaz, A; Zuddas, A, 2013) |
| "To establish the efficacy and safety of methylphenidate (MPH) treatment for attention deficit hyperactivity disorder (ADHD) in a group of children and young people with learning disability and severe epilepsy." | 4.89 | Methylphenidate treatment of attention deficit hyperactivity disorder in young people with learning disability and difficult-to-treat epilepsy: evidence of clinical benefit. ( Aylett, SE; Fosi, T; Lax-Pericall, MT; Neville, BG; Scott, RC, 2013) |
| "This retrospective study delineated the efficacy of antiepileptic drugs in preventing the need for methylphenidate in patients with benign childhood epilepsy with centrotemporal spikes and attention deficit hyperactivity disorder." | 4.88 | Does a normalizing electroencephalogram in benign childhood epilepsy with centrotemporal spikes abort attention deficit hyperactivity disorder? ( Fattal-Valevski, A; Goldberg-Stern, H; Kramer, U; Schneebaum-Sender, N, 2012) |
| " There are no studies which demonstrate that short or long-term treatment with methylphenidate increases the risk of seizures." | 4.86 | Attention deficit and hyperactivity disorder in people with epilepsy: diagnosis and implications to the treatment. ( Casella, EB; Koneski, JA, 2010) |
| "Medication with methylphenidate should be avoided in patients with vulnerability to schizophrenia and in drug addiction, but reported cases without these risk factors demonstrate that a careful and regular psychiatric monitoring is essential in all patients treated with methylphenidate." | 4.86 | Methylphenidate-induced psychosis in adult attention-deficit/hyperactivity disorder: report of 3 new cases and review of the literature. ( Kis, B; Kraemer, M; Uekermann, J; Wiltfang, J, 2010) |
| " Methylphenidate (MPH) has shown high response rates and no increase in seizures in small trials." | 4.84 | Attention-deficit/hyperactivity disorder in pediatric patients with epilepsy: review of pharmacological treatment. ( Gonzalez-Heydrich, J; Torres, AR; Whitney, J, 2008) |
| "Literature review using a National Library of Medicine database search for 1975 through March 1997 on the terms attention deficit disorder with hyperactivity, methylphenidate, stimulants, and stimulant abuse and dependence." | 4.80 | Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. ( Bezman, RJ; Genel, M; Goldman, LS; Slanetz, PJ, 1998) |
| "Methylphenidate (MPH) is a central nervous stimulant, which is mainly used in attention deficit hyperactivity disorder (ADHD) and narcolepsy." | 4.31 | Characteristics and outcomes of cases with methylphenidate abuse, dependence or withdrawal: an analysis of spontaneous reports in EudraVigilance. ( Bachmann, CJ; Hartmayer, LT; Hoffmann, F; Jobski, K, 2023) |
| "To investigate the prevalence of core attention-deficit/hyperactivity disorder (ADHD) symptoms in Chinese narcolepsy type 1 (NT1) patients and to explore mood, quality of life, and executive function in narcolepsy patients with or without ADHD and the response to Methylphenidate Hydrochloride Extended-release tablets (ER-MPH) treatment." | 4.12 | A comparison of mood, quality of life and executive function among narcolepsy type 1 patients with or without ADHD symptoms in China. ( Dong, X; Han, F; Li, C; Qu, S; Wang, M; Wang, P; Xu, L, 2022) |
| " Little is known about whether the beneficial effect of methylphenidate is persistent in individuals with other comorbid mental disorders and epilepsy." | 4.12 | Methylphenidate and TBI in ADHD and co-occurring epilepsy and mental disorders: a self-controlled case series study. ( Chen, VC; Chen, YL; Dewey, ME; Gossop, M; Lee, CT; Yang, YH, 2022) |
| "In this report, we discuss the case of a 9-year-old male with Attention Deficit Hyperactivity Disorder (ADHD) on long-term methylphenidate and guanfacine who experienced acute orofacial dystonia that resolved immediately with the administration of benztropine." | 4.12 | Unprovoked Dystonic Reaction in a Child Taking Long-Term Methylphenidate. ( Fromm, C; Mattio, B; Pagliaro, A; Paulson, N; Vidal, J, 2022) |
| " (2020) present a systematic review with meta-analyses that reports the efficacy of five treatments for children with attention-deficit hyperactivity disorder symptoms in the context of autism spectrum disorder - (a) methylphenidate; (b) atomoxetine; (c) guanfacine; (d) aripiprazole; and (e) risperidone." | 4.02 | Commentary: Identifying individualized predictions of response in ADHD pharmacotherapy - a commentary on Rodrigues et al. (2020). ( Bloch, MH; Farhat, LC, 2021) |
| "Patients aged 5-18 years with a methylphenidate (MPH) prescription and an incident poisoning diagnosis between January 2001 and June 2020 were identified from the Hong Kong Clinical Data Analysis and Reporting System." | 4.02 | Treatment with Methylphenidate for Attention Deficit Hyperactivity Disorder (ADHD) and the Risk of All-Cause Poisoning in Children and Adolescents: A Self-Controlled Case Series Study. ( Chan, EW; Chui, CSL; Coghill, D; Gao, L; Hon, KL; Ip, P; Li, X; Lum, TYS; Man, KKC; Tse, ML; Wong, ICK; Wong, KHTW, 2021) |
| "Of 29 604 individuals prescribed methylphenidate between Jan 1, 2001, and Dec 31, 2017, 269 (199 males and 70 females) had incident seizures." | 3.96 | Association between methylphenidate treatment and risk of seizure: a population-based, self-controlled case-series study. ( Besag, FMC; Coghill, D; Cross, JH; Ip, P; Lau, WCY; Man, KKC; Wong, ICK, 2020) |
| "In a multisite, randomized study (CTN-0029), a 3-month course of Osmotic-Release Oral System Methylphenidate (OROS-MPH) improved smoking cessation in a group of patients with higher baseline severity in Attention-Deficit/Hyperactivity Disorder (ADHD)." | 3.91 | Differential Posttreatment Outcomes of Methylphenidate for Smoking Cessation for Individuals With ADHD. ( Covey, LS; Hu, MC; Luo, SX; Nunes, EV; Winhusen, TM, 2019) |
| "Maternal smoking during pregnancy, a form of developmental nicotine exposure (DNE), is associated with increased nicotine use and neurodevelopmental disorders such as ADHD in children." | 3.91 | Developmental nicotine exposure precipitates multigenerational maternal transmission of nicotine preference and ADHD-like behavioral, rhythmometric, neuropharmacological, and epigenetic anomalies in adolescent mice. ( Buck, JM; Knopik, VS; O'Neill, HC; Sanders, KN; Stitzel, JA; Wageman, CR, 2019) |
| "Case 1: A 30-year-old woman with depression and ADHD took duloxetine 90 mg daily and methylphenidate 36 mg daily during pregnancy and breastfeeding." | 3.88 | Infant Exposure to Methylphenidate and Duloxetine During Lactation. ( Collin-Lévesque, L; El-Ghaddaf, Y; Ferreira, E; Genest, M; Jutras, M; Leclair, G; Panchaud, A; Weisskopf, E, 2018) |
| "The aim of the present study was to characterize patterns of use of methylphenidate (MPH), a prescription stimulant medication recommended in the treatment of attention deficit hyperactivity disorder (ADHD) and of narcolepsy, in France, both in children and adults, over a 3-year period." | 3.88 | Patterns and profiles of methylphenidate use both in children and adults. ( Boucherie, Q; Frauger, E; Lepelley, M; Mallaret, M; Micallef, J; Pauly, V, 2018) |
| "We aimed to investigate the effectiveness and safety of methylphenidate (MPH), and especially its influence on seizures, in subjects with attention-deficit/hyperactivity disorder (ADHD) and epilepsy through a retrospective chart review of subjects treated with MPH in a clinical setting." | 3.88 | Relationship Between Aggravation of Seizures and Methylphenidate Treatment in Subjects with Attention-Deficit/Hyperactivity Disorder and Epilepsy. ( Choi, HW; Kim, HW; Ko, TS; Park, J; Shon, SH; Yum, MS, 2018) |
| "Actigraphic analysis showed a higher number of night awakenings in the epilepsy + ADHD groups; they were most prominent in the group without methylphenidate (p = 0." | 3.85 | Evaluation of sleep organization in patients with attention deficit hyperactivity disorder (ADHD) and ADHD as a comorbidity of epilepsy. ( Kalil Neto, F; Nunes, ML, 2017) |
| " Withdrawal of the narcolepsy treatment and initiation of haloperidol 1 mg/day (the only antipsychotic treatment she could tolerate) improved the delusions, hallucinations and dysphoria but worsened the narcolepsy symptoms." | 3.85 | Narcolepsy-cataplexy and psychosis: a case study. ( Arango-Lopez, C; Canellas-Dols, F; Delgado, C; Peraita-Adrados, R, 2017) |
| " Women who received amphetamine-dextroamphetamine or methylphenidate monotherapy in the first half of pregnancy were compared with unexposed women." | 3.85 | Placental Complications Associated With Psychostimulant Use in Pregnancy. ( Bateman, BT; Cohen, JM; Desai, RJ; Gray, KJ; Hernández-Díaz, S; Huybrechts, KF; Mogun, H; Park, Y; Patorno, E, 2017) |
| " Thus, a decline in state anxiety while performing a cognitive task when taking methylphenidate would discriminate between ADHD patients and controls." | 3.85 | Methylphenidate Reduces State Anxiety During a Continuous Performance Test That Distinguishes Adult ADHD Patients From Controls. ( Aviram, S; Bloch, Y; Braw, Y; Levkovitz, Y; Mimouni Bloch, A; Nitzan, U; Segev, A, 2017) |
| "Though both lisdexamfetamine dimesylate and methylphenidate are widely used among pediatricians today for treatment of ADHD, reports of life-threatening water intoxication as a result of overdose is rare." | 3.85 | Methylphenidate Overdose Causing Secondary Polydipsia and Severe Hyponatremia in an 8-Year-Old Boy. ( Kaagaza, M; Krishna, AS; Lefevre, C; Patel, V; Wittkamp, M, 2017) |
| "We describe a case whereby a 15-year-old female with treatment-resistant obsessive-compulsive disorder (OCD) was treated with methylphenidate for co-morbid attention deficit hyperactivity disorder (ADHD)." | 3.85 | Methylphenidate in the treatment of an adolescent female with obsessive-compulsive disorder and attention deficit hyperactivity disorder: a case report. ( Dowling, N; King, J; Leow, F, 2017) |
| " We report a case with sequences of CAP followed by bruxism and catathrenia in a 10-y-old male patient with a diagnosis of attention deficit hyperactivity disorder in treatment with methylphenidate." | 3.85 | Cyclic Alternating Pattern Associated with Catathrenia and Bruxism in a 10-Year-Old Patient. ( Adrianzén-Álvarez, F; Duque, KR; Palacios-García, J; Villafuerte-Trisolini, B; Vizcarra-Escobar, D, 2017) |
| " The primary objective of the current study was to assess differences in blood pressure and heart rate before and after induction of anesthesia between patients on chronic amphetamine or methylphenidate therapy who receive their normal dose preoperatively compared to patients in whom the prescribed medication was withheld." | 3.85 | Hemodynamic profile and behavioral characteristics during induction of anesthesia in pediatric patients with attention deficit hyperactivity disorder. ( Cartabuke, RS; Rice, J; Tobias, JD; Tumin, D, 2017) |
| "The purpose of this study is to determine the risk of developing depressive disorders by evaluating children with attention-deficit/hyperactivity disorder (ADHD) in comparison to controls that do not have ADHD, as well as to analyze whether the medications used to treat ADHD, methylphenidate (MPH) and atomoxetine (ATX), influence the risk of depression." | 3.83 | Attention-deficit hyperactivity disorder, its treatment with medication and the probability of developing a depressive disorder: A nationwide population-based study in Taiwan. ( Lee, MJ; Lee, SY; Lee, TL; Shyu, YC; Wang, LJ; Yang, CJ; Yang, KC; Yuan, SS, 2016) |
| "In this study, we aimed to evaluate the relationship between attention-deficit/hyperactivity disorder (ADHD) during childhood and subsequent diagnoses of bipolar disorder (BD), as well as to determine whether the pharmacotherapy for ADHD (methylphenidate and atomoxetine) influence the risks of developing BD." | 3.83 | Attention-deficit hyperactivity disorder, its pharmacotherapy, and the risk of developing bipolar disorder: A nationwide population-based study in Taiwan. ( Lee, SY; Lee, TL; Shyu, YC; Wang, LJ; Yang, CJ; Yang, KC; Yuan, SS, 2016) |
| " The primary objective of this study was to determine if a combination of cetirizine + methylphenidate is effective in children with comorbid ADHD and allergic rhinitis." | 3.83 | Attention Deficit Disorder and Allergic Rhinitis: Are They Related? ( Heffron, M; Melamed, I, 2016) |
| "Past research with the spontaneously hypertensive rat (SHR) model of attention deficit/hyperactivity disorder showed that adolescent methylphenidate treatment enhanced cocaine abuse risk in SHR during adulthood." | 3.81 | Methylphenidate treatment beyond adolescence maintains increased cocaine self-administration in the spontaneously hypertensive rat model of attention deficit/hyperactivity disorder. ( Baskin, BM; Dwoskin, LP; Kantak, KM, 2015) |
| "This study investigated whether interictal epileptiform discharges (IED) on a baseline routine EEG in children with ADHD was associated with the occurrence of epileptic seizures (Sz) or influenced the use of methylphenidate (MPH) during 2 years follow-up." | 3.81 | Attention deficit/hyperactivity disorder and interictal epileptiform discharges: it is safe to use methylphenidate? ( Aurlien, D; Herigstad, A; Larsen, TK; Socanski, D; Thomsen, PH, 2015) |
| "To determine via a case-only design whether the use of methylphenidate hydrochloride or atomoxetine hydrochloride reduces the risk of injuries among children and adolescents with ADHD." | 3.81 | Injury prevention by medication among children with attention-deficit/hyperactivity disorder: a case-only study. ( Garbe, E; Horn, J; Langner, I; Lindemann, C; Mikolajczyk, R; Schmedt, N, 2015) |
| "This study estimated the risk of developing psychotic disorders by comparing children with ADHD to non-ADHD controls, and to examine whether methylphenidate (MPH) treatment influences the risks of psychotic disorders." | 3.81 | Attention-deficit/hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia spectrum disorders: A nationwide population-based study in Taiwan. ( Lee, SY; Lee, TL; Shyu, YC; Wang, LJ; Yang, CJ; Yang, KC; Yuan, SS, 2015) |
| " Is this also the case with methylphenidate, an amphetamine-like psychostimulant used in attention-deficit hyperactivity disorder (especially in children) and also in narcolepsy? Cases of pulmonary hypertension and heart valve disease have been reported with methylphenidate, including in children." | 3.81 | Methylphenidate: pulmonary hypertension and heart valve disease. ( , 2015) |
| "The aims of this study were to evaluate the neuropsychological characteristics of the restrictive (R) subtype according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition and the attention-deficit/hyperactivity disorder (ADHD) combined (CB) type and predominantly inattentive (PI) type subtypes and to evaluate whether methylphenidate (MPH) affects neurocognitive test battery scores according to these subtypes." | 3.80 | Effect of methylphenidate on neurocognitive test battery: an evaluation according to the diagnostic and statistical manual of mental disorders, fourth edition, subtypes. ( Ardic, UA; Durak, S; Ercan, E; Ercan, ES; Ipci, M; Yuce, D, 2014) |
| "To retrospectively examine response to stimulant treatment in patients with epilepsy and ADHD symptoms as predicted by seizure freedom for six months, use of methylphenidate (MPH) versus amphetamine (AMP) preparations, cognitive level, and medical records were searched for patients under the age of 18 with epilepsy and ADHD symptoms treated with MPH or AMP (n=36, age=10." | 3.80 | Comparing stimulant effects in youth with ADHD symptoms and epilepsy. ( Azeem, MW; Biederman, J; Bourgeois, B; Gonzalez-Heydrich, J; Gumlak, S; Hickory, M; Hsin, O; Kimball, K; Mezzacappa, E; Mrakotsky, C; Rober, A; Torres, A, 2014) |
| "The aim of this study was to compare the effect of methylphenidate (MPH) versus MPH + parent training in children with ADHD and oppositional defiant disorder/conduct disorder (ODD/CD) over a 12-month period." | 3.80 | No beneficial effects of adding parent training to methylphenidate treatment for ADHD + ODD/CD children: a 1-year prospective follow-up study. ( Ardic, UA; Durak, S; Ercan, ES; Kutlu, A, 2014) |
| "This randomized clinical trial of methylphenidate in children with intellectual disability (ID) by Simonoff et al." | 3.79 | Commentary: Filling out the evidence base for treatment of attention-deficit hyperactivity disorder symptoms in children with intellectual and developmental disability: conclusions for clinicians--a response to Simonoff et al. (2013). ( Eugene Arnold, L, 2013) |
| "The commentary by Arnold (2013) raises a number of interesting issues and speculations about the action of methylphenidate in children with intellectual disability (ID) and associated neurodevelopmental disorders, such as autism spectrum disorders." | 3.79 | Commentary: RCT of optimal dose methylphenidate in children and adolescents with severe ADHD and ID--a reply to Arnold (2013). ( Baird, G; Bernard, S; Simonoff, E; Taylor, E, 2013) |
| "On a behavioral level, we show that boys with epilepsy-related ADHD as well as those with developmental ADHD performed similarly poorly on tasks with high cognitive load when compared to healthy controls, and that intake of methylphenidate improved performance almost to normal levels in both ADHD groups." | 3.78 | Attention-deficit/hyperactivity disorder in childhood epilepsy: a neuropsychological and functional imaging study. ( Bechtel, N; Capone, A; Klarhöfer, M; Kobel, M; Opwis, K; Penner, IK; Scheffler, K; Schmitt-Mechelke, T; Specht, K; Weber, P, 2012) |
| "Cigarette smoking, nicotine replacement therapy, and smokeless tobacco use during pregnancy are associated with cognitive disabilities later in life in children exposed prenatally to nicotine." | 3.78 | Prenatal nicotine exposure mouse model showing hyperactivity, reduced cingulate cortex volume, reduced dopamine turnover, and responsiveness to oral methylphenidate treatment. ( Bhide, PG; Biederman, J; Spencer, TJ; Xu, Y; Zhang, X; Zhu, J, 2012) |
| "An 11-year-old boy with attention deficit/hyperactivity disorder (ADHD) presented with visual hallucinations several years after starting methylphenidate (MPH)." | 3.77 | Methylphenidate-induced visual hallucinations. ( Curatolo, P; Giana, G; Giovinazzo, S; Porfirio, MC, 2011) |
| "A 31-year-old male, diagnosed with schizophrenia and receiving maintenance treatment with olanzapine, was prescribed methylphenidate for comorbid attention deficit hyperactivity disorder (adhd)." | 3.76 | [Antipsychotic agents and stimulants: a judicious combination?]. ( de Jong, MH; Eussen, ML; van Gool, AR, 2010) |
| "There are controversial evidence in the literature on the role of comorbid anxiety disorders (ANX) in the improvement of attention-deficit/hyperactivity disorder (ADHD) symptoms with methylphenidate (MPH) treatment." | 3.75 | Response to methylphenidate in children and adolescents with ADHD: does comorbid anxiety disorders matters? ( Garcia, SP; Guimarães, J; Martinez, AL; Polanczyk, G; Rohde, LA; Zampieri, JF, 2009) |
| "A 15-year-old boy with attention-deficit hyperactivity disorder (ADHD) presented with complex visual hallucinations of rats running around and touching and smelling him soon after receiving a first low dose of methylphenidate." | 3.75 | Methylphenidate induction of complex visual hallucinations. ( Halevy, A; Shuper, A, 2009) |
| "Attention deficit hyperactivity disorder (ADHD) is prevalent in adult cocaine abusers." | 3.73 | Response to cocaine, alone and in combination with methylphenidate, in cocaine abusers with ADHD. ( Collins, SL; Evans, SM; Foltin, RW; Kleber, HD; Levin, FR, 2006) |
| "The aims of this study were to investigate fine motor skills of children with both attention-deficit-hyperactivity disorder (ADHD) and developmental coordination disorder (DCD) and those of a control group, and to examine the effects of methylphenidate on these skills." | 3.73 | Fine motor skills and effects of methylphenidate in children with attention-deficit-hyperactivity disorder and developmental coordination disorder. ( Flapper, BC; Houwen, S; Schoemaker, MM, 2006) |
| "Atomoxetine and OROS methylphenidate were successfully used concomitantly in a 10-year-old boy suffering from attention-deficit/hyperactivity disorder (ADHD) with comorbid bipolar disorder and Tourette syndrome (TS)." | 3.73 | Concomitant use of atomoxetine and OROS-methylphenidate in a 10-year-old child suffering from attention-deficit/hyperactivity disorder with comorbid bipolar disorder and Tourette syndrome. ( Benarroch, F; Gross-Tsur, V; Jaworowski, S, 2006) |
| "In the recent past, psychiatrists and paediatricians have avoided prescribing stimulant medication, such as methylphenidate and dexamphetamine to patients with autism spectrum disorders (ASD) because of both doubts about efficacy and concern that these medications make stereotypies worse." | 3.73 | Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study. ( Baird, G; Gringras, P; Pityaratstian, N; Santosh, PJ; Tavare, E, 2006) |
| "The aim of this study was to assess whether once-daily Concerta extended-release (XR) methylphenidate (MPH) is associated with: (1) better compliance; (2) decreased likelihood of accidents/injuries; and (3) lower health-care resource use over a 1-year period than 3-times-daily immediate-release (IR) MPH in children with attention deficit hyperactivity disorder (ADHD)." | 3.72 | Effect of methylphenidate formulation for attention deficit hyperactivity disorder on patterns and outcomes of treatment. ( Hwang, P; Lage, M, 2004) |
| " The first involves the case of the arthritis drug celecoxib (Celebrex), where the study lasted 12 months but the authors only presented 6 months of data." | 3.72 | Multiple comparisons in drug efficacy studies: scientific or marketing principles? ( Leo, J, 2004) |
| "9 mg/kg methylphenidate loading dose, serial plasma level determinations, self-scored mood ratings, and measures of motor persistence were gathered on eight previously unmedicated boys with attention deficit disorder with hyperactivity (ADHD) during a 9-h period." | 3.71 | Correlations between motor persistence and plasma levels in methylphenidate-treated boys with ADHD. ( Curran, S; Feldman, B; Gardner, R; Greenhill, LL; Perel, JM; Puig-Antich, J; Rudolph, G, 2001) |
| "Attention-deficit/hyperactivity disorder (ADHD) is common among cocaine abusers seeking treatment." | 3.70 | Methylphenidate treatment for cocaine abusers with adult attention-deficit/hyperactivity disorder: a pilot study. ( Evans, SM; Kleber, HD; Levin, FR; McDowell, DM, 1998) |
| " We report two cases of an adverse effect of dyskinesia and bruxism when MPH was given to children maintained on valproic acid." | 3.70 | Adverse response to methylphenidate in combination with valproic acid. ( Gara, L; Roberts, W, 2000) |
| " Methylphenidate hydrochloride ('Ritalin') was the prescribers' most popular agent and 'narcolepsy' was the most frequently cited clinical indication for psychostimulants." | 3.70 | Psychostimulants and psychiatrists: the Trent Adult Psychiatry Psychostimulant Survey. ( Bramble, D, 2000) |
| "Methylphenidate (MPH; Ritalin: methyl-alpha-phenyl-2-piperidinacetate hydrochloride) is utilized for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy." | 3.70 | Liquid-liquid extraction using 96-well plate format in conjunction with liquid chromatography/tandem mass spectrometry for quantitative determination of methylphenidate (Ritalin) in human plasma. ( Bakhtiar, R; Ramos, L; Tse, FL, 2000) |
| "This study used data from a completed longitudinal study to examine the effects of methylphenidate on 6-12-year-old boys presumably at risk for bipolar disorder." | 3.70 | Stimulant treatment in young boys with symptoms suggesting childhood mania: a report from a longitudinal study. ( Arthur, C; Carlson, GA; Kramer, JR; Loney, J; Salisbury, H, 2000) |
| "We report a patient who developed paroxysmal kinesigenic dystonia shortly after initiation of therapy with methylphenidate for presumed attention deficit-hyperactivity disorder." | 3.69 | Paroxysmal kinesigenic dystonia after methylphenidate administration. ( Gay, CT; Ryan, SG, 1994) |
| "We report difficulty with conscious sedation of a child taking methylphenidate for attention deficit disorder and possible delayed adverse interaction of ketamine and methylphenidate resulting in severe nausea, vomiting and dehydration." | 3.69 | Unexpected interaction of methylphenidate (Ritalin) with anaesthetic agents. ( Fox, L; Ririe, DG; Ririe, KL; Sethna, NF, 1997) |
| "This case describes the beneficial effect on the binge eating component of bulimia nervosa of methylphenidate, which was prescribed to treat comorbid attention-deficit/hyperactivity disorder." | 3.69 | Efficacy of methylphenidate in bulimia nervosa comorbid with attention-deficit hyperactivity disorder: a case report. ( Moskowitz, A; Schweickert, LA; Strober, M, 1997) |
| "High and low-aggressive boys with attention deficit-hyperactivity disorder (ADHD) were compared and the effects of methylphenidate were examined on measures from three domains of aggression: (1) directly observed verbal and nonverbal aggressive behaviors exhibited in the context of a day treatment program, (2) aggressive responding when provoked during a laboratory task, and (3) social information processing patterns exhibited on tasks designed to tap the putative cognitive components of aggression." | 3.68 | Aggression in boys with attention deficit-hyperactivity disorder: methylphenidate effects on naturalistically observed aggression, response to provocation, and social information processing. ( Lang, AR; Murphy, DA; Pelham, WE, 1992) |
| "The onset, duration, and offset of pemoline action to improve cognitive performance is examined intensively in 25 prepubescent males suffering from attention-deficit disorder with hyperactivity (ADDH)." | 3.68 | Pharmacodynamics of pemoline in attention deficit disorder with hyperactivity. ( Perel, JM; Sallee, FR; Stiller, RL, 1992) |
| " These cases were selected from a prior quantitative study in which three antihistamines (meclizine, cyclizine, dimenhydrinate) and three stimulants (pemoline, methylphenidate, dextroamphetamine) were tested in variable combinations (using a specific clinical method) for favorable responses by 100 children characterized by diagnostic evidence of learning disabilities and cerebellar-vestibular dysfunctioning." | 3.68 | Dramatic favorable responses of children with learning disabilities or dyslexia and attention deficit disorder to antimotion sickness medications: four case reports. ( Levinson, HN, 1991) |
| "We investigated the effects of background anger, provocation, and methylphenidate on emotional, physiological, and behavioral responding in children with attention-deficit hyperactivity disorder (ADHD) with and without concurrent aggression." | 3.68 | Effects of background anger, provocation, and methylphenidate on emotional arousal and aggressive responding in attention-deficit hyperactivity disordered boys with and without concurrent aggressiveness. ( Cummings, EM; Greiner, AR; Milich, R; Murphy, DA; Pelham, WE; Schaughency, EA, 1991) |
| "A case is reported of a young woman with attention deficit disorder and concomitant borderline personality disorder who was successfully treated with methylphenidate." | 3.67 | Treatment of attention deficit and borderline personality disorders with psychostimulants: case report. ( Hooberman, D; Stern, TA, 1984) |
| "Growth hormone (GH) and 3-methoxy-4-hydroxyphenelethylene glycol (MHPG) response was measured hourly for 4 hours in 8 children with Attention Deficit Disorder with Hyperactivity (ADD+H) following an acute single-dose of clonidine." | 3.67 | Possible change in noradrenergic receptor sensitivity following methylphenidate treatment: growth hormone and MHPG response to clonidine challenge in children with attention deficit disorder and hyperactivity. ( Anderson, G; Clark, L; Cohen, DJ; Hunt, RD, 1984) |
| "Effects of methylphenidate on measures related to reading were studied in a group of nine boys who had attention deficit disorder with hyperactivity; a double-blind crossover design using active drug and placebo was used." | 3.67 | Effects of methylphenidate on reading in children with attention deficit disorder. ( Ballinger, CT; Nolen, PA; Varley, CK, 1984) |
| "To test the hypothesis that any change in urinary noradrenergic excretion accompanies drug-induced improvement in attention deficit disorder with hyperactivity, the authors gave pemoline (mean dose, 2." | 3.67 | Pemoline and urinary excretion of catecholamines and indoleamines in children with attention deficit disorder. ( Karoum, F; Linnoila, M; Sallee, R; Zametkin, AJ, 1986) |
| "Children with attention deficit disorder with hyperactivity were given either methylphenidate hydrochloride or dextroamphetamine sulfate to compare the effects on urinary excretion of catecholamines, indoleamines, and phenylethylamine (PEA)." | 3.67 | Stimulants, urinary catecholamines, and indoleamines in hyperactivity. A comparison of methylphenidate and dextroamphetamine. ( Brown, GL; Chuang, LW; Karoum, F; Linnoila, M; Rapoport, JL; Wyatt, RJ; Zametkin, AJ, 1985) |
| "Methylphenidate is widely used in the treatment of school-age children with attention deficit disorder with hyperactivity (ADDH)." | 3.67 | Sustained release methylphenidate: pharmacokinetic studies in ADDH males. ( Birmaher, B; Cooper, TB; Fried, J; Greenhill, LL; Maminski, B, 1989) |
| "High-affinity [3H]imipramine binding to platelets was investigated in 11 boys with attention deficit disorder and hyperactivity (ADDH) before and after 28 days of methylphenidate (MPH) treatment, and the results were compared to [3H]imipramine binding parameters (Kd, Bmax) of 10 age-matched normal boys." | 3.67 | Imipramine binding to platelets of children with attention deficit disorder with hyperactivity. ( Bernhout, E; Rehavi, M; Tyano, S; Weitz, R; Weizman, A, 1988) |
| " methylphenidate (MPH) challenge on beta-endorphin (beta-EP), growth hormone (GH), prolactin (Prl) and cortisol was investigated in 16 children suffering from attention deficit disorder with hyperactivity (ADDH) before and after 4 weeks MPH treatment." | 3.67 | Effects of acute and chronic methylphenidate administration on beta-endorphin, growth hormone, prolactin and cortisol in children with attention deficit disorder and hyperactivity. ( Dick, J; Gil-Ad, I; Laron, Z; Tyano, S; Weitz, R; Weizman, R, 1987) |
| "Children with attention deficit disorder with hyperactivity were treated with methylphenidate HCl (0." | 3.67 | The effect of methylphenidate on urinary catecholamine excretion in hyperactivity: a partial replication. ( Hamburger, SD; Zametkin, AJ, 1988) |
| "This study examined whether methylphenidate normalizes the behavior of hyperactive children (ADDH)." | 3.67 | The normalizing effects of methylphenidate on the classroom behavior of ADDH children. ( Abikoff, H; Gittelman, R, 1985) |
| "A case is presented in which a hyperactive child with secondary enuresis had a dramatic response to both syndromes of methylphenidate therapy." | 3.66 | Enuresis: a new look at stimulant therapy. ( Diamond, JM; Stein, JM, 1983) |
| "In a child with minimal brain dysfunction, we found that chorea was related to the major central effect of methylphenidate and probably to the effect of the drug on central catecholaminergic systems." | 3.66 | Methylphenidate-induced chorea: case report and pharmacologic implications. ( Klawans, HL; Nausieda, PA; Weiner, WJ, 1978) |
| "Methylphenidate is a first-line treatment for ADHD; its contribution to sleep problems in adult ADHD is currently unclear." | 3.30 | Effects of methylphenidate on subjective sleep parameters in adults with ADHD: a prospective, non-randomized, non-blinded 6-week trial. ( Fagerlund, B; Glenthøj, B; Habekost, T; Jepsen, JRM; le Sommer, J; Low, AM; Vangkilde, S, 2023) |
| " Further research is needed to evaluate effects of higher average dosing and adherence to treatment, multi-modal treatments and preventative interventions in the community." | 3.30 | Randomised controlled trial of the short-term effects of osmotic-release oral system methylphenidate on symptoms and behavioural outcomes in young male prisoners with attention deficit hyperactivity disorder: CIAO-II study. ( Asherson, PJ; Bedding, M; Forrester, A; Giannulli, L; Ginsberg, Y; Holland, R; Howitt, S; Johansson, L; Kelly, C; Khan, K; Kretzschmar, I; Landau, S; Lawrie, SM; Mansfield, M; Marsh, C; McCafferty, C; Müller-Sedgwick, U; Strang, J; Thomson, LDG; Williamson, G; Wilson, L; Young, S, 2023) |
| "Methylphenidate, a first-line treatment for attention-deficit/hyperactivity disorder (ADHD), is thought to influence dopaminergic neurotransmission in the nucleus accumbens (NAc) and its associated brain circuitry, but this hypothesis has yet to be systematically tested." | 3.30 | Methylphenidate Enhances Spontaneous Fluctuations in Reward and Cognitive Control Networks in Children With Attention-Deficit/Hyperactivity Disorder. ( Cai, W; Makita, K; Menon, V; Mizuno, Y; Silk, TJ; Supekar, K; Takiguchi, S; Tomoda, A, 2023) |
| " Results underscore the need to consider dosing as well as parent preference when utilizing combined treatment approaches." | 3.30 | Single and Combined Effects of Multiple Intensities of Behavioral Modification and Methylphenidate for Children with ADHD in the Home Setting. ( Burrows-MacLean, L; Chacko, A; Coles, EK; Fabiano, GA; Garefino, A; Gnagy, EM; Macphee, FL; Massetti, GM; Merrill, BM; Pelham, WE; Robb Mazzant, J; Walker, K; Waschbusch, DA; Waxmonsky, JG; Wymbs, BT; Wymbs, F, 2023) |
| "Methylphenidate is a widely used and effective treatment for attention-deficit/hyperactivity disorder (ADHD), yet the underlying neural mechanisms and their relationship to changes in behavior are not fully understood." | 3.30 | Bayesian dynamical system analysis of the effects of methylphenidate in children with attention-deficit/hyperactivity disorder: a randomized trial. ( Cai, W; Menon, V; Mizuno, Y; Tomoda, A, 2023) |
| " The syrup dosage is 5cc every 8 h, and MP will have a stabilized dose for 8 weeks during the study." | 3.11 | The effect of Rosa canina L. and a polyherbal formulation syrup in patients with attention-deficit/hyperactivity disorder: a study protocol for a multicenter randomized controlled trial. ( Abniki, E; Bahrami, M; Dadmehr, M; Golsorkhi, H; Kamalinejad, M; Montazerlotfelahi, H; Qorbani, M; Sabbaghzadegan, S; Vafaee-Shahi, M, 2022) |
| "Methylphenidate is a widely used first-line treatment for attention deficit/hyperactivity disorder (ADHD), but the underlying circuit mechanisms are poorly understood." | 3.11 | Methylphenidate remediates aberrant brain network dynamics in children with attention-deficit/hyperactivity disorder: A randomized controlled trial. ( Cai, W; Makita, K; Menon, V; Mizuno, Y; Supekar, K; Takiguchi, S; Tomoda, A, 2022) |
| "Methylphenidate and placebo were titrated to a maximum dose of 1·25 mg/kg per day administered orally twice daily, and behavioural parent training and the educational intervention were delivered weekly through 90 min sessions with both the child and parent, conducted by two psychologists or learning therapists." | 3.11 | Efficacy and safety of methylphenidate and behavioural parent training for children aged 3-5 years with attention-deficit hyperactivity disorder: a randomised, double-blind, placebo-controlled, and sham behavioural parent training-controlled trial. ( Dalmaso, BB; de Morais, EM; de Sousa Gurgel, W; Del Prette, G; Leibenluft, E; Pilatti, CD; Polanczyk, GV; Rohde, LA; Salum, GA; Sugaya, LS, 2022) |
| " The most frequent adverse events during dose optimization were headache, decreased appetite, and insomnia." | 3.11 | Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adult Laboratory Classroom Study of the Efficacy and Safety of PRC-063 (Extended-Release Methylphenidate) for the Treatment of ADHD. ( Bhaskar, S; Childress, A; Cutler, AJ; Donnelly, G; Marraffino, AH, 2022) |
| " The result showed no significant difference comparing PRC-063 with placebo in serious treatment-emergent adverse events (TEAEs) (RR = 0." | 3.01 | Efficacy and Safety of PRC-063 for Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-analysis From Randomized Controlled Trials. ( Chen, G; Gao, H; Wang, J; Wang, T; Yang, S; Yu, Z; Zhu, S, 2023) |
| "Methylphenidate treatment may lower the risk of all-cause fractures from both study designs; however, further evidence is needed about the treatment duration and sex effect." | 3.01 | Treatment with methylphenidate and the risk of fractures among children and young people: A systematic review and self-controlled case series study. ( Cheung, CL; Coghill, D; Fan, M; Gao, L; Ge, GMQ; Ip, P; Lau, WCY; Man, KKC; Wong, ICK; Wong, KHTW, 2023) |
| "Methylphenidate treatment duration ranged from 1 to 425 days, with a mean duration of 28." | 3.01 | Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). ( Callesen, HE; Darling Rasmussen, P; Gluud, C; Groth, C; Huus, CL; Kirubakaran, R; Pereira Ribeiro, J; Schaug, JP; Simonsen, E; Skoog, M; Storebø, OJ; Storm, MRO; Zwi, M, 2023) |
| " It is important that future research addresses the current weaknesses in this area, which include small sample sizes, variability of selection criteria, variability of the type and dosage of supplementation, and short follow-up times." | 3.01 | Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents. ( Gillies, D; Leach, MJ; Perez Algorta, G, 2023) |
| "Selegiline is an irreversible, selective type-B monoamine oxidase inhibitor (MAOI) approved for Parkison's disease-oral and major depressive disorder-transdermal formulation) resulting in non-selective MAOI activity at oral doses≥20 mg/day." | 3.01 | Efficacy and safety of selegiline across different psychiatric disorders: A systematic review and meta-analysis of oral and transdermal formulations. ( Birkenhager, TK; Caiazza, C; Cattaneo, CI; de Bartolomeis, A; Fornaro, M; Gillman, K; Iasevoli, F; Rossano, F; Ruhé, HG; Sobrino, A; Solini, N; Stahl, S; Van den Eynde, V; Vellucci, A; Zotti, N, 2023) |
| "Nicotine has been less widely studied with alternative ADHD pharmacotherapy bupropion, but we also discuss this research." | 3.01 | The co-use of nicotine and prescription psychostimulants: A review of their behavioral and neuropharmacological interactions. ( Bevins, RA; McNealy, KR; Weyrich, L, 2023) |
| " Further investigations containing larger sample sizes, longer supplementation periods, and dose-response evaluations are required to replicate these findings in ADHD children more confidently." | 3.01 | Resveratrol adjunct to methylphenidate improves symptoms of attention-deficit/hyperactivity disorder: a randomized, double-blinded, placebo-controlled clinical trial. ( Akhondzadeh, S; Ashraf-Ganjouei, A; Bagheri, S; Mohammadi, MR; Moradi, K; Rafeiy-Torghabeh, M, 2021) |
| "Adverse event rates for insomnia (15." | 3.01 | Effect of a Multi-Layer, Extended-Release Methylphenidate Formulation (PRC-063) on Sleep in Adults with ADHD: A Randomized, Double-Blind, Forced-Dose, Placebo-Controlled Trial Followed by a 6-month Open-Label Extension. ( Cataldo, M; Donnelly, G; He, E; Khullar, A; Surman, C; Weiss, MD, 2021) |
| "Methylphenidate (MPH) is an important drug that modulates the catecholaminergic system." | 2.94 | Task experience eliminates catecholaminergic effects on inhibitory control - A randomized, double-blind cross-over neurophysiological study. ( Beste, C; Mückschel, M; Roessner, V, 2020) |
| " Among 433 randomized patients, adverse events (AEs) were documented and analyzed on an "as received" basis during week 0-52." | 2.94 | Safety Profile of Methylphenidate Under Long-Term Treatment in Adult ADHD Patients - Results of the COMPAS Study. ( Abdel-Hamid, M; Alm, B; Berger, M; Borel, P; Colla, M; Graf, E; Heßmann, P; Huss, M; Jacob, C; Jans, T; Kis, B; Lücke, C; Matthies, S; Müller, HHO; Philipsen, A; Retz, W; Rösler, M; Sobanski, E; van Elst, LT, 2020) |
| "Methylphenidate was associated with greater improvements in Aggressive Behavior and Somatic Complaints of CBCL and in Conduct subscale of self-reported SDQ at week 24 compared with atomoxetine." | 2.90 | Comparative Efficacy of Methylphenidate and Atomoxetine on Emotional and Behavioral Problems in Youths with Attention-Deficit/Hyperactivity Disorder. ( Gau, SS; Shang, CY; Shih, HH, 2019) |
| " The objectives were to evaluate DR/ER-MPH pharmacokinetic (PK) properties in healthy adults, including dose proportionality, food effect, the potential of accumulation using multiple-dose modeling, and bioavailability compared to an immediate-release MPH (IR MPH)." | 2.90 | Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate: Evaluation of Dose Proportionality, Food Effect, Multiple-Dose Modeling, and Comparative Bioavailability with Immediate-Release Methylphenidate in Healthy Adults. ( DeSousa, NJ; Gobburu, JVS; Incledon, B; Liu, T; McLean, A; Po, MD; Sallee, FR, 2019) |
| "The benefits of long-term use of methylphenidate treatment in children and adolescents with attention deficit hyperactivity disorder (ADHD), as frequently prescribed in clinical practice, are unclear." | 2.90 | Continued Benefits of Methylphenidate in ADHD After 2 Years in Clinical Practice: A Randomized Placebo-Controlled Discontinuation Study. ( Bierens, M; Buitelaar, JK; Dietrich, A; Hoekstra, PJ; Kleine Deters, R; Matthijssen, AM; van de Loo-Neus, GHH; van den Hoofdakker, BJ, 2019) |
| " The frequencies of adverse events were similar between the two groups." | 2.90 | Efficacy and safety of tipepidine as adjunctive therapy in children with attention-deficit/hyperactivity disorder: Randomized, double-blind, placebo-controlled clinical trial. ( Akhondzadeh, S; Bagheri, S; Dehbozorghi, S; Mohammadi, MR; Moradi, K; Shokraee, K, 2019) |
| "6 mg/kg of immediate-release MPH dosed TID)." | 2.87 | How do stimulant treatments for ADHD work? Evidence for mediation by improved cognition. ( Colder, CR; Fosco, WD; Hawk, LW; Pelham, WE; Rosch, KS; Waxmonsky, JG, 2018) |
| " This analysis sought to develop a population pharmacokinetic (PK)/pharmacodynamic (PD) model to describe MPH XR-ODT PD-response data in a classroom study and use the model to simulate PD responses for a range of body weights and doses." | 2.87 | Population Pharmacokinetic-Pharmacodynamic Modeling of a Novel Methylphenidate Extended-Release Orally Disintegrating Tablet in Pediatric Patients With Attention-Deficit/Hyperactivity Disorder. ( Engelking, D; McMahen, R; Sikes, CR; Teuscher, NS, 2018) |
| " The average dosage of MPH in the group with ADHD was 0." | 2.84 | Empathy and Facial Expression Recognition in Children With and Without Attention-Deficit/Hyperactivity Disorder: Effects of Stimulant Medication on Empathic Skills in Children with Attention-Deficit/Hyperactivity Disorder. ( Gokce, S; Gumustas, F; Sabuncuoglu, O; Yilmaz, I; Yulaf, Y, 2017) |
| " Safety assessments included adverse event (AE) monitoring and the Columbia-Suicide Severity Rating Scale (C-SSRS)." | 2.84 | Efficacy and Safety of a Chewable Methylphenidate Extended-Release Tablet in Children with Attention-Deficit/Hyperactivity Disorder. ( Belden, H; Berry, SA; Chappell, P; Childress, A; Orazem, J; Palumbo, D; Sherman, N; Walters, F; Wigal, SB, 2017) |
| "Methylphenidate has prominent effects in the dopamine-rich striatum that are absent for the selective norepinephrine transporter inhibitor atomoxetine." | 2.84 | Striatal Activation Predicts Differential Therapeutic Responses to Methylphenidate and Atomoxetine. ( Bédard, AV; Fan, J; Halperin, JM; Hildebrandt, TB; Ivanov, I; Newcorn, JH; Schulz, KP; Stein, MA, 2017) |
| " Safety measures included spontaneously reported treatment-emergent adverse events (TEAEs) and two TEAEs of special interest, appetite suppression and insomnia (with direct questioning on sleep disturbance)." | 2.84 | Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder. ( Arnold, VK; Bostrom, S; Cutler, AJ; DeSousa, NJ; Incledon, B; López, FA; Marraffino, A; Newcorn, JH; Pliszka, SR; Sallee, FR; Wilens, TE, 2017) |
| " Adverse events were numerically less frequent with Omega-3/6 or MPH + Omega-3/6 than MPH alone." | 2.84 | Efficacy and Safety of Omega-3/6 Fatty Acids, Methylphenidate, and a Combined Treatment in Children With ADHD. ( Barragán, E; Breuer, D; Döpfner, M, 2017) |
| " Safety assessments included adverse events (AEs), physical examinations, electrocardiograms (ECGs), and the Columbia Suicide Severity Rating Scale (C-SSRS)." | 2.84 | Efficacy, Safety, and Tolerability of an Extended-Release Orally Disintegrating Methylphenidate Tablet in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder in the Laboratory Classroom Setting. ( Childress, AC; Cutler, AJ; Kollins, SH; Marraffino, A; Sikes, CR, 2017) |
| "OROS methylphenidate-treated subjects exhibited a significantly greater mean (SD) AISRS score improvement than placebo subjects (-17." | 2.84 | Randomized, 6-Week, Placebo-Controlled Study of Treatment for Adult Attention-Deficit/Hyperactivity Disorder: Individualized Dosing of Osmotic-Release Oral System (OROS) Methylphenidate With a Goal of Symptom Remission. ( Armstrong, RB; Ascher, S; Goodman, DW; Ma, YW; Rostain, AL; Starr, HL, 2017) |
| "Methylphenidate was superior to placebo in improving ADHD symptoms and a broad range of neurocognitive functions; however, effects sizes regarding the effects of dose vary substantially between functions." | 2.82 | Meta-analysis: Dose-Dependent Effects of Methylphenidate on Neurocognitive Functioning in Children With Attention-Deficit/Hyperactivity Disorder. ( Bet, P; de Vries, R; Luman, M; Oosterlaan, J; Staff, A; Twisk, J; Vertessen, K, 2022) |
| " Trials of amphetamines, atomoxetine, bupropion, clonidine, guanfacine, methylphenidate, and modafinil with a placebo arm and reporting data on headache as an adverse event, were included." | 2.82 | Headache in ADHD as comorbidity and a side effect of medications: a systematic review and meta-analysis. ( Banaschewski, T; Bölte, S; Buitelaar, JK; Coghill, D; Cortese, S; Häge, A; Hohmann, S; Jonsson, U; Nobel Norrman, H; Pan, PY; Şahpazoğlu Çakmak, SS, 2022) |
| " However, robust evidence-base regarding the effects of doses and dosing strategies of stimulants on clinical outcomes in the treatment of children/adolescents with ADHD is currently lacking and stimulants are often underdosed in clinical practice." | 2.82 | The effects of stimulant dose and dosing strategy on treatment outcomes in attention-deficit/hyperactivity disorder in children and adolescents: a meta-analysis. ( Avila-Quintero, VJ; Behling, E; Bloch, MH; Cortese, S; Farhat, LC; Flores, JM; Lombroso, A; Polanczyk, GV, 2022) |
| "Methylphenidate (MPH) is a central nervous system (CNS) stimulant known for its effectiveness in the treatment of Attention Deficit Hyperactivity Disorder (ADHD), a neuropsychiatric condition that has a high incidence in childhood and affects behavior and cognition." | 2.82 | Evidence of methylphenidate effect on mitochondria, redox homeostasis, and inflammatory aspects: Insights from animal studies. ( Foschiera, LN; Schmitz, F; Wyse, ATS, 2022) |
| " In general, both stimulants are rapidly absorbed with relatively poor bioavailability and short half-lives." | 2.82 | The Pharmacokinetics and Pharmacogenomics of Psychostimulants. ( Markowitz, JS; Melchert, PW, 2022) |
| "Attention Deficit Hyperactivity Disorder is a neurodevelopmental disorder with three presentations: inattentive, hyperactive/impulsive and combined." | 2.82 | Therapeutic Approaches for ADHD by Developmental Stage and Clinical Presentation. ( Beltran-Navarro, B; Galvez-Contreras, AY; Gonzalez-Castaneda, RE; Gonzalez-Perez, O; Vargas-de la Cruz, I, 2022) |
| "Methylphenidate is a drug widely prescribed to treat ADHD." | 2.82 | "Real-world" effectiveness of methylphenidate in improving the academic achievement of Attention-Deficit Hyperactivity Disorder diagnosed students-A systematic review. ( da Silveira, VT; de Faria, JCM; Duarte, LJR; Ferreira, LA; Menezes de Pádua, C; Perini, E, 2022) |
| "Methylphenidate was titrated using a double-blind placebo controlled procedure in 6 weeks, followed by a stable dose for 4 weeks." | 2.82 | A randomized controlled trial into the effects of neurofeedback, methylphenidate, and physical activity on EEG power spectra in children with ADHD. ( Bink, M; Geladé, K; Janssen, TW; Maras, A; Oosterlaan, J; van Mourik, R, 2016) |
| "To determine the pharmacokinetic (PK) profile of a proprietary formulation of methylphenidate (MPH) in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) in a phase 1 study." | 2.82 | A Single-Dose, Single-Period Pharmacokinetic Assessment of an Extended-Release Orally Disintegrating Tablet of Methylphenidate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. ( Childress, A; McMahen, R; Newcorn, J; Sikes, C; Stark, JG; Tengler, M, 2016) |
| "There was a trend for less insomnia in the agomelatine group versus MPH-treated group (4% vs." | 2.82 | Agomelatine as a Treatment for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: A Double-Blind, Randomized Clinical Trial. ( Akhondzadeh, S; Khiabany, M; Kohi, A; Mohammadi, MR; Mohammadinejad, P; Salardini, E; Shahriari, M; Zeinoddini, A, 2016) |
| "The aim of this study was to assess the type and frequency of adverse events (AEs) in children with attention-deficit/hyperactivity disorder (ADHD) treated with methylphenidate or atomoxetine over a 5-year period in a large naturalistic study." | 2.80 | Safety of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): Data from the Italian National ADHD Registry. ( Arcieri, R; Capuano, A; Chiarotti, F; Cortese, S; Curatolo, P; Germinario, EA; Margari, L; Panei, P, 2015) |
| "Lisdexamfetamine dimesylate (LDX) is a long-acting, prodrug stimulant therapy for patients with attention-deficit/hyperactivity disorder (ADHD)." | 2.79 | Efficacy of lisdexamfetamine dimesylate throughout the day in children and adolescents with attention-deficit/hyperactivity disorder: results from a randomized, controlled trial. ( Banaschewski, T; Bloomfield, R; Civil, R; Coghill, DR; Dittmann, RW; Lecendreux, M; Otero, IH; Squires, LA; Zuddas, A, 2014) |
| " Simulations using the fitted parameters determined how changes in fast absorption rate constant k0fast, and slow absorption rate constant KAslow affected curve shape and BE determination using Cmax, AUCINF and PAUC." | 2.79 | Impact of release mechanism on the pharmacokinetic performance of PAUC metrics for three methylphenidate products with complex absorption. ( Jackson, A, 2014) |
| "Methylphenidate treatment reduces attention deficit hyperactivity disorder symptoms and the risk for relapse to substance use in criminal offenders with attention deficit hyperactivity disorder and substance dependence." | 2.79 | Methylphenidate for attention deficit hyperactivity disorder and drug relapse in criminal offenders with substance dependence: a 24-week randomized placebo-controlled trial. ( Beck, O; Franck, J; Guterstam, J; Jayaram-Lindström, N; Konstenius, M; Philips, B, 2014) |
| " Although treatment-emergent adverse events were reported more frequently in the OROS MPH group (81." | 2.79 | A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of osmotic-controlled release oral delivery system methylphenidate HCl in adults with attention-deficit/hyperactivity disorder in Japan. ( Kashimoto, Y; Koh, T; Matsumura, T; Saito, Y; Takahashi, N; Tominaga, Y, 2014) |
| "The purpose of this study was to investigate whether the availability of both dextroamphetamine and methylphenidate provides an opportunity to minimize adverse events in a pediatric attention-deficit/hyperactivity disorder (ADHD) stimulant trial." | 2.79 | Minimizing adverse events while maintaining clinical improvement in a pediatric attention-deficit/hyperactivity disorder crossover trial with dextroamphetamine and methylphenidate. ( Aabech, HS; Ramtvedt, BE; Sundet, K, 2014) |
| " Adverse events (AEs) and serious adverse events (SAEs) were reported at the end of extension study for events monitored from (1) maintenance of effect phase baseline (core study; 12 months) and (2) extension study baseline (6 months)." | 2.79 | Long-term (1 year) safety and efficacy of methylphenidate modified-release long-acting formulation (MPH-LA) in adults with attention-deficit hyperactivity disorder: a 26-week, flexible-dose, open-label extension to a 40-week, double-blind, randomised, pla ( Arngrim, T; Chen, CW; Gandhi, P; Ginsberg, Y; Huss, M; Kumar, V; Philipsen, A, 2014) |
| "Lisdexamfetamine dimesylate (LDX) is a long-acting prodrug stimulant for the treatment of attention-deficit/hyperactivity disorder (ADHD)." | 2.78 | Efficacy and safety of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder and recent methylphenidate use. ( Adeyi, B; Babcock, T; Burtea, T; Dirks, B; Duncan, D; Jain, R; Lasser, R; Renna, J; Scheckner, B, 2013) |
| "We explored two different methods of determining adverse events (AEs) among methylphenidate (MPH)-treated adolescents with attention-deficit/hyperactivity disorder (ADHD)." | 2.78 | Two different solicitation methods for obtaining information on adverse events associated with methylphenidate in adolescents: a 12-week multicenter, open-label study. ( Choi, J; Hong, SD; Joung, YS; Kim, JH; Lee, MS; Lee, SI, 2013) |
| "Methylphenidate was individually titrated to an optimal dose." | 2.77 | Prepotent response inhibition predicts treatment outcome in attention deficit/hyperactivity disorder. ( Emmelkamp, PM; Geurts, HM; Oosterlaan, J; Prins, PJ; van der Oord, S, 2012) |
| "There was no difference in days of substance use or ADHD symptom outcomes over time in adolescents with MDD or those without MDD treated with OROS-MPH or placebo." | 2.77 | Major depression and treatment response in adolescents with ADHD and substance use disorder. ( Mikulich-Gilbertson, SK; Min, SJ; Riggs, PD; Tamm, L; Trello-Rishel, K; Warden, D; Winhusen, T, 2012) |
| "5 hr before dosing and 1, 2, 4, 10, 11, and 12." | 2.77 | Time course of treatment effect of OROS® methylphenidate in children with ADHD. ( Armstrong, RB; Ascher, S; Damaraju, CV; O'Neill, J; Schwarzman, L; Starr, HL, 2012) |
| "OROS-MPH treatment at the adequate dosage can achieve higher remission and recovery rates, produce greater functional improvement, and result in better treatment adherence than IR-MPH treatment." | 2.77 | Naturalistic exploration of the effect of osmotic release oral system-methylphenidate on remission rate and functional improvement in Taiwanese children with attention-deficit-hyperactivity disorder. ( Chang, HL; Cheng, H; Hsu, CD; Hsu, YC; Huang, CF; Huang, YF; Huang, YH; Huang, YS; Liang, HY; Liu, HC; Liu, HJ; Liu, SI; Pan, CH; Tzang, RF; Wang, YC; Wu, YY; Yang, PC; Yeh, CB, 2012) |
| " The two lower dosages showed a good tolerability profile, but the higher dosage of bavisant was less well tolerated, as evidenced by the incidence of total TEAEs (61." | 2.77 | Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder. ( Cooper, K; Daly, EJ; Gassmann-Mayer, C; Pandina, GJ; Weisler, RH, 2012) |
| " Outcomes continued to improve during the subsequent 47-week open-label extension with OROS-methylphenidate delivered at a flexible daily dosage of up to 1." | 2.77 | Long-term functional outcome in adult prison inmates with ADHD receiving OROS-methylphenidate. ( Ginsberg, Y; Grann, M; Hirvikoski, T; Lindefors, N, 2012) |
| "The purpose of this study was to identify the optimal dose of osmotic release oral system methylphenidate (OROS-MPH) using a dosage forced-titration scheme to achieve symptomatic remission in children with attention- deficit/hyperactivity disorder (ADHD)." | 2.77 | Remission in children and adolescents diagnosed with attention-deficit/hyperactivity disorder via an effective and tolerable titration scheme for osmotic release oral system methylphenidate. ( Chan, CH; Chang, HL; Chen, SJ; Chen, YS; Chou, MC; Chou, WJ; Hou, PH; Hsu, JW; Huang, CF; Huang, YF; Huang, YS; Hwang, KL; Liang, HY; Lin, CC; Lin, DY; Liu, HJ; Pan, CH; Tang, CS; Wu, YY; Yeh, CB, 2012) |
| "Bupropion has a comparable safety and efficacy profile with methylphenidate in children and adolescents with ADHD." | 2.77 | Bupropion versus methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder: randomized double-blind study. ( Akhondzadeh, S; Ashrafi, M; Jafarinia, M; Khajavi, D; Modabbernia, A; Mohammadi, MR; Tabrizi, M; Yadegari, N, 2012) |
| " Dosing began at 36 mg/d, with titration in 18-mg increments every 7 days until a predefined outcome (efficacy threshold, maximum dosage of 108 mg/d, or limiting adverse event)." | 2.76 | Long-term safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: an open-label, dose-titration, 1-year study. ( Adler, LA; Berwaerts, J; Cooper, K; Harrison, DD; Orman, C; Palumbo, J; Silber, S; Starr, HL, 2011) |
| "Nicotine withdrawal was not found to differ significantly between treatment groups during the first 14 days following the start of medication prior to the target quit date (p = 0." | 2.76 | Methylphenidate for treating tobacco dependence in non-attention deficit hyperactivity disorder smokers: a pilot randomized placebo-controlled trial. ( Croghan, IT; Ebbert, JO; Hays, JT; Hurt, RD; Schroeder, DR; Sood, A, 2011) |
| " After determining individualized OROS MPH dosing (18-54 mg/day), 71 subjects received blinded treatment (OROS MPH or placebo then vice versa) on each of 2 laboratory school days, separated by 1 week." | 2.76 | Academic, behavioral, and cognitive effects of OROS® methylphenidate on older children with attention-deficit/hyperactivity disorder. ( Armstrong, RB; Brams, M; Schuck, S; Starr, HL; Wigal, SB; Wigal, T; Williamson, D, 2011) |
| "The side effect profile as assessed by the SERS was similar to that of previous studies with insomnia, decreased appetite, and headaches showing significant treatment effects (p < 0." | 2.76 | Relation between therapeutic response and side effects induced by methylphenidate as observed by parents and teachers of children with ADHD. ( Bhat, V; Grizenko, N; Joober, R; Lee, J; Polotskaia, A; Sengupta, S, 2011) |
| "Methylphenidate (MPH) is an efficient treatment to reduce behavioral symptoms of attention-deficit/hyperactivity disorder (ADHD); however, its impact on cognitive functioning has not been sufficiently demonstrated so far." | 2.76 | Effects of methylphenidate on intelligence and attention components in boys with attention-deficit/hyperactivity disorder. ( Daseking, M; Goldbeck, L; Hellwig-Brida, S; Keller, F; Petermann, F, 2011) |
| "To examine the pharmacokinetics (PKs) and pharmacodynamics (PDs) of OROS methylphenidate (OROS MPH) dosed once daily (QD) versus an early standard regimen (immediate-release [IR] MPH dosed three times daily [TID]) under various breakfast conditions." | 2.76 | Pharmacokinetics and therapeutic effect of OROS methylphenidate under different breakfast conditions in children with attention-deficit/hyperactivity disorder. ( Gupta, S; Heverin, E; Starr, HL; Wigal, SB, 2011) |
| " Further, exploratory analyses on teacher and parent ratings on attention-deficit/hyperactivity disorder and on externalizing symptoms during the day revealed no evidence for the superiority of Concerta over Medikinet retard in an equivalent daily dosage throughout the day." | 2.76 | Comparison of the efficacy of two different modified release methylphenidate preparations for children and adolescents with attention-deficit/hyperactivity disorder in a natural setting: comparison of the efficacy of Medikinet(®) retard and Concerta(®)--a ( Ammer, R; Döpfner, M; Fischer, R; Ose, C; Scherag, A, 2011) |
| " Serial blood samples were obtained before and after drug administration for determination of plasma methylphenidate concentrations and standard pharmacokinetic parameters." | 2.76 | Single-dose pharmacokinetics of NWP06, an extended-release methylphenidate suspension, in children and adolescents with ADHD. ( Berry, SA; Childress, AC; Sallee, FR, 2011) |
| " Parents and teachers assessed each child's response on placebo and three MPH dosage levels using the Vanderbilt ADHD rating scales." | 2.76 | Pharmacogenetic predictors of methylphenidate dose-response in attention-deficit/hyperactivity disorder. ( Brinkman, WB; Epstein, JN; Froehlich, TE; Graham, AJ; Kahn, RS; Langberg, JM; Melguizo Castro, MS; Nick, TG; Stein, MA, 2011) |
| "Psychostimulants are effective treatments for attention-deficit/hyperactivity disorder (ADHD) but may be associated with euphoric effects, misuse/diversion, and adverse effects." | 2.76 | Subjective effects, misuse, and adverse effects of osmotic-release methylphenidate treatment in adolescent substance abusers with attention-deficit/hyperactivity disorder. ( Adler, LA; Davies, RD; Lewis, DF; Riggs, PD; Somoza, EC; Sonne, S; Winhusen, TM, 2011) |
| "Decreased appetite and insomnia were more common at higher dose levels for both stimulants." | 2.76 | Dose effects and comparative effectiveness of extended release dexmethylphenidate and mixed amphetamine salts. ( Aryal, S; Charney, E; Gruber, R; Newcorn, JH; Sable, C; Stein, MA; Waldman, ID, 2011) |
| " Larger studies with higher doses combined with individual dosage and longer follow-up periods are warranted." | 2.75 | Sustained release methylphenidate for the treatment of ADHD in amphetamine abusers: a pilot study. ( Beck, O; Franck, J; Jayaram-Lindström, N; Konstenius, M, 2010) |
| "Methylphenidate (MPH) is a psychostimulant commonly used to manage ADHD symptoms." | 2.75 | Manganese in children with attention-deficit/hyperactivity disorder: relationship with methylphenidate exposure. ( Benko, CR; Cordeiro, ML; Costa, MT; Cunha, A; Farias, AC; Farias, LG; McCracken, JT, 2010) |
| "Buspirone has a favorable side-effects profile." | 2.75 | Buspirone versus methylphenidate in the treatment of attention deficit hyperactivity disorder: a double-blind and randomized trial. ( Amini, H; Davari-Ashtiani, R; Mazhabdar, H; Razjouyan, K; Shahrbabaki, ME, 2010) |
| " Attentional performance increased differentially as a function of MPH dose, with some tasks showing linear improvement with higher dosage whereas more complex tasks in particular showed inverse U-shaped patterns of MPH effects." | 2.75 | Sex differences in attentional performance and their modulation by methylphenidate in children with attention-deficit/hyperactivity disorder. ( Günther, T; Herpertz-Dahlmann, B; Konrad, K, 2010) |
| "The aim of this study was to evaluate dose-response characteristics in adolescents with attention-deficit/hyperactivity disorder (ADHD) treated with once-daily OROS methylphenidate (OROS MPH) during the 4-week, open-label, escalating dose-titration phase of a larger multisite, placebo-controlled trial." | 2.75 | Dose-response characteristics in adolescents with attention-deficit/hyperactivity disorder treated with OROS methylphenidate in a 4-week, open-label, dose-titration study. ( Cooper, KM; Newcorn, JH; Stein, MA, 2010) |
| "Declarative memory deficits are common in untreated adults with attention-deficit hyperactivity disorder (ADHD), but limited evidence exists to support improvement after treatment with methylphenidate." | 2.75 | Methylphenidate significantly improves declarative memory functioning of adults with ADHD. ( Bekker, EM; Buitelaar, JK; Kooij, JJ; Olivier, B; Verbaten, MN; Verster, JC; Volkerts, ER, 2010) |
| "The Wender-Reimherr Adult Attention Deficit Disorder Scale (WRAADDS) measured outcome." | 2.75 | OROS methylphenidate in the treatment of adults with ADHD: a 6-month, open-label, follow-up study. ( Halls, C; Marchant, BK; Reimherr, FW; Strong, RE; Williams, ED, 2010) |
| "Behavioral reinforcement of tic suppression resulted in lower rates of tics compared to baseline, but dMPH did not enhance this suppression." | 2.75 | Testing tic suppression: comparing the effects of dexmethylphenidate to no medication in children and adolescents with attention-deficit/hyperactivity disorder and Tourette's disorder. ( Bauer, CC; Brandt, BC; Castellanos, FX; Coffey, BJ; Conelea, C; Howard, J; Kemp, JJ; Lawrence, ZE; Lipinski, CM; Lyon, GJ; Samar, SM; Trujillo, MR; Woods, D, 2010) |
| " The pharmacokinetic population consisted of 33 children and 31 adolescents." | 2.75 | Single- and multiple-dose pharmacokinetics of methylphenidate administered as methylphenidate transdermal system or osmotic-release oral system methylphenidate to children and adolescents with attention deficit hyperactivity disorder. ( Buckwalter, M; Katic, A; Pierce, D; Webster, K, 2010) |
| " The mean daily dosage at phase 1 endpoint was 78." | 2.75 | A randomized, 3-phase, 34-week, double-blind, long-term efficacy study of osmotic-release oral system-methylphenidate in adults with attention-deficit/hyperactivity disorder. ( Biederman, J; Doyle, R; Hammerness, P; Kotarski, M; Mick, E; Spencer, T; Surman, C, 2010) |
| "3%) of 65 children was reduced sufficiently after stimulant dosage adjustment and behavioral therapy to preclude adjunctive medication." | 2.75 | Stimulant-responsive and stimulant-refractory aggressive behavior among children with ADHD. ( Blader, JC; Jensen, PS; Kafantaris, V; Pliszka, SR; Schooler, NR, 2010) |
| " Plasma concentrations of d- and l-MPH were determined and pharmacokinetic parameters were calculated." | 2.75 | The single-dose pharmacokinetics of NWP06, a novel extended-release methylphenidate oral suspension. ( Berry, SA; Childress, AC, 2010) |
| " Intensity and frequency of adverse events were comparable between the two formulations." | 2.75 | A double-blind, randomized, placebo/active controlled crossover evaluation of the efficacy and safety of Ritalin ® LA in children with attention-deficit/hyperactivity disorder in a laboratory classroom setting. ( Fleischhaker, C; Haessler, F; Heiser, P; Hennighausen, K; Huss, M; Klatt, J; Linder, M; Oehler, KU; Schmidt, M; Schulte-Markworth, M; Schulz, E; Sieder, C; Tracik, F; Warnke, A, 2010) |
| "Methylphenidate (MPH) is an effective medication to improve these cognitive difficulties." | 2.74 | Effects of methylphenidate on working memory functioning in children with attention deficit/hyperactivity disorder. ( Bechtel, N; Klarhöfer, M; Kobel, M; Opwis, K; Penner, IK; Scheffler, K; Specht, K; Weber, P, 2009) |
| " d-MPH-ER was well tolerated; the most common adverse events (>15%) were headache, insomnia, and decreased appetite." | 2.74 | Long-term effectiveness and safety of dexmethylphenidate extended-release capsules in adult ADHD. ( Adler, LA; Jiang, H; McGough, JJ; Muniz, R; Spencer, T, 2009) |
| "A significant dose-response reduction in eating was observed across all genotypes (p < 0." | 2.74 | Dopamine-related genotypes and the dose-response effect of methylphenidate on eating in attention-deficit/hyperactivity disorder youths. ( Epstein, LH; Erbe, R; Gnagy, EM; Leddy, JJ; Mahaney, P; Paluch, RA; Pelham, WE; Salis, RJ; Waxmonsky, JG, 2009) |
| "OROS methylphenidate was well tolerated." | 2.74 | Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. ( Adler, LA; Orman, C; Palumbo, J; Silber, S; Spencer, T; Starr, HL; Zimmerman, B, 2009) |
| " Serial blood samples were collected after each MTS application and pharmacokinetic (PK) parameters for d,l-MPH were calculated." | 2.74 | Effects of application to two different skin sites on the pharmacokinetics of transdermal methylphenidate in pediatric patients with attention-deficit/hyperactivity disorder. ( Campbell, D; González, MA; Rubin, J, 2009) |
| " Adverse events were mild to moderate in severity and similar to previous observations for this class of neurostimulants." | 2.74 | Efficacy and safety of dexmethylphenidate extended-release capsules administered once daily to children with attention-deficit/hyperactivity disorder. ( Childress, AC; Gerstner, O; Lopez, F; Muniz, R; Post, A; Spencer, T; Thulasiraman, A, 2009) |
| " However, the effects of long-term use have not been systematically evaluated." | 2.74 | Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials. ( Abikoff, HB; Boellner, SW; Bukstein, OG; Civil, R; Findling, RL; Turnbow, JM; Wigal, SB, 2009) |
| "Safety assessments included adverse events (AEs), vital signs, physical examination, clinical laboratory tests, the Pediatric Daytime Sleepiness Scale, and the Pittsburgh Side Effects Rating Scale." | 2.74 | Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. ( Ginsberg, LD; Greenbaum, M; Murphy, WR; Spencer, TJ, 2009) |
| " We conducted a randomized crossover trial with MPH and placebo (2 weeks each) combined with aripiprazole in children and adolescents (n = 16; 8-17 years old) with JBPD and ADHD who had a significant response in manic symptoms with aripiprazole but still presented clinically significant symptoms of ADHD." | 2.74 | Methylphenidate combined with aripiprazole in children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder: a randomized crossover trial. ( Ketzer, CR; Pheula, GF; Rohde, LA; Tramontina, S; Zeni, CP, 2009) |
| " Children whose aggressive behavior persisted at the conclusion of the lead-in phase were randomly assigned to receive double-blind, flexibly dosed divalproex or a placebo adjunctive to stimulant for 8 weeks." | 2.74 | Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy. ( Blader, JC; Jensen, PS; Kafantaris, V; Pliszka, SR; Schooler, NR, 2009) |
| "This study compared the methylphenidate (MPH) dose-response profiles of children with the Predominantly Inattentive (PI) and Combined (CB) subtypes of attention-deficit/hyperactivity disorder (ADHD)." | 2.74 | Stimulant drug response in the predominantly inattentive and combined subtypes of attention-deficit/hyperactivity disorder. ( Gilbert, S; Ivanov, I; Lara, R; Newcorn, J; Solanto, M; Vail, L, 2009) |
| "Methylphenidate is a leading first-line treatment for ADHD (AD/HD)." | 2.74 | Effects of once-daily oral and transdermal methylphenidate on sleep behavior of children with ADHD. ( Arnold, LE; Bukstein, OG; Faraone, SV; Findling, RL; Glatt, SJ; Lopez, FA, 2009) |
| "OROS methylphenidate was more effective than IR methylphenidate (p = 0." | 2.73 | Effect of switching drug formulations from immediate-release to extended-release OROS methylphenidate : a chart review of Spanish adults with attention-deficit hyperactivity disorder. ( Bosch, R; Casas, M; Castells, X; Ferrer, M; Gómez, N; Martínez, Y; Nogueira, M; Ramos-Quiroga, JA; Valero, S; Yelmo, S, 2008) |
| " Adverse events were monitored throughout the study period." | 2.73 | Efficacy and safety of extended-release dexmethylphenidate compared with d,l-methylphenidate and placebo in the treatment of children with attention-deficit/hyperactivity disorder: a 12-hour laboratory classroom study. ( Brams, M; Mao, A; McCague, K; Muniz, R; Pestreich, L; Silva, R, 2008) |
| "To evaluate the pharmacokinetic properties of the methylphenidate transdermal system (MTS) in pediatric patients diagnosed with ADHD (attention-deficit/hyperactivity disorder) in a laboratory school setting." | 2.73 | Pharmacokinetics of methylphenidate transdermal system (MTS): results from a laboratory classroom study. ( Dixon, CM; McGough, JJ; Pierce, D; Wigal, SB, 2008) |
| "OROS methylphenidate was well tolerated and was associated with significant improvement in maternal ADHD symptoms and parenting." | 2.73 | Efficacy of osmotic-release oral system (OROS) methylphenidate for mothers with attention-deficit/hyperactivity disorder (ADHD): preliminary report of effects on ADHD symptoms and parenting. ( Chronis-Tuscano, A; Conlon, CJ; Efron, LA; Jiles, CD; Jones, HA; Pian, J; Robb, AS; Rooney, ME; Seymour, KE; Stein, MA; Wagner, SA, 2008) |
| "This study does not support the expectation that optimally dosed stimulant treated children with ADHD should routinely receive psychosocial treatment to further reduce ADHD- and related symptoms." | 2.73 | Does brief, clinically based, intensive multimodal behavior therapy enhance the effects of methylphenidate in children with ADHD? ( Emmelkamp, PM; Oosterlaan, J; Prins, PJ; van der Oord, S, 2007) |
| " The dosage of Concerta was adjusted by the investigators based on symptoms and safety assessments performed on a weekly basis." | 2.73 | Efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder. ( Cheong, S; Cho, IH; Choi, JW; Hong, SD; Kim, EJ; Kim, JH; Kim, SY; Lee, SI; Lim, TS; Oh, EY; Park, JH; Park, MK; Park, S, 2007) |
| "Once-daily d-MPH-ER at 20 mg, 30 mg, or 40 mg is a safe and effective treatment for adults with ADHD." | 2.73 | Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder. ( Adler, LA; Jiang, H; McGough, JJ; Muniz, R; Pestreich, L; Spencer, TJ, 2007) |
| "Methylphenidate was associated with significant improvement that was most evident at the ." | 2.73 | Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures. ( Aman, MG; Arnold, LE; Carroll, DH; Chuang, SZ; Cronin, P; Davies, M; McCracken, JT; McDougle, CJ; Posey, DJ; Ramadan, Y; Scahill, L; Shah, B; Swiezy, NB; Tierney, E; Vitiello, B; Wheeler, C; Witwer, AN; Young, C, 2007) |
| "05), with significant linear dose-response relationships evident for both domains." | 2.73 | Preliminary evidence of beneficial effects of methylphenidate on listening comprehension in children with attention-deficit/hyperactivity disorder. ( Bedard, AC; Hogg-Johnson, S; McInnes, A; Tannock, R, 2007) |
| " Pharmacokinetic analysis was conducted on 14 patients (1 female, 13 male; mean age: 9." | 2.73 | Single-dose pharmacokinetics of multilayer-release methylphenidate and immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder. ( Bode, T; Darke, AC; Donnelly, GA; Quinn, D; Reiz, JL, 2007) |
| " A nonlinear model was used to derive three pharmacokinetic (PK) values for analysis: Peak plasma concentration (C(max)), half-life (t(1/2)), and clearance (CL)." | 2.73 | Pharmacokinetics of methylphenidate in preschoolers with attention-deficit/hyperactivity disorder. ( Greenhill, L; Gupta, S; Kapelinski, A; Lerner, M; Martinez, J; Modi, NB; Posner, K; Stehli, A; Steinhoff, K; Swanson, J; Wigal, SB; Wigal, T, 2007) |
| "Methylphenidate was administered twice daily (8 a." | 2.73 | Is age-at-onset criterion relevant for the response to methylphenidate in attention-deficit/hyperactivity disorder? ( Belmonte-de-Abreu, P; Benetti, L; Faraone, SV; Grevet, EH; Reinhardt, MC; Rohde, LA; Victor, MM, 2007) |
| "Clonidine was well tolerated despite the frequency of sedation and did offer some benefit." | 2.73 | Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes. ( Bukstein, OG; Daviss, WB; McDERMOTT, MP; Palumbo, DR; Pelham, WE; Sallee, FR, 2008) |
| "In methylphenidate-treated patients, 4." | 2.73 | A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. ( Buitelaar, JK; Casas, M; Kooij, JJ; Lee, E; Medori, R; Niemelä, A; Ramos-Quiroga, JA; Trott, GE, 2008) |
| "Treatment with methylphenidate resulted in increased sleep efficiency as well as a subjective feeling of improved restorative value of sleep." | 2.73 | Sleep in adults with attention deficit hyperactivity disorder (ADHD) before and during treatment with methylphenidate: a controlled polysomnographic study. ( Alm, B; Kettler, N; Schredl, M; Sobanski, E, 2008) |
| "Methylphenidate dose was optimized over 5 weeks using 10-, 15-, 20-, or 30-mg patches worn for 9 hours." | 2.73 | Varying the wear time of the methylphenidate transdermal system in children with attention-deficit/hyperactivity disorder. ( Abikoff, HB; Boellner, SW; Childress, AC; López, FA; Manos, MJ; Turnbow, JM; Wigal, SB; Wilens, TE, 2008) |
| " Adverse events and vital signs were assessed." | 2.73 | Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study. ( Adler, LA; Michelson, D; Moore, RJ; Spencer, TJ; Williams, DW, 2008) |
| "Methylphenidate is an effective short-term treatment for oppositional behavior in children with comorbid ADHD and chronic multiple tic disorder." | 2.73 | Methylphenidate in children with oppositional defiant disorder and both comorbid chronic multiple tic disorder and ADHD. ( Gadow, KD; Nolan, EE; Schneider, J; Sprafkin, J; Sverd, J, 2008) |
| " The results from the literature underline the necessity of caution and patient monitoring when risperidone dosing is modified during methylphenidate therapy." | 2.72 | Movement disorders and use of risperidone and methylphenidate: a review of case reports and an analysis of the WHO database in pharmacovigilance. ( Burden, AM; Stämpfli, D; Weiler, S, 2021) |
| "Methylphenidate was associated with a nonsignificant elevated risk of dropout due to adverse events." | 2.72 | Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis. ( Ameis, SH; Anagnostou, E; Anderson, KK; Beswick, A; Gorman, DA; Lai, MC; Rodrigues, R; Szatmari, P, 2021) |
| "Methylphenidate (MPH) is an efficacious treatment for ADHD but concerns have been raised about potential adverse effects of extended treatment on growth." | 2.72 | Long term methylphenidate exposure and growth in children and adolescents with ADHD. A systematic review and meta-analysis. ( Balia, C; Banaschewski, T; Buitelaar, JK; Carucci, S; Coghill, D; Danckaerts, M; Dittmann, RW; Gagliano, A; Garas, P; Hollis, C; Inglis, S; Konrad, K; Kovshoff, H; Lampis, A; Liddle, EB; McCarthy, S; Nagy, P; Panei, P; Romaniello, R; Sonuga-Barke, E; Usala, T; Wong, ICK; Zuddas, A, 2021) |
| "Methylphenidate (MPH) is a stimulant, FDA-approved for the treatment of ADHD, and often used for ADHD in the setting of pediatric epilepsy." | 2.72 | Methylphenidate for attention problems in epilepsy patients: Safety and efficacy. ( Adams, J; Devinsky, O; Leeman-Markowski, BA; Martin, SP; Meador, KJ, 2021) |
| "Treatment with methylphenidate is associated with clinically significant improvement of ADHD symptoms in 60-75% of patients." | 2.72 | Attention deficit/hyperactivity disorder and epilepsy. ( Auvin, S; Rheims, S, 2021) |
| " Subjects successfully completing the dose titration phase (n = 177) (ie, tolerated and responded to treatment and adhered to the protocol) were randomized to receive 2 weeks' treatment with their individualized dosage of OROS methylphenidate (18, 36, 54, or 72 mg once daily) or placebo." | 2.72 | Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. ( Bailey, CE; Bloom, L; Bukstein, O; Casat, C; Conners, CK; Cooper, KM; Coury, D; Denisco, MJ; Duby, J; Greenhill, L; Gu, J; Halstead, P; Kratochvil, CJ; Lerner, M; Lynch, JM; McBurnett, K; McGough, J; Newcorn, J; Stein, MA; Wilens, TE; Zimmerman, BA, 2006) |
| "OROS-methylphenidate (OROS-MPH) is a once-daily controlled-release formulation of methylphenidate (MPH) developed to overcome some of the limitations associated with IR-MPH and first-generation sustained-release formulations." | 2.72 | A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder. ( Binder, CE; Prinzo, RS; Steele, M; Swanson, J; Wang, J; Weiss, M, 2006) |
| "Methylphenidate (MPH) has been shown to be effective in the treatment of attention deficits in children with attention deficit hyperactivity disorder (ADHD)." | 2.72 | Effects of methylphenidate on multiple components of attention in children with attention deficit hyperactivity disorder. ( Bormann-Kischkel, C; Kübber, S; Lange, KW; Linder, M; Mecklinger, L; Prell, S; Tucha, O; Walitza, S, 2006) |
| " Headache, anorexia, and insomnia were the most frequently reported treatment-related adverse events." | 2.72 | Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder. ( Bukstein, O; Greenhill, L; Lerner, M; McBurnett, K; McGough, JJ; Stein, M; Wilens, TE, 2006) |
| "5%) spontaneously reported adverse events suspected as drug related." | 2.72 | Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder. ( Ball, RR; Greenhill, LL; Jiang, H; Levine, A; Muniz, R; Pestreich, L, 2006) |
| "Methylphenidate (MPH) is a drug of choice for treating attention-deficit/hyperactivity disorder (ADHD), although its use has been complicated by its short duration of action." | 2.72 | Methylphenidate blood levels and therapeutic response in children with attention-deficit hyperactivity disorder: I. Effects of different dosing regimens. ( Chang, WW; Foley, M; McGreenery, CE; McKay, G; Midha, KK; Polcari, A; Teicher, MH; Valente, E, 2006) |
| "The authors explored genetic moderators of symptom reduction and side effects in methylphenidate-treated preschool-age children diagnosed with attention-deficit/hyperactivity disorder (ADHD)." | 2.72 | Pharmacogenetics of methylphenidate response in preschoolers with ADHD. ( Abikoff, H; Chuang, S; Cunningham, C; Davies, M; Ghuman, J; Greenhill, L; Kastelic, E; Kollins, S; McCRACKEN, J; McGOUGH, J; Moyzis, R; Posner, K; Riddle, M; Shigawa, S; Skrobala, A; Swanson, J; Vitiello, B; Wigal, S; Wigal, T, 2006) |
| " Pulse, blood pressure, and the presence of treatment emergent adverse events (AEs), parent and teacher AE ratings, and vital signs were recorded in each phase." | 2.72 | Safety and tolerability of methylphenidate in preschool children with ADHD. ( Abikoff, H; Chuang, S; Davies, M; Ghuman, J; Greenhill, L; Kollins, S; McCRACKEN, J; McGOUGH, J; Posner, K; Riddle, M; Skrobala, A; Stehli, A; Swanson, J; Thorp, B; Vitiello, B; Wigal, S; Wigal, T, 2006) |
| "Examined the impact of late-afternoon stimulant dosing on parent and parent-child domains." | 2.71 | The impact of late-afternoon stimulant dosing for children with ADHD on parent and parent-child domains. ( Aronoff, HR; Chronis, AM; Gnagy, EM; Pelham, WE; Roberts, JE, 2003) |
| "The duration of action of the immediate-release formulation of methylphenidate hydrochloride is short (3 to 4 hours), and 3 times daily dosing is thought to maximize effectiveness across a 12-hour day." | 2.71 | Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies. ( Gupta, S; Lam, A; Lerner, M; Lindemulder, E; Modi, N; Shoulson, I; Swanson, J; Wigal, S, 2003) |
| "The current study was aimed at (a) investigating the effect of three doses methylphenidate (MPH) and placebo on inhibition of a prepotent response, inhibition of an ongoing response, and interference control in Attention Deficit/Hyperactivity Disorder (AD/HD), and (b) studying dose-response relations for the three forms of response inhibition." | 2.71 | The effect of methylphenidate on three forms of response inhibition in boys with AD/HD. ( Meiran, N; Morein-Zamir, S; Oosterlaan, J; Scheres, A; Schut, H; Sergeant, JA; Swanson, J; Vlasveld, L, 2003) |
| "The safety and efficacy of treatment with antiepilepsy drugs combined with methylphenidate were determined by assessing seizure frequency, changes in ADHD symptoms, the Conners' Rating Scales, EEG differences, and side effects." | 2.71 | Use of methylphenidate for attention-deficit hyperactivity disorder in patients with epilepsy or electroencephalographic abnormalities. ( Erdemoglu, AK; Gucuyener, K; Kockar, AI; Senol, S; Serdaroglu, A; Soysal, S, 2003) |
| "Selegiline is a type B monoamine oxidase inhibitor (MAOI) that is metabolized to amphetamine and methamphetamine stimulant compounds that may be useful in the treatment of ADHD." | 2.71 | Selegiline in the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial. ( Akhondzadeh, S; Amini, H; Arabgol, F; Davari-Ashtiani, R; Tavakolian, R, 2003) |
| " We then increased dosage to 15 mg 3 times daily for 2 weeks and administered a complete reassessment on the final day." | 2.71 | The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. ( Bouffard, R; Hechtman, L; Iaboni-Kassab, F; Minde, K, 2003) |
| "OROS methylphenidate HCL (MPH) is a recently developed long-acting stimulant medication used to treat attention-deficit/hyperactivity disorder (ADHD)." | 2.71 | A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. ( Black, DO; Conlon, C; Newcorn, JH; Pearl, PL; Robb, AS; Sarampote, CS; Seymour, KE; Stein, MA; Waldman, ID, 2003) |
| "We used a sequential approach to evaluate the relative and combined effects of different types of behavioral treatments, as well as dosage of methylphenidate (MPH), on the disruptive behavior of 3 students who had been diagnosed with attention deficit hyperactivity disorder." | 2.71 | Sequential evaluation of behavioral treatments and methylphenidate dosage for children with attention deficit hyperactivity disorder. ( Gulley, V; Hupp, S; LeVelle, J; Northup, J; Ridgway, A; Spera, S, 2003) |
| " The adverse events reported were generally mild or moderate, and were similar in both groups." | 2.71 | Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder. ( Biederman, J; Edson, K; Karlsson, G; Markabi, S; Pohlmann, H; Quinn, D; Weidenman, M; Weiss, M; Wigal, S, 2003) |
| "Theophylline is a psychomotor stimulant most widely used as a broncodilator." | 2.71 | Efficacy of theophylline compared to methylphenidate for the treatment of attention-deficit hyperactivity disorder in children and adolescents: a pilot double-blind randomized trial. ( Akhondzadeh, S; Izadian, ES; Kashani, L; Mohammadi, MR; Ohadinia, S, 2004) |
| " After having received various dosing levels of a stimulant in a placebo-controlled crossover design, best dose was assigned based on the lowest Abbreviated Symptoms Questionnaire T score received in a given week." | 2.71 | A prospective study of stimulant response in preschool children: insights from ROC analyses. ( Findling, RL; Manos, MJ; Schubel, EA; Short, EJ, 2004) |
| " Under each treatment condition, participants were maintained on their medication dosage for 7 days, then drove a sophisticated driving simulator at 2 p." | 2.71 | Impact of methylphenidate delivery profiles on driving performance of adolescents with attention-deficit/hyperactivity disorder: a pilot study. ( Cox, DJ; Hankin, CS; Kovatchev, B; Merkel, RL; Penberthy, JK, 2004) |
| "Methylphenidate's efficacy was assessed by both objective and subjective measures." | 2.71 | An open-label pilot study of methylphenidate in the treatment of cocaine dependent patients with adult attention deficit/hyperactivity disorder. ( Barrett, JA; Bridge, TP; Ciraulo, DA; Harrer, JM; Mezinskis, JP; Montgomery, MA; Rotrosen, JP; Somoza, EC; Vanderburg, DG; Winhusen, TM; Wulsin, LR, 2004) |
| "To evaluate the impact of adherence and medication status on effectiveness and adverse effects of stimulant use in children with attention-deficit/hyperactivity disorder (ADHD) over 5 years." | 2.71 | Stimulant treatment over five years: adherence, effectiveness, and adverse effects. ( Charach, A; Ickowicz, A; Schachar, R, 2004) |
| " Analysis of dose-response curves revealed significant linear components of trend on measures tapping sustained attention, visual selective attention, auditory selective attention, as well as two tasks tapping inhibition/impulsivity: delay of gratification and match-to-sample." | 2.71 | Treatment effects of methylphenidate on cognitive functioning in children with mental retardation and ADHD. ( Casat, CD; Cleveland, LA; Faria, LP; Jerger, SW; Lachar, D; Lane, DM; Loveland, KA; Payne, CD; Pearson, DA; Roache, JD; Santos, CW, 2004) |
| "Methylphenidate seems to be an effective treatment for ODD, as well as for ADHD itself." | 2.71 | The effect of methylphenidate on oppositional defiant disorder comorbid with attention deficit/hyperactivity disorder. ( Gomes, F; Mattos, P; Pastura, G; Serra-Pinheiro, MA; Souza, I, 2004) |
| "This study analyzes the incidence of tics reported across five studies of children with ADHD who received methylphenidate (MPH)-based therapy as part of the clinical development program for once-daily OROS MPH (CONCERTA McNeil Consumer & Specialty Pharmaceuticals, Fort Washington, PA)." | 2.71 | Emergence of tics in children with ADHD: impact of once-daily OROS methylphenidate therapy. ( Co-Chien, H; Faraone, SV; Lynch, J; Palumbo, D; Spencer, T, 2004) |
| "The aim of this study was to investigate the effects of ongoing methylphenidate (MPH) on ADHD-related and autistic symptoms in Pervasive Developmental Disorders (PDD) in children who did not present any adverse effects to an initial acute dose administered at the clinic." | 2.71 | Methylphenidate for pervasive developmental disorders: safety and efficacy of acute single dose test and ongoing therapy: an open-pilot study. ( Cianchetti, C; Di Martino, A; Melis, G; Zuddas, A, 2004) |
| "Risperidone-treated patients had clinically and statistically significant reductions in both disruptive behavior and hyperactivity subscale scores, compared to placebo, regardless of concomitant stimulant use." | 2.71 | Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ. ( Aman, MG; Binder, C; Turgay, A, 2004) |
| "Given the dosing limitations of methylphenidate short-acting preparations in treating ADHD, galenics with longer release of the substance were developed mainly to avoid drug intake during school hours." | 2.71 | Comparative efficacy of once-a-day extended-release methylphenidate, two-times-daily immediate-release methylphenidate, and placebo in a laboratory school setting. ( Banaschewski, T; Breuer, D; Döpfner, M; Freisleder, FJ; Gerber, WD; Gerber-von Müller, G; Günter, M; Hässler, F; Lehmkuhl, G; Ose, C; Rothenberger, A; Schmeck, K; Sinzig, J; Stadler, C; Uebel, H, 2004) |
| " Children were assigned on the basis of their pre-trial dosage to either high (Metadate CD 60 mg; Concerta 54 mg), medium (Metadate CD 40 mg; Concerta 36 mg) or low doses (Metadate CD 20 mg; Concerta 18 mg) of MPH, and attended a laboratory school on the 7th day for assessment at 7 sessions across the day." | 2.71 | Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data. ( Coghill, D; DeCory, HH; Hatch, SJ; Sonuga-Barke, EJ; Swanson, JM, 2004) |
| "Methylphenidate has four optical isomers due to two asymmetries (erythro-threo and dextro-levo)." | 2.71 | Comparative pharmacodynamics and plasma concentrations of d-threo-methylphenidate hydrochloride after single doses of d-threo-methylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in a double-blind, placebo-controlled, crossover labora ( Cooper, T; Dariani, M; Hirsch, S; Ottolini, Y; Quinn, D; Roffman, M; Swanson, J; Wigal, S; Zeldis, J, 2004) |
| "Methylphenidate led to an increase in activation in this region but had no effect on task performance." | 2.71 | The effects of methylphenidate on neural systems of attention in attention deficit hyperactivity disorder. ( Gore, JC; Marchione, KE; Shafritz, KM; Shaywitz, BA; Shaywitz, SE, 2004) |
| "Methylphenidate proves to be an effective and well tolerated treatment for symptoms of ADHD in adults in the short term." | 2.71 | Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. ( Boonstra, AM; Buitelaar, JK; Burger, H; Kalma, LE; Kooij, JJ; Van der Linden, PD, 2004) |
| "Children surviving acute lymphoblastic leukemia (ALL) and malignant brain tumors (BTs) have a higher incidence of attention and learning problems in school than do their healthy peers." | 2.71 | Short-term efficacy of methylphenidate: a randomized, double-blind, placebo-controlled trial among survivors of childhood cancer. ( Bonner, M; Brown, R; Christensen, R; Gururangan, S; Helton, S; Kaplan, S; Khan, RB; Mulhern, RK; Reddick, WE; Wu, S; Xiong, X, 2004) |
| " Future studies are needed to confirm these findings and to evaluate chronic dosing with d-MPH." | 2.71 | Open-label study of dexmethylphenidate hydrochloride in children and adolescents with attention deficit hyperactivity disorder. ( Cecil, JT; Faleck, H; Khetani, V; Kowalik, S; Patin, J; Silva, R; Tilker, HA, 2004) |
| "Methylphenidate treatment did not significantly affect SDS of height, weight, BMI, IGF-I and IGFBP-3 in the long run." | 2.71 | Height, weight, IGF-I, IGFBP-3 and thyroid functions in prepubertal children with attention deficit hyperactivity disorder: effect of methylphenidate treatment. ( Bereket, A; Haklar, G; Karaman, MG; Ozbay, F; Turan, S; Yazgan, MY, 2005) |
| "02 years), underwent a 4-week, double-blinded, crossover trial with forced weekly dosage changes." | 2.71 | Dopamine transporter genotype and methylphenidate dose response in children with ADHD. ( Conlon, C; Cook, EH; Kim, SJ; Robb, AS; Sarampote, CS; Seymour, KE; Stein, MA; Waldman, ID, 2005) |
| "001), while inhibitory control showed a quadratic dose-response curve (p < 0." | 2.71 | Clinical evaluation of subjective and objective changes in motor activity and attention in children with attention-deficit/hyperactivity disorder in a double-blind methylphenidate trial. ( Günther, T; Heinzel-Gutenbrunner, M; Herpertz-Dahlmann, B; Konrad, K, 2005) |
| "Methylphenidate did not produce any changes in coherence values." | 2.71 | Effects of methylphenidate on EEG coherence in attention-deficit/hyperactivity disorder. ( Abbott, I; Barry, RJ; Clarke, AR; Croft, RJ; Hsu, CI; Johnstone, SJ; Lawrence, CA; Magee, CA; McCarthy, R; Selikowitz, M, 2005) |
| "Methylphenidate was superior to placebo on the primary outcome measure, with effect sizes ranging from 0." | 2.71 | Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. ( , 2005) |
| "Methylphenidate is a standard pharmaceutical intervention for ADHD." | 2.70 | An experimental comparison of Pycnogenol and methylphenidate in adults with Attention-Deficit/Hyperactivity Disorder (ADHD). ( Dodd, DK; Green, L; Paull, JC; Sparrow, EP; Tenenbaum, S, 2002) |
| " The food effect on early drug exposure and the pharmacokinetic profiles up to 8 h after dosing of the two extended-release stimulants were directly compared using partial area (AUC(p4h), AUC(p6h) and AUC(p8h)) fed/fasted ratios." | 2.70 | Effect of food on early drug exposure from extended-release stimulants: results from the Concerta, Adderall XR Food Evaluation (CAFE) Study. ( Auiler, JF; Gelotte, CK; Liu, K; Lynch, JM, 2002) |
| "M." | 2.70 | The effects of stimulant therapy, EEG biofeedback, and parenting style on the primary symptoms of attention-deficit/hyperactivity disorder. ( George, S; Monastra, DM; Monastra, VJ, 2002) |
| "To examine the trajectory of methylphenidate (MPH) dosage over time, following a controlled titration, and to ascertain how accurately the titration was able to predict effective long-term treatment in children with attention-deficit/hyperactivity disorder (ADHD)." | 2.70 | Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA. ( Abikoff, HB; Arnold, LE; Bukstein, OG; Cantwell, DP; Elliott, GR; Greenhill, LL; Hechtman, L; Hinshaw, SP; Jensen, PS; March, JS; Newcorn, JH; Severe, JB; Swanson, JM; Vitiello, B, 2001) |
| "The MTA titration protocol validated the efficacy of weekend MPH dosing and established a total daily dose limit of 35 mg of MPH for children weighing less than 25 kg." | 2.70 | Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. ( Abikoff, HB; Arnold, LE; Bukstein, OG; Clevenger, W; Conners, CK; Davies, M; Elliott, GR; Greenhill, LL; Hechtman, L; Hinshaw, SP; Hoza, B; Jensen, PS; Kraemer, HC; March, JS; Newcorn, JH; Severe, JB; Swanson, JM; Vitiello, B; Wells, K; Wigal, T; Wu, M, 2001) |
| " Previous long-acting stimulants and preparations have shown effects equivalent to twice-daily dosing of MPH." | 2.70 | Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. ( Burrows-Maclean, L; Chronis, AM; Coles, EK; Fabiano, GA; Fielbelkorn, K; Forehand, GL; Gnagy, EM; Hoffman, MT; Lock, TM; Meichenbaum, DL; Morrisey, SM; Morse, GD; Nguyen, CA; Onyango, AN; Panahon, CJ; Pelham, WE; Steiner, RL; Williams, A, 2001) |
| "Children with attention-deficit/hyperactivity disorder (ADHD; n = 282), all subtypes, ages 6 to 12 years, were randomized to placebo (n = 90), immediate-release methylphenidate (IR MPH) 3 times a day (tid; dosed every 4 hours; n = 97), or OROS MPH once a day (qd; n = 95) in a double-blind, 28-day trial." | 2.70 | Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder. ( Atkins, M; August, G; Bukstein, O; Greenhill, LL; McBurnett, K; Palumbo, D; Pelham, W; Swanson, J; Wilens, T; Wolraich, ML, 2001) |
| "Methylphenidate was titrated over 1 week to a maximum dose of 0." | 2.70 | Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. ( Arndt, S; Bever-Stille, KA; Gaffney, GR; Holman, TL; Kuperman, S; Lund, BC; Moser, DJ; Paulsen, JS; Perry, PJ, 2001) |
| "To determine the single-dose bioavailability of 20-mg Metadate CD (methylphenidate HCI, USP) Extended-Release Capsules sprinkled onto 1 level tablespoon (15 mL) of applesauce relative to an intact capsule under fasted conditions in healthy adults." | 2.70 | Methylphenidate bioavailability in adults when an extended-release multiparticulate formulation is administered sprinkled on food or as an intact capsule. ( Benedict, MF; Hatch, SJ; Pentikis, HS; Simmons, RD, 2002) |
| "Forty-six of 93 children with neurofibromatosis type 1 (NF1) were found to satisfy the diagnostic criteria for attention-deficit-hyperactivity disorder (ADHD)." | 2.70 | Treatment of ADHD in neurofibromatosis type 1. ( Kluwe, L; Leark, RA; Mautner, VF; Thakker, SD, 2002) |
| " Statistical comparisons of specific somatic complaints indicated minimal agreement between parents and children in contrast to the nearly identical parent-child dose-response curves." | 2.70 | Attention-Deficit/Hyperactivity Disorder and methylphenidate: a dose-response analysis and parent-child comparison of somatic complaints. ( Moffitt, C; Randall, R; Rapport, MD, 2002) |
| "Methylphenidate was found to reduce pro- and anti-saccadic reaction times, error correction times, and the proportion of direction errors during the anti-saccade task." | 2.70 | Effects of methylphenidate on saccadic responses in patients with ADHD. ( Fischer, B; Hartnegg, K; Jr Fischer, B; Klein, C, 2002) |
| " Multiple data analytic methods were used with the goal of (a) describing the shape of the dose-response curves across multiple measures of social functioning, (b) determining the percentage of adolescents whose social behavior improved in response to MPH, and (c) assessing the incremental gains that result from increases in dose." | 2.69 | Dosage effects of methylphenidate on the social behavior of adolescents diagnosed with attention-deficit hyperactivity disorder. ( Bukstein, O; Evans, S; Gnagy, E; Greiner, A; Molina, B; Myak, C; Pelham, WE; Presnell, M; Smith, BH; Willoughby, M, 1998) |
| " In general, methylphenidate was tolerated relatively well, with no children withdrawing because of adverse effects." | 2.69 | Short-term side effects of stimulant medication are increased in preschool children with attention-deficit/hyperactivity disorder: a double-blind placebo-controlled study. ( Bennett, S; Firestone, P; Mercer, J; Musten, LM; Pisterman, S, 1998) |
| " Subjective ratings by both teachers and parents were examined for dosage level effects and medication type effects." | 2.69 | Differential effectiveness of methylphenidate and Adderall in school-age youths with attention-deficit/hyperactivity disorder. ( Findling, RL; Manos, MJ; Short, EJ, 1999) |
| " These results suggest differential dosage effects and a dissociation between dose levels and aspects of processing." | 2.69 | Effect of methylphenidate on attention in children with attention deficit hyperactivity disorder (ADHD): ERP evidence. ( Humphries, T; Malone, MA; Roberts, W; Rovet, J; Sunohara, GA; Taylor, MJ, 1999) |
| " A nonlinear regression model was applied to estimate overall population values of MP clearance and elimination half-life (t1/2), assuming a one-component model with first-order absorption and elimination, and further assuming that clearance is linearly related to body weight." | 2.69 | Population pharmacokinetics of methylphenidate in children with attention-deficit hyperactivity disorder. ( Greenblatt, DJ; Harmatz, JS; Oesterheld, JR; Parmelee, DX; Sallee, FR; Shader, RI, 1999) |
| " In study I, relative efficacy was determined for three dosing patterns of methylphenidate: a standard twice-daily profile, a flat profile, and an ascending profile." | 2.69 | Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children. ( Agler, D; Flynn, D; Guinta, D; Gupta, S; Lerner, M; Shoulson, I; Swanson, J; Wigal, S; Williams, L, 1999) |
| "1) To compare standard twice-daily methylphenidate (MPH) dosing with a single morning dose of MPH and of Adderall during a typical school-day time period, and 2) to conduct a dose-response study of the effects of a late-afternoon (3:30 PM) dose of MPH and Adderall on evening behavior and side effects." | 2.69 | A comparison of morning-only and morning/late afternoon Adderall to morning-only, twice-daily, and three times-daily methylphenidate in children with attention-deficit/hyperactivity disorder. ( Aronoff, HR; Burrows-MacLean, L; Chronis, AM; Fabiano, GA; Gnagy, EM; Meichenbaum, DL; Onyango, AN; Pelham, WE; Steiner, RL; Williams, A, 1999) |
| " Dosage was adjusted at the end of weeks 1 and 2 via an algorithm based on teacher and parent ratings." | 2.69 | A double-blind, placebo-controlled study of Adderall and methylphenidate in the treatment of attention-deficit/hyperactivity disorder. ( Browne, RG; Olvera, RL; Pliszka, SR; Wynne, SK, 2000) |
| " Results indicated that 3 children were able to accurately report their medication status at levels greater than chance, whereas the accuracy of reports by all children was related to dosage level, differences in behavior, and the presence of adverse effects." | 2.69 | Testing the ability of children with attention deficit hyperactivity disorder to accurately report the effects of medication on their behavior. ( Ardoin, SP; Martens, BK, 2000) |
| "Treatment with methylphenidate resulted in marked reductions of hyperactive, disruptive, and aggressive behavior, which was evident even for the 0." | 2.68 | School observations of children with attention-deficit hyperactivity disorder and comorbid tic disorder: effects of methylphenidate treatment. ( Gadow, KD; Nolan, E; Sprafkin, J; Sverd, J, 1995) |
| " Therefore, three-times-a-day dosing should be considered for those children exhibiting ADHD symptoms in the evening." | 2.68 | Effects of late-afternoon methylphenidate administration on behavior and sleep in attention-deficit hyperactivity disorder. ( Abikoff, H; Blader, JC; Foley, CA; Kent, JD; Koplewicz, HS, 1995) |
| " Dissociations of dose effects on cognitive function and behavior were demonstrated: Dose-response functions for changes in behavior were linear, whereas the function for response inhibition was U-shaped." | 2.68 | Methylphenidate and cognitive flexibility: dissociated dose effects in hyperactive children. ( Logan, G; Schachar, R; Tannock, R, 1995) |
| "A double-blind crossover design was used in an acute dosage trial to assess effects of three dosages (0." | 2.68 | Do high doses of stimulants impair flexible thinking in attention-deficit hyperactivity disorder? ( Barr, RG; Desilets, J; Douglas, VI; Sherman, E, 1995) |
| "Parents of children with mental retardation or borderline IQ who took part in two drug studies were surveyed by mail 4 weeks after their involvement." | 2.68 | Consumer satisfaction with involvement in drug research: a social validity study. ( Aman, MG; Wolford, PL, 1995) |
| "Methylphenidate appears to be a safe and effective treatment for attention-deficit hyperactivity disorder in the majority of children with comorbid tic disorder." | 2.68 | Efficacy of methylphenidate for attention-deficit hyperactivity disorder in children with tic disorder. ( Ezor, SN; Gadow, KD; Nolan, EE; Sprafkin, J; Sverd, J, 1995) |
| "Methylphenidate was titrated to the maximum effective dose of 0." | 2.68 | Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. ( Allen, AJ; Arndt, SV; Barrickman, LL; Herrmann, KJ; Kuperman, S; Perry, PJ; Schumacher, E, 1995) |
| "Seventeen children with attention deficit disorder (ADHD) and 10 normal controls performed two tasks while event-related potentials were recorded." | 2.68 | Spatial orienting and focused attention in attention deficit hyperactivity disorder. ( Abikoff, H; Novak, GP; Solanto, M, 1995) |
| "Pindolol treatment was associated with a higher incidence of paraesthesias and with more intense nightmares and hallucinations than MPH or placebo treatment." | 2.68 | Pindolol and methylphenidate in children with attention-deficit hyperactivity disorder. Clinical efficacy and side-effects. ( Buitelaar, JK; Kuiper, M; Swaab-Barneveld, H; van der Gaag, RJ, 1996) |
| " Both interventions proved effective for improving neurocognitive test performance and behavior, although broad-band ratings revealed dose-response curves different from those obtained from the neurocognitive tests." | 2.68 | Methylphenidate and attentional training. Comparative effects on behavior and neurocognitive performance in twin girls with attention-deficit/hyperactivity disorder. ( Denney, C; Goya, S; Isaacs, P; Loo, S; Rapport, MD; Scanlan, S, 1996) |
| " Although the titration protocol is complex, the study's individual dosing approach and algorithms for openly managing ADHD children's medication over time will be of interest to clinicians in office practice." | 2.68 | Medication treatment strategies in the MTA Study: relevance to clinicians and researchers. ( Abikoff, HB; Arnold, LE; Cantwell, DP; Conners, CK; Elliott, G; Greenhill, LL; Hechtman, L; Hinshaw, SP; Hoza, B; Jensen, PS; March, JS; Newcorn, J; Pelham, WE; Severe, JB; Swanson, JM; Vitiello, B; Wells, K, 1996) |
| "To evaluate the short-term efficacy and side effects associated with two methylphenidate hydrochloride (MPH) dosing patterns." | 2.68 | Methylphenidate dosing: twice daily versus three times daily. ( Blackwell, B; Blondis, TA; Fishkin, J; O'Brien, T; Roizen, NJ; Schnitzler, ER; Stein, MA; Szumowski, E, 1996) |
| " In Study 1, we examined covert visual spatial orienting in ADHD and comparison boys, Study 2 comprised a dose-response study of methylphenidate for the ADHD group, and Study 3 was an investigation of biological and adoptive parents." | 2.68 | Covert visual spatial attention in boys with attention deficit hyperactivity disorder: lateral effects, methylphenidate response and results for parents. ( Hinshaw, SP; Nigg, JT; Swanson, JM, 1997) |
| "Attention-deficit hyperactivity disorder (ADHD) children participated in a double-blind placebo-controlled study in which the effects of a dosage of 15 mg methylphenidate (MPH) on auditory and visual selective attention tasks was determined by presenting frequent (90%) and infrequent (10%) stimuli in both relevant and irrelevant input channels." | 2.68 | Effects of methylphenidate on event-related potentials and performance of attention-deficit hyperactivity disorder children in auditory and visual selective attention tasks. ( Buitelaar, JK; Camfferman, G; Jonkman, LM; Kemner, C; Koelega, HS; van Engeland, H; vd Gaag, RJ; Verbaten, MN, 1997) |
| "Methylphenidate is a useful adjunct in the treatment of some children with Williams syndrome." | 2.68 | Treatment of children with Williams syndrome with methylphenidate. ( Bawden, HN; MacDonald, GW; Shea, S, 1997) |
| "To compare the side effect profiles of methylphenidate (MPH) and dexamphetamine (DEX) in children with attention deficit hyperactivity disorder (ADHD), as well as to determine which symptoms are genuine adverse effects of stimulant medication, as opposed to aspects of the child's underlying behavioral phenotype." | 2.68 | Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial. ( Barker, M; Efron, D; Jarman, F, 1997) |
| " Side effects increased slightly with the high dosage of medication but remained mild." | 2.68 | Effects of methylphenidate on preschool children with ADHD: cognitive and behavioral functions. ( Bennett, S; Firestone, P; Mercer, J; Musten, LM; Pisterman, S, 1997) |
| "Methylphenidate has short-term positive effects on children and adolescents with CD." | 2.68 | Clinical efficacy of methylphenidate in conduct disorder with and without attention deficit hyperactivity disorder. ( Abikoff, H; Ganeles, D; Klass, E; Klein, RG; Pollack, S; Seese, LM, 1997) |
| " However, the degree of improvement at times varied substantially across dosage and area of functioning." | 2.68 | Comprehensive school-based behavioral assessment of the effects of methylphenidate. ( Gulley, V; Northup, J, 1997) |
| " Twelve attention deficit with hyperactivity disorder (ADHD) children performed a Continuous Performance Test involving a button-press response to the letter X (CPT-X) under the influence of MPH in a double-blind placebo controlled acute dosage design." | 2.67 | Methylphenidate influences on both early and late ERP waves of ADHD children in a continuous performance test. ( Buitelaar, J; Koelega, HS; Overtoom, CC; Swaab-Barneveld, H; van der Gaag, RJ; van Engeland, H; Verbaten, MN, 1994) |
| " Transient sedation lasting 2 to 3 days occurred after initial administration or dosage increase; otherwise, clonidine was well tolerated." | 2.67 | Clonidine therapy for comorbid attention deficit hyperactivity disorder and conduct disorder: preliminary findings in a children's inpatient unit. ( Mandoki, MW; Schvehla, TJ; Sumner, GS, 1994) |
| "Fenfluramine dosage was gradually increased to a standardized dose of 1." | 2.67 | Fenfluramine and methylphenidate in children with mental retardation and attention deficit hyperactivity disorder: laboratory effects. ( Aman, MG; Arnold, LE; Kern, RA; McGhee, DE, 1993) |
| " The P3a and P3b latencies were significantly longer in the ADHD children on baseline testing; there were no latency differences between the groups of children when the normal controls were compared with the ADHD children on their optimal drug dosage (as determined by extensive behavioural and cognitive assessments)." | 2.67 | Changes in event-related potentials with stimulant medication in children with attention deficit hyperactivity disorder. ( Logan, WJ; Malone, MA; Taylor, MJ; Voros, JG, 1993) |
| " No dose-response relationship was found for either stimulant." | 2.67 | Classroom academic performance: improvement with both methylphenidate and dextroamphetamine in ADHD boys. ( Elia, J; Gullotta, CS; Rapoport, JL; Welsh, PA, 1993) |
| " Side effect ratings and EKGs were done weekly." | 2.67 | Side effects of methylphenidate and desipramine alone and in combination in children. ( Biancaniello, TM; Carlson, GA; Kelly, KL; Pataki, CS; Rapport, MD, 1993) |
| "Nineteen children with attention deficit disorder (ADD) participated in a double-blind trial consisting of four 2-week phases: sustained-release methylphenidate (MPH); standard MPH; a combination of standard and sustained-release MPH; and placebo." | 2.67 | Effects of sustained-release and standard preparations of methylphenidate on attention deficit disorder. ( Borgstedt, AD; Brumaghim, JT; Fitzpatrick, PA; Klorman, R, 1992) |
| "Covert antisocial behaviors such as stealing, destroying property, and cheating carry high risk for delinquency." | 2.67 | Covert antisocial behavior in boys with attention-deficit hyperactivity disorder: external validation and effects of methylphenidate. ( Heller, T; Hinshaw, SP; McHale, JP, 1992) |
| "Forty-six Attention Deficit Disorder (ADD) adolescents took a Continuous Performance Test (CPT) under placebo and methylphenidate (35." | 2.67 | Methylphenidate speeds evaluation processes of attention deficit disorder adolescents during a continuous performance test. ( Borgstedt, AD; Brumaghim, JT; Fitzpatrick, PA; Klorman, R, 1991) |
| "The response of 23 children with attention deficit disorder (ADD) with hyperactivity (+H) and 17 children with ADD without hyperactivity (-H) to three doses of methylphenidate (5, 10, and 15 mg twice a day) was evaluated in a triple-blind, placebo-controlled cross-over design using parent and teacher ratings of behavior, laboratory tests of ADD symptoms, and behavioral observations during academic performance." | 2.67 | Attention deficit disorder with and without hyperactivity: clinical response to three dose levels of methylphenidate. ( Barkley, RA; DuPaul, GJ; McMurray, MB, 1991) |
| "The adverse side effects of methylphenidate were evaluated in 27 children with attention deficit hyperactivity disorder and IQs of 48 to 74 who participated in a double-blind study of two doses of methylphenidate and placebo." | 2.67 | Adverse side effects of methylphenidate among mentally retarded children with ADHD. ( Breaux, AM; Feldman, H; Gosling, A; Handen, BL; McAuliffe, S, 1991) |
| "Methylphenidate was administered to two groups of boys, ages 8 through 11." | 2.67 | Differential effects of stimulant medication on reading performance of boys with hyperactivity with and without conduct disorder. ( Cantwell, DP; Forness, SR; Hanna, GL; Swanson, JM; Youpa, D, 1991) |
| "Dextroamphetamine tended to produce more compulsive behaviors, which were also more likely to resemble clinical obsessive-compulsive disorder (OCD), than did methylphenidate." | 2.67 | Motor/vocal tics and compulsive behaviors on stimulant drugs: is there a common vulnerability? ( Amass, J; Borcherding, BG; Elia, J; Keysor, CS; Rapoport, JL, 1990) |
| "Forty-eight attention deficit disorder patients, 12 to 18 years old and without previous stimulant therapy, received a double-blind trial of methylphenidate and placebo for 3 weeks each." | 2.67 | Clinical effects of a controlled trial of methylphenidate on adolescents with attention deficit disorder. ( Borgstedt, AD; Brumaghim, JT; Fitzpatrick, PA; Klorman, R, 1990) |
| "Attention deficit (ADDH) children self-paced the delivery of response pairs for paired-associate learning at about the rate previously shown to be conducive to relatively good learning in attention deficit." | 2.66 | Self-paced learning in children with attention deficit disorder with hyperactivity. ( Dalby, JT; Kinsbourne, M; Swanson, JM, 1989) |
| " Among the issues discussed are (a) differences between peer and adult provocation and (b) the roles of medication dosage and multimodality intervention for promoting socially competent behavior in children with ADHD." | 2.66 | Anger control in response to verbal provocation: effects of stimulant medication for boys with ADHD. ( Buhrmester, D; Heller, T; Hinshaw, SP, 1989) |
| " Performance on both tasks was better at a dosage of 1." | 2.66 | Effects of methylphenidate on inhibitory control in hyperactive children. ( Carr, RP; Chajczyk, D; Logan, GD; Schachar, RJ; Tannock, R, 1989) |
| "Some ADDH subjects displayed particularly large increases in output following methylphenidate and may represent an atypical subgroup of children who became overaroused on medication." | 2.66 | Does methylphenidate constrict cognitive functioning? ( Solanto, MV; Wender, EH, 1989) |
| " A multi-step analysis was used to examine the dose-response relationship, contribution of pre-stimulus levels of HR (i." | 2.66 | Attention deficit disorder and methylphenidate: a multi-step analysis of dose-response effects on children's cardiovascular functioning. ( DuPaul, GJ; Kelly, KL; Rapport, MD, 1988) |
| "This paper uses the example of an attention deficit disordered adolescent to illustrate how double-blind placebo controlled and multi-dose adjustment designs can be successfully implemented in routine clinical practice." | 2.66 | Assessing and treating attention deficit disorder in adolescents. The clinical application of a single-case research design. ( Kutcher, SP, 1986) |
| " Dosage should be directly manipulated in pediatric psychopharmacological studies and the practice of using mg/kg dosage schedules may no longer be necessary." | 2.66 | Hyperactivity and methylphenidate: rate-dependent effects on attention. ( DuPaul, GJ; Rapport, MD, 1986) |
| "Methylphenidate was an effective treatment over a 3-week period." | 2.66 | Which boys respond to stimulant medication? A controlled trial of methylphenidate in boys with disruptive behaviour. ( Everitt, B; Rutter, M; Schachar, R; Taylor, E; Thorley, G; Wieselberg, HM, 1987) |
| " Using signal detection theory methylphenidate significantly increased sensitivity (d) and did not change response bias (beta), independent of the dosage (5 to 20 mg/d)." | 2.66 | [Attention in hyperkinetic children: a signal detection analysis of the effect of methylphenidate]. ( Rossel, E, 1987) |
| "In the first study, 13 boys with attention deficit disorder participating in a summer treatment program went through a double-blind, within-subject trial of each form of methylphenidate and placebo." | 2.66 | Sustained release and standard methylphenidate effects on cognitive and social behavior in children with attention deficit disorder. ( Bijlsma, JJ; Hoza, J; Milich, R; Moorer, S; Pelham, WE; Schmidt, C; Sturges, J, 1987) |
| "The diagnosis of attention deficit disorder, residual type, should be considered in patients with prominent complaints of impulsivity, restlessness, emotional lability, and hot temper who do not suffer from schizophrenia or major mood disorder and do not have symptoms of schizotypal or borderline personality disorders." | 2.66 | A controlled study of methylphenidate in the treatment of attention deficit disorder, residual type, in adults. ( Reimherr, FW; Ward, M; Wender, PH; Wood, D, 1985) |
| "Methylphenidate (Ritalin) has been shown to have differential effects on hyperactive children's behavior as a function of dose level." | 2.66 | Methylphenidate in hyperactive children: differential effects of dose on academic, learning, and social behavior. ( Birmingham, BK; DuPaul, GJ; Rapport, MD; Stoner, G; Tucker, S, 1985) |
| "The short-term, dose-response effects of methylphenidate hydrochloride were evaluated on academic and social classroom measures in 29 children with attention deficit disorder." | 2.66 | Methylphenidate and children with attention deficit disorder. Dose effects on classroom academic and social behavior. ( Bender, ME; Booth, S; Caddell, J; Moorer, SH; Pelham, WE, 1985) |
| " Three dosage levels were used: placebo, 0." | 2.66 | Methylphenidate: rate-dependent drug effects in hyperactive boys. ( Weber, K, 1985) |
| "The impulsivity component of attention deficit disorder with hyperactivity requires regulation because its effects interfere with children's school performance and persist into adulthood." | 2.66 | Attention deficit disorder with hyperactivity: differential effects of methylphenidate on impulsivity. ( Birmingham, BK; DuPaul, GJ; Masse, G; Rapport, MD; Stoner, G, 1985) |
| " Further, these findings support previous observations that hyperactive patients' cognitive processing is optimized by a dosage of 0." | 2.65 | Effects of two doses of methylphenidate on cross-situational and borderline hyperactive children's evoked potentials. ( Bauer, LO; Borgstedt, AD; Coons, HW; Halpern, WI; Klorman, R; Salzman, LF, 1983) |
| "Following the hypothesis that attention deficit disorder in adults (attention deficit disorder, residual type; ADD, RT), as well as in children, is associated with decreased central dopaminergic activity, the authors measured lumbar cerebrospinal fluid monoamine metabolites in a group of adults with ADD, RT and matched control subjects." | 2.65 | Cerebrospinal fluid homovanillic acid and 5-hydroxy-indoleacetic acid in adults with attention deficit disorder, residual type. ( Ebert, MH; Reimherr, FW; Wender, PH; Wood, DR, 1984) |
| " The clinically titrated methylphenidate dosage levels for the subjects were related both to the augmenter-reducer classification and to pretreatment HR levels; that is, subjects who were ERP reducers and/or had higher HR levels, especially under reward conditions, were blindly titrated at higher levels than those who were augmenters and/or had lower HR levels." | 2.65 | Effects of reward and methylphenidate on heart rate response morphology of augmenting and reducing children. ( Ackerman, PT; Dykman, RA; Holcomb, PJ, 1984) |
| " The median drug dosage was ." | 2.65 | Effects of methylphenidate (Ritalin) on information processing in hyperactive children. ( Borkowski, JG; Reid, MK, 1984) |
| " Learning took place under placebo and under the child's regular dosage of methylphenidate." | 2.65 | State-dependent learning in children receiving methylphenidate. ( Shea, VT, 1982) |
| " Dosage was significantly associated with the decrease in height and weight percentile." | 2.65 | Growth of hyperactive children on maintenance regimen of methylphenidate. ( Gittelman, R; Mattes, JA, 1983) |
| " However, none of the measurements showed a significant difference between the conditions when methylphenidate was given with breakfast and the condition when methylphenidate was given 30 minutes before breakfast." | 2.65 | Methylphenidate hydrochloride given with or before breakfast: I. Behavioral, cognitive, and electrophysiologic effects. ( Baren, M; Deutsch, C; Sandman, CA; Swanson, JM, 1983) |
| "Four groups of children referred for attention disorders, learning disorders, or both were blindly titrated at statistically equivalent dosage levels of methylphenidate and improved more or less equivalently on several measures of attentiveness (cognitive style tests and reaction time)." | 2.65 | Methylphenidate effects on cognitive style and reaction time in four groups of children. ( Ackerman, PT; Dykman, RA; Holcomb, PJ; McCray, DS, 1982) |
| "Methylphenidate was added to both dosages, as well as administered alone." | 2.65 | Responses to methylphenidate and varied doses of caffeine in children with attention deficit disorder. ( Garfinkel, BD; Sloman, L; Webster, CD, 1981) |
| " Mean dosage levels, individually titrated by the team psychiatrist, were highest for the reading-disabled group, lowest for those with suspected attention disorders." | 2.65 | Effects of methylphenidate on selective and sustained attention in hyperactive, reading-disabled, and presumably attention-disordered boys. ( Ackerman, PT; Dykman, RA; McCray, DS, 1980) |
| "Eight children with minimal brain dysfunction were studied for their individual responses to two stimulant medications--methylphenidate hydrochloride and caffeine citrate." | 2.64 | Individual responses to methylphenidate and caffeine in children with minimal brain dysfunction. ( Garfinkel, BD; Sloman, L; Webster, CD, 1975) |
| "Fifty children with minimal brain dysfunction who had handwriting deficits received methylphenidate or placebo under double-blind conditions." | 2.64 | The effects of methylphenidate on the handwriting of children with minimal brain dysfunction. ( Artner, J; Lerer, MP; Lerer, RJ, 1977) |
| " Any long-term psychotropic treatment in childhood raises concerns about possible adverse neurological and psychiatric outcomes." | 2.61 | Neurological and psychiatric adverse effects of long-term methylphenidate treatment in ADHD: A map of the current evidence. ( Ansari, MT; Banaschewski, T; Buitelaar, JK; Carucci, S; Coghill, D; Danckaerts, M; Dittmann, RW; Falissard, B; Garas, P; Groom, MJ; Hall, CL; Hollis, C; Inglis, SK; Kochhar, P; Konrad, K; Kovshoff, H; Krinzinger, H; Liddle, EB; McCarthy, S; Nagy, P; Neubert, A; Roberts, S; Sayal, K; Sonuga-Barke, E; Wong, ICK; Xia, J; Zuddas, A, 2019) |
| "Methylphenidate is a first-line treatment for ADHD, however no previous meta-analysis has evaluated its overall efficacy for ADHD in children with comorbid intellectual disability (ID) or borderline intellectual functioning." | 2.61 | Therapeutic effects of methylphenidate for attention-deficit/hyperactivity disorder in children with borderline intellectual functioning or intellectual disability: A systematic review and meta-analysis. ( Carvalho, AF; Chen, TY; Chen, YW; Cheng, YS; Li, DJ; Lin, PY; Stubbs, B; Sun, CK; Tseng, PT; Wu, CK; Wu, MK, 2019) |
| " Food and Drug Administration (FDA) partial area under the curve (pAUC) bioavailability metrics have improved discrimination between specific generic MR-MPH products." | 2.61 | Drug Regimen Individualization for Attention-Deficit/Hyperactivity Disorder: Guidance for Methylphenidate and Dexmethylphenidate Formulations. ( Koller, L; Nguyen, LV; Patrick, KS; Radke, JL; Raymond, JR; Rodriguez, W; Straughn, AB, 2019) |
| "Methylphenidate is a widely-used drug for the treatment of attention deficit/hyperactivity disorder (ADHD) and other neuropsychiatric disorders." | 2.61 | How does methylphenidate affect default mode network? A systematic review. ( Goncalves, R; Pedroso, S; Santos, PH, 2019) |
| "Sleep disturbances are a feature of attention-deficit/hyperactivity disorder (ADHD) and an adverse event (AE) of methylphenidate treatment." | 2.61 | Sleep-Associated Adverse Events During Methylphenidate Treatment of Attention-Deficit/Hyperactivity Disorder: A Meta-Analysis. ( Cortese, S; Faraone, SV; Komolova, M; Po, MD, 2019) |
| "To determine the evidence on dose titration and adverse events associated with dose titration of stimulants for ADHD." | 2.61 | Evaluation of Methylphenidate Safety and Maximum-Dose Titration Rationale in Attention-Deficit/Hyperactivity Disorder: A Meta-analysis. ( Ching, C; Eslick, GD; Poulton, AS, 2019) |
| "We report on a case of severe chronic pain in a child with undiagnosed comorbid autism spectrum disorder and attention deficit hyperactivity disorder, where significant improvements in pain and function occurred following methylphenidate medication and parental behavioural training." | 2.58 | A case report and literature review of autism and attention deficit hyperactivity disorder in paediatric chronic pain. ( Bölte, S; von Heijne, M; Wicksell, RK; Wiwe Lipsker, C, 2018) |
| " Concerning adverse events associated with the treatment, our systematic review of randomised clinical trials (RCTs) demonstrated no increase in serious adverse events, but a high proportion of participants suffered a range of non-serious adverse events." | 2.58 | Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies. ( Aagaard, L; Buch Rasmussen, K; Gauci, D; Gerner, T; Gillies, D; Gluud, C; Groth, C; Håkonsen, SJ; Holmskov, M; Kielsholm, ML; Kirubakaran, R; Krogh, HB; Magnusson, FL; Moreira-Maia, CR; Nielsen, SS; Pedersen, N; Ramstad, E; Rosendal, S; Simonsen, E; Skoog, M; Storebø, OJ; Zwi, M, 2018) |
| " In one study, tics limited further dosage increases of methylphenidate." | 2.58 | Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. ( Osland, ST; Pringsheim, T; Steeves, TD, 2018) |
| " The anorexigenic effect of methylphenidate has been demonstrated in preclinical studies although the dosage and the administration routes differ in animals from those used for human beings." | 2.55 | [The effect of methylphenidate on appetite and weight]. ( Bou Khalil, R; Fares, N; Richa, S; Saliba, Y; Tamraz, J, 2017) |
| "To study in more depth the relationship between type, dose, or duration of methylphenidate offered to children and adolescents with attention deficit hyperactivity disorder and their risks of gastrointestinal adverse events based on our Cochrane systematic review." | 2.55 | Gastrointestinal adverse events during methylphenidate treatment of children and adolescents with attention deficit hyperactivity disorder: A systematic review with meta-analysis and Trial Sequential Analysis of randomised clinical trials. ( Gillies, D; Gluud, C; Groth, C; Holmskov, M; Krogh, HB; Magnusson, FL; Moreira-Maia, CR; Ramstad, E; Simonsen, E; Skoog, M; Storebø, OJ; Zwi, M, 2017) |
| "Methylphenidate derivatives were associated with a significantly decreased risk of irritability compared to placebo (risk ratio [RR] = 0." | 2.55 | Risk of Irritability With Psychostimulant Treatment in Children With ADHD: A Meta-Analysis. ( Bloch, MH; Cohen, SC; Coughlin, CG; Ferracioli-Oda, E; Leckman, JF; Mulqueen, JM; Stuckelman, ZD, 2017) |
| "Children with autistic spectrum disorder (ASD) frequently present with inattention, impulsivity and hyperactivity, which are the cardinal symptoms of attention deficit hyperactivity disorder (ADHD)." | 2.55 | Methylphenidate for children and adolescents with autism spectrum disorder. ( Deckx, L; Sturman, N; van Driel, ML, 2017) |
| " Withdrawals due to all-cause, adverse effects and lack of efficacy were defined as primary outcomes evaluating the safety of such medications." | 2.55 | An Evaluation on the Efficacy and Safety of Treatments for Attention Deficit Hyperactivity Disorder in Children and Adolescents: a Comparison of Multiple Treatments. ( Gao, J; He, S; Li, Y; Wang, Q; Zhang, Y, 2017) |
| " Outcomes like response rate, ADHD Rating Scale (ADHD-RS) score, and adverse events were compared between ATX and MPH treatments." | 2.55 | Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: Meta-analysis based on head-to-head trials. ( Fang, Q; Liu, Q; Qin, L; Zhang, H, 2017) |
| " Given that immediate-release and/or tablet/capsule formulations may decrease adherence to methylphenidate treatment, several drug companies have been developing novel long-acting and/or liquid/chewable formulations that may improve adherence as well as (for long-acting formulations) reduce abuse potential, decrease stigma associated with multiple administrations per day, and decrease the potential for adverse effects related to dosage peak." | 2.55 | New Formulations of Methylphenidate for the Treatment of Attention-Deficit/Hyperactivity Disorder: Pharmacokinetics, Efficacy, and Tolerability. ( Cortese, S; D'Acunto, G; Konofal, E; Masi, G; Vitiello, B, 2017) |
| " Areas covered: Physical adverse effects, psychiatric adverse events and brain development Expert opinion: Some physical adverse events have been described (e." | 2.55 | An update on the safety of psychostimulants for the treatment of attention-deficit/hyperactivity disorder. ( Dietrich, A; Groenman, AP; Hoekstra, PJ; Schweren, LJ, 2017) |
| " Methylphenidate is safe in healthy children and has shown to have no cardiac side effects in these patients." | 2.53 | Psychopharmacology of Attention-Deficit Hyperactivity Disorder: Effects and Side Effects. ( Golmirzaei, J; Hamzei, E; Kamal, MA; Mahboobi, H; Mushtaq, G; Yazdanparast, M, 2016) |
| "Amphetamine dependence is relatively common in Sweden and it is the most frequently used substance among patients with intravenous drug abuse." | 2.53 | [Substitution therapy tested against amphetamine dependence]. ( Bloniecki Kallio, V; Franck, J; Guterstam, J, 2016) |
| "Methylphenidate (MPD) is a central nervous system (CNS) stimulant, which belongs to the phenethylamine group and is mainly used in the treatment of attention deficit hyperactive disorder (ADHD)." | 2.53 | From Clinical Application to Cognitive Enhancement: The Example of Methylphenidate. ( Busardò, FP; Cipolloni, L; Frati, P; Kyriakou, C; Zaami, S, 2016) |
| " Deviations from suggested routes of administration such as crushing, chewing, intravenous administration, or snorting stimulant medication may alter the release rate, absorption, and bioavailability of the active drug." | 2.53 | Safety and efficacy considerations due to misuse of extended-release formulations of stimulant medications. ( Jain, R; Stark, JG, 2016) |
| " For patients with pre-existing tic disorders, the usual recommended dosing of stimulants should be used because supratherapeutic doses of this class of medications, specifically dextroamphetamine, have shown to exacerbate tic disorders." | 2.53 | Attention Deficit Hyperactive Disorder and Occurrence of Tic Disorders in Children and Adolescents-What is the Verdict. ( Cooke, T; So, TY, 2016) |
| "Clinical practice currently restricts the use of psychostimulant medications in children with tics or a family history of tics for fear that tics will develop or worsen as a side effect of treatment." | 2.52 | Meta-Analysis: Risk of Tics Associated With Psychostimulant Use in Randomized, Placebo-Controlled Trials. ( Bloch, MH; Cohen, SC; Coughlin, CG; Ferracioli-Oda, E; Leckman, JF; Mulqueen, JM; Stuckelman, ZD, 2015) |
| "Methylphenidate was compared to placebo (175 trials) or no intervention (10 trials)." | 2.52 | Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). ( Buch Rasmussen, K; Forsbøl, B; Gauci, D; Gillies, D; Gluud, C; Groth, C; Holmskov, M; Kirubakaran, R; Krogh, HB; Magnusson, FL; Moreira-Maia, CR; Nilausen, TD; Ramstad, E; Rosendal, S; Simonsen, E; Skoog, M; Storebø, OJ; Zwi, M, 2015) |
| "Methylphenidate was associated with an increased risk of non-serious adverse events (1." | 2.52 | Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: Cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trials. ( Forsbøl, B; Gauci, D; Gillies, D; Gluud, C; Groth, C; Holmskov, M; Kirubakaran, R; Krogh, HB; Magnusson, FL; Moreira-Maia, CR; Nilausen, TD; Ramstad, E; Rasmussen, KB; Rosendal, S; Simonsen, E; Skoog, M; Storebø, OJ; Zwi, M, 2015) |
| " This review provides an overview of current understanding of MPH efficacy, safety, and dosage in adult and pediatric ADHD patients, as well as adult animal studies and pioneering studies in juvenile animals treated with MPH." | 2.52 | Evolution of the Study of Methylphenidate and Its Actions on the Adult Versus Juvenile Brain. ( Gao, WJ; Urban, KR, 2015) |
| "Treatment with methylphenidate, which blocks dopamine and noradrenaline transporters, is clinically efficacious in reducing the symptoms of ADHD." | 2.50 | Meta-analysis of the association between dopamine transporter genotype and response to methylphenidate treatment in ADHD. ( Ettinger, U; Kambeitz, J; Romanos, M, 2014) |
| "Methylphenidate (MPH) is an effective treatment for ADHD symptoms, but its impact on cognition is less clearly understood." | 2.50 | Effects of methylphenidate on cognitive functions in children and adolescents with attention-deficit/hyperactivity disorder: evidence from a systematic review and a meta-analysis. ( Coghill, DR; Currie, J; Gagliano, A; Pedroso, S; Seth, S; Usala, T, 2014) |
| "A bibliographic search was performed in the MEDLINE, EMBASE and PsycINFO databases for prospective studies evaluating the incidence of adverse events (AEs) in children and adolescents treated for ADHD." | 2.50 | Safety of medicines used for ADHD in children: a review of published prospective clinical trials. ( Bonati, M; Clavenna, A, 2014) |
| "Methylphenidate (MPH) plays a principal role in the multimodal treatment of attention-deficit/hyperactivity disorder (ADHD)." | 2.50 | An evaluation of the pharmacokinetics of methylphenidate for the treatment of attention-deficit/ hyperactivity disorder. ( Banaschewski, T; Döpfner, M; Frölich, J; Görtz-Dorten, A, 2014) |
| "Desipramine and placebo were similar on "all-cause treatment discontinuation" (RD -0." | 2.50 | Tricyclic antidepressants for attention deficit hyperactivity disorder (ADHD) in children and adolescents. ( Castells, X; Ehimare, UP; Otasowie, J; Smith, CH, 2014) |
| " However, their pharmacokinetic profiles differ with respect to peak plasma levels and the rate at which peak levels are attained and decline." | 2.49 | Comparison of the pharmacokinetics and clinical efficacy of new extended-release formulations of methylphenidate. ( Maldonado, R, 2013) |
| "Comorbid psychiatric disorders should be addressed with disorder-specific therapies while associated symptoms also often improve with treatment of the ADHD core symptoms." | 2.49 | [Adult attention deficit/hyperactivity disorder, associated symptoms and comorbid psychiatric disorders: diagnosis and pharmacological treatment]. ( Alm, B; Paslakis, G; Schredl, M; Sobanski, E, 2013) |
| " Because of its short duration of effect, MPH-IR had to be dosed multiple times daily." | 2.49 | The use of methylphenidate hydrochloride extended-release oral suspension for the treatment of ADHD. ( Childress, A; Sallee, FR, 2013) |
| " Recent studies have suggested that early life exposure of healthy rodent models to methylphenidate resulted in altered sleep/wake cycle, heightened stress reactivity, and, in fact, a dosage previously thought of as therapeutic depressed neuronal function in juvenile rats." | 2.49 | Methylphenidate and the juvenile brain: enhancement of attention at the expense of cortical plasticity? ( Gao, WJ; Urban, KR, 2013) |
| "Methylphenidate (MPH) is a first line option in the psychopharmacologic treatment of adults with Attention-Deficit/Hyperactivity Disorder (ADHD)." | 2.49 | Pharmacogenetics of response to methylphenidate in adult patients with Attention-Deficit/Hyperactivity Disorder (ADHD): a systematic review. ( Bau, CH; Contini, V; Grevet, EH; Rohde, LA; Rovaris, DL; Victor, MM, 2013) |
| "Methylphenidate was more efficacious than placebo for reducing ADHD symptoms and it was associated with a higher proportion of patients dropping out due to adverse effects." | 2.49 | Treatment discontinuation with methylphenidate in adults with attention deficit hyperactivity disorder: a meta-analysis of randomized clinical trials. ( Capellà, D; Castells, X; Cunill, R, 2013) |
| "Methylphenidate is a centrally acting sympathomimetic used for the treatment of attention deficit/hyperactivity disorder in children and adolescents and for narcolepsy in adults." | 2.49 | First trimester in utero exposure to methylphenidate. ( Aagaard, L; Damkier, P; Dideriksen, D; Hallas, J; Pottegård, A, 2013) |
| " Adverse effects were also evaluated." | 2.49 | Efficacy and adverse effects of venlafaxine in children and adolescents with ADHD: a systematic review of non-controlled and controlled trials. ( Berk, M; Freeman, RD; Ghanizadeh, A, 2013) |
| " While medications for ADHD are generally well-tolerated, there are common, although less severe, as well as rare but severe adverse events AEs during treatment with ADHD drugs." | 2.49 | Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. ( Banaschewski, T; Buitelaar, J; Coghill, D; Cortese, S; Danckaerts, M; Dittmann, RW; Graham, J; Holtmann, M; Sergeant, J; Taylor, E, 2013) |
| "To assess how threshold oppositional defiant disorder (ODD), inattention, and hyperactivity-impulsivity affect the response to atomoxetine versus methylphenidate." | 2.48 | How oppositionality, inattention, and hyperactivity affect response to atomoxetine versus methylphenidate: a pooled meta-analysis. ( Granger, RE; Hazell, PL; Kohn, MR; van Wyk, GW; Walton, RJ, 2012) |
| "Placebo and pharmacodynamic (PD) models were developed which link temporal measures of efficacy in children with attention deficit hyperactivity disorder (ADHD) and methylphenidate (MPH) plasma concentrations from adults." | 2.48 | Population pharmacodynamic modeling of various extended-release formulations of methylphenidate in children with attention deficit hyperactivity disorder via meta-analysis. ( Berwaerts, J; Gibiansky, E; Gibiansky, L; Kimko, H; Massarella, J; Starr, HL; Wiegand, F, 2012) |
| "Methylphenidate displays a high degree of effectiveness and safety in the treatment of adults at doses of around 1 mg/kg/day." | 2.48 | [Diagnosis and treatment of attention deficit hyperactivity disorder in adults]. ( Bosch, R; Casas, M; Chalita, PJ; Palomar, G; Prats, L; Ramos-Quiroga, JA; Vidal, R, 2012) |
| " In seeking to optimize individual response and outcomes to stimulant therapy, important considerations include the selection of stimulant class, the choice of long- or short-acting stimulant formulations, addressing effectively any emergent adverse effects and strategies aimed at enhancing adherence to dosing regimen and persistence on therapy." | 2.48 | Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options. ( Coghill, D; Hechtman, L; Hodgkins, P; Shaw, M, 2012) |
| "OROS methylphenidate (MPH) was evaluated in two large adult clinical trials, and in 2008 it was approved in the USA to treat ADHD in adults aged up to 65 years." | 2.47 | OROS methylphenidate hydrochloride for adult patients with attention deficit/hyperactivity disorder. ( McBurnett, K; Starr, HL, 2011) |
| " A dose-response relationship was found, indicating that efficacy could be increased by SMD 0." | 2.47 | Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-regression analysis. ( Bosch, R; Casas, M; Castells, X; Nogueira, M; Ramos-Quiroga, JA; Rigau, D; Vidal, X, 2011) |
| "High incidence of sleep disorders in children with ADHD may be associated with a substantial impact on their quality of life and exacerbation of ADHD symptoms." | 2.47 | Pharmacological treatment of ADHD and the short and long term effects on sleep. ( Guilleminault, C; Huang, YS; Tsai, MH, 2011) |
| "Inclusion criteria were at least two epileptic seizures in the previous 6 months and a diagnosis of ADHD based on DSM-IV criteria." | 2.47 | Efficacy and safety of methylphenidate in treating ADHD symptoms in children and adolescents with uncontrolled seizures: a Brazilian sample study and literature review. ( Agertt, F; Casella, EB; Ferreira, MG; Koneski, JA, 2011) |
| " The adverse events related to the therapy with IR-MPH, OROS-MPH or AHC were mild and the incidence rates of adverse events were not significantly different among the three groups." | 2.47 | [Effectiveness and safety of methylphenidate and atomoxetine for attention deficit hyperactivity disorder: a systematic review]. ( Lv, XZ; Shu, Z; Wu, SS; Zhan, SY; Zhang, YW, 2011) |
| "In patients with attention deficit disorder complicated by epilepsy, stimulant therapy is generally safe, provided seizures are controlled by antiepileptic medication." | 2.47 | Utility of the electroencephalogram in attention deficit hyperactivity disorder. ( Millichap, JG; Millichap, JJ; Stack, CV, 2011) |
| "Methylphenidate treatment is recommended in cases when ADHD diagnosis was confirmed." | 2.47 | [Efficacy and safety of stimulants and non-stimulants in adults with attention deficit hyperactivity disorder (ADHD)]. ( Golubchik, P; Sever, J; Weizman, A, 2011) |
| " To address the question of long-term use of MPH, we published the data of 30 chronically treated children and also saw no difference compared to untreated children." | 2.46 | Prospective follow-up studies found no chromosomal mutagenicity of methylphenidate therapy in ADHD affected children. ( Gerlach, M; Kämpf, K; Oli, RG; Stopper, H; Walitza, S; Warnke, A, 2010) |
| " Unfortunately, results of current ADHD pharmacogenetic studies have not been entirely consistent, possibly due to differences in study design, medication dosing regimens and outcome measures." | 2.46 | Progress and promise of attention-deficit hyperactivity disorder pharmacogenetics. ( Froehlich, TE; McGough, JJ; Stein, MA, 2010) |
| "Pharmacological treatment for attention deficit hyperactivity disorder, although highly effective, presents a marked variability in clinical response, optimal dosage needed and tolerability." | 2.46 | A current update on ADHD pharmacogenomics. ( Genro, JP; Hutz, MH; Kieling, C; Rohde, LA, 2010) |
| "Methylphenidate appears to cause minor increases in BP and HR." | 2.46 | Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder. ( Besag, FM; Stiefel, G, 2010) |
| " Coefficients of variance of pharmacokinetic measures can estimate the levels of pharmacokinetic variability based on the measurable variance between different individuals receiving the same dose of stimulant (interindividual variability) and within the same individual over multiple administrations (intraindividual variability)." | 2.46 | Pharmacokinetic variability of long-acting stimulants in the treatment of children and adults with attention-deficit hyperactivity disorder. ( Adeyi, BA; Ermer, JC; Pucci, ML, 2010) |
| " There is little information on the long-term safety of methylphenidate in adults, although the number of serious adverse effects reported to regulatory authorities has, so far, been low." | 2.45 | Safety of therapeutic methylphenidate in adults: a systematic review of the evidence. ( Godfrey, J, 2009) |
| " The relationship between dosage and effect size was explored by weighted regression analysis." | 2.45 | Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder. ( Becker, T; Fegert, JM; Kilian, R; Koesters, M; Weinmann, S, 2009) |
| "Children with Fetal Alcohol Spectrum Disorders (FASD) may have significant neurobehavioural problems persisting into adulthood." | 2.45 | Systematic review of interventions for children with Fetal Alcohol Spectrum Disorders. ( Bower, C; Elliott, EJ; Peadon, E; Rhys-Jones, B, 2009) |
| "To review recent literature on the different stimulant preparations regarding efficacy and safety in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) and describe advantages and disadvantages of the many available dosage formulations." | 2.45 | An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder. ( Angstadt, K; Bogart, GT; Chavez, B; Ehret, MJ; Goldberg, KR; Paulino, RE; Sopko, MA, 2009) |
| "Methylphenidate treatment is equally efficient in children with isolated attention-deficit hyperactivity disorder and in children with attention-deficit hyperactivity disorder and epilepsy (70%-77%)." | 2.45 | Attention-deficit disorders and epilepsy in childhood: incidence, causative relations and treatment possibilities. ( Goldberg-Stern, H; Kaufmann, R; Shuper, A, 2009) |
| "Approximately half of children with Tourette's syndrome experience comorbid attention-deficit/hyperactivity disorder (ADHD)." | 2.45 | Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. ( Bloch, MH; Landeros-Weisenberger, A; Leckman, JF; Panza, KE, 2009) |
| "d-Amphetamine has a mechanism independent of neuronal firing rate, displacing intraneuronal stores of catecholamines, delaying their reuptake and inhibiting catabolism by monoamine oxidase." | 2.45 | The neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety. ( Cheetham, SC; Heal, DJ; Smith, SL, 2009) |
| " They are generally safe in special populations." | 2.45 | Safety of stimulant treatment in attention deficit hyperactivity disorder: Part I. ( Kuchibhatla, A; Merkel, RL, 2009) |
| "Methylphenidate (MPH) is a central nervous system stimulant that is mainly used for Attention-Deficit/Hyperactivity Disorder (ADHD)." | 2.44 | Methylphenidate exposure in juvenile period elicits locomotion changes and anxiolytic-like behavior in adulthood: Evidence using zebrafish as a translational model. ( Barcellos, LJG; Berton, N; Biazus, IC; do Prado, L; Fortuna, M; Freddo, N; Nardi, J; Oliveira, AP; Pompermaier, A; Rossato-Grando, LG; Siqueira, L; Soares, SM; Tamagno, WA; Varela, ACC, 2024) |
| " The disadvantages of such formulations include the need for multiple daily dosing and a potential for abuse." | 2.44 | Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review. ( Findling, RL, 2008) |
| "Hyperkinetic or attention deficit hyperactivity disorders (ADHD) are characterized by three symptoms: attention deficit, hyperactivity and impulsiveness." | 2.44 | [My child is so restless]. ( Schlamp, D, 2007) |
| " These issues include: (1) sequencing and dosage of treatments being combined and compared; (2) difficulty drawing valid conclusions about individual components of treatment when treatment packages are employed; (3) differing results emerging from measurement tools that purportedly measure the same domain; and (4) the resultant difficulty in reaching a summary conclusion when multiple outcome measures yielding conflicting results are used." | 2.44 | Multimodal treatments for childhood attention-deficit/hyperactivity disorder: interpreting outcomes in the context of study designs. ( Hoza, B; Hurt, E; Kaiser, NM, 2007) |
| "Children and adolescents with autism spectrum disorders and intellectual disability have a high prevalence of attention-deficit/hyperactive disorder, mood disorders, catatonia and repetitive behaviours compared with children without autism." | 2.44 | Children with autism spectrum disorders and intellectual disability. ( McCarthy, J, 2007) |
| " The methylphenidate transdermal system (MTS) is the first stimulant patch dosage formulation to be approved by the US Food and Drug Administration for the treatment of the symptoms of ADHD in children aged 6 to 12 years." | 2.44 | Practical management of cutaneous reactions to the methylphenidate transdermal system: recommendations from a dermatology expert panel consensus meeting. ( Fowler, JF; Paller, AS; Warshaw, EM; Zirwas, MJ, 2008) |
| "Methylphenidate treatment produces an increase in dopamine (DA) signaling through multiple actions, including blockade of the DA reuptake transporter and amplification of DA response duration, disinhibition of DA D2 autoreceptors and amplification of DA tone, and activation of D1 receptors on the postsynaptic neuron." | 2.44 | Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder. ( Wilens, TE, 2008) |
| " Although MPH is a racemic compound composed of a 50:50 mixture of dexmethylphenidate (d-MPH) and l-methylphenidate (l-MPH), animal and human studies have confirmed that the d-MPH isomer is responsible for the pharmacodynamic effect of MPH." | 2.44 | Does chirality matter? pharmacodynamics of enantiomers of methylphenidate in patients with attention-deficit/hyperactivity disorder. ( Quinn, D, 2008) |
| "Methylphenidate is a first-line therapy for attention deficit hyperactivity disorder, the most prevalent neuropsychiatric disorder of childhood." | 2.43 | Methylphenidate HCl: therapy for attention deficit hyperactivity disorder. ( Capp, PK; Conlon, C; Pearl, PL, 2005) |
| "Methylphenidate has been rigorously studied and found to be a safe and effective drug." | 2.43 | [Attention deficit hyperactivity disorder: pharmacological options that are not "Ritalin"]. ( Gross-Tsur, V; Shmueli, D, 2005) |
| "Adolescents tend to have shorter substance use histories therefore they often experience emergency/acute care health treatment resulting from substance use related trauma and/or overdose." | 2.43 | Adolescent substance use: brief interventions by emergency care providers. ( Burke, PJ; O'Sullivan, J; Vaughan, BL, 2005) |
| "Methylphenidate (MPH) is a CNS agent thought to act on dopamine and noradrenaline (norepinephrine) pathways and thereby blocks the reuptake of these neurotransmitters into the presynaptic neuron." | 2.43 | Methylphenidate transdermal system: In attention-deficit hyperactivity disorder in children. ( Anderson, VR; Scott, LJ, 2006) |
| " Clinical trials have shown OROS MPH to have a continued action over a 12-h period, to be superior to placebo and to be as effective as immediate-release MPH dosed three times daily, in reducing symptoms of attention-deficit hyperactivity disorder, with similar incidence of side effects." | 2.43 | Osmotic, controlled-release methylphenidate for the treatment of ADHD. ( Coghill, D; Seth, S, 2006) |
| "Dexmethylphenidate is a chirally pure d-isomer of the racemic mixture of methylphenidate." | 2.43 | Dexmethylphenidate extended-release capsules for the treatment of attention deficit hyperactivity disorder. ( Kowalik, S; Minami, H; Silva, R, 2006) |
| "Methylphenidate is still the treatment of choice for the condition and, although it has been shown that neither methylphenidate nor other psychostimulants provoke seizures, there is still a possibility that seizure frequency may increase in children with active epilepsy." | 2.43 | Optimizing therapy of seizures in children and adolescents with ADHD. ( Aldenkamp, AP; Arzimanoglou, A; Reijs, R; Van Mil, S, 2006) |
| " The oral bioavailability of MPH in females may be lower than in males." | 2.42 | Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: focus on methylphenidate formulations. ( Markowitz, JS; Patrick, KS; Straughn, AB, 2003) |
| "Methylphenidate, the most common treatment for attention deficit hyperactivity disorder (ADHD), increases extracellular dopamine in the brain, which is associated with its reinforcing as well as its therapeutic effects." | 2.42 | Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. ( Swanson, JM; Volkow, ND, 2003) |
| "When used to treat children with Attention Deficit Hyperactivity Disorder, methylphenidate (MPH) acts primarily by blocking the dopamine (DA) transporter (DAT) and increasing extracellular DA in the striatum." | 2.42 | Serum and brain concentrations of methylphenidate: implications for use and abuse. ( Swanson, JM; Volkow, ND, 2003) |
| " Children with ADHD treated with stimulants for as long as 2 years continue to benefit from the treatment, with improvements observed in ADHD symptoms, comorbid oppositional defiant disorder, and academic and social functioning, with no significant problems of tolerance or adverse effects." | 2.42 | Long-term use of stimulants in children with attention deficit hyperactivity disorder: safety, efficacy, and long-term outcome. ( Greenfield, B; Hechtman, L, 2003) |
| "Methylphenidate is a rapidly absorbed medication that, in its d-isomer form, readily penetrates the CNS, particularly the striatum." | 2.42 | Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate. ( Doffing, MA; Wolraich, ML, 2004) |
| " Methylphenidate and amphetamine-based stimulants are now available in longer-acting, once-daily and shorter-acting divided dosing schedules." | 2.42 | Pharmacological management of attention-deficit hyperactivity disorder. ( Reeves, G; Schweitzer, J, 2004) |
| "Dexmethylphenidate was generally well tolerated in children with ADHD; adverse events were consistent with those known to be associated with agents containing methylphenidate." | 2.41 | Dexmethylphenidate. ( Figgitt, DP; Keating, GM, 2002) |
| ", blood pressure [BP], heart rate [HR], height/weight) are mostly transient, dose-dependent, easily rectified with dosage adjustments, and considered minor from a clinical perspective considering the breadth and level of improvement in behavior and cognitive functioning observed in most children." | 2.41 | Attention deficit/hyperactivity disorder and methylphenidate. A review of height/weight, cardiovascular, and somatic complaint side effects. ( Moffitt, C; Rapport, MD, 2002) |
| "Dexmethylphenidate is a schedule II drug." | 2.41 | Dexmethylphenidate--Novartis/Celgene. Focalin, D-MPH, D-methylphenidate hydrochloride, D-methylphenidate, dexmethylphenidate, dexmethylphenidate hydrochloride. ( , 2002) |
| "Methylphenidate (Ritalin) is a commonly used central nervous stimulant." | 2.41 | Ritalin revisited: does it really help in neurological injury? ( Kajs-Wyllie, M, 2002) |
| "Treatment with methylphenidate has been advocated in patients with traumatic brain injury and stroke, cancer patients, and those with human immunodeficiency virus infection." | 2.41 | Methylphenidate: its pharmacology and uses. ( Challman, TD; Lipsky, JJ, 2000) |
| " It attempts to arrive at a reasonable upper limit of dosage for clinical purposes." | 2.41 | How high a dose of stimulant medication in adult attention deficit hyperactivity disorder? ( Sachdev, PS; Trollor, JN, 2000) |
| " Mounting controversy over the widespread use of methylphenidate and possible life-threatening effects from its long-term use make it imperative that alternative modalities be implemented for ADHD management." | 2.41 | Attention deficit/hyperactivity disorder (ADHD) in children: rationale for its integrative management. ( Kidd, PM, 2000) |
| "Methylphenidate also has an adverse event profile that requires consideration." | 2.41 | How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. ( King, J; Langford, S; Moher, D; Pham, B; Schachter, HM, 2001) |
| " Although the US FDA approved MPH in the 1960s, the pharmacokinetic (PK) properties of serum concentrations of MPH in children with ADHD were not described until the 1980s, and then in only a few cases." | 2.41 | Pharmacokinetic and pharmacodynamic properties of stimulants: implications for the design of new treatments for ADHD. ( Swanson, JM; Volkow, ND, 2002) |
| "Rapid-release psychostimulants are commonly used to treat attention-deficit hyperactivity disorder (ADHD), but midday dosing requirements and poor compliance rates have prompted the development of sustained-release formulations." | 2.40 | Optimizing ADHD therapy with sustained-release methylphenidate. ( Carson, DS; Lawrence, DB; Lawrence, JD, 1997) |
| " It is both well tolerated and efficacious in the treatment of attention deficit hyperactivity disorder, and is associated with few serious adverse effects." | 2.40 | Safety issues in the use of methylphenidate. An American perspective. ( Rappley, MD, 1997) |
| "Clonidine has not been adequately examined but seems to have small or uncertain effects." | 2.40 | Antidepressants in the treatment of attention-deficit/hyperactivity disorder. ( Popper, CW, 1997) |
| " Since psychostimulant treatment often requires frequent dosing and may be associated with unacceptable side effects and risks, other classes of medication have been studied as possible treatment alternatives." | 2.40 | Psychopharmacology of ADHD: children and adolescents. ( Dogin, JW; Findling, RL, 1998) |
| "However, current substance abuse precludes use of the drug and former abuse liability and social adjustment problems are relative contraindications." | 2.40 | [Central nervous system stimulants and their potential risk of abuse in hyperkinetic disorders]. ( Aanonsen, NO, 1999) |
| "Methylphenidate is a short-acting stimulant with a duration of action of 1 to 4 hours and a pharmacokinetic half-life of 2 to 3 hours." | 2.40 | Pharmacokinetics and clinical effectiveness of methylphenidate. ( Abernethy, DR; Cross, JT; Kimko, HC, 1999) |
| " Thirty-two reports (29 studies) evaluated adverse effects of drug therapy; many of the side effects associated with stimulant use appear to be relatively mild and of short duration and to respond to dosing or timing adjustments." | 2.40 | Treatment of attention-deficit/hyperactivity disorder. ( Boyle, M; Cunningham, C; Jadad, AR; Kim, M; Schachar, R, 1999) |
| "Evaluations for ADHD and substance abuse were completed." | 2.39 | The dual diagnosis of attention-deficit/hyperactivity disorder and substance abuse: case reports and literature review. ( Isaacson, JH; Musial, J; Schubiner, H; Tzelepis, A; Warbasse, LH; Zacharek, M, 1995) |
| " Included are the drugs' putative mechanisms of action, pharmacology, toxicology, indications for their use, short-term and long-term actions, adverse effects, specific dosing regimens, therapeutic monitoring techniques, alternative medications, and drug interactions." | 2.38 | Pharmacologic treatment of attention deficit hyperactivity disorder. ( Greenhill, LL, 1992) |
| "Those disorders discussed are attention deficit disorder, conduct disorders, anxiety disorders, sleep disorders, schizophrenia, autism, Tourette's syndrome, mental retardation, depressive illness, manic depressive illness, eating disorders, and enuresis." | 2.37 | Pharmacologic treatment of psychiatric and neurodevelopmental disorders in children and adolescents (Part 1). ( McDaniel, KD, 1986) |
| "The diagnosis of attention deficit disorder must be confirmed before drug therapy is started, and parents must be counseled about the use of stimulant medications." | 2.37 | Use of stimulant medications in children. ( Morgan, AM, 1988) |
| "Methylphenidate was the most frequently used drug and Sweden had the highest use reaching 25/1000 in 2020 compared to 16/1000 and 18/1000 in Denmark and Norway, respectively." | 1.91 | Trends in use of attention deficit hyperactivity disorder medication among children and adolescents in Scandinavia in 2010-2020. ( Andersen, JH; Cesta, CE; Furu, K; Hartz, I; Rasmussen, L; Reutfors, J; Sørensen, AMS; Wesselhöeft, R, 2023) |
| "Methylphenidate is a stimulant used to treat attention deficit and hyperactivity disorder (ADHD)." | 1.91 | Pre-clinical evidence that methylphenidate increases motivation and/or reward preference to search for high value rewards. ( Baltazar, G; Da Cunha, C; Esaki, JY; Fuentes, R; Levcik, D; Pochapski, JA; Pulido, LN; Sanchez, WN; Stresser, JL; Sugi, A, 2023) |
| "The Monitor Mental Health and Substance Use (2021) shows that almost one in twenty students has used ADHD medication for non-medical use at least once in the past year." | 1.91 | [ADHD medication to improve academic performance?] ( Bakker, M; van den Berk-Bulsink, MJE; van der Horst, M, 2023) |
| "The concomitant use of MPHs and SSRIs showed generally safe profiles in adolescent ADHD patients with depression." | 1.91 | Safety outcomes of selective serotonin reuptake inhibitors in adolescent attention-deficit/hyperactivity disorder with comorbid depression: ( Alhambra, DP; Kim, C; Kim, SJ; Lee, DY; Lee, J; Lee, S; Lee, YH; Park, J; Park, RW; Shin, Y; Tan, EH; Yang, SJ, 2023) |
| "Methylphenidate (MPH) is a psychostimulant which inhibits the uptake of dopamine and norepinephrine transporters, DAT and NET, and is mostly used to treat Attention Deficit/Hyperactivity Disorder." | 1.91 | An exploratory analysis of the performance of methylphenidate regimens based on a PKPD model of dopamine and norepinephrine transporter occupancy. ( Nekka, F; Robaey, P; Soufsaf, S, 2023) |
| " After controlling for the effects of these variables using propensity scores, there was little evidence of an effect on growth (24 months height velocity SD score difference -0·07 (95% CI -0·18 to 0·04; p=0·20) or increased risk of psychiatric or neurological adverse events in the methylphenidate group compared with the no-methylphenidate group." | 1.91 | Long-term safety of methylphenidate in children and adolescents with ADHD: 2-year outcomes of the Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE) study. ( Banaschewski, T; Buitelaar, J; Carucci, S; Coghill, D; Danckaerts, M; Dittmann, RW; Falissard, B; Garas, P; Häge, A; Hollis, C; Inglis, SK; Konrad, K; Kovshoff, H; Liddle, E; Man, KKC; McCarthy, S; Nagy, P; Neubert, A; Rosenthal, E; Sonuga-Barke, EJS; Wong, ICK; Zuddas, A, 2023) |
| "Clonidine was associated with markedly higher clinical efficacy vs." | 1.91 | Efficacy of clonidine in the treatment of children with tic disorder co-morbid with attention deficit hyperactivity disorder. ( Hu, B; Huang, XH; Wang, GL; Yuan, Y; Zeng, KD; Zhang, W, 2023) |
| " HC received 30 mg methylphenidate (MPH) and ADHD patients received either MPH or lisdexamphetamine (LDX) as selected by their clinician, with dosage individually determined for optimal effect." | 1.91 | Salience and hedonic experience as predictors of central stimulant treatment response in ADHD - A resting state fMRI study. ( Msghina, M; Rode, J; Runnamo, R; Thunberg, P, 2023) |
| "Adult patients with ADHD, who are not treated with MPH (-MPH), showed varied Arg/NO pathway, but Arg bioavailability seemed to be consistent over the groups." | 1.91 | l-Arginine/nitric oxide pathway and oxidative stress in adults with ADHD: Effects of methylphenidate treatment. ( Beckmann, B; Böhme, P; Emons, B; Hanusch, B; Juckel, G; Lücke, T; Sinningen, K; Tsikas, D, 2023) |
| "Methylphenidate is an effective first-line treatment for attention-deficit/hyperactivity disorder (ADHD)." | 1.91 | The Adverse Effects and Nonmedical Use of Methylphenidate Before and After the Outbreak of COVID-19: Machine Learning Analysis. ( Kim, E; Lee, H; Oh, S; Park, S; Purja, S; Shin, H; Yuniar, CT, 2023) |
| "Methylphenidate (2." | 1.91 | Complex Attention-Deficit/Hyperactivity Disorder in a Bilingual Child with Down Syndrome and Intellectual Disability. ( Carroll, G; Fogler, J; Froehlich, T; Moore, T; Nyp, SS; Soccorso, C, 2023) |
| "Methylphenidate (MPH) has been used for decades to treat attention-deficit/hyperactivity disorder (ADHD) and narcolepsy." | 1.91 | Dichotomous effect of methylphenidate on microglia and astrocytes: Insights from in vitro and animal studies. ( Leitão, RA; Lourenço, T; Muga, M; Novo, JP; Sanches, ES; Silva, AP, 2023) |
| "Although methylphenidate (MPH) used for treatment of attention deficit hyperactivity disorder (ADHD) are considered safe in healthy children and adolescents in the short and medium term, there is a widespread concern about long-term cardiovascular safety." | 1.72 | The impact of methylphenidate treatment on the functional and structural properties of the left ventricle: A medium-term prospective study. ( Arias Vivas, E; Bote Gascon, M; García Ron, A; Rodriguez Mesa, M, 2022) |
| " Heart rate and blood pressure were measured at dosing and 1, 2, and 3 hours afterwards." | 1.72 | Acute Tolerability of Methylphenidate in Treatment-Naïve Children with ADHD: An Analysis of Naturalistically Collected Data from Clinical Practice. ( Amianto, F; D'Acunto, G; Davico, C; Falcone, F; Fantozzi, P; Favole, I; Lenzi, F; Levantini, V; Liboni, F; Masi, G; Muratori, P; Pfanner, C; Simonelli, V; Villafranca, A; Vitiello, B, 2022) |
| "Methylphenidate (MPH) is the treatment of first choice for developmental ADHD." | 1.72 | Moderators and Other Predictors of Methylphenidate Response in Children and Adolescents with ADHD. ( D'Aiello, B; De Rossi, P; Di Vara, S; Menghini, D; Pretelli, I; Vicari, S, 2022) |
| " Nonetheless, patients' growth and the appropriateness of drug dosage should be closely monitored." | 1.72 | Growth Hormone and Thyroid Function in Children With Attention Deficit Hyperactivity Disorder Undergoing Drug Therapy. ( Chou, WJ; Huang, YH; Lee, SY; Wang, LJ, 2022) |
| "Methylphenidate was the drug used by the highest percentage of the population (2." | 1.72 | [Trend in medicines use for attention deficit hyperactivity disorder in children and adolescents (2010-2019).] ( Alberola López, S; Andrés de Llano, JM; Gutiérrez-Abejón, E; Prieto Antolín, B, 2022) |
| "The main reason for pharmacological treatment of FASD children is attention deficit hyperactivity disorder (ADHD), and methylphenidate (MPH) is the drug of choice." | 1.72 | Influence of ( Białecka, M; Brzuchalski, B; Grzywacz, E; Machoy-Mokrzyńska, A; Malinowski, D; Pierzchlińska, A; Śmiarowska, M, 2022) |
| "Methylphenidate has many general side effects including ocular findings." | 1.72 | Does methylphenidate treatment affect functional and structural ocular parameters in patients with attention deficit hyperactivity disorder? - A prospective, one year follow-up study. ( Atilla, H; Bingöl-Kızıltunç, P; Yürümez, E, 2022) |
| "The drug use history and drug abuse motivation scale were collected at admission." | 1.72 | Time-dependent affective disturbances in abstinent patients with methylphenidate use disorder. ( Mao, F; Sun, P; Wang, N; Xu, J; Yuan, TF; Zhang, Y, 2022) |
| "Methylphenidate is a 'prescription only' drug against attention disorders which is increasingly used by adults." | 1.72 | General practice database on mortality in adults on methylphenidate: cohort study. ( Cheung, K; Stricker, B; Verhamme, K, 2022) |
| "Methylphenidate was most frequently implicated (63%)." | 1.72 | Poisonings with ADHD medication in children under the age of 5 years in Australia: a retrospective study, 2004-2019. ( Arbaeen, A; Cairns, R; Wheate, NJ, 2022) |
| " While each of these medications have their own distinct pharmacokinetic profile, the extent to which pharmacogenetics effects their pharmacokinetic parameters is best described in atomoxetine, followed by methylphenidate." | 1.72 | The Pharmacogenetic Impact on the Pharmacokinetics of ADHD Medications. ( Brown, JT, 2022) |
| " Human mesenchymal stem cells (hMSCs) were incubated with a therapeutic plasma dosage of modafinil, atomoxetine and guanfacine." | 1.72 | Psychostimulants Modafinil, Atomoxetine and Guanfacine Impair Bone Cell Differentiation and MSC Migration. ( Böker, KO; Di Fazio, P; Jäckle, K; Lehmann, W; Schilling, AF; Wagener, N; Weiser, L, 2022) |
| "Methylphenidate (MPH) is an indirect-acting sympathomimetic drug and structurally related to amphetamine." | 1.72 | Acute myocardial infarction due to spontaneous coronary artery dissection in a 6-year-old boy with ADHD on the third day of treatment with methylphenidate. ( Becker, M; Kerst, G; Ostermayer, S; Pitzer, M; Pohlmann, U; Rascher, W; Stammschulte, T, 2022) |
| "He developed transient orofacial dyskinesia and upper extremity choreoathetosis as a result which did not abate during his time in the emergency department." | 1.62 | Long-acting Methylphenidate Induced Transient Orofacial Dyskinesia and Upper Extremity Choreoathetosis: A Case Report. ( Anand, V; Trombetta, D; Vik, T, 2021) |
| "Methylphenidate's effects were evident at 0." | 1.62 | Frontal Cortical Monoamine Release, Attention, and Working Memory in a Perinatal Nicotine Exposure Mouse Model Following Kappa Opioid Receptor Antagonism. ( Bhide, PG; Biederman, J; Eskow Jaunarajs, KL; McCarthy, DM; Spencer, TJ; Zhang, L, 2021) |
| "Methylphenidate (MPH) was started at 0." | 1.62 | Drug holidays may not affect processing speed while they may reduce beneficial effects on resistance to interference among children with treated with methylphenidate: a single-center, prospective study. ( Akay, AP; Göl Özcan, G; İmrek, Y; Öztürk, Y; Özyurt, G; Sari, M; Tufan, AE, 2021) |
| "Although the relationship between attention-deficit/hyperactivity disorder (ADHD) and transport accidents has been shown, there is limited information on the relationship between medication and dose-response effects and transport accident risk." | 1.62 | Association of psychiatric comorbidities with the risk of transport accidents in ADHD and MPH. ( Chen, VC; Chen, YL; Gossop, M; Liu, YC; Yang, YH, 2021) |
| "Although attention-deficit/hyperactivity disorder (ADHD) is widely studied, problems regarding the adverse effect risks and non-responder problems still need to be addressed." | 1.62 | Synergistic efficacy and diminished adverse effect profile of composite treatment of several ADHD medications. ( Adil, KJ; Cheong, JH; Han, SH; Jeon, SJ; Kim, HJ; Kim, HY; Kim, R; Kwon, KJ; Mabunga, DFN; Park, D; Ryu, O; Shin, CY; Valencia, S, 2021) |
| "To evaluate the validity of online information regarding the adverse effects of methylphenidate." | 1.62 | Can parents believe websites' information about methylphenidate's side effects? ( Arsac England, T; Tuthill, D, 2021) |
| "Accurate estimation of daily dosage and duration of medication use is essential to pharmacoepidemiological studies using electronic healthcare databases." | 1.62 | Prediction of treatment dosage and duration from free-text prescriptions: an application to ADHD medications in the Swedish prescribed drug register. ( Chang, Z; Chen, Q; D'Onofrio, BM; Ghirardi, L; Lagerberg, T; Larsson, H; Viktorin, A; Zhang, L, 2021) |
| "Methylphenidate was effective and safe in treating ADHD in 76% of cases in children with DS, with few serious side effects to report." | 1.62 | Efficacy and safety of methylphenidate on attention deficit hyperactivity disorder in children with Down syndrome. ( Cieuta-Walti, C; Conte, M; Durand, S; Falquero, S; Labidi, A; Mégarbané, A; Mircher, C; Prioux, E; Ravel, A; Roche, M; Stora, S; Toulas, J, 2021) |
| "Only daytime sleepiness was more common for those receiving α2-adrenergic agonists vs stimulants (38% vs 3%); several adverse effects were reported more commonly for those receiving stimulants vs α2-adrenergic agonists, including moodiness/irritability (50% vs 29%), appetite suppression (38% vs 7%), and difficulty sleeping (21% vs 11%)." | 1.62 | α2-Adrenergic Agonists or Stimulants for Preschool-Age Children With Attention-Deficit/Hyperactivity Disorder. ( Barbaresi, W; Bax, A; Blum, NJ; Cacia, J; Deavenport-Saman, A; Friedman, S; Harstad, E; LaRosa, A; Loe, IM; Mittal, S; Shults, J; Tulio, S; Vanderbilt, D, 2021) |
| "Methylphenidate has been an established treatment for ADHD, but due to its relatively short half-life, numerous intermediate- and long-acting products have been developed." | 1.62 | Update on methylphenidate and dexmethylphenidate formulations for children with attention-deficit/hyperactivity disorder. ( Ehret, MJ; Pheils, J, 2021) |
| "The findings suggest that the IN-DA treatment has potential for use in the treatment of ADHD; however, caution must be exercised when determining the dosage to be administered, because too much dopamine may have negative effects." | 1.62 | Acute intranasal dopamine application counteracts the reversal learning deficit of spontaneously hypertensive rats in an attentional set-shifting task. ( Chao, OY; Huston, JP; Li, JS; Mattern, C; Yang, SS; Yang, YM, 2021) |
| "Methylphenidate (MP) is a commonly prescribed psychostimulant to individuals with Attention Deficit Hyperactivity Disorder, and is often used illicitly among healthy individuals with intermittent breaks to coincide with breaks from school." | 1.56 | Brief and extended abstinence from chronic oral methylphenidate treatment produces reversible behavioral and physiological effects. ( Carias, E; Connor, C; Hadjiargyrou, M; Kalinowski, L; Komatsu, DE; Mackintosh, M; Martin, C; Popoola, D; Richer, K; Smith, L; Somanesan, R; Thanos, PK, 2020) |
| "Methylphenidate (MPH), which is a psychostimulant drug, has been often prescribed for the treatment of ADHD in patients." | 1.56 | Effects of medications on ventricular repolarization in children with attention deficit hyperactivity disorder. ( Akpinar, M; Esedova, C; İrdem, A; Türkmenoğlu, YE; Uysal, T, 2020) |
| "Sleep problems is the most common side effect of methylphenidate (MPH) treatment in ADHD youth and carry potential to negatively impact long-term self-regulatory functioning." | 1.56 | Prediction of sleep side effects following methylphenidate treatment in ADHD youth. ( Hong, SB; Kim, BN; Kim, JW; McMakin, DL; Ryan, ND; Sharma, V; Yoo, JH; Zalesky, A, 2020) |
| "Methylphenidate (MPH) is a dopamine transporter (DAT) inhibitor used to treat attention-deficit/hyperactivity-disorder (ADHD)." | 1.56 | Ventral striatum supports Methylphenidate therapeutic effects on impulsive choices expressed in temporal discounting task. ( Drui, G; Martinez, E; Météreau, É; Pasquereau, B; Saga, Y; Tremblay, L, 2020) |
| " We used mixed-effects logistic regression models to personalize the dosage of Methylphenidate (MPH) in ADHD." | 1.56 | Individualizing the dosage of Methylphenidate in children with attention deficit hyperactivity disorder. ( Fotouhi, A; Hoseini, M; Mahmoudi-Gharaei, J; Mozaffarpur, SA; Shirafkan, H; Yaseri, M, 2020) |
| " Studies using standardized dosing schemes for longer durations and evaluating sleep with objective measurements may clarify the differential effects of treatments on sleep among children with ADHD." | 1.56 | Sleep habits of children diagnosed with attention/ deficit/ hyperactivity disorder and effects of treatment on sleep related parameters. ( Sarıgedik, E; Tufan, AE; Yektaş, Ç, 2020) |
| "Methylphenidate did not increase 24-h heart rates, whereas omega-3 fatty acid supplementation significantly decreased elevated heart rates and increased HRV in adolescents with IST." | 1.56 | Diagnosis and management of an inappropriate sinus tachycardia in adolescence based upon a Holter ECG: A retrospective analysis of 479 patients. ( Baumann, C; Buchhorn, R; Gündogdu, S; Rakowski, U; Willaschek, C, 2020) |
| " Secondary endpoints comprise patient evaluation (Wender-Reimherr self-report, WR-SR), safety, tolerability, and dosage of MPH." | 1.56 | Methylphenidate treatment of adult ADHD patients improves the degree of ADHD severity under routine conditions. ( Ammer, R; Fischer, R; Ose, C; Retz, W; Rösler, M, 2020) |
| "Methylphenidate (MPH) is a psychostimulant drug used as first-line treatment for ADHD and it inhibits dopamine and norepinephrine reuptake transporters." | 1.56 | Is contrast sensitivity a physiological marker in attention-deficit hyperactivity disorder? ( Atas, PBU; Berker, M; Çankaya, C; Ceylan, OM; Dönmez, YE; Güntürkün, PN; Özcan, ÖÖ, 2020) |
| "Methylphenidate is an established treatment for attention-deficit hyperactivity disorder that also has abuse potential." | 1.51 | Role of homeostatic feedback mechanisms in modulating methylphenidate actions on phasic dopamine signaling in the striatum of awake behaving rats. ( Burrell, MH; Fuller, JA; Hyland, BI; Lipski, J; Liyanagama, K; Wickens, JR; Yee, AG, 2019) |
| "Methylphenidate (MPH) is a piperidine similar to amphetamines, and is indicated for attention deficit hyperactivity disorder." | 1.51 | Methylphenidate and stuttering. ( Azzouz, B; Claustre, G; Djerada, Z; Herlem, E; Morel, A; Trenque, A; Trenque, T, 2019) |
| "Methylphenidate is a central nervous system stimulant that is structurally close to amphetamine and acts as a norepinephrine and dopamine reuptake inhibitor." | 1.51 | [Supervised off-label prescribing of methylphenidate in adult ADHD]. ( Amad, A; Bordet, R; Brigadeau, F; Carton, L; Cottencin, O; Danel, T; Deheul, S; Devos, D; Dondaine, T; Gautier, S; Marquié, C; Ménard, O, 2019) |
| "Methylphenidate (MP) is a commonly prescribed psychostimulant for Attention Deficit Hyperactivity Disorder (ADHD)." | 1.51 | Weekday-only chronic oral methylphenidate self-administration in male rats: Reversibility of the behavioral and physiological effects. ( Carias, E; Fricke, D; Hadjiargyrou, M; Kalinowski, L; Komatsu, DE; Martin, C; Popoola, D; Smith, L; Somanesan, R; Thanos, PK; Vijayashanthar, A, 2019) |
| "The study has demonstrated lower risk of stress fractures with concurrent MP use." | 1.51 | Lower risk of stress fractures in young adults with ADHD under chronic treatment with methylphenidate. ( Ankory, R; Chechik, O; Dolkart, O; Karakis, I; Rotman, D; Schermann, H; Shlaifer, A; Yoffe, V, 2019) |
| " The optimization of the benefit-risk ratio can be achieved by identifying the most adequate dose (and/or dosage regimen) jointly with the best-performing in vivo release properties of a drug." | 1.51 | A General Framework for Assessing In vitro/In vivo Correlation as a Tool for Maximizing the Benefit-Risk Ratio of a Treatment Using a Convolution-Based Modeling Approach. ( Babiskin, A; Bressolle-Gomeni, F; Fang, LL; Faraone, SV; Gomeni, R; Spencer, TJ, 2019) |
| "Amphetamine use was associated with a greater risk of psychosis than methylphenidate." | 1.51 | Psychosis with Methylphenidate or Amphetamine in Patients with ADHD. ( Castro, VM; Hsu, J; Moran, LV; Ongur, D; Perlis, RH; Schneeweiss, S, 2019) |
| "Methylphenidate (MPH) is a first line drug for attention-deficit/hyperactivity disorder (ADHD), yet the neuronal mechanisms underlying the condition and the treatment are still not fully understood." | 1.51 | Effects of methylphenidate on the ERP amplitude in youth with ADHD: A double-blind placebo-controlled cross-over EEG study. ( Gothelf, D; Horowitz, I; Levit-Binnun, N; Moses, E; Naim-Feil, J; Rubinson, M, 2019) |
| "Methylphenidate (MPD) is a widely prescribed psychostimulant for the treatment of attention deficit hyperactivity disorder, and is growing in use as a recreational drug and academic enhancer." | 1.51 | Glutaminergic signaling in the caudate nucleus is required for behavioral sensitization to methylphenidate. ( Dafny, N; Floren, S; Kharas, N; King, N; Thomas, M, 2019) |
| "We found significant intraclass correlations in family member response to methylphenidate-immediate release and side effect profile, including emotional symptoms and loss of appetite and weight." | 1.51 | High Familial Correlation in Methylphenidate Response and Side Effect Profile. ( Brand-Gothelf, A; Dubnov-Raz, G; Gazer-Snitovsky, M; Gothelf, D; Weizman, A, 2019) |
| " After 3 months 2/8 (25%, CI 95%: 8-65%) showed improvements, remaining 75% has been increased dosage of methylphenidate." | 1.51 | Attention-deficit/hyperactivity disorder and enuresis: a study about effectiveness of treatment with methylphenidate or desmopressin in a pediatric population. ( Ferrara, P; Ianniello, F; Mariotti, P; Petitti, T; Quattrocchi, E; Sannicandro, V; Sbordone, A, 2019) |
| "Methylphenidate is a stimulant drug commonly prescribed to individuals with attention-deficit/hyperactivity disorder." | 1.48 | Effect of Biperiden Treatment in Acute Orofacial and Extremity Dyskinesia With Methylphenidate Therapy. ( Arslan, E; Arslan, EA; Göksu, Ö; Kilinç, A, 2018) |
| "Methylphenidate is a first-line therapeutic option for treating attention-deficit/hyperactivity disorder (ADHD); however, elicited changes on resting-state functional networks (RSFNs) are not well understood." | 1.48 | Treatment effect of methylphenidate on intrinsic functional brain network in medication-naïve ADHD children: A multivariate analysis. ( Choi, J; Jeong, B; Kim, D; Yoo, JH, 2018) |
| "Does methylphenidate cause liver damage? An analysis of ad hoc reports to the "Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM)" Abstract." | 1.48 | [Does methylphenidate cause liver damage? An analysis of ad hoc reports to the "Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM)"]. ( Fekete, S; Gerlach, M; Romanos, M, 2018) |
| "Methylphenidate (MPH) has been shown to modulate the amplitude of the no-go P3 component of the event-related potential (ERP; Øgrim, Aasen, & Brunner, 2016)." | 1.48 | Methylphenidate selectively modulates one sub-component of the no-go P3 in pediatric ADHD medication responders. ( Aasen, IE; Brunner, JF; Kropotov, J; Øgrim, G, 2018) |
| "We propose a novel semi-automatic approach to design biomarkers for capturing pharmacodynamic effects induced by pharmacological agents on the spectral power of electroencephalography (EEG) recordings." | 1.48 | Semi-Automated Biomarker Discovery from Pharmacodynamic Effects on EEG in ADHD Rodent Models. ( Cichocki, A; Hasegawa, M; Hiroyama, S; Horiuchi, M; Jurica, P; Li, J; Nishitomi, K; Ogawa, K; Struzik, ZR; Takahara, Y; Yokota, T, 2018) |
| " This article evaluates the pharmacokinetic parameters and relative bioavailability of MPH ERCT when chewed versus swallowed whole." | 1.48 | Relative Bioavailability of Methylphenidate Extended-release Chewable Tablets Chewed Versus Swallowed Whole. ( Abbas, R; Berry, SA; Childress, AC; Nagraj, P; Palumbo, DR; Rolke, R, 2018) |
| " Therefore, the aim of this retrospective observational study is to evaluate the influence of psychostimulants on BMI-sds and height-sds in a pediatric cohort with ADHD from an outpatient clinic, and to study the correlation between psychostimulant dosage and BMI-sds and height-sds change." | 1.48 | Psychostimulants: Influence on Body Mass Index and Height in a Pediatric Population with Attention-Deficit/Hyperactivity Disorder? ( Knibbe, CAJ; Lentferink, YE; van de Garde, EMW; van der Vorst, MMJ, 2018) |
| " The most common adverse effects in subjects still on treatment with MPH were decreased appetite (28%), dry mouth (24%), anxiousness/restlessness and increased pulse frequency (19% each), decreased sexual desire (17%), and perspiration (15%)." | 1.48 | Long-Term Tolerability and Safety of Pharmacological Treatment of Adult Attention-Deficit/Hyperactivity Disorder: A 6-Year Prospective Naturalistic Study. ( Edvinsson, D; Ekselius, L, 2018) |
| "Methylphenidate treatment does not have an effect on performance-based measures of delay aversion and executive functioning, but may have significant effects on self-reported delay aversion and executive functioning." | 1.48 | Delay Aversion and Executive Functioning in Adults With Attention-Deficit/Hyperactivity Disorder: Before and After Stimulant Treatment. ( Fagerlund, B; Glenthøj, B; Habekost, T; Jepsen, JRM; le Sommer, J; Low, AM; Sonuga-Barke, E; Vangkilde, S, 2018) |
| " Multivariate regression analysis confirmed an inverse dose-response association between MP and fractures in men (p < 0." | 1.48 | Lower risk of fractures under methylphenidate treatment for ADHD: A dose-response effect. ( Ankory, R; Gurel, R; Kadar, A; Karakis, I; Schermann, H; Snir, N; Sternheim, A; Yoffe, V, 2018) |
| "Treatment with methylphenidate (5 mg/kg), the most commonly used medication for ADHD, improved attention and normalized expression levels of dopamine-related genes in THRSP OE mice." | 1.48 | Overexpression of the Thyroid Hormone-Responsive (THRSP) Gene in the Striatum Leads to the Development of Inattentive-like Phenotype in Mice. ( Abiero, A; Botanas, CJ; Cheong, JH; Custodio, RJP; de la Peña, JB; Dela Peña, IJ; Kim, BN; Kim, HJ; Kim, M; Ryoo, ZY; Sayson, LV, 2018) |
| "Childhood narcolepsy is associated with various emotional, behavioural and cognitive dysfunctions as well as with psychiatric and neurodevelopmental disorders: anxiety, depression, attention deficit hyperactivity disorder and psychosis." | 1.48 | Childhood narcolepsy and autism spectrum disorders: four case reports. ( Dudova, I; Hrdlicka, M; Mohaplova, M; Nevsimalova, S; Prihodova, I, 2018) |
| "Methylphenidate was the most commonly used ADHD medication in most countries." | 1.48 | Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases. ( Bahmanyar, S; Berard, A; Bilder, S; Boukhris, T; Bushnell, G; Chan, EW; Coghill, D; Crystal, S; Furu, K; Ip, P; KaoYang, YH; Karlstad, Ø; Kieler, H; Kubota, K; Lai, EC; Macias Saint-Gerons, D; Man, KKC; Martikainen, JE; Maura, G; Montero, D; Moore, N; Nakamura, H; Neumann, A; Pate, V; Pottegård, A; Pratt, NL; Raman, SR; Roughead, EE; Sturkenbroom, MCJM; Stürmer, T; Su, CC; Wong, ICK; Zoega, H, 2018) |
| "Methylphenidate was the most commonly prescribed drug, followed by atomoxetine and lisdexamfetamine." | 1.46 | ADHD in Germany: Trends in Diagnosis and Pharmacotherapy. ( Bachmann, CJ; Hoffmann, F; Philipsen, A, 2017) |
| " We explored differences in test scores between current methylphenidate users versus never users and methylphenidate users who stopped treatment at least 6 months before the test, early versus late starters, different dosage of methylphenidate, and concurrent antipsychotic or asthma treatment." | 1.46 | Methylphenidate use and school performance among primary school children: a descriptive study. ( Bos, JH; Çiçek, R; de Vries, TW; Hak, E; Hoekstra, PJ; van der Schans, J; Vardar, S, 2017) |
| " The mean methylphenidate hydrochloride dosage was 0." | 1.46 | Lens opacities in children using methylphenidate hydrochloride. ( Duman, NS; Duman, R; Sarı Gökten, E, 2017) |
| "Methylphenidate treatment improves the working memory, inhibitory control and mental flexibility of ADHD boys." | 1.46 | Attention-deficit/hyperactivity disorder: the impact of methylphenidate on working memory, inhibition capacity and mental flexibility. ( Bolfer, C; Carreira, WS; Casella, BB; Casella, EB; Pacheco, SP; Tsunemi, MH, 2017) |
| "Methylphenidate (MPH) is a prescription stimulant used to treat attention-deficit hyperactivity disorder." | 1.46 | Methylphenidate disintegration from oral formulations for intravenous use by experienced substance users. ( Asgrimsson, V; Bjarnadottir, GD; Bragadottir, H; Haraldsson, HM; Johannsson, M; Magnusson, A; Rafnar, BO; Sigurdsson, E; Snorradottir, I; Steingrimsson, S, 2017) |
| "Treatment with methylphenidate and/or atomoxetine increased choice of the large, delayed reward in SHR/NCrl and Wistar rats and changed, in varying degrees, mRNA levels of Nr4a2, Btg2, and Homer2, genes with previously described roles in neuropsychiatric disorders characterized by impulsivity." | 1.46 | Methylphenidate and Atomoxetine-Responsive Prefrontal Cortical Genetic Overlaps in "Impulsive" SHR/NCrl and Wistar Rats. ( Cheong, JH; de la Peña, JB; Dela Peña, I; Dela Peña, IJ; Han, DH; Kim, BN; Kim, HJ; Ryu, JH; Shin, CY, 2017) |
| "Methylphenidate was also found to produce activation of the cortical EEG in anaesthetised rats." | 1.46 | Effect of methylphenidate on visual responses in the superior colliculus in the anaesthetised rat: Role of cortical activation. ( Dommett, EJ; Haensel, JX; Hetherington, L; Overton, PG; Riley, TB; Turner, AC, 2017) |
| " Lack of longitudinal follow-up studies of dosing and adverse effects has resulted in conflicting treatment guidelines." | 1.46 | Methylphenidate doses in Attention Deficit/Hyperactivity Disorder and comorbid substance use disorders. ( Brandt, L; D'Onofrio, B; Franck, J; Larsson, H; Skoglund, C, 2017) |
| "Our study evaluated adverse events of therapeutic failure (and specifically reduced duration of action) with the use of a branded product, Osmotic Release Oral System (OROS) methylphenidate, which is approved for the treatment of attention deficit/hyperactivity disorder, and a generic product (methylphenidate, methylphenidate ER-C), which was approved for marketing in Canada based on bioequivalence to OROS methylphenidate." | 1.46 | Differences in Adverse Event Reporting Rates of Therapeutic Failure Between Two Once-daily Extended-release Methylphenidate Medications in Canada: Analysis of Spontaneous Adverse Event Reporting Databases. ( Almagor, D; Castillon, G; Park-Wyllie, L; Sherman, SE; van Stralen, J, 2017) |
| "Methylphenidate (MPH) is a prescription-stimulant medication which is authorized in France for two indications: attention-deficit hyperactivity disorder in children (aged≥6years) and narcolepsy in cases where modafinil is ineffective (for children and adults)." | 1.46 | Methylphenidate: Gender trends in adult and pediatric populations over a 7year period. ( Boucherie, Q; Braunstein, D; Ehrhardt, C; Frauger, E; Micallef, J; Pauly, V; Ronflé, E; Thirion, X, 2017) |
| "After dose escalation, the hair loss resolved." | 1.46 | Resolution of methylphenidate osmotic release oral system-induced hair loss in two siblings after dose escalation. ( Ardic, UA; Ercan, ES, 2017) |
| " No occurrences of suicidal ideation or behavior were recorded; the most common open-label treatment-emergent adverse events were typical of stimulant use: decreased appetite, insomnia, and abdominal pain." | 1.46 | Efficacy, Safety, and Tolerability of a Novel Methylphenidate Extended-Release Oral Suspension (MEROS) in ADHD. ( Belden, HW; Berry, SA; Childress, AC; Findling, RL; Robb, AS; Wigal, SB, 2017) |
| "Methylphenidate (MPH) is a stimulant drug and an effective treatment for attention-deficit/hyperactivity disorder (ADHD) in both children and adults." | 1.46 | The age-dependent effects of a single-dose methylphenidate challenge on cerebral perfusion in patients with attention-deficit/hyperactivity disorder. ( Bottelier, MA; Bouziane, C; Mutsaerts, H; Reneman, L; Schrantee, A; Tamminga, H, 2017) |
| "The treatment with methylphenidate had no beneficial effect on the rats' performance regardless of the DSP4 treatment." | 1.46 | Effects of methylphenidate on attention in Wistar rats treated with the neurotoxin N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP4). ( Hauser, J; Lange, KW; Reissmann, A; Sontag, TA; Tucha, O, 2017) |
| "In this article, accounting for day-to-day children's activities and using up-to-date pharmacokinetic knowledge of methylphenidate, we propose a computational approach for the identification of the most suitable dosing regimens of immediate-release formulations of methylphenidate based on constraints on drug concentration and time frame of activities, defined through therapeutic boxes." | 1.46 | An Evaluation Approach for the Performance of Dosing Regimens in Attention-Deficit/Hyperactivity Disorder Treatment. ( Barrière, O; Bonnefois, G; Li, J; Nekka, F; Robaey, P, 2017) |
| "Conduct disorder was significantly higher in patients with DP, whereas ODD was significantly higher in the DESR and non-ED groups (P < 0." | 1.46 | Effect of Methylphenidate on Emotional Dysregulation in Children With Attention-Deficit/Hyperactivity Disorder + Oppositional Defiant Disorder/Conduct Disorder. ( Akyol Ardic, U; Ercan, ES; Kutlu, A, 2017) |
| "The most common comorbidities were substance use disorders (39." | 1.43 | Psychiatric Comorbidity at the Time of Diagnosis in Adults With ADHD: The CAT Study. ( Balanzá-Martínez, V; García-García, P; Piñeiro-Dieguez, B; Soler-López, B, 2016) |
| " The entire sample (N = 14) demonstrated a reduction in the mean score on the Inattention Scale from clinically significant (T-score > 65) to not clinically significant (T-score < 65) when patients were changed from non-OROS to OROS at the same dosage (mean T-score reduction = 23, p < ." | 1.43 | Not All Generic Concerta Is Created Equal: Comparison of OROS Versus Non-OROS for the Treatment of ADHD. ( Boan, AD; Kral, MC; Lally, MD, 2016) |
| "There is no questionnaire to specifically monitor perceived adverse events of methylphenidate (MPH) on cognition, motivation, and mood." | 1.43 | Reports of Perceived Adverse Events of Stimulant Medication on Cognition, Motivation, and Mood: Qualitative Investigation and the Generation of Items for the Medication and Cognition Rating Scale. ( Banaschewski, T; Buitelaar, JK; Carucci, S; Coghill, D; Danckaerts, M; Dittmann, RW; Falissard, B; Grimshaw, DG; Hollis, C; Inglis, S; Konrad, K; Kovshoff, H; Liddle, E; McCarthy, S; Nagy, P; Sonuga-Barke, EJ; Thompson, M; Wong, IC; Zuddas, A, 2016) |
| "Methylphenidate (MPH) is a widely prescribed stimulant compound that may be effective against ADHD symptoms in children and adults." | 1.43 | A candidate gene investigation of methylphenidate response in adult attention-deficit/hyperactivity disorder patients: results from a naturalistic study. ( Fredriksen, M; Haavik, J; Hegvik, TA; Jacobsen, KK; Zayats, T, 2016) |
| " Recent products offer convenience in terms of dosing and timing of drug administration to improve symptom control, but efficacy is similar among all MPH-ER products." | 1.43 | Methylphenidate HCL for the treatment of ADHD in children and adolescents. ( Childress, AC, 2016) |
| "Methylphenidate was initiated in 61 patients, including 55 in whom a follow-up evaluation was available." | 1.43 | ADHD in childhood epilepsy: Clinical determinants of severity and of the response to methylphenidate. ( Arzimanoglou, A; Auvin, S; Berquin, P; Cances, C; Castelneau, P; Gaillard, S; Herbillon, V; Isnard, H; Kassai, B; Mercier, C; Nabbout, R; Napuri, S; Nguyen The Tich, S; Rheims, S; Villega, F; Villeneuve, N, 2016) |
| " A recorded diagnosis (either a primary or secondary cause) of any of the following cardiovascular adverse events: arrhythmias (ICD-10 (international classification of diseases, 10th revision) codes I44, I45, I47, I48, I49), hypertension (codes I10-I15), myocardial infarction (code I21), ischemic stroke (code I63), or heart failure (code I50)." | 1.43 | Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. ( Park, BJ; Pratt, NL; Roughead, EE; Shin, JY, 2016) |
| "To determine the prevalence of sleep disorders in children with attention-deficit/hyperactivity disorder (ADHD) and in a control population." | 1.43 | Prevalence of sleep disorders and their relationship with core symptoms of inattention and hyperactivity in children with attention-deficit/hyperactivity disorder. ( Crespo-Eguílaz, N; Guillén-Grima, F; Sánchez-Carpintero, R; Vélez-Galarraga, R, 2016) |
| "Methylphenidate was used by 88 % of drug users." | 1.43 | Use of drugs for ADHD among adults-a multinational study among 15.8 million adults in the Nordic countries. ( Bahmanyar, S; Furu, K; Karlstad, Ø; Kieler, H; Martikainen, JE; Pottegård, A; Zoëga, H, 2016) |
| "Methylphenidate treatment for ADHD and CD has acute effects on these processes." | 1.43 | Acute effects of methylphenidate on impulsivity and attentional behavior among adolescents comorbid for ADHD and conduct disorder. ( Acheson, A; Dougherty, DM; Hill-Kapturczak, N; Mathias, CW; Olvera, RL; Ryan, SR, 2016) |
| "Methylphenidate (MPH) is a commonly used stimulant medication for treating attention-deficit/hyperactivity disorder (ADHD)." | 1.42 | A preliminary study on methylphenidate-regulated gene expression in lymphoblastoid cells of ADHD patients. ( Heupel, J; Hilscher, M; Jacob, C; Kittel-Schneider, S; Kopf, J; Lesch, KP; Reichert, S; Reif, A; Schmidt, B; Scholz, CJ; Schwarz, R; Volkert, J; Weber, H; Weissflog, L, 2015) |
| "7 %) had treatment-related adverse events with one case being serious; 23 patients (8." | 1.42 | Effectiveness and safety of a long-acting, once-daily, two-phase release formulation of methylphenidate (Ritalin ® LA) in school children under daily practice conditions. ( Bilke-Hentsch, O; Haertling, F; Mueller, B, 2015) |
| "Treatment with methylphenidate resulted in normalisation of the resting state to task activation pattern." | 1.42 | Normalisation of frontal theta activity following methylphenidate treatment in adult attention-deficit/hyperactivity disorder. ( Asherson, P; Banaschewski, T; Brandeis, D; Kuntsi, J; McLoughlin, G; Skirrow, C, 2015) |
| "The rate of trauma-related ED admission was lower during exposed periods compared with nonexposed periods (incidence rate ratio [IRR]: 0." | 1.42 | Methylphenidate and the risk of trauma. ( Chan, EW; Coghill, D; Douglas, I; Ip, P; Leung, LP; Man, KK; Tsui, MS; Wong, IC; Wong, WH, 2015) |
| " In this study, we characterized the clinical profile of children and adolescents for whom a once-daily lower dose of OROS-MPH combined with a shorter-acting agent was more tolerable than single higher OROS-MPH dose." | 1.42 | The clinical profile of children with ADHD that require OROS-methylphenidate combined with shorter-acting formulations. ( Terkel-Dawer, R; Zelnik, N, 2015) |
| "Methylphenidate (MPH) is a widely prescribed stimulant drug for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents." | 1.42 | Effects of long-term methylphenidate treatment in adolescent and adult rats on hippocampal shape, functional connectivity and adult neurogenesis. ( Bouet, V; Boulouard, M; Dauphin, F; Dijkhuizen, RM; Freret, T; Homberg, JR; Klomp, A; Lucassen, PJ; Meerhoff, GF; Reneman, L; van der Marel, K, 2015) |
| "The age, sex, leading diagnosis, prescribed medication, and dosage of each patient were recorded anonymously twice a year." | 1.42 | [Hyperkinetic disorders in childhood and adolescence- an analysis of KinderAGATE 2009-2012]. ( Haen, E; Rexroth, CA; Stegmann, B; Wenzel-Seifert, K, 2015) |
| "Methylphenidate was well tolerated with no significant side effects." | 1.42 | Extended-release Methylphenidate Treatment and Outcomes in Comorbid Social Anxiety Disorder and Attention-deficit/Hyperactivity Disorder: 2 Case Reports. ( Çelebi, F; Ertekin, E; Kahn, DA; Koyuncu, A, 2015) |
| "Methylphenidate dose and SHSS increase were negatively correlated with baseline SHSS scores." | 1.42 | Methylphenidate facilitates hypnotizability in adults with ADHD: a naturalistic cohort study. ( Abramowitz, EG; Bonne, O; Lotan, A, 2015) |
| "A new multilayer-bead formulation of extended-release methylphenidate hydrochloride (MPH-MLR) has been evaluated in pharmacokinetic studies in healthy adults and in Phase III efficacy/safety studies in children and adolescents with attention deficit hyperactivity disorder (ADHD)." | 1.42 | Population pharmacokinetics of methylphenidate hydrochloride extended-release multiple-layer beads in pediatric subjects with attention deficit hyperactivity disorder. ( Adjei, A; Findling, RL; Greenhill, LL; Kupper, RJ; Teuscher, NS; Wigal, S, 2015) |
| "We present a case of adverse neurological effects of methylphenidate therapy for attention deficit and hyperactivity disorder (ADHD)." | 1.42 | Neurological adverse effects of methylphenidate may be misdiagnosed as meningoencephalitis. ( Bakshi, D; Snell, LB, 2015) |
| "Pharmacological treatment of attention deficit hyperactivity disorder (ADHD) includes stimulant and non-stimulant medications." | 1.42 | Combined methylphenidate and atomoxetine pharmacotherapy in attention deficit hyperactivity disorder. ( Atar, B; Aydin, C; Kose, S; Ozbaran, B; Yuzuguldu, O, 2015) |
| "Methylphenidate was the most frequently prescribed psychostimulant." | 1.42 | Psychostimulant prescribing trends in a paediatric population in Ireland: a national cohort study. ( Bennett, K; Boland, F; Fahey, T; Galvin, R; Kelly, D; Motterlini, N; Reulbach, U, 2015) |
| "Methylphenidate as a psycho stimulant drug has been prescribed in neuropsychiatric disorders to increase cognition and attention therefore is a medication of choice for attention-deficit/hyperactivity disorder however long-term administration of central nervous system stimulant produces tolerance on cognitive behavior." | 1.42 | Attenuation of methylphenidate-induced tolerance on cognition by buspirone co-administration. ( Alam, N; Khan, SS; Najam, R, 2015) |
| " We hypothesized that the risk of an emotional side effect to methylphenidate (MPH) treatment may be associated with NTF3 genotypes." | 1.40 | Neurotrophin 3 genotype and emotional adverse effects of osmotic-release oral system methylphenidate (OROS-MPH) in children with attention-deficit/hyperactivity disorder. ( Cho, SC; Chung, US; Han, DH; Kim, BN; Kim, JH; Kim, JW; Park, S; Shin, MS; Shin, YM; Son, JW, 2014) |
| "Methylphenidate (MPH) is an effective treatment to improve attentional difficulties in children with attention deficit/hyperactivity disorder (ADHD)." | 1.40 | Methylphenidate improves some but not all measures of attention, as measured by the TEA-Ch in medication-naïve children with ADHD. ( Barry, E; Bellgrove, MA; Fitzgerald, M; Gill, M; Hammond, P; Johnson, KA; Kirley, A; McNicholas, F; Paton, K; Robertson, IH, 2014) |
| "To psychometrically assess cognitive domains in adolescents with ADHD during long-term open treatment with robust dosing of extended-release methylphenidate (OROS MPH)." | 1.40 | Assessment of cognitive domains during treatment with OROS methylphenidate in adolescents with ADHD. ( Biederman, J; Fried, R; Hammerness, P; Meller, B; Petty, C, 2014) |
| "Diagnoses of SUD and alcohol abuse were obtained from The Danish Psychiatric Central Register." | 1.40 | ADHD, stimulant treatment in childhood and subsequent substance abuse in adulthood - a naturalistic long-term follow-up study. ( Dalsgaard, S; Frydenberg, M; Mortensen, PB; Thomsen, PH, 2014) |
| "Baseline oppositional defiant disorder (ODD) and conduct disorder (CD) scores were correlated with the CGI-S score; however, no association was found between core ADHD symptom severity and the CGI-S score." | 1.40 | Effect of OROS methylphenidate on encopresis in children with attention-deficit/hyperactivity disorder. ( Bilgiç, A; Hergüner, S; Yılmaz, S, 2014) |
| "Methylphenidate is an important element of therapeutic strategies for ADHD." | 1.40 | [Cardiovascular risks and management during Attention Deficit Hyperactivity Disorder treatment with methylphenidate]. ( Acquaviva, E; Bange, F; Delorme, R; Le Heuzey, MF; Mouren, MC, 2014) |
| "The association of substance use disorders (SUD) with attention-deficit disorder (ADHD), co-morbid mental disorders, and medication has only been studied in isolation and in rather small samples." | 1.40 | Substance use disorders in association with attention-deficit/hyperactivity disorder, co-morbid mental disorders, and medication in a nationwide sample. ( Bisgaard, C; Steinhausen, HC, 2014) |
| "Methylphenidate treatment for ADHD was associated with both symptom alleviation in children with ADHD and improvement in parental depressive mood and quality of life, suggesting that the effects of treatment could go beyond symptom improvement in ADHD." | 1.40 | Parental quality of life and depressive mood following methylphenidate treatment of children with attention-deficit hyperactivity disorder. ( Chang, JS; Cho, SC; Hwang, JW; Kim, B; Kim, BN; Kim, Y, 2014) |
| " Whereas there was a linear dose-response curve for medication in NBM, the dose-response curves flattened considerably in LBM and HBM." | 1.40 | A dose-ranging study of behavioral and pharmacological treatment in social settings for children with ADHD. ( Burrows-MacLean, L; Chacko, A; Coles, EK; Fabiano, GA; Garefino, A; Gnagy, EM; Hoffman, MT; Pelham, WE; Walker, KS; Waschbusch, DA; Waxmonsky, JG; Wymbs, BT; Wymbs, F, 2014) |
| "To investigate the effect of parent training combined with methylphenidate treatment on family relationships in children with attention deficit/hyperactivity disorder (ADHD)." | 1.40 | [Effect of parent training in combination with methylphenidate treatment on family relationships for children with attention deficit/hyperactivity disorder]. ( Ding, KJ; Kang, CY; Li, XR; Liu, RX; Wan, S; Wang, YJ; Xuan, X; Yang, RX; Zhang, Y; Zhao, XR, 2014) |
| "In patients treated with atomoxetine who had available dosing information (N = 134), Cox proportional hazards revealed lower (< 0." | 1.40 | Predictors of pharmacological treatment outcomes with atomoxetine or methylphenidate in patients with attention-deficit/hyperactivity disorder from China, Egypt, Lebanon, Russian Federation, Taiwan, and United Arab Emirates. ( Altin, M; Desaiah, D; El-Shafei, A; Faries, D; Feng, Q; Gado, M; Serebryakova, E; Treuer, T; Wu, S, 2014) |
| "The SHR successfully model ADHD and cocaine abuse comorbidity and show differential effects of adolescent ADHD medications on cocaine intake and cue reactivity during adulthood." | 1.40 | Cocaine-seeking behavior in a genetic model of attention-deficit/hyperactivity disorder following adolescent methylphenidate or atomoxetine treatments. ( Baskin, BB; Dwoskin, LP; Harvey, RC; Jordan, CJ; Kantak, KM, 2014) |
| "Bedwetting is a common cause of isolation in children as well as loss of self-esteem and other psychological distress for the child and the family." | 1.40 | Treating enuresis in a patient with ADHD: application of a novel behavioural modification therapy. ( Montañes, F; Ruiz-Manrique, G; Tajima-Pozo, K, 2014) |
| "Methylphenidate-based treatments must therefore be implemented after a specialist has evaluated the patient and be prescribed following the recommendations." | 1.40 | [Prescription of methylphenidate for children: importance of recommendations to limit misuse]. ( Amar, M; Bétaud, C; Chéron-Blümel, A; Grall-Bronnec, M; Jolliet, P; Péron, E; Victorri-Vigneau, C, 2014) |
| "Methylphenidate was used first for 59." | 1.40 | Treatment receipt and outcomes from a clinic employing the attention-deficit/hyperactivity disorder treatment guideline of the children's medication algorithm project. ( McLennan, JD; Vallerand, IA; Wagner, DJ, 2014) |
| "Methylphenidate prescriptions were evaluated to determine possible drug holiday use through different analyses of dispensing patterns." | 1.40 | Drug holiday utilisation in ADHD-diagnosed children and adolescents in South Africa. ( McCartney, J; Regnart, J; Truter, I, 2014) |
| "OROS-methylphenidate was reported as the most helpful methylphenidate class formulation, with 74% reporting it at least somewhat helpful." | 1.39 | Caregiver survey of pharmacotherapy to treat attention deficit/hyperactivity disorder in individuals with Williams syndrome. ( Andridge, RR; Coury, DL; Foster, JE; Martens, MA; McClure, KE; Seyfer, DL, 2013) |
| "15 Methylphenidate (Mph)-treated and 15 Mph-free children of the ADHD-combined type and 17 control children performed a selective attention task with three feedback conditions: no-feedback, gain and loss." | 1.39 | Processing of continuously provided punishment and reward in children with ADHD and the modulating effects of stimulant medication: an ERP study. ( Althaus, M; Groen, Y; Tucha, O; Wijers, AA, 2013) |
| "Frequencies of cancer diagnoses in these groups were compared." | 1.39 | The association between medication for attention-deficit/hyperactivity disorder and cancer. ( Helenius, D; Steinhausen, HC, 2013) |
| " ADHD and associated psychiatric symptoms, medication status and dosage frequency, treatment adherence and adverse events were assessed at baseline and after a median treatment length with Medikinet(®) retard of 70 days." | 1.39 | A non-interventional study of extended-release methylphenidate in the routine treatment of adolescents with ADHD: effectiveness, safety and adherence to treatment. ( Döpfner, M; Fischer, R; Ose, C; Sobanski, E, 2013) |
| "However, in patients with active seizures, the results are somewhat contradictory." | 1.39 | Methylphenidate and continuous spike and wave during sleep in a child with attention deficit hyperactivity disorder. ( Bridgemohan, CH; Marin-Valencia, I; Shankar, M; Sheen, VL; Torres, AR, 2013) |
| "Methylphenidate (MPH) has been shown to be effective in the treatment of attention deficit hyperactivity disorder (ADHD) in children." | 1.39 | An observational study of response heterogeneity in children with attention deficit hyperactivity disorder following treatment switch to modified-release methylphenidate. ( Döpfner, M; Hautmann, C; Rothenberger, A, 2013) |
| " An association between two CES1 SNP markers and the occurrence of sadness as a side effect of short-acting methylphenidate was found." | 1.39 | Methylphenidate side effect profile is influenced by genetic variation in the attention-deficit/hyperactivity disorder-associated CES1 gene. ( Barry, E; Bellgrove, MA; Fitzgerald, M; Gill, M; Hawi, Z; Johnson, KA; Kirley, A; Lambert, D; McNicholas, F, 2013) |
| "Methylphenidate is a medication used routinely in the management of attention deficit hyperactivity disorder." | 1.39 | Methylphenidate-induced erections in a prepubertal child. ( Brady, CM; Kelly, BD; Lundon, DJ; McGuinness, D, 2013) |
| "Methylphenidate is a short-acting stimulant." | 1.39 | Methylphenidate-induced acute orofacial and extremity dyskinesia. ( Donmez, A; Isik, B; Orun, E; Sonmez, FM; Tas, T; Yilmaz, AE, 2013) |
| " Simulations using the fitted parameters determined how changes in fast absorption rate constant (K0Fast) and fraction available (F1) affected curve shape and BE determination using Cmax, AUCINF and PAUC." | 1.39 | Use of partial AUC (PAUC) to evaluate bioequivalence--a case study with complex absorption: methylphenidate. ( Fourie Zirkelbach, J; Jackson, AJ; Schuirmann, DJ; Wang, Y, 2013) |
| "Melatonin was higher in children with predominantly hyperactive-impulsive/conduct disorder subtype." | 1.39 | Methylphenidate effects on blood serotonin and melatonin levels may help to synchronise biological rhythms in children with ADHD. ( Augustin-Morales, MD; Contreras-Chova, F; Cubero-Millán, I; Justicia-Martínez, F; Khaldy-Belkadi, H; Molina-Carballo, A; Muñoz-Hoyos, A; Naranjo-Gómez, A; Ruiz-Ramos, MJ; Uberos, J, 2013) |
| "Treatment with methylphenidate or nisoxetine ameliorated CAR impairments in DAT-KO mice." | 1.39 | Impaired cliff avoidance reaction in dopamine transporter knockout mice. ( Hall, FS; Kasahara, Y; Kobayashi, H; Numachi, Y; Sakakibara, Y; Sora, I; Uchiumi, O; Uhl, GR; Yamashita, M; Yoshida, S, 2013) |
| " During the treatment period the investigators titrated the OROS-MPH dosage on the basis of symptom severity and side effects." | 1.38 | Norepinephrine transporter -3081(A/T) and alpha-2A-adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS-methylphenidate treatment. ( Bellgrove, MA; Cho, SC; Cummins, TD; Kim, BN; Kim, JW, 2012) |
| "Methylphenidate pretreatment reduced responding for methylphenidate in SHR but did not affect self-administration behaviors of Wistar rats (PR)." | 1.38 | Methylphenidate treatment in the spontaneously hypertensive rat: influence on methylphenidate self-administration and reinstatement in comparison with Wistar rats. ( Cheong, JH; dela Peña, I; dela Peña, JB; Lee, JC; Ryu, JH; Shin, CY; Sohn, AR; Yoon, SY, 2012) |
| "Reports on sudden cardiac death (SCD) of children and adolescents treated with stimulant agents have raised concerns regarding the need for cardiovascular monitoring and risk stratification schedules." | 1.38 | Late potentials in the signal-averaged electrocardiogram in pre-pubertal children with ADHD, before and after methylphenidate treatment. ( Glazer, J; Golubchik, P; Imbar, S; Nahshoni, E; Sever, J; Shoval, G; Strasberg, B; Weizman, A; Zalsman, G, 2012) |
| " We have not found examples of ADHD in children who use increased dosage of sustained release of methylphenidate leading to depressive symptomatology." | 1.38 | Depressive symptoms as a side effect of the sustained release form of methylphenidate in a 7-year-old boy with attention-deficit hyperactivity disorder. ( Lakić, A, 2012) |
| "An example application is based on two treatments for attention deficit hyperactivity disorder (ADHD): osmotic-release oral system methylphenidate (OROS-MPH) and lisdexamfetamine dimesylate (LDX)." | 1.38 | Identifying patient subgroups who benefit most from a treatment: using administrative claims data to uncover treatment heterogeneity. ( Betts, KA; Erder, MH; Hodgkins, P; Parikh, K; Setyawan, J; Signorovitch, JE; Wu, EQ; Xie, J; Yang, H, 2012) |
| "Methylphenidate (MPH) has long been used to treat attention-deficit/hyperactivity disorder (ADHD); however, its cellular mechanisms of action and potential effects on prefrontal cortical circuitry are not well understood, particularly in the developing brain system." | 1.38 | Distinct age-dependent effects of methylphenidate on developing and adult prefrontal neurons. ( Gao, WJ; Urban, KR; Waterhouse, BD, 2012) |
| "Methylphenidate was the top prescription dispensed to adolescents (aged 12-17 years)." | 1.38 | Trends of outpatient prescription drug utilization in US children, 2002-2010. ( Chai, G; Governale, L; McMahon, AW; Murphy, D; Staffa, J; Trinidad, JP, 2012) |
| "Comorbid antisocial personality disorder was a negative predictor of long CS treatment duration." | 1.38 | Predictive factors for more than 3 years' duration of central stimulant treatment in adult attention-deficit/hyperactivity disorder: a retrospective, naturalistic study. ( Gjervan, B; Nordahl, HM; Rasmussen, K; Torgersen, T, 2012) |
| " Neither chronic administration of ABT-418 nor MPH affected the learning performance during training in the Morris water maze." | 1.38 | A comparative study of the effects of ABT-418 and methylphenidate on spatial memory in an animal model of ADHD. ( Guo, L; Guo, T; Liu, K; Yang, C, 2012) |
| " The CEPAC members and clinical experts recommended the increased use of parent behavior training as first-line therapy for preschoolers and emphasized the importance of proper monitoring of and dosing for all children who receive medication for their ADHD symptoms." | 1.38 | Management strategies for attention-deficit/hyperactivity disorder: a regional deliberation on the evidence. ( Colby, JA; Emond, SK; Ollendorf, DA; Pearson, SD; Reed, SJ, 2012) |
| "Our intensive pharmacosurveillance monitoring program was performed to increase the number of adverse drug reactions (ADRs) recorded in the Italian spontaneous reporting database, and to systematically collect more thorough data about atomoxetine (ATX) and methylphenidate (MPH) safety in the pediatric setting." | 1.38 | Safety of attention-deficit/hyperactivity disorder medications in children: an intensive pharmacosurveillance monitoring study. ( Bravaccio, C; Capuano, A; Granato, R; Grimaldi, G; Panei, P; Parretta, E; Pascotto, A; Rafaniello, C; Rinaldi, B; Rossi, F; Ruggiero, S; Sportiello, L, 2012) |
| "Methylphenidate treatment did not significantly affect height, weight, or overweight status." | 1.37 | Body mass index of children with attention-deficit/hyperactivity disorder. ( Berger, I; Dubnov-Raz, G; Perry, A, 2011) |
| "Treatment with methylphenidate normalises this threshold, rendering their pattern of task-related DMN deactivation indistinguishable from that of typically developing children." | 1.37 | Task-related default mode network modulation and inhibitory control in ADHD: effects of motivation and methylphenidate. ( Batty, MJ; Groom, MJ; Hollis, C; Liddle, EB; Liddle, PF; Liotti, M; Scerif, G; Totman, JJ, 2011) |
| "Childhood cancer survivors' attention improved after 1 month on MPH." | 1.37 | Parent and teacher ratings of attention during a year-long methylphenidate trial in children treated for cancer. ( Ashford, JM; Conklin, HM; Kahalley, LS; Netson, KL; Wu, S; Xiong, X, 2011) |
| " Compared with WKY and WIS rats, SHRs with previous methylphenidate treatment acquired cocaine self-administration faster, identified cocaine as a highly efficacious reinforcer by displaying an upward shift in the cocaine dose-response function, and showed the greatest motivation to self-administer cocaine by exhibiting the highest progressive ratio breakpoints." | 1.37 | Methylphenidate treatment in adolescent rats with an attention deficit/hyperactivity disorder phenotype: cocaine addiction vulnerability and dopamine transporter function. ( Deaciuc, A; Dwoskin, LP; Harvey, RC; Kantak, KM; Sen, S, 2011) |
| "Methylphenidate can enhance cognitive performance in ADHD patients thus evaluating their IQ scores, although the effect size seems to be relatively small." | 1.37 | Effect of methylphenidate on intelligence quotient scores in Chinese children with attention-deficit/hyperactivity disorder. ( Jin, X; Zhang, L; Zhang, Y, 2011) |
| "Some patients with photosensitive epilepsy use this sensitivity to induce seizures or epileptiform discharges on the electroencephalogram." | 1.37 | Clinical response to methylphenidate in a patient with self-induced photosensitive epilepsy. ( Arroyo-González, R; Fernández-Jaén, A; Fernández-Mayoralas, DM; Gómez-Caicoya, A; Jareño, NM, 2011) |
| "Methylphenidate is a psychostimulant drug indicated for the treatment of attention-deficit hyperactivity disorder (ADHD)." | 1.37 | Patterns of methylphenidate use and assessment of its abuse and diversion in two French administrative areas using a proxy of deviant behaviour determined from a reimbursement database: main trends from 2005 to 2008. ( Coudert, H; Frauger, E; Micallef, J; Natali, F; Pauly, V; Pradel, V; Reggio, P; Thirion, X, 2011) |
| "Methylphenidate-treated children with ADHD had more dyskinesia than children in the control group." | 1.37 | Methylphenidate treatment and dyskinesia in children with attention-deficit/hyperactivity disorder. ( Balázs, J; Czobor, P; Dallos, G; Gádoros, J; Keresztény, A, 2011) |
| "In France, attention deficit disorder (ADHD) has traditionally met with two opposing approaches (biological and psychoanalytic)." | 1.37 | [Attention deficit disorder: multidisciplinary observational study over 1 year]. ( Billard, C; Chambry, J; Cohen de Lara, A; Delteil-Pinton, F; Guinard, M; Idiart, ME; Lacaze, E, 2011) |
| " Recently a transdermal delivery system has been developed which can allow symptom control all day long but with greater dosing flexibility." | 1.37 | Methylphenidate delivery mechanisms for the treatment of children with attention deficit hyperactivity disorder: heterogeneity in parent preferences. ( Dewilde, S; Falconer, S; Hodgkins, P; Lloyd, A; Sasané, R; Sonuga Barke, E, 2011) |
| " Choice of therapy is increasingly influenced by treatment satisfaction and patient preference, with once-daily modified-release methylphenidate (MPH-MR) formulations offering clear benefits compared with immediate-release (IR) dosage forms." | 1.37 | An observational study of once-daily modified-release methylphenidate in ADHD: quality of life, satisfaction with treatment and adherence. ( Becker, A; Breuer, D; Döpfner, M; Rothenberger, A, 2011) |
| "16% of patients permanently discontinued treatment due to adverse events." | 1.37 | An observational study of once-daily modified-release methylphenidate in ADHD: effectiveness on symptoms and impairment, and safety. ( Breuer, D; Döpfner, M; Görtz-Dorten, A; Rothenberger, A, 2011) |
| "Methylphenidate is an amphetamine psychostimulant used as a symptomatic treatment for attention-deficit hyperactivity disorder." | 1.37 | Methylphenidate: growth retardation. ( , 2011) |
| " Patients were followed for 1 year for dosage change, switch (change to non-MPH treatment), augmentation, persistence (number days on index medication) and adherence (days supplied/days persistent)." | 1.37 | Treatment outcomes with methylphenidate formulations among patients with ADHD: retrospective claims analysis of a managed care population. ( Christensen, L; Harley, C; Hodgkins, P; Liu, F; Sasané, R, 2011) |
| " Long-term administration of MPH in childhood may have adverse effects on growth." | 1.37 | Long-term effects of short-acting methylphenidate on growth rates of children with attention deficit hyperactivity disorder at Queen Sirikit National Institute of Child Health. ( Maipang, P; Moungnoi, P, 2011) |
| "Dexmethylphenidate XR is a stimulant treatment in a single isomer form, and has an efficacy and tolerability similar to two doses of immediate-release (IR) dexmethylphenidate when taken 4 hours apart, but is dosed at half of the usual d,l-methylphenidate dose." | 1.36 | Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy. ( Kratochvil, CJ; May, DE, 2010) |
| " The risk of adverse drug-drug interaction(s) is present when metabolic inhibitors are combined with known or suspected substrates of a given enzyme." | 1.36 | Identification of selected therapeutic agents as inhibitors of carboxylesterase 1: potential sources of metabolic drug interactions. ( Appel, DI; Markowitz, JS; Peterson, YK; Wang, Z; Zhu, HJ, 2010) |
| "Methylphenidate has short-term symptomatic efficacy but also many adverse effects, including a risk of sudden death." | 1.36 | Atomoxetine. Attention-deficit/hyperactivity disorder: no better than methylphenidate. ( , 2010) |
| "Methylphenidate (MP) is widely used to treat attention deficit hyperactivity disorder (ADHD)." | 1.36 | Dopamine D4 receptors modulate brain metabolic activity in the prefrontal cortex and cerebellum at rest and in response to methylphenidate. ( Delis, F; Desco, M; Gispert, JD; Grandy, DK; Michaelides, M; Pascau, J; Rubinstein, M; Thanos, PK; Volkow, ND; Wang, GJ, 2010) |
| " Despite their efficacy and long history of use, there is concern about their potential for adverse cardiovascular effects in children and adolescents." | 1.36 | Cardiovascular safety of stimulant medications for pediatric attention-deficit hyperactivity disorder. ( Muniz, R; Silva, RR; Skimming, JW, 2010) |
| "Using an Nf1 optic glioma (OPG) GEM model, we report novel defects in non-selective and selective attention without an accompanying hyperactivity phenotype." | 1.36 | Reduced striatal dopamine underlies the attention system dysfunction in neurofibromatosis-1 mutant mice. ( Brown, JA; Conyers, SB; Emnett, RJ; Gutmann, DH; O'Malley, KL; White, CR; Wozniak, DF; Yuede, CM, 2010) |
| "25), diagnosed with ADHD and treated with methylphenidate at a minimal dosage of 10 mg per day." | 1.36 | Increased dental trauma in children with attention deficit hyperactivity disorder treated with methylphenidate--a pilot study. ( Brinsky-Rapoport, T; Katz-Sagi, H; Matot, I; Ram, D; Redlich, M, 2010) |
| "MPH and ATM generally produced inverted-U dose-response curves, with improvement occurring at moderate doses, but not at higher doses." | 1.36 | Methylphenidate and atomoxetine enhance prefrontal function through α2-adrenergic and dopamine D1 receptors. ( Arnsten, AF; Gamo, NJ; Wang, M, 2010) |
| "Attainment of a stable dosing regimen was defined as no change in type of drug (including a switch from an immediate release (IR) to a long-acting (LA) formulation), strength, and number of pills per day for five consecutive dispensings." | 1.36 | Treatment stabilization in children and adolescents with attention-deficit/hyperactivity disorder: data from the Netherlands. ( Hodgkins, P; Meijer, W; Sasané, R, 2010) |
| "Methylphenidate (MPH) has been shown to block the norepinephrine transporter (NET), and genetic investigations have demonstrated that the norepinephrine transporter gene (SLC6A2) is associated with ADHD." | 1.36 | Possible association of norepinephrine transporter -3081(A/T) polymorphism with methylphenidate response in attention deficit hyperactivity disorder. ( Cho, SC; Hong, SB; Kim, BN; Kim, JW; Shin, MS; Yoo, HJ, 2010) |
| "Adult Attention Deficit Disorder is increasingly diagnosed and treated." | 1.36 | Acute myocardial infarction related to methylphenidate for adult attention deficit disorder. ( Thompson, J; Thompson, JR, 2010) |
| "Attention deficit hyperactivity disorder is associated with reduced cortical blood flow that is reversible with exposure to the psychostimulant methylphenidate (MPH)." | 1.35 | Juvenile methylphenidate modulates reward-related behaviors and cerebral blood flow by decreasing cortical D3 receptors. ( Andersen, SL; Brenhouse, HC; Napierata, L; Sonntag, KC, 2008) |
| "Treatment with methylphenidate at an early age (P21 to P35) did not alter ethanol consumption in adult SHR or WKY, suggesting that it does not increase susceptibility to ethanol addiction in these rats." | 1.35 | Methylphenidate does not increase ethanol consumption in a rat model for attention-deficit hyperactivity disorder-the spontaneously hypertensive rat. ( Howells, FM; Russell, VA; Soeters, HS, 2008) |
| "Methylphenidate is a psychostimulant that acts blocking the dopamine transporter has been used as an effective treatment for Attention Deficit Hyperactivity Disorder." | 1.35 | Cerebral DARPP-32 expression after methylphenidate administration in young and adult rats. ( Gomes, KM; Gomez, MV; Inácio, CG; Martins, MR; Quevedo, J; Réus, GZ; Romano-Silva, MA; Rosa, DV; Soares, EC; Souza, BR; Souza, RP; Valvassori, SS, 2009) |
| " Second, the long-term effect of chronic administration of 2 mg/kg per day MPH at two different developmental stages (days 25-39 or 50-64) on the striatal 5-HTT density was examined in both rat strains at day 90." | 1.35 | Development of 5-HT transporter density and long-term effects of methylphenidate in an animal model of ADHD. ( Becker, A; Bock, N; Manzke, T; Roessner, V; Rothenberger, A, 2009) |
| "To evaluate stimulant dosing patterns in the community treatment of children with attention-deficit/hyperactivity disorder (ADHD)." | 1.35 | Stimulant dosing for children with ADHD: a medical claims analysis. ( Marcus, S; Olfson, M; Wan, G, 2009) |
| "Although dyslexia is widely diagnosed and affects a very important portion of the childhood population, a conceptual definition of the condition is still lacking." | 1.35 | [Dyslexia: a disease, a disorder or something else?]. ( Artigas-Pallarés, J, 2009) |
| "Methylphenidate is a potent central nervous system stimulant that exerts its effects by increasing synaptic levels of dopamine and norepinephrine." | 1.35 | A case of acute cardiomyopathy and pericarditis associated with methylphenidate. ( Dadfarmay, S; Dixon, J, 2009) |
| "Citalopram was being investigated in three ongoing clinical trials lasting 8-24 weeks in 423 patients aged 7-18 years." | 1.35 | Opening the white boxes: the licensing documentation of efficacy and safety of psychotropic medicines for children. ( Aagaard, L; Hansen, EH; Thirstrup, S, 2009) |
| " Medication dosing was flexible, with titration to a maximum of 30 mg/day." | 1.35 | The open-label treatment of attention-deficit/hyperactivity disorder in 4- and 5-year-old children with beaded methylphenidate. ( Fried, J; Greenhill, L; Gugga, SS; Maayan, L; Paykina, N; Strauss, T, 2009) |
| " Data on adverse events and DAT1 3' genotypes were combined from two, double-blind, placebo-controlled, crossover studies of MPH conducted in child psychiatric outpatient clinics in Montreal and Washington, D." | 1.35 | Dopamine transporter genotype and stimulant side effect factors in youth diagnosed with attention-deficit/hyperactivity disorder. ( Cook, EH; Grizenko, N; Gruber, R; Joober, R; Leventhal, BL; Stein, MA, 2009) |
| "Methylphenidate is a piperidine derivative structurally related to amphetamines and acts as a central nervous system stimulant." | 1.35 | Methylphenidate has positive hypocholesterolemic and hypotriglyceridemic effects: new data. ( Charach, G; Grosskopf, I; Kaysar, N; Rabinovich, A; Weintraub, M, 2009) |
| "Safety concerns about central nervous system stimulants for the treatment of attention-deficit/hyperactivity disorder (ADHD) include adverse cardiac effects." | 1.35 | Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD. ( Gerhard, T; Saidi, A; Shuster, J; Winterstein, AG, 2009) |
| "Following reports of sudden death in patients taking medication to treat attention-deficit hyperactivity disorder (ADHD), this study aimed to identify cases of death in patients prescribed stimulants and atomoxetine and to determine any association between these and sudden death." | 1.35 | Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database. ( Cranswick, N; McCarthy, S; Potts, L; Taylor, E; Wong, IC, 2009) |
| "Dexmethylphenidate is a single-isomer stimulant medication approved for the treatment of attention deficit hyperactivity disorder (ADHD)." | 1.35 | Dexmethylphenidate for attention deficit hyperactivity disorder. ( Coury, D, 2009) |
| "Methylphenidate (MPH) is an effective medication for the treatment of attention deficit hyperactivity disorder (ADHD)." | 1.35 | Variability of response time as a predictor of methylphenidate treatment response in korean children with attention deficit hyperactivity disorder. ( Cheon, KA; Ha, EH; Joung, YS; Kim, BN; Lee, SH; Shin, DW; Shin, YJ; Song, DH; Yoo, HJ, 2009) |
| "Treatment with methylphenidate has long been considered as a first choice for disabling forms of ADHD, but recent data do not show evidence for superiority of methylphenidate compared to non pharmacological approach at long-term." | 1.35 | [Attention deficit disorder in childhood]. ( Van Bogaert, P, 2009) |
| " Currently, there have been few reports in the anesthetic literature examining ADHD patients who have had long-term use of methylphenidate, especially the extended-release formulation." | 1.35 | General anesthesia in a juvenile with attention-deficit hyperactivity disorder accompanied by long-term use of methylphenidate (Concerta). ( Chan, KH; Chang, CH; Huang, YC; Tang, GJ; Ting, CK; Yang, CF, 2009) |
| "Excessive daytime sleepiness due to any cause can result in various symptoms similar to those used for the diagnosis of attention deficit/hyperactivity disorder (ADHD)." | 1.35 | Sleep and daytime sleepiness in methylphenidate medicated and un-medicated children with attention-deficit/hyperactivity disorder (ADHD). ( Ashwal, J; Bentley, A; Cockcroft, K, 2009) |
| "Methylphenidate (MPH) is an efficacious and normally well-tolerated treatment for attention-deficit/hyperactivity disorder (ADHD)." | 1.35 | Measuring methylphenidate response in attention-deficit/hyperactvity disorder: how are laboratory classroom-based measures related to parent ratings? ( Coghill, D; DeBacker, M; Sonuga-Barke, EJ; Swanson, J, 2009) |
| "To use growth mixture modelling (GMM) to identify subgroups of children with attention deficit hyperactive disorder (ADHD) who have different pharmacodynamic profiles in response to extended release methylphenidate as assessed in a laboratory classroom setting." | 1.35 | Heterogeneity in the pharmacodynamics of two long-acting methylphenidate formulations for children with attention deficit/hyperactivity disorder. A growth mixture modelling analysis. ( Coghill, D; Hatch, S; Sonuga-Barke, EJ; Swanson, JM; Van Lier, P; Vandenberghe, M; Wigal, S, 2008) |
| "Methylphenidate-OROS is a cost-effective treatment for youths with ADHD for whom treatment with IR methylphenidate is suboptimal." | 1.35 | Long-acting methylphenidate-OROS in youths with attention-deficit hyperactivity disorder suboptimally controlled with immediate-release methylphenidate: a study of cost effectiveness in The Netherlands. ( Annemans, L; de Jong-van den Berg, LT; Faber, A; Kalverdijk, LJ; Postma, MJ; Tobi, H; van Agthoven, M, 2008) |
| "Methylphenidate treatment resulted in improved information processing, e." | 1.35 | Driving-related risks and impact of methylphenidate treatment on driving in adults with attention-deficit/hyperactivity disorder (ADHD). ( Alm, B; Kettler, N; Mattern, R; Sabljic, D; Skopp, G; Sobanski, E; Strohbeck-Kühner, P, 2008) |
| "However, it has been demonstrated that drug addiction is associated with dopaminergic system changes that may affect MPH brain effects, emphasizing the need to better understand MPH actions in subjects with ADHD+SUD." | 1.35 | Methylphenidate DAT binding in adolescents with Attention-Deficit/ Hyperactivity Disorder comorbid with Substance Use Disorder--a single photon emission computed tomography with [Tc(99m)]TRODAT-1 study. ( Bressan, RA; Fu, YK; Hoexter, MQ; Júnior, N; Pechansky, F; Rohde, LA; Schaefer, T; Shih, MC; Szobot, CM, 2008) |
| " Similar side effect profile, superior adherence, and improved efficacy were demonstrated in intra-individual comparison of the OROS and IR methylphenidate forms." | 1.35 | National survey of adherence, efficacy, and side effects of methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan. ( Chang, HL; Chen, SJ; Cheng, H; Chou, MC; Chou, WJ; Gau, SS; Hsu, YC; Huang, YF; Huang, YS; Liang, HY; Lu, HH; Tang, CS; Tzang, RF; Wu, YY, 2008) |
| "Even when controlling for substance use disorder, age at stimulant treatment initiation was significantly and positively related to the later development of antisocial personality disorder." | 1.35 | Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood. ( Castellanos, FX; Howell, KH; Klein, RG; Mannuzza, S; Moulton, JL; Roizen, ER; Truong, NL, 2008) |
| " Since therapeutic MPH in humans is typically administered orally, oral dosing methods that have been verified in the rodent model are of value." | 1.34 | A novel method for oral stimulant administration in the neonate rat and similar species. ( Eppolito, AK; Huff, TB; Smith, LN; Smith, RF; Wheeler, TL, 2007) |
| " Trial length, dosing schedule and efficacy assessment differed per physician." | 1.34 | Use of double-blind placebo-controlled N-of-1 trials among stimulant-treated youths in The Netherlands: a descriptive study. ( de Jong-van den Berg, LT; Faber, A; Keizer, RJ; Tobi, H; van den Berg, PB, 2007) |
| "Treatment with methylphenidate (MPH) entails a dependency risk as MPH is a psychotropic drug." | 1.34 | [Methylphenidate prescriptions in the city of Cologne: overrepresentation of privately insured patients. Results of an analysis based on prescription data]. ( Bessou, H; Puteanus, U; Zeeb, H, 2007) |
| "Treatment with methylphenidate (MPH) in the United States has increased to a current prescription rate of > 5 million per year." | 1.34 | Does methylphenidate cause a cytogenetic effect in children with attention deficit hyperactivity disorder? ( Gerlach, M; Romanos, M; Stopper, H; Walitza, S; Warnke, A; Werner, B, 2007) |
| "The comorbidity of seizures, epilepsy, and attention-deficit-hyperactivity disorder (ADHD) prompted the examination of whether atomoxetine use for ADHD is associated with an increased risk of seizures." | 1.34 | Seizure risk in patients with attention-deficit-hyperactivity disorder treated with atomoxetine. ( Allen, AJ; Ball, S; Bangs, ME; Dunn, D; Edison, T; Holdridge, KC; Jin, L; Wernicke, JF; Zhang, S, 2007) |
| " Regarding a minimum requirement of 5 days weekly dosage and drug holidays, cases that took more than 70% of the recommended methylphenidate dose at the end of the first year were described as compliant." | 1.34 | [Sociodemographic and clinical factors associated with compliance to methylphenidate treatment in children with attention deficit hyperactivity disorder]. ( Aysev, A; Bilgiç, A; Gürkan, K; Kiliç, BG, 2007) |
| " Data available from prescriptions and analyzed were: age, sex and place of residence of the patient, dosage prescribed, date of prescription, place of practice and medical specialization of doctors." | 1.34 | [Hyperactivity and prescription of Ritalin in the canton of Vaud (Switzerland), 2002]. ( Dubois-Arber, F; Huissoud, T; Jeannin, A, 2007) |
| "As a presumptive side effect, a lowered seizure threshold due to medication with methylphenidate remains controversial." | 1.34 | [Quantitative effect of treatment with methylphenidate on EEG--a pilot study]. ( Kerdar, MS; Romanos, M; Scheuerpflug, P; Srdinko, P; Warnke, A; Wewetzer, C, 2007) |
| "Methylphenidate (MPH) is a centrally acting (psycho)stimulant which reversibly blocks the dopamine re-uptake transporter." | 1.34 | Association of Parkinson's disease with symptoms of attention deficit hyperactivity disorder in childhood. ( Gerlach, M; Herhaus, G; Lange, KW; Melfsen, S; Müller, T; Scheuerpflug, P; Walitza, S; Warnke, A, 2007) |
| "Methylphenidate treatment also resulted in rCBF increase in superior prefrontal and reduction in ventral higher visual areas bilaterally." | 1.33 | Regional cerebral blood flow in children with attention deficit hyperactivity disorder: comparison before and after methylphenidate treatment. ( Cho, SC; Chung, JK; Kang, E; Kim, BN; Kim, YK; Lee, DS; Lee, JS; Lee, MC, 2005) |
| " (total daily MPH IR dosage 45 mg)." | 1.33 | [Long-acting methylphenidate. An alternative medical therapy for adult patients with attention deficit hyperactivity disorder]. ( Alm, B; Sobanski, E, 2005) |
| " Thus, our findings have implications for the long-term use of MPH in ADHD." | 1.33 | Methylphenidate differentially regulates c-fos and fosB expression in the developing rat striatum. ( Brown, RE; Carrey, N; Chase, TD; Wilkinson, M, 2005) |
| " This paper draws upon data from a qualitative empirical study to investigate parents' use of the moral ideal of authenticity as part of their narrative justifications for dosing decisions and actions." | 1.33 | Will the "real boy" please behave: dosing dilemmas for parents of boys with ADHD. ( Singh, I, 2005) |
| "Methylphenidate was administered for a period of 9 to 20 months." | 1.33 | Dopamine transporter in attention-deficit hyperactivity disorder normalizes after cessation of methylphenidate. ( Blom-Coenjaerts, C; Feron, FJ; Hendriksen, JG; Jolles, J; Kessels, AG; van Kroonenburgh, MJ; Vles, JS; Weber, WE, 2005) |
| "Methylphenidate is a cornerstone of attention-deficit/hyperactivity disorder (ADHD) treatment." | 1.33 | Successful desensitization of methylphenidate-induced rash. ( Confino-Cohen, R; Goldberg, A, 2005) |
| "Methylphenidate (MPH) is a psychostimulant effective in treating attention-deficit/hyperactivity disorder (ADHD)." | 1.33 | Different adaptations in ventral tegmental area dopamine neurons in control and ethanol exposed rats after methylphenidate treatment. ( Choong, KC; Shen, RY, 2006) |
| "To determine whether long-term treatment of attention deficit hyperactivity disorder (ADHD) with methylphenidate influences the growth in height and weight of children." | 1.33 | [Influence of methylphenidate on growth of school age children with attention deficit hyperactivity disorder]. ( Du, ML; Liu, MN; Zhang, HY; Zhuang, SQ, 2005) |
| "We consider drug-induced cerebral vasculitis as the most likely cause of recurrent ischaemic strokes in the absence of any pathological findings during the diagnostic work-up." | 1.33 | Cerebral vasculitis following oral methylphenidate intake in an adult: a case report. ( Kucinski, T; Röther, J; Thomalla, G; Weiller, C, 2006) |
| "Methylphenidate (MPH) is a potential therapeutic tool for Attention Deficit with Hyperactivity Disorders (ADHD)." | 1.33 | [Benefit of the extended-release methylphenidate formulations: a comparative study in childhood]. ( Barthez, MA; Brault, F; Castelnau, P; Deseille-Turlotte, G; Favreau, A; Giraudeau, B; Krier, C, 2006) |
| "Dexmethylphenidate XR was generally well tolerated in children, adolescents and adults with ADHD, with an adverse-event profile typical of MPH." | 1.33 | Dexmethylphenidate extended release: in attention-deficit hyperactivity disorder. ( Keating, GM; Robinson, DM, 2006) |
| "Methylphenidate is a stimulant used in the treatment of attention deficit hyperactivity disorder in children and is subject to abuse." | 1.33 | Methylphenidate abuse in Texas, 1998-2004. ( Forrester, MB, 2006) |
| "Findings indicate that multiple daily dosing of MPH increases the likelihood of poor adherence, particularly in adolescents, and that poor adherence is associated with impaired maternal/family process." | 1.33 | Determinants of adherence to methylphenidate and the impact of poor adherence on maternal and family measures. ( Chiu, YN; Chou, MC; Gau, CS; Gau, SS; Shen, HY; Tang, CS, 2006) |
| "Methylphenidate is a stimulant medication that is sometimes used as an antidepressant in bipolar adults and is frequently used in children with comorbid bipolar and attention-deficit disorder." | 1.33 | Naturalistic long-term use of methylphenidate in bipolar disorder. ( El-Mallakh, RS; Lydon, E, 2006) |
| "To test the effects of a standard dosage of the psychostimulant methylphenidate (MPH) - which significantly enhances intracortical inhibition but had no effects on intracortical facilitation in children with attention-deficit hyperactivity disorder (ADHD) - on intracortical excitability in healthy subjects." | 1.32 | Methylphenidate and intracortical excitability: opposite effects in healthy subjects and attention-deficit hyperactivity disorder. ( Heinrich, H; Moll, GH; Rothenberger, A, 2003) |
| " Measures of regional cerebral blood flow (rCBF) using positron emission tomography (PET) were acquired at rest for ten adult subjects with ADHD during both an unmedicated state and after a 3-week period of chronic dosing with a clinically optimal dose of MPH." | 1.32 | A positron emission tomography study of methylphenidate in adults with ADHD: alterations in resting blood flow and predicting treatment response. ( Grafton, ST; Hanford, RB; Hoffman, JM; Kilts, CD; Lee, DO; Schweitzer, JB; Tagamets, MA, 2003) |
| "Attention Deficit Disorder with Hyperactivity is a significant burden on clinical services and long-term planning is required." | 1.32 | Current practice in the management of Attention Deficit Disorder with Hyperactivity (ADHD). ( Inman, S; Parr, JR; Ward, A, 2003) |
| "Although attention deficit hyperactivity disorder is thought to be present in preschoolers, there are no clear guidelines for dosing stimulant medications in this population." | 1.32 | High-dose methylphenidate treatment of attention deficit hyperactivity disorder in a preschooler. ( Butz, AM; Cozen, MA; Lipkin, PH, 2003) |
| " There was no clear dose-response relationship." | 1.32 | Effects of once-daily osmotic-release methylphenidate on blood pressure and heart rate in children with attention-deficit/hyperactivity disorder: results from a one-year follow-up study. ( Biederman, J; Lerner, M; Wilens, TE, 2004) |
| "Drug treatment for attention deficit disorder (ADD) was rare in the United Kingdom (UK) until in the mid-1990s." | 1.32 | Incidence and prevalence of drug-treated attention deficit disorder among boys in the UK. ( Black, C; Jick, H; Kaye, JA, 2004) |
| "The newer treatments for ADHD offer advantages over immediate-release methyphenidate in dosing schedule and duration of action that may be of particular benefit to adolescent and adult patients." | 1.32 | Review of new compounds available in Australia for the treatment of attention-deficit hyperactivity disorder. ( Hazell, P, 2004) |
| "Methylphenidate (MPH) is an effective symptomatic treatment of attention deficit hyperactivity disorder (ADHD), but the mechanisms of its therapeutic action have not been fully elucidated." | 1.31 | Effects of methylphenidate discontinuation on cerebral blood flow in prepubescent boys with attention deficit hyperactivity disorder. ( Acton, PD; Austin, G; Elman, I; Krikorian, G; Langleben, DD; Monterosso, JR; Portnoy, O; Ridlehuber, HW; Strauss, HW, 2002) |
| " These initial efficacy and side effect studies in the LSP provided missing information about the basic pharmacokinetic (PK) and pharmacodynamic (PD) properties of MPH and AMP and produced some new discoveries (i." | 1.31 | The use of a laboratory school protocol to evaluate concepts about efficacy and side effects of new formulations of stimulant medications. ( Freid, J; Greenhill, L; Lerner, M; Posner, K; Steinhoff, K; Swanson, JM; Wigal, S; Wigal, T, 2002) |
| "Ten previously untreated adults with attention deficit hyperactivity disorder (ADHD) were investigated before and after 4 weeks of treatment with a dose of 3x5 mg methylphenidate/d by single photon emission computed tomography (SPECT) with [Tc-99m]TRODAT-1, the first Tc-99m labelled SPECT ligand specifically binding to the dopamine transporter (DAT)." | 1.31 | Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography. ( Dresel, SH; Krause, J; Krause, KH; Kung, HF; Tatsch, K, 2000) |
| "Methylphenidate treatment (3 mg/kg daily for 14 days) did not normalize the decreased electrically-stimulated release of [(3)H]dopamine from SHR caudate-putamen slices nor did it affect postsynaptic D(2) receptor function." | 1.31 | Methylphenidate affects striatal dopamine differently in an animal model for attention-deficit/hyperactivity disorder--the spontaneously hypertensive rat. ( de Villiers, AS; Lamm, MC; Russell, VA; Sagvolden, T; Taljaard, JJ, 2000) |
| "Criteria of attention deficit disorder with hyperactivity are defined in DSM IV and CIM 10." | 1.31 | [Attention deficit disorder with hyperactivity in children: diagnosis and therapeutic management]. ( Vallée, L, 2000) |
| "Methylphenidate exposure was associated with symptom development in 31% of cases." | 1.31 | Characterization of methylphenidate exposures reported to a regional poison control center. ( White, SR; Yadao, CM, 2000) |
| " Although this study could not address the problem of the match directly, it is generating important leads for research on the use of psychosocial strategies to enhance the scope and durability of treatment gains while decreasing the risks attendant upon long-term use of medication." | 1.31 | ADHD treatment in the 21st century: pushing the envelope. ( Whalen, CK, 2001) |
| " Recent studies suggest that Adderall, a psychostimulant indicated for the treatment of ADHD, may provide an efficacious, less frequently dosed alternative to methylphenidate." | 1.31 | Retrospective comparison of Adderall and methylphenidate in the treatment of attention deficit hyperactivity disorder. ( Grcevich, S; Marcellino, B; Rowane, WA; Sullivan-Hurst, S, 2001) |
| " The present study extends these results by addressing the issue of clinical significance using drug-placebo and drug-drug response curve analyses of the same data." | 1.31 | Efficacy of Adderall and methylphenidate in attention deficit hyperactivity disorder: a reanalysis using drug-placebo and drug-drug response curve methodology. ( Biederman, J; Faraone, SV; Olvera, RL; Pliszka, SR; Skolnik, R, 2001) |
| "This report suggests that myoclonus may be a side effect of sertraline in some adolescents." | 1.31 | Myoclonus during prolonged treatment with sertraline in an adolescent patient. ( Ghaziuddin, N; Iqbal, A; Khetarpal, S, 2001) |
| "Treatment with methylphenidate was more effective and better tolerated than treatment with clonidine." | 1.31 | [Functioning, comorbidity and treatment of 141 adults with attention deficit hyperactivity disorder (ADHD) at a psychiatric outpatient department]. ( Aeckerlin, LP; Buitelaar, JK; Kooij, JJ, 2001) |
| "Methylphenidate is a CNS stimulant that is thought to block the reuptake of dopamine and noradrenaline (norepinephrine) into the presynaptic neuron." | 1.31 | Methylphenidate (OROS formulation). ( Jarvis, B; Keating, GM; McClellan, K, 2001) |
| "Gabapentin is an anticonvulsant drug released in the United States in 1993 for use as adjunctive therapy in refractory partial epilepsy." | 1.31 | Gabapentin and methylphenidate treatment of a preadolescent with attention deficit hyperactivity disorder and bipolar disorder. ( Bailey, K; Hamrin, V, 2001) |
| " The average daily dosage prescribed differed little among general practitioners, pediatricians and psychiatrists, unlike the mean interval between successive prescriptions: 89." | 1.31 | Prescription of methylphenidate to children and youth, 1990-1996. ( Armstrong, RW; Lalonde, CE; McGrail, KM; Miller, AR, 2001) |
| " The differences were attributable to differences in drug-acquisition costs and the need for in-school dosing of twice-daily and thrice-daily medications." | 1.31 | Pharmacotherapies for attention-deficit/hyperactivity disorder: expected-cost analysis. ( Carotenuto, I; Conners, CK; Einarson, TR; Findling, R; Iskedjian, M; Jensen, PS; Lau, H; Magar, R; Marchetti, A; Murphy, EL; Wineburg, E, 2001) |
| "Methylphenidate (Ritalin) is an effective drug in the treatment of attention deficit hyperactivity disorder." | 1.31 | Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications. ( Ding, YS; Fowler, JS; Franceschi, D; Gatley, SJ; Gifford, A; Logan, J; Maynard, L; Swanson, JM; Volkow, ND; Wang, GJ; Zhu, W, 2002) |
| "Methylphenidate was prescribed to 1." | 1.31 | Methylphenidate use for attention deficit hyperactivity disorder in northern Israel--a controversial issue. ( Fogelman, Y; Kahan, E, 2001) |
| "Methylphenidate prevalence was relatively low." | 1.31 | Prevalence of methylphenidate use and change over a two-year period: a nationwide study of 2- to 11-year-old Canadian children. ( Baillargeon, RH; Robaey, P; Romano, E; Tremblay, RE; Wu, HX, 2002) |
| "To determine whether treatment of attention deficit hyperactivity disorder (ADHD) with methylphenidate hydrochloride or pemoline diminishes the response to growth hormone (GH) therapy in patients with idiopathic GH deficiency (IGHD) or idiopathic short stature (ISS)." | 1.30 | Response to growth hormone in attention deficit hyperactivity disorder: effects of methylphenidate and pemoline therapy. ( Blethen, SL; Breen, TJ; Julius, JR; Rao, JK, 1998) |
| "When methylphenidate was administered to the ADHD groups, both groups improved in performance on the CPT." | 1.30 | Components of attention in children with complex partial seizures with and without ADHD. ( Semrud-Clikeman, M; Wical, B, 1999) |
| "Methylphenidate was used as a model compound." | 1.30 | Liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry enantiomeric separation of dl-threo-methylphenidate, (Ritalin) using a macrocyclic antibiotic as the chiral selector. ( Bakhtiar, R; Hayes, M; Majumdar, T; Ramos, L; Tse, F, 1999) |
| " Higher dosage was associated with fewer diagnoses of alcoholism or suicide attempts." | 1.30 | Childhood inattention-overactivity, aggression, and stimulant medication history as predictors of young adult outcomes. ( Loney, J; Paternite, CE; Salisbury, H; Whaley, MA, 1999) |
| "Children with ADHD and Oppositional Defiant Disorder (ODD) prescribed stimulants reported feeling better behaved." | 1.30 | Do stimulants improve self-esteem in children with ADHD and peer problems? ( Cantwell, DP; Feinberg, DT; Frankel, F; Myatt, R, 1999) |
| " The dosage was increased until behavioral change was achieved, using a decrement in scores of less than or equal to 1 on a commonly used rating scale or until the maximum tolerated dose was achieved." | 1.30 | Association of the dopamine transporter gene (DAT1) with poor methylphenidate response. ( Comings, DE; Winsberg, BG, 1999) |
| "In this study we approach problems related to the dosage and specific action of methylphenidate, its effects at cognitive and social levels, possible side-effects and limitations to its usage, and methods for evaluation of the response to treatment in the school environment." | 1.30 | [The evaluation of the effects of pharmacological treatment of children with attention deficit hyperactivity disorder]. ( Amado, L; Presentación, MJ; Roselló, B, 1999) |
| "The major use of methylphenidate is for treatment of attention deficit hyperactivity disorder." | 1.29 | The use of methylphenidate in Michigan. ( Gardiner, JC; Houang, RT; Jetton, JR; Rappley, MD, 1995) |
| " Personal or family tic history, medication selection, or dosage was not related to onset of T/D." | 1.29 | Tics and dyskinesias associated with stimulant treatment in attention-deficit hyperactivity disorder. ( Adesman, AR; Goldstein, IJ; Lipkin, PH, 1994) |
| "Two children with attention deficit disorder treated with methylphenidate as a simple drug developed fixed drug eruption of the scrotum." | 1.28 | Fixed drug eruption of the scrotum due to methylphenidate. ( Ashkenazi, A; Cohen, HA; Frydman, M; Gross, S; Nussinovitch, M, 1992) |
| " Dosage after 4 weeks averaged 1." | 1.28 | Effects of high methylphenidate doses on the cognitive performance of hyperactive children. ( Klein, RG, 1991) |
| "Children with Minimal Brain Dysfunction (MBD) are vulnerable in society." | 1.28 | [Ritalin: a stimulating drug in the treatment of children with minimal brain dysfunction (MBD)]. ( Flapper, BC; Heltzel, A; Koopman, HM, 1989) |
| "With methylphenidate treatment, the mean scores on the ADD-H Comprehensive Teacher Rating Scale displayed an increase in attention span and a decrease in hyperactivity, the Connors' Parent Rating Scale-Revised showed a significant decrease in ADD/H behavior, and the Gordon Diagnostic System mean scores indicated no significant change." | 1.28 | Parent, teacher, child. A trilateral approach to attention deficit disorder. ( Atkinson, AW; Cohen, ML; Kelly, PC, 1989) |
| " Newborns and premature infants can metabolize and eliminate diazepam, although the parent drug has a longer half-life and decreased rate of biotransformation to its primary metabolites than in older children and adults." | 1.27 | Pharmacokinetics of benzodiazepines and psychostimulants in children. ( Coffey, B; Greenblatt, DJ; Shader, RI, 1983) |
| "This research tested the hypothesis that a relatively modest dose of stimulant medication would produce optimal effects on cognitive and impulse control performance when compared to three other dosage levels in hyperactive school children." | 1.27 | How much stimulant medication is appropriate for hyperactive school children? ( Brown, RT; Slimmer, LW; Wynne, ME, 1984) |
| " The augmenters were blindly titrated at significantly lower dosage levels than the reducers." | 1.27 | Auditory ERP augmentation-reduction and methylphenidate dosage needs in attention and reading disordered children. ( Ackerman, PT; Dykman, RA; Holcomb, PJ; McCray, DS, 1983) |
| "Despite the fact that 57% of the ADDH group were reported to experience restless sleep on structured parental rating forms, they did not show any sleep architecture abnormalities on polysomnographic recordings when compared with the normals at baseline other than decreased rapid eye movement (REM) activity." | 1.27 | Sleep architecture and REM sleep measures in prepubertal children with attention deficit disorder with hyperactivity. ( Davies, M; Goetz, R; Greenhill, L; Hanlon, C; Puig-Antich, J, 1983) |
| "A subcategory of patients with borderline personality disorder (BPD) who also meet criteria for attention deficit disorder (ADD) has recently been described." | 1.27 | Use of imipramine for attention deficit disorder in a borderline patient. ( Denton, C; Satel, S; Southwick, S, 1988) |
| "Children who have attention deficit disorder with (or without) hyperactivity are handicapped by their inability to concentrate and control their impulsivity, especially while in school." | 1.27 | Clinical management of children with hyperactivity. A shift in diagnostic and therapeutic emphasis. ( Hesterly, SO, 1986) |
| "Each patient with Attention Deficit Disorder (ADD), with or without hyperactivity, is unique in the variety and severity of the handicapping conditions associated with ADD." | 1.27 | Attention deficit disorder children with or without hyperactivity. Which behaviors are helped by stimulants? ( Sleator, EK; Ullmann, RK, 1985) |
| "Early signs of Tourette's syndrome may be difficult to distinguish from hyperactive and attention disordered symptoms, leading the clinician to consider, treatment with stimulants." | 1.26 | Stimulant medications precipitate Tourette's syndrome. ( Cohen, DJ; Detlor, J; Kremenitzer, MW; Lowe, TL; Shaywitz, BA, 1982) |
| "Early signs of Tourette's syndrome may be difficult to distinguish from hyperactive and attention disordered symptoms, leading the clinician to consider treatment with stimulants." | 1.26 | Stimulant medications precipitate Tourette's syndrome. ( Cohen, DJ; Detlor, J; Kremenitzer, MW; Lowe, TL; Shaywitz, BA, 1982) |
| " Total milligrams per day dosage, milligrams per kilogram per day dosage and duration of treatment per year were analysed in the medicated hyperactive children and their growth was compared with the other two groups." | 1.26 | Effect of methylphenidate hydrochloride on stature of hyperactive children. ( Cohen, MN; Kalachnik, JE; Sleator, EK; Sprague, RL; Ullmann, RK, 1982) |
| " For all dosage groups behavior and attention improved with increased dosage, and the best scores were associated with the highest drug levels." | 1.26 | Optimal dosages of methylphenidate for improving the learning and behavior of hyperactive children. ( Charles, L; Schain, R; Zelniker, T, 1981) |
| "The authors treated two children with Gilles de la Tourette's disease and one child with a probable combination of Gilles de la Tourette's disease and minimal brain dysfunction with methylphenidate, which resulted in exacerbation of symptoms." | 1.26 | The use of methylphenidate and imipramine in Gilles de la Tourette's disease in children. ( Fras, I; Karlavage, J, 1977) |
| " No correlations were found between dosage level and changes in weight and height percentiles." | 1.26 | Growth of hyperkinetic children taking methylphenidate, dextroamphetamine, or imipramine/desipramine. ( Gross, MD, 1976) |
| "The clinical diagnosis in 19 cases was minimal brain dysfunction (MBD), and in one case, Gilles de la Tourette syndrome." | 1.26 | Tics following methylphenidate administration. A report of 20 cases. ( Bemporad, JR; Denckla, MB; MacKay, MC, 1976) |
| "Methylphenidate is a useful, proven method for the effective treatment of minimal brain dysfunction (MBD)." | 1.26 | Methylphenidate: a review. ( Majovski, LV; Oettinger, L, 1976) |
| "Minimal brain dysfunction is a neurodevelopmental disorder which can be found in nearly 20% of school children." | 1.26 | Minimal brain dysfunction/specific learning disability: a clinical approach for the primary physician. ( Levy, HB, 1976) |
| "Thirty adolescents with histories of minimal brain dysfunction who had been treated for at least six months with chemotherapy were compared with 30 adolescents who had not been so treated." | 1.25 | Childhood chemotherapy and later drug abuse and growth curve: a follow-up study of 30 adolescents. ( Beck, L; Langford, WS; Mackay, M; Sum, G, 1975) |
| " Methylphenidate is given in 1-3 daily doses; treatment is commenced with small doses, and after 2-4 days the dosage is increased until behaviour changes." | 1.25 | [Methylphenidat (Ritalin) as a psychotropic drug in children with minimal brain dysfunction and epilepsy]. ( Kind, CR, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 400 (10.71) | 18.7374 |
| 1990's | 408 (10.92) | 18.2507 |
| 2000's | 1187 (31.78) | 29.6817 |
| 2010's | 1360 (36.41) | 24.3611 |
| 2020's | 380 (10.17) | 2.80 |
| Authors | Studies |
|---|---|
| Trombetta, D | 1 |
| Vik, T | 3 |
| Anand, V | 1 |
| Müller, AR | 1 |
| Zinkstok, JR | 1 |
| Rommelse, NNJ | 1 |
| van de Ven, PM | 1 |
| Roes, KCB | 1 |
| Wijburg, FA | 1 |
| de Rooij-Askes, E | 1 |
| Linders, C | 1 |
| Boot, E | 1 |
| van Eeghen, AM | 1 |
| Vertessen, K | 1 |
| Luman, M | 6 |
| Staff, A | 1 |
| Bet, P | 2 |
| de Vries, R | 1 |
| Twisk, J | 1 |
| Oosterlaan, J | 20 |
| Robinson, AM | 3 |
| Eggleston, RL | 2 |
| Bucci, DJ | 3 |
| Morris, SSJ | 1 |
| Musser, ED | 2 |
| Tenenbaum, RB | 1 |
| Ward, AR | 1 |
| Raiker, JS | 6 |
| Coles, EK | 10 |
| Pan, PY | 2 |
| Jonsson, U | 1 |
| Şahpazoğlu Çakmak, SS | 1 |
| Häge, A | 10 |
| Hohmann, S | 5 |
| Nobel Norrman, H | 1 |
| Buitelaar, JK | 40 |
| Banaschewski, T | 44 |
| Cortese, S | 27 |
| Coghill, D | 40 |
| Bölte, S | 2 |
| Umair, HM | 1 |
| Sandler, RD | 1 |
| Alunno, A | 1 |
| Matucci-Cerinic, M | 1 |
| Hughes, M | 1 |
| Kaalund-Brok, K | 1 |
| Houmann, TB | 1 |
| Hebsgaard, MB | 1 |
| Lauritsen, MG | 1 |
| Lundstrøm, LH | 1 |
| Grønning, H | 1 |
| Darling, L | 1 |
| Reinert-Petersen, S | 1 |
| Petersen, MA | 1 |
| Jepsen, JRM | 5 |
| Pagsberg, AK | 3 |
| Plessen, KJ | 1 |
| Rasmussen, HB | 2 |
| Jeppesen, P | 1 |
| Halperin, D | 1 |
| Stavsky, A | 1 |
| Kadir, R | 1 |
| Drabkin, M | 1 |
| Wormser, O | 1 |
| Yogev, Y | 1 |
| Dolgin, V | 1 |
| Proskorovski-Ohayon, R | 1 |
| Perez, Y | 1 |
| Nudelman, H | 1 |
| Stoler, O | 1 |
| Rotblat, B | 1 |
| Lifschytz, T | 1 |
| Lotan, A | 2 |
| Meiri, G | 1 |
| Gitler, D | 1 |
| Birk, OS | 1 |
| Manza, P | 2 |
| Shokri-Kojori, E | 2 |
| Wiers, CE | 1 |
| Kroll, D | 2 |
| Feldman, D | 2 |
| McPherson, K | 2 |
| Biesecker, E | 1 |
| Dennis, E | 2 |
| Johnson, A | 2 |
| Kelleher, A | 1 |
| Qu, S | 2 |
| Tomasi, D | 4 |
| Wang, GJ | 12 |
| Volkow, ND | 19 |
| Yechiam, E | 3 |
| Zeif, D | 1 |
| Melo, V | 1 |
| Zaccariello, M | 1 |
| Girard, E | 1 |
| Croarkin, P | 1 |
| Romanowicz, M | 1 |
| Rhodes, SM | 4 |
| Lages, YV | 1 |
| Maisonnette, SS | 1 |
| Rosseti, FP | 1 |
| Galvão, BO | 1 |
| Landeira-Fernandez, J | 1 |
| Haleem, DJ | 1 |
| Salman, T | 1 |
| Nawaz, S | 1 |
| Ikram, H | 1 |
| Boesen, K | 6 |
| Jørgensen, KJ | 4 |
| Gøtzsche, PC | 7 |
| Lee, SM | 2 |
| Cheong, HK | 1 |
| Oh, IH | 4 |
| Hong, M | 5 |
| Yuan, D | 1 |
| Zhang, M | 5 |
| Huang, Y | 2 |
| Wang, X | 1 |
| Jiao, J | 1 |
| Paulus, MP | 1 |
| Kuplicki, R | 1 |
| Victor, TA | 1 |
| Yeh, HW | 1 |
| Khalsa, SS | 1 |
| Pham, MN | 1 |
| Hudnall, MT | 1 |
| Fantus, RJ | 1 |
| Lai, JD | 1 |
| Ambulkar, SS | 1 |
| Wren, JM | 1 |
| Bennett, NE | 1 |
| Auffenberg, GB | 1 |
| Chu, DI | 1 |
| Brannigan, RE | 1 |
| Halpern, JA | 1 |
| Akkaya, S | 2 |
| Ulusoy, DM | 1 |
| Doğan, H | 1 |
| Arslan, ME | 1 |
| Briegel, W | 1 |
| Enokizono, T | 1 |
| Ohto, T | 1 |
| Tanaka, M | 1 |
| Maruo, K | 1 |
| Mizuguchi, T | 1 |
| Sano, Y | 1 |
| Kandori, A | 1 |
| Takada, H | 1 |
| Hafeez, S | 1 |
| Saquib, J | 1 |
| Qureshi, NE | 1 |
| Jaeschke, RR | 2 |
| Çetin, FH | 2 |
| Barış Usta, M | 1 |
| Aydın, S | 1 |
| Güven, AS | 1 |
| García Ron, A | 2 |
| Rodriguez Mesa, M | 1 |
| Arias Vivas, E | 1 |
| Bote Gascon, M | 1 |
| Farhat, LC | 3 |
| Flores, JM | 1 |
| Behling, E | 1 |
| Avila-Quintero, VJ | 1 |
| Lombroso, A | 1 |
| Polanczyk, GV | 10 |
| Bloch, MH | 6 |
| Arvidsson, M | 2 |
| Franck, J | 9 |
| Ackehed, G | 1 |
| Pettersson Bergstrand, M | 1 |
| Ekström, L | 1 |
| Rosenborg, S | 1 |
| Dahl, ML | 2 |
| Crouzet, L | 1 |
| Gramond, A | 1 |
| Suehs, C | 1 |
| Fabbro-Peray, P | 1 |
| Abbar, M | 1 |
| Lopez-Castroman, J | 1 |
| Foschiera, LN | 1 |
| Schmitz, F | 1 |
| Wyse, ATS | 1 |
| Masi, G | 8 |
| Pfanner, C | 3 |
| Liboni, F | 1 |
| Lenzi, F | 2 |
| Villafranca, A | 2 |
| D'Acunto, G | 2 |
| Fantozzi, P | 2 |
| Falcone, F | 1 |
| Simonelli, V | 1 |
| Muratori, P | 4 |
| Levantini, V | 1 |
| Favole, I | 1 |
| Amianto, F | 1 |
| Davico, C | 1 |
| Vitiello, B | 36 |
| D'Aiello, B | 3 |
| Di Vara, S | 3 |
| De Rossi, P | 4 |
| Pretelli, I | 3 |
| Vicari, S | 4 |
| Menghini, D | 3 |
| Mazzetti, C | 1 |
| Gonzales Damatac, C | 1 |
| Sprooten, E | 1 |
| Ter Huurne, N | 1 |
| Jensen, O | 2 |
| Paludan-Müller, AS | 1 |
| Voetterl, H | 1 |
| van Wingen, G | 1 |
| Michelini, G | 3 |
| Griffiths, KR | 2 |
| Gordon, E | 8 |
| DeBeus, R | 1 |
| Korgaonkar, MS | 2 |
| Loo, SK | 9 |
| Palmer, D | 4 |
| Breteler, R | 1 |
| Denys, D | 2 |
| Arnold, LE | 29 |
| du Jour, P | 1 |
| van Ruth, R | 1 |
| Jansen, J | 1 |
| van Dijk, H | 1 |
| Arns, M | 3 |
| Surman, CBH | 3 |
| Walsh, DM | 2 |
| Merrill, BM | 5 |
| Mattfeld, AT | 1 |
| Macphee, FL | 4 |
| Ramos, MC | 1 |
| Zhao, X | 3 |
| Altszuler, AR | 3 |
| Schooler, JW | 1 |
| Coxe, S | 1 |
| Gnagy, EM | 26 |
| Greiner, AR | 9 |
| Pelham, WE | 70 |
| Wang, LJ | 17 |
| Huang, YH | 3 |
| Chou, WJ | 7 |
| Lee, SY | 11 |
| Mckenzie, A | 1 |
| Meshkat, S | 1 |
| Lui, LMW | 1 |
| Ho, R | 1 |
| Di Vincenzo, JD | 1 |
| Ceban, F | 1 |
| Cao, B | 1 |
| McIntyre, RS | 5 |
| Inci Izmir, SB | 1 |
| Ipci, M | 3 |
| Ercan, ES | 8 |
| Kamimura-Nishimura, KI | 1 |
| Brinkman, WB | 3 |
| Epstein, JN | 7 |
| Zhang, Y | 8 |
| Altaye, M | 2 |
| Simon, J | 2 |
| Modi, AC | 1 |
| Froehlich, TE | 5 |
| Prieto Antolín, B | 1 |
| Gutiérrez-Abejón, E | 1 |
| Alberola López, S | 1 |
| Andrés de Llano, JM | 1 |
| Lee, YH | 3 |
| Ouyang, CS | 1 |
| Chiu, YH | 1 |
| Chiang, CT | 1 |
| Wu, RC | 1 |
| Yang, RC | 1 |
| Lin, LC | 1 |
| Stevanovic, D | 1 |
| Wentz, E | 1 |
| Nasic, S | 1 |
| Knez, R | 1 |
| Śmiarowska, M | 1 |
| Brzuchalski, B | 1 |
| Grzywacz, E | 1 |
| Malinowski, D | 1 |
| Machoy-Mokrzyńska, A | 1 |
| Pierzchlińska, A | 1 |
| Białecka, M | 1 |
| Battisti, A | 1 |
| Lazzaro, G | 1 |
| Pani, P | 1 |
| Costanzo, F | 1 |
| Ni, AM | 1 |
| Bowes, BS | 1 |
| Ruff, DA | 1 |
| Cohen, MR | 1 |
| Selaskowski, B | 2 |
| Staerk, C | 1 |
| Braun, N | 2 |
| Matthies, S | 11 |
| Graf, E | 13 |
| Colla, M | 11 |
| Jacob, C | 14 |
| Sobanski, E | 21 |
| Alm, B | 19 |
| Roesler, M | 4 |
| Retz, W | 17 |
| Retz-Junginger, P | 7 |
| Kis, B | 8 |
| Abdel-Hamid, M | 7 |
| Huss, M | 17 |
| Jans, T | 12 |
| Tebartz van Elst, L | 7 |
| Berger, M | 8 |
| Lux, S | 2 |
| Mayr, A | 1 |
| Philipsen, A | 23 |
| Hacker, CM | 1 |
| Rust, NC | 1 |
| Bingöl-Kızıltunç, P | 1 |
| Yürümez, E | 1 |
| Atilla, H | 1 |
| Groom, MJ | 5 |
| Zetterström, TSC | 2 |
| Quansah, E | 2 |
| Grootveld, M | 2 |
| Heal, DJ | 4 |
| Gosden, J | 1 |
| Smith, SL | 3 |
| Fu, Z | 1 |
| Yuan, J | 1 |
| Pei, X | 1 |
| Zhang, K | 1 |
| Xu, C | 1 |
| Hu, N | 1 |
| Xie, R | 2 |
| Zhao, Y | 1 |
| Wang, Y | 8 |
| Yang, L | 14 |
| Cao, Q | 3 |
| Roy, S | 1 |
| Mandal, N | 1 |
| Ray, A | 2 |
| Roy, PK | 1 |
| Bhattacharyya, A | 1 |
| Saha, PK | 1 |
| Shram, MJ | 1 |
| Setnik, B | 1 |
| Webster, L | 2 |
| Guenther, S | 1 |
| Mickle, TC | 1 |
| Braeckman, R | 1 |
| Kanski, J | 1 |
| Martin, A | 3 |
| Kelsh, D | 1 |
| Vince, BD | 1 |
| Barrett, AC | 1 |
| Ramos, M | 1 |
| Connor, CM | 1 |
| Lonigan, CJ | 1 |
| Burger, L | 1 |
| Morrow, AS | 1 |
| Swanson, JM | 55 |
| Waxmonsky, JG | 16 |
| Higgins, GA | 1 |
| Silenieks, LB | 1 |
| Golsorkhi, H | 1 |
| Qorbani, M | 1 |
| Kamalinejad, M | 1 |
| Sabbaghzadegan, S | 1 |
| Bahrami, M | 1 |
| Vafaee-Shahi, M | 1 |
| Montazerlotfelahi, H | 1 |
| Abniki, E | 1 |
| Dadmehr, M | 1 |
| Low, AM | 5 |
| Vangkilde, S | 8 |
| le Sommer, J | 4 |
| Fagerlund, B | 5 |
| Glenthøj, B | 5 |
| Habekost, T | 5 |
| Mizuno, Y | 3 |
| Cai, W | 3 |
| Supekar, K | 2 |
| Makita, K | 2 |
| Takiguchi, S | 3 |
| Tomoda, A | 5 |
| Menon, V | 3 |
| Asherson, PJ | 2 |
| Johansson, L | 2 |
| Holland, R | 2 |
| Bedding, M | 1 |
| Forrester, A | 1 |
| Giannulli, L | 1 |
| Ginsberg, Y | 10 |
| Howitt, S | 2 |
| Kretzschmar, I | 1 |
| Lawrie, SM | 1 |
| Marsh, C | 1 |
| Kelly, C | 1 |
| Mansfield, M | 1 |
| McCafferty, C | 1 |
| Khan, K | 1 |
| Müller-Sedgwick, U | 1 |
| Strang, J | 2 |
| Williamson, G | 1 |
| Wilson, L | 1 |
| Young, S | 2 |
| Landau, S | 2 |
| Thomson, LDG | 1 |
| Childress, AC | 16 |
| Markowitz, JS | 9 |
| Melchert, PW | 1 |
| Quintero, J | 4 |
| Rodríguez-Quiroga, A | 1 |
| Álvarez-Mon, MÁ | 1 |
| Mora, F | 1 |
| Rostain, AL | 6 |
| Rosenau, PT | 2 |
| van den Hoofdakker, BJ | 5 |
| Matthijssen, AM | 3 |
| van de Loo-Neus, GHH | 3 |
| Hoekstra, PJ | 12 |
| Dietrich, A | 4 |
| Wang, P | 2 |
| Wang, M | 2 |
| Li, C | 2 |
| Dong, X | 1 |
| Xu, L | 1 |
| Han, F | 1 |
| Facharztmagazine, R | 1 |
| Kaiser, A | 2 |
| Broeder, C | 1 |
| Cohen, JR | 4 |
| Douw, L | 1 |
| Reneman, L | 11 |
| Schrantee, A | 8 |
| Cataldo, M | 2 |
| Donnelly, G | 3 |
| Cutler, AJ | 5 |
| Childress, A | 21 |
| Mikl, J | 2 |
| Bhaskar, S | 2 |
| Waxmonsky, J | 4 |
| Jackson, AJ | 2 |
| Foehl, HC | 2 |
| Contreras, D | 2 |
| Piña, R | 2 |
| Carvallo, C | 1 |
| Godoy, F | 1 |
| Ugarte, G | 2 |
| Zeise, M | 1 |
| Rozas, C | 2 |
| Morales, B | 2 |
| Sørensen, AMS | 1 |
| Wesselhöeft, R | 1 |
| Andersen, JH | 1 |
| Reutfors, J | 5 |
| Cesta, CE | 4 |
| Furu, K | 8 |
| Hartz, I | 1 |
| Rasmussen, L | 1 |
| Wang, J | 5 |
| Ni, XQ | 1 |
| Li, LM | 1 |
| Liao, YZ | 1 |
| Chen, Y | 3 |
| Huang, CL | 1 |
| Zerón-Rugerio, MF | 1 |
| Alda, JA | 1 |
| Carpio-Arias, TV | 1 |
| Izquierdo-Pulido, M | 1 |
| Cambras, T | 1 |
| Lenartowicz, A | 2 |
| Diaz-Fong, JP | 1 |
| Bilder, RM | 5 |
| McGough, JJ | 24 |
| McCracken, JT | 19 |
| Vera, JD | 1 |
| Pipe, A | 1 |
| Ravindran, N | 1 |
| Paric, A | 1 |
| Patterson, B | 2 |
| Van Ameringen, M | 1 |
| Ravindran, AV | 1 |
| Xu, J | 2 |
| Wang, N | 1 |
| Sun, P | 1 |
| Mao, F | 1 |
| Yuan, TF | 1 |
| Hagan, AJ | 1 |
| Verity, SJ | 1 |
| Stricker, B | 1 |
| Cheung, K | 4 |
| Verhamme, K | 1 |
| Pulido, LN | 1 |
| Pochapski, JA | 1 |
| Sugi, A | 1 |
| Esaki, JY | 1 |
| Stresser, JL | 1 |
| Sanchez, WN | 1 |
| Baltazar, G | 1 |
| Levcik, D | 1 |
| Fuentes, R | 1 |
| Da Cunha, C | 1 |
| Arbaeen, A | 1 |
| Wheate, NJ | 1 |
| Cairns, R | 2 |
| Brown, JT | 2 |
| Wagener, N | 1 |
| Lehmann, W | 1 |
| Weiser, L | 4 |
| Jäckle, K | 1 |
| Di Fazio, P | 1 |
| Schilling, AF | 1 |
| Böker, KO | 1 |
| Lannes, A | 1 |
| Del Giovane, C | 3 |
| Cipriani, A | 3 |
| Revet, A | 1 |
| Chatterjee, M | 2 |
| Saha, S | 2 |
| Maitra, S | 1 |
| Sinha, S | 2 |
| Mukhopadhyay, K | 2 |
| Galvez-Contreras, AY | 1 |
| Vargas-de la Cruz, I | 1 |
| Beltran-Navarro, B | 1 |
| Gonzalez-Castaneda, RE | 1 |
| Gonzalez-Perez, O | 1 |
| Blasco-Fontecilla, H | 3 |
| Moyano-Ramírez, E | 1 |
| Méndez-González, O | 1 |
| Rodrigo-Yanguas, M | 1 |
| Martin-Moratinos, M | 1 |
| Bella-Fernández, M | 1 |
| Trempler, I | 1 |
| Heimsath, A | 1 |
| Nieborg, J | 1 |
| Bradke, B | 1 |
| Schubotz, RI | 1 |
| Ohrmann, P | 1 |
| Thanos, PK | 4 |
| McCarthy, M | 2 |
| Senior, D | 1 |
| Watts, S | 1 |
| Connor, C | 2 |
| Hammond, N | 1 |
| Blum, K | 1 |
| Hadjiargyrou, M | 3 |
| Komatsu, D | 1 |
| Steiner, H | 1 |
| Sugaya, LS | 1 |
| Salum, GA | 2 |
| de Sousa Gurgel, W | 1 |
| de Morais, EM | 1 |
| Del Prette, G | 1 |
| Pilatti, CD | 1 |
| Dalmaso, BB | 1 |
| Leibenluft, E | 2 |
| Rohde, LA | 50 |
| Nasser, A | 2 |
| Hull, JT | 1 |
| Liranso, T | 1 |
| Fry, N | 2 |
| Rubin, J | 2 |
| Singh, A | 1 |
| Balasundaram, MK | 1 |
| Ramos-Quiroga, JA | 16 |
| Richarte, V | 4 |
| Soto, I | 1 |
| Targhetta, M | 1 |
| Ward, J | 1 |
| Perulero, N | 1 |
| Rogne, A | 3 |
| Hassel, B | 3 |
| Sveinsdóttir, HS | 3 |
| Christensen, C | 3 |
| Þorsteinsson, H | 3 |
| Lavalou, P | 3 |
| Parker, MO | 3 |
| Shkumatava, A | 3 |
| Norton, WHJ | 3 |
| Andriambeloson, E | 3 |
| Wagner, S | 3 |
| Karlsson, KÆ | 3 |
| Hervig, ME | 3 |
| Toschi, C | 3 |
| Petersen, A | 4 |
| Gether, U | 3 |
| Robbins, TW | 8 |
| Cohen, JM | 4 |
| Srinivas, C | 3 |
| Karlstad, Ø | 6 |
| Teicher, MH | 10 |
| Bolger, E | 3 |
| Hafezi, P | 4 |
| Garcia, LCH | 3 |
| McGreenery, CE | 5 |
| Ohashi, K | 4 |
| Khan, A | 3 |
| Henry, TR | 2 |
| Fogleman, ND | 2 |
| Nugiel, T | 3 |
| Nunes, MEN | 1 |
| Zuanetti, PA | 1 |
| Hamad, APA | 1 |
| Guo, J | 1 |
| Luo, X | 1 |
| Kong, Y | 1 |
| Li, B | 1 |
| Si, B | 1 |
| Sun, L | 4 |
| Song, Y | 2 |
| van den Berk-Bulsink, MJE | 1 |
| Bakker, M | 1 |
| van der Horst, M | 1 |
| Bakhshi, S | 1 |
| Tehrani-Doost, M | 2 |
| Batouli, SAH | 1 |
| Gürbüzer, N | 1 |
| Ceyhun, HA | 1 |
| Öztürk, N | 1 |
| Kasali, K | 1 |
| Xu, Y | 2 |
| Chung, H | 1 |
| Shu, M | 1 |
| Liu, Y | 3 |
| Qiu, H | 1 |
| Konofal, E | 5 |
| Lecendreux, M | 6 |
| Bizot, JC | 3 |
| Lormier, AT | 1 |
| Figadère, B | 1 |
| Silk, TJ | 3 |
| Hartmayer, LT | 1 |
| Hoffmann, F | 2 |
| Bachmann, CJ | 2 |
| Jobski, K | 1 |
| Panfil, K | 1 |
| Small, R | 1 |
| Kirkpatrick, K | 1 |
| Bang Madsen, K | 1 |
| Robakis, TK | 1 |
| Liu, X | 3 |
| Momen, N | 1 |
| Larsson, H | 9 |
| Dreier, JW | 1 |
| Kildegaard, H | 1 |
| Groth, JB | 1 |
| Newcorn, JH | 30 |
| Hove Thomsen, P | 1 |
| Munk-Olsen, T | 1 |
| Bergink, V | 1 |
| Logan, J | 7 |
| Yonga, MV | 1 |
| Biesecker, C | 1 |
| Yuan, K | 1 |
| Wang, WT | 1 |
| Butman, JA | 1 |
| Ouadih-Moran, M | 1 |
| Muñoz-Hoyos, A | 8 |
| D'Marco, L | 1 |
| Molina-Carballo, A | 7 |
| Seiquer, I | 2 |
| Checa-Ros, A | 3 |
| Löhman, M | 4 |
| Domingo, B | 2 |
| Östlund, M | 2 |
| Jansson, L | 2 |
| Sifeddine, W | 1 |
| Ba-M'hamed, S | 1 |
| Landry, M | 1 |
| Bennis, M | 1 |
| Zhu, S | 1 |
| Wang, T | 1 |
| Yang, S | 1 |
| Yu, Z | 1 |
| Gao, H | 1 |
| Chen, G | 1 |
| Kim, C | 1 |
| Lee, DY | 1 |
| Park, J | 2 |
| Yang, SJ | 1 |
| Tan, EH | 1 |
| Alhambra, DP | 1 |
| Lee, S | 3 |
| Kim, SJ | 4 |
| Lee, J | 4 |
| Park, RW | 1 |
| Shin, Y | 1 |
| Majarwitz, DJ | 1 |
| Perumareddi, P | 1 |
| Huber, F | 1 |
| Schulz, J | 1 |
| Schlack, R | 2 |
| Hölling, H | 1 |
| Ravens-Sieberer, U | 1 |
| Meyer, T | 1 |
| Rothenberger, A | 27 |
| Wang, B | 1 |
| Becker, A | 6 |
| Pazos-Pérez, A | 1 |
| Piñeiro-Ramil, M | 1 |
| Franco-Trepat, E | 1 |
| Guillán-Fresco, M | 1 |
| López-López, V | 1 |
| Jorge-Mora, A | 1 |
| Alonso-Pérez, A | 1 |
| Gómez, R | 1 |
| Smith, DR | 1 |
| Strupp, BJ | 1 |
| Sibeoni, J | 1 |
| Manolios, E | 1 |
| Hausser, C | 1 |
| Delage, R | 1 |
| Baylé, F | 2 |
| Speranza, M | 2 |
| Verneuil, L | 1 |
| Revah-Levy, A | 1 |
| Gao, L | 2 |
| Man, KKC | 7 |
| Fan, M | 1 |
| Ge, GMQ | 1 |
| Lau, WCY | 3 |
| Cheung, CL | 1 |
| Ip, P | 6 |
| Wong, KHTW | 2 |
| Wong, ICK | 10 |
| Soufsaf, S | 2 |
| Robaey, P | 5 |
| Nekka, F | 3 |
| Liao, HC | 1 |
| Lin, FJ | 1 |
| Hsu, CN | 1 |
| Gau, SS | 16 |
| Wang, CC | 1 |
| Akhlaque, E | 1 |
| Sibley, MH | 5 |
| Faraone, SV | 49 |
| Nigg, JT | 2 |
| Lee, L | 2 |
| Arunajadai, S | 1 |
| Erensen, JG | 1 |
| Goodman, DW | 3 |
| Moran, LV | 2 |
| Inglis, SK | 4 |
| Buitelaar, J | 12 |
| Carucci, S | 12 |
| Danckaerts, M | 13 |
| Dittmann, RW | 11 |
| Falissard, B | 6 |
| Garas, P | 6 |
| Hollis, C | 14 |
| Konrad, K | 13 |
| Kovshoff, H | 9 |
| Liddle, E | 5 |
| McCarthy, S | 15 |
| Neubert, A | 5 |
| Nagy, P | 10 |
| Rosenthal, E | 6 |
| Sonuga-Barke, EJS | 2 |
| Zuddas, A | 24 |
| Storebø, OJ | 14 |
| Storm, MRO | 1 |
| Pereira Ribeiro, J | 1 |
| Skoog, M | 5 |
| Groth, C | 6 |
| Callesen, HE | 1 |
| Schaug, JP | 1 |
| Darling Rasmussen, P | 1 |
| Huus, CL | 1 |
| Zwi, M | 11 |
| Kirubakaran, R | 4 |
| Simonsen, E | 13 |
| Gluud, C | 14 |
| Takahara, Y | 2 |
| Ota, T | 2 |
| Nakanishi, Y | 1 |
| Ueda, S | 1 |
| Jurica, P | 2 |
| Struzik, ZR | 2 |
| Nishitomi, K | 2 |
| Iida, J | 3 |
| Kishimoto, T | 2 |
| Cichocki, A | 2 |
| Hasegawa, M | 2 |
| Ogawa, K | 2 |
| de Lucca, MS | 1 |
| Pimentel, MEO | 1 |
| Raimundo, CKO | 1 |
| Henriques, BD | 1 |
| Moreira, TR | 1 |
| Cardoso, SA | 1 |
| de Miranda, DM | 1 |
| Gillies, D | 6 |
| Leach, MJ | 1 |
| Perez Algorta, G | 1 |
| Wiggs, KK | 1 |
| Becker, SP | 2 |
| Khoubbieh, F | 1 |
| Erdogan, CS | 1 |
| Onel, T | 1 |
| Yildirim, E | 1 |
| Sumer, E | 1 |
| Yaba, A | 1 |
| Yilmaz, B | 1 |
| Rossano, F | 1 |
| Caiazza, C | 1 |
| Sobrino, A | 1 |
| Solini, N | 1 |
| Vellucci, A | 1 |
| Zotti, N | 1 |
| Fornaro, M | 1 |
| Gillman, K | 1 |
| Cattaneo, CI | 1 |
| Van den Eynde, V | 1 |
| Birkenhager, TK | 1 |
| Ruhé, HG | 2 |
| Stahl, S | 1 |
| Iasevoli, F | 1 |
| de Bartolomeis, A | 1 |
| van Stralen, J | 4 |
| Parhar, G | 1 |
| Parhar, A | 1 |
| Tourjman, V | 1 |
| Khattak, S | 1 |
| Ahmed, T | 1 |
| Donnelly, GAE | 3 |
| Ratz, J | 1 |
| Mercan Isik, C | 1 |
| Uzun Cicek, A | 1 |
| Altuntas, EE | 1 |
| Bora, A | 1 |
| Sari, SA | 1 |
| Akkus, S | 1 |
| Jacobs, D | 1 |
| Bruschettini, M | 1 |
| Axelsson, I | 1 |
| Karsten Juhl Jørgensen, K | 1 |
| Fukumoto, S | 1 |
| Imanari, E | 1 |
| Tomari, S | 1 |
| Higashi, T | 1 |
| Kosaka, H | 1 |
| Zeng, KD | 1 |
| Wang, GL | 1 |
| Yuan, Y | 3 |
| Zhang, W | 1 |
| Huang, XH | 1 |
| Hu, B | 1 |
| McNealy, KR | 1 |
| Weyrich, L | 1 |
| Bevins, RA | 2 |
| Pagnier, M | 1 |
| Rocha, NS | 1 |
| Correa, RDESA | 1 |
| Dias, ACM | 1 |
| Bueno, CDF | 1 |
| Rode, J | 1 |
| Runnamo, R | 1 |
| Thunberg, P | 1 |
| Msghina, M | 1 |
| Giacobini, M | 2 |
| Ahnemark, E | 2 |
| Medin, E | 2 |
| Freilich, J | 1 |
| Andersson, M | 1 |
| Ma, Y | 2 |
| Gudbrandsdottir, RK | 1 |
| Sigurdsson, E | 2 |
| Ingimarsson, O | 1 |
| Burrows-MacLean, L | 9 |
| Wymbs, BT | 5 |
| Chacko, A | 6 |
| Walker, K | 1 |
| Wymbs, F | 2 |
| Garefino, A | 3 |
| Robb Mazzant, J | 2 |
| Massetti, GM | 2 |
| Waschbusch, DA | 10 |
| Fabiano, GA | 9 |
| Sinningen, K | 1 |
| Emons, B | 1 |
| Böhme, P | 2 |
| Juckel, G | 2 |
| Hanusch, B | 1 |
| Beckmann, B | 1 |
| Tsikas, D | 1 |
| Lücke, T | 1 |
| Cascone, AD | 1 |
| Calabro, F | 1 |
| Foran, W | 1 |
| Larsen, B | 1 |
| Parr, AC | 1 |
| Tervo-Clemmens, B | 1 |
| Luna, B | 1 |
| Kowalczyk, OS | 2 |
| Cubillo, AI | 3 |
| Criaud, M | 1 |
| Giampietro, V | 5 |
| O'Daly, OG | 1 |
| Mehta, MA | 4 |
| Rubia, K | 12 |
| Tschudi, L | 1 |
| Fischer, SKM | 1 |
| Perlov, E | 4 |
| Baumgartner, MR | 1 |
| Soyka, M | 1 |
| Müller, TJ | 1 |
| Seifritz, E | 1 |
| Mutschler, J | 1 |
| Shin, H | 1 |
| Yuniar, CT | 1 |
| Oh, S | 1 |
| Purja, S | 1 |
| Park, S | 15 |
| Lee, H | 2 |
| Kim, E | 4 |
| Yang, C | 2 |
| Meng, Y | 1 |
| Dang, Y | 1 |
| Van Gerpen, S | 1 |
| Soundy, T | 1 |
| Brodersen, B | 1 |
| Kuś, J | 1 |
| Saramowicz, K | 1 |
| Czerniawska, M | 1 |
| Wiese, W | 1 |
| Siwecka, N | 1 |
| Rozpędek-Kamińska, W | 1 |
| Kucharska-Lusina, A | 1 |
| Strzelecki, D | 1 |
| Majsterek, I | 1 |
| Moore, T | 1 |
| Soccorso, C | 1 |
| Fogler, J | 1 |
| Carroll, G | 1 |
| Froehlich, T | 2 |
| Nyp, SS | 2 |
| Mattingly, GW | 3 |
| Yates, JR | 3 |
| Broderick, MR | 1 |
| Berling, KL | 1 |
| Gieske, MG | 1 |
| Osborn, E | 1 |
| Nelson, MR | 1 |
| Wright, MR | 1 |
| Snellman, A | 1 |
| Carlberg, S | 1 |
| Olsson, L | 1 |
| Parlatini, V | 1 |
| Radua, J | 3 |
| Solanes Font, A | 1 |
| Wichers, R | 1 |
| Maltezos, S | 2 |
| Sanefuji, M | 2 |
| Dell'Acqua, F | 1 |
| Catani, M | 1 |
| Thiebaut de Schotten, M | 1 |
| Murphy, D | 2 |
| Nardi, J | 1 |
| Freddo, N | 1 |
| Biazus, IC | 1 |
| Oliveira, AP | 1 |
| Soares, SM | 1 |
| Fortuna, M | 1 |
| Varela, ACC | 1 |
| Siqueira, L | 1 |
| Pompermaier, A | 1 |
| Tamagno, WA | 1 |
| do Prado, L | 1 |
| Berton, N | 1 |
| Barcellos, LJG | 1 |
| Rossato-Grando, LG | 1 |
| Novo, JP | 1 |
| Muga, M | 1 |
| Lourenço, T | 1 |
| Sanches, ES | 1 |
| Leitão, RA | 2 |
| Silva, AP | 2 |
| Alexander, GD | 1 |
| Cavanah, LR | 1 |
| Goldhirsh, JL | 1 |
| Huey, LY | 2 |
| Piper, BJ | 1 |
| Cartabia, M | 2 |
| Finazzi, S | 1 |
| Bonati, M | 9 |
| Shom, S | 1 |
| Dutta, N | 1 |
| López-Pinar, C | 1 |
| Fornés-Ferrer, V | 1 |
| Euscher, R | 1 |
| van Elst, LT | 3 |
| Masiran, R | 1 |
| Ilias, MNA | 1 |
| Yubbu, P | 1 |
| Fuller, JA | 1 |
| Burrell, MH | 1 |
| Yee, AG | 1 |
| Liyanagama, K | 1 |
| Lipski, J | 1 |
| Wickens, JR | 3 |
| Hyland, BI | 1 |
| Traicu, A | 2 |
| Grizenko, N | 24 |
| Fortier, MÈ | 5 |
| Fageera, W | 4 |
| Sengupta, SM | 9 |
| Joober, R | 22 |
| Trenque, T | 2 |
| Claustre, G | 1 |
| Herlem, E | 1 |
| Djerada, Z | 1 |
| Trenque, A | 1 |
| Morel, A | 1 |
| Azzouz, B | 1 |
| Sarfati, S | 1 |
| Nakdimon, I | 1 |
| Tsodyks, J | 1 |
| Assa, A | 1 |
| Gordon, B | 1 |
| Vallée, M | 1 |
| Ruuskanen, E | 1 |
| Leitch, S | 1 |
| Sciberras, E | 2 |
| Evans, S | 4 |
| Kalinowski, L | 2 |
| Somanesan, R | 2 |
| Carias, E | 2 |
| Richer, K | 1 |
| Smith, L | 2 |
| Martin, C | 2 |
| Mackintosh, M | 1 |
| Popoola, D | 2 |
| Komatsu, DE | 2 |
| Campa, A | 1 |
| Li, T | 3 |
| Marshall, R | 1 |
| Babocsai, L | 1 |
| Humphery, H | 1 |
| Gnagy, E | 6 |
| Swanson, J | 23 |
| Hanć, T | 1 |
| Fallahazad, N | 1 |
| Pliszka, SR | 17 |
| Levi-Shachar, O | 2 |
| Gvirts, HZ | 6 |
| Goldwin, Y | 2 |
| Bloch, Y | 8 |
| Shamay-Tsoory, S | 2 |
| Zagoory-Sharon, O | 1 |
| Feldman, R | 1 |
| Maoz, H | 7 |
| Siddiqi, SU | 1 |
| Dedlow, ER | 1 |
| Luo, SX | 3 |
| Covey, LS | 8 |
| Hu, MC | 8 |
| Winhusen, TM | 7 |
| Nunes, EV | 9 |
| Yuan, H | 2 |
| Ni, X | 2 |
| Zheng, M | 1 |
| Han, X | 2 |
| Yu, M | 1 |
| Krinzinger, H | 1 |
| Hall, CL | 1 |
| Ansari, MT | 1 |
| Kochhar, P | 1 |
| Roberts, S | 1 |
| Sayal, K | 6 |
| Sonuga-Barke, E | 13 |
| Xia, J | 3 |
| Liddle, EB | 5 |
| Weibel, S | 1 |
| Menard, O | 2 |
| Ionita, A | 1 |
| Boumendjel, M | 1 |
| Cabelguen, C | 1 |
| Kraemer, C | 1 |
| Micoulaud-Franchi, JA | 2 |
| Bioulac, S | 4 |
| Perroud, N | 2 |
| Sauvaget, A | 1 |
| Carton, L | 2 |
| Gachet, M | 1 |
| Lopez, R | 1 |
| Sluiter, MN | 1 |
| de Vries, YA | 1 |
| Koning, LG | 1 |
| Hak, E | 4 |
| Bos, JHJ | 2 |
| Schuiling-Veninga, CCM | 2 |
| Batstra, L | 1 |
| Doornenbal, JM | 1 |
| de Jonge, P | 1 |
| Baas, M | 1 |
| Boot, N | 1 |
| van Gaal, S | 1 |
| de Dreu, CKW | 1 |
| Cools, R | 1 |
| Türkmenoğlu, YE | 1 |
| Esedova, C | 1 |
| Akpinar, M | 1 |
| Uysal, T | 1 |
| İrdem, A | 1 |
| Dravland, JE | 1 |
| Cui, Z | 1 |
| Liu, H | 1 |
| Poulton, AS | 6 |
| Eslick, GD | 2 |
| Sun, CK | 1 |
| Tseng, PT | 1 |
| Wu, CK | 1 |
| Li, DJ | 2 |
| Chen, TY | 1 |
| Stubbs, B | 1 |
| Carvalho, AF | 1 |
| Chen, YW | 1 |
| Lin, PY | 2 |
| Cheng, YS | 1 |
| Wu, MK | 1 |
| Furukawa, E | 1 |
| da Costa, RQM | 1 |
| Bado, P | 1 |
| Hoefle, S | 1 |
| Vigne, P | 1 |
| Monteiro, M | 1 |
| Moll, J | 1 |
| Tripp, G | 4 |
| Mattos, P | 6 |
| Yoo, JH | 3 |
| Sharma, V | 3 |
| Kim, JW | 22 |
| McMakin, DL | 1 |
| Hong, SB | 12 |
| Zalesky, A | 2 |
| Kim, BN | 33 |
| Ryan, ND | 2 |
| da Silva, BS | 4 |
| Leffa, DT | 2 |
| Beys-da-Silva, WO | 1 |
| Torres, ILS | 2 |
| Rovaris, DL | 8 |
| Victor, MM | 15 |
| Mota, NR | 6 |
| Oliveira, C | 1 |
| Sabnis, R | 1 |
| Peña, RD | 1 |
| Campos, AR | 1 |
| Grevet, EH | 15 |
| Santi, L | 1 |
| Bau, CHD | 5 |
| Contini, V | 9 |
| Vollebregt, MA | 2 |
| Kenemans, JL | 6 |
| Deboer, T | 1 |
| Cain, SW | 1 |
| Elliott, GR | 11 |
| Fallahpour, K | 1 |
| Caballero-Puntiverio, M | 3 |
| Lerdrup, LS | 2 |
| Arvastson, L | 1 |
| Aznar, S | 1 |
| Andreasen, JT | 4 |
| Strauß, M | 2 |
| Reif, A | 9 |
| Ulke, C | 2 |
| Paucke, M | 2 |
| Sander, C | 1 |
| Hegerl, U | 2 |
| Weber, H | 2 |
| Heupel, J | 3 |
| Kopf, J | 2 |
| Kittel-Schneider, S | 6 |
| Takagi, S | 1 |
| Yamashiro, Y | 1 |
| Sugihara, G | 2 |
| Takahashi, H | 2 |
| Matsuura, M | 1 |
| Asherson, P | 13 |
| Fahy, T | 1 |
| Forester, A | 1 |
| Lawrie, S | 1 |
| Thomson, L | 1 |
| Schonwald, A | 2 |
| Chan, E | 2 |
| Hardy, P | 1 |
| Zeise, ML | 1 |
| Rojas, P | 1 |
| Noorazar, SG | 1 |
| Malek, A | 1 |
| Aghaei, SM | 1 |
| Yasamineh, N | 1 |
| Kalejahi, P | 1 |
| Chappuy, M | 1 |
| Boulanger, A | 1 |
| Nourredine, M | 1 |
| Fourneret, P | 3 |
| Rolland, B | 3 |
| Chen, T | 1 |
| Sun, YB | 1 |
| Song, YC | 1 |
| Lu, M | 1 |
| Weiss, MD | 5 |
| Efron, D | 6 |
| Mulraney, M | 1 |
| Hiscock, H | 1 |
| Hearps, S | 1 |
| Martinez, E | 1 |
| Pasquereau, B | 1 |
| Drui, G | 1 |
| Saga, Y | 1 |
| Météreau, É | 1 |
| Tremblay, L | 1 |
| Bhat, V | 2 |
| Rotem, A | 1 |
| Ben-Sheetrit, J | 1 |
| Newcorn, J | 6 |
| Danieli, Y | 1 |
| Peskin, M | 2 |
| Golubchik, P | 13 |
| Ben-Hayun, R | 1 |
| Weizman, A | 23 |
| Manor, I | 6 |
| Fernández Manso, B | 1 |
| Villora Morcillo, N | 1 |
| Taboas Pereira, MA | 1 |
| Elipe Maldonado, C | 1 |
| DeFroda, SF | 1 |
| Quinn, M | 1 |
| Yang, DS | 1 |
| Daniels, AH | 1 |
| Owens, BD | 1 |
| Tural Hesapcıoglu, S | 1 |
| Kandemir, G | 1 |
| Peraita-Adrados, R | 2 |
| Medrano-Martinez, P | 1 |
| Peirano, P | 1 |
| Algarín, C | 1 |
| Lillo-Triguero, L | 1 |
| Fırat, S | 1 |
| Gul, H | 1 |
| Aysev, A | 3 |
| Ponnou, S | 1 |
| Haliday, H | 1 |
| Rajala, AZ | 1 |
| Populin, LC | 1 |
| Jenison, RL | 1 |
| Castells, X | 9 |
| Ramon, M | 1 |
| Cunill, R | 4 |
| Olivé, C | 1 |
| Serrano, D | 1 |
| Bonvicini, C | 2 |
| Maj, C | 1 |
| Baune, BT | 1 |
| Scassellati, C | 2 |
| Jean-Tron, MG | 1 |
| Márquez-González, H | 1 |
| Barragán-Pérez, E | 1 |
| Barajas-Nava, LA | 1 |
| Rezende, ART | 1 |
| Pacheco, SP | 2 |
| Branco, SCC | 1 |
| Fernandes, RDC | 1 |
| Boldrini, CR | 1 |
| Doria Filho, U | 1 |
| Bazán, PR | 1 |
| Amaro Junior, E | 1 |
| Reed, UC | 1 |
| Casella, EB | 6 |
| Rodríguez Hernández, PJ | 1 |
| Betancort Montesinos, M | 1 |
| Peñate Castro, W | 1 |
| Shirafkan, H | 1 |
| Mahmoudi-Gharaei, J | 1 |
| Fotouhi, A | 1 |
| Mozaffarpur, SA | 1 |
| Yaseri, M | 1 |
| Hoseini, M | 1 |
| Redondo, B | 1 |
| Molina, R | 1 |
| Vera, J | 1 |
| Barrett, BT | 1 |
| Jiménez, R | 1 |
| Davydenko, S | 1 |
| Rösler, M | 17 |
| Mavrides, N | 1 |
| Coffey, BJ | 2 |
| Millenet, S | 1 |
| Ölçücü, MT | 1 |
| Kiliç, HT | 1 |
| Yildirim, K | 1 |
| Ateş, F | 1 |
| Fosco, WD | 4 |
| Rosch, KS | 4 |
| Hawk, LW | 10 |
| Ross, L | 1 |
| Sapre, V | 1 |
| Stanislaus, C | 1 |
| Mac Avin, M | 1 |
| Teeling, M | 1 |
| Bennett, KE | 1 |
| Martiny, K | 1 |
| Nielsen, NP | 5 |
| Wiig, EH | 5 |
| Hadar, Y | 2 |
| Hocherman, S | 2 |
| Lamm, O | 2 |
| Tirosh, E | 8 |
| Limandri, BJ | 1 |
| Yektaş, Ç | 1 |
| Tufan, AE | 4 |
| Sarıgedik, E | 1 |
| Suzuki, S | 1 |
| Kimura, R | 1 |
| Maegawa, S | 1 |
| Nakata, M | 1 |
| Hagiwara, M | 1 |
| Guvenmez, O | 1 |
| Cubuk, M | 1 |
| Gunes, S | 2 |
| Bertolucci, G | 1 |
| Tacchi, A | 1 |
| Mückschel, M | 2 |
| Roessner, V | 8 |
| Beste, C | 4 |
| Bluschke, A | 4 |
| Zink, N | 1 |
| Dutt, M | 1 |
| Dharavath, RN | 1 |
| Kaur, T | 1 |
| Chopra, K | 1 |
| Sharma, S | 2 |
| Walhovd, KB | 1 |
| Amlien, I | 1 |
| Rohani, DA | 1 |
| Groote, I | 1 |
| Bjørnerud, A | 1 |
| Fjell, AM | 1 |
| Sánchez-Guillén, I | 1 |
| Almorín-Fernández-Vigo, I | 1 |
| Fernández-Vigo, JI | 1 |
| de-Pablo-Gómez-de-Liaño, L | 1 |
| Kudsieh, B | 1 |
| Fernández-Vigo, JA | 1 |
| Rafeiy-Torghabeh, M | 1 |
| Ashraf-Ganjouei, A | 1 |
| Moradi, K | 2 |
| Bagheri, S | 2 |
| Mohammadi, MR | 15 |
| Akhondzadeh, S | 15 |
| Russell, D | 2 |
| Stein, MA | 19 |
| Besag, FMC | 1 |
| Cross, JH | 1 |
| Michielsen, M | 2 |
| Kleef, D | 1 |
| Bijlenga, D | 3 |
| Zwennes, C | 1 |
| Dijkhuizen, K | 1 |
| Smulders, J | 1 |
| Hazewinkel, A | 1 |
| Beekman, ATF | 2 |
| Kooij, JJS | 4 |
| Horowitz, I | 3 |
| Avirame, K | 1 |
| Naim-Feil, J | 3 |
| Rubinson, M | 3 |
| Moses, E | 3 |
| Gothelf, D | 7 |
| Levit-Binnun, N | 3 |
| El Marroun, H | 2 |
| Dierckx, B | 2 |
| Visser, LE | 3 |
| Stricker, BH | 3 |
| Stämpfli, D | 1 |
| Weiler, S | 1 |
| Burden, AM | 1 |
| Charach, G | 2 |
| Karniel, E | 1 |
| Grosskopf, I | 2 |
| Rabinovich, A | 2 |
| Charach, L | 1 |
| Oh, Y | 2 |
| Joung, YS | 7 |
| Choi, J | 4 |
| Chen, VC | 6 |
| Yang, YH | 11 |
| Yu Kuo, T | 1 |
| Lu, ML | 1 |
| Tseng, WT | 1 |
| Hou, TY | 1 |
| Yeh, JY | 1 |
| Lee, CT | 2 |
| Chen, YL | 5 |
| Lee, MJ | 5 |
| Dewey, ME | 2 |
| Gossop, M | 3 |
| Miller, J | 1 |
| Perera, B | 1 |
| Shankar, R | 1 |
| Shellenberg, TP | 1 |
| Stoops, WW | 2 |
| Lile, JA | 1 |
| Rush, CR | 2 |
| Andrade, C | 2 |
| Piacentino, D | 1 |
| Kotzalidis, GD | 1 |
| Maniscalco, I | 1 |
| Pompili, M | 1 |
| Giupponi, G | 1 |
| Hiemke, C | 2 |
| Conca, A | 1 |
| Grimmsmann, T | 1 |
| Himmel, W | 1 |
| Mehri, M | 1 |
| Chehrzad, MM | 1 |
| Mardani, A | 1 |
| Maleki, M | 1 |
| Dianatinasab, M | 1 |
| Kousha, M | 2 |
| Assari, S | 1 |
| Rosetti, MF | 1 |
| Ulloa, E | 1 |
| Mayer, P | 1 |
| Palacios-Cruz, L | 1 |
| de la Peña, FR | 1 |
| Hudson, R | 1 |
| Rodrigues, R | 1 |
| Lai, MC | 1 |
| Beswick, A | 1 |
| Gorman, DA | 1 |
| Anagnostou, E | 2 |
| Szatmari, P | 1 |
| Anderson, KK | 1 |
| Ameis, SH | 1 |
| Buchhorn, R | 3 |
| Baumann, C | 1 |
| Gündogdu, S | 1 |
| Rakowski, U | 1 |
| Willaschek, C | 2 |
| Zhang, L | 5 |
| McCarthy, DM | 2 |
| Eskow Jaunarajs, KL | 1 |
| Biederman, J | 57 |
| Spencer, TJ | 23 |
| Bhide, PG | 4 |
| Fischer, R | 10 |
| Ose, C | 10 |
| Ammer, R | 5 |
| Kim, Y | 5 |
| Je, NK | 1 |
| Kok, FM | 1 |
| Groen, Y | 4 |
| Fuermaier, ABM | 2 |
| Tucha, O | 14 |
| Yde Ohki, CM | 1 |
| Grossmann, L | 1 |
| Alber, E | 1 |
| Dwivedi, T | 1 |
| Berger, G | 1 |
| Werling, AM | 2 |
| Walitza, S | 11 |
| Grünblatt, E | 2 |
| Osuagwu, FC | 1 |
| Osuagwu, VC | 1 |
| Machoka, AM | 1 |
| Lücke, C | 3 |
| Heßmann, P | 1 |
| Borel, P | 5 |
| Müller, HHO | 2 |
| Alamiri, B | 4 |
| Naguy, A | 8 |
| Addicott, MA | 3 |
| Pearson, JM | 1 |
| Schechter, JC | 2 |
| Sapyta, JJ | 2 |
| Kollins, SH | 24 |
| Dönmez, YE | 1 |
| Özcan, ÖÖ | 1 |
| Çankaya, C | 1 |
| Berker, M | 1 |
| Atas, PBU | 1 |
| Güntürkün, PN | 1 |
| Ceylan, OM | 1 |
| Balia, C | 1 |
| Gagliano, A | 3 |
| Lampis, A | 1 |
| Inglis, S | 3 |
| Panei, P | 11 |
| Romaniello, R | 1 |
| Usala, T | 3 |
| Elliott, J | 1 |
| Johnston, A | 1 |
| Husereau, D | 1 |
| Kelly, SE | 1 |
| Eagles, C | 1 |
| Charach, A | 6 |
| Hsieh, SC | 1 |
| Bai, Z | 1 |
| Hossain, A | 1 |
| Skidmore, B | 1 |
| Tsakonas, E | 1 |
| Chojecki, D | 1 |
| Mamdani, M | 1 |
| Wells, GA | 1 |
| Fredriksen, M | 7 |
| Golparian, N | 1 |
| Beiske, K | 1 |
| Stavem, K | 1 |
| Shah, R | 1 |
| Padhy, S | 1 |
| Kohli, A | 1 |
| Pereira-Sanchez, V | 2 |
| Franco, AR | 2 |
| Vieira, D | 1 |
| de Castro-Manglano, P | 2 |
| Soutullo, C | 4 |
| Milham, MP | 1 |
| Castellanos, FX | 14 |
| Dark, C | 1 |
| Williams, C | 1 |
| Bellgrove, MA | 10 |
| Hawi, Z | 6 |
| Bryson-Richardson, RJ | 1 |
| Uchida, CL | 2 |
| Po, MD | 3 |
| DeSousa, NJ | 4 |
| Incledon, B | 4 |
| Tsai, CS | 2 |
| Chou, MC | 7 |
| Ünsel Bolat, G | 1 |
| Ornoy, A | 1 |
| Koren, G | 2 |
| Ponnet, K | 1 |
| Tholen, R | 1 |
| De Bruyn, S | 1 |
| Wouters, E | 1 |
| Van Ouytsel, J | 1 |
| Walrave, M | 1 |
| Van Hal, G | 1 |
| Kedem, S | 1 |
| Yust-Katz, S | 1 |
| Carter, D | 1 |
| Levi, Z | 1 |
| Kedem, R | 1 |
| Dickstein, A | 1 |
| Daher, S | 1 |
| Katz, LH | 1 |
| Friedrich, B | 1 |
| Bridler, R | 1 |
| Sanabra, M | 1 |
| Gómez, T | 1 |
| Alda-Díez, JA | 2 |
| Al Awami, R | 1 |
| Albanna, A | 1 |
| Joshi, G | 2 |
| Wilens, T | 10 |
| Firmin, ES | 1 |
| Hoskova, B | 1 |
| Göl Özcan, G | 1 |
| Öztürk, Y | 1 |
| Sari, M | 1 |
| İmrek, Y | 1 |
| Özyurt, G | 2 |
| Akay, AP | 4 |
| Johansson, V | 1 |
| Sandin, S | 1 |
| Chang, Z | 3 |
| Taylor, MJ | 4 |
| Lichtenstein, P | 3 |
| D'Onofrio, BM | 3 |
| Hellner, C | 1 |
| Halldner, L | 1 |
| Leeman-Markowski, BA | 1 |
| Adams, J | 3 |
| Martin, SP | 1 |
| Devinsky, O | 1 |
| Meador, KJ | 2 |
| Faison, SL | 1 |
| Adewole, T | 1 |
| Odebo, O | 1 |
| Schwabe, S | 1 |
| Wang, Z | 3 |
| Maletic, V | 1 |
| Petroff, D | 1 |
| Huang, J | 1 |
| Bogatsch, H | 1 |
| Hoffmann, K | 1 |
| Heuser, I | 2 |
| Ahlers, E | 1 |
| Gallinat, J | 1 |
| Schöttle, D | 1 |
| Fallgatter, A | 2 |
| Ethofer, T | 1 |
| Unterecker, S | 1 |
| Mandali, A | 1 |
| Sethi, A | 2 |
| Cercignani, M | 2 |
| Harrison, NA | 2 |
| Voon, V | 2 |
| Chang, JC | 1 |
| Lin, HY | 4 |
| Lv, J | 1 |
| Tseng, WI | 1 |
| Shalev, H | 1 |
| Mizrakli, Y | 1 |
| Zeadna, A | 1 |
| Harlev, A | 1 |
| Levitas, E | 2 |
| Ifergane, G | 1 |
| Lunenfeld, E | 1 |
| Novack, V | 1 |
| Har-Vardi, I | 1 |
| Chaumette, B | 1 |
| Labbe, A | 5 |
| Cândido, RCF | 1 |
| Menezes de Padua, CA | 1 |
| Golder, S | 2 |
| Junqueira, DR | 1 |
| Ishizuya, A | 1 |
| Enomoto, M | 1 |
| Tachimori, H | 1 |
| Kitamura, S | 1 |
| Mishima, K | 1 |
| Rheims, S | 3 |
| Auvin, S | 3 |
| Huang, KL | 2 |
| Hsu, JW | 3 |
| Tsai, SJ | 2 |
| Bai, YM | 2 |
| Chen, TJ | 2 |
| Chen, MH | 2 |
| Hillegers, MHJ | 1 |
| Campez, M | 1 |
| Little, K | 1 |
| Kikuchi, D | 1 |
| Obara, T | 2 |
| Tokunaga, M | 1 |
| Shiozawa, M | 1 |
| Takahashi, A | 1 |
| Ito, M | 1 |
| Hino, H | 1 |
| Miura, R | 1 |
| Hayakawa, S | 1 |
| Watanabe, Y | 2 |
| Chen, YC | 2 |
| Wu, LK | 1 |
| Lee, MS | 7 |
| Kung, YL | 1 |
| Quednow, BB | 1 |
| Leutritz, AL | 1 |
| McNeill, RV | 2 |
| Pierick, AR | 1 |
| Lynn, M | 1 |
| McCracken, CM | 1 |
| Oster, ME | 1 |
| Iannucci, GJ | 1 |
| Evans, SW | 6 |
| Zhand, N | 1 |
| Harvey, P | 1 |
| Osborne, R | 1 |
| Hatko, A | 1 |
| Stuyt, M | 1 |
| Labelle, A | 1 |
| Ho, HY | 1 |
| Wong, CK | 1 |
| Wu, SY | 1 |
| Hsiao, RC | 2 |
| Yen, CF | 3 |
| Stammschulte, T | 1 |
| Pitzer, M | 1 |
| Rascher, W | 1 |
| Becker, M | 1 |
| Pohlmann, U | 1 |
| Ostermayer, S | 1 |
| Kerst, G | 1 |
| Brunkhorst-Kanaan, N | 1 |
| Libutzki, B | 1 |
| Liu, YC | 1 |
| Park, D | 1 |
| Mabunga, DFN | 1 |
| Adil, KJ | 1 |
| Ryu, O | 1 |
| Valencia, S | 1 |
| Kim, R | 1 |
| Kim, HJ | 6 |
| Cheong, JH | 12 |
| Kwon, KJ | 1 |
| Kim, HY | 1 |
| Han, SH | 1 |
| Jeon, SJ | 1 |
| Shin, CY | 6 |
| De Serrano, AR | 1 |
| Hughes, KA | 1 |
| Rodd, FH | 1 |
| Aoki, S | 1 |
| Kaizaki-Mitsumoto, A | 1 |
| Hattori, N | 1 |
| Numazawa, S | 1 |
| Braund, TA | 1 |
| Kohn, MR | 4 |
| Clarke, S | 6 |
| Williams, LM | 4 |
| Sommer, JL | 1 |
| Oranje, B | 2 |
| Dor-Ziderman, Y | 1 |
| Zeev-Wolf, M | 1 |
| Hirsch Klein, E | 1 |
| Bar-Oz, D | 1 |
| Nitzan, U | 4 |
| Segev, A | 3 |
| Goldstein, A | 1 |
| Koubi, M | 1 |
| Mendelovic, S | 1 |
| Gvirts, H | 1 |
| Tamminga, HGH | 2 |
| Bottelier, MA | 6 |
| Bouziane, C | 6 |
| Geurts, HM | 6 |
| Groenman, AP | 3 |
| Juhl Jørgensen, K | 1 |
| Openneer, TJC | 1 |
| Arsac England, T | 1 |
| Tuthill, D | 1 |
| Lagerberg, T | 1 |
| Chen, Q | 3 |
| Ghirardi, L | 1 |
| Viktorin, A | 3 |
| Pagliaro, A | 1 |
| Mattio, B | 1 |
| Paulson, N | 1 |
| Fromm, C | 1 |
| Vidal, J | 1 |
| Allami, S | 1 |
| Abuzeid, MY | 1 |
| Hulsbosch, AK | 1 |
| De Meyer, H | 1 |
| Beckers, T | 1 |
| Van Liefferinge, D | 1 |
| Van der Oord, S | 6 |
| Roche, M | 1 |
| Mircher, C | 1 |
| Toulas, J | 1 |
| Prioux, E | 1 |
| Conte, M | 1 |
| Ravel, A | 1 |
| Falquero, S | 1 |
| Labidi, A | 1 |
| Stora, S | 1 |
| Durand, S | 1 |
| Mégarbané, A | 1 |
| Cieuta-Walti, C | 1 |
| Levinson, B | 1 |
| Adjei, AL | 3 |
| Harstad, E | 1 |
| Shults, J | 1 |
| Barbaresi, W | 1 |
| Bax, A | 1 |
| Cacia, J | 1 |
| Deavenport-Saman, A | 1 |
| Friedman, S | 1 |
| LaRosa, A | 1 |
| Loe, IM | 1 |
| Mittal, S | 1 |
| Tulio, S | 1 |
| Vanderbilt, D | 1 |
| Blum, NJ | 4 |
| Pheils, J | 1 |
| Ehret, MJ | 3 |
| Li, JS | 1 |
| Yang, SS | 1 |
| Huston, JP | 1 |
| Chao, OY | 1 |
| Yang, YM | 1 |
| Mattern, C | 1 |
| Gering, A | 1 |
| Poulet, E | 1 |
| Geoffray, MM | 1 |
| Jurek, L | 1 |
| Kawai, C | 1 |
| Mori, K | 3 |
| Tanioka, T | 1 |
| Betriana, F | 1 |
| Mori, T | 1 |
| Ito, H | 1 |
| Veluri, N | 1 |
| Patel, RS | 1 |
| Meng, HR | 1 |
| Suenaga, T | 1 |
| Edamura, M | 1 |
| Fukuda, A | 1 |
| Ishida, Y | 1 |
| Nakahara, D | 1 |
| Murakami, G | 1 |
| Surman, C | 9 |
| Khullar, A | 1 |
| He, E | 1 |
| Chen, HL | 1 |
| Sasaki, Y | 1 |
| Tsujii, N | 2 |
| Sasaki, S | 1 |
| Sunakawa, H | 1 |
| Toguchi, Y | 1 |
| Tanase, S | 1 |
| Saito, K | 1 |
| Shinohara, R | 1 |
| Kurokouchi, T | 1 |
| Sugimoto, K | 1 |
| Itagaki, K | 1 |
| Yoshida, Y | 1 |
| Namekata, S | 1 |
| Takahashi, M | 1 |
| Harada, I | 1 |
| Hakosima, Y | 1 |
| Inazaki, K | 1 |
| Yoshimura, Y | 1 |
| Mizumoto, Y | 1 |
| Okada, T | 3 |
| Usami, M | 2 |
| Wilens, TE | 27 |
| Hammerness, PG | 5 |
| Sallee, FR | 16 |
| Norman, LJ | 1 |
| Sudre, G | 1 |
| Bouyssi-Kobar, M | 1 |
| Sharp, W | 1 |
| Shaw, P | 3 |
| Zhou, P | 2 |
| Wolraich, ML | 7 |
| Cao, AH | 2 |
| Jia, FY | 1 |
| Liu, B | 1 |
| Zhu, L | 2 |
| Li, X | 3 |
| Peng, B | 1 |
| Yang, T | 2 |
| Chen, J | 4 |
| Cheng, Q | 2 |
| Chen, L | 2 |
| Tiwawatpakorn, N | 1 |
| Worachotekamjorn, J | 1 |
| Tassanakijpanich, N | 1 |
| Purper-Ouakil, D | 7 |
| Ros, T | 2 |
| Acquaviva, E | 5 |
| Baumeister, S | 1 |
| Bousquet, E | 1 |
| Bussalb, A | 1 |
| Delhaye, M | 1 |
| Delorme, R | 5 |
| Drechsler, R | 1 |
| Goujon, A | 1 |
| Mayaud, L | 2 |
| Mechler, K | 3 |
| Menache, C | 1 |
| Revol, O | 1 |
| Tagwerker, F | 1 |
| Brandeis, D | 4 |
| González-Pinto, A | 1 |
| Arrojo, M | 1 |
| Bernardo, M | 1 |
| Sáiz, PA | 1 |
| Flórez, G | 1 |
| Torrens, M | 1 |
| Tirado-Muñoz, J | 1 |
| Fonseca, F | 1 |
| Arranz, B | 1 |
| Garriga, M | 1 |
| Goikolea, JM | 1 |
| Zorrilla, I | 1 |
| Becoña, E | 1 |
| López, A | 1 |
| San, L | 1 |
| Cubero-Millán, I | 5 |
| Fernández-López, L | 3 |
| Machado-Casas, I | 4 |
| Jerez-Calero, A | 1 |
| Blanca-Jover, E | 1 |
| Cantarero-Malagón, AM | 1 |
| Uberos, J | 5 |
| Fife, D | 1 |
| Voss, EA | 1 |
| Hardin, J | 1 |
| Rofael, H | 1 |
| Solomon, ID | 1 |
| Ryan, PB | 1 |
| Stang, P | 1 |
| Marraffino, AH | 1 |
| Deng, L | 1 |
| Zhao, Q | 1 |
| Møllegaard Jepsen, JR | 1 |
| Boyle, D | 1 |
| de Faria, JCM | 1 |
| Duarte, LJR | 1 |
| Ferreira, LA | 1 |
| da Silveira, VT | 1 |
| Menezes de Pádua, C | 1 |
| Perini, E | 1 |
| Chan, EW | 4 |
| Chui, CSL | 1 |
| Hon, KL | 1 |
| Tse, ML | 1 |
| Lum, TYS | 1 |
| Mashiana, MK | 1 |
| Irfanullah, Z | 1 |
| Khawaja, H | 1 |
| Khawaja, IS | 1 |
| Schenck, CH | 1 |
| Moore, TJ | 1 |
| Wirtz, PW | 1 |
| Kruszewski, SP | 1 |
| Alexander, GC | 1 |
| Akmatov, MK | 1 |
| Holstiege, J | 1 |
| Bätzing, J | 1 |
| Stevenson, J | 1 |
| Turan, S | 2 |
| Ermiş, Ç | 1 |
| Tunctürk, M | 1 |
| Pekcanlar, AA | 1 |
| Sujkowska, E | 1 |
| Sowa-Kućma, M | 1 |
| Maeder, J | 1 |
| Mancini, V | 1 |
| Sandini, C | 1 |
| Journal, F | 1 |
| Schneider, M | 1 |
| Kliegel, M | 1 |
| Eliez, S | 2 |
| Bron, EE | 2 |
| Klein, S | 3 |
| Rombouts, SARB | 1 |
| Arslan, EA | 1 |
| Arslan, E | 1 |
| Kilinç, A | 1 |
| Göksu, Ö | 1 |
| Gumustas, F | 2 |
| Yilmaz, I | 2 |
| Yulaf, Y | 1 |
| Gokce, S | 1 |
| Sabuncuoglu, O | 2 |
| Bou Khalil, R | 1 |
| Fares, N | 1 |
| Saliba, Y | 1 |
| Tamraz, J | 1 |
| Richa, S | 1 |
| Duric, NS | 2 |
| Assmus, J | 2 |
| Gundersen, D | 2 |
| Duric Golos, A | 1 |
| Elgen, IB | 2 |
| Verlaet, AA | 1 |
| Ceulemans, B | 1 |
| Verhelst, H | 1 |
| Van West, D | 1 |
| De Bruyne, T | 1 |
| Pieters, L | 1 |
| Savelkoul, HF | 1 |
| Hermans, N | 1 |
| van der Schans, J | 3 |
| Çiçek, R | 1 |
| Vardar, S | 1 |
| Bos, JH | 2 |
| de Vries, TW | 3 |
| Chierrito de Oliveira, D | 1 |
| Guerrero de Sousa, P | 1 |
| Borges Dos Reis, C | 1 |
| Tonin, FS | 3 |
| Maria Steimbach, L | 1 |
| Virtuoso, S | 1 |
| Fernandez-Llimos, F | 3 |
| Pontarolo, R | 1 |
| Cristina Conegero Sanches, A | 1 |
| Mahajnah, M | 1 |
| Sharkia, R | 1 |
| Shorbaji, N | 1 |
| Zelnik, N | 4 |
| Rapaport, M | 1 |
| Gomeni, R | 2 |
| Bressolle-Gomeni, F | 2 |
| Fang, L | 1 |
| Babiskin, A | 2 |
| Stuhec, M | 5 |
| Locatelli, I | 5 |
| Duman, NS | 1 |
| Duman, R | 2 |
| Sarı Gökten, E | 2 |
| Bäck, S | 1 |
| Gustafsson, J | 1 |
| Kim, D | 2 |
| Jeong, B | 2 |
| Azran, C | 1 |
| Langguth, P | 1 |
| Dahan, A | 1 |
| Kalil Neto, F | 1 |
| Nunes, ML | 1 |
| Zimmer, L | 2 |
| Chien, WC | 1 |
| Chung, CH | 1 |
| Lin, FH | 1 |
| Yeh, CB | 6 |
| Huang, SY | 1 |
| Lu, RB | 1 |
| Chang, HA | 1 |
| Kao, YC | 1 |
| Chiang, WS | 1 |
| Chou, YC | 1 |
| Tsao, CH | 1 |
| Wu, YF | 1 |
| Tzeng, NS | 1 |
| Stern, HP | 1 |
| Lipman, J | 1 |
| Andersen, SL | 5 |
| Bossaer, JB | 1 |
| Thigpen, J | 1 |
| Cupertino, RB | 2 |
| Schuch, JB | 1 |
| Kappel, DB | 1 |
| Müller, D | 1 |
| Bandeira, CE | 1 |
| Karam, RG | 7 |
| Silberstein, RB | 2 |
| Levy, F | 6 |
| Pipingas, A | 2 |
| Farrow, M | 2 |
| Cohen, HA | 2 |
| Savitsky, B | 1 |
| Ashkenasi, A | 3 |
| Hoshen, M | 1 |
| Shonka, S | 1 |
| French, WP | 2 |
| Strickland, J | 1 |
| Miller, L | 1 |
| Bolfer, C | 1 |
| Tsunemi, MH | 1 |
| Carreira, WS | 1 |
| Casella, BB | 1 |
| Kara, T | 1 |
| Akaltun, İ | 2 |
| Rietjens, SJ | 1 |
| Hondebrink, L | 1 |
| Jorna, T | 1 |
| de Vries, I | 1 |
| Wigal, SB | 28 |
| Berry, SA | 7 |
| Belden, H | 1 |
| Walters, F | 1 |
| Chappell, P | 2 |
| Sherman, N | 1 |
| Orazem, J | 1 |
| Palumbo, D | 6 |
| Sheffer, M | 1 |
| Aries, E | 1 |
| El Louali, F | 1 |
| Ovaert, C | 1 |
| Kortekaas-Rijlaarsdam, AF | 3 |
| Holmskov, M | 6 |
| Moreira-Maia, CR | 5 |
| Ramstad, E | 4 |
| Magnusson, FL | 5 |
| Krogh, HB | 6 |
| Riera, M | 1 |
| Tobias, A | 1 |
| Blanco, L | 1 |
| Capellà, D | 2 |
| Song, I | 2 |
| Lee, EK | 1 |
| Shin, JY | 4 |
| Moukhtarian, TR | 1 |
| Cooper, RE | 2 |
| Vassos, E | 1 |
| Moran, P | 1 |
| White, T | 1 |
| Schulz, KP | 2 |
| Bédard, AV | 1 |
| Fan, J | 2 |
| Hildebrandt, TB | 1 |
| Ivanov, I | 3 |
| Halperin, JM | 5 |
| Bjarnadottir, GD | 1 |
| Johannsson, M | 1 |
| Magnusson, A | 1 |
| Rafnar, BO | 1 |
| Steingrimsson, S | 1 |
| Asgrimsson, V | 1 |
| Snorradottir, I | 1 |
| Bragadottir, H | 1 |
| Haraldsson, HM | 1 |
| Wu, ZM | 1 |
| Bralten, J | 1 |
| An, L | 2 |
| Cao, QJ | 5 |
| Cao, XH | 2 |
| Liu, L | 1 |
| Mennes, M | 1 |
| Zang, YF | 3 |
| Franke, B | 5 |
| Hoogman, M | 1 |
| Wang, YF | 13 |
| Choudhry, Z | 3 |
| Martínez-Aguayo, JC | 1 |
| Arancibia, M | 1 |
| Meza-Concha, N | 1 |
| Bustamante, C | 1 |
| Pérez-Bracchiglione, J | 1 |
| Madrid, E | 1 |
| Íbias, J | 1 |
| Daniels, CW | 1 |
| Miguéns, M | 1 |
| Pellón, R | 1 |
| Sanabria, F | 1 |
| Fostick, L | 1 |
| Canellas-Dols, F | 1 |
| Delgado, C | 1 |
| Arango-Lopez, C | 1 |
| Stuckelman, ZD | 2 |
| Mulqueen, JM | 2 |
| Ferracioli-Oda, E | 2 |
| Cohen, SC | 2 |
| Coughlin, CG | 2 |
| Leckman, JF | 5 |
| Saiz, LC | 1 |
| Erviti, J | 1 |
| Santosh, P | 6 |
| Resmi, H | 1 |
| Güney, SA | 2 |
| Erkuran, HÖ | 2 |
| Sargin, E | 1 |
| Topuzoglu, A | 1 |
| Coskun, M | 4 |
| Adak, I | 1 |
| Solleveld, MM | 1 |
| Puts, NAJ | 1 |
| Lucassen, PJ | 3 |
| Baskin, BM | 2 |
| Nic Dhonnchadha, BÁ | 1 |
| Dwoskin, LP | 11 |
| Kantak, KM | 9 |
| Dela Peña, I | 6 |
| Dela Peña, IJ | 2 |
| de la Peña, JB | 3 |
| Han, DH | 15 |
| Ryu, JH | 4 |
| Groß, V | 1 |
| Lam, AP | 3 |
| Schuemie, MJ | 1 |
| Sturkenboom, MCJM | 1 |
| Morkem, R | 1 |
| Patten, S | 1 |
| Queenan, J | 1 |
| Barber, D | 1 |
| Landén, M | 2 |
| Ketter, TA | 1 |
| Dell'Osso, B | 1 |
| Wilson, J | 1 |
| Jaber, L | 2 |
| Rigler, S | 2 |
| Shuper, A | 4 |
| Diamond, G | 2 |
| Van den Driessche, C | 1 |
| Bastian, M | 1 |
| Peyre, H | 4 |
| Stordeur, C | 2 |
| Bahadori, S | 1 |
| Sackur, J | 1 |
| Manfredi, A | 2 |
| Nieri, G | 1 |
| Milone, A | 2 |
| Naenen-Hernani, K | 1 |
| Palazón-Bru, A | 1 |
| Colomina-Climent, F | 1 |
| Gil-Guillén, VF | 1 |
| Díez-Suárez, A | 1 |
| Vallejo-Valdivielso, M | 1 |
| Marín-Méndez, JJ | 1 |
| Soutullo, CA | 1 |
| Zhang, YC | 1 |
| Zhu, XQ | 1 |
| Zhang, XH | 1 |
| Harris, J | 1 |
| Liao, YT | 3 |
| Kuo, TY | 3 |
| Liang, HY | 7 |
| Huang, KY | 2 |
| Wang, TN | 2 |
| Lee, Y | 3 |
| Mowinckel, AM | 1 |
| Alnæs, D | 1 |
| Pedersen, ML | 1 |
| Ziegler, S | 1 |
| Kaufmann, T | 1 |
| Endestad, T | 1 |
| Westlye, LT | 1 |
| Biele, G | 1 |
| Rodrigues-Tartari, R | 1 |
| Swardfager, W | 1 |
| Cogo-Moreira, H | 1 |
| Gomez-Sanchez, CI | 1 |
| Carballo, JJ | 1 |
| Riveiro-Alvarez, R | 1 |
| Soto-Insuga, V | 1 |
| Rodrigo, M | 1 |
| Mahillo-Fernandez, I | 1 |
| Abad-Santos, F | 1 |
| Dal-Ré, R | 1 |
| Ayuso, C | 1 |
| Danborg, PB | 1 |
| Simonsen, AL | 1 |
| Kosse, RC | 1 |
| Bouvy, ML | 1 |
| Philbert, D | 1 |
| Koster, ES | 1 |
| Hetherington, L | 1 |
| Dommett, EJ | 2 |
| Turner, AC | 1 |
| Riley, TB | 1 |
| Haensel, JX | 1 |
| Overton, PG | 2 |
| Skoglund, C | 2 |
| Brandt, L | 3 |
| D'Onofrio, B | 2 |
| Ferguson, B | 1 |
| de Ruiter, MB | 2 |
| Frick, G | 1 |
| Yan, B | 1 |
| Pliszka, S | 3 |
| Courtabessis, E | 1 |
| Pupier, F | 1 |
| Surig, L | 1 |
| Picot, MC | 1 |
| Nogué, E | 1 |
| Macioce, V | 1 |
| Stein, E | 1 |
| Park-Wyllie, L | 2 |
| Castillon, G | 1 |
| Sherman, SE | 1 |
| Almagor, D | 2 |
| Alipio-Jocson, V | 1 |
| Inoyama, K | 1 |
| Bartlett, V | 1 |
| Sandhu, S | 1 |
| Oso, J | 1 |
| Barry, JJ | 1 |
| Loring, DW | 1 |
| Sweitzer, MM | 1 |
| Kozink, RV | 1 |
| Hallyburton, M | 2 |
| English, J | 2 |
| Oliver, JA | 1 |
| McClernon, FJ | 3 |
| Grobe, TG | 1 |
| Li, Y | 5 |
| Yin, A | 1 |
| Sun, X | 2 |
| Zhang, J | 5 |
| Li, W | 2 |
| Fan, Z | 1 |
| Zhu, Y | 1 |
| Wang, H | 1 |
| Dong, H | 1 |
| Wu, S | 5 |
| Xiong, L | 1 |
| Ehrhardt, C | 1 |
| Boucherie, Q | 2 |
| Pauly, V | 3 |
| Braunstein, D | 1 |
| Ronflé, E | 1 |
| Thirion, X | 2 |
| Frauger, E | 3 |
| Micallef, J | 3 |
| Coelho-Santos, V | 1 |
| Cardoso, FL | 1 |
| Fontes-Ribeiro, CA | 1 |
| van der Koog, L | 1 |
| Tjioe, MA | 1 |
| Bijker, BJ | 1 |
| Hernández-Díaz, S | 3 |
| Bateman, BT | 2 |
| Park, Y | 1 |
| Desai, RJ | 1 |
| Gray, KJ | 1 |
| Patorno, E | 1 |
| Mogun, H | 2 |
| Huybrechts, KF | 3 |
| Liang, SH | 1 |
| Lin, TC | 2 |
| Kelsen, BA | 1 |
| Pretus, C | 1 |
| Corrales, M | 3 |
| Picado, M | 3 |
| Carmona, S | 3 |
| Vilarroya, Ó | 4 |
| Avcil, S | 1 |
| van der Veen-Mulders, L | 1 |
| Nauta, MH | 1 |
| Emmelkamp, P | 1 |
| Edvinsson, D | 2 |
| Ekselius, L | 2 |
| Sturman, N | 1 |
| Deckx, L | 1 |
| van Driel, ML | 1 |
| Müller, H | 1 |
| Soleimani, R | 1 |
| Salehi, Z | 1 |
| Soltanipour, S | 1 |
| Hasandokht, T | 1 |
| Jalali, MM | 1 |
| Bostrom, S | 1 |
| Arnold, VK | 1 |
| Marraffino, A | 2 |
| López, FA | 7 |
| Akyol Ardıç, Ü | 2 |
| Aygüneş, D | 1 |
| Yüce, D | 2 |
| Durak, S | 3 |
| Kosova, B | 1 |
| Toriumi, K | 1 |
| Tanaka, J | 1 |
| Mamiya, T | 1 |
| Alkam, T | 1 |
| Kim, HC | 1 |
| Nitta, A | 1 |
| Nabeshima, T | 2 |
| Myer, NM | 1 |
| Boland, JR | 1 |
| Fekete, S | 1 |
| Romanos, M | 14 |
| Gerlach, M | 14 |
| Howes, OD | 1 |
| Rogdaki, M | 1 |
| Findon, JL | 1 |
| Wichers, RH | 1 |
| Charman, T | 1 |
| King, BH | 1 |
| Loth, E | 1 |
| McAlonan, GM | 1 |
| Parr, JR | 2 |
| Povey, C | 1 |
| Wallace, S | 1 |
| Simonoff, E | 6 |
| Murphy, DG | 1 |
| Bröms, G | 1 |
| Christensen, LB | 1 |
| Einarsdóttir, K | 1 |
| Engeland, A | 1 |
| Gissler, M | 1 |
| Karlsson, P | 1 |
| Kieler, H | 3 |
| Lahesmaa-Korpinen, AM | 1 |
| Nørgaard, M | 1 |
| Sørensen, HT | 1 |
| Zoega, H | 8 |
| Scrandis, DA | 1 |
| Moreno-García, I | 1 |
| Meneres-Sancho, S | 1 |
| Camacho-Vara de Rey, C | 1 |
| Servera, M | 2 |
| Wiwe Lipsker, C | 1 |
| von Heijne, M | 1 |
| Wicksell, RK | 1 |
| Vogt, H | 1 |
| Lunde, C | 1 |
| Ardic, UA | 3 |
| Wall, M | 1 |
| Covey, L | 1 |
| Scodes, JM | 1 |
| Levin, FR | 12 |
| Winhusen, T | 10 |
| Angyal, N | 2 |
| Horvath, EZ | 1 |
| Tarnok, Z | 3 |
| Richman, MJ | 1 |
| Bognar, E | 2 |
| Lakatos, K | 2 |
| Sasvari-Szekely, M | 3 |
| Nemoda, Z | 3 |
| Pagerols, M | 2 |
| Sánchez-Mora, C | 2 |
| Rovira, P | 1 |
| Soler Artigas, M | 1 |
| Garcia-Martínez, I | 2 |
| Calvo-Sánchez, E | 1 |
| Cormand, B | 3 |
| Casas, M | 15 |
| Ribasés, M | 3 |
| Miller, EM | 1 |
| Quintero, JE | 1 |
| Pomerleau, F | 1 |
| Huettl, P | 1 |
| Gerhardt, GA | 1 |
| Glaser, PEA | 1 |
| Cohen, A | 1 |
| Plonsky-Toder, M | 1 |
| Tombor, L | 1 |
| Kakuszi, B | 1 |
| Papp, S | 1 |
| Réthelyi, J | 1 |
| Bitter, I | 1 |
| Czobor, P | 2 |
| Ghajar, A | 1 |
| Aghajan-Nashtaei, F | 1 |
| Afarideh, M | 1 |
| Miller, JW | 1 |
| Aasen, IE | 1 |
| Øgrim, G | 1 |
| Kropotov, J | 1 |
| Brunner, JF | 1 |
| Espadas, M | 1 |
| Insa, I | 1 |
| Chamorro, M | 1 |
| Collin-Lévesque, L | 1 |
| El-Ghaddaf, Y | 1 |
| Genest, M | 1 |
| Jutras, M | 1 |
| Leclair, G | 1 |
| Weisskopf, E | 1 |
| Panchaud, A | 1 |
| Ferreira, E | 1 |
| Wei, HT | 1 |
| Su, TP | 1 |
| Li, CT | 1 |
| Lin, WC | 1 |
| Chang, WH | 1 |
| Snircova, E | 2 |
| Marcincakova Husarova, V | 1 |
| Ondrejka, I | 4 |
| Hrtanek, I | 2 |
| Farsky, I | 1 |
| Nosalova, G | 2 |
| Crunelle, CL | 4 |
| van den Brink, W | 3 |
| Moggi, F | 1 |
| Konstenius, M | 4 |
| van de Glind, G | 1 |
| Demetrovics, Z | 1 |
| Coetzee, C | 1 |
| Luderer, M | 1 |
| Schellekens, A | 1 |
| Matthys, F | 1 |
| Lepelley, M | 1 |
| Mallaret, M | 1 |
| Iaccarino, MA | 1 |
| Philpotts, LL | 1 |
| Zafonte, R | 1 |
| Critchley, HD | 1 |
| Armstrong, B | 1 |
| Nanan, RK | 1 |
| Maire, J | 1 |
| Bouvard, MP | 1 |
| Rizzo, AA | 3 |
| Sagaspe, P | 1 |
| Philip, P | 1 |
| Yokota, T | 1 |
| Horiuchi, M | 1 |
| Hiroyama, S | 1 |
| Li, J | 4 |
| Hamerman, H | 1 |
| Jang, B | 1 |
| Song, J | 2 |
| Kim, J | 3 |
| Kim, K | 3 |
| Kim, S | 1 |
| Shin, HY | 1 |
| Kwon, JY | 1 |
| Kim, YH | 1 |
| Belden, HW | 3 |
| Wajsbrot, DB | 1 |
| Nagraj, P | 2 |
| Abbas, R | 2 |
| Ruiz, P | 1 |
| Calliari, A | 1 |
| Genovese, P | 1 |
| Scorza, C | 1 |
| Pautassi, RM | 1 |
| Kaya, GÇ | 2 |
| Kose, S | 2 |
| Yazıcıoğlu, ÇE | 1 |
| Oğuz, K | 1 |
| Keskin, D | 1 |
| Baykara, B | 1 |
| Emiroğlu, Nİ | 2 |
| Eren, MŞ | 1 |
| Kızıldağ, S | 1 |
| Ertay, T | 1 |
| Özsoylu, D | 1 |
| Miral, S | 2 |
| Durak, H | 2 |
| Gönül, AS | 1 |
| Rolke, R | 1 |
| Palumbo, DR | 3 |
| Winters, DE | 1 |
| Fukui, S | 1 |
| Hulvershorn, LA | 1 |
| Colder, CR | 1 |
| Pedersen, N | 1 |
| Kielsholm, ML | 1 |
| Nielsen, SS | 1 |
| Gerner, T | 2 |
| Rosendal, S | 3 |
| Buch Rasmussen, K | 2 |
| Gauci, D | 3 |
| Håkonsen, SJ | 1 |
| Aagaard, L | 5 |
| Preiskorn, J | 1 |
| Studer, S | 1 |
| Rauh, R | 1 |
| Lukačin, R | 2 |
| Geffert, C | 1 |
| Fleischhaker, C | 3 |
| Clement, HW | 2 |
| Schulz, E | 5 |
| Biscaldi, M | 1 |
| Pievsky, MA | 1 |
| McGrath, RE | 1 |
| Lentferink, YE | 1 |
| van de Garde, EMW | 1 |
| Knibbe, CAJ | 1 |
| van der Vorst, MMJ | 1 |
| King, SA | 1 |
| Casavant, MJ | 1 |
| Spiller, HA | 1 |
| Hodges, NL | 1 |
| Chounthirath, T | 1 |
| Smith, GA | 1 |
| Okumura, Y | 1 |
| Saito, T | 1 |
| Negoro, H | 2 |
| Fujita, J | 1 |
| Lewis, YD | 1 |
| Dvora, S | 1 |
| Feffer, K | 2 |
| Carmel, Z | 3 |
| Levkovitz, Y | 5 |
| Ben-Ami, IS | 1 |
| Ankory, R | 3 |
| Kadar, A | 2 |
| Rotman, D | 2 |
| Snir, N | 2 |
| Schermann, H | 3 |
| López-Villalobos, JA | 2 |
| Sacristán-Martín, AM | 2 |
| Garrido-Redondo, M | 2 |
| Martínez-Rivera, MT | 2 |
| López-Sánchez, MV | 2 |
| Rodríguez-Molinero, L | 2 |
| Camina-Gutiérrez, AB | 2 |
| Andrés-de Llano, J | 1 |
| Cerrillo-Urbina, AJ | 1 |
| García-Hermoso, A | 1 |
| Pardo-Guijarro, MJ | 1 |
| Sánchez-López, M | 1 |
| Santos-Gómez, JL | 1 |
| Martínez-Vizcaíno, V | 1 |
| Kim, JI | 3 |
| Shin, I | 1 |
| Suhaiban, H | 1 |
| Javanbakht, A | 1 |
| Frampton, JE | 1 |
| Sudnawa, KK | 1 |
| Chirdkiatgumchai, V | 1 |
| Ruangdaraganon, N | 1 |
| Khongkhatithum, C | 1 |
| Udomsubpayakul, U | 1 |
| Jirayucharoensak, S | 1 |
| Israsena, P | 1 |
| Mulet, CT | 1 |
| Arroyo-Mora, LE | 1 |
| Leon, LA | 1 |
| DeCaprio, AP | 1 |
| Spooner, C | 1 |
| Kohn, M | 4 |
| Osland, ST | 1 |
| Steeves, TD | 1 |
| Pringsheim, T | 2 |
| Schoppmeyer, M | 1 |
| Levy, T | 1 |
| Ibrahim, K | 2 |
| Donyai, P | 2 |
| Faltinsen, E | 3 |
| Kawabe, K | 1 |
| Horiuchi, F | 1 |
| Kondo, S | 1 |
| Matsumoto, M | 2 |
| Seo, K | 1 |
| Oka, Y | 1 |
| Ueno, SI | 1 |
| Operto, FF | 1 |
| Mazza, R | 1 |
| Campanozzi, S | 1 |
| Pastorino, GM | 1 |
| Amadori, E | 1 |
| Coppola, G | 1 |
| Weiss, M | 14 |
| Mattingly, G | 2 |
| Nordbrock, E | 4 |
| Kupper, RJ | 5 |
| Jaite, C | 2 |
| van Noort, BM | 1 |
| Vloet, TD | 1 |
| Kappel, V | 2 |
| Geissler, J | 1 |
| Warnke, A | 20 |
| Groß-Lesch, S | 4 |
| Hennighausen, K | 5 |
| Haack-Dees, B | 2 |
| Schneider-Momm, K | 1 |
| Hänig, S | 3 |
| von Gontard, A | 4 |
| Poustka, L | 4 |
| Gentschow, L | 5 |
| Freitag, CM | 3 |
| Becker, K | 6 |
| Engelking, D | 2 |
| McMahen, R | 3 |
| Sikes, CR | 3 |
| Choi, HW | 1 |
| Yum, MS | 2 |
| Ko, TS | 2 |
| Shon, SH | 1 |
| Kim, HW | 4 |
| Baker, AS | 1 |
| Freeman, MP | 1 |
| Adamo, N | 2 |
| Mohr-Jensen, C | 2 |
| Hayes, AJ | 2 |
| Atkinson, LZ | 2 |
| Tessari, L | 1 |
| Barbui, C | 2 |
| Purgato, M | 2 |
| Steinhausen, HC | 10 |
| Shokraneh, F | 2 |
| Lukić, P | 1 |
| Teuscher, NS | 2 |
| Dondaine, T | 1 |
| Deheul, S | 1 |
| Marquié, C | 1 |
| Brigadeau, F | 1 |
| Amad, A | 1 |
| Devos, D | 1 |
| Danel, T | 1 |
| Bordet, R | 1 |
| Cottencin, O | 2 |
| Gautier, S | 1 |
| Colaneri, N | 1 |
| Keim, SA | 1 |
| Adesman, A | 4 |
| Liang, EF | 1 |
| Lim, SZ | 1 |
| Tam, WW | 1 |
| Ho, CS | 1 |
| Zhang, MW | 1 |
| Ho, RC | 1 |
| Gurel, R | 1 |
| Yoffe, V | 2 |
| Sternheim, A | 1 |
| Karakis, I | 2 |
| Custodio, RJP | 1 |
| Botanas, CJ | 1 |
| Kim, M | 2 |
| Sayson, LV | 1 |
| Abiero, A | 1 |
| Ryoo, ZY | 1 |
| Ackermann, S | 1 |
| Halfon, O | 1 |
| Fornari, E | 1 |
| Urben, S | 1 |
| Bader, M | 1 |
| Fu, AT | 1 |
| Fricke, D | 1 |
| Vijayashanthar, A | 1 |
| Ide, S | 1 |
| Ikekubo, Y | 1 |
| Hua, J | 1 |
| Takamatsu, Y | 3 |
| Uhl, GR | 3 |
| Sora, I | 6 |
| Ikeda, K | 4 |
| Andres-De Llano, JM | 1 |
| Pakdaman, F | 1 |
| Irani, F | 1 |
| Tajikzadeh, F | 1 |
| Jabalkandi, SA | 1 |
| Prihodova, I | 1 |
| Dudova, I | 1 |
| Mohaplova, M | 1 |
| Hrdlicka, M | 1 |
| Nevsimalova, S | 1 |
| Raman, SR | 3 |
| Bahmanyar, S | 2 |
| Berard, A | 1 |
| Bilder, S | 1 |
| Boukhris, T | 1 |
| Bushnell, G | 1 |
| Crystal, S | 2 |
| KaoYang, YH | 1 |
| Kubota, K | 1 |
| Lai, EC | 1 |
| Martikainen, JE | 2 |
| Maura, G | 1 |
| Moore, N | 1 |
| Montero, D | 1 |
| Nakamura, H | 1 |
| Neumann, A | 1 |
| Pate, V | 1 |
| Pottegård, A | 7 |
| Pratt, NL | 2 |
| Roughead, EE | 2 |
| Macias Saint-Gerons, D | 1 |
| Stürmer, T | 3 |
| Su, CC | 2 |
| Sturkenbroom, MCJM | 1 |
| Möhring, W | 1 |
| Klupp, S | 1 |
| Grob, A | 1 |
| Kadkhoda Mezerji, F | 1 |
| Moharreri, F | 1 |
| Mohammadpour, AH | 1 |
| Elyasi, S | 1 |
| Tarrant, N | 1 |
| Roy, M | 2 |
| Deb, S | 1 |
| Odedra, S | 1 |
| Retzer, A | 1 |
| Roy, A | 1 |
| Shlaifer, A | 1 |
| Dolkart, O | 1 |
| Chechik, O | 1 |
| Yan, L | 2 |
| Lionarons, JM | 1 |
| Hellebrekers, DMJ | 1 |
| Klinkenberg, S | 1 |
| Faber, CG | 1 |
| Vles, JSH | 1 |
| Hendriksen, JGM | 1 |
| Grazioli, S | 1 |
| Mauri, M | 1 |
| Crippa, A | 1 |
| Maggioni, E | 1 |
| Molteni, M | 1 |
| Brambilla, P | 1 |
| Nobile, M | 1 |
| Patrick, KS | 6 |
| Radke, JL | 1 |
| Raymond, JR | 1 |
| Koller, L | 1 |
| Nguyen, LV | 1 |
| Rodriguez, W | 1 |
| Straughn, AB | 4 |
| Cipriani, C | 1 |
| Pitzianti, MB | 2 |
| Matteucci, C | 2 |
| D'Agati, E | 5 |
| Miele, MT | 1 |
| Rapaccini, V | 1 |
| Grelli, S | 1 |
| Curatolo, P | 8 |
| Sinibaldi-Vallebona, P | 1 |
| Pasini, A | 5 |
| Balestrieri, E | 2 |
| Martinhago, F | 1 |
| Granato, MF | 1 |
| Ferraro, AA | 1 |
| Lellis, DM | 1 |
| Friedrich, J | 1 |
| Schreiter, ML | 1 |
| Ponce De Leon, B | 1 |
| Owens, M | 1 |
| Hayashi, W | 1 |
| Iwanami, A | 1 |
| Berger, C | 1 |
| Müller-Godeffroy, J | 1 |
| Marx, I | 1 |
| Reis, O | 1 |
| Buchmann, J | 4 |
| Dück, A | 1 |
| Haro-García, A | 1 |
| Uberos-Fernández, J | 1 |
| Villas-Boas, CB | 2 |
| Chierrito, D | 2 |
| Sanches, ACC | 2 |
| Hsu, SP | 1 |
| Wang, DY | 1 |
| Min, MY | 1 |
| Fu, YS | 1 |
| Oliva, F | 1 |
| Carezana, C | 1 |
| Nibbio, G | 1 |
| Bramante, S | 1 |
| Portigliatti Pomeri, A | 1 |
| Maina, G | 1 |
| Shih, HH | 1 |
| Shang, CY | 5 |
| Mama, Y | 1 |
| Icht, M | 1 |
| Alrashidi, F | 1 |
| Elsori, DH | 1 |
| Gnanavel, S | 1 |
| Picon, FA | 6 |
| Sato, JR | 1 |
| Anés, M | 2 |
| Vedolin, LM | 1 |
| Mazzola, AA | 1 |
| Valentini, BB | 1 |
| Breda, V | 3 |
| Silva, K | 1 |
| da Silva, N | 1 |
| Rohde, LAP | 1 |
| Partain, PI | 1 |
| White, J | 2 |
| Hammerness, P | 14 |
| Bundesen, C | 1 |
| Elsori, D | 1 |
| Jiang, HY | 1 |
| Zhang, X | 2 |
| Jiang, CM | 1 |
| Fu, HB | 1 |
| Karakus, Y | 1 |
| Cak Esen, T | 1 |
| Shalev, L | 1 |
| Tsamir, D | 1 |
| Grupe, M | 1 |
| Larsen, CW | 1 |
| Dietz, AG | 1 |
| Fang, LL | 1 |
| Tsai, CY | 1 |
| Tsai, TH | 1 |
| Tsai, IJ | 1 |
| Chen, SC | 1 |
| Yu, BY | 1 |
| Suen, LK | 1 |
| Yu, J | 1 |
| Ho, FY | 1 |
| Yang, JJ | 1 |
| Yeung, WF | 1 |
| Robe, A | 1 |
| Dobrean, A | 1 |
| Cristea, IA | 1 |
| Păsărelu, CR | 1 |
| Predescu, E | 1 |
| Fitzpatrick, CM | 2 |
| Chin, WC | 1 |
| Huang, YS | 14 |
| Chou, YH | 1 |
| Wang, CH | 1 |
| Chen, KT | 1 |
| Hsu, JF | 1 |
| Hsu, SC | 1 |
| Bonnefois, G | 2 |
| Borg Skoglund, L | 1 |
| Baziar, S | 1 |
| Aqamolaei, A | 1 |
| Khadem, E | 1 |
| Mortazavi, SH | 1 |
| Naderi, S | 1 |
| Sahebolzamani, E | 1 |
| Mortezaei, A | 1 |
| Jalilevand, S | 1 |
| Shahmirzadi, M | 1 |
| Buck, JM | 1 |
| Sanders, KN | 1 |
| Wageman, CR | 1 |
| Knopik, VS | 1 |
| Stitzel, JA | 1 |
| O'Neill, HC | 1 |
| Egeland, J | 1 |
| Haavik, J | 4 |
| Fasmer, OB | 1 |
| Miguel, PM | 1 |
| Deniz, BF | 1 |
| Confortim, HD | 1 |
| Bronauth, LP | 1 |
| de Oliveira, BC | 1 |
| Alves, MB | 1 |
| Silveira, PP | 1 |
| Pereira, LO | 1 |
| López-López, A | 1 |
| Poch-Olivé, ML | 1 |
| López-Pisón, J | 1 |
| Cardo-Jalón, E | 1 |
| Liu, T | 1 |
| Gobburu, JVS | 1 |
| McLean, A | 2 |
| Guler Aksu, G | 1 |
| Akdere, P | 1 |
| Toros, F | 1 |
| Zammit, N | 1 |
| Muscat, R | 1 |
| Panzenhagen, AC | 1 |
| Salvi, AA | 1 |
| Pires, GN | 1 |
| Ongur, D | 1 |
| Hsu, J | 1 |
| Castro, VM | 1 |
| Perlis, RH | 1 |
| Schneeweiss, S | 1 |
| Todorovac, A | 1 |
| Ydedahl-Jensen, E | 1 |
| Koplewicz, HS | 4 |
| Mancera, N | 1 |
| Wadia, HP | 1 |
| Stevens, T | 1 |
| Sangkuhl, K | 1 |
| Altman, RB | 1 |
| Klein, TE | 1 |
| Grebla, R | 1 |
| Setyawan, J | 7 |
| Park, C | 1 |
| Richards, KM | 1 |
| Nwokeji, ED | 1 |
| Pawaskar, M | 1 |
| Haim Erder, M | 1 |
| Lawson, KA | 1 |
| Steingard, R | 1 |
| Taskiran, S | 2 |
| Connor, DF | 8 |
| Werner, AL | 1 |
| Ebert, D | 2 |
| Friedel, E | 2 |
| Bubl, A | 1 |
| Bach, M | 1 |
| Bubl, E | 1 |
| Yoshida, M | 1 |
| Kikuchi, S | 1 |
| Satoh, M | 1 |
| Morikawa, Y | 1 |
| Ooba, N | 1 |
| Yamaguchi, H | 1 |
| Mano, N | 1 |
| Santos, PH | 1 |
| Goncalves, R | 1 |
| Pedroso, S | 2 |
| de Mello, JCP | 1 |
| Komolova, M | 1 |
| Pertermann, M | 1 |
| Bierens, M | 1 |
| Kleine Deters, R | 1 |
| Korn, L | 1 |
| Hassan, K | 1 |
| Fainshtein, N | 1 |
| Yusov, N | 1 |
| Davidovitch, N | 1 |
| Ching, C | 1 |
| Verhamme, KMC | 1 |
| Herings, R | 1 |
| Wilms, W | 1 |
| Woźniak-Karczewska, M | 1 |
| Corvini, PF | 1 |
| Chrzanowski, Ł | 1 |
| Quinn, PD | 1 |
| Hechtman, L | 27 |
| Wang, S | 2 |
| Selig, JP | 1 |
| King, N | 1 |
| Floren, S | 1 |
| Kharas, N | 1 |
| Thomas, M | 1 |
| Dafny, N | 2 |
| Jarczok, TA | 1 |
| Haase, R | 1 |
| Thiemann, U | 1 |
| Bender, S | 1 |
| Dehbozorghi, S | 1 |
| Shokraee, K | 1 |
| Tulay, EE | 1 |
| Beser, B | 1 |
| Elagoz Yuksel, M | 1 |
| Arikan, K | 1 |
| Tarhan, N | 2 |
| Metin, B | 2 |
| Munasur-Naidoo, AP | 1 |
| Truter, I | 3 |
| Adorjan, K | 1 |
| Karch, S | 1 |
| Martin, G | 1 |
| Plörer, D | 1 |
| Winter, C | 1 |
| Hantschk, I | 1 |
| Koller, G | 1 |
| Erbas, B | 1 |
| Pogarell, O | 1 |
| Butzbach, M | 1 |
| Aschenbrenner, S | 1 |
| Weisbrod, M | 1 |
| Tucha, L | 4 |
| Smith, A | 4 |
| Barrett, N | 4 |
| Brammer, M | 6 |
| Simmons, A | 4 |
| Prats, M | 1 |
| Motaharifard, MS | 1 |
| Effatpanah, M | 2 |
| Karimi, M | 1 |
| Rahimi, H | 1 |
| Yasrebi, SA | 1 |
| Nejatbakhsh, F | 1 |
| Christian, W | 1 |
| Aviram, S | 2 |
| Braw, Y | 2 |
| Mimouni Bloch, A | 1 |
| Lensing, MB | 2 |
| Zeiner, P | 3 |
| Sandvik, L | 1 |
| Opjordsmoen, S | 1 |
| Rostain, A | 1 |
| Jensen, PS | 19 |
| Miesle, LM | 1 |
| Wilton, L | 3 |
| Murray, M | 3 |
| Hodgkins, P | 18 |
| Wong, IC | 11 |
| Bushe, CJ | 1 |
| Savill, NC | 1 |
| Mitra, D | 2 |
| Davis, K | 2 |
| Fridman, M | 3 |
| Shaw, M | 3 |
| Harpin, V | 4 |
| Alvarez-Gomez, MJ | 1 |
| Vrijens, M | 1 |
| Thompson, M | 5 |
| Yardley, L | 1 |
| Sonuga-Barke, EJ | 10 |
| Kawada, T | 1 |
| Smith, BH | 9 |
| Bukstein, O | 14 |
| Reichow, B | 1 |
| Volkmar, FR | 1 |
| Shin, MS | 18 |
| Cho, SC | 23 |
| Kim, JH | 8 |
| Son, JW | 4 |
| Shin, YM | 4 |
| Chung, US | 7 |
| Schwenck, C | 2 |
| Schneider, T | 1 |
| Schreckenbach, J | 1 |
| Zenglein, Y | 1 |
| Gensthaler, A | 1 |
| Taurines, R | 2 |
| Schneider, W | 1 |
| Ni, HC | 3 |
| Lin, YJ | 3 |
| Huang, HC | 3 |
| Yang, LK | 3 |
| Sembower, MA | 1 |
| Ertischek, MD | 1 |
| Buchholtz, C | 1 |
| Dasgupta, N | 1 |
| Schnoll, SH | 1 |
| Shalev, R | 3 |
| Santos, K | 3 |
| Palmini, A | 2 |
| Radziuk, AL | 2 |
| Rotert, R | 2 |
| Bastos, F | 2 |
| Booij, L | 1 |
| Fernandes, BS | 1 |
| Sakakihara, Y | 2 |
| Martens, MA | 1 |
| Seyfer, DL | 1 |
| Andridge, RR | 1 |
| Foster, JE | 1 |
| McClure, KE | 1 |
| Coury, DL | 2 |
| Burgard, DA | 1 |
| Fuller, R | 1 |
| Becker, B | 1 |
| Ferrell, R | 1 |
| Dinglasan-Panlilio, MJ | 1 |
| Murray, ML | 3 |
| Insuk, S | 1 |
| Neubert, AC | 1 |
| Sinibaldi, L | 1 |
| Paloscia, C | 1 |
| Douzgou, S | 1 |
| Romeo, E | 1 |
| Pizzuti, A | 1 |
| Meichenbaum, DL | 4 |
| Carson, P | 1 |
| Fox, S | 1 |
| Ali, MU | 1 |
| Beckett, J | 1 |
| Lim, CG | 2 |
| Itaborahy, C | 1 |
| Ortega, F | 1 |
| Bahali, K | 2 |
| Ipek, H | 1 |
| Uneri, OS | 1 |
| Wijers, AA | 2 |
| Althaus, M | 2 |
| Helenius, D | 1 |
| Bart, O | 1 |
| Daniel, L | 1 |
| Dan, O | 1 |
| Bar-Haim, Y | 1 |
| Braun, S | 1 |
| Russo, L | 3 |
| Zeidler, J | 1 |
| Linder, R | 1 |
| Hong, Q | 3 |
| Pan, XQ | 3 |
| Guo, M | 3 |
| Fei, L | 2 |
| Guo, XR | 3 |
| Tong, ML | 3 |
| Chi, X | 3 |
| Na, KS | 1 |
| Lee, SI | 4 |
| Hong, SD | 3 |
| Shim, SH | 1 |
| Yang, J | 4 |
| Kim, EJ | 3 |
| Park, JH | 5 |
| Kambeitz, J | 1 |
| Ettinger, U | 1 |
| Bolea-Alamanac, BM | 1 |
| Green, A | 1 |
| Verma, G | 1 |
| Maxwell, P | 1 |
| Davies, SJ | 2 |
| Cubillo, A | 5 |
| Smith, AB | 4 |
| Lange, KW | 12 |
| Cummins, TD | 3 |
| Maldonado, R | 1 |
| Somkuwar, SS | 3 |
| Darna, M | 2 |
| Heinrich, H | 5 |
| Studer, P | 2 |
| Moll, GH | 6 |
| Kratz, O | 2 |
| Paton, K | 1 |
| Hammond, P | 1 |
| Barry, E | 3 |
| Fitzgerald, M | 5 |
| McNicholas, F | 3 |
| Kirley, A | 5 |
| Robertson, IH | 3 |
| Gill, M | 6 |
| Johnson, KA | 3 |
| Fried, R | 3 |
| Petty, C | 4 |
| Meller, B | 1 |
| Stray, LL | 3 |
| Kristensen, Ø | 1 |
| Lomeland, M | 1 |
| Skorstad, M | 1 |
| Stray, T | 2 |
| Tønnessen, FE | 1 |
| Ramtvedt, BE | 3 |
| Røinås, E | 1 |
| Aabech, HS | 2 |
| Sundet, KS | 1 |
| Scerif, G | 3 |
| Liddle, PF | 3 |
| Batty, MJ | 3 |
| Liotti, M | 5 |
| Hollis, CP | 2 |
| Meisel, V | 1 |
| Garcia-Banda, G | 1 |
| Cardo, E | 3 |
| Moreno, I | 1 |
| Skokauskas, N | 1 |
| Hitoshi, K | 1 |
| Shuji, H | 1 |
| Frodl, T | 2 |
| Ding, KJ | 2 |
| Liu, YF | 1 |
| Kang, CY | 2 |
| Liu, RX | 2 |
| Li, XR | 2 |
| Wan, S | 2 |
| Jain, R | 4 |
| Babcock, T | 1 |
| Burtea, T | 1 |
| Dirks, B | 1 |
| Adeyi, B | 2 |
| Scheckner, B | 1 |
| Lasser, R | 1 |
| Renna, J | 1 |
| Duncan, D | 1 |
| Eugene Arnold, L | 1 |
| Taylor, E | 21 |
| Baird, G | 4 |
| Bernard, S | 2 |
| Wigal, T | 24 |
| Telang, F | 3 |
| Jayne, M | 1 |
| Wong, CT | 2 |
| Han, H | 1 |
| Fowler, JS | 10 |
| Zhu, W | 3 |
| Coghill, DR | 7 |
| Otero, IH | 1 |
| Civil, R | 6 |
| Bloomfield, R | 2 |
| Squires, LA | 2 |
| Senior, HE | 2 |
| McKinlay, L | 2 |
| Nikles, J | 1 |
| Schluter, PJ | 2 |
| Carmont, SA | 2 |
| Waugh, MC | 2 |
| Epps, A | 2 |
| Lloyd, O | 1 |
| Mitchell, GK | 4 |
| Semeijn, EJ | 1 |
| Sandra Kooij, JJ | 2 |
| Comijs, HC | 1 |
| Deeg, DJH | 1 |
| Socanski, D | 2 |
| Aurlien, D | 2 |
| Herigstad, A | 2 |
| Thomsen, PH | 5 |
| Larsen, TK | 2 |
| Brunklaus, A | 1 |
| Dorris, L | 1 |
| Zuberi, SM | 1 |
| Veltman, DJ | 1 |
| van Emmerik-van Oortmerssen, K | 2 |
| Dom, G | 2 |
| Schoevers, RA | 1 |
| Booij, J | 2 |
| Montoya, A | 2 |
| Kutzelnigg, A | 1 |
| Deberdt, W | 1 |
| Umehara, M | 1 |
| Ago, Y | 1 |
| Kawanai, T | 1 |
| Fujita, K | 1 |
| Hiramatsu, N | 1 |
| Takuma, K | 1 |
| Matsuda, T | 1 |
| Tsviban, L | 1 |
| Shamay-Tsoory, SG | 2 |
| Watemberg, N | 1 |
| Kim, SW | 2 |
| Lee, JH | 2 |
| Lee, SH | 4 |
| Hong, HJ | 2 |
| Lee, MG | 2 |
| Yook, KH | 2 |
| Pearson, DA | 5 |
| Santos, CW | 4 |
| Aman, MG | 19 |
| Casat, CD | 6 |
| Mansour, R | 2 |
| Lane, DM | 4 |
| Loveland, KA | 4 |
| Bukstein, OG | 11 |
| Jerger, SW | 3 |
| Factor, P | 1 |
| Vanwoerden, S | 1 |
| Perez, E | 1 |
| Cleveland, LA | 4 |
| Döpfner, M | 32 |
| Arcieri, R | 5 |
| Johnson, M | 2 |
| Anderson, C | 2 |
| Higgins, N | 2 |
| Ogrim, G | 1 |
| Hestad, KA | 1 |
| Djalali, S | 1 |
| Yoo, HJ | 12 |
| Sheen, VL | 1 |
| Shankar, M | 1 |
| Marin-Valencia, I | 1 |
| Bridgemohan, CH | 1 |
| Torres, AR | 2 |
| Durá Travé, T | 1 |
| Diez Bayona, V | 1 |
| Yoldi Petri, ME | 1 |
| Aguilera Albesa, S | 1 |
| Isaksson, J | 1 |
| Hogmark, Å | 1 |
| Nilsson, KW | 1 |
| Lindblad, F | 1 |
| Badashova, KK | 1 |
| Posey, DJ | 2 |
| Scahill, L | 7 |
| Tierney, E | 5 |
| Whelan, F | 3 |
| Chuang, SZ | 8 |
| Davies, M | 17 |
| Shah, B | 3 |
| McDougle, CJ | 6 |
| Nurmi, EL | 1 |
| Tzang, RF | 5 |
| Chang, YC | 2 |
| Chen, CC | 2 |
| Tanaka, H | 1 |
| Miyajima, T | 1 |
| Paslakis, G | 2 |
| Schredl, M | 2 |
| Kipp, HL | 3 |
| Fernández-Jaén, A | 3 |
| Martín Fernández-Mayoralas, D | 1 |
| Fernández-Perrone, AL | 1 |
| Calleja-Pérez, B | 2 |
| Muñoz-Jareño, N | 1 |
| López-Arribas, S | 1 |
| Cassidy, TA | 2 |
| McNaughton, EC | 1 |
| Varughese, S | 2 |
| Zulueta, M | 1 |
| Butler, SF | 2 |
| Jackson, A | 1 |
| Amiri, A | 1 |
| Torabi Parizi, G | 1 |
| Saadat, F | 1 |
| Modabbernia, MJ | 1 |
| Najafi, K | 1 |
| Atrkar Roushan, Z | 1 |
| Modesto-Lowe, V | 1 |
| Chaplin, M | 1 |
| Soovajian, V | 1 |
| Meyer, A | 1 |
| Salisbury-Afshar, E | 1 |
| Fuentes, J | 1 |
| Puvanendran, K | 2 |
| Berquin, P | 3 |
| De Bruyckere, K | 1 |
| Quail, D | 1 |
| Escobar, R | 1 |
| Martin, CA | 4 |
| Nuzzo, PA | 1 |
| Ranseen, JD | 1 |
| Kleven, MS | 1 |
| Guenthner, G | 2 |
| Williams, Y | 1 |
| Walsh, SL | 1 |
| Li, L | 1 |
| Zhuo, CJ | 1 |
| Ahmed, R | 1 |
| Borst, J | 1 |
| Wei, YC | 1 |
| Aslani, P | 1 |
| Lipkin, PH | 3 |
| Bolea-Alamanac, B | 1 |
| Damkier, P | 2 |
| Hautmann, C | 4 |
| Dalsgaard, S | 4 |
| Nielsen, HS | 2 |
| Simonsen, M | 2 |
| Germinario, EA | 3 |
| Vella, S | 3 |
| Chiarotti, F | 4 |
| Park, MH | 4 |
| Yatsuga, C | 1 |
| Toyohisa, D | 1 |
| Fujisawa, TX | 1 |
| Nishitani, S | 1 |
| Shinohara, K | 1 |
| Matsuura, N | 1 |
| Ikeda, S | 1 |
| Muramatsu, M | 1 |
| Hamada, A | 1 |
| Gormez, V | 1 |
| Avery, B | 1 |
| Mann, H | 1 |
| McBurnett, K | 9 |
| Turnbow, J | 4 |
| Rugino, T | 1 |
| White, C | 2 |
| Youcha, S | 1 |
| Pelaz, A | 1 |
| Doepfner, M | 2 |
| Meyer, E | 1 |
| Mortensen, PB | 2 |
| Frydenberg, M | 1 |
| Urban, KR | 3 |
| Gao, WJ | 4 |
| Kasparek, T | 1 |
| Theiner, P | 2 |
| Filova, A | 1 |
| Schoenfelder, E | 1 |
| English, JS | 1 |
| Dew, RE | 1 |
| Lane, SD | 1 |
| Brown, A | 1 |
| Seidman, LJ | 4 |
| Valera, EM | 2 |
| Makris, N | 2 |
| Lomedico, A | 1 |
| Jayaram-Lindström, N | 2 |
| Guterstam, J | 2 |
| Beck, O | 3 |
| Philips, B | 1 |
| Yılmaz, S | 3 |
| Bilgiç, A | 6 |
| Langner, D | 2 |
| Schumacher-Stien, M | 2 |
| Heinrich, V | 2 |
| Kornmann, C | 2 |
| Bürger, A | 2 |
| McClure, I | 2 |
| Ho, V | 1 |
| Tazkarji, B | 1 |
| Auten, B | 1 |
| Treister, R | 1 |
| Eisenberg, E | 1 |
| Demeter, N | 1 |
| Pud, D | 1 |
| Reale, L | 2 |
| Clavenna, A | 2 |
| del Campo, N | 1 |
| Fryer, TD | 1 |
| Hong, YT | 1 |
| Smith, R | 1 |
| Brichard, L | 1 |
| Acosta-Cabronero, J | 1 |
| Chamberlain, SR | 2 |
| Tait, R | 1 |
| Izquierdo, D | 1 |
| Regenthal, R | 1 |
| Dowson, J | 1 |
| Suckling, J | 2 |
| Baron, JC | 1 |
| Aigbirhio, FI | 1 |
| Sahakian, BJ | 10 |
| Müller, U | 2 |
| Hergüner, S | 5 |
| Hennig, O | 1 |
| Reddy, DS | 1 |
| Timimi, S | 1 |
| Brigham, G | 2 |
| Somoza, EC | 4 |
| Seth, S | 2 |
| Currie, J | 1 |
| Carpentier, PJ | 2 |
| Cai, E | 1 |
| Jolicoeur, C | 2 |
| Ter-Stepanian, M | 6 |
| Akça, OF | 1 |
| Sharma, A | 1 |
| Couture, J | 1 |
| De Crescenzo, F | 1 |
| Armando, M | 1 |
| Mazzone, L | 1 |
| Ciliberto, M | 1 |
| Sciannamea, M | 1 |
| Figueroa, C | 1 |
| Janiri, L | 1 |
| Quested, D | 1 |
| Gahr, M | 1 |
| Freudenmann, RW | 1 |
| Kölle, MA | 1 |
| Schönfeldt-Lecuona, C | 1 |
| Blader, JC | 5 |
| Kafantaris, V | 3 |
| Foley, CA | 2 |
| Crowell, JA | 1 |
| Carlson, GA | 6 |
| Sauder, CL | 1 |
| Margulies, DM | 1 |
| Sinha, C | 1 |
| Sverd, J | 15 |
| Matthews, TL | 2 |
| Bailey, BY | 2 |
| Daviss, WB | 4 |
| Fosi, T | 1 |
| Lax-Pericall, MT | 1 |
| Scott, RC | 1 |
| Neville, BG | 1 |
| Aylett, SE | 1 |
| Wu, CL | 1 |
| Hwang, FM | 1 |
| Young, KB | 1 |
| Tsai, MH | 2 |
| Chu, SM | 1 |
| Bange, F | 1 |
| Le Heuzey, MF | 5 |
| Mouren, MC | 4 |
| Ioannidis, K | 1 |
| Serfontein, J | 1 |
| Alegria, AA | 2 |
| Brammer, MJ | 2 |
| Bisgaard, C | 1 |
| Dolina, S | 1 |
| Margalit, D | 1 |
| Malitsky, S | 1 |
| Rabinkov, A | 1 |
| Hoertel, N | 1 |
| Limosin, F | 1 |
| Fox, O | 1 |
| Adi-Japha, E | 1 |
| Karni, A | 3 |
| Mergy, MA | 1 |
| Gowrishankar, R | 1 |
| Davis, GL | 1 |
| Jessen, TN | 1 |
| Wright, J | 1 |
| Stanwood, GD | 1 |
| Hahn, MK | 1 |
| Blakely, RD | 2 |
| Frölich, J | 3 |
| Breuer, D | 13 |
| Görtz-Dorten, A | 5 |
| Amonn, F | 1 |
| Lambert, D | 1 |
| Tvedten, T | 1 |
| Arngrim, T | 4 |
| Carter, K | 2 |
| Chen, CW | 3 |
| Kumar, V | 3 |
| Moreno, A | 2 |
| Duñó, L | 2 |
| Hoekzema, E | 2 |
| Martín, LM | 1 |
| Fauquet, J | 1 |
| Vives-Gilabert, Y | 1 |
| Bulbena, A | 3 |
| Conzelmann, A | 4 |
| Gerdes, AB | 1 |
| Mucha, RF | 3 |
| Weyers, P | 3 |
| Lesch, KP | 7 |
| Bähne, CG | 1 |
| Fallgatter, AJ | 3 |
| Renner, TJ | 3 |
| Pauli, P | 4 |
| Kim, B | 6 |
| Chang, JS | 1 |
| Hwang, JW | 6 |
| Querne, L | 1 |
| Fall, S | 1 |
| Le Moing, AG | 1 |
| Bourel-Ponchel, E | 1 |
| Delignières, A | 1 |
| Simonnot, A | 1 |
| de Broca, A | 1 |
| Gondry-Jouet, C | 1 |
| Boucart, M | 1 |
| Walker, KS | 4 |
| Hoffman, MT | 7 |
| Sever, J | 6 |
| Stephanson, N | 1 |
| Sandqvist, S | 1 |
| Takahashi, N | 1 |
| Koh, T | 1 |
| Tominaga, Y | 1 |
| Saito, Y | 1 |
| Kashimoto, Y | 1 |
| Matsumura, T | 1 |
| Piñeiro-Dieguez, B | 1 |
| Balanzá-Martínez, V | 1 |
| García-García, P | 3 |
| Soler-López, B | 2 |
| Barragán, E | 1 |
| Reddick, WE | 2 |
| Taghipour, DJ | 1 |
| Glass, JO | 1 |
| Ashford, J | 1 |
| Xiong, X | 3 |
| Bonner, M | 2 |
| Khan, RB | 2 |
| Conklin, HM | 2 |
| Newman, DP | 1 |
| Eramudugolla, R | 1 |
| Vance, A | 3 |
| Bron, TI | 2 |
| Boonstra, AM | 5 |
| Breuk, M | 1 |
| Pardoen, WF | 1 |
| Beekman, AT | 2 |
| Kooij, JJ | 14 |
| Ganelin-Cohen, E | 1 |
| Kim, TH | 2 |
| Seo, WS | 1 |
| Shin, DW | 3 |
| Woo, YJ | 1 |
| Yoo, H | 1 |
| Lee, JS | 6 |
| Lim, MH | 1 |
| Chung, YC | 1 |
| Jung, CH | 1 |
| Yoo, HK | 2 |
| Sharpe, K | 1 |
| Shoptaw, S | 1 |
| Nikles, CJ | 6 |
| Lloyd, OT | 1 |
| Agay, N | 2 |
| Findling, RL | 25 |
| Dinh, S | 1 |
| Schouw, ML | 1 |
| Klomp, A | 2 |
| Tamminga, HG | 3 |
| Schrantee, AG | 1 |
| Boer, F | 3 |
| Rijsman, R | 1 |
| Lindauer, RJ | 2 |
| Reitsma, HB | 1 |
| Zhu, J | 3 |
| Lee, KP | 1 |
| Öner, Ö | 2 |
| Yilmaz, EŞ | 1 |
| Karadağ, H | 1 |
| Vural, M | 1 |
| Vural, EH | 1 |
| Akbulat, A | 1 |
| Gürsöz, H | 1 |
| Türkçapar, H | 1 |
| Kerman, S | 1 |
| Yabuki, Y | 1 |
| Shioda, N | 1 |
| Maeda, T | 1 |
| Hiraide, S | 1 |
| Togashi, H | 3 |
| Fukunaga, K | 1 |
| Zhao, XR | 1 |
| Xuan, X | 1 |
| Wang, YJ | 1 |
| Yang, RX | 1 |
| Feldman, HM | 3 |
| Reiff, MI | 1 |
| Salgado, CA | 7 |
| Silva, KL | 5 |
| Vitola, ES | 5 |
| Guimarães-da-Silva, PO | 2 |
| Blaya-Rocha, P | 2 |
| Belmonte-de-Abreu, PS | 1 |
| Bau, CH | 10 |
| Skirrow, C | 2 |
| Tye, C | 1 |
| McLoughlin, G | 2 |
| Rijsdijk, F | 1 |
| Banaschweski, T | 1 |
| Kuntsi, J | 2 |
| Justicia-Martínez, F | 2 |
| Moreno-Madrid, F | 1 |
| Moreno-García, L | 1 |
| León, J | 1 |
| Luna-Del-Castillo, JD | 3 |
| Sugama, M | 3 |
| Ishizaki, A | 3 |
| Roskell, NS | 1 |
| Zimovetz, EA | 2 |
| Kuriyan, AB | 1 |
| Chiang, HL | 3 |
| Ise, E | 1 |
| Wolff Metternich-Kaizman, T | 2 |
| Schürmann, S | 4 |
| Rademacher, C | 2 |
| Sundet, K | 2 |
| Husarova, V | 1 |
| Bittsansky, M | 1 |
| Dobrota, D | 1 |
| Geirs, DP | 1 |
| Halldórsson, M | 4 |
| Bucci, MP | 2 |
| Seassau, M | 1 |
| Larger, S | 1 |
| Bui-Quoc, E | 1 |
| Gerard, CL | 1 |
| Treuer, T | 3 |
| Feng, Q | 1 |
| Desaiah, D | 1 |
| Altin, M | 1 |
| El-Shafei, A | 1 |
| Serebryakova, E | 1 |
| Gado, M | 1 |
| Faries, D | 3 |
| Reinhardt, D | 1 |
| Tarver, J | 1 |
| Daley, D | 1 |
| Golubchik, L | 1 |
| Sever, JM | 1 |
| Elbe, D | 1 |
| Barr, AM | 1 |
| Honer, WG | 1 |
| Procyshyn, RM | 1 |
| Zimmermann, AM | 1 |
| Jene, T | 1 |
| Wolf, M | 1 |
| Görlich, A | 1 |
| Gurniak, CB | 1 |
| Sassoè-Pognetto, M | 1 |
| Witke, W | 1 |
| Friauf, E | 1 |
| Rust, MB | 1 |
| Javelot, H | 1 |
| Glay-Ribau, C | 1 |
| Ligier, F | 1 |
| Weiner, L | 1 |
| Didelot, N | 1 |
| Messaoudi, M | 1 |
| Socha, M | 1 |
| Body-Lawson, F | 1 |
| Kabuth, B | 1 |
| Jordan, CJ | 2 |
| Harvey, RC | 4 |
| Baskin, BB | 1 |
| Hallas, J | 3 |
| Choi, JW | 4 |
| Kang, KD | 3 |
| Jung, HY | 1 |
| Renshaw, PF | 4 |
| Lin, DY | 2 |
| Kratochvil, CJ | 12 |
| Xu, W | 1 |
| Jin, L | 2 |
| D'Souza, DN | 1 |
| Kielbasa, W | 1 |
| Allen, AJ | 6 |
| Yamashita, H | 1 |
| Torisu, H | 1 |
| Takada, Y | 1 |
| Imanaga, H | 1 |
| Matsunaga, M | 1 |
| Ishizaki, Y | 1 |
| Sakai, Y | 1 |
| Yoshida, K | 1 |
| Hara, T | 1 |
| Davies, W | 1 |
| Humby, T | 1 |
| Trent, S | 1 |
| Eddy, JB | 1 |
| Ojarikre, OA | 1 |
| Wilkinson, LS | 1 |
| Benard, V | 1 |
| Guardia, D | 1 |
| Vaiva, G | 1 |
| Comim, CM | 2 |
| Gomes, KM | 3 |
| Réus, GZ | 3 |
| Petronilho, F | 1 |
| Ferreira, GK | 1 |
| Streck, EL | 1 |
| Dal-Pizzol, F | 1 |
| Quevedo, J | 3 |
| Fried, M | 1 |
| Tsitsiashvili, E | 1 |
| Bonneh, YS | 1 |
| Sterkin, A | 1 |
| Wygnanski-Jaffe, T | 1 |
| Epstein, T | 3 |
| Polat, U | 1 |
| Robb, AS | 5 |
| Ercan, E | 1 |
| Tomlinson, A | 1 |
| Grayson, B | 1 |
| Marsh, S | 1 |
| Harte, MK | 1 |
| Barnes, SA | 1 |
| Marshall, KM | 1 |
| Neill, JC | 1 |
| Sohn, A | 1 |
| Noh, M | 1 |
| Gonzalez-Heydrich, J | 5 |
| Hsin, O | 2 |
| Gumlak, S | 1 |
| Kimball, K | 1 |
| Rober, A | 1 |
| Azeem, MW | 1 |
| Hickory, M | 1 |
| Mrakotsky, C | 2 |
| Torres, A | 3 |
| Mezzacappa, E | 1 |
| Bourgeois, B | 2 |
| Meftagh, SD | 1 |
| Najimi, A | 1 |
| Mohammadi, N | 1 |
| Ghanizadeh, A | 12 |
| Rahimi, C | 1 |
| Amini, MM | 1 |
| Tajima-Pozo, K | 1 |
| Ruiz-Manrique, G | 1 |
| Montañes, F | 1 |
| Bink, M | 6 |
| van Nieuwenhuizen, C | 1 |
| Popma, A | 1 |
| Bongers, IL | 1 |
| van Boxtel, GJ | 1 |
| Bubnik, MG | 2 |
| Sjölander, A | 1 |
| Runeson, B | 1 |
| Bédard, AC | 8 |
| Krone, B | 1 |
| Rajwan, E | 1 |
| Lee, WH | 1 |
| Moon, DS | 1 |
| Bahn, GH | 4 |
| Wu, CC | 2 |
| Tsai, YF | 1 |
| Tarko, L | 1 |
| Spencer, T | 24 |
| Pope, A | 1 |
| Grossman, R | 1 |
| McDermott, K | 1 |
| Woodworth, KY | 1 |
| Sugrue, D | 1 |
| Bogner, R | 1 |
| Chéron-Blümel, A | 1 |
| Grall-Bronnec, M | 1 |
| Victorri-Vigneau, C | 1 |
| Péron, E | 1 |
| Bétaud, C | 1 |
| Jolliet, P | 1 |
| Amar, M | 1 |
| Dallos, G | 2 |
| Balázs, J | 4 |
| Verster, JC | 3 |
| Roth, T | 1 |
| Eiland, LS | 1 |
| Bell, EA | 1 |
| Erramouspe, J | 1 |
| Sahin, S | 1 |
| Yuce, M | 1 |
| Alacam, H | 1 |
| Karabekiroglu, K | 1 |
| Say, GN | 1 |
| Salıs, O | 1 |
| Norum, J | 1 |
| Olsen, AI | 1 |
| Nohr, FI | 1 |
| Heyd, A | 1 |
| Totth, A | 1 |
| Ayaz, M | 1 |
| Ayaz, AB | 1 |
| Soylu, N | 1 |
| Yüksel, S | 1 |
| Gandhi, P | 2 |
| Mouri, A | 1 |
| Hoshino, Y | 1 |
| Narusawa, S | 1 |
| Ikegami, K | 1 |
| Mizoguchi, H | 1 |
| Murata, Y | 1 |
| Yoshimura, T | 1 |
| Jerome, L | 7 |
| Garg, J | 1 |
| Arun, P | 1 |
| Chavan, BS | 1 |
| Jensen, LS | 2 |
| Dalhoff, K | 1 |
| Kasahara, Y | 2 |
| Kubo, Y | 2 |
| Imbert, B | 1 |
| Labrune, N | 1 |
| Lancon, C | 1 |
| Simon, N | 2 |
| Warrer, P | 2 |
| Hansen, EH | 3 |
| Katzman, MA | 2 |
| Sternat, T | 1 |
| Blasey, C | 1 |
| Rekshan, W | 1 |
| Rush, AJ | 1 |
| Palmer, DM | 1 |
| Kaplan, C | 1 |
| Awudu, GA | 1 |
| Besag, FM | 2 |
| Beyer von Morgenstern, S | 1 |
| Becker, I | 1 |
| Sinzig, J | 3 |
| Antel, J | 1 |
| Albayrak, Ö | 2 |
| Heusch, G | 1 |
| Hebebrand, J | 4 |
| Kishikawa, Y | 1 |
| Kawahara, Y | 1 |
| Yamada, M | 1 |
| Kaneko, F | 1 |
| Kawahara, H | 1 |
| Nishi, A | 1 |
| Girardi, P | 1 |
| Schwarz, R | 2 |
| Scholz, CJ | 1 |
| Weissflog, L | 1 |
| Schmidt, B | 1 |
| Reichert, S | 2 |
| Volkert, J | 1 |
| Hilscher, M | 1 |
| Gonzales, EL | 1 |
| Barbaresi, WJ | 3 |
| Katusic, SK | 3 |
| Colligan, RC | 3 |
| Weaver, AL | 3 |
| Leibson, CL | 2 |
| Jacobsen, SJ | 3 |
| Fung, DS | 1 |
| Wong, JC | 1 |
| Ng, KH | 1 |
| Cheok, CC | 1 |
| Kiing, JS | 1 |
| Chong, SC | 1 |
| Lou, J | 1 |
| Daniel, ML | 1 |
| Ong, D | 1 |
| Low, C | 1 |
| Aljunied, SM | 1 |
| Choi, PM | 1 |
| Mehrotra, K | 1 |
| Kee, C | 1 |
| Leung, I | 1 |
| Yen, LC | 1 |
| Wong, G | 1 |
| Lee, PY | 1 |
| Chin, B | 1 |
| Ng, HC | 1 |
| Song, IC | 2 |
| Sohn, CH | 2 |
| Goos, V | 1 |
| Bjerregaard, BK | 2 |
| Kortegaard, LS | 1 |
| Patsopoulos, NA | 2 |
| Weiser, M | 2 |
| Johnston, BA | 1 |
| Matthews, K | 4 |
| Steele, JD | 1 |
| Otasowie, J | 1 |
| Ehimare, UP | 1 |
| Smith, CH | 1 |
| Brinson, H | 1 |
| Mulas, F | 2 |
| Roca, P | 1 |
| Ros-Cervera, G | 1 |
| Gandía-Benetó, R | 1 |
| Ortiz-Sánchez, P | 1 |
| Martínez-Serrano, S | 2 |
| Tortosa-Pinto, P | 2 |
| Ruiz-López, A | 2 |
| Casey, BJ | 2 |
| Durston, S | 3 |
| Harrison, BJ | 1 |
| Fornito, A | 1 |
| Kwack, YS | 1 |
| Sohn, SH | 2 |
| Bhang, SY | 3 |
| Choi, HY | 3 |
| Lee, YJ | 3 |
| Kim, SO | 1 |
| Shon, S | 1 |
| Lee, HJ | 1 |
| Choi, JH | 1 |
| Clemow, DB | 1 |
| Walker, DJ | 1 |
| Slama, H | 1 |
| Fery, P | 1 |
| Verheulpen, D | 1 |
| Vanzeveren, N | 1 |
| Van Bogaert, P | 2 |
| Lampert, A | 1 |
| Tesarz, J | 1 |
| Volkert, AK | 1 |
| Wesche, D | 1 |
| Wild, B | 1 |
| Schwab, M | 1 |
| Haefeli, WE | 1 |
| Guertin, J | 1 |
| LeLorier, J | 1 |
| Durand, M | 1 |
| Gow, R | 1 |
| Holbrook, A | 1 |
| Levine, M | 2 |
| Wagner, DJ | 1 |
| Vallerand, IA | 1 |
| McLennan, JD | 1 |
| Haertling, F | 1 |
| Mueller, B | 1 |
| Bilke-Hentsch, O | 1 |
| Farbstein, I | 1 |
| Mansbach-Kleinfeld, I | 1 |
| Auerbach, JG | 1 |
| Ponizovsky, AM | 1 |
| Apter, A | 4 |
| Russo, LJ | 1 |
| Carlqvist, P | 1 |
| Yorbik, O | 2 |
| Mutlu, C | 2 |
| Ozilhan, S | 1 |
| Eryilmaz, G | 1 |
| Isiten, N | 1 |
| Alparslan, S | 1 |
| Saglam, E | 1 |
| Regnart, J | 1 |
| McCartney, J | 1 |
| Schweren, LJ | 3 |
| Hartman, CA | 1 |
| Zwiers, MP | 1 |
| Heslenfeld, DJ | 1 |
| van der Meer, D | 1 |
| Wehmeier, PM | 2 |
| Wrenn, CC | 1 |
| Heitzer, AM | 1 |
| Roth, AK | 1 |
| Nawrocki, L | 1 |
| Valdovinos, MG | 1 |
| de Luis-García, R | 1 |
| Cabús-Piñol, G | 1 |
| Imaz-Roncero, C | 1 |
| Argibay-Quiñones, D | 1 |
| Barrio-Arranz, G | 1 |
| Aja-Fernández, S | 1 |
| Alberola-López, C | 1 |
| Dahl, AA | 1 |
| Martinsen, EW | 1 |
| Klungsøyr, O | 1 |
| Peleikis, DE | 2 |
| Söderlund, GB | 1 |
| Eckernäs, D | 1 |
| Holmblad, O | 1 |
| Bergquist, F | 2 |
| Duda, TA | 1 |
| Casey, JE | 1 |
| McNevin, N | 1 |
| Giana, G | 2 |
| Romano, E | 4 |
| Porfirio, MC | 2 |
| D'Ambrosio, R | 1 |
| Giovinazzo, S | 2 |
| Troianiello, M | 1 |
| Barlocci, E | 1 |
| Travaglini, D | 1 |
| Granstrem, O | 1 |
| Pascale, E | 1 |
| Tarani, L | 1 |
| Laviola, G | 3 |
| Adriani, W | 3 |
| Greenhill, LL | 42 |
| Adjei, A | 3 |
| Stehli, A | 5 |
| Helseth, SA | 1 |
| Onyango, AN | 5 |
| Wymbs, FA | 1 |
| Nichols-Lopez, K | 1 |
| Maia, CR | 3 |
| Caye, A | 2 |
| Deakin, TK | 1 |
| Polanczyk, CA | 2 |
| Man, KK | 1 |
| Douglas, I | 2 |
| Leung, LP | 1 |
| Tsui, MS | 1 |
| Wong, WH | 1 |
| Chen, CK | 7 |
| Wassef, N | 1 |
| Khan, N | 1 |
| Munir, S | 1 |
| Gow, RV | 1 |
| Hibbeln, JR | 1 |
| Parletta, N | 1 |
| Peles, E | 1 |
| Schreiber, S | 1 |
| Linzy, S | 1 |
| Domani, Y | 1 |
| Adelson, M | 1 |
| Tekin, U | 1 |
| Soyata, AZ | 1 |
| Oflaz, S | 1 |
| Belmonte-de-Abreu, P | 6 |
| Prada, P | 1 |
| Nicastro, R | 1 |
| Zimmermann, J | 1 |
| Hasler, R | 1 |
| Aubry, JM | 2 |
| van Avendonk, MJ | 1 |
| Hassink-Franke, LJ | 1 |
| Stijntjes, F | 1 |
| Wiersma, T | 1 |
| Burgers, JS | 1 |
| Guerro-Prado, D | 1 |
| Mardomingo-Sanz, ML | 1 |
| Ortiz-Guerra, JJ | 1 |
| Mikolajczyk, R | 1 |
| Horn, J | 1 |
| Schmedt, N | 1 |
| Langner, I | 4 |
| Lindemann, C | 3 |
| Garbe, E | 4 |
| Jacobsson, L | 1 |
| Hägglöf, B | 1 |
| Schawo, S | 1 |
| van der Kolk, A | 2 |
| Bouwmans, C | 1 |
| Annemans, L | 2 |
| Postma, M | 1 |
| van Agthoven, M | 3 |
| Hakkaart-van Roijen, L | 1 |
| Hodgkins, PS | 1 |
| Kahle, JS | 1 |
| Erder, MH | 3 |
| Marshall, SW | 2 |
| Gaynes, BN | 2 |
| Haynes, K | 2 |
| Naftel, AJ | 2 |
| Dalhoff, KP | 1 |
| Lufi, D | 3 |
| Bassin-Savion, S | 1 |
| Rubel, L | 1 |
| Švab, V | 2 |
| Munda, B | 1 |
| Hagino, Y | 2 |
| Sato, A | 1 |
| Takahashi, T | 1 |
| Nagasawa, SY | 1 |
| Mizuguchi, M | 1 |
| Terkel-Dawer, R | 1 |
| Chen, YJ | 2 |
| Lo, YC | 1 |
| Tseng, WY | 2 |
| Greenhill, L | 16 |
| Kocher, J | 1 |
| Adams, P | 1 |
| Gazer-Snitovsky, M | 1 |
| Brand-Gothelf, A | 2 |
| Dubnov-Raz, G | 2 |
| Librero, J | 1 |
| Izquierdo-María, R | 1 |
| García-Gil, M | 1 |
| Peiró, S | 1 |
| Shakibaei, F | 1 |
| Radmanesh, M | 1 |
| Salari, E | 1 |
| Mahaki, B | 1 |
| van der Marel, K | 1 |
| Bouet, V | 1 |
| Meerhoff, GF | 1 |
| Freret, T | 1 |
| Boulouard, M | 1 |
| Dauphin, F | 1 |
| Homberg, JR | 1 |
| Dijkhuizen, RM | 1 |
| Ishii-Takahashi, A | 1 |
| Takizawa, R | 1 |
| Nishimura, Y | 1 |
| Kawakubo, Y | 1 |
| Hamada, K | 1 |
| Okuhata, S | 1 |
| Kawasaki, S | 1 |
| Kuwabara, H | 1 |
| Shimada, T | 1 |
| Todokoro, A | 1 |
| Igarashi, T | 1 |
| Watanabe, K | 1 |
| Yamasue, H | 1 |
| Kato, N | 1 |
| Kasai, K | 1 |
| Kano, Y | 1 |
| Kieling, RR | 2 |
| Palmini, AL | 2 |
| Neeman, R | 1 |
| Mimouni-Bloch, A | 1 |
| Stegmann, B | 1 |
| Rexroth, CA | 1 |
| Wenzel-Seifert, K | 1 |
| Haen, E | 2 |
| Koyuncu, A | 1 |
| Çelebi, F | 1 |
| Ertekin, E | 1 |
| Kahn, DA | 1 |
| Shin, SM | 1 |
| Shin, HN | 1 |
| Park, BJ | 2 |
| van der Voet, M | 1 |
| Harich, B | 1 |
| Schenck, A | 1 |
| Hu, LY | 1 |
| Lin, YL | 1 |
| Chang, HS | 1 |
| Lu, T | 1 |
| Lin, WS | 1 |
| Bonne, O | 1 |
| Abramowitz, EG | 1 |
| Reimherr, FW | 16 |
| Marchant, BK | 10 |
| Gift, TE | 2 |
| Steans, TA | 2 |
| Wender, PH | 15 |
| Bruxel, EM | 2 |
| Salatino-Oliveira, A | 3 |
| Akutagava-Martins, GC | 1 |
| Tovo-Rodrigues, L | 1 |
| Genro, JP | 9 |
| Zeni, CP | 4 |
| Chazan, R | 4 |
| Schmitz, M | 4 |
| Arcos-Burgos, M | 2 |
| Hutz, MH | 15 |
| Verkuijl, N | 1 |
| Perkins, M | 1 |
| Fazel, M | 2 |
| Caballero, B | 1 |
| Anderson, CS | 1 |
| Sikirica, V | 3 |
| von Kieseritzky, K | 1 |
| Katayama, K | 1 |
| Yamashita, Y | 3 |
| Yatsuga, S | 1 |
| Koga, Y | 1 |
| Matsuishi, T | 3 |
| Wigal, S | 18 |
| Machado, FS | 1 |
| Caetano, SC | 1 |
| Hounie, AG | 1 |
| Scivoletto, S | 1 |
| Muszkat, M | 2 |
| Gattás, IG | 1 |
| Andrade, ÊR | 1 |
| Rosário, MC | 1 |
| Papanikolau, A | 1 |
| Snell, LB | 1 |
| Bakshi, D | 1 |
| Karila, L | 2 |
| Lazzaretto, D | 1 |
| Yershova, K | 1 |
| Abikoff, H | 25 |
| Paykina, N | 2 |
| Riddle, MA | 10 |
| Zwanzger, U | 2 |
| Holtmann, M | 6 |
| Freitag, C | 2 |
| Ihorst, G | 3 |
| Guney, E | 1 |
| Alisik, M | 1 |
| Tunca, H | 1 |
| Tas Torun, Y | 1 |
| Iseri, E | 1 |
| Isik Taner, Y | 1 |
| Cayci, B | 1 |
| Erel, O | 1 |
| Ince Tasdelen, B | 1 |
| Karakaya, E | 1 |
| Oztop, DB | 1 |
| Özayhan, HY | 1 |
| Pan, YL | 1 |
| Huang, LW | 1 |
| Bayram, Ö | 1 |
| Ozbaran, B | 1 |
| Yuzuguldu, O | 1 |
| Atar, B | 1 |
| Aydin, C | 1 |
| Larrañaga-Fragoso, P | 1 |
| Noval, S | 1 |
| Rivero, JC | 1 |
| Boto-de-los-Bueis, A | 1 |
| Fallesen, P | 2 |
| Wildeman, C | 2 |
| Unal, GA | 4 |
| Kenar, AN | 1 |
| Herken, H | 5 |
| Kiroglu, Y | 4 |
| Su, Y | 2 |
| Li, H | 2 |
| Fang, F | 2 |
| Xu, T | 2 |
| Lu, H | 1 |
| Xie, L | 2 |
| Zhuo, J | 1 |
| Qu, J | 1 |
| Lima, J | 1 |
| Berlin, I | 2 |
| Nunes, E | 2 |
| Långström, N | 1 |
| Lindefors, N | 3 |
| Capuano, A | 2 |
| Margari, L | 1 |
| Mizuno, K | 1 |
| Yamazaki, M | 1 |
| Asano, M | 1 |
| Kato, S | 1 |
| Kuriyama, K | 1 |
| Sadato, N | 1 |
| Gurbuz, F | 1 |
| Gurbuz, BB | 1 |
| Celik, GG | 1 |
| Yildirim, V | 1 |
| Ucakturk, SA | 1 |
| Seydaoglu, G | 1 |
| Ucakturk, EM | 1 |
| Topaloglu, AK | 1 |
| Yuksel, B | 1 |
| Boland, F | 1 |
| Galvin, R | 1 |
| Reulbach, U | 1 |
| Motterlini, N | 1 |
| Kelly, D | 2 |
| Bennett, K | 1 |
| Fahey, T | 1 |
| Morein-Zamir, S | 2 |
| Shyu, YC | 7 |
| Yuan, SS | 7 |
| Yang, CJ | 7 |
| Yang, KC | 7 |
| Lee, TL | 7 |
| Chinthapalli, K | 1 |
| Stella, SF | 1 |
| Wagner, F | 1 |
| Pianca, TG | 2 |
| Krieger, FV | 1 |
| Cruz, LN | 1 |
| Alaşehirli, B | 1 |
| Oguz, E | 1 |
| Gokcen, C | 2 |
| Erbagcı, AB | 1 |
| Orkmez, M | 1 |
| Demiryurek, AT | 1 |
| Serrano Grasa, R | 1 |
| Blanco Lago, R | 1 |
| Huete Hernani, B | 1 |
| Pérez Martinez, DA | 1 |
| Mamey, MR | 1 |
| Barbosa-Leiker, C | 1 |
| McPherson, S | 1 |
| Burns, GL | 1 |
| Parks, C | 1 |
| Roll, J | 1 |
| Tagaya, H | 1 |
| Murayama, N | 1 |
| Fukase, Y | 1 |
| Gunes, H | 1 |
| Adaletli, H | 1 |
| Park, SY | 1 |
| Cheon, KA | 8 |
| Alam, N | 1 |
| Najam, R | 1 |
| Khan, SS | 1 |
| Chou, TL | 1 |
| Chia, S | 1 |
| Yang, H | 2 |
| Cheng, D | 1 |
| Cai, X | 1 |
| Signorovitch, J | 1 |
| Xie, J | 2 |
| Alpaslan, AH | 1 |
| Coşkun, KŞ | 1 |
| Kocak, U | 1 |
| Gorücü, Y | 1 |
| Lally, MD | 1 |
| Kral, MC | 1 |
| Boan, AD | 1 |
| Börger, NA | 1 |
| Koerts, J | 1 |
| Thome, J | 1 |
| Safer, DJ | 10 |
| dos Santos Pereira, M | 1 |
| Sathler, MF | 1 |
| Valli, Tda R | 1 |
| Marques, RS | 1 |
| Ventura, AL | 1 |
| Peccinalli, NR | 1 |
| Fraga, MC | 1 |
| Manhães, AC | 1 |
| Kubrusly, R | 1 |
| Untucht, R | 1 |
| Salavert, J | 1 |
| Moreno-Alcázar, A | 1 |
| Caseras, X | 1 |
| Palomar, G | 2 |
| Bosch, R | 7 |
| Salvador, R | 1 |
| McKenna, PJ | 1 |
| Pomarol-Clotet, E | 1 |
| Barkla, XM | 1 |
| McArdle, PA | 1 |
| Newbury-Birch, D | 1 |
| Amyx, ML | 1 |
| Hastings, KB | 1 |
| Reynolds, EJ | 1 |
| Weakley, JA | 1 |
| Dinkel, S | 1 |
| Patzel, B | 1 |
| Schlander, M | 6 |
| Zhong, P | 1 |
| Liu, W | 1 |
| Yan, Z | 2 |
| Bui, Q | 1 |
| Melzer, E | 2 |
| Evans, R | 1 |
| Marcincakova-Husarova, V | 1 |
| Kulhan, T | 1 |
| Chen, CY | 3 |
| Bussing, R | 2 |
| Hartzema, AG | 1 |
| Shuster, JJ | 1 |
| Segal, R | 1 |
| Winterstein, AG | 4 |
| Nilausen, TD | 2 |
| Forsbøl, B | 2 |
| Golmirzaei, J | 1 |
| Mahboobi, H | 1 |
| Yazdanparast, M | 1 |
| Mushtaq, G | 1 |
| Kamal, MA | 1 |
| Hamzei, E | 1 |
| Rasmussen, KB | 1 |
| Zheng, Y | 2 |
| Liang, JM | 1 |
| Gao, HY | 1 |
| Yang, ZW | 1 |
| Jia, FJ | 1 |
| Liang, YZ | 1 |
| Li, R | 2 |
| Xie, SN | 1 |
| Zhuo, JM | 1 |
| Hawkes, N | 1 |
| Frank, E | 1 |
| Ozon, C | 1 |
| Nair, V | 1 |
| Othee, K | 1 |
| Ghosh, M | 1 |
| Holman, CD | 2 |
| Preen, DB | 2 |
| Bardo, MT | 5 |
| Wu, SH | 1 |
| Wang, K | 1 |
| Wang, WQ | 1 |
| Wang, F | 2 |
| Montgomery, W | 1 |
| Janssen, TW | 4 |
| Geladé, K | 5 |
| van Mourik, R | 5 |
| Maras, A | 5 |
| Yun, SW | 1 |
| Chung, U | 1 |
| Park, IH | 1 |
| Bloniecki Kallio, V | 1 |
| Lachaine, J | 1 |
| Mathurin, K | 1 |
| Ji, NY | 1 |
| Mann, A | 1 |
| Li, A | 1 |
| Radwan, K | 1 |
| Karnik, NS | 1 |
| Keenan, K | 1 |
| Corominas, M | 2 |
| Thomas, BL | 1 |
| Viljoen, M | 2 |
| Busardò, FP | 1 |
| Kyriakou, C | 1 |
| Cipolloni, L | 1 |
| Zaami, S | 1 |
| Frati, P | 1 |
| González-Carpio Hernández, G | 1 |
| Serrano Selva, JP | 1 |
| Mulder, R | 1 |
| Hazell, P | 4 |
| Rucklidge, JJ | 1 |
| Malhi, GS | 1 |
| Merrill, RM | 1 |
| Thygerson, SM | 1 |
| Palmer, CA | 1 |
| Woidich, E | 2 |
| Müller, M | 1 |
| Jacob, CP | 2 |
| Owen, M | 1 |
| Wallach Kildemoes, H | 1 |
| Hwang Gu, SL | 1 |
| Barnett, R | 2 |
| Spiegel, S | 1 |
| Renner, T | 2 |
| Schnetzler, L | 1 |
| Stopper, H | 5 |
| Dunlop, AJ | 1 |
| Newman, LK | 1 |
| Daniels, B | 1 |
| Wood, DA | 1 |
| Brett, J | 1 |
| Yarmolovsky, J | 1 |
| Szwarc, T | 1 |
| Schwartz, M | 1 |
| Geva, R | 1 |
| Mercier, C | 2 |
| Roche, S | 1 |
| Gaillard, S | 2 |
| Kassai, B | 2 |
| Arzimanoglou, A | 3 |
| Herbillon, V | 2 |
| Roy, P | 1 |
| Zanetti, M | 1 |
| Didoni, A | 2 |
| Fortinguerra, F | 1 |
| Mondini, M | 1 |
| Bushe, C | 1 |
| Day, K | 1 |
| Reed, V | 1 |
| Karlsdotter, K | 1 |
| Berggren, L | 1 |
| Pitcher, A | 1 |
| Televantou, F | 1 |
| Haynes, V | 1 |
| Grimshaw, DG | 1 |
| Platt, LM | 1 |
| Koch, RL | 1 |
| Huizenga, HM | 1 |
| Battel, L | 1 |
| Kieling, C | 2 |
| Aurich, NK | 1 |
| da Costa, JC | 1 |
| Almqvist, C | 1 |
| DʼOnofrio, BM | 1 |
| Semerci, B | 1 |
| Tufan, E | 1 |
| Şanlı, I | 1 |
| Punja, S | 2 |
| Schmid, CH | 2 |
| Hartling, L | 2 |
| Urichuk, L | 2 |
| Vohra, S | 2 |
| Brovedani, P | 1 |
| Pisano, S | 1 |
| Hegvik, TA | 1 |
| Jacobsen, KK | 1 |
| Zayats, T | 1 |
| Pillidge, K | 1 |
| Porter, AJ | 1 |
| Young, JW | 1 |
| Stanford, SC | 2 |
| Inci Kenar, AN | 3 |
| Güler, H | 1 |
| Albuz, B | 1 |
| Erdal, ME | 2 |
| Chung, J | 1 |
| Tchaconas, A | 1 |
| Meryash, D | 1 |
| Xu, D | 1 |
| Patel, V | 1 |
| Krishna, AS | 1 |
| Lefevre, C | 1 |
| Kaagaza, M | 1 |
| Wittkamp, M | 1 |
| Wong, I | 1 |
| Coghill, DC | 1 |
| Waldon, J | 1 |
| Begum, E | 1 |
| Gendron, M | 2 |
| Rusak, B | 1 |
| Andreou, P | 1 |
| Rajda, M | 1 |
| Corkum, P | 4 |
| Moeller, SJ | 1 |
| Konova, AB | 1 |
| Parvaz, MA | 1 |
| Goldstein, RZ | 1 |
| Fogler, JM | 1 |
| Chermá, MD | 1 |
| Josefsson, M | 1 |
| Rydberg, I | 1 |
| Woxler, P | 1 |
| Trygg, T | 1 |
| Hollertz, O | 1 |
| Gustafsson, PA | 2 |
| Stark, JG | 2 |
| Tengler, M | 1 |
| Sikes, C | 1 |
| Villeneuve, N | 1 |
| Napuri, S | 1 |
| Cances, C | 1 |
| Castelneau, P | 1 |
| Nguyen The Tich, S | 1 |
| Villega, F | 1 |
| Isnard, H | 1 |
| Nabbout, R | 1 |
| Jackson, JW | 1 |
| Salardini, E | 1 |
| Zeinoddini, A | 1 |
| Kohi, A | 1 |
| Mohammadinejad, P | 1 |
| Khiabany, M | 1 |
| Shahriari, M | 1 |
| Beau-Lejdstrom, R | 1 |
| Evans, SJ | 1 |
| Smeeth, L | 1 |
| Bock, J | 2 |
| Breuer, S | 1 |
| Poeggel, G | 1 |
| Braun, K | 2 |
| Pleiter, JC | 1 |
| Schuiling-Veninga, CC | 1 |
| Ludvigsson, M | 1 |
| Haenni, A | 1 |
| Burcu, M | 1 |
| Zito, JM | 4 |
| Metcalfe, L | 1 |
| Underwood, H | 1 |
| Tepeli, E | 1 |
| Lukkes, JL | 1 |
| Freund, N | 1 |
| Thompson, BS | 1 |
| Meda, S | 1 |
| Wenthur, CJ | 1 |
| Huang, TS | 2 |
| Tsai, GE | 1 |
| Lane, HY | 1 |
| Levitt, J | 2 |
| Del'Homme, M | 3 |
| Cowen, J | 3 |
| Sturm, A | 3 |
| Hellemann, G | 3 |
| Sugar, C | 2 |
| Hanada, G | 1 |
| Cho, AL | 1 |
| Walshaw, P | 1 |
| Piacentini, J | 1 |
| Meppelink, R | 1 |
| de Bruin, EI | 1 |
| Bögels, SM | 1 |
| Vélez-Galarraga, R | 1 |
| Guillén-Grima, F | 1 |
| Crespo-Eguílaz, N | 1 |
| Sánchez-Carpintero, R | 1 |
| Park, H | 1 |
| Yu, SL | 1 |
| Jee, S | 1 |
| Song, DH | 5 |
| Im, WY | 1 |
| Kang, J | 1 |
| Cooke, T | 1 |
| So, TY | 1 |
| Demirci, E | 1 |
| Erdogan, A | 2 |
| Dobson-Belaire, W | 1 |
| Charland, K | 1 |
| Le Lorier, J | 1 |
| Kwak, YS | 1 |
| Starr, HL | 11 |
| Ma, YW | 1 |
| Ascher, S | 3 |
| Armstrong, RB | 3 |
| Mutsaerts, HJ | 1 |
| Zwinderman, AH | 1 |
| Groote, IR | 1 |
| Rombouts, SA | 1 |
| Niessen, WJ | 1 |
| Opmeer, BC | 1 |
| Morash-Conway, J | 1 |
| Amado, L | 2 |
| Jarque, S | 1 |
| Ceccato, R | 1 |
| Mahmood, MM | 1 |
| Wright, RA | 1 |
| Kubilis, P | 1 |
| Beard, SM | 1 |
| Bischof, M | 1 |
| Mauskopf, JA | 1 |
| Clarke, AR | 11 |
| Barry, RJ | 11 |
| Baker, IE | 1 |
| McCarthy, R | 11 |
| Selikowitz, M | 11 |
| Savulich, G | 1 |
| Piercy, T | 1 |
| Brühl, AB | 1 |
| Fox, C | 1 |
| Rowe, JB | 1 |
| O'Brien, JT | 1 |
| Yan, CG | 1 |
| Maier, S | 1 |
| Klöppel, S | 1 |
| Killius, C | 1 |
| Rump, M | 1 |
| Niijima-Yaoita, F | 1 |
| Nagasawa, Y | 1 |
| Tsuchiya, M | 1 |
| Arai, Y | 1 |
| Tadano, T | 1 |
| Tan-No, K | 1 |
| Park, JE | 1 |
| Mayseless, N | 1 |
| Lewis, DY | 1 |
| Barnea, Y | 1 |
| Nielsen, B | 1 |
| Ozel-Kizil, ET | 1 |
| Kokurcan, A | 1 |
| Aksoy, UM | 1 |
| Kanat, BB | 1 |
| Sakarya, D | 1 |
| Bastug, G | 1 |
| Colak, B | 1 |
| Altunoz, U | 1 |
| Kirici, S | 1 |
| Demirbas, H | 1 |
| Oncu, B | 2 |
| King, J | 2 |
| Dowling, N | 1 |
| Leow, F | 1 |
| Pitzianti, M | 2 |
| Casarelli, L | 1 |
| Pontis, M | 1 |
| Kaunzinger, I | 1 |
| Soleimani, AA | 1 |
| Ahmadi, N | 1 |
| Davoodi, E | 1 |
| Sinibaldi Vallebona, P | 1 |
| Malpas, C | 1 |
| Gao, J | 1 |
| He, S | 1 |
| Wang, Q | 1 |
| Owens, J | 3 |
| Chang, WW | 2 |
| Kapellen, TM | 1 |
| Reimann, R | 1 |
| Kiess, W | 1 |
| Kostev, K | 1 |
| Reiz, JL | 5 |
| White, CN | 1 |
| Isiten, HN | 1 |
| Cebi, M | 1 |
| Sutcubasi Kaya, B | 1 |
| Ruiz-Ramos, MJ | 2 |
| Ng, QX | 1 |
| Dougherty, DM | 1 |
| Olvera, RL | 3 |
| Acheson, A | 1 |
| Hill-Kapturczak, N | 1 |
| Ryan, SR | 1 |
| Mathias, CW | 1 |
| Greven, P | 1 |
| Curtice, TG | 1 |
| Makin, C | 1 |
| Katic, A | 3 |
| Sirin, DY | 1 |
| Gumustas, SA | 1 |
| Batmaz, AG | 1 |
| Isyar, M | 1 |
| Mahirogullari, M | 1 |
| Emilsson, M | 1 |
| Öhnström, G | 1 |
| Marteinsdottir, I | 1 |
| Pribilova, N | 1 |
| Paclt, I | 3 |
| Kollarova, P | 1 |
| Kohoutova, M | 1 |
| Dezortova, M | 1 |
| Hajek, M | 1 |
| Csemy, L | 1 |
| Lee, YS | 1 |
| Sohn, JH | 1 |
| Keresztény, Á | 2 |
| Ferenczi-Dallos, G | 1 |
| Velő, S | 1 |
| Gádoros, J | 5 |
| Janssen, TWP | 1 |
| Weeda, WD | 1 |
| Melamed, I | 1 |
| Heffron, M | 1 |
| Dose, C | 1 |
| Buerger, M | 1 |
| Schuermann, S | 1 |
| Woitecki, K | 1 |
| Bearss, K | 1 |
| Sarhangian, R | 1 |
| Gillespie, S | 1 |
| Postorino, V | 1 |
| Ekinci, O | 1 |
| Direk, MÇ | 1 |
| Teke, H | 1 |
| Ekinci, N | 1 |
| Yıldırım, F | 1 |
| Okuyaz, Ç | 1 |
| Mohammadpour, N | 1 |
| Jazayeri, S | 2 |
| Djalali, M | 1 |
| Hosseini, M | 1 |
| Davari-Ashtiani, R | 3 |
| Karami, E | 1 |
| Chui, CS | 1 |
| Belchenko, D | 1 |
| Lempa, B | 1 |
| Mutsaerts, H | 1 |
| Tamminga, H | 1 |
| Septier, M | 1 |
| Stough, CK | 1 |
| Anderson, RH | 1 |
| Liu, Q | 1 |
| Zhang, H | 2 |
| Fang, Q | 1 |
| Qin, L | 1 |
| Borenstein, M | 1 |
| Higgins, JP | 1 |
| Hedges, LV | 1 |
| Rothstein, HR | 1 |
| Bhatti, S | 1 |
| Woldbye, DP | 1 |
| Villafuerte-Trisolini, B | 1 |
| Adrianzén-Álvarez, F | 1 |
| Duque, KR | 1 |
| Palacios-García, J | 1 |
| Vizcarra-Escobar, D | 1 |
| Hauser, J | 1 |
| Reissmann, A | 1 |
| Sontag, TA | 2 |
| Bet, PM | 1 |
| Barrière, O | 1 |
| Cheng, J | 1 |
| Liu, A | 2 |
| Shi, MY | 1 |
| Fan, F | 1 |
| Cannon, EN | 1 |
| Cartabuke, RS | 1 |
| Tobias, JD | 1 |
| Rice, J | 1 |
| Tumin, D | 1 |
| de Zeeuw, EL | 1 |
| van Beijsterveldt, CEM | 1 |
| Ehli, EA | 1 |
| de Geus, EJC | 1 |
| Boomsma, DI | 2 |
| Jahangard, L | 1 |
| Akbarian, S | 1 |
| Haghighi, M | 1 |
| Ahmadpanah, M | 1 |
| Keshavarzi, A | 1 |
| Bajoghli, H | 1 |
| Sadeghi Bahmani, D | 1 |
| Holsboer-Trachsler, E | 1 |
| Brand, S | 1 |
| Kutlu, A | 2 |
| Hennissen, L | 1 |
| Bakker, MJ | 1 |
| Ferrara, P | 1 |
| Sannicandro, V | 1 |
| Ianniello, F | 1 |
| Quattrocchi, E | 1 |
| Sbordone, A | 1 |
| Petitti, T | 1 |
| Mariotti, P | 1 |
| Ruiz-Rodado, V | 1 |
| Probert, F | 1 |
| Rausch, TL | 1 |
| Kendall, DL | 1 |
| Kover, ST | 1 |
| Louw, EM | 1 |
| Zsilavecz, UL | 1 |
| Van der Merwe, A | 1 |
| Leung, PW | 2 |
| Chan, JK | 1 |
| Chen, LH | 1 |
| Lee, CC | 1 |
| Hung, SF | 2 |
| Ho, TP | 1 |
| Tang, CP | 1 |
| Moyzis, RK | 1 |
| Huang, YC | 2 |
| Inci, SB | 1 |
| Godfrey, J | 1 |
| Harrison, C | 1 |
| Charles, J | 1 |
| Britt, H | 1 |
| Cox, DJ | 10 |
| Valero, S | 1 |
| Nogueira, M | 2 |
| Gómez, N | 1 |
| Yelmo, S | 1 |
| Ferrer, M | 1 |
| Martínez, Y | 1 |
| Nymark, TB | 1 |
| Hovland, A | 1 |
| Bjørnstad, H | 1 |
| Nielsen, EW | 1 |
| Koesters, M | 1 |
| Becker, T | 2 |
| Kilian, R | 1 |
| Fegert, JM | 3 |
| Weinmann, S | 2 |
| Arabgol, F | 2 |
| Panaghi, L | 1 |
| Hebrani, P | 1 |
| Wohl, M | 2 |
| Orejarena, S | 1 |
| Boni, C | 1 |
| Asch, M | 1 |
| Gorwood, P | 2 |
| Mayes, R | 3 |
| Bagwell, C | 1 |
| Erkulwater, J | 1 |
| Morley, CP | 1 |
| Drtilkova, I | 1 |
| Sery, O | 1 |
| Uhrova, A | 1 |
| Zackova, M | 1 |
| Balastikova, B | 1 |
| Znojil, V | 1 |
| Sengupta, S | 3 |
| Schmitz, N | 3 |
| Schwartz, G | 8 |
| Bellingham, J | 2 |
| Polotskaia, A | 2 |
| Stepanian, MT | 1 |
| Goto, Y | 1 |
| Grace, AA | 1 |
| Rapport, MD | 23 |
| Kofler, MJ | 1 |
| Coiro, MM | 1 |
| Sarver, DE | 1 |
| Alderson, RM | 1 |
| Muniz, R | 13 |
| Brams, M | 9 |
| Mao, A | 3 |
| McCague, K | 4 |
| Pestreich, L | 7 |
| Silva, R | 7 |
| Devilbiss, DM | 1 |
| Berridge, CW | 2 |
| Napierata, L | 1 |
| Brenhouse, HC | 1 |
| Sonntag, KC | 1 |
| Rafalovich, A | 2 |
| Bright, GM | 1 |
| Giblin, J | 3 |
| Borrello, M | 1 |
| Steinhausen, H- | 1 |
| Sergeant, J | 5 |
| Waugh, JL | 1 |
| Miller, VS | 1 |
| Chudnow, RS | 1 |
| Dowling, MM | 1 |
| Karama, S | 2 |
| Ben Amor, L | 2 |
| Ciampi, A | 1 |
| Mbekou, V | 2 |
| Lageix, P | 3 |
| Baron, C | 2 |
| Soeters, HS | 1 |
| Howells, FM | 2 |
| Russell, VA | 4 |
| Mikami, AY | 4 |
| Cox, BS | 1 |
| Coleman, MT | 1 |
| Mahmood, A | 1 |
| Sood, A | 2 |
| Moore, M | 4 |
| Burket, R | 4 |
| Merkel, RL | 10 |
| Thorell, LB | 1 |
| Dahlström, K | 1 |
| Raj, YP | 1 |
| So, CY | 1 |
| Jun, JY | 1 |
| Cho, DY | 2 |
| Gainsbury, S | 1 |
| Pan, XX | 1 |
| Ma, HW | 2 |
| Wan, B | 1 |
| Dai, XM | 1 |
| Dupuy, FE | 2 |
| Pedersen, SJ | 1 |
| Taylor, AF | 1 |
| Kuo, FE | 1 |
| Seitler, BN | 1 |
| Pierce, D | 2 |
| Dixon, CM | 1 |
| Gai, E | 2 |
| Aimac, S | 1 |
| Sharp, WS | 2 |
| Morrison, M | 1 |
| Eckstrand, K | 1 |
| Greenstein, DK | 1 |
| Clasen, LS | 1 |
| Evans, AC | 1 |
| Rapoport, JL | 14 |
| Polanczyk, G | 9 |
| Pelz, R | 1 |
| Kooij, S | 1 |
| van der Meulen, E | 1 |
| Mick, E | 15 |
| Cook, EH | 3 |
| Cormier, E | 1 |
| Schecklmann, M | 2 |
| Hummel, B | 1 |
| Roos, M | 1 |
| von Mering, C | 1 |
| Reichmann, H | 1 |
| Kendall, T | 1 |
| Perez, A | 1 |
| Taylor, C | 1 |
| Harel, Y | 1 |
| Appleboim, N | 1 |
| Lavie, M | 1 |
| Achiron, A | 1 |
| DeVito, EE | 2 |
| Blackwell, AD | 3 |
| Clark, L | 3 |
| Kent, L | 2 |
| Dezsery, AM | 2 |
| Turner, DC | 2 |
| Aitken, MR | 1 |
| Neale, B | 2 |
| Middleton, FA | 3 |
| Soileau, EJ | 1 |
| Ginsberg, ML | 1 |
| Ghuman, JK | 10 |
| Anthony, BJ | 1 |
| Donker, Fv | 1 |
| Riordan, G | 1 |
| Wilmshurst, J | 1 |
| Mendhekar, DN | 2 |
| Daly, MW | 1 |
| Custer, G | 1 |
| McLeay, PD | 1 |
| Witt, KL | 2 |
| Shelby, MD | 1 |
| Itchon-Ramos, N | 1 |
| Faircloth, M | 1 |
| Kissling, GE | 1 |
| Chrisman, AK | 2 |
| Ravi, H | 1 |
| Murli, H | 1 |
| Mattison, DR | 3 |
| Zoroglu, S | 3 |
| Kämpf, K | 2 |
| Artamonov, N | 1 |
| Gnana Oli, R | 1 |
| Wirth, S | 2 |
| Kummer, A | 1 |
| Teixeira, A | 1 |
| Souza, RP | 2 |
| Soares, EC | 1 |
| Rosa, DV | 1 |
| Souza, BR | 1 |
| Valvassori, SS | 2 |
| Inácio, CG | 2 |
| Martins, MR | 2 |
| Gomez, MV | 1 |
| Romano-Silva, MA | 1 |
| Perkins, JS | 1 |
| González, MA | 5 |
| Kobel, M | 2 |
| Bechtel, N | 2 |
| Weber, P | 4 |
| Specht, K | 2 |
| Klarhöfer, M | 2 |
| Scheffler, K | 2 |
| Opwis, K | 2 |
| Penner, IK | 2 |
| Skriboth-Schandl, S | 1 |
| Deutsch, CK | 1 |
| Dube, WV | 1 |
| McIlvane, WJ | 1 |
| Dillo, W | 1 |
| Bessling, S | 1 |
| Emrich, HM | 2 |
| Ohlmeier, MD | 2 |
| Torres-Reveron, A | 1 |
| Gray, JD | 1 |
| Melton, JT | 1 |
| Punsoni, M | 1 |
| Tabori, NE | 1 |
| Ward, MJ | 1 |
| Frys, K | 1 |
| Iadecola, C | 1 |
| Milner, TA | 1 |
| Overtoom, CC | 3 |
| Bekker, EM | 2 |
| van der Molen, MW | 2 |
| Verbaten, MN | 10 |
| Robinson, R | 1 |
| King, S | 3 |
| Frankland, BW | 1 |
| Andrade, BF | 1 |
| Jacques, S | 1 |
| Corkum, PV | 2 |
| Cummings, MR | 1 |
| O'Connor, B | 1 |
| Majumdar, A | 2 |
| Verley, J | 1 |
| Massetti, GA | 1 |
| Arnold, FW | 1 |
| Garefino, AC | 1 |
| Robb, JA | 1 |
| Durukan, I | 1 |
| Türkbay, T | 1 |
| Cöngöloğlu, A | 1 |
| Barron, E | 1 |
| Yang, PB | 1 |
| Swann, AC | 1 |
| Nissley-Tsiopinis, J | 1 |
| Gallagher, R | 2 |
| Zambenedetti, M | 1 |
| Seyffert, M | 1 |
| Boorady, R | 2 |
| McCarthy, J | 2 |
| Koo, MS | 1 |
| Namkoong, K | 1 |
| Thomson, A | 1 |
| Paliokosta, E | 1 |
| Xenitidis, K | 1 |
| Manzke, T | 1 |
| Bock, N | 2 |
| Kawatani, M | 1 |
| Nakai, A | 1 |
| Mayumi, M | 1 |
| Hiratani, M | 2 |
| Chronis-Tuscano, A | 1 |
| Seymour, KE | 3 |
| Jones, HA | 1 |
| Jiles, CD | 1 |
| Rooney, ME | 1 |
| Conlon, CJ | 1 |
| Efron, LA | 1 |
| Wagner, SA | 1 |
| Pian, J | 1 |
| Lahti, TA | 1 |
| Partonen, T | 1 |
| Wagner, KD | 1 |
| Yan, TC | 1 |
| McQuillin, A | 1 |
| Thapar, A | 2 |
| Hunt, SP | 1 |
| Gurling, H | 1 |
| Jacobi-Polishook, T | 1 |
| Shorer, Z | 1 |
| Melzer, I | 1 |
| Adler, LA | 11 |
| Jiang, H | 3 |
| Olfson, M | 5 |
| Marcus, S | 1 |
| Wan, G | 1 |
| Potts, L | 3 |
| de Soysa, R | 1 |
| Williams, T | 3 |
| Ikari, M | 1 |
| Artigas-Pallarés, J | 1 |
| Vaquerizo-Madrid, J | 1 |
| Ramírez-Arenas, M | 1 |
| Cáceres-Marzal, C | 1 |
| Arias-Castro, S | 1 |
| Fernández-Carbonero, M | 1 |
| Valverde-Palomares, R | 1 |
| Valdizán, JR | 1 |
| Izaguerri-Gracia, AC | 1 |
| Andersen, LL | 1 |
| Spencer, SV | 1 |
| Richards, JB | 1 |
| Shiels, K | 5 |
| Oldani, MJ | 1 |
| Dadfarmay, S | 1 |
| Dixon, J | 2 |
| van der Meere, JJ | 1 |
| Shalev, RS | 6 |
| Borger, N | 2 |
| Wiersema, JR | 1 |
| Pires, VA | 2 |
| Pamplona, FA | 2 |
| Pandolfo, P | 2 |
| Fernandes, D | 1 |
| Prediger, RD | 2 |
| Takahashi, RN | 3 |
| Pappadopulos, E | 1 |
| Chait, AR | 1 |
| Chuang, S | 5 |
| Wells, KC | 5 |
| Pelham, W | 3 |
| Cooper, T | 4 |
| Elliott, G | 6 |
| Guimarães, AP | 4 |
| Zeni, C | 4 |
| Roman, T | 10 |
| Thirstrup, S | 1 |
| Hsu, YC | 3 |
| Chen, SJ | 3 |
| Wu, YY | 6 |
| Huang, YF | 4 |
| Cheng, H | 3 |
| Janknegt, R | 1 |
| Faber, A | 4 |
| Rodrigues Pereira, R | 1 |
| Kalverdijk, LJ | 3 |
| Leddy, JJ | 1 |
| Salis, RJ | 1 |
| Paluch, RA | 1 |
| Mahaney, P | 1 |
| Erbe, R | 1 |
| Epstein, LH | 1 |
| Hong, J | 1 |
| Dilla, T | 1 |
| Arellano, J | 1 |
| Garcia, SP | 1 |
| Guimarães, J | 1 |
| Zampieri, JF | 1 |
| Martinez, AL | 1 |
| Maayan, L | 1 |
| Fried, J | 3 |
| Strauss, T | 1 |
| Gugga, SS | 2 |
| Atmaca, M | 1 |
| Ozler, S | 1 |
| Topuz, M | 1 |
| Goldstein, S | 3 |
| Einecke, U | 1 |
| Doyle, R | 8 |
| McCreary, M | 1 |
| Becker, J | 1 |
| Blouin, B | 1 |
| Maddeaux, C | 1 |
| Stanley Firestone, J | 1 |
| Davis, MT | 1 |
| Wilson, HK | 2 |
| Orduña, V | 1 |
| Valencia-Torres, L | 1 |
| Bouzas, A | 1 |
| Zimmerman, B | 3 |
| Silber, S | 2 |
| Palumbo, J | 2 |
| Orman, C | 2 |
| Keen, D | 2 |
| Hadijikoumi, I | 2 |
| Edel, MA | 1 |
| Pfütze, EM | 1 |
| Lieder, A | 1 |
| Assion, HJ | 1 |
| Ribbert, H | 1 |
| Brüne, M | 2 |
| Ponsa, I | 1 |
| Bielsa, A | 2 |
| Ordeig, MT | 1 |
| Morell, M | 1 |
| Miró, R | 1 |
| de Cid, R | 1 |
| Estivill, X | 1 |
| Bayés, M | 1 |
| Hervás, A | 1 |
| Peadon, E | 1 |
| Rhys-Jones, B | 1 |
| Bower, C | 1 |
| Elliott, EJ | 1 |
| Mulder, LJ | 1 |
| Minderaa, RB | 3 |
| Chavez, B | 1 |
| Sopko, MA | 1 |
| Paulino, RE | 1 |
| Goldberg, KR | 1 |
| Angstadt, K | 1 |
| Bogart, GT | 1 |
| Dopheide, JA | 2 |
| Halari, R | 4 |
| Christakou, A | 1 |
| Kaufmann, R | 1 |
| Goldberg-Stern, H | 2 |
| Halevy, A | 1 |
| Campbell, D | 1 |
| Gruber, R | 5 |
| Leventhal, BL | 1 |
| Kaysar, N | 1 |
| Weintraub, M | 1 |
| Daniels, SR | 1 |
| Gerhard, T | 2 |
| Shuster, J | 1 |
| Saidi, A | 1 |
| Taéron, C | 1 |
| Panza, KE | 1 |
| Landeros-Weisenberger, A | 1 |
| Bogle, KE | 1 |
| Vendruscolo, LF | 1 |
| Izídio, GS | 1 |
| Thornhill, S | 1 |
| Lacourse, E | 2 |
| Surman, CB | 3 |
| Adamson, JJ | 1 |
| Kenealy, DC | 1 |
| Dobrovolsky, VN | 1 |
| Boctor, SY | 1 |
| Twaddle, NC | 1 |
| Doerge, DR | 1 |
| Bishop, ME | 1 |
| Manjanatha, MG | 1 |
| Kimoto, T | 1 |
| Miura, D | 1 |
| Heflich, RH | 1 |
| Ferguson, SA | 2 |
| Kuehn, BM | 2 |
| Gutnik, I | 1 |
| Ben-Dor, DH | 2 |
| Tyano, S | 6 |
| Zalsman, G | 6 |
| Lecavalier, L | 2 |
| Gelenberg, A | 1 |
| Wright, R | 1 |
| Rice, S | 1 |
| Ghuman, HS | 4 |
| Fort, C | 1 |
| Lopez, F | 2 |
| Gerstner, O | 1 |
| Thulasiraman, A | 1 |
| Post, A | 1 |
| Ludwig, HT | 2 |
| Matte, B | 1 |
| Katz, B | 2 |
| Li, F | 1 |
| Chen, RH | 2 |
| Mohammad, AM | 3 |
| Mace, FC | 2 |
| Prager, KL | 1 |
| Thomas, K | 1 |
| Kochy, J | 1 |
| Dyer, TJ | 1 |
| Perry, L | 1 |
| Pritchard, D | 3 |
| Ludolph, AG | 2 |
| Kölch, M | 1 |
| Plener, PL | 1 |
| Schulze, UM | 1 |
| Spröber, N | 1 |
| Wolff Metternich, T | 1 |
| Greenfield, SA | 1 |
| McLeod, M | 1 |
| Laubscher, T | 1 |
| Regier, L | 1 |
| Jensen, B | 1 |
| Cheetham, SC | 1 |
| Kuchibhatla, A | 1 |
| Chang, HL | 4 |
| Ko, NC | 1 |
| Niederhofer, H | 4 |
| Lubke, GH | 1 |
| Hudziak, JJ | 1 |
| Derks, EM | 1 |
| van Bijsterveldt, TCEM | 1 |
| Reynolds, B | 1 |
| Mazzullo, RJ | 1 |
| Rhodes, JD | 2 |
| Gangloff, BP | 1 |
| Boellner, SW | 2 |
| Abikoff, HB | 15 |
| Turnbow, JM | 3 |
| Cranswick, N | 1 |
| Salehi, B | 1 |
| Imani, R | 1 |
| Fallah, J | 1 |
| Mohammadi, M | 2 |
| Tasviechi, AA | 1 |
| Vossoughi, A | 1 |
| Rezazadeh, SA | 3 |
| Warton, FL | 1 |
| Poulton, A | 5 |
| Nanan, R | 1 |
| Medori, R | 5 |
| Menegassi, M | 1 |
| Mello, ED | 1 |
| Guimarães, LR | 1 |
| Matte, BC | 2 |
| Driemeier, F | 1 |
| Pedroso, GL | 1 |
| Manos, M | 1 |
| Frazier, TW | 3 |
| Landgraf, JM | 2 |
| LoVecchio, F | 1 |
| Ozimek, J | 1 |
| Sawyers, B | 1 |
| Thole, D | 1 |
| Manganiello, M | 1 |
| Leung, MC | 1 |
| Tietjens, JR | 1 |
| Trinh, T | 1 |
| Baweja, S | 1 |
| Suddath, R | 2 |
| Smalley, SL | 1 |
| Sugar, CA | 1 |
| Coury, D | 2 |
| Utzinger, L | 4 |
| Schillinger, M | 2 |
| Georgiopoulous, A | 1 |
| Doyle, RL | 2 |
| Martelon, M | 3 |
| Brodziak, K | 3 |
| Georgiopoulos, A | 2 |
| Greenbaum, M | 2 |
| Ginsberg, LD | 1 |
| Murphy, WR | 1 |
| Cannon, M | 1 |
| Pelham, WH | 1 |
| Tramontina, S | 2 |
| Ketzer, CR | 1 |
| Pheula, GF | 1 |
| Tutkunkardas, MD | 1 |
| Stauber, J | 1 |
| Schaaff, N | 1 |
| Koutsouleris, N | 1 |
| Scheuerecker, J | 1 |
| Ewers, M | 1 |
| Omerovic, M | 1 |
| Opgen-Rhein, M | 1 |
| Hampel, H | 1 |
| Reiser, M | 1 |
| Möller, HJ | 1 |
| Meisenzahl, E | 1 |
| Ha, EH | 2 |
| Shin, YJ | 1 |
| Bilbow, A | 1 |
| Clifford, S | 1 |
| DeSoysa, R | 1 |
| Planner, C | 1 |
| Schooler, NR | 2 |
| Fung, D | 1 |
| Lee, TS | 1 |
| Brimble, MJ | 1 |
| Hart, T | 2 |
| Whyte, J | 3 |
| Ellis, C | 1 |
| Chervoneva, I | 1 |
| Sousa, NO | 2 |
| Zeni, GD | 1 |
| Roberts, KL | 1 |
| Cahill, JD | 1 |
| Bozzolo, DR | 1 |
| McKay, M | 1 |
| Beckett-Thurman, L | 1 |
| Patel, A | 2 |
| Gürkan, K | 3 |
| Türkoglu, S | 2 |
| Kiliç, BG | 2 |
| Uslu, R | 1 |
| Ptacek, R | 1 |
| Kuzelova, H | 1 |
| Zukov, I | 1 |
| Fischer, S | 1 |
| Moen, MD | 1 |
| Keam, SJ | 1 |
| Janols, LO | 1 |
| Liliemark, J | 1 |
| Klintberg, K | 1 |
| von Knorring, AL | 1 |
| Wang, HR | 1 |
| Paik, KW | 1 |
| Chang, CH | 1 |
| Yang, CF | 1 |
| Tang, GJ | 1 |
| Chan, KH | 1 |
| Ting, CK | 1 |
| Oli, RG | 1 |
| Hill, M | 1 |
| Anney, RJ | 1 |
| May, DE | 1 |
| Cockcroft, K | 1 |
| Ashwal, J | 1 |
| Bentley, A | 1 |
| Solanto, M | 2 |
| Vail, L | 1 |
| Gilbert, S | 1 |
| Lara, R | 1 |
| Atzori, P | 1 |
| Danjou, F | 1 |
| DeBacker, M | 2 |
| Marques, FZ | 1 |
| Bertuzzi, GP | 2 |
| Galland, BC | 2 |
| Tripp, EG | 2 |
| Taylor, BJ | 2 |
| de Jong, MH | 1 |
| Eussen, ML | 1 |
| van Gool, AR | 1 |
| Sanford, ME | 1 |
| Czajkowski, LA | 1 |
| Tomb, DA | 1 |
| McLaren, JL | 1 |
| Cauble, S | 1 |
| Barnett, RJ | 1 |
| Fernández-Mayoralas, DM | 2 |
| Pardos, A | 1 |
| Muñoz Jareño, N | 1 |
| Yoon, IY | 1 |
| Chung, S | 1 |
| Kim, CW | 1 |
| Park, SK | 1 |
| Zhu, HJ | 2 |
| Appel, DI | 1 |
| Peterson, YK | 1 |
| Adler, LD | 1 |
| Nierenberg, AA | 1 |
| Kiefer, F | 1 |
| Diehl, A | 1 |
| Zhou, M | 1 |
| Rebholz, H | 1 |
| Brocia, C | 1 |
| Warner-Schmidt, JL | 1 |
| Fienberg, AA | 1 |
| Nairn, AC | 1 |
| Greengard, P | 1 |
| Flajolet, M | 1 |
| Ruocco, LA | 2 |
| Carnevale, UA | 1 |
| Treno, C | 1 |
| Sadile, AG | 4 |
| Melisi, D | 1 |
| Arra, C | 1 |
| Ibba, M | 2 |
| Schirru, C | 1 |
| Carboni, E | 3 |
| Fettahoglu, EC | 1 |
| Satilmis, A | 1 |
| Ozatalay, E | 1 |
| Stevens, JR | 1 |
| George, RA | 1 |
| Fusillo, S | 2 |
| Stern, TA | 2 |
| van den Ban, E | 2 |
| Souverein, P | 1 |
| Swaab, H | 2 |
| van Engeland, H | 11 |
| Heerdink, R | 1 |
| Egberts, T | 1 |
| Jaffee, WB | 2 |
| Bailey, GL | 2 |
| Riggs, P | 2 |
| McDonald, L | 1 |
| Weiss, RD | 2 |
| Flisher, AJ | 1 |
| Sorsdahl, K | 1 |
| Hatherill, S | 1 |
| Chehil, S | 1 |
| Krause, J | 7 |
| Skrodzki, K | 1 |
| Rothermel, B | 1 |
| Sagvolden, T | 7 |
| Dasbanerjee, T | 1 |
| Walaas, SI | 1 |
| Weissman, J | 2 |
| Ashare, RL | 1 |
| Ellertsen, B | 1 |
| Koneski, JA | 2 |
| Deckert, J | 2 |
| Herpertz, S | 1 |
| Vitaliano, G | 1 |
| Polcari, A | 6 |
| Dyer, C | 1 |
| Gadow, KD | 20 |
| Nolan, EE | 12 |
| Advokat, C | 2 |
| Lang, HC | 1 |
| Scheffler, RM | 2 |
| Hu, TW | 1 |
| Robison, RJ | 4 |
| Olsen, JL | 2 |
| Kondo, DG | 1 |
| Pollak, Y | 2 |
| Shomaly, HB | 1 |
| Weiss, PL | 2 |
| Gross-Tsur, V | 11 |
| Farias, AC | 1 |
| Cunha, A | 1 |
| Benko, CR | 1 |
| Costa, MT | 1 |
| Farias, LG | 1 |
| Cordeiro, ML | 1 |
| Shriki, L | 1 |
| Weizer, M | 1 |
| Yu, ZJ | 1 |
| Parker-Kotler, C | 1 |
| Tran, K | 1 |
| Weller, RA | 2 |
| Weller, EB | 2 |
| Schentag, J | 1 |
| Ballow, CH | 1 |
| Panahon, CJ | 2 |
| Forehand, GL | 2 |
| Tresco, KE | 3 |
| Lopez-Williams, A | 2 |
| Gray, A | 1 |
| Williams, ED | 5 |
| Strong, RE | 5 |
| Halls, C | 4 |
| Soni, P | 4 |
| Gale, PD | 2 |
| Zappitelli, M | 1 |
| Gumy, C | 1 |
| Huissoud, T | 2 |
| Dubois-Arber, F | 2 |
| Stasik, D | 1 |
| Laufkötter, R | 2 |
| Brigham, GS | 1 |
| Liu, DS | 1 |
| Green, CA | 2 |
| Croghan, IT | 2 |
| Leimberger, JD | 2 |
| Lewis, DF | 3 |
| Dorer, EM | 1 |
| Wong, P | 1 |
| Simchon, Y | 1 |
| Rehavi, M | 2 |
| Whitney, J | 3 |
| Waber, D | 1 |
| Forbes, P | 1 |
| Dodds, A | 2 |
| Rao, S | 2 |
| Macmillan, C | 1 |
| Demaso, DR | 1 |
| de Moor, C | 1 |
| Aleardi, M | 6 |
| Kotarski, M | 2 |
| Williams, CG | 1 |
| Uebel, H | 4 |
| Albrecht, B | 2 |
| Kirov, R | 1 |
| Heise, A | 1 |
| Freisleder, FJ | 2 |
| Gerber, WD | 4 |
| Günter, M | 3 |
| Hässler, F | 3 |
| Poustka, F | 5 |
| Bigarella, MP | 1 |
| Shahrbabaki, ME | 1 |
| Razjouyan, K | 1 |
| Amini, H | 2 |
| Mazhabdar, H | 1 |
| Damiani, D | 2 |
| Casella, E | 1 |
| Taylor, N | 1 |
| Fauset, A | 1 |
| McRae-Clark, AL | 1 |
| Brady, KT | 1 |
| Hartwell, KJ | 1 |
| White, K | 1 |
| Carter, RE | 1 |
| Hergüner, AS | 1 |
| Thakur, GA | 2 |
| Schlochtermeier, L | 2 |
| Stoy, M | 2 |
| Schlagenhauf, F | 2 |
| Wrase, J | 2 |
| Park, SQ | 1 |
| Lehmkuhl, U | 4 |
| Heinz, A | 2 |
| Ströhle, A | 2 |
| Kraemer, M | 1 |
| Uekermann, J | 1 |
| Wiltfang, J | 1 |
| Günther, T | 5 |
| Herpertz-Dahlmann, B | 7 |
| Cooper, KM | 3 |
| Karaman, MG | 2 |
| Atalay, F | 1 |
| Szobot, CM | 6 |
| Shih, MC | 2 |
| Hoexter, MQ | 2 |
| Júnior, N | 2 |
| Pechansky, F | 3 |
| Bressan, RA | 2 |
| Tomás Vila, M | 1 |
| Aleu Pérez-Gramunt, M | 1 |
| Beseler Soto, B | 1 |
| Benac Prefasi, M | 1 |
| Pantoja Martínez, J | 1 |
| Pitarch Castellano, I | 1 |
| Monuteaux, MC | 1 |
| Hennessy, S | 1 |
| Schelleman, H | 1 |
| Daniel, GW | 1 |
| Bilker, WB | 1 |
| Kimmel, SE | 1 |
| Guevara, J | 1 |
| Cziraky, MJ | 1 |
| Strom, BL | 1 |
| Roman, MW | 1 |
| Burnside, J | 1 |
| Melmed, R | 1 |
| Volkerts, ER | 1 |
| Olivier, B | 2 |
| Michaelides, M | 1 |
| Pascau, J | 1 |
| Gispert, JD | 2 |
| Delis, F | 1 |
| Grandy, DK | 2 |
| Desco, M | 1 |
| Rubinstein, M | 2 |
| Aguilera-Albesa, S | 1 |
| Yoldi-Petri, ME | 3 |
| Molins-Castiella, T | 1 |
| Durá-Travé, T | 3 |
| Martinson, J | 1 |
| Tang, HY | 1 |
| Murray, DW | 7 |
| Akın, A | 1 |
| Çiftçi, K | 1 |
| Ay, ME | 1 |
| Bicer, D | 1 |
| Bozkurt, OH | 1 |
| Münir, K | 1 |
| Yazgan, Y | 2 |
| Fumagalli, F | 1 |
| Cattaneo, A | 1 |
| Caffino, L | 1 |
| Racagni, G | 1 |
| Gennarelli, M | 1 |
| Riva, MA | 1 |
| Silva, RR | 5 |
| Skimming, JW | 1 |
| Murray, MJ | 1 |
| Boyes, C | 1 |
| Du, M | 1 |
| Zhuang, S | 1 |
| Lepping, P | 1 |
| Huber, M | 2 |
| Lyon, GJ | 1 |
| Samar, SM | 1 |
| Conelea, C | 1 |
| Trujillo, MR | 1 |
| Lipinski, CM | 1 |
| Bauer, CC | 1 |
| Brandt, BC | 1 |
| Kemp, JJ | 1 |
| Lawrence, ZE | 1 |
| Howard, J | 1 |
| Woods, D | 1 |
| Stiefel, G | 1 |
| Buckwalter, M | 1 |
| Webster, K | 1 |
| Brown, JA | 3 |
| Emnett, RJ | 1 |
| White, CR | 1 |
| Yuede, CM | 1 |
| Conyers, SB | 1 |
| O'Malley, KL | 1 |
| Wozniak, DF | 2 |
| Gutmann, DH | 2 |
| Katz-Sagi, H | 1 |
| Redlich, M | 1 |
| Brinsky-Rapoport, T | 1 |
| Matot, I | 2 |
| Ram, D | 1 |
| Drerup, JM | 1 |
| Hayashi, K | 1 |
| Cui, H | 1 |
| Mettlach, GL | 1 |
| Long, MA | 1 |
| Marvin, M | 1 |
| Goldberg, MS | 1 |
| Lutter, M | 1 |
| Bibb, JA | 1 |
| Hazell, PL | 3 |
| Dickson, R | 1 |
| Walton, RJ | 2 |
| Granger, RE | 2 |
| Wyk, GW | 1 |
| Rockhill, C | 1 |
| Althoff, RR | 1 |
| Mrazek, DA | 1 |
| Gamo, NJ | 1 |
| Arnsten, AF | 3 |
| Walter Soria, N | 1 |
| Belaus, A | 1 |
| Galván, C | 1 |
| Ana Pasquali, M | 1 |
| Velez, P | 1 |
| Del Carmen Montes, C | 1 |
| Beltramo, DM | 1 |
| Goetz, M | 2 |
| Akay, A | 1 |
| Herczeg, I | 1 |
| Dobrescu, I | 1 |
| Jin, X | 2 |
| Riley, AW | 1 |
| Martényi, F | 1 |
| Harrison, G | 1 |
| Zarinara, AR | 1 |
| Hazrati, N | 1 |
| Tabrizi, M | 3 |
| Rezaie, F | 1 |
| Sumner, CR | 1 |
| Haynes, VS | 1 |
| Sasané, R | 4 |
| Meijer, W | 1 |
| Fradin, KN | 1 |
| Frandin, KN | 1 |
| Baler, RD | 1 |
| Sawada, M | 1 |
| Tanaka, S | 1 |
| Sadamatsu, M | 1 |
| Koffarnus, MN | 1 |
| Katz, JL | 1 |
| Perry, A | 1 |
| Berger, I | 2 |
| Schubert, I | 1 |
| Köster, I | 1 |
| Lehmkuhl, G | 10 |
| Manos, MJ | 10 |
| Gibbins, C | 1 |
| Rubin, R | 1 |
| Moon, E | 2 |
| Heiser, P | 3 |
| Oehler, KU | 1 |
| Linder, M | 4 |
| Haessler, F | 5 |
| Schmidt, M | 2 |
| Schulte-Markworth, M | 1 |
| Sieder, C | 1 |
| Klatt, J | 2 |
| Tracik, F | 1 |
| Turner, CA | 1 |
| Xie, D | 1 |
| Zimmerman, BM | 1 |
| Calarge, CA | 1 |
| Rowles, BM | 1 |
| Totman, JJ | 1 |
| Ermer, JC | 1 |
| Adeyi, BA | 1 |
| Pucci, ML | 1 |
| Netson, KL | 1 |
| Ashford, JM | 1 |
| Kahalley, LS | 1 |
| Cerqueira, CC | 1 |
| Polina, ER | 1 |
| Pålsson, E | 1 |
| Söderlund, G | 1 |
| Klamer, D | 1 |
| Eikeland, T | 1 |
| Berry, KJ | 2 |
| Johnston, JE | 1 |
| Mielke, PW | 1 |
| Jhung, K | 1 |
| David, S | 2 |
| Trovero, F | 2 |
| Henin, A | 1 |
| Moore, CM | 1 |
| Sen, S | 1 |
| Deaciuc, A | 1 |
| Scherag, A | 2 |
| dela Peńa, IC | 1 |
| Ahn, HS | 1 |
| Choi, JY | 1 |
| Yildiz, O | 1 |
| Sismanlar, SG | 1 |
| Memik, NC | 1 |
| Karakaya, I | 1 |
| Agaoglu, B | 1 |
| Moavero, R | 1 |
| Negrao, BL | 1 |
| Bipath, P | 1 |
| van der Westhuizen, D | 1 |
| Chae, S | 1 |
| Steinberg-Epstein, R | 1 |
| Dejonckheere, J | 5 |
| van Oene, JC | 2 |
| Schäuble, B | 10 |
| Trott, GE | 6 |
| Cooper, K | 2 |
| Berwaerts, J | 4 |
| Harrison, DD | 1 |
| Comstock, EJ | 1 |
| Scherag, S | 1 |
| Barth, N | 1 |
| Hinney, A | 1 |
| Volpe, RJ | 1 |
| Briesch, AM | 1 |
| Langberg, JM | 2 |
| Narad, ME | 1 |
| Antonini, TN | 1 |
| Simon, JO | 1 |
| Dietrich, K | 1 |
| Börner, J | 1 |
| Neraal, T | 2 |
| Rigau, D | 1 |
| Vidal, X | 1 |
| Souverein, PC | 1 |
| Egberts, TC | 1 |
| Heerdink, ER | 2 |
| Reichl, S | 1 |
| Lange, KM | 1 |
| Hurt, RD | 2 |
| Ebbert, JO | 1 |
| Schroeder, DR | 1 |
| Hays, JT | 1 |
| Kaplan, G | 1 |
| van Wyk, GW | 1 |
| Knutson, B | 1 |
| Wilner, N | 1 |
| Kazemi, MR | 1 |
| Zia, E | 1 |
| Tobaiqy, M | 1 |
| Stewart, D | 1 |
| Helms, PJ | 1 |
| Williams, J | 1 |
| Crum, J | 1 |
| Steer, C | 1 |
| McLay, J | 1 |
| Niimi, K | 1 |
| Nishioka, C | 1 |
| Miyamoto, T | 1 |
| Takahashi, E | 1 |
| Miyoshi, I | 1 |
| Itakura, C | 1 |
| Yamashita, T | 1 |
| Acosta, MT | 2 |
| McNiel, AD | 1 |
| Muzzin, KB | 1 |
| DeWald, JP | 1 |
| McCann, AL | 1 |
| Schneiderman, ED | 1 |
| Scofield, J | 1 |
| Campbell, PR | 1 |
| Foreman, DM | 1 |
| Morton, S | 1 |
| Prehn-Kristensen, A | 1 |
| Krauel, K | 1 |
| Hinrichs, H | 1 |
| Fischer, J | 1 |
| Malecki, U | 1 |
| Schuetze, H | 1 |
| Wolff, S | 1 |
| Jansen, O | 1 |
| Duezel, E | 1 |
| Baving, L | 1 |
| Hsiao, CC | 3 |
| Chiang, YL | 2 |
| Ree, SC | 1 |
| Wu, YW | 1 |
| Shang, ZY | 2 |
| Gray, KM | 1 |
| Riggs, PD | 4 |
| Min, SJ | 2 |
| Mikulich-Gilbertson, SK | 2 |
| Bandyopadhyay, D | 1 |
| Li, JJ | 1 |
| Li, ZW | 1 |
| Wang, SZ | 1 |
| Qi, FH | 1 |
| Zhao, L | 1 |
| Lv, H | 1 |
| Li, AY | 1 |
| Fernández-Fernández, MA | 1 |
| Rufo-Campos, M | 1 |
| Mateos-Checa, R | 1 |
| Muñoz-Cabello, B | 1 |
| Madruga-Garrido, M | 1 |
| Blanco-Martínez, B | 1 |
| Keating, GM | 8 |
| Gómez-Caicoya, A | 1 |
| Jareño, NM | 1 |
| Arroyo-González, R | 1 |
| Gerwe, M | 2 |
| Stollhoff, K | 3 |
| Mossakowski, J | 1 |
| Kuehle, HJ | 1 |
| Goertz, U | 1 |
| Schaefer, C | 1 |
| Bogdanow, M | 1 |
| Heger, S | 3 |
| Medina, JA | 1 |
| Netto, TL | 1 |
| Medina, AC | 1 |
| Botter, D | 1 |
| Orbetelli, R | 1 |
| Scaramuzza, LF | 1 |
| Sinnes, EG | 1 |
| Vilela, M | 1 |
| Miranda, MC | 1 |
| López-Muñoz, F | 2 |
| Alamo, C | 2 |
| Loro, M | 1 |
| García-Campos, N | 1 |
| Baier, M | 1 |
| Rubio, B | 1 |
| Hernández, S | 1 |
| Verche, E | 1 |
| Martín, R | 1 |
| González-Pérez, P | 1 |
| Williamson, D | 3 |
| Armstrong, R | 1 |
| Britton, GB | 1 |
| Chelonis, JJ | 2 |
| Johnson, TA | 1 |
| Kubacak, B | 1 |
| Edwards, MC | 2 |
| Paule, MG | 2 |
| Niederkirchner, K | 2 |
| Slawik, L | 2 |
| Wermelskirchen, D | 1 |
| Rettig, K | 4 |
| Natali, F | 1 |
| Pradel, V | 1 |
| Reggio, P | 1 |
| Coudert, H | 1 |
| Guilleminault, C | 2 |
| Schuck, S | 1 |
| Meijer, WM | 1 |
| Won, H | 1 |
| Mah, W | 1 |
| Hahm, EK | 1 |
| Kim, MH | 1 |
| Cho, S | 1 |
| Jang, H | 1 |
| Seo, J | 1 |
| Jeong, J | 1 |
| Choi, SY | 1 |
| Kang, C | 1 |
| Jardin, B | 2 |
| Looby, A | 1 |
| Earleywine, M | 1 |
| Borowski, C | 1 |
| Pianca, T | 1 |
| Ludwig, H | 1 |
| Hidas, A | 1 |
| Noy, AF | 1 |
| Birman, N | 1 |
| Shapira, J | 1 |
| Steinberg, D | 1 |
| Moskovitz, M | 1 |
| March, JS | 9 |
| Marcus, SC | 5 |
| Durkin, M | 1 |
| Adamou, M | 1 |
| Niemelä, A | 2 |
| Dejonkheere, J | 2 |
| van Oene, J | 1 |
| Alloway, TP | 1 |
| Agertt, F | 1 |
| Ferreira, MG | 1 |
| Sequi, M | 1 |
| Callegari-Jacques, SM | 1 |
| Segal, S | 1 |
| Khayrallah, M | 1 |
| Wooters, TE | 1 |
| Lv, XZ | 1 |
| Shu, Z | 1 |
| Zhang, YW | 1 |
| Wu, SS | 1 |
| Zhan, SY | 1 |
| Jawad, AF | 1 |
| Clarke, AT | 1 |
| Power, TJ | 4 |
| Vansickel, AR | 1 |
| Glaser, PE | 1 |
| Poole, MM | 1 |
| Bidwell, LC | 1 |
| Jain, M | 1 |
| Vélez, JI | 1 |
| Palacio, LG | 1 |
| Balog, J | 1 |
| Roessler, E | 1 |
| Pineda, D | 1 |
| Londoño, AC | 1 |
| Palacio, JD | 1 |
| Arbelaez, A | 1 |
| Lopera, F | 1 |
| Elia, J | 15 |
| Hakonarson, H | 1 |
| Seitz, C | 1 |
| Palmason, H | 1 |
| Meyer, J | 1 |
| Hemminger, U | 1 |
| Romanos, J | 1 |
| Bailey-Wilson, JE | 1 |
| Muenke, M | 1 |
| Franke, AG | 1 |
| Konrad, A | 1 |
| Lieb, K | 1 |
| Banerjee, J | 1 |
| Bhojani, S | 1 |
| Emcy, N | 1 |
| Croghan, I | 1 |
| Adler, L | 2 |
| Eysbouts, Y | 1 |
| Salmelainen, P | 1 |
| Hellwig-Brida, S | 1 |
| Daseking, M | 1 |
| Keller, F | 1 |
| Petermann, F | 5 |
| Goldbeck, L | 1 |
| Gupta, S | 7 |
| Heverin, E | 1 |
| Yeh, HH | 2 |
| Chen, KH | 1 |
| Chang, IS | 2 |
| Wu, EC | 2 |
| Lin, KM | 2 |
| Schaldecker, M | 1 |
| Aucktor, S | 1 |
| Brast, J | 1 |
| Kirchgässner, K | 1 |
| Mühlberger, A | 1 |
| Hoza, B | 15 |
| Sams, SE | 3 |
| Vallano, G | 3 |
| Carter, RL | 1 |
| Chambry, J | 1 |
| Billard, C | 1 |
| Guinard, M | 1 |
| Lacaze, E | 1 |
| Idiart, ME | 1 |
| Delteil-Pinton, F | 1 |
| Cohen de Lara, A | 1 |
| Song, SH | 1 |
| Lloyd, A | 1 |
| Dewilde, S | 1 |
| Falconer, S | 1 |
| Sonuga Barke, E | 1 |
| Hariri, AR | 1 |
| Heinzerling, LM | 1 |
| Pichler, W | 1 |
| Anliker, MD | 1 |
| Wolff, C | 1 |
| Alfred, A | 1 |
| Lindermüller, A | 1 |
| Mattejat, F | 2 |
| Zardoya-Santos, P | 2 |
| Hofecker, M | 1 |
| Waechter, S | 2 |
| Prins, PJ | 5 |
| Emmelkamp, PM | 4 |
| Tanidir, C | 1 |
| Gerber-von Müller, G | 2 |
| Andrasik, F | 1 |
| Niederberger, U | 1 |
| Siniatchkin, M | 1 |
| Kowalski, JT | 1 |
| Petermann, U | 4 |
| Millichap, JG | 8 |
| Millichap, JJ | 1 |
| Stack, CV | 1 |
| Davies, RD | 2 |
| Mikulich-Gilbertson, S | 1 |
| Klein, C | 2 |
| Macdonald, M | 1 |
| Haynes, L | 1 |
| Haminton, N | 1 |
| Hodgkins, C | 1 |
| Whitmore, E | 1 |
| Trello-Rishel, K | 3 |
| Tamm, L | 4 |
| Acosta, MC | 1 |
| Royer-Malvestuto, C | 1 |
| Subramaniam, G | 2 |
| Fishman, M | 1 |
| Holmes, BW | 1 |
| Kaye, ME | 1 |
| Vargo, MA | 1 |
| Woody, GE | 1 |
| Liu, D | 1 |
| Warden, D | 1 |
| Ensat, F | 1 |
| Edelbauer, M | 1 |
| Wechselberger, G | 1 |
| Marusich, JA | 2 |
| Beckmann, JS | 2 |
| Gipson, CD | 3 |
| Walter, D | 1 |
| Agster, KL | 1 |
| Clark, BD | 1 |
| Shumsky, JS | 1 |
| Wang, HX | 1 |
| Waterhouse, BD | 2 |
| Kordon, A | 1 |
| Kim, H | 1 |
| Heo, HI | 1 |
| Kim, DH | 1 |
| Ko, IG | 1 |
| Lee, SS | 1 |
| Kim, SE | 1 |
| Kim, BK | 1 |
| Kim, TW | 1 |
| Ji, ES | 1 |
| Kim, JD | 1 |
| Choi, YW | 1 |
| Kim, CJ | 1 |
| Schneider, MK | 1 |
| Gougleris, G | 1 |
| Verhoeven, WM | 1 |
| Tulen, JH | 1 |
| Zoratto, F | 1 |
| Diggs-Andrews, KA | 1 |
| Mach, RH | 1 |
| Barner, JC | 2 |
| Khoza, S | 1 |
| Oladapo, A | 1 |
| Christensen, L | 1 |
| Harley, C | 1 |
| Liu, F | 1 |
| Chambers, NA | 1 |
| Pascoe, E | 1 |
| Kaplanian, S | 1 |
| Forsyth, I | 1 |
| McCuddy, WT | 1 |
| Shuai, L | 2 |
| Chan, RC | 1 |
| Nick, TG | 1 |
| Melguizo Castro, MS | 1 |
| Graham, AJ | 1 |
| Kahn, RS | 1 |
| Sonne, S | 1 |
| Byreddy, S | 1 |
| Moungnoi, P | 1 |
| Maipang, P | 1 |
| Green, T | 2 |
| Avda, S | 1 |
| Dotan, I | 2 |
| Zarchi, O | 2 |
| Basel-Vanagaite, L | 1 |
| Kang, SG | 1 |
| Hanwella, R | 1 |
| Senanayake, M | 1 |
| de Silva, V | 1 |
| Damaraju, CV | 2 |
| Schwarzman, L | 1 |
| O'Neill, J | 1 |
| Yoon, SY | 1 |
| Lee, JC | 2 |
| dela Peña, JB | 1 |
| Sohn, AR | 2 |
| Qin, J | 1 |
| Wang, LW | 1 |
| Zou, LP | 1 |
| Jin, XM | 1 |
| Qi, YL | 1 |
| Gong, ME | 1 |
| Yin, QY | 1 |
| Mai, JN | 1 |
| Jing, J | 1 |
| Luo, XY | 1 |
| Li, HB | 1 |
| Kuang, GF | 1 |
| Yi, MJ | 1 |
| Zhu, XH | 1 |
| Yao, YB | 1 |
| Monden, Y | 1 |
| Dan, H | 1 |
| Nagashima, M | 1 |
| Dan, I | 1 |
| Kyutoku, Y | 1 |
| Okamoto, M | 1 |
| Yamagata, T | 1 |
| Momoi, MY | 1 |
| Watanabe, E | 1 |
| van der Vorst, E | 1 |
| Wilson, Z | 1 |
| La Porta, LS | 1 |
| Algon, SA | 1 |
| Prowler, ML | 1 |
| Cartwright, ST | 1 |
| McKenna, PA | 1 |
| Laracy, S | 1 |
| Takeda, T | 1 |
| Borgmann-Winter, K | 1 |
| Waldman, ID | 3 |
| Charney, E | 1 |
| Aryal, S | 1 |
| Sable, C | 1 |
| Weinberger, R | 1 |
| Diamond, A | 1 |
| Berant, M | 1 |
| Hirschfeld, L | 1 |
| Frisch, A | 2 |
| Nahshoni, E | 2 |
| Glazer, J | 1 |
| Strasberg, B | 1 |
| Imbar, S | 1 |
| Shoval, G | 1 |
| Chen, YH | 2 |
| Lin, XX | 1 |
| Chen, H | 1 |
| Liu, YY | 1 |
| Lin, GX | 1 |
| Wei, LX | 1 |
| Hong, YL | 1 |
| Rickards, H | 1 |
| Cavanna, AE | 1 |
| Worrall, R | 1 |
| Gallinas-Victoriano, F | 1 |
| De Benedictis, L | 1 |
| Dumais, A | 1 |
| Landry, P | 1 |
| Baack, J | 1 |
| Malcherek, S | 1 |
| Erbe, K | 1 |
| Blom, JD | 1 |
| Schmitt-Mechelke, T | 1 |
| Capone, A | 1 |
| Wang, YC | 1 |
| Hsu, CD | 1 |
| Yang, PC | 2 |
| Liu, HJ | 2 |
| Liu, SI | 1 |
| Pan, CH | 2 |
| Huang, CF | 2 |
| Liu, HC | 1 |
| Treceño, C | 1 |
| Martín Arias, LH | 1 |
| Sáinz, M | 1 |
| Salado, I | 1 |
| García Ortega, P | 1 |
| Velasco, V | 1 |
| Jimeno, N | 1 |
| Escudero, A | 1 |
| Velasco, A | 1 |
| Carvajal, A | 1 |
| Wigal, TL | 2 |
| Telang, FW | 1 |
| Howland, RH | 1 |
| Huang, C | 1 |
| Allison, PD | 1 |
| Kimko, H | 1 |
| Gibiansky, E | 1 |
| Gibiansky, L | 1 |
| Massarella, J | 1 |
| Wiegand, F | 1 |
| Batra, AS | 1 |
| Alexander, ME | 1 |
| Silka, MJ | 1 |
| Lewis, H | 1 |
| Lewis, J | 1 |
| Duerden, EG | 1 |
| Tannock, R | 16 |
| Dockstader, C | 1 |
| Störk, D | 1 |
| Louzã, MR | 1 |
| de Oliveira, IR | 1 |
| Rocha, FL | 1 |
| Morris, SM | 1 |
| Petibone, DM | 1 |
| Lin, WJ | 1 |
| Chen, JJ | 1 |
| Brault, MC | 1 |
| Schmitt, K | 1 |
| Gold, A | 1 |
| Rauch, WA | 1 |
| Kahraman-Lanzerath, B | 1 |
| Knospe, EL | 1 |
| Davis, M | 1 |
| Singh, H | 1 |
| Yu, L | 1 |
| Wang, YW | 1 |
| Wang, JM | 1 |
| Yang, LJ | 1 |
| Lei, GF | 1 |
| Chalita, PJ | 1 |
| Vidal, R | 1 |
| Prats, L | 1 |
| Idiazábal-Alecha, MA | 2 |
| Kosno, M | 1 |
| Bruggisser, M | 1 |
| Bodmer, M | 1 |
| Liechti, ME | 1 |
| Mlynarova, E | 1 |
| Krsek, P | 1 |
| Ruwald, MH | 1 |
| Ruwald, AC | 1 |
| Tønder, N | 1 |
| Trujillo-Orrego, N | 1 |
| Ibáñez, A | 1 |
| Pineda, DA | 1 |
| Kang, H | 1 |
| Duong, S | 1 |
| Chung, K | 1 |
| Lee, HL | 1 |
| Woo, TS | 1 |
| Lee, HC | 1 |
| Huang, WS | 1 |
| Lo, MC | 1 |
| Chang, CJ | 1 |
| Ma, KH | 1 |
| Shyu, JF | 1 |
| Vergouwen, T | 1 |
| Gorissen-Van Eenige, M | 1 |
| Mines, MA | 1 |
| Jope, RS | 1 |
| Glintborg, D | 1 |
| Moreno, SI | 1 |
| Goez, HR | 1 |
| Scott, O | 1 |
| Nevo, N | 1 |
| Bennett-Back, O | 1 |
| Strand, MT | 1 |
| Bubnik, M | 1 |
| Grau-López, L | 1 |
| Roncero, C | 1 |
| Navarro, MC | 1 |
| Lakić, A | 1 |
| Lange, M | 1 |
| Norton, W | 1 |
| Coolen, M | 1 |
| Chaminade, M | 1 |
| Merker, S | 1 |
| Proft, F | 1 |
| Schmitt, A | 1 |
| Vernier, P | 1 |
| Bally-Cuif, L | 1 |
| Weisler, RH | 1 |
| Pandina, GJ | 1 |
| Daly, EJ | 1 |
| Gassmann-Mayer, C | 1 |
| Hirvikoski, T | 1 |
| Grann, M | 1 |
| Lung, FW | 1 |
| Chiou, SS | 2 |
| Fuh, JL | 1 |
| Signorovitch, JE | 1 |
| Parikh, K | 1 |
| Betts, KA | 1 |
| Wu, EQ | 2 |
| Chen, YS | 1 |
| Lin, CC | 1 |
| Tang, CS | 3 |
| Hou, PH | 1 |
| Hwang, KL | 1 |
| Chan, CH | 1 |
| Kelly, BD | 1 |
| Lundon, DJ | 1 |
| McGuinness, D | 1 |
| Brady, CM | 1 |
| Klassen, LJ | 1 |
| Bilkey, TS | 1 |
| Chokka, P | 1 |
| Ghasri, P | 1 |
| Gattu, S | 1 |
| Saedi, N | 1 |
| Ganesan, AK | 1 |
| Ishisaka, M | 1 |
| Kakefuda, K | 1 |
| Oyagi, A | 1 |
| Ono, Y | 1 |
| Tsuruma, K | 1 |
| Shimazawa, M | 1 |
| Kitaichi, K | 1 |
| Hara, H | 2 |
| Perera, H | 2 |
| Jeewandara, KC | 1 |
| Seneviratne, S | 1 |
| Guruge, C | 1 |
| Moshe, K | 1 |
| Chadwick, O | 1 |
| Liang, H | 1 |
| Whitwell, S | 1 |
| Riemer, K | 1 |
| Sharma, K | 1 |
| Sharma, SP | 1 |
| Wood, N | 1 |
| Kelly, J | 1 |
| Golaszewski, A | 1 |
| Kennedy, J | 1 |
| Rodney, L | 1 |
| West, N | 1 |
| Walwyn, R | 1 |
| Jichi, F | 1 |
| Varga, MD | 1 |
| Zamora, J | 1 |
| Velásquez, A | 1 |
| Troncoso, L | 1 |
| Barra, P | 1 |
| Guajardo, K | 1 |
| Castillo-Duran, C | 1 |
| Haghighat, R | 1 |
| Chai, G | 1 |
| Governale, L | 1 |
| McMahon, AW | 1 |
| Trinidad, JP | 1 |
| Staffa, J | 1 |
| Schulz-Juergensen, S | 1 |
| Thiemann, A | 1 |
| Gebhardt, J | 1 |
| Baumgarten-Walczak, A | 1 |
| Eggert, P | 1 |
| Baumeister, AA | 2 |
| Henderson, K | 1 |
| Pow, JL | 1 |
| Rothman, KJ | 1 |
| Ólafsson, Ö | 1 |
| Baldursson, G | 2 |
| Almarsdóttir, AB | 1 |
| Jónsdóttir, S | 1 |
| Valdimarsdóttir, UA | 1 |
| Winkel, P | 1 |
| Lance, EI | 1 |
| Shapiro, BK | 1 |
| Rash, JA | 1 |
| Aguirre-Camacho, A | 1 |
| Stieglitz, RD | 1 |
| Yilmaz, AE | 1 |
| Donmez, A | 1 |
| Orun, E | 1 |
| Tas, T | 1 |
| Isik, B | 1 |
| Sonmez, FM | 1 |
| Jafarinia, M | 1 |
| Modabbernia, A | 1 |
| Ashrafi, M | 1 |
| Khajavi, D | 1 |
| Yadegari, N | 1 |
| Kasander, MV | 1 |
| Spuijbroek, AT | 1 |
| Lee, TH | 1 |
| Lee, CH | 1 |
| Kim, IH | 1 |
| Yan, BC | 1 |
| Kwon, SH | 1 |
| Park, OK | 1 |
| Ahn, JH | 1 |
| Cho, JH | 1 |
| Won, MH | 1 |
| Kim, SK | 1 |
| Atherton, J | 1 |
| Gizenko, N | 1 |
| Ridha, J | 1 |
| Kraut, AA | 3 |
| Schad-Hansjosten, T | 1 |
| Schreyer-Mehlhop, I | 1 |
| Mikolajczyk, RT | 3 |
| Harvey, DW | 1 |
| Morrall, M | 1 |
| Neilly, E | 1 |
| Murdoch-Eaton, D | 1 |
| Spanagel, R | 1 |
| Geller, D | 1 |
| Petty, CR | 1 |
| Ponsioen, AJ | 1 |
| Ten Brink, EL | 1 |
| Nakonezny, PA | 2 |
| Acosta, M | 1 |
| Bailey, G | 1 |
| Herring, WJ | 1 |
| Baranak, C | 1 |
| Liu, K | 3 |
| Snavely, DB | 1 |
| Lines, CR | 1 |
| Michelson, D | 3 |
| Fang, SY | 1 |
| Halmøy, A | 1 |
| Torgersen, T | 1 |
| Gjervan, B | 1 |
| Nordahl, HM | 1 |
| Rasmussen, K | 1 |
| Kohlboeck, G | 1 |
| Heitmueller, D | 1 |
| Neumann, C | 1 |
| Tiesler, C | 1 |
| Heinrich, J | 1 |
| Heinrich-Weltzien, R | 1 |
| Hickel, R | 1 |
| Koletzko, S | 1 |
| Herbarth, O | 1 |
| Kühnisch, J | 1 |
| Singh, I | 4 |
| Caserta, DA | 1 |
| Short, EJ | 7 |
| Raleigh, KL | 1 |
| Giuliano, KC | 1 |
| Pucci, NC | 1 |
| Clerkin, SM | 1 |
| Tang, CY | 1 |
| Heffner, JL | 1 |
| Schneebaum-Sender, N | 1 |
| Fattal-Valevski, A | 1 |
| Kramer, U | 1 |
| Mardomingo-Sanz, MJ | 1 |
| Guo, T | 1 |
| Guo, L | 1 |
| Lillemoen, PK | 1 |
| Kjosavik, SR | 1 |
| Hunskår, S | 1 |
| Ruths, S | 1 |
| Fourie Zirkelbach, J | 1 |
| Schuirmann, DJ | 1 |
| Thakur, G | 1 |
| Yang, R | 1 |
| Mao, S | 1 |
| Zhao, Z | 1 |
| Sánchez-Pérez, AM | 1 |
| García-Avilés, Á | 1 |
| Albert Gascó, H | 1 |
| Sanjuán, J | 1 |
| Olucha-Bordonau, FE | 1 |
| Papaseit, E | 1 |
| García-Algar, O | 1 |
| Simó, S | 1 |
| Pichini, S | 1 |
| Farré, M | 1 |
| Gross-Lesch, S | 1 |
| Jung, M | 1 |
| Schulte-Altedorneburg, M | 1 |
| Bliznak, L | 1 |
| Burghardt, R | 1 |
| Salbach-Andrae, H | 1 |
| Naranjo-Gómez, A | 1 |
| Contreras-Chova, F | 1 |
| Augustin-Morales, MD | 1 |
| Khaldy-Belkadi, H | 1 |
| Kubas, HA | 1 |
| Backenson, EM | 1 |
| Wilcox, G | 1 |
| Piercy, JC | 1 |
| Hale, JB | 1 |
| Truong, C | 1 |
| Emond, SK | 1 |
| Ollendorf, DA | 1 |
| Colby, JA | 1 |
| Reed, SJ | 1 |
| Pearson, SD | 1 |
| Ouchi, H | 1 |
| Ono, K | 1 |
| Murakami, Y | 1 |
| Matsumoto, K | 1 |
| Jick, H | 2 |
| Wilson, A | 2 |
| Wiggins, P | 1 |
| Chamberlin, DP | 1 |
| Dideriksen, D | 1 |
| Sheldrick, RC | 1 |
| Leslie, LK | 1 |
| Rodday, AM | 1 |
| Parsons, SK | 1 |
| Saunders, TS | 1 |
| Wong, JB | 1 |
| Freeman, RD | 1 |
| Berk, M | 1 |
| Assareh, M | 1 |
| Davari Ashtiani, R | 1 |
| Khademi, M | 2 |
| Rai, A | 1 |
| Nikoo, M | 1 |
| de Zeeuw, P | 1 |
| Canals, C | 1 |
| Richarte Fernández, V | 1 |
| Soliva, JC | 2 |
| Rovira, M | 2 |
| Tobeña, A | 1 |
| Pérez de los Cobos, J | 1 |
| Siñol, N | 1 |
| Pérez, V | 1 |
| Trujols, J | 1 |
| Ruggiero, S | 1 |
| Rafaniello, C | 1 |
| Bravaccio, C | 1 |
| Grimaldi, G | 1 |
| Granato, R | 1 |
| Pascotto, A | 1 |
| Sportiello, L | 1 |
| Parretta, E | 1 |
| Rinaldi, B | 1 |
| Rossi, F | 1 |
| Taragin, D | 1 |
| Berman, S | 1 |
| Budman, SH | 1 |
| Eaton, TA | 1 |
| Beery, SH | 1 |
| Quay, HC | 2 |
| Musafia, B | 1 |
| Rosenberg, G | 1 |
| Campbell, SB | 1 |
| Douglas, VI | 6 |
| Morgenstern, G | 1 |
| Galeiha, A | 1 |
| Hajiaghaee, R | 1 |
| Graham, J | 1 |
| Renes, JS | 1 |
| de Ridder, MA | 1 |
| Breukhoven, PE | 1 |
| Lem, AJ | 1 |
| Hokken-Koelega, AC | 1 |
| Hauk, L | 1 |
| Tait, PR | 1 |
| Garnett, SP | 1 |
| Cowell, CT | 2 |
| Baur, LA | 1 |
| Lyne, A | 1 |
| Squires, L | 1 |
| Westover, AN | 1 |
| Adinoff, B | 1 |
| Vongpatanasin, W | 1 |
| Zou, QH | 1 |
| Katya, R | 1 |
| Wächter, S | 1 |
| Geppert, C | 1 |
| Tassin, DH | 1 |
| Moody, KR | 1 |
| Yamashita, M | 1 |
| Sakakibara, Y | 1 |
| Hall, FS | 1 |
| Numachi, Y | 1 |
| Yoshida, S | 1 |
| Kobayashi, H | 1 |
| Uchiumi, O | 1 |
| Ciccone, PE | 1 |
| Heiligenstein, JH | 1 |
| Dittmann, R | 1 |
| Wernicke, J | 1 |
| Casat, C | 2 |
| Milton, D | 1 |
| Hagerman, RJ | 1 |
| Miller, LJ | 1 |
| McGrath-Clarke, J | 1 |
| Riley, K | 1 |
| Goldson, E | 1 |
| Harris, SW | 1 |
| Church, K | 1 |
| Bonnell, J | 1 |
| Ognibene, TC | 1 |
| McIntosh, DN | 1 |
| Stiefelhagen, P | 1 |
| Roe, C | 2 |
| Croft, RJ | 3 |
| Tenenbaum, S | 1 |
| Paull, JC | 1 |
| Sparrow, EP | 1 |
| Dodd, DK | 1 |
| Green, L | 1 |
| Anderson, CM | 4 |
| Lowen, SB | 4 |
| Dorrego, MF | 1 |
| Canevaro, L | 1 |
| Kuzis, G | 1 |
| Sabe, L | 1 |
| Starkstein, SE | 1 |
| Meisler, JG | 1 |
| Szobot, C | 3 |
| Martins, S | 2 |
| Kusaga, A | 2 |
| Koeda, T | 2 |
| Kaneko, M | 1 |
| Yamada, S | 1 |
| McFadyen, MP | 1 |
| Brown, RE | 2 |
| Carrey, N | 3 |
| Sane, N | 1 |
| Figgitt, DP | 1 |
| Ramchandani, P | 3 |
| Joughin, C | 3 |
| Schubiner, H | 3 |
| Saules, KK | 1 |
| Arfken, CL | 1 |
| Johanson, CE | 1 |
| Schuster, CR | 1 |
| Lockhart, N | 1 |
| Edwards, A | 1 |
| Donlin, J | 1 |
| Pihlgren, E | 1 |
| Auiler, JF | 1 |
| Lynch, JM | 2 |
| Gelotte, CK | 1 |
| Zetterström, R | 3 |
| Levenson, D | 2 |
| Lyseng-Williamson, KA | 1 |
| Senecky, Y | 1 |
| Lobel, D | 1 |
| Diamond, GW | 1 |
| Weitz, R | 6 |
| Inbar, D | 4 |
| Manzi, S | 1 |
| Law, T | 1 |
| Shannon, MW | 1 |
| Cornell, S | 1 |
| Flick, GL | 1 |
| Williams, L | 5 |
| Agler, D | 5 |
| Lerner, M | 17 |
| Vishio, J | 1 |
| Yartz, AR | 1 |
| Lock, TM | 2 |
| Ickowicz, A | 8 |
| Krause, KH | 6 |
| Dresel, S | 3 |
| Kung, HF | 3 |
| Tatsch, K | 4 |
| Lochmüller, H | 1 |
| Bond, D | 1 |
| Moffitt, C | 2 |
| Coetzee, M | 1 |
| Kaminer, Y | 1 |
| Morales, A | 1 |
| Roselló, B | 2 |
| Pitarch, I | 1 |
| Abad, L | 1 |
| Miranda-Casas, A | 1 |
| Ygual-Fernández, A | 1 |
| Mulas-Delgado, F | 1 |
| Roselló-Miranda, B | 1 |
| Bó, RM | 1 |
| Ding, YS | 4 |
| Gatley, SJ | 6 |
| Langleben, DD | 3 |
| Acton, PD | 2 |
| Austin, G | 3 |
| Elman, I | 3 |
| Krikorian, G | 2 |
| Monterosso, JR | 1 |
| Portnoy, O | 1 |
| Ridlehuber, HW | 2 |
| Strauss, HW | 1 |
| Dunn, M | 1 |
| Schmidt, JK | 1 |
| Plück, J | 2 |
| Dirksen, SJ | 1 |
| D'Imperio, JM | 1 |
| Birdsall, D | 1 |
| Hatch, SJ | 6 |
| Polli, JE | 1 |
| Morgan, JA | 1 |
| Woolley, JB | 1 |
| Heyman, I | 1 |
| Kajs-Wyllie, M | 1 |
| Drimmer, EJ | 1 |
| Mautner, VF | 2 |
| Roache, JD | 3 |
| Lachar, D | 4 |
| Faria, LP | 3 |
| Monastra, VJ | 1 |
| Monastra, DM | 1 |
| George, S | 1 |
| Chua, HC | 1 |
| Barkley, RA | 17 |
| Chronis, AM | 5 |
| Roberts, JE | 1 |
| Aronoff, HR | 3 |
| Huang, B | 1 |
| Lam, A | 1 |
| Shoulson, I | 2 |
| Modi, N | 1 |
| Lindemulder, E | 1 |
| Ding, GA | 1 |
| Yu, GH | 1 |
| Chen, SF | 1 |
| Chen, YY | 2 |
| Wang, XM | 1 |
| Badihi, N | 1 |
| Manor, O | 3 |
| Lopez, M | 2 |
| Crismon, ML | 2 |
| Toprac, MG | 1 |
| Hughes, CW | 1 |
| Emslie, GJ | 2 |
| Boemer, C | 1 |
| Scheres, A | 3 |
| Meiran, N | 1 |
| Schut, H | 1 |
| Vlasveld, L | 1 |
| Sergeant, JA | 5 |
| Fritze, J | 1 |
| Schmauss, M | 1 |
| Cunha, RD | 2 |
| MacMaster, FP | 2 |
| Sparkes, SJ | 1 |
| Khan, SC | 1 |
| Kusumakar, V | 1 |
| Ketzer, C | 2 |
| Parente, MA | 2 |
| Kapczinski, F | 1 |
| Daley, KC | 1 |
| Dixit, SP | 1 |
| Pandey, MN | 1 |
| Dubey, GP | 1 |
| Stein, M | 3 |
| Conners, CK | 20 |
| Atkins, M | 2 |
| August, G | 2 |
| Wolraich, M | 5 |
| Kaga, M | 1 |
| Miyamoto, S | 2 |
| Wang, G | 1 |
| Ding, Y | 1 |
| Jensen, P | 2 |
| Inoff-Germain, G | 1 |
| Klein, R | 2 |
| Mannuzza, S | 4 |
| Steinhoff, K | 3 |
| Posner, K | 14 |
| Freid, J | 1 |
| Beyer, DH | 1 |
| Finkleson, J | 1 |
| Shaffer, D | 1 |
| Gillberg, C | 1 |
| Kennedy, JL | 2 |
| Rapoport, J | 1 |
| Volkow, N | 1 |
| Ueno, K | 1 |
| Yoshioka, M | 2 |
| Gucuyener, K | 2 |
| Erdemoglu, AK | 1 |
| Senol, S | 2 |
| Serdaroglu, A | 1 |
| Soysal, S | 1 |
| Kockar, AI | 1 |
| Schweitzer, JB | 1 |
| Lee, DO | 1 |
| Hanford, RB | 1 |
| Tagamets, MA | 1 |
| Hoffman, JM | 1 |
| Grafton, ST | 1 |
| Kilts, CD | 1 |
| Concar, D | 1 |
| Fuchs, T | 1 |
| Birbaumer, N | 2 |
| Lutzenberger, W | 1 |
| Gruzelier, JH | 1 |
| Kaiser, J | 1 |
| Ibay, AD | 1 |
| Bascelli, LM | 1 |
| Graves, RS | 1 |
| Hill, J | 1 |
| Walsh, DJ | 1 |
| Baverstock, AC | 1 |
| Finlay, F | 1 |
| Ward, A | 1 |
| Inman, S | 1 |
| Logan, GD | 3 |
| Hogg-Johnson, S | 2 |
| Schachar, R | 13 |
| Noorloos, J | 1 |
| Gunning, B | 2 |
| Vles, JS | 4 |
| Feron, FJ | 4 |
| Hendriksen, JG | 4 |
| Jolles, J | 4 |
| van Kroonenburgh, MJ | 2 |
| Weber, WE | 2 |
| Tjon Pian Gi, CV | 1 |
| Broeren, JPA | 1 |
| Starreveld, JS | 1 |
| A Versteegh, FG | 1 |
| Kowatch, RA | 2 |
| Sethuraman, G | 1 |
| Hume, JH | 1 |
| Kromelis, M | 1 |
| Weinberg, WA | 5 |
| Buican, B | 1 |
| Navalta, CP | 1 |
| Butz, AM | 1 |
| Cozen, MA | 1 |
| Seifert, J | 1 |
| Scheuerpflug, P | 4 |
| Zillessen, KE | 2 |
| Galili-Weisstub, E | 1 |
| Segman, RH | 1 |
| Rise, L | 1 |
| Stuart, JE | 1 |
| Specter, E | 1 |
| Smolen, A | 1 |
| Hopfer, C | 1 |
| Teale, PD | 2 |
| Reite, ML | 2 |
| Lisska, MC | 1 |
| Rivkees, SA | 1 |
| Galanter, CA | 1 |
| Baird, R | 1 |
| Oster, MI | 1 |
| Lowe, N | 1 |
| Mullins, C | 1 |
| Daly, G | 1 |
| Waldman, I | 2 |
| McCarron, M | 1 |
| O'Donnell, D | 2 |
| Tavakolian, R | 1 |
| Elliot, M | 1 |
| Sachs, L | 1 |
| Bird, H | 1 |
| Kraemer, HC | 3 |
| Comarda, A | 1 |
| Hindshaw, SP | 1 |
| Severe, JB | 8 |
| Gabriel, KH | 1 |
| Harding, KL | 1 |
| Judah, RD | 1 |
| Gant, C | 1 |
| Clarke, DC | 1 |
| Fogelman, Y | 2 |
| Vinker, S | 2 |
| Guy, N | 1 |
| Kahan, E | 2 |
| Corrigan, B | 1 |
| Kepple, J | 1 |
| Freestone, S | 1 |
| Bakhtiar, R | 3 |
| Hossain, M | 1 |
| Brown, LN | 2 |
| Vickers, JN | 2 |
| Vance, AL | 1 |
| Maruff, P | 3 |
| Abramowicz, MJ | 1 |
| Van Haecke, P | 1 |
| Demedts, M | 1 |
| Delcroix, M | 1 |
| Kemner, C | 8 |
| van der Gugten, J | 1 |
| Westenberg, H | 2 |
| Maes, RA | 2 |
| Koelega, HS | 6 |
| Airaksinen, E | 1 |
| Airaksinen, MM | 1 |
| Sharav, VH | 2 |
| Bouffard, R | 1 |
| Minde, K | 3 |
| Iaboni-Kassab, F | 1 |
| Cooper, N | 2 |
| Maayan, R | 1 |
| Yoran-Hegesh, R | 1 |
| Strous, R | 1 |
| Nechmad, A | 1 |
| Averbuch, E | 1 |
| Spivak, B | 1 |
| Sarampote, CS | 2 |
| Conlon, C | 3 |
| Pearl, PL | 2 |
| Black, DO | 1 |
| Gulley, V | 4 |
| Northup, J | 8 |
| Hupp, S | 1 |
| Spera, S | 1 |
| LeVelle, J | 1 |
| Ridgway, A | 2 |
| Pumeranz, O | 1 |
| Peretz, G | 1 |
| Dekel, S | 1 |
| Horesh, N | 1 |
| Fischel, T | 1 |
| Goldberg, PH | 1 |
| Kanbayashi, Y | 1 |
| Nakane, A | 1 |
| Klein, RG | 13 |
| Moulton, JL | 2 |
| Greenfield, B | 6 |
| Quinn, D | 10 |
| Markabi, S | 1 |
| Weidenman, M | 1 |
| Edson, K | 1 |
| Karlsson, G | 1 |
| Pohlmann, H | 1 |
| Presburger, G | 1 |
| Burg, M | 1 |
| Steinberg, T | 1 |
| Baldwin, RL | 2 |
| Insel, TR | 1 |
| Hyman, SE | 1 |
| Aron, AR | 1 |
| Dowson, JH | 2 |
| Frances, C | 1 |
| Hoizey, G | 1 |
| Millart, H | 1 |
| Yang, P | 2 |
| Chung, LC | 1 |
| Chen, CS | 1 |
| Avale, ME | 1 |
| Falzone, TL | 1 |
| Gelman, DM | 1 |
| Low, MJ | 1 |
| Sangal, RB | 6 |
| Sangal, JM | 2 |
| Pagano, C | 1 |
| Hanisch, C | 2 |
| Kitazawa, S | 1 |
| Hirabayashi, S | 2 |
| Kobayashi, M | 1 |
| Strawn, MN | 1 |
| Flake, RA | 1 |
| Feild, CR | 1 |
| Meaux, JB | 1 |
| Goodyer, IM | 1 |
| Kollins, S | 7 |
| Nguyen, AS | 1 |
| DeCory, HH | 3 |
| Hirshe Dirksen, SJ | 1 |
| Jin, C | 1 |
| Kociancic, T | 1 |
| Reed, MD | 1 |
| Artigas Pallares, J | 1 |
| Doffing, MA | 1 |
| Jonkman, LM | 6 |
| Böcker, KB | 1 |
| Kashani, L | 1 |
| Izadian, ES | 1 |
| Ohadinia, S | 1 |
| Schubel, EA | 1 |
| Martinussen, R | 2 |
| Penberthy, JK | 2 |
| Kovatchev, B | 6 |
| Hankin, CS | 1 |
| Bridge, TP | 1 |
| Rotrosen, JP | 1 |
| Vanderburg, DG | 1 |
| Harrer, JM | 1 |
| Mezinskis, JP | 1 |
| Montgomery, MA | 1 |
| Ciraulo, DA | 1 |
| Wulsin, LR | 1 |
| Barrett, JA | 1 |
| Leonard, BE | 1 |
| McCartan, D | 1 |
| King, DJ | 1 |
| Frey, J | 1 |
| Smidt, J | 1 |
| Sommerlad, C | 1 |
| Remschmidt, H | 5 |
| Kaye, JA | 1 |
| Black, C | 1 |
| de Andrade, ER | 1 |
| Scheuer, C | 1 |
| Golan, N | 2 |
| Shahar, E | 1 |
| Ravid, S | 1 |
| Pillar, G | 2 |
| Rea, M | 1 |
| Baviera, M | 1 |
| Invernizzi, W | 1 |
| Carli, M | 1 |
| Ghirardi, O | 1 |
| Caprioli, A | 1 |
| Reeves, G | 1 |
| Schweitzer, J | 1 |
| Vaccaro, M | 1 |
| Grieb-Neff, P | 1 |
| Risser, A | 1 |
| Polansky, M | 1 |
| Coslett, HB | 1 |
| Payne, CD | 2 |
| Henderson, JA | 1 |
| Schmidt-Troschke, SO | 1 |
| Ostermann, T | 1 |
| Melcher, D | 1 |
| Schuster, R | 1 |
| Erben, CM | 1 |
| Matthiessen, PF | 1 |
| Weiss, G | 6 |
| Respitz, C | 1 |
| Kouri, J | 1 |
| Blum, C | 2 |
| Etcovitch, J | 4 |
| Fleiss, K | 4 |
| Pollack, S | 5 |
| Cousins, L | 3 |
| Martin, D | 2 |
| Maynard, L | 2 |
| Pappas, N | 2 |
| Wong, C | 2 |
| Vaska, P | 1 |
| Morgan, JC | 1 |
| Winter, WC | 1 |
| Wooten, GF | 1 |
| Fredericks, EM | 1 |
| Serra-Pinheiro, MA | 1 |
| Souza, I | 1 |
| Pastura, G | 1 |
| Gomes, F | 1 |
| McCubbin, M | 1 |
| Cohen, D | 1 |
| Martini, N | 1 |
| Donnelly, M | 1 |
| Haby, MM | 1 |
| Carter, R | 1 |
| Andrews, G | 1 |
| Vos, T | 1 |
| Mott, TF | 1 |
| Leach, L | 1 |
| Johnson, L | 1 |
| Silvagni, A | 1 |
| Lynch, J | 1 |
| Co-Chien, H | 1 |
| Eizirik, M | 1 |
| Di Martino, A | 2 |
| Melis, G | 1 |
| Cianchetti, C | 2 |
| Foley, M | 2 |
| Binder, C | 2 |
| Turgay, A | 2 |
| Schmeck, K | 3 |
| Stadler, C | 3 |
| Metternich, TW | 1 |
| Joseph, A | 3 |
| Couzin, J | 1 |
| Gordon, SM | 1 |
| Tulak, F | 1 |
| Troncale, J | 1 |
| Leins, U | 1 |
| Strehl, U | 1 |
| Ozdag, MF | 1 |
| Ulas, UH | 1 |
| Hamamcioglu, K | 1 |
| Vural, O | 1 |
| Thompson, MJ | 1 |
| Brooke, XM | 1 |
| West, CA | 1 |
| Johnson, HR | 1 |
| Bumby, EJ | 1 |
| Brodrick, P | 1 |
| Pepe, G | 1 |
| Laver-Bradbury, C | 1 |
| Scott, N | 1 |
| Sim, MG | 1 |
| Hulse, G | 1 |
| Khong, E | 1 |
| Amor, LB | 3 |
| Boivin, DB | 1 |
| Bokhari, F | 1 |
| Kang, E | 1 |
| Lee, DS | 3 |
| Kim, YK | 1 |
| Chung, JK | 1 |
| Lee, MC | 1 |
| Feifel, D | 1 |
| Zeldis, JB | 2 |
| Wasdell, M | 1 |
| Patin, J | 2 |
| Hirsch, S | 1 |
| Ottolini, Y | 1 |
| Dariani, M | 1 |
| Roffman, M | 1 |
| Zeldis, J | 1 |
| Shafritz, KM | 2 |
| Marchione, KE | 1 |
| Gore, JC | 1 |
| Shaywitz, SE | 10 |
| Shaywitz, BA | 13 |
| Gasior, M | 1 |
| Bergman, J | 1 |
| Kallman, MJ | 1 |
| Paronis, CA | 1 |
| Burger, H | 2 |
| Van der Linden, PD | 1 |
| Kalma, LE | 1 |
| Sinzig, JK | 1 |
| Stephani, U | 1 |
| Sevecke, K | 2 |
| Mulhern, RK | 1 |
| Kaplan, S | 2 |
| Helton, S | 1 |
| Christensen, R | 1 |
| Brown, R | 1 |
| Gururangan, S | 1 |
| Pataki, CS | 4 |
| Feinberg, DT | 2 |
| McCabe, SE | 1 |
| Teter, CJ | 1 |
| Boyd, CJ | 1 |
| Guthrie, SK | 1 |
| Steingard, RJ | 1 |
| Tan, M | 1 |
| Appleton, R | 1 |
| Foy, JM | 1 |
| Earls, MF | 1 |
| Miller, AR | 3 |
| Lalonde, CE | 2 |
| McGrail, KM | 2 |
| Pereira, RR | 1 |
| van de Wetering, BJ | 1 |
| Rappley, MD | 3 |
| Alaghband-Rad, J | 1 |
| Tehranidoost, M | 1 |
| Mesgarpour, B | 1 |
| Soori, H | 1 |
| Rowe, DL | 1 |
| Robinson, PA | 1 |
| Fone, KC | 1 |
| Nutt, DJ | 1 |
| Lindsay, RL | 2 |
| Levine, AJ | 1 |
| Johnson, DE | 2 |
| West, SA | 1 |
| Bohan, TP | 1 |
| Tilker, HA | 1 |
| Cecil, JT | 1 |
| Kowalik, S | 3 |
| Khetani, V | 1 |
| Faleck, H | 1 |
| Hamarman, S | 1 |
| Fossella, J | 1 |
| Ulger, C | 1 |
| Brimacombe, M | 1 |
| Dermody, J | 1 |
| Lage, M | 1 |
| Hwang, P | 1 |
| Colley, M | 1 |
| Johnson, LA | 1 |
| Safranek, S | 1 |
| Friemoth, J | 1 |
| Kwon, A | 2 |
| Clark, S | 1 |
| Scott, M | 2 |
| Podolski, A | 1 |
| Ditterline, JW | 1 |
| Morris, MC | 1 |
| Moore, H | 1 |
| Leo, J | 1 |
| Salbach, H | 1 |
| Lenz, K | 1 |
| Vogel, R | 1 |
| Felsing, D | 1 |
| Jou, R | 1 |
| Handen, B | 1 |
| Hardan, A | 1 |
| Oades, RD | 1 |
| Viggiano, D | 1 |
| Devoto, P | 1 |
| Aase, H | 1 |
| Johansen, EB | 1 |
| Dodson, WW | 1 |
| Quinn, PO | 2 |
| Greiner, A | 2 |
| Rancurello, M | 1 |
| Rodríguez-Vázquez, S | 1 |
| Guerrero-Gallo, D | 1 |
| Vicent-Sardinero, X | 1 |
| Mattos, L | 1 |
| Hernández-Muela, S | 1 |
| Gandía, R | 1 |
| Prince, J | 2 |
| Herzig, K | 1 |
| Faraone, S | 1 |
| Jon, DI | 1 |
| Rosenberg, M | 1 |
| Bryois, C | 1 |
| Nanzer, N | 1 |
| Etter, M | 1 |
| Bertschy, G | 1 |
| Bereket, A | 1 |
| Haklar, G | 1 |
| Ozbay, F | 2 |
| Yazgan, MY | 1 |
| Clavarino, AM | 1 |
| Del Mar, CB | 3 |
| Rosa-Neto, P | 1 |
| Lou, HC | 2 |
| Cumming, P | 2 |
| Pryds, O | 2 |
| Karrebaek, H | 1 |
| Lunding, J | 1 |
| Gjedde, A | 2 |
| Huskamp, HA | 1 |
| Deverka, PA | 1 |
| Epstein, AM | 1 |
| Epstein, RS | 1 |
| McGuigan, KA | 1 |
| Muriel, AC | 1 |
| Frank, RG | 1 |
| Baillargeon, RH | 2 |
| Fortier, I | 1 |
| Wu, HX | 2 |
| Zoccolillo, M | 1 |
| Tremblay, RE | 2 |
| Stevens, S | 1 |
| Zernike, K | 1 |
| McGough, J | 7 |
| McCracken, J | 6 |
| Walkup, J | 1 |
| Riddle, M | 6 |
| Oatis, M | 2 |
| Skrobala, A | 7 |
| March, J | 3 |
| Gammon, P | 1 |
| Robinson, J | 1 |
| Lazell, R | 1 |
| McMahon, DJ | 1 |
| Ritz, L | 2 |
| Lake, M | 1 |
| Walkup, JT | 2 |
| Lewin, T | 1 |
| Sly, K | 1 |
| Ridderinkhof, KR | 1 |
| Jin, Z | 1 |
| Weng, XC | 1 |
| Zeng, YW | 1 |
| Cox, D | 1 |
| Breton, M | 1 |
| Robeva, R | 1 |
| Kalbfleisch, ML | 1 |
| Loboschefski, T | 1 |
| Murphy, KR | 1 |
| O'Connell, T | 1 |
| Benjamin, E | 1 |
| Salek, S | 1 |
| Ezzell, CE | 1 |
| Caserta, D | 1 |
| Morse, G | 1 |
| Hamilton, J | 1 |
| Heinzel-Gutenbrunner, M | 1 |
| Varan, A | 1 |
| Deniz, U | 1 |
| Chase, TD | 1 |
| Wilkinson, M | 1 |
| Johnstone, SJ | 4 |
| Abbott, I | 1 |
| Magee, CA | 1 |
| Hsu, CI | 1 |
| Lawrence, CA | 3 |
| Broyd, SJ | 2 |
| Brown, RT | 10 |
| Amler, RW | 1 |
| Freeman, WS | 1 |
| Perrin, JM | 1 |
| Stein, MT | 4 |
| Pierce, K | 1 |
| Hood, J | 1 |
| Rankin, PM | 1 |
| Isaacs, E | 1 |
| Hermens, DF | 3 |
| Capp, PK | 1 |
| Wan, GJ | 3 |
| Kemner, JE | 2 |
| Wienke, AL | 1 |
| Kuczenski, R | 1 |
| Segal, DS | 1 |
| Hyde, C | 1 |
| Walters, JR | 2 |
| O'Driscoll, GA | 1 |
| Dépatie, L | 1 |
| Holahan, AL | 1 |
| Savion-Lemieux, T | 1 |
| Barr, RG | 5 |
| Gimpel, GA | 1 |
| Collett, BR | 1 |
| Veeder, MA | 1 |
| Gifford, JA | 1 |
| Sneddon, P | 1 |
| Bushman, B | 1 |
| Hughes, K | 1 |
| Odell, JD | 1 |
| Siesser, WB | 2 |
| Cheng, SY | 2 |
| McDonald, MP | 2 |
| Lijffijt, M | 1 |
| ter Wal, A | 1 |
| Quik, EH | 1 |
| Kariyawasam, SH | 2 |
| Koralagama, A | 1 |
| Jayawardane, P | 1 |
| Leonhard, C | 1 |
| Beck, M | 1 |
| Sanchez, RJ | 1 |
| Bettinger, T | 1 |
| Wilson, JP | 1 |
| Kramer, PD | 1 |
| Hoffmaster, B | 1 |
| Litton, P | 1 |
| White, GB | 1 |
| Hughes, J | 1 |
| Griggins, C | 1 |
| Krautkramer, CJ | 1 |
| Preston, RJ | 1 |
| Neef, NA | 1 |
| Bicard, DF | 1 |
| Endo, S | 1 |
| Correia Filho, AG | 1 |
| Bodanese, R | 1 |
| Silva, TL | 1 |
| Alvares, JP | 1 |
| Aman, M | 2 |
| Gilbert, DL | 2 |
| Ridel, KR | 2 |
| Lipps, TD | 2 |
| Wassermann, EM | 2 |
| Wienbruch, C | 1 |
| Paul, I | 1 |
| Bauer, S | 1 |
| Kivelitz, H | 1 |
| Langley, K | 1 |
| Turic, D | 1 |
| Peirce, TR | 1 |
| Mills, S | 1 |
| Van Den Bree, MB | 1 |
| Owen, MJ | 1 |
| O'Donovan, MC | 1 |
| Ben-Pazi, H | 1 |
| Bergman, H | 1 |
| la Fougere, C | 3 |
| Ackenheil, M | 2 |
| Dresel, SH | 3 |
| Hugtenburg, JG | 2 |
| Griekspoor, JE | 1 |
| De Boer, I | 1 |
| Tso, YH | 1 |
| Egberts, AC | 1 |
| Evans, SM | 6 |
| Brooks, DJ | 4 |
| Kalbag, AS | 1 |
| Garawi, F | 4 |
| Ruud, A | 1 |
| Arnesen, P | 1 |
| Vildalen, S | 1 |
| Vesterhus, P | 1 |
| Klasen, H | 1 |
| Verhulst, FC | 1 |
| Donker, GA | 1 |
| Groenhof, F | 1 |
| van der Veen, WJ | 1 |
| McDonnell, MA | 1 |
| Dougherty, M | 3 |
| Sabini, J | 1 |
| Monterosso, J | 2 |
| Trèmols, V | 1 |
| Tomàs, J | 1 |
| Raheb, C | 1 |
| Batlle, S | 1 |
| Battel, S | 1 |
| Garcia, JA | 1 |
| Glied, S | 1 |
| Crowe, M | 1 |
| Foster, M | 1 |
| Hinshaw, S | 1 |
| Wells, K | 5 |
| Blom-Coenjaerts, C | 1 |
| Kessels, AG | 1 |
| Shmueli, D | 1 |
| Conant-Norville, DO | 1 |
| Tofler, IR | 1 |
| van der Meulen, EM | 1 |
| Bakker, SC | 1 |
| Pauls, DL | 1 |
| Oteman, N | 1 |
| Kruitwagen, CL | 1 |
| Pearson, PL | 1 |
| Sinke, RJ | 1 |
| Pestreich, LK | 1 |
| Confino-Cohen, R | 1 |
| Goldberg, A | 1 |
| Kopecky, H | 1 |
| Chang, HT | 1 |
| Klorman, R | 18 |
| Thatcher, JE | 2 |
| Borgstedt, AD | 15 |
| Shen, RY | 1 |
| Choong, KC | 1 |
| Oberlin, BG | 1 |
| Alford, JL | 1 |
| Marrocco, RT | 1 |
| Collins, SL | 1 |
| Foltin, RW | 1 |
| Kleber, HD | 3 |
| Kitayama, S | 1 |
| Sogawa, C | 1 |
| Hoare, P | 2 |
| Ettrich, C | 2 |
| Spender, Q | 2 |
| Tamhne, R | 2 |
| Tinline, C | 2 |
| Schmit, M | 1 |
| Barkin, S | 1 |
| Vergnaud, S | 1 |
| Augustyniak, PN | 1 |
| Kourrich, S | 1 |
| Rezazadeh, SM | 1 |
| Stewart, J | 1 |
| Arvanitogiannis, A | 1 |
| Samuels, JA | 1 |
| Franco, K | 1 |
| Wan, F | 1 |
| Sorof, JM | 1 |
| Zhang, HY | 1 |
| Du, ML | 1 |
| Zhuang, SQ | 1 |
| Liu, MN | 1 |
| Muskalla, B | 1 |
| MacDonald Fredericks, E | 1 |
| Owens, JA | 1 |
| Sangal, J | 1 |
| Burke, PJ | 1 |
| O'Sullivan, J | 1 |
| Vaughan, BL | 1 |
| El-Zein, RA | 2 |
| Hay, MJ | 2 |
| Lopez, MS | 2 |
| Bondy, ML | 2 |
| Morris, DL | 2 |
| Legator, MS | 2 |
| Abdel-Rahman, SZ | 2 |
| Mays, DA | 1 |
| Findling, R | 2 |
| Lubow, RE | 1 |
| Braunstein-Bercovitz, H | 1 |
| Blumenthal, O | 1 |
| Kaplan, O | 1 |
| Toren, P | 3 |
| Prince, JB | 2 |
| Hansen, L | 1 |
| Kovacina, B | 1 |
| Kemner, J | 1 |
| de Jong, CA | 1 |
| Dijkstra, BA | 1 |
| Verbrugge, CA | 1 |
| Krabbe, PF | 1 |
| Harpold, T | 1 |
| Dunkel, S | 1 |
| Rodnick, JE | 1 |
| Swezey, A | 1 |
| Karande, S | 1 |
| Duby, J | 1 |
| Bailey, CE | 1 |
| Denisco, MJ | 1 |
| Halstead, P | 1 |
| Bloom, L | 1 |
| Zimmerman, BA | 1 |
| Gu, J | 1 |
| Llorente, AM | 2 |
| Voigt, RG | 3 |
| Jensen, CL | 1 |
| Berretta, MC | 1 |
| Kennard Fraley, J | 1 |
| Heird, WC | 2 |
| Concannon, PE | 1 |
| Tang, YP | 1 |
| Thomalla, G | 1 |
| Kucinski, T | 1 |
| Weiller, C | 1 |
| Röther, J | 1 |
| Lage, MJ | 1 |
| Steele, M | 1 |
| Prinzo, RS | 1 |
| Binder, CE | 1 |
| Shea, SE | 1 |
| Gureasko-Moore, S | 1 |
| Dupaul, GJ | 16 |
| White, GP | 1 |
| Flapper, BC | 3 |
| Houwen, S | 1 |
| Schoemaker, MM | 2 |
| Haffner, J | 1 |
| Roos, J | 1 |
| Goldstein, N | 1 |
| Parzer, P | 1 |
| Resch, F | 2 |
| Katz, J | 2 |
| Tillery, KL | 2 |
| Cao, H | 1 |
| To, T | 1 |
| Bhat, M | 1 |
| Gehricke, JG | 1 |
| Whalen, CK | 19 |
| Jamner, LD | 1 |
| Baeyens, D | 1 |
| Roeyers, H | 1 |
| D'Haese, L | 1 |
| Pieters, F | 1 |
| Hoebeke, P | 1 |
| Vande Walle, J | 1 |
| van der Feltz-Cornelis, CM | 2 |
| Aldenkamp, AP | 2 |
| Robertson, MM | 1 |
| Ash, B | 1 |
| Grönlund, MA | 1 |
| Aring, E | 1 |
| Landgren, M | 1 |
| Hellström, A | 1 |
| Prell, S | 1 |
| Mecklinger, L | 2 |
| Bormann-Kischkel, C | 1 |
| Kübber, S | 1 |
| Krumm, B | 1 |
| McCarthy, AM | 1 |
| Kelly, MW | 1 |
| Johnson, S | 1 |
| Roman, J | 1 |
| Zimmerman, MB | 1 |
| van den Bergh, FS | 1 |
| Bloemarts, E | 1 |
| Chan, JS | 1 |
| Groenink, L | 1 |
| Oosting, RS | 1 |
| Zuvekas, SH | 1 |
| Norquist, GS | 1 |
| Zhao, J | 1 |
| Miller, LR | 1 |
| Favreau, A | 1 |
| Deseille-Turlotte, G | 1 |
| Brault, F | 1 |
| Giraudeau, B | 1 |
| Krier, C | 1 |
| Barthez, MA | 1 |
| Castelnau, P | 1 |
| Lechner, E | 1 |
| Figueroa, M | 1 |
| Chen, S | 1 |
| Aydin, A | 1 |
| Monkul, ES | 1 |
| Taşçi, C | 1 |
| Robinson, DM | 1 |
| Schweitzer, K | 1 |
| Hazel-Fernandez, LA | 1 |
| Wallace, JM | 1 |
| Cook, S | 1 |
| Braslow, KJ | 1 |
| Watson, MA | 1 |
| Varley, C | 1 |
| Cummins, TK | 1 |
| Hervey, AS | 1 |
| Tonev, ST | 2 |
| Hoagwood, K | 1 |
| Hinshaw, SP | 18 |
| Hervey-Jumper, H | 1 |
| Douyon, K | 1 |
| Franco, KN | 1 |
| Mazei-Robinson, MS | 1 |
| Forrester, MB | 1 |
| Wojnowski, L | 1 |
| Slatkoff, J | 1 |
| Clavarino, A | 2 |
| McNairn, N | 2 |
| Merhar, S | 1 |
| Badreldin, N | 1 |
| Shen, HY | 2 |
| Chiu, YN | 1 |
| Gau, CS | 2 |
| Jaworowski, S | 1 |
| Benarroch, F | 1 |
| Anderson, VR | 3 |
| Scott, LJ | 1 |
| Cameron, SJ | 1 |
| McDowell, M | 1 |
| Griffin, S | 1 |
| Hodges, Z | 1 |
| Weatherly, H | 1 |
| Asseburg, C | 1 |
| Richardson, G | 1 |
| Drummond, M | 1 |
| Riemsma, R | 1 |
| Wolf, U | 1 |
| Golombek, U | 1 |
| Diefenbacher, A | 1 |
| Gierow, W | 3 |
| Weber, S | 2 |
| Hoeppner, J | 3 |
| Klauer, T | 2 |
| Wittstock, M | 1 |
| Benecke, R | 2 |
| Wolters, A | 2 |
| Ross, RG | 1 |
| Brook, U | 1 |
| Boaz, M | 1 |
| Suter, W | 1 |
| Martus, HJ | 1 |
| Elhajouji, A | 1 |
| Reich, W | 1 |
| Huang, H | 1 |
| Todd, RD | 2 |
| Gorman, EB | 1 |
| Ball, RR | 1 |
| Levine, A | 1 |
| Waldron, T | 1 |
| Lee, HY | 1 |
| Bonnet-Brilhault, F | 1 |
| Broly, F | 1 |
| Blanc, R | 1 |
| Furet, Y | 1 |
| Barthélémy, C | 1 |
| Paintaud, G | 1 |
| Gauthier, J | 1 |
| de Guzman, R | 1 |
| Chi, TC | 1 |
| Pfiffner, L | 1 |
| Nebel-Schwalm, M | 1 |
| Owens, EB | 1 |
| Unni, JC | 1 |
| Okazaki, S | 1 |
| Ozaki, H | 1 |
| Josef Gildehaus, F | 1 |
| Hacker, M | 1 |
| Koch, W | 1 |
| Hahn, K | 2 |
| Klein, HE | 1 |
| Sklar, P | 1 |
| Santosh, PJ | 1 |
| Pityaratstian, N | 1 |
| Tavare, E | 1 |
| Gringras, P | 1 |
| Muneoka, K | 1 |
| Kuwagata, M | 1 |
| Iwata, M | 1 |
| Shirayama, Y | 1 |
| Ogawa, T | 1 |
| Takigawa, M | 1 |
| Langendijk, PN | 1 |
| Wilde, AA | 1 |
| Meusers, M | 1 |
| Schreiner, A | 1 |
| Wheeler, TL | 1 |
| Eppolito, AK | 1 |
| Smith, LN | 1 |
| Huff, TB | 1 |
| Smith, RF | 1 |
| Thorndike, F | 1 |
| Muller, C | 1 |
| Pierce, DM | 1 |
| Valente, E | 1 |
| McKay, G | 1 |
| Midha, KK | 5 |
| de Jong-van den Berg, LT | 3 |
| Tobi, H | 3 |
| Soong, WT | 1 |
| Levin-Epstein, M | 1 |
| Gadow, K | 1 |
| Wasdell, MB | 1 |
| Reingold, LS | 1 |
| Morrill, MS | 1 |
| Lydon, E | 1 |
| El-Mallakh, RS | 1 |
| Oyemade, A | 1 |
| Patel, M | 1 |
| Polzer, J | 1 |
| Bangs, ME | 3 |
| Zhang, S | 2 |
| Dellva, MA | 1 |
| Tauscher-Wisniewski, S | 1 |
| Acharya, N | 1 |
| Watson, SB | 1 |
| Ghuman, J | 6 |
| Cunningham, C | 11 |
| Bauzo, A | 1 |
| Kastelic, E | 4 |
| Shigawa, S | 1 |
| Moyzis, R | 1 |
| Thorp, B | 1 |
| Kim, SY | 1 |
| Park, MK | 1 |
| Oh, EY | 1 |
| Lim, TS | 1 |
| Cheong, S | 1 |
| Cho, IH | 1 |
| Blondeau, C | 1 |
| Dellu-Hagedorn, F | 1 |
| Fathalli, F | 1 |
| Torkaman-Zehi, A | 1 |
| Ter Stepanian, M | 1 |
| Stümpfig, S | 2 |
| Dziura, J | 1 |
| Posey, D | 1 |
| Young, C | 2 |
| Stolberg, SG | 1 |
| Keizer, RJ | 1 |
| van den Berg, PB | 1 |
| Aharonovich, E | 2 |
| Bisaga, A | 2 |
| Brooks, D | 1 |
| Raby, WN | 1 |
| Rubin, E | 2 |
| Oberpichler-Schwenk, H | 1 |
| Connolly, M | 1 |
| Wambera, K | 1 |
| Jan, JE | 1 |
| Plioplys, S | 1 |
| Dunn, DW | 3 |
| Minami, H | 2 |
| Walcher-Andris, E | 1 |
| Li, HY | 1 |
| Yang, CM | 1 |
| Chen, NH | 1 |
| Pietrzak, RH | 1 |
| Mollica, CM | 1 |
| Snyder, PJ | 1 |
| Vinker, R | 1 |
| Elhayany, A | 1 |
| Fallu, A | 1 |
| Richard, C | 1 |
| Prinzo, R | 1 |
| Keulers, EH | 1 |
| Wassenberg, R | 1 |
| Wuisman-Frerker, MG | 1 |
| Lu, CK | 1 |
| Kuang, TM | 1 |
| Chou, JC | 1 |
| Reijs, R | 1 |
| Van Mil, S | 1 |
| Graindorge, C | 1 |
| Brownell, MD | 1 |
| Mayer, T | 1 |
| Chateau, D | 1 |
| Sharp, BW | 1 |
| Craig, R | 1 |
| Horner, WE | 1 |
| Schmidt, AW | 1 |
| Rollema, H | 1 |
| Knight, M | 1 |
| Cak, HT | 1 |
| Cetin, FC | 1 |
| Prabhuswamy, M | 1 |
| Srinath, S | 1 |
| Girimaji, S | 1 |
| Seshadri, S | 1 |
| Sutton, V | 2 |
| Schuh, K | 2 |
| Kelsey, D | 1 |
| Ramadan, Y | 1 |
| Witwer, AN | 1 |
| Swiezy, NB | 1 |
| Cronin, P | 1 |
| Carroll, DH | 1 |
| Wheeler, C | 1 |
| Eagle, DM | 1 |
| Tufft, MR | 1 |
| Goodchild, HL | 1 |
| Mestas, R | 1 |
| Pachler, M | 1 |
| Prasad, S | 1 |
| Poole, L | 1 |
| Zeitlin, H | 1 |
| Jamdar, S | 1 |
| Jain, U | 3 |
| Ahmed, TS | 2 |
| Donnelly, GA | 4 |
| Harsanyi, Z | 3 |
| Darke, AC | 4 |
| Carrey, NJ | 1 |
| Gaudet, L | 1 |
| Schmidt, MH | 3 |
| McInnes, A | 1 |
| Bingcang, C | 1 |
| Rayens, MK | 1 |
| Kelly, TH | 1 |
| Greydanus, DE | 1 |
| Pratt, HD | 1 |
| Patel, DR | 1 |
| Pundir, M | 1 |
| Nagarkar, AN | 1 |
| Panda, NK | 1 |
| Bode, T | 1 |
| Leitner, Y | 2 |
| Barak, R | 2 |
| Giladi, N | 1 |
| Peretz, C | 1 |
| Eshel, R | 1 |
| Gruendlinger, L | 1 |
| Hausdorff, JM | 2 |
| Chenault, N | 1 |
| Houzé, B | 1 |
| Herpin, A | 1 |
| Pothion, S | 1 |
| Schlamp, D | 1 |
| Cavadas, M | 1 |
| Pereira, LD | 1 |
| van de Wiel, NM | 1 |
| Matthys, W | 1 |
| Cohen-Kettenis, PT | 1 |
| Maassen, GH | 1 |
| Lochman, JE | 1 |
| Kirchler, E | 1 |
| Gruber, L | 1 |
| Kühle, HJ | 1 |
| Kinkelbur, J | 1 |
| Andes, K | 1 |
| Heidorn, FM | 1 |
| Zeyer, S | 1 |
| Rautzenberg, P | 1 |
| Jansen, F | 1 |
| Carlson, CL | 4 |
| Armenteros, JL | 1 |
| Lewis, JE | 1 |
| Davalos, M | 1 |
| Malone, RP | 1 |
| Waheed, A | 1 |
| Calver, J | 1 |
| Sanfilippo, FM | 1 |
| Bulsara, M | 1 |
| Chao, CC | 1 |
| Kapelinski, A | 1 |
| Martinez, J | 1 |
| Modi, NB | 1 |
| Pae, CU | 1 |
| Harvey, WJ | 1 |
| Reid, G | 1 |
| Poulin, C | 1 |
| Vandenberghe, M | 2 |
| Tahiroglu, AY | 1 |
| Avci, A | 1 |
| Van Someren, EJ | 1 |
| Hester, DM | 1 |
| Strohschein, LA | 1 |
| He, H | 1 |
| Qian, Y | 1 |
| Feng, L | 1 |
| Raby, W | 1 |
| Mariani, J | 1 |
| Sprafkin, J | 10 |
| Schneider, J | 2 |
| Bessou, H | 1 |
| Zeeb, H | 1 |
| Puteanus, U | 1 |
| Golden, W | 1 |
| Kinggard, TE | 1 |
| Werner, B | 1 |
| Wernicke, JF | 1 |
| Holdridge, KC | 1 |
| Edison, T | 1 |
| Ball, S | 1 |
| Dunn, D | 1 |
| Doniger, GM | 1 |
| Simon, ES | 1 |
| Kronenberger, WG | 2 |
| Giauque, AL | 2 |
| Lafata, DE | 1 |
| Bohnstedt, BN | 1 |
| Maxey, LE | 1 |
| Perez, R | 1 |
| Glahn, D | 1 |
| Semrud-Clikeman, M | 3 |
| Besnyo, M | 1 |
| Tremmery, S | 1 |
| Steyaert, J | 1 |
| Molenberghs, G | 1 |
| Kalff, AC | 1 |
| Hurks, PP | 1 |
| Katragadda, S | 1 |
| Rashid, J | 1 |
| Mitelman, S | 1 |
| Sukhodolsky, DG | 1 |
| Williams White, S | 1 |
| Solanto, MV | 9 |
| Schulz, K | 1 |
| Pradhan, K | 1 |
| Reinhardt, MC | 1 |
| Benetti, L | 1 |
| Quintana, H | 2 |
| Cherlin, EA | 1 |
| Duesenberg, DA | 1 |
| Ramsey, JL | 1 |
| Feldman, PD | 1 |
| Kelsey, DK | 1 |
| Guzman, R | 1 |
| Lien, MT | 1 |
| Carlson, JS | 1 |
| Hunter-Oehmke, S | 1 |
| Knapp, KA | 1 |
| Kaiser, NM | 1 |
| Hurt, E | 1 |
| Giefer, EE | 1 |
| Treadwell-Deering, D | 1 |
| Evankovich, K | 1 |
| Lotze, T | 1 |
| Young, JL | 1 |
| Johnson, SH | 1 |
| Davidson, MC | 1 |
| Reiss, AL | 1 |
| Garrett, A | 1 |
| Glover, G | 1 |
| Vitolo, A | 1 |
| Kotler, LA | 1 |
| Jarrett, MA | 1 |
| Spicer, J | 1 |
| Lütschg, J | 2 |
| Fahnenstich, H | 1 |
| Prox, V | 1 |
| Zedler, M | 1 |
| Ziegenbein, M | 1 |
| Dietrich, DE | 1 |
| Kösters, M | 1 |
| Yang, JW | 1 |
| Ko, YH | 1 |
| Han, C | 1 |
| Kim, SH | 1 |
| Joe, SH | 1 |
| Jung, IK | 1 |
| Amiri, S | 1 |
| Nouroozinejad, GH | 1 |
| Kahbazi, M | 1 |
| Knölker, U | 1 |
| Gehrke, M | 1 |
| Brünger, M | 1 |
| Mick, EO | 1 |
| Michel, E | 1 |
| Martin, J | 2 |
| Moss, SB | 1 |
| Nair, R | 1 |
| Vallarino, A | 1 |
| Humphreys, C | 1 |
| Garcia-Bournissen, F | 1 |
| Ito, S | 1 |
| Birnbaum, HG | 1 |
| Zhang, HF | 3 |
| Ivanova, JI | 1 |
| Yang, E | 1 |
| Mallet, D | 1 |
| Keane, H | 1 |
| Jeannin, A | 1 |
| Schultz, BK | 1 |
| Asheim, H | 2 |
| Nilsen, KB | 2 |
| Johansen, K | 2 |
| Weih, M | 1 |
| Thürauf, N | 1 |
| Bleich, S | 1 |
| Kornhuber, J | 1 |
| Grund, T | 1 |
| Teuchert-Noodt, G | 1 |
| Busche, A | 1 |
| Neddens, J | 1 |
| Brummelte, S | 1 |
| Dawirs, RR | 1 |
| Thompson, A | 1 |
| van Melis, JJ | 1 |
| Markus, CR | 1 |
| Darredeau, C | 1 |
| Barrett, SP | 1 |
| Pihl, RO | 1 |
| Reichel, CM | 1 |
| Linkugel, JD | 1 |
| Jezierski, G | 1 |
| Zehle, S | 1 |
| Gruss, M | 1 |
| Wood, JG | 1 |
| Crager, JL | 1 |
| Delap, CM | 1 |
| Heiskell, KD | 1 |
| Murphy, K | 2 |
| Ramsay, JR | 1 |
| Gualtieri, CT | 10 |
| Johnson, LG | 1 |
| Tharoor, H | 1 |
| Lobos, EA | 1 |
| Reiersen, AM | 1 |
| Kooij, JS | 1 |
| Vermeulen, SH | 1 |
| Heister, AG | 1 |
| Wang, JS | 1 |
| Donovan, JL | 1 |
| Jiang, Y | 1 |
| Gibson, BB | 1 |
| DeVane, CL | 2 |
| Kerdar, MS | 1 |
| Srdinko, P | 1 |
| Wewetzer, C | 1 |
| Novak, SP | 1 |
| Kroutil, LA | 1 |
| Williams, RL | 1 |
| Van Brunt, DL | 1 |
| Caci, H | 1 |
| Melvin, GA | 1 |
| Fisher, P | 1 |
| Evans, L | 2 |
| Skrobala, AM | 4 |
| Scharko, AM | 1 |
| Hardy, KK | 1 |
| Yates, T | 1 |
| Melfsen, S | 1 |
| Herhaus, G | 1 |
| Müller, T | 1 |
| Uhlíkova, P | 1 |
| Vaneckova, M | 1 |
| Morcinek, T | 1 |
| Seidel, Z | 1 |
| Krasensky, J | 1 |
| Danes, J | 1 |
| Mahon, AD | 1 |
| Stephens, BR | 1 |
| Cole, AS | 1 |
| Hsu, HY | 1 |
| Chao, MC | 1 |
| Thompson, J | 1 |
| Thompson, JR | 1 |
| Knellwolf, AL | 1 |
| Deligne, J | 1 |
| Auleley, GR | 1 |
| Palmieri, S | 1 |
| Boisgard, CB | 1 |
| Autret-Leca, E | 1 |
| Gleason, MM | 1 |
| Egger, HL | 1 |
| Lieberman, AF | 1 |
| Luby, JL | 1 |
| Scahill, LD | 2 |
| Scheeringa, MS | 1 |
| Stafford, B | 1 |
| Wise, B | 1 |
| Zeanah, CH | 1 |
| Neufang, S | 1 |
| Fink, GR | 1 |
| McNamara, NK | 1 |
| Demeter, CA | 1 |
| Stansbrey, RJ | 1 |
| Gracious, BL | 1 |
| Whipkey, R | 1 |
| Calabrese, JR | 1 |
| Dupont, RL | 1 |
| Bucher, RH | 1 |
| Wilford, BB | 1 |
| Coleman, JJ | 1 |
| Alexander, DM | 1 |
| Keage, HA | 1 |
| Clark, CR | 2 |
| Clarke, SD | 1 |
| Lamb, C | 1 |
| Jacobson-Kram, D | 1 |
| Mattison, D | 1 |
| Shelby, M | 1 |
| Slikker, W | 1 |
| Tice, R | 1 |
| Witt, K | 1 |
| Panton, R | 1 |
| Ironside, S | 1 |
| Macpherson, M | 1 |
| Lauth, B | 1 |
| Meidad, S | 2 |
| Zemishlany, Z | 1 |
| Barton, R | 1 |
| Van Lier, P | 1 |
| Hatch, S | 1 |
| Baptista-Neto, L | 1 |
| Sandler, AD | 1 |
| Bodfish, JW | 1 |
| Sandler, A | 1 |
| Glesne, C | 1 |
| Geller, G | 1 |
| Heriot, SA | 1 |
| Evans, IM | 1 |
| Foster, TM | 1 |
| Sgambati, S | 1 |
| Rotrosen, J | 1 |
| Sawtelle, R | 1 |
| Mao, AR | 1 |
| Bush, G | 1 |
| Holmes, J | 1 |
| Shin, LM | 1 |
| Patel, NC | 1 |
| McDERMOTT, MP | 2 |
| Harris, P | 1 |
| Willemsen, MA | 1 |
| van der Wal, KG | 1 |
| Perwien, AR | 1 |
| Vaughan, B | 1 |
| Busner, J | 2 |
| Saylor, KE | 1 |
| Buermeyer, CM | 1 |
| Swindle, R | 1 |
| Postma, MJ | 1 |
| Kiguchi, M | 2 |
| Fujita, S | 2 |
| Shimizu, N | 2 |
| Koshikawa, N | 2 |
| Wandschneider, R | 1 |
| Neumeyer, M | 1 |
| Herpertz, SC | 1 |
| da Silva, TL | 1 |
| Sabljic, D | 1 |
| Skopp, G | 1 |
| Kettler, N | 2 |
| Mattern, R | 1 |
| Strohbeck-Kühner, P | 1 |
| Bental, B | 1 |
| Lee, E | 1 |
| Cassaday, HJ | 1 |
| Finger, BC | 1 |
| Horsley, RR | 1 |
| Laiba, E | 1 |
| Eisenberg, J | 1 |
| Lerer, E | 1 |
| Israel, S | 1 |
| Gritsenko, I | 1 |
| Ebstein, RP | 1 |
| Kereszturi, E | 1 |
| Farkas, L | 1 |
| Berul, CI | 1 |
| Elkort, MS | 1 |
| Rose, S | 1 |
| Goldman, W | 1 |
| Seltzer, R | 1 |
| Reuman, P | 1 |
| Rey, JM | 2 |
| Kurscheidt, JC | 1 |
| Peiler, P | 1 |
| Behnken, A | 1 |
| Abel, S | 1 |
| Pedersen, A | 1 |
| Suslow, T | 1 |
| Keage, H | 1 |
| Perruchoud, C | 1 |
| Chollet-Rivier, M | 1 |
| Schaefer, T | 2 |
| Fu, YK | 1 |
| Cox, M | 1 |
| Kelly, SP | 1 |
| Dáibhis, A | 1 |
| Daly, M | 1 |
| Keavey, M | 1 |
| Watchorn, A | 1 |
| Crosbie, J | 1 |
| Miceli, PC | 1 |
| Vaughan, BS | 2 |
| Vanderschuren, LJ | 1 |
| Trezza, V | 1 |
| Griffioen-Roose, S | 1 |
| Schiepers, OJ | 1 |
| Van Leeuwen, N | 1 |
| De Vries, TJ | 1 |
| Schoffelmeer, AN | 1 |
| Welsh, JP | 1 |
| Ko, C | 1 |
| Hsu, WT | 1 |
| Zepf, FD | 1 |
| Demisch, L | 1 |
| Schmitt, M | 1 |
| Wöckel, L | 1 |
| DelBello, MP | 1 |
| Lu, HH | 1 |
| Melmed, RD | 1 |
| Pratt, RD | 1 |
| Saylor, K | 1 |
| Buermeyer, C | 1 |
| Khan, S | 1 |
| Ruaro, P | 1 |
| Walcher, M | 1 |
| Kronenberg, G | 1 |
| Ende, G | 1 |
| Deuschle, M | 1 |
| Warshaw, EM | 1 |
| Paller, AS | 1 |
| Fowler, JF | 1 |
| Zirwas, MJ | 1 |
| Harpin, VA | 1 |
| Aghakhani, K | 1 |
| Oki, H | 1 |
| Cools, AR | 1 |
| Truong, NL | 1 |
| Roizen, ER | 1 |
| Howell, KH | 1 |
| Wetzel, MW | 1 |
| Glatt, SJ | 1 |
| Singh, T | 1 |
| Kerstetter, KA | 1 |
| Dembro, KA | 1 |
| Mutebi, MM | 1 |
| Deschepper, CF | 1 |
| da Silva, MA | 1 |
| Louza, M | 1 |
| Kassubek, J | 1 |
| Glaser, C | 1 |
| Wunderlich, A | 1 |
| Buck, AK | 1 |
| Reske, SN | 1 |
| Mottaghy, FM | 1 |
| Syed, RH | 1 |
| Moore, TL | 1 |
| Quintero-Gutiérrez, FJ | 1 |
| Williams, DW | 1 |
| Moore, RJ | 1 |
| Kulkarni, RS | 1 |
| Rowley, HL | 1 |
| Larue, RH | 1 |
| Hawkins, MF | 1 |
| Seale, L | 1 |
| Dor, T | 1 |
| Nevo, Y | 1 |
| Goldzweig, G | 1 |
| Montiel-Nava, C | 1 |
| Bauermeister, JJ | 2 |
| Ersche, KD | 1 |
| Salmond, CH | 1 |
| Greiner, C | 1 |
| Enss, E | 1 |
| Butter, HJ | 2 |
| Lapierre, Y | 2 |
| Firestone, P | 7 |
| Blank, A | 2 |
| Lowe, TL | 2 |
| Cohen, DJ | 10 |
| Detlor, J | 2 |
| Kremenitzer, MW | 2 |
| Kavale, K | 1 |
| Thurber, S | 1 |
| Walker, CE | 1 |
| Hartley, LR | 1 |
| Denollet, J | 1 |
| Coffey, B | 1 |
| Shader, RI | 3 |
| Greenblatt, DJ | 2 |
| Slimmer, LW | 2 |
| Wynne, ME | 6 |
| Szekely, GA | 1 |
| Belmaker, RH | 1 |
| Hicks, RE | 4 |
| Mayo, JP | 2 |
| Schroeder, SR | 2 |
| Gauthier, M | 1 |
| Coons, HW | 4 |
| Peloquin, LJ | 1 |
| Bauer, LO | 2 |
| Ryan, RM | 1 |
| Perlmutter, RA | 1 |
| Salzman, LF | 6 |
| Hunt, RD | 6 |
| Halliday, R | 6 |
| Callaway, E | 6 |
| Naylor, H | 2 |
| Halpern, WI | 1 |
| Ebert, MH | 1 |
| Wood, DR | 4 |
| Varley, CK | 6 |
| Trupin, EW | 2 |
| Anderson, GM | 5 |
| Rosenthal, JH | 1 |
| Welsh, RJ | 2 |
| McKay, SE | 1 |
| Bareuther, CM | 1 |
| Mattes, JA | 5 |
| Boswell, L | 1 |
| Oliver, H | 1 |
| Hooberman, D | 1 |
| Anderson, G | 1 |
| Pozzi, M | 1 |
| Hartley, L | 2 |
| Rosse, RB | 1 |
| Licamele, WL | 4 |
| Henker, B | 17 |
| Karlsson, J | 3 |
| Strzelecki, E | 1 |
| Murphy, JV | 3 |
| Ballinger, CT | 1 |
| Nolen, PA | 1 |
| Golinko, BE | 2 |
| Ackerman, PT | 5 |
| Holcomb, PJ | 3 |
| Dykman, RA | 5 |
| Poole, SR | 1 |
| Knowles, RC | 1 |
| McCray, DS | 3 |
| Lynch, M | 1 |
| Richardson, E | 4 |
| Heiman, EM | 1 |
| Fiedler, NL | 1 |
| Ullman, DG | 1 |
| Diamond, JM | 1 |
| Stein, JM | 1 |
| Nicolle, FI | 1 |
| Clampit, MK | 1 |
| Pirkle, JB | 1 |
| Cohen, NJ | 3 |
| Sullivan, J | 2 |
| Novak, C | 2 |
| Keens, S | 1 |
| Puig-Antich, J | 4 |
| Novacenko, H | 1 |
| Solomon, M | 3 |
| Anghern, C | 1 |
| Florea, J | 2 |
| Goetz, R | 2 |
| Fiscina, B | 2 |
| Sachar, EJ | 2 |
| Stephens, RS | 1 |
| Skinner, R | 1 |
| El-Defrawi, MH | 1 |
| Schmidt, K | 3 |
| Sanchez-Kappraff, M | 1 |
| Vargas, P | 1 |
| Wein, S | 1 |
| Peeke, S | 1 |
| Prael, R | 1 |
| Reus, V | 1 |
| Romahn, G | 1 |
| Göbel, D | 1 |
| Reid, MK | 1 |
| Borkowski, JG | 1 |
| Prior, M | 1 |
| Wallace, M | 1 |
| Milton, I | 1 |
| Raskin, LA | 1 |
| Perlman, T | 1 |
| Shen, YC | 1 |
| Winsberg, BG | 9 |
| Kupietz, SS | 6 |
| Yepes, LE | 1 |
| Nissen, G | 2 |
| Satterfield, JH | 5 |
| Schell, AM | 2 |
| Barb, SD | 1 |
| Kreuzer, EM | 1 |
| Pappas, BA | 2 |
| Vogel, RA | 1 |
| Wilson, JH | 1 |
| Mueller, RA | 2 |
| Breese, GR | 2 |
| Millard, WJ | 1 |
| Standish, LJ | 1 |
| Sverg, J | 1 |
| Hungund, BL | 1 |
| Young, NL | 1 |
| Shea, VT | 1 |
| Gittelman, R | 6 |
| Cunningham, CE | 4 |
| Rogeness, GA | 1 |
| Macedo, CA | 1 |
| Sandman, CA | 1 |
| Deutsch, C | 1 |
| Baren, M | 3 |
| Chan, YP | 1 |
| Soldin, SS | 1 |
| Thiessen, JJ | 1 |
| Macleod, SM | 1 |
| Logan, W | 1 |
| Garfinkel, BD | 4 |
| Sloman, L | 5 |
| O'Neill, I | 1 |
| Voelker, S | 1 |
| Gdowski, CL | 1 |
| Hanlon, C | 1 |
| McLaughlin, JF | 1 |
| Tso, Y | 1 |
| Dotemoto, S | 1 |
| Webster, CD | 3 |
| Cowart, VS | 2 |
| Myers, GJ | 1 |
| Libb, JW | 1 |
| Thompson, L | 2 |
| Glusker, P | 1 |
| Yellin, AM | 2 |
| Hopwood, JH | 1 |
| Greenberg, LM | 3 |
| Jatlow, P | 3 |
| Young, JG | 2 |
| Pierce, RN | 1 |
| Dubey, DR | 1 |
| Wargin, W | 1 |
| Kanoy, R | 1 |
| Patrick, K | 1 |
| Shen, CD | 1 |
| Youngblood, W | 1 |
| Gan, J | 1 |
| Cantwell, DP | 10 |
| Hobbes, G | 3 |
| Flintoff, MM | 1 |
| Barron, RW | 1 |
| Ledlow, A | 1 |
| Kinsbourne, M | 5 |
| Murphy, HA | 1 |
| Bailey, JS | 1 |
| Chapel, JL | 2 |
| Adams, W | 1 |
| Kalachnik, JE | 1 |
| Sprague, RL | 2 |
| Sleator, EK | 5 |
| Cohen, MN | 1 |
| Ullmann, RK | 4 |
| Charles, L | 2 |
| Schain, R | 2 |
| Zelniker, T | 1 |
| Helwig, C | 1 |
| Kelly, MJ | 1 |
| Goodman, JT | 2 |
| Davey, J | 1 |
| Ferguson, HB | 1 |
| Trites, RL | 1 |
| Peters, DA | 1 |
| Taub, H | 1 |
| Chamberlein, HR | 1 |
| Bala, SP | 1 |
| Cohen, B | 1 |
| Morris, AG | 1 |
| Atkin, A | 1 |
| Kates, W | 1 |
| Irwin, M | 1 |
| Belendiuk, K | 1 |
| McCloskey, K | 1 |
| Freedman, DX | 1 |
| Bhatara, V | 1 |
| Michael, RL | 1 |
| Dainer, KB | 1 |
| Anderson, EE | 1 |
| Clement, PW | 2 |
| Oettinger, L | 3 |
| Finck, D | 1 |
| Kauffman, RE | 1 |
| Smith-Wright, D | 1 |
| Reese, CA | 1 |
| Simpson, R | 1 |
| Jones, F | 1 |
| Loney, J | 8 |
| Harbauer, H | 1 |
| Whitehouse, D | 1 |
| Shah, U | 1 |
| Palmer, FB | 1 |
| Halpern, F | 1 |
| Rubinstein, B | 1 |
| Chambers, W | 1 |
| Klein, DF | 2 |
| Delamater, A | 1 |
| Porges, SW | 1 |
| Bohrer, RE | 1 |
| Keren, G | 1 |
| Cheung, MN | 1 |
| Franks, GJ | 1 |
| Drasgow, F | 1 |
| Van Davelaar, MJ | 1 |
| Cherek, DR | 1 |
| Mayes, SD | 2 |
| Crites, DL | 1 |
| Bixler, EO | 2 |
| Humphrey, FJ | 1 |
| Mattison, RE | 1 |
| Kruesi, MJ | 3 |
| Gulotta, CS | 2 |
| Mefford, IN | 2 |
| Potter, WZ | 3 |
| Ritchie, GF | 4 |
| Sternlicht, HC | 1 |
| Wells, SR | 1 |
| Nolan, E | 1 |
| Lurie, S | 1 |
| O'Quinn, A | 1 |
| Kwasman, A | 1 |
| Tinsley, BJ | 1 |
| Lepper, HS | 1 |
| Hess, LE | 1 |
| Bennett, DS | 2 |
| Simeon, JG | 1 |
| Wiggins, DM | 1 |
| Williams, E | 1 |
| Kent, JD | 1 |
| Logan, G | 1 |
| Weinberg, HA | 1 |
| Desilets, J | 1 |
| Sherman, E | 1 |
| Wilkison, PC | 1 |
| Kircher, JC | 1 |
| McMahon, WM | 1 |
| Sloane, HN | 1 |
| Wolford, PL | 1 |
| van der Meere, J | 4 |
| Rosenthal, NE | 1 |
| Van der Gaag, RJ | 4 |
| Swaab-Barneveld, H | 3 |
| Kuiper, M | 2 |
| Tzelepis, A | 1 |
| Isaacson, JH | 1 |
| Warbasse, LH | 1 |
| Zacharek, M | 1 |
| Musial, J | 1 |
| Pleak, RR | 1 |
| Ajibola, O | 1 |
| Burke, MS | 1 |
| Josephson, A | 1 |
| Lightsey, A | 1 |
| Schmidt, ME | 1 |
| Borcherding, BG | 4 |
| Elin, RJ | 1 |
| Hosseini, JM | 1 |
| McFarlin, KE | 1 |
| Hamburger, S | 1 |
| Gardiner, JC | 1 |
| Jetton, JR | 1 |
| Houang, RT | 1 |
| Ablon, JS | 2 |
| Lapey, K | 1 |
| Ezor, SN | 2 |
| Barrickman, LL | 1 |
| Perry, PJ | 2 |
| Kuperman, S | 2 |
| Arndt, SV | 1 |
| Herrmann, KJ | 1 |
| Schumacher, E | 1 |
| Zametkin, AJ | 7 |
| Suffin, SC | 1 |
| Emory, WH | 1 |
| Wozniak, J | 1 |
| Connor, D | 1 |
| Daly, JM | 1 |
| Fritsch, SL | 1 |
| de Quirós, GB | 1 |
| Palmer, RL | 1 |
| Rufo, DT | 1 |
| Sayegh, L | 2 |
| Papineau, D | 2 |
| de Sonneville, LM | 2 |
| Njiokiktjien, C | 2 |
| Bos, H | 1 |
| Young, ES | 1 |
| Perros, P | 1 |
| Price, GW | 1 |
| Sadler, T | 1 |
| Strayhorn, JM | 1 |
| Anderson, PD | 1 |
| Johnson, CR | 2 |
| Handen, BL | 9 |
| Lubetsky, MJ | 1 |
| Sacco, KA | 1 |
| Janosky, J | 3 |
| McAuliffe, S | 4 |
| Breaux, AM | 4 |
| Feldman, H | 5 |
| Malone, MA | 7 |
| Kershner, JR | 3 |
| Schvehla, TJ | 1 |
| Mandoki, MW | 1 |
| Sumner, GS | 1 |
| Vinson, DC | 1 |
| van Reekum, R | 1 |
| Links, PS | 1 |
| Brumaghim, JT | 9 |
| Fitzpatrick, PA | 5 |
| Strauss, J | 5 |
| Goldstein, IJ | 1 |
| Adesman, AR | 2 |
| Pawliuk, N | 1 |
| Granger, DA | 4 |
| Fargason, RE | 1 |
| Ford, CV | 1 |
| Johnston, C | 3 |
| Fine, S | 3 |
| Gulotta, C | 1 |
| Rose, SR | 1 |
| Marin, G | 1 |
| Rubinstein, S | 1 |
| Silver, LB | 3 |
| Gay, CT | 1 |
| Ryan, SG | 1 |
| Matochik, JA | 2 |
| Liebenauer, LL | 1 |
| King, AC | 2 |
| Szymanski, HV | 1 |
| Cohen, RM | 2 |
| Gunning, WB | 1 |
| Stoner, G | 5 |
| Carey, SP | 1 |
| Ikeda, MJ | 1 |
| Shinn, MR | 1 |
| Kern, RA | 4 |
| McGhee, DE | 3 |
| Sadeh, A | 1 |
| Munvez, R | 1 |
| Lavie, P | 1 |
| Voros, JG | 2 |
| Logan, WJ | 2 |
| Forney, J | 1 |
| Parker-Fisher, S | 1 |
| Jones, M | 1 |
| Risser, MG | 1 |
| Bowers, TG | 1 |
| Javitt, DC | 2 |
| Silipo, GS | 2 |
| Doneshka, P | 1 |
| Carlson, C | 2 |
| Dixon, MJ | 1 |
| Blank, R | 1 |
| Welsh, PA | 1 |
| Gullotta, CS | 1 |
| Farber, JM | 1 |
| Kelly, KL | 7 |
| Biancaniello, TM | 1 |
| Frank, Y | 1 |
| Pataki, C | 1 |
| Huessy, HR | 4 |
| Funk, JB | 1 |
| Chessare, JB | 1 |
| Weaver, MT | 1 |
| Exley, AR | 1 |
| Cook, JR | 1 |
| Mausbach, T | 1 |
| Burd, L | 1 |
| Gascon, GG | 1 |
| Slotnick, HB | 1 |
| Johnson, RD | 1 |
| Hankey, B | 1 |
| Reynolds, BW | 1 |
| Ahmann, PA | 2 |
| Waltonen, SJ | 1 |
| Olson, KA | 1 |
| Theye, FW | 2 |
| Van Erem, AJ | 1 |
| LaPlant, RJ | 1 |
| Nordahl, TE | 1 |
| Gross, M | 1 |
| Semple, WE | 1 |
| Novak, GP | 1 |
| Kessler, S | 1 |
| Block, RW | 1 |
| Roberts, J | 1 |
| Riddall, MW | 1 |
| Kaufman, G | 1 |
| Malone, A | 1 |
| Rogers, WB | 1 |
| Leutwyler, K | 1 |
| St Dennis, C | 1 |
| Synoground, G | 1 |
| Guerreiro, MM | 1 |
| Montenegro, MA | 1 |
| Piva, RT | 1 |
| Moura-Ribeiro, MV | 1 |
| Melnick, SM | 1 |
| Foodman, A | 1 |
| McPhillips, K | 1 |
| Herning, RI | 1 |
| Marsh, WL | 3 |
| Hamburger, SD | 4 |
| Damico, SK | 1 |
| Armstrong, MB | 1 |
| Loo, S | 1 |
| Isaacs, P | 1 |
| Goya, S | 1 |
| Denney, C | 2 |
| Scanlan, S | 1 |
| Blondis, TA | 2 |
| Schnitzler, ER | 1 |
| O'Brien, T | 1 |
| Fishkin, J | 1 |
| Blackwell, B | 1 |
| Szumowski, E | 1 |
| Roizen, NJ | 1 |
| Schertz, M | 1 |
| Alfieri, NE | 1 |
| Bienkowski, RS | 1 |
| Mauk, JE | 1 |
| McComas, JJ | 1 |
| Green, C | 1 |
| Carr, DE | 1 |
| Corrigall, R | 1 |
| Ford, T | 1 |
| Harding, M | 1 |
| Puumala, T | 1 |
| Ruotsalainen, S | 1 |
| Jäkälä, P | 1 |
| Koivisto, E | 1 |
| Riekkinen, P | 1 |
| Sirviö, J | 1 |
| Fine, EM | 1 |
| Krusch, DA | 1 |
| Eldar, S | 2 |
| Sela, BA | 1 |
| Wolmer, L | 2 |
| Koren, S | 2 |
| Reiss, A | 2 |
| Weizman, R | 3 |
| Laor, N | 2 |
| Myronuk, LD | 1 |
| Cotter, L | 1 |
| Diller, L | 2 |
| Harper, CR | 2 |
| Davies Schraufnagel, C | 1 |
| Brumback, RA | 4 |
| Harby, K | 1 |
| Jones, SM | 1 |
| Kaplan, PE | 1 |
| Bartlik, B | 2 |
| Harmon, G | 1 |
| Ririe, DG | 1 |
| Ririe, KL | 1 |
| Sethna, NF | 1 |
| Fox, L | 1 |
| Camfferman, G | 3 |
| vd Gaag, RJ | 1 |
| Osborne, P | 1 |
| Tumuluru, R | 1 |
| Rojahn, J | 1 |
| del Medico, V | 1 |
| Schweickert, LA | 1 |
| Strober, M | 2 |
| Moskowitz, A | 1 |
| O'Toole, K | 1 |
| Abramowitz, A | 2 |
| Morris, R | 1 |
| Dulcan, M | 1 |
| Lawrence, JD | 1 |
| Lawrence, DB | 1 |
| Carson, DS | 1 |
| Schraufnagel, CD | 1 |
| Losier, BJ | 1 |
| McGrath, PJ | 1 |
| Klein, RM | 1 |
| dosReis, S | 2 |
| Magder, LS | 1 |
| Giedd, JN | 1 |
| McCurry, L | 1 |
| Cronquist, S | 1 |
| Jones, K | 1 |
| Broussard, C | 1 |
| DiGiovanni, G | 1 |
| Herring, M | 1 |
| Fusilier, I | 3 |
| Hanchey, A | 1 |
| Kayser, KH | 1 |
| Wacker, DP | 1 |
| Derby, KM | 1 |
| Andelman, MS | 1 |
| Golonka, Z | 1 |
| Stoner, EA | 1 |
| Sunohara, GA | 2 |
| Kash, IJ | 1 |
| Schachar, RJ | 6 |
| Silbergeld, A | 1 |
| Eshet, R | 1 |
| Bawden, HN | 2 |
| MacDonald, GW | 1 |
| Shea, S | 1 |
| Durst, R | 1 |
| Rebaudengo-Rosca, P | 1 |
| Higgins, RW | 1 |
| Campbell, L | 1 |
| Roberts, W | 4 |
| Humphries, T | 2 |
| Trane, ST | 2 |
| Auci, DL | 1 |
| Fikrig, S | 1 |
| Rodriquez, J | 1 |
| Feeney, DJ | 1 |
| Klykylo, WM | 1 |
| Möcks, P | 1 |
| Lay, B | 1 |
| Eisert, HG | 1 |
| Fojkar, R | 1 |
| Fritz-Sigmund, D | 1 |
| Marcus, A | 1 |
| Musaeus, B | 1 |
| Koplowitz, S | 1 |
| Anderson, T | 1 |
| McMurray, MB | 4 |
| Fletcher, JM | 1 |
| Richters, JE | 1 |
| Schiller, E | 1 |
| Vereen, D | 1 |
| Jarman, F | 2 |
| Barker, M | 2 |
| Detterman, DK | 1 |
| Thompson, LA | 1 |
| Morrow, R | 1 |
| Parish-Plass, J | 1 |
| Musten, LM | 2 |
| Pisterman, S | 2 |
| Bennett, S | 2 |
| Mercer, J | 2 |
| Wender, EH | 4 |
| Bartell, SS | 1 |
| Klass, E | 1 |
| Ganeles, D | 2 |
| Seese, LM | 1 |
| Popper, CW | 1 |
| Swanson, V | 2 |
| Roane, H | 1 |
| Borrero, J | 1 |
| Kouris, S | 1 |
| Yudell, RS | 1 |
| Eppright, TD | 1 |
| Bradley, S | 1 |
| Vogel, SJ | 1 |
| Williamson, HA | 1 |
| Goldman, LS | 1 |
| Genel, M | 1 |
| Bezman, RJ | 1 |
| Slanetz, PJ | 1 |
| Vitulano, L | 1 |
| King, RA | 1 |
| Guinta, D | 2 |
| Browne, R | 2 |
| Waslick, B | 1 |
| Flynn, D | 4 |
| Crowley, KL | 1 |
| Fineberg, E | 3 |
| Regino, R | 1 |
| Cantwell, D | 4 |
| Swartwood, MO | 2 |
| Swartwood, JN | 2 |
| Lubar, JF | 2 |
| Timmermann, DL | 1 |
| Zimmerman, AW | 1 |
| Muenchen, RA | 1 |
| de Boer, D | 1 |
| Waslik, B | 1 |
| Crowley, K | 1 |
| Molina, B | 2 |
| Myak, C | 1 |
| Presnell, M | 1 |
| Willoughby, M | 1 |
| Garland, EJ | 1 |
| Guardiola, A | 1 |
| Terra, AR | 1 |
| Pereira, KR | 1 |
| Rotta, NT | 1 |
| Jarman, FC | 2 |
| Barker, MJ | 2 |
| Oesterheld, JR | 3 |
| Kofoed, L | 1 |
| Tervo, R | 1 |
| Fogas, B | 2 |
| Fiechtner, H | 2 |
| Musser, CJ | 1 |
| Mundt, P | 1 |
| Broste, SK | 1 |
| Mueller-Rizner, N | 1 |
| Morrow, RC | 1 |
| Morrow, AL | 1 |
| Haislip, G | 1 |
| McDowell, DM | 2 |
| Dogin, JW | 1 |
| Rao, JK | 1 |
| Julius, JR | 1 |
| Breen, TJ | 1 |
| Blethen, SL | 1 |
| Smithee, JA | 1 |
| Hitzemann, R | 1 |
| Seeman, P | 1 |
| Madras, BK | 1 |
| Kolko, DJ | 2 |
| Vaidya, CJ | 1 |
| Kirkorian, G | 1 |
| Desmond, JE | 1 |
| Glover, GH | 1 |
| Gabrieli, JD | 1 |
| Mahalick, DM | 1 |
| Carmel, PW | 1 |
| Greenberg, JP | 1 |
| Molofsky, W | 1 |
| Heary, RF | 1 |
| Marks, D | 1 |
| Zampella, E | 1 |
| Hodosh, R | 1 |
| von der Schmidt, E | 1 |
| Lie, N | 1 |
| Shapiro, SK | 1 |
| Newland, MC | 1 |
| Sheppard, DM | 1 |
| Bradshaw, JL | 1 |
| Mattingley, JB | 1 |
| Lee, P | 1 |
| Charatan, F | 2 |
| Walter, JM | 1 |
| Marx, J | 1 |
| Higgins, ES | 1 |
| Schaller, JL | 2 |
| Behar, D | 2 |
| Wical, B | 1 |
| Sigler, M | 1 |
| Kronenberg, J | 1 |
| Lindenmayer, JP | 1 |
| Doron, A | 1 |
| Mendlovic, S | 1 |
| Gaoni, B | 1 |
| Aanonsen, NO | 2 |
| Mathiesen, T | 1 |
| Berman, T | 1 |
| Ambrosini, PJ | 1 |
| Byrne, JM | 1 |
| DeWolfe, NA | 1 |
| Beattie, TL | 1 |
| Midlam, JK | 1 |
| Shapiro, CJ | 1 |
| Forehand, G | 1 |
| Nguyen, A | 1 |
| Brink, S | 1 |
| Stemerdink, N | 1 |
| Grossman, S | 1 |
| Denney, CB | 2 |
| Diamond, IR | 1 |
| Huete, J | 1 |
| Bruce, T | 1 |
| Freeland, J | 1 |
| Edwards, S | 1 |
| Shafer, MA | 2 |
| Levine, S | 2 |
| Breggin, PR | 2 |
| Bryhn, G | 1 |
| Bjercke, C | 1 |
| Truyen, K | 1 |
| Strand, G | 1 |
| Barron, J | 1 |
| Robison, LM | 2 |
| Sclar, DA | 2 |
| Skaer, TL | 2 |
| Galin, RS | 2 |
| Gibbs, N | 1 |
| Rogers, A | 1 |
| Parker, RA | 1 |
| Hartman, EE | 1 |
| Chavez, H | 1 |
| Ozolins, D | 1 |
| Losek, JD | 1 |
| Diller, LH | 4 |
| Kempton, S | 1 |
| Luk, E | 1 |
| Costin, J | 1 |
| Pantelis, C | 1 |
| Kettle, L | 1 |
| Roper, MT | 1 |
| Sloan, MT | 1 |
| Dulcan, MK | 4 |
| Hoven, C | 1 |
| Bird, HR | 1 |
| Payne, JD | 1 |
| Lurier, A | 1 |
| Murray, PJ | 1 |
| Rowan, A | 1 |
| Williams, JH | 1 |
| Butte, NF | 1 |
| Treuth, MS | 1 |
| Rovet, J | 1 |
| Harmatz, JS | 1 |
| Parmelee, DX | 1 |
| Law, SF | 1 |
| Alsop, B | 1 |
| Tucker, SM | 1 |
| Tomazic, T | 1 |
| Levine, MD | 1 |
| Accardo, PJ | 1 |
| Ramos, L | 2 |
| Majumdar, T | 1 |
| Hayes, M | 1 |
| Tse, F | 1 |
| Udrea, D | 1 |
| Kardatzke, D | 1 |
| Ram, A | 1 |
| White, JN | 1 |
| Paternite, CE | 1 |
| Salisbury, H | 2 |
| Whaley, MA | 1 |
| Frankel, F | 1 |
| Myatt, R | 1 |
| Cherland, E | 1 |
| Fitzpatrick, R | 1 |
| Crutchley, A | 1 |
| Temlett, JA | 1 |
| Williams, A | 2 |
| Steiner, RL | 2 |
| Kent, MA | 1 |
| Camfield, CS | 1 |
| Camfield, PR | 1 |
| Dech, B | 1 |
| Comings, DE | 1 |
| Kimko, HC | 1 |
| Cross, JT | 1 |
| Abernethy, DR | 1 |
| Rimer, P | 1 |
| Aspide, R | 1 |
| Fresiello, A | 1 |
| de Filippis, G | 1 |
| Gironi Carnevale, UA | 1 |
| Papa, M | 1 |
| Sellitti, S | 1 |
| Castaneda, R | 1 |
| Levy, R | 1 |
| Hardy, M | 1 |
| Trujillo, M | 1 |
| Davis, HT | 1 |
| O'Malley, KD | 1 |
| Koplin, B | 1 |
| Dohner, VA | 1 |
| Gardner, JF | 1 |
| Boles, M | 1 |
| Lynch, F | 1 |
| Coyle, JT | 1 |
| Glod, CA | 1 |
| Maas, LC | 1 |
| Carey, WB | 2 |
| Sarkis, EH | 1 |
| Rees, A | 1 |
| Ferrell, RE | 1 |
| Gara, L | 1 |
| Bramble, D | 1 |
| Aggarwal, A | 1 |
| Lillystone, D | 1 |
| Trott, G | 1 |
| Smeyers, P | 1 |
| Presentación, MJ | 1 |
| Seward, R | 2 |
| Jadad, AR | 1 |
| Boyle, M | 1 |
| Browne, RG | 1 |
| Wynne, SK | 1 |
| Ancilletta, B | 1 |
| Muglia, P | 2 |
| Tse, FL | 1 |
| Kalb, C | 1 |
| McNeal, RE | 1 |
| Roberts, MC | 1 |
| Barone, VJ | 1 |
| Binder, LM | 1 |
| Dixon, MR | 1 |
| Ghezzi, PM | 1 |
| Frijters, J | 1 |
| Tahir, E | 1 |
| Cirakoglu, B | 1 |
| Challman, TD | 1 |
| Lipsky, JJ | 1 |
| Doyle, AE | 1 |
| Lahat, E | 1 |
| Ben-Shlomo, A | 1 |
| Bistritzer, T | 1 |
| Marshall, E | 2 |
| Sachdev, PS | 1 |
| Trollor, JN | 1 |
| Malever, M | 1 |
| Morris, J | 1 |
| Hill, R | 1 |
| Reeve, R | 1 |
| Kafka, MP | 1 |
| Hennen, J | 1 |
| Bouvard, M | 1 |
| Mouren-Siméoni, MC | 1 |
| de Villiers, AS | 1 |
| Lamm, MC | 1 |
| Taljaard, JJ | 1 |
| Kramer, JR | 1 |
| Arthur, C | 1 |
| Lubetsky, M | 1 |
| Miller, AL | 1 |
| Kidd, PM | 1 |
| Vallée, L | 2 |
| LaFougere, C | 1 |
| Brinkbäumer, K | 1 |
| 't Jong, GW | 1 |
| van den Anker, JN | 1 |
| Calloway, P | 1 |
| White, SR | 1 |
| Yadao, CM | 1 |
| Babcock, Q | 1 |
| Byrne, T | 1 |
| Wingert, P | 1 |
| Accardo, P | 1 |
| Shute, N | 1 |
| Niedermeyer, E | 1 |
| Dobson, R | 1 |
| Segal, A | 1 |
| Clevenger, W | 1 |
| Wu, M | 1 |
| Murray, LK | 1 |
| Ardoin, SP | 1 |
| Martens, BK | 1 |
| Ripley, A | 1 |
| Kotsopoulos, S | 1 |
| Spivak, M | 1 |
| Ruskin, DN | 1 |
| Bergstrom, DA | 1 |
| Shenker, A | 1 |
| Freeman, LE | 1 |
| Baek, D | 1 |
| Fukui, R | 1 |
| Yoshida, I | 1 |
| Impicciatore, P | 1 |
| Pandolfini, C | 1 |
| Hemmer, SA | 1 |
| Pasternak, JF | 1 |
| Zecker, SG | 2 |
| Trommer, BL | 2 |
| Greene, RW | 1 |
| Hill, P | 1 |
| Reitman, D | 2 |
| Hupp, SD | 2 |
| O'Callaghan, PM | 1 |
| Grcevich, S | 1 |
| Rowane, WA | 1 |
| Marcellino, B | 1 |
| Sullivan-Hurst, S | 1 |
| Stordahl, H | 1 |
| Horrigan, JP | 1 |
| Roesch, TA | 1 |
| Ginsburg, GS | 1 |
| Kau, AS | 1 |
| Keller, WD | 1 |
| Morrisey, SM | 1 |
| Nguyen, CA | 1 |
| Fielbelkorn, K | 1 |
| Morse, GD | 1 |
| Adrian, N | 1 |
| Lynskey, MT | 1 |
| Hall, W | 1 |
| Brodeur, DA | 1 |
| Pond, M | 1 |
| Bodenstein, L | 1 |
| Skolnik, R | 1 |
| Lewis, BR | 1 |
| Aoun, SL | 1 |
| Bernstein, GA | 1 |
| Crow, SJ | 1 |
| Ghaziuddin, N | 1 |
| Iqbal, A | 1 |
| Khetarpal, S | 1 |
| Perel, JM | 2 |
| Rudolph, G | 1 |
| Feldman, B | 1 |
| Curran, S | 1 |
| Gardner, R | 1 |
| Harwood, TM | 1 |
| Beutler, LE | 1 |
| Pisecco, S | 1 |
| Huzinec, C | 1 |
| Curtis, D | 1 |
| Thiruchelvam, D | 1 |
| Weisfelt, M | 1 |
| Schrier, AC | 1 |
| de Leeuw, MC | 1 |
| Aeckerlin, LP | 1 |
| Riccio, CA | 1 |
| Waldrop, JJ | 1 |
| Reynolds, CR | 1 |
| Lowe, P | 1 |
| Strik, WK | 1 |
| Altenderfer, L | 1 |
| Baron-Myak, C | 1 |
| Levin, ED | 1 |
| Silva, D | 1 |
| Canu, W | 1 |
| Lan, I | 1 |
| McClellan, K | 1 |
| Jarvis, B | 1 |
| Fogas, BS | 1 |
| Novak, V | 1 |
| Grov, B | 1 |
| Garåsen, H | 1 |
| Kehoe, WA | 1 |
| Abbott, MB | 1 |
| Levin, RH | 1 |
| Gianarris, WJ | 1 |
| Golden, CJ | 1 |
| Greene, L | 1 |
| Francis, S | 1 |
| Fine, J | 1 |
| Hamrin, V | 1 |
| Bailey, K | 1 |
| Kolata, G | 1 |
| Frei, H | 1 |
| Thurneysen, A | 1 |
| Seeger, G | 1 |
| Schloss, P | 1 |
| Wagner, MW | 1 |
| Kramer, AF | 1 |
| Cepeda, NJ | 1 |
| Cepeda, ML | 1 |
| Ilgin, N | 1 |
| Gokcora, N | 1 |
| Sener, S | 1 |
| Lena, SM | 1 |
| Chidambaram, U | 1 |
| Panarella, C | 1 |
| Sambasivan, K | 1 |
| Armstrong, RW | 1 |
| Schachter, HM | 1 |
| Pham, B | 1 |
| Langford, S | 1 |
| Moher, D | 1 |
| Pillow, DR | 2 |
| Marchetti, A | 1 |
| Magar, R | 1 |
| Lau, H | 1 |
| Murphy, EL | 1 |
| Wineburg, E | 1 |
| Carotenuto, I | 1 |
| Einarson, TR | 1 |
| Iskedjian, M | 1 |
| Ross, DC | 1 |
| Fischhoff, J | 1 |
| Davenport, B | 1 |
| Middelkoop, HA | 1 |
| van Gils, K | 1 |
| Chen, Z | 1 |
| Gaffney, GR | 1 |
| Lund, BC | 1 |
| Bever-Stille, KA | 1 |
| Arndt, S | 1 |
| Holman, TL | 1 |
| Moser, DJ | 1 |
| Paulsen, JS | 1 |
| Franceschi, D | 1 |
| Gifford, A | 1 |
| Jaffe, SL | 2 |
| Joshi, SV | 1 |
| Bernet, W | 1 |
| Arnold, V | 1 |
| Beitchman, J | 1 |
| Benson, RS | 1 |
| Kinlan, J | 1 |
| McClellan, J | 1 |
| Rue, D | 1 |
| Shaw, JA | 1 |
| Stock, S | 1 |
| Kurlan, R | 1 |
| Fox, GB | 1 |
| Pan, JB | 1 |
| Esbenshade, TA | 1 |
| Bennani, YL | 1 |
| Black, LA | 1 |
| Faghih, R | 1 |
| Hancock, AA | 1 |
| Decker, MW | 1 |
| Masellis, M | 1 |
| Basile, VS | 1 |
| Ozdemir, V | 1 |
| Macciardi, FM | 1 |
| Sund, AM | 1 |
| Zaw, F | 1 |
| Handley, SL | 1 |
| Yamazaki, K | 1 |
| Pentikis, HS | 1 |
| Simmons, RD | 1 |
| Benedict, MF | 1 |
| Greenhouse, J | 1 |
| Wolfson, L | 1 |
| Fitzpatrick, E | 1 |
| O'Callaghan, P | 1 |
| LeBlanc, M | 1 |
| Liebelt, EL | 1 |
| Klein-Schwartz, W | 1 |
| Ueno, KI | 1 |
| Ohashi, S | 1 |
| Hoshino, A | 1 |
| Fujita, T | 1 |
| Saito, H | 1 |
| Minami, M | 1 |
| Rodrigues, ST | 1 |
| Baldwin, L | 1 |
| Kluwe, L | 1 |
| Thakker, SD | 1 |
| Leark, RA | 1 |
| Schwartz, J | 1 |
| Holtkamp, K | 1 |
| Peters-Wallraf, B | 1 |
| Wüller, S | 1 |
| Pfäaffle, R | 1 |
| Randall, R | 1 |
| Winkelaar, PG | 1 |
| Jr Fischer, B | 1 |
| Fischer, B | 1 |
| Hartnegg, K | 1 |
| Tervo, RC | 1 |
| Azuma, S | 1 |
| Sawyer, MG | 1 |
| Graetz, BW | 1 |
| Clark, JJ | 1 |
| Baghurst, PA | 1 |
| Rosa Neto, P | 1 |
| Lou, H | 1 |
| Hastings, JE | 1 |
| Fras, I | 1 |
| Karlavage, J | 1 |
| Kaffman, M | 1 |
| Sher, A | 1 |
| Bar-Sinai, N | 1 |
| Eggers, C | 1 |
| Christopher, J | 1 |
| Huestis, R | 1 |
| Smeltzer, DJ | 2 |
| Zucker, K | 1 |
| Authier, J | 1 |
| Donaldson, J | 1 |
| Prica, G | 1 |
| Alperin, E | 1 |
| Ensz, G | 1 |
| Langhorne, JE | 1 |
| Leary, PM | 2 |
| Arens, L | 1 |
| Marshall, S | 1 |
| Schadle, S | 1 |
| Klopper, JH | 1 |
| Gordon, JW | 1 |
| Weiner, WJ | 1 |
| Nausieda, PA | 1 |
| Klawans, HL | 1 |
| Hurst, DL | 1 |
| Zahn, TP | 2 |
| Little, BC | 2 |
| Packer, S | 1 |
| Prinz, RJ | 1 |
| Mishalow, J | 1 |
| Joad, J | 1 |
| Zetin, M | 1 |
| Janowsky, DS | 1 |
| Judd, LL | 1 |
| Rosenfeld, AA | 1 |
| Rie, HE | 2 |
| Rie, ED | 1 |
| Stewart, S | 1 |
| Ambuel, JP | 1 |
| Johnson, GE | 1 |
| Seals, JR | 1 |
| Wolfenberger-Haessig, C | 1 |
| Weber, A | 1 |
| Levine, EM | 1 |
| Kozak, C | 1 |
| Shaiova, CH | 1 |
| Lerer, RJ | 1 |
| Lerer, MP | 1 |
| Artner, J | 1 |
| Bellak, L | 1 |
| Gross, MD | 3 |
| Mann, HB | 1 |
| Greenspan, SI | 1 |
| Renshaw, D | 1 |
| Denckla, MB | 1 |
| Bemporad, JR | 1 |
| MacKay, MC | 2 |
| Lewis, JA | 1 |
| Young, R | 1 |
| Huestis, RD | 1 |
| Palmer, S | 1 |
| Schain, RJ | 1 |
| Abate, F | 1 |
| Beck, L | 2 |
| Langford, WS | 1 |
| Mackay, M | 1 |
| Sum, G | 1 |
| Kind, CR | 1 |
| Ordoña, TT | 1 |
| Sulzbacher, SI | 1 |
| Majovski, LV | 1 |
| Levy, HB | 1 |
| Metzger, MA | 1 |
| Schiørbeck, HK | 1 |
| Rugland, AL | 1 |
| Spinnangr, I | 1 |
| Sagvolden, G | 1 |
| Rosenberg, DR | 1 |
| Crowner, S | 1 |
| Thomas, C | 1 |
| Gourash, L | 1 |
| Ruel, JM | 2 |
| Hickey, CP | 1 |
| Srinivas, NR | 4 |
| Hubbard, JW | 4 |
| Tao, KT | 1 |
| Ashkenazi, A | 1 |
| Nussinovitch, M | 1 |
| Gross, S | 1 |
| Frydman, M | 1 |
| Murphy, DA | 6 |
| Lang, AR | 1 |
| Buhrmester, D | 3 |
| MacDonald, V | 1 |
| Matier, K | 1 |
| Sathaye, N | 1 |
| Wright, V | 1 |
| Danon, M | 1 |
| Stiller, RL | 1 |
| Kelly, DP | 1 |
| Aylward, GP | 1 |
| Abramowitz, AJ | 1 |
| Eckstrand, D | 1 |
| O'Leary, SG | 1 |
| Forness, SR | 2 |
| Youpa, D | 2 |
| Hanna, GL | 2 |
| Alston, CY | 1 |
| Romney, DM | 1 |
| Gosling, A | 3 |
| Heller, T | 2 |
| McHale, JP | 1 |
| Vannatta, K | 1 |
| Milich, R | 10 |
| Licht, BG | 3 |
| Greenslade, KE | 2 |
| Vodde-Hamilton, M | 2 |
| Hall, CW | 1 |
| Kataria, S | 1 |
| Hart-Santora, D | 1 |
| Hart, LL | 1 |
| Pandit, F | 1 |
| Levinson, HN | 1 |
| Johnson, GH | 1 |
| Brown, FR | 1 |
| Porter, B | 1 |
| Bar-David, Y | 1 |
| Galil, A | 1 |
| Mino, Y | 1 |
| Ohara, H | 1 |
| Cummings, EM | 1 |
| Schaughency, EA | 1 |
| DiTraglia, J | 1 |
| Goldstein, E | 1 |
| Keith, RW | 1 |
| Engineer, P | 1 |
| Elliger, TJ | 1 |
| Turbott, SH | 3 |
| Korchinski, ED | 1 |
| Anastopoulos, AD | 1 |
| Hanna, G | 1 |
| Liu, C | 1 |
| Robin, AL | 1 |
| Brenner, S | 1 |
| Eastman, J | 1 |
| Bachmann, P | 1 |
| Erikson, A | 1 |
| Sjögren, H | 1 |
| Kjellberg, E | 1 |
| Marks, RE | 2 |
| Wilsher, CP | 2 |
| Merry, SN | 2 |
| Ratey, JJ | 1 |
| Greenberg, MS | 1 |
| Lindem, KJ | 1 |
| Hoeppner, JA | 1 |
| Ouellette, EM | 1 |
| Heilman, KM | 1 |
| Voeller, KK | 1 |
| Nadeau, SE | 1 |
| Bowen, J | 1 |
| Fenton, T | 1 |
| Rappaport, L | 1 |
| Horn, WF | 1 |
| Ialongo, NS | 1 |
| Pascoe, JM | 1 |
| Greenberg, G | 1 |
| Packard, T | 1 |
| Wagner, A | 1 |
| Puttler, L | 1 |
| Keysor, CS | 3 |
| Lexchin, J | 1 |
| Fischer, M | 1 |
| Edelbrock, C | 1 |
| Smallish, L | 1 |
| Hilhorst, RC | 1 |
| Siegel, LS | 2 |
| Offord, DR | 2 |
| Wagner, JL | 1 |
| Brostë, SM | 1 |
| Ploof, DL | 1 |
| Edelbrock, CS | 2 |
| Robbins, K | 2 |
| Greenstein, JJ | 1 |
| Guthrie, KJ | 1 |
| Hoover, MD | 1 |
| Dahl, RE | 1 |
| Amass, J | 1 |
| Paolicelli, L | 1 |
| Kaplan, SL | 1 |
| Kupietz, S | 2 |
| Wassermann, E | 1 |
| Segal, B | 1 |
| McBride, MC | 5 |
| Loeb, S | 3 |
| Heath, CT | 1 |
| Wright, HH | 1 |
| Batey, SR | 1 |
| Potashkin, BD | 1 |
| Beckles, N | 1 |
| Wultz, B | 1 |
| Moser, EI | 1 |
| Moser, MB | 1 |
| Sebrechts, MM | 2 |
| Vincent, J | 1 |
| Leger, P | 1 |
| Harper, GW | 1 |
| Clinton, J | 1 |
| Thiele, C | 1 |
| Lindgren, S | 2 |
| Stromquist, A | 1 |
| Davis, C | 1 |
| Watson, D | 1 |
| McDaniel, KD | 1 |
| Linnoila, M | 2 |
| Karoum, F | 2 |
| Sallee, R | 1 |
| Goldberg, RL | 1 |
| Davy, T | 1 |
| Rodgers, CL | 1 |
| Brown, GL | 1 |
| Chuang, LW | 1 |
| Wyatt, RJ | 1 |
| Allen, RP | 1 |
| Vore, M | 1 |
| Potts, BD | 1 |
| Kryscio, RJ | 1 |
| Norton, JC | 1 |
| Madigan, JM | 1 |
| Heffron, WM | 1 |
| Liu, JP | 1 |
| Phillips, S | 1 |
| Quinn, SO | 1 |
| Quinn, EP | 1 |
| Clayton, CJ | 1 |
| Vyse, SA | 2 |
| Dalby, JT | 1 |
| Jewesson, B | 1 |
| Crumrine, P | 1 |
| Alvin, R | 1 |
| Teodori, J | 1 |
| Payton, JB | 1 |
| Burkhart, JE | 1 |
| Hersen, M | 1 |
| Helsel, WJ | 1 |
| Walker, JL | 2 |
| Sturges, J | 3 |
| Hoza, J | 3 |
| Stevenson, RD | 1 |
| Carr, RP | 2 |
| Chajczyk, D | 1 |
| Donney, VK | 1 |
| Poppen, R | 1 |
| Knoll, E | 1 |
| Chandler, ML | 1 |
| Barnhill, JL | 1 |
| Patterson, DR | 2 |
| Koopman, HM | 1 |
| Heltzel, A | 1 |
| Sexson, SB | 2 |
| Paolicelli, LM | 1 |
| Huber, A | 1 |
| Laski, K | 1 |
| Henriksen, L | 1 |
| Bruhn, P | 1 |
| Børner, H | 1 |
| Nielsen, JB | 1 |
| Birmaher, B | 2 |
| Cooper, TB | 1 |
| Maminski, B | 1 |
| Erhardt, D | 1 |
| Dunnington, RE | 1 |
| Cohen, ML | 2 |
| Kelly, PC | 2 |
| Atkinson, AW | 2 |
| Bernhout, E | 1 |
| Dillon, DC | 1 |
| Salzman, IJ | 1 |
| Schulsinger, DA | 1 |
| Sackler, AM | 1 |
| Weltman, AS | 1 |
| Golden, GS | 1 |
| Krager, JM | 1 |
| Walker, WO | 1 |
| Caskey, OL | 1 |
| Bylsma, FW | 1 |
| Pivik, RT | 1 |
| Kløve, H | 1 |
| Dick, J | 1 |
| Gil-Ad, I | 1 |
| Laron, Z | 1 |
| Cotton, MF | 1 |
| Rothberg, AD | 1 |
| Morgan, AM | 1 |
| Landa, B | 1 |
| Amin, K | 1 |
| O'Neill, ME | 2 |
| Britton, BG | 2 |
| Evans, RW | 2 |
| Amara, I | 1 |
| Caine, ED | 1 |
| Chiverton, P | 1 |
| Bamford, KA | 1 |
| Rediess, S | 1 |
| Shiao, J | 1 |
| Wiener, JM | 1 |
| Archer, T | 1 |
| Fredriksson, A | 1 |
| Sundström, E | 1 |
| Luthman, J | 1 |
| Lewander, T | 1 |
| Söderberg, U | 1 |
| Jonsson, G | 1 |
| Siegel, L | 1 |
| Reiter, G | 1 |
| Foley, C | 1 |
| Walker, MK | 1 |
| Porter, LS | 1 |
| Cornblatt, B | 2 |
| Murray, JB | 1 |
| Tucker, SB | 1 |
| Schoeler, T | 1 |
| Maitinsky, S | 1 |
| Mendell, N | 1 |
| Bloom, AS | 1 |
| Russell, LJ | 1 |
| Weisskopf, B | 1 |
| Blackerby, JL | 1 |
| Conte, R | 1 |
| Satel, S | 1 |
| Southwick, S | 1 |
| Denton, C | 1 |
| Borcherding, B | 1 |
| Thompson, K | 1 |
| Kruesi, M | 1 |
| Bartko, J | 1 |
| Weingartner, H | 1 |
| Fulton, AI | 1 |
| Yates, WR | 1 |
| Rumain, B | 1 |
| Syrigou-Papavasiliou, A | 1 |
| Lycaki, H | 1 |
| LeWitt, PA | 1 |
| Verma, NP | 1 |
| Spivak, D | 1 |
| Chayasirisobhon, S | 1 |
| Berlin, CM | 1 |
| Borden, KA | 4 |
| Clingerman, SR | 4 |
| Geniesse, R | 1 |
| Spunt, AL | 2 |
| Jones, TJ | 1 |
| Kutcher, SP | 1 |
| Katz, S | 1 |
| Struve, FA | 1 |
| Reeves, JC | 1 |
| Werry, JS | 1 |
| Wallander, JL | 1 |
| Michelli, JA | 1 |
| Thorley, G | 2 |
| Wieselberg, HM | 1 |
| Everitt, B | 1 |
| Rutter, M | 2 |
| Rossel, E | 1 |
| Granger, D | 2 |
| Kliewer, W | 1 |
| Spencer, J | 1 |
| Satterfield, BT | 2 |
| Kappraff, MS | 1 |
| Mørkrid, L | 1 |
| Qiao, ZG | 1 |
| Reichelt, KL | 1 |
| Winsberg, B | 1 |
| Matinsky, S | 1 |
| Castro, J | 1 |
| Copeland, L | 1 |
| Woolson, R | 1 |
| Schmidt, C | 1 |
| Bijlsma, JJ | 1 |
| Moorer, S | 1 |
| Wieselberg, M | 1 |
| Nasrallah, HA | 1 |
| Olson, SC | 1 |
| McCalley-Whitters, M | 1 |
| Kramer, J | 1 |
| Jacoby, CG | 1 |
| Crowe, D | 1 |
| McGrath, P | 1 |
| Brunstetter, RW | 1 |
| Koehler-Troy, C | 1 |
| Malenbaum, R | 1 |
| Schleser, R | 1 |
| Porrino, LJ | 1 |
| Lucignani, G | 1 |
| Wood, D | 1 |
| Ward, M | 1 |
| Birmingham, BK | 2 |
| Tucker, S | 1 |
| Bender, ME | 1 |
| Caddell, J | 1 |
| Booth, S | 1 |
| Moorer, SH | 1 |
| Pollard, S | 1 |
| Weber, K | 1 |
| Hesterly, SO | 1 |
| Kimball, JG | 1 |
| Medenis, R | 1 |
| Becker-Mattes, A | 1 |
| Ottinger, DR | 1 |
| Halpin, B | 1 |
| Miller, M | 1 |
| Demian, L | 1 |
| Hannemann, R | 1 |
| Frances, A | 1 |
| Eichlseder, W | 1 |
| Smith, NF | 1 |
| Grossman, LK | 1 |
| Grossman, NJ | 1 |
| Angrist, B | 1 |
| McConnell, H | 1 |
| Masse, G | 1 |
| Ondrusek, MG | 1 |
| Finley, C | 1 |
| Gawin, F | 1 |
| Riordan, C | 1 |
| Kleber, H | 1 |
| Solomons, G | 1 |
| Faigel, HC | 1 |
| Sroufe, LA | 2 |
| Stewart, MA | 1 |
| Seger, EY | 1 |
| Hallum, G | 1 |
| Feinberg, I | 1 |
| Hibi, S | 1 |
| Braun, M | 1 |
| Cavness, C | 1 |
| Westerman, G | 1 |
| Small, A | 1 |
| Levitis, KA | 1 |
| Ney, PG | 1 |
| Eisenberg, L | 1 |
| Taylor, R | 1 |
| Lesser, LI | 1 |
| Saul, RE | 1 |
| Erenberg, G | 2 |
| Omenn, GS | 2 |
| Sonies, BC | 1 |
| West, WD | 1 |
| Wright, FS | 1 |
| Green, RP | 1 |
| Scales, SM | 1 |
| Rosser, PL | 1 |
| Reece, RM | 1 |
| Friedman, R | 1 |
| Dale, EP | 1 |
| Wagner, JH | 1 |
| Verret, S | 1 |
| Peters, JE | 1 |
| Haddock, ST | 1 |
| Nichamin, SJ | 1 |
| Howell, MC | 1 |
| Rever, GW | 1 |
| Scholl, ML | 1 |
| Trowbridge, F | 1 |
| Rutledge, A | 1 |
| Schwartz, ML | 1 |
| Pizzo, SV | 1 |
| McKee, PA | 1 |
| Cohn, HD | 1 |
| Vildoso de Palacios, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Relationship Between CES1 Genotype and Methylphenidate Response in Children With ADHD - INDICES Work Package 6[NCT04366609] | 207 participants (Actual) | Observational | 2012-05-01 | Completed | |||
| Adherence to Antidepressant Treatment in Subjects With Depression[NCT03388164] | Phase 2 | 23 participants (Actual) | Interventional | 2018-01-01 | Terminated (stopped due to The study was terminated early based on the planned interim analysis that did not meet criteria for continuation.) | ||
| Third Generation Cognitive Behavioural Therapy Versus Treatment-as-usual for Attention Deficit and Hyperactivity Disorder: a Randomized, 2-parallel-group, Evaluator Blinded, Superiority Trial[NCT03437772] | 248 participants (Actual) | Observational | 2018-02-19 | Completed | |||
| Effectiveness of Methylphenidate Late Formula to Reduce Cannabis Use in Young Cannabis-Related Patients and Attention Deficit Disorder Hyperactivity[NCT03481959] | Phase 3 | 3 participants (Actual) | Interventional | 2019-05-07 | Terminated (stopped due to insufficient recrutement in the study) | ||
| Treatments for Fathers With Attention Deficit/Hyperactivity Disorder (ADHD) and Their At-Risk Children (Fathers Too)[NCT02675400] | Phase 4 | 19 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| An Open International Multicentre Long-Term Follow Up Study to Evaluate Safety of Prolonged Release OROS Methlyphenidate in Adults With Attention Deficit Hyperactivity Disorder[NCT00307684] | Phase 3 | 155 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| A 6-month, Open-label Extension to a 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in the Treatment of Adult Patients With Childhood-onset ADHD[NCT01338818] | Phase 3 | 299 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| Real-world Evidence of Duration of Adhansia XR for Treatment of ADHD (RE-DAX): An Open-label Pragmatic Study to Assess the Real-world Effectiveness of Adhansia XR in Treatment of Adult and Adolescent Patients With ADHD in the United States[NCT04507204] | Phase 4 | 267 participants (Actual) | Interventional | 2020-07-30 | Terminated (stopped due to (due to administrative reasons not related to efficacy or safety.)) | ||
| Examining Tolerance to CNS Stimulants in ADHD[NCT02039908] | Phase 4 | 267 participants (Actual) | Interventional | 2013-04-30 | Completed | ||
| An Eight-Week, Randomized, Double-Blind Comparison of Guanfacine, Focalin XR, and the Combination, With a Twelve Month Open-Label Extension for the Treatment of ADHD in Pediatric Subjects Aged 7 to 14 Years[NCT00429273] | Phase 4 | 212 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Early Interventions in Children With Attention Deficit/Hyperactivity Disorder: Randomized Controlled Trial Comparing Methylphenidate Parental Training in Treating Preschool Children With Attention Deficit / Hyperactivity Disorder[NCT02807870] | Phase 4 | 153 participants (Actual) | Interventional | 2016-06-30 | Completed | ||
| Novel Approach to Stimulant Induced Weight Suppression and Its Impact on Growth[NCT01109849] | Phase 3 | 230 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| Comparing The Effects Of Cognitive Behavioral Therapy And Motor Learning Technique in Adults With Attention Deficit Hyperactivity Disorder.[NCT06064032] | 36 participants (Anticipated) | Interventional | 2023-10-02 | Not yet recruiting | |||
| Efficacy of Pharmacologic Management of ADHD in Children and Youth With Autism Spectrum Disorder[NCT05916339] | Phase 4 | 500 participants (Anticipated) | Interventional | 2023-10-01 | Not yet recruiting | ||
| Ph 3 Multicenter OL Treatment-optimized RDBPC Forced-withdrawal, Parallel Grp Study to Evaluate Safety & Efficacy of Evening Dosed HLD200, a Novel DR/ER Formulation (DELEXIS) of MPH HCl in Children Aged 6-12 With ADHD in Classroom Setting[NCT02493777] | Phase 3 | 125 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| Clinical and Pharmacogenetic Study of Attention Deficit With Hyperactivity Disorder (ADHD)[NCT00483106] | Phase 4 | 885 participants (Actual) | Interventional | 1999-11-30 | Completed | ||
| Clinical and Neuropsychological Validity of Attention-Deficit Hyperactivity Disorder in Adulthood[NCT00550667] | 1,120 participants (Actual) | Observational | 2007-10-01 | Completed | |||
| A 12-Month Open Label Safety Study of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR®) in Children Ages 4-5 Years Diagnosed With Attention-Deficit/Hyperactivity Disorder (ADHD)[NCT02677519] | Phase 4 | 120 participants (Anticipated) | Interventional | 2016-09-30 | Not yet recruiting | ||
| A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Multi-Center Study Measuring the Efficacy and Safety of PRC-063 in Adult ADHD Patients[NCT02139124] | Phase 3 | 375 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| A Six-month, Open-label, Multi-center Study of the Safety and Efficacy of PRC-063 in Adults and Adolescents With ADHD[NCT02168127] | Phase 3 | 360 participants (Actual) | Interventional | 2014-05-31 | Completed | ||
| Ph 3 Multicenter DBRCT Parallel Group Study to Evaluate Safety & Efficacy of Evening-dosed HLD200, a Novel Delayed & Extended Release Formulation (DELEXIS) of MPH HCl, on Post-waking, Early Morning Function in Children Aged 6-12 With ADHD[NCT02520388] | Phase 3 | 163 participants (Actual) | Interventional | 2015-08-31 | Completed | ||
| Adjuvant Effects of Vitamin A and Vitamin D Supplementation on Treatment of Children With ADHD:A Randomized, Double Blind, Placebo-controlled, Multicentric Trial.[NCT04284059] | Phase 4 | 504 participants (Anticipated) | Interventional | 2021-02-25 | Recruiting | ||
| Effectiveness of a Personalized Neurofeedback Training Device (ADHD@Home) as Compared With Methylphenidate in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: A Multicentre Randomized Clinical Study[NCT02778360] | Phase 1/Phase 2 | 179 participants (Anticipated) | Interventional | 2016-08-31 | Recruiting | ||
| Attention Deficit/Hyperactivity Disorder (ADHD) Medications in Japan: A Retrospective Cohort Study of Label Compliance[NCT04113551] | 17,418 participants (Actual) | Observational | 2019-10-01 | Completed | |||
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Adult Laboratory Classroom Study to Evaluate the Safety and Efficacy of PRC-063 Compared to Placebo in Adults With ADHD[NCT03618030] | Phase 3 | 288 participants (Actual) | Interventional | 2018-08-21 | Completed | ||
| Effect of a Polyphenol-rich Plant Extract on Attention-Deficit Hyperactivity Disorder (ADHD): A Randomized, Double Blind, Placebo and Active Product Controlled Multicenter Trial.[NCT02700685] | Phase 3 | 88 participants (Actual) | Interventional | 2017-09-01 | Completed | ||
| Sleep Patterns in Children and Adolescents With ADHD: Impact on Cognitive Functions and Quality of Life[NCT03737552] | 84 participants (Actual) | Observational | 2019-04-23 | Completed | |||
| The Effects of a Single Dose of Methylphenidate on Motor Performance[NCT04283604] | Phase 4 | 200 participants (Anticipated) | Interventional | 2021-05-27 | Recruiting | ||
| A Multicenter, Dose-optimized, Double-blind, Randomized, Placebo-controlled Study To Evaluate The Efficacy Of Nwp09 In Pediatric Patients With Attention Deficit Hyperactivity Disorder (Adhd) In A Laboratory Classroom[NCT01654250] | Phase 3 | 90 participants (Actual) | Interventional | 2012-07-31 | Completed | ||
| Measuring and Predicting Response to Atomoxetine and Methylphenidate[NCT00183391] | Phase 4 | 232 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| Influence of Stimulant Medication on Brain Processes for Decision Making in Attention Deficit Hyperactivity Disorder[NCT01831622] | Phase 4 | 131 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| Assessment of Pharmacogenomics Testing for Improving Pediatric ADHD Psychopharmacological Treatment: A Randomized Controlled Trial[NCT03730870] | 21 participants (Actual) | Interventional | 2019-02-28 | Terminated (stopped due to This study's genetic testing laboratory has suspended operations pending discussions with the FDA concerning clinical interpretation of pharmacogenomics tests.) | |||
| A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years Wit[NCT01552902] | Phase 4 | 549 participants (Actual) | Interventional | 2012-04-03 | Completed | ||
| A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Dose-optimization Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Att[NCT01552915] | Phase 4 | 464 participants (Actual) | Interventional | 2012-04-17 | Completed | ||
| A Pilot Study of Osmotic-Release Methylphenidate in Initiating and Maintaining Abstinence in Smokers With ADHD[NCT00253747] | Phase 3 | 255 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| Pediatric Attention Deficit Hyperactivity Disorder: Predicting Clinical Response to Stimulant Medication From Single-dose Changes in Event Related Potentials[NCT02695355] | Phase 2 | 87 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| Rehabilitació Assistida Amb Cavalls Posttractament oncològic en Nens i Adolescents: Efectes físics i psicològics[NCT04070131] | 30 participants (Anticipated) | Interventional | 2019-10-15 | Active, not recruiting | |||
| Gene-environment Interactions and Brain Functional Connectivity Associated With Norepinephrine System Genes in Attention Deficit Hyperactivity Disorder[NCT01912352] | 83 participants (Actual) | Interventional | 2010-05-31 | Completed | |||
| International Study to Predict Optimised Treatment Response to Short or Long Acting Methylphenidate in Children and Adolescents With Attention Deficit/Hyperactivity Disorder.[NCT00863499] | Phase 4 | 1,344 participants (Anticipated) | Interventional | 2009-10-31 | Active, not recruiting | ||
| Effects of EEG- Microstate Neurofeedback on Attention and Impulsivity in Adult Attention-deficit/Hyperactivity Disorder (ADHD) and Neurotypical Controls[NCT05582928] | 60 participants (Anticipated) | Interventional | 2022-09-19 | Recruiting | |||
| The Effects of Methylphenidate (MPH) and Non-invasive Brain Stimulation (tDCS) on Inhibitory Control Children With Attention-Deficit/Hyperactivity Disorder (ADHD)[NCT04964427] | 26 participants (Actual) | Interventional | 2021-02-08 | Completed | |||
| A Randomized-Controlled Trial: the Effectiveness of a Single-session of Mindfulness Based Cognitive Training on CVC and Core Symptoms in Children and Adolescents With ADHD[NCT04316832] | 70 participants (Actual) | Interventional | 2020-10-30 | Completed | |||
| An Electroencephalography Study of the Effects of Psychostimulants on Dynamic Patterns of Cognitive Task-based Functional Connectivity in Youths With Attention Deficit Hyperactivity Disorder[NCT02318017] | 75 participants (Anticipated) | Interventional | 2014-12-31 | Not yet recruiting | |||
| Assessing Cognitive Performance Among Adults With Attention Disorders Working on Treadmill[NCT05243186] | Phase 2/Phase 3 | 30 participants (Anticipated) | Interventional | 2021-10-01 | Recruiting | ||
| Motivated Behavior in Adults With and Without ADHD[NCT02630017] | Phase 2 | 51 participants (Actual) | Interventional | 2016-03-07 | Completed | ||
| The Effects of Health Promotion Program for the Caregivers of Attention Deficit/Hyperactivity Disorders Children[NCT05547945] | 60 participants (Anticipated) | Interventional | 2018-05-19 | Recruiting | |||
| Phase 2: A Prospective Observational Study of Feasibility and Tentative Effectiveness of Multi-Systemic and Multicomponent Family-Based Intervention for Families of Children With Neuropsychiatric and/or Psychiatric Disorder(s).[NCT02250339] | 230 participants (Anticipated) | Observational | 2013-12-31 | Completed | |||
| Efficacy and Learning Skill After OROS Methylphenidate Treatment in Adolescents With Attention-Deficit/Hyperactivity Disorder: A 12-week, Multi-center, Open-label Study[NCT01060150] | Phase 4 | 115 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| Prevention of Cigarette Smoking in ADHD Youth With Concerta[NCT00181714] | Phase 4 | 203 participants (Actual) | Interventional | 2003-11-30 | Completed | ||
| Comparing the Efficacy of Methylphenidate, Dextroamphetamine and Placebo in Children Diagnosed With ADHD[NCT01220440] | Phase 4 | 36 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| A Phase III, Randomised, Double-Blind, Multicentre, Parallel-Group, Placebo- and Active-Controlled, Dose-Optimisation Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity[NCT00763971] | Phase 3 | 336 participants (Actual) | Interventional | 2008-11-17 | Completed | ||
| Effects of Structured Skills Training Group in Treatment of ADHD in Adults: a Controlled Multicentre Study[NCT02685254] | 120 participants (Anticipated) | Interventional | 2016-02-01 | Completed | |||
| Comparative Evaluation of Plaque Removal Efficacy of Electric Toothbrushes Between Children With Attention Deficit And Hyperactivity Disorder And Healthy Children[NCT05935254] | 52 participants (Actual) | Interventional | 2022-01-29 | Completed | |||
| Gut Microbiome and Serum Metabolome Alterations in Attention-deficit/Hyperactivity Disorder Patients[NCT03447223] | 207 participants (Actual) | Observational | 2018-03-20 | Completed | |||
| Double-Blind, Placebo-Controlled Trial of Flexible Dose Divalproex Sodium Adjunctive to Stimulant Treatment for Aggressive Children With Attention-Deficit Hyperactivity Disorder[NCT00228046] | Phase 4 | 40 participants (Anticipated) | Interventional | 2004-01-31 | Completed | ||
| Adjunctive Treatment With Divalproex or Risperidone for Aggression Refractory to Stimulant Monotherapy Among Children With ADHD[NCT00794625] | Phase 4 | 270 participants (Anticipated) | Interventional | 2008-11-30 | Recruiting | ||
| A 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate HCl Extended Release in the Treatment of Adult Patients With Childhood-onset ADHD[NCT01259492] | Phase 3 | 725 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| ADHD Treatment: Comparative and Combined Dosage Effects[NCT00050622] | 154 participants (Actual) | Interventional | 2001-09-30 | Completed | |||
| The Characteristics of Prepulse Inhibition in Children and Adolescents Suffering From Attention Deficit Disorder: With and Without Medication.[NCT02344784] | 46 participants (Actual) | Observational | 2015-01-31 | Active, not recruiting | |||
| A Follow-up, Family Study on Attention-deficit Hyperactivity Disorder[NCT00417781] | 1,800 participants (Actual) | Observational | 2005-01-31 | Completed | |||
| Endophenotype, Molecular Genetic Study on Attention-deficit/ Hyperactivity Disorder[NCT00529906] | 200 participants (Actual) | Observational | 2007-08-31 | Completed | |||
| Effect of Game-based High-Intensity Interval Training Program on the Executive Function of Children With ADHD: Protocol of A Randomized Controlled Trial[NCT05308758] | 42 participants (Anticipated) | Interventional | 2021-01-01 | Active, not recruiting | |||
| Analysis of the Therapeutic Effect of Blood Flow Reconstruction in the Treatment of Intracranial Dissection Aneurysm of Vertebral Artery[NCT06134557] | 200 participants (Anticipated) | Observational | 2023-11-20 | Not yet recruiting | |||
| Acute Effects of Exercise in College Students With ADHD[NCT03666416] | 48 participants (Anticipated) | Interventional | 2018-10-08 | Active, not recruiting | |||
| A Fixed-Dose, Randomized, Double-Blind, Placebo-Controlled Study of LY2216684 in Pediatric Patients With Attention Deficit/Hyperactivity Disorder[NCT00922636] | Phase 2/Phase 3 | 340 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| Effectiveness of a Tailored Occupational Therapy Intervention for Women With Attention-Deficit/Hyperactivity Disorder (ADHD)[NCT03203928] | 23 participants (Actual) | Interventional | 2017-09-15 | Completed | |||
| The Relative Efficacy of Aerobic Exercise in the Treatment of Adults With Attention Deficit Hyperactivity Disorder (ADHD) Versus Medication Only and the Combination of the Two: A Pilot Study[NCT02788851] | 70 participants (Anticipated) | Interventional | 2016-04-30 | Active, not recruiting | |||
| Methylphenidate in Adults With Attention Deficit/Hyperactivity Disorder[NCT02951754] | Phase 4 | 600 participants (Anticipated) | Interventional | 2002-02-28 | Recruiting | ||
| A Randomized, Double-Blind Study of the Time Course of Response to Biphentin® Methylphenidate Hydrochloride ER Capsules Compared to Placebo in Children 6 to 12 Years With Attention Deficit Hyperactivity Disorder in Analog Classroom Setting[NCT01269463] | Phase 3 | 26 participants (Actual) | Interventional | 2011-01-19 | Completed | ||
| Efficacy and Safety/Tolerability of Methylphenidate Transdermal System (MTS) for Before-School Dysfunction in Children With Attention Deficit Hyperactivity Disorder (ADHD)[NCT00586157] | Phase 4 | 36 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| ADHD and Nutrition: The Influence of Omega-3 on ADHD Related Symptoms[NCT02986672] | 330 participants (Anticipated) | Interventional | 2017-11-03 | Active, not recruiting | |||
| Developmental Trajectory of Brain Structural Connectivity and Cognitive Function From Childhood to Adulthood[NCT01677793] | 140 participants (Actual) | Observational | 2012-01-01 | Completed | |||
| Clinical, Environmental, Neurocognitive, Brain Imaging, and Genetic Validity of Autism and Attention-deficit Hyperactivity Disorder[NCT00916851] | 300 participants (Actual) | Observational | 2010-08-01 | Completed | |||
| A Randomized, Parallel, Double-Blind Efficacy and Safety Study of Biphentin Methylphenidate HCl Extended Release Capsules Compared to Placebo in Children and Adolescents 6 to 18 Years With Attention Deficit Hyperactivity Disorder (ADHD)[NCT01239030] | Phase 3 | 230 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| Prevalence of Stuttering in Children With ADHD at Sohag University Hospital[NCT05383430] | 50 participants (Anticipated) | Observational | 2022-06-30 | Not yet recruiting | |||
| A Phase 3b, Double-blind, Randomised, Active-controlled, Parallel Group Study to Assess the Time to Response of Lisdexamfetamine Dimesylate to Atomoxetine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disor[NCT01106430] | Phase 3 | 267 participants (Actual) | Interventional | 2010-06-28 | Completed | ||
| Pharmacogenetic Studies on Attention Deficit Hyperactivity Disorder[NCT00916786] | 240 participants (Actual) | Observational | 2009-08-01 | Completed | |||
| A Single Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy of PR OROS Methylphenidate Followed by Open-Label Extension, in Swedish Male Prison Inmates With ADHD[NCT00482313] | Phase 3 | 30 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| Cost-effectiveness of the Treatment of Attention Deficit/Hyperactivity Disorder With Methylphenidate Immediate-release in Brazil[NCT01705613] | 120 participants (Actual) | Observational | 2014-04-30 | Completed | |||
| Virtual Reality Attention Management Program for Improving Attention in Children[NCT03221244] | 50 participants (Anticipated) | Interventional | 2016-06-02 | Recruiting | |||
| An Open, Self-Controlled, Prospective Study of Concerta on Cognitive Functions, Efficacy and Tolerance in the Pediatric Patients With Attention Deficit Hyperactivity Disorder (ADHD)[NCT01933880] | Phase 4 | 194 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| Train Your Brain? Exercise and Neurofeedback Intervention for ADHD[NCT01363544] | Phase 2/Phase 3 | 112 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Randomized Control Study of Concerta and Strattera on the Improvement of Executive Function in Attention Deficit Hyperactivity Disorder Children[NCT01065259] | Phase 4 | 262 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Concerta in the Treatment of Adult ADHD and a Comparison of Four Adult ADHD Scales and Effects on Personality[NCT02215538] | Phase 2/Phase 3 | 47 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| Methylphenidate Transdermal System (MTS) in the Treatment of Adult ADHD[NCT00506285] | Phase 3 | 92 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects[NCT01470261] | 1,398 participants (Actual) | Observational | 2012-02-29 | Completed | |||
| Open Label Study for the Use of Transcranial Ultrasound Treatment of Attention Deficit Hyperactive Disorder[NCT04497363] | 100 participants (Anticipated) | Interventional | 2020-07-01 | Enrolling by invitation | |||
| A Randomized, Multicenter, Double-Blind, Placebo Controlled, Parallel Group Study of NT0102 in Children (Ages 6 12 Years) With Attention-Deficit Hyperactivity Disorder[NCT01835548] | Phase 3 | 87 participants (Actual) | Interventional | 2013-07-31 | Completed | ||
| Prevalence of Tics in Childern With Acute Deficit Hyper Activity Syndrom[NCT03817710] | 100 participants (Anticipated) | Observational | 2019-10-01 | Not yet recruiting | |||
| A Placebo Controlled Double-Blind, Parallel Group, Individualizing Dosing Study Optimizing Treatment of Adults With Attention Deficit Hyperactivity Disorder to an Effective Response With OROS Methylphenidate[NCT00937040] | Phase 4 | 357 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| A Phase IV, Dose Optimized, Open Label, Evaluation of the Effect Foquest® (Methylphenidate HCl Controlled Release) on Sleep in Children Aged 6-12 With Attention Deficit Hyperactivity Disorder[NCT04741516] | Phase 4 | 41 participants (Actual) | Interventional | 2020-12-01 | Active, not recruiting | ||
| Enhancement of Psychosocial Functioning, Quality of Life, Satisfaction With Medication and Medication Compliance of Methylphenidate Treatment by Psychosocial Intervention and Support[NCT01660425] | 100 participants (Anticipated) | Interventional | 2012-05-31 | Active, not recruiting | |||
| Differences by Sex and Genotype in the Effects of Stress on Executive Functions[NCT04273880] | Phase 1 | 146 participants (Anticipated) | Interventional | 2018-04-28 | Recruiting | ||
| Integrated Brain, Body and Social Intervention (IBBS) for Attention Deficit Hyperactivity Disorder (ADHD)[NCT01542528] | 117 participants (Actual) | Interventional | 2012-03-31 | Completed | |||
| Measurement of Cytogenetic Endpoints in Lymphocytes of Children Diagnosed With Attention Deficit/Hyperactivity Disorder (ADHD) and Treated With Methylphenidate or Adderall[NCT00341029] | 84 participants | Observational | 2005-12-07 | Completed | |||
| 1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain[NCT01844700] | Phase 4 | 14 participants (Actual) | Interventional | 2013-07-31 | Terminated (stopped due to very slow recruitment, no sufficient results) | ||
| Efficacy of Concerta in Treating ADHD in Mothers of Children With ADHD[NCT00318981] | Phase 4 | 40 participants | Interventional | 2004-12-31 | Completed | ||
| 2/2 Treating Mothers With ADHD and Their Young Children Via Telehealth: A Hybrid Type I Effectiveness-Implementation Trial[NCT04240756] | Phase 3 | 240 participants (Anticipated) | Interventional | 2020-08-06 | Recruiting | ||
| Multimodal Treatment Study of Children With ADHD[NCT00000388] | Phase 4 | 0 participants | Interventional | 1998-09-30 | Completed | ||
| Uptake to Colorectal Cancer Screening in Familiar-risk Population: A Randomized Controlled Trial Comparing Immunochemical Fecal Occult Blood Test With Colonoscopy[NCT02567045] | 260 participants (Actual) | Interventional | 2016-02-25 | Completed | |||
| Compliance Survey of ADHD Medication for Optimal Satisfaction (COSMOS)[NCT00460720] | 591 participants (Actual) | Observational | Completed | ||||
| Long-Duration Stimulant Treatment of ADHD in Young Children-Feasibility Study[NCT00257725] | Phase 4 | 11 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| A Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Titration Study to Evaluate the Efficacy and Safety of CONCERTA (Methylphenidate HCl) Extended-release Tablets in Adults With Attention Deficit Hyperactivity Disorder at Doses of 36 mg, 54 mg, 72 mg[NCT00326391] | Phase 3 | 229 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| Impact of Relationship of Epilepsy and Attention Deficit Hyperactive Disorder[NCT03806946] | 100 participants (Actual) | Observational | 2019-02-15 | Completed | |||
| A Multi-Center, Open Label, Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder[NCT03337646] | Phase 4 | 48 participants (Actual) | Interventional | 2018-09-26 | Active, not recruiting | ||
| A Phase III, Multi-center, Open-label Study of Methylphenidate Transdermal System (MTS) in Pediatric Patients Aged 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD)[NCT00151957] | Phase 3 | 450 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| A Phase IIB, Randomized, Double-blind, Multi-Center, Placebo-Controlled, Dose-Optimization, 3-way Cross-Over, Analog Classroom Study to Assess the Efficacy, Duration of Effect, Tolerability and Safety of 4- and 6- Hour Wear Times of Methylphenidate Transd[NCT00151970] | Phase 2 | 128 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| A Phase II, Open-Label Co-Administration Study of SPD503 and Psychostimulants in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)[NCT00151996] | Phase 2 | 75 participants (Actual) | Interventional | 2004-08-16 | Completed | ||
| Clonidine in Attention Deficit Hyperactivity Disorder (ADHD) Treatment (CAT)[NCT00031395] | Phase 3 | 122 participants (Actual) | Interventional | 1999-09-30 | Completed | ||
| Aripiprazole Associated With Methylphenidate in Children and Adolescents With Bipolar Disorder and ADHD: A Randomized Cross-Over Placebo Controlled Trial[NCT00305370] | Phase 4 | 20 participants (Anticipated) | Interventional | 2005-08-31 | Completed | ||
| A Prospective, Open-Label, Multi-Center Study Evaluating the Safety and Tolerability of Methylphenidate Transdermal System (MTS) in Children Aged 6-12 Previously Treated With Extended-Release Methylphenidate Product.[NCT00151983] | Phase 3 | 175 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Rhodiola Rosea in Adults With Attention Deficit/Hyperactivity Disorder[NCT02737020] | Phase 4 | 60 participants (Anticipated) | Interventional | 2016-04-30 | Recruiting | ||
| [NCT01124032] | 30 participants (Anticipated) | Interventional | 2010-05-31 | Not yet recruiting | |||
| An Evaluation of the Safety and Effectiveness of CONCERTA® (Methylphenidate Hydrochloride), up to 72 mg Daily, in Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)[NCT00249353] | Phase 3 | 220 participants (Actual) | Interventional | 2002-03-31 | Completed | ||
| A Phase IIIb, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled, Dose Optimization Study, Designed to Evaluate the Efficacy and Safety of MTS in Adolescents Aged 13-17 Years With ADHD[NCT00499863] | Phase 3 | 217 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| A Double Blind, Placebo-Controlled Crossover Study to Determine the Effects of Methylphenidate on Driving Ability in Adult Patients With Attention-Deficit Hyperactivity Disorder[NCT00223561] | Phase 4 | 18 participants | Interventional | 2003-02-28 | Completed | ||
| A Phase IIIb, Long-Term, Open-Label, Multi-Center, Extension Study Designed to Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)[NCT00501293] | Phase 3 | 163 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| An Open-Label, Dose-Titration, Long-Term Safety Study to Evaluate CONCERTA (Methylphenidate HCL) Extended-release Tablets at Doses of 36 mg, 54 mg, 72 mg, 90 mg, and 108 mg Per Day in Adults With Attention Deficit Hyperactivity Disorder[NCT00326300] | Phase 3 | 560 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| Investigating the Efficacy of Cognitive Behavioral Therapy in Patients With Substance Use Disorder and Comorbid ADHD. A Randomized Controlled Trial With Cognitive Behavioral Therapy[NCT01431235] | 184 participants (Actual) | Interventional | 2011-08-31 | Completed | |||
| Implementation of Parent Training Through the Use of Virtual Reality: a Randomized, Controlled, Single-blind Study[NCT05809388] | 68 participants (Anticipated) | Interventional | 2022-10-26 | Recruiting | |||
| Efficacy of Methylphenidate for Treating Tobacco Dependence[NCT00549640] | Phase 2 | 80 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| A Double-Blind Comparison of Concerta and Placebo in Adults With Attention Deficit Hyperactivity Disorder[NCT00181571] | Phase 4 | 297 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| The ABC Study: A Double-Blind, Randomized, Placebo-Controlled, Crossover Study Evaluating the Academic, Behavioral, and Cognitive Effects of CONCERTA on Older Children With ADHD[NCT00799409] | Phase 4 | 78 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| Candidate Gene Screening for 6-14 Year Old Patients With ADHD (Attention Deficit/ Hyperactivity Disorder)[NCT03018574] | 100 participants (Actual) | Observational | 2016-05-31 | Completed | |||
| An Open-label Prospective Trial to Evaluate Functional Outcomes of OROS Methylphenidate in Children With ADHD (FOSCO)[NCT01012622] | Phase 4 | 142 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| Randomized Controlled Trial of Osmotic-Release Methylphenidate (OROS-MPH) for Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents With Substance Use Disorders (SUD)[NCT00264797] | Phase 3 | 303 participants (Actual) | Interventional | 2006-02-28 | Completed | ||
| Response Variability in Children With ADHD[NCT01238822] | Phase 4 | 96 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| Open Label Study of the Effect of Individualizing Daytrana Wear-times on Sleep in Children 6-12 Years Old With Attention Deficit Hyperactivity Disorder (ADHD)[NCT00989950] | 26 participants (Actual) | Interventional | 2009-12-31 | Completed | |||
| Sleep and Tolerability of Extended Release Dexmethylphenidate vs. Mixed Amphetamine Salts: A Double Blind, Placebo Controlled Study (SAT STUDY)[NCT00393042] | Phase 3 | 77 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI[NCT02148783] | Phase 2 | 11 participants (Actual) | Interventional | 2014-09-30 | Terminated (stopped due to Recruitment was slower than anticipated. Incomplete neuropsychological outcome measures obtained.) | ||
| The Effects of Yoga on Attention, Impulsivity and Hyperactivity in Pre-school Age Children With ADHD Symptoms[NCT02642666] | 23 participants (Actual) | Interventional | 2015-12-31 | Completed | |||
| A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Multicenter Study of 3 Dosages of JNJ-31001074 in the Treatment of Adult Subjects With Attention-Deficit/Hyperactivity Disorder[NCT00880217] | Phase 2 | 430 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Effects of Expectation, Medication and Placebo on Objective and Self-rated Performance During the Quantified Behavior Test in Patients With Untreated ADHD and Substance Use Disorder[NCT02477280] | Phase 4 | 39 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| Effects of Expectation, Medication and Placebo on Objective and Self-rated Performance During the Quantified Behavior Test in Patients With Untreated ADHD[NCT02473185] | Phase 4 | 40 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| Social Skills Training and Standard Treatment Versus Standard Treatment of Children With ADHD - Attention Deficit Hyperactivity Disorder. Attachment Problems Among Children With ADHD[NCT00937469] | 55 participants (Actual) | Interventional | 2009-08-31 | Completed | |||
| The Assessment of Efficacy and Tolerability of Methylphenidate vs. Risperidone in the Treatment of Children and Adolescents With ADHD and Disruptive Disorders[NCT02063945] | Phase 4 | 5 participants (Actual) | Interventional | 2017-02-01 | Terminated (stopped due to Major difficulties recruiting participants) | ||
| A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study To Evaluate the Safety And Efficacy Of Prolonged Release OROS Methylphenidate Hydrochloride (18, 36 and 72 mg/Day), With Open-Label Extension, In Adults With [NCT00246220] | Phase 3 | 402 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| Children With ADHD Symptoms: Comorbid Conditions, Cognitive and Social Performance[NCT01252446] | 187 participants (Anticipated) | Observational | 2008-09-30 | Recruiting | |||
| A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Incomplete Block, Two-period, Crossover Clinical Trial to Study the Safety and Efficacy of MK0249, 10 mg, for Adult Patients, Ages 18 to 55, With Attention Deficit Hyperactivity Disorder (ADHD)[NCT00475735] | Phase 2 | 72 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| A Randomized, Multi-center, Double-blind, Placebo-controlled, Cross-over Study Evaluating the Safety and Efficacy of Dex-Methylphenidate Extended Release 30 mg vs. 20 mg as Measured by SKAMP-Combined Scores in Children With Attention-Deficit/Hyperactivity[NCT00776009] | Phase 4 | 165 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| NWP06 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)- A Laboratory Classroom Study[NCT00904670] | Phase 3 | 45 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| Therapeutic Use of Repetitive Transcranial Magnetic Stimulation (rTMS) in Pediatric Autism Spectrum Disorder (ASD) and Attention Deficit Hyperactivity Cohorts (ADHD): a Randomized, Sham-controlled Study.[NCT06069323] | 80 participants (Anticipated) | Interventional | 2023-06-01 | Recruiting | |||
| Fatigue in Sarcoidosis - A Feasibility Study Investigating the Treatment of Fatigue in Stable Sarcoidosis Patients Using Methylphenidate[NCT02643732] | 30 participants (Anticipated) | Interventional | 2016-11-30 | Recruiting | |||
| Screening, Efficacy, and Safety Study Evaluating OROS (Methylphenidate HCl), Ritalin and Placebo in Children With ADHD[NCT00269776] | Phase 3 | 0 participants | Interventional | 1998-11-30 | Completed | ||
| A Single-blind, Randomised, Sham Controlled, Phase IIa Exploratory Clinical Trial, to Examine the Safety and Efficacy of BGX-3006 (tPCS) on Paediatric ADHD Participants.[NCT02323633] | Phase 2 | 48 participants (Anticipated) | Interventional | 2015-01-31 | Not yet recruiting | ||
| Circuitry Assessment and Reinforcement Training Effects on Recovery (CARTER)[NCT04290988] | 80 participants (Anticipated) | Interventional | 2020-09-23 | Suspended (stopped due to Lack of funding for the time being) | |||
| Cognitive Rehabilitation (Mega Team) and Its Effects on Emotional and Behavioral Regulation in ADHD, ASD, and CHD[NCT03502239] | 440 participants (Anticipated) | Interventional | 2018-05-26 | Recruiting | |||
| Dose Response Pharmacogenetic Study of ADHD[NCT00663442] | Phase 4 | 48 participants (Actual) | Interventional | 1999-12-31 | Completed | ||
| Effect of Methylphenidate on Ecologic Function in Paediatric Acquired Brain Injury Population[NCT02227056] | Phase 2 | 34 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| Learning Impairments Among Survivors of Childhood Cancer[NCT00576472] | Phase 4 | 469 participants (Actual) | Interventional | 2000-01-31 | Completed | ||
| Effectiveness of the Quotient® ADHD Assessment in a System of Care[NCT02094612] | 207 participants (Actual) | Interventional | 2014-03-31 | Terminated | |||
| Methylphenidate Effect on Performing Humphrey Visual Fields[NCT02162381] | 32 participants (Actual) | Interventional | 2014-06-30 | Completed | |||
| Efficacy of Cognitive Behavioral Therapy in Treatment of Adults With Attention Deficit Hyperactivity Disorder[NCT02210728] | 200 participants (Anticipated) | Interventional | 2006-04-30 | Active, not recruiting | |||
| Treatment of Adult ADHD in Methadone Patients[NCT00061087] | Phase 2/Phase 3 | 115 participants (Actual) | Interventional | 1998-02-28 | Completed | ||
| Long-term Safety and Effectiveness of OROS (Methylphenidate HCl) in Children With ADHD[NCT00269815] | Phase 3 | 0 participants | Interventional | Completed | |||
| Methylphenidate for Hyperactivity and Impulsiveness in Children and Adolescents With Pervasive Developmental Disorders[NCT00025779] | 60 participants | Interventional | 2001-10-31 | Completed | |||
| Quillivant XR in Children With Attention Deficit/Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD): A Pilot Study[NCT02255565] | Phase 4 | 36 participants (Actual) | Interventional | 2014-09-30 | Completed | ||
| A Multi-center Randomized Parallel Group Study Evaluating Treatment Outcomes of Concerta (Extended Release Methylphenidate) and Strattera (Atomoxetine) in Children With Attention-deficit/Hyperactivity Disorder[NCT00866996] | Phase 4 | 1,323 participants (Actual) | Interventional | Completed | |||
| The Effectiveness of CONCERTA® vs. Usual Clinical Care With Immediate Release Methylphenidate (IR MPH) in Children (6-12 Years) With Attention Deficit Hyperactivity Disorder (ADHD): A Randomized, Open-Label Trial[NCT00304681] | Phase 3 | 147 participants (Actual) | Interventional | Completed | |||
| A Phase II, Randomized, Double-blind, Multi-center, Placebo-controlled, Dose Optimization, Analog Classroom, Crossover Study Designed to Assess the Time Course of Treatment Effect, Tolerability and Safety of Methylphenidate Transdermal System (MTS) in Ped[NCT00466791] | Phase 2 | 93 participants (Actual) | Interventional | 2004-08-31 | Completed | ||
| Cognitive Restructuring in ADHD: Functional Training[NCT02827188] | 46 participants (Actual) | Interventional | 2016-09-26 | Completed | |||
| Methylphenidate Treatment for Cocaine Abuse and ADHD[NCT00136734] | Phase 1 | 124 participants (Actual) | Interventional | 1998-04-30 | Completed | ||
| Methylphenidate Efficacy and Safety in ADHD Preschoolers[NCT00018863] | Phase 3 | 165 participants | Interventional | 2001-04-01 | Completed | ||
| Characterization of Endogenous Melatonin Profiles in Children With Autism Spectrum Disorder.[NCT00691080] | 58 participants (Actual) | Observational | 2007-09-30 | Completed | |||
| Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder[NCT01238575] | Phase 4 | 62 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
| Validation of Sleep Questionnaires in the Down Syndrome Population[NCT03771469] | 81 participants (Actual) | Interventional | 2018-06-25 | Active, not recruiting | |||
| An Open-label Study Evaluating the Safety and Effectiveness of OROS Methylphenidate Hydrochloride (CONCERTA) in Adults With Attention Deficit Hyperactivity Disorder[NCT00246207] | Phase 3 | 32 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| The Effects of Ketamine and Guanfacine on Working Memory in Healthy Subjects[NCT01600885] | 16 participants (Actual) | Interventional | 2008-08-31 | Completed | |||
| Examination of a Novel Cognitive-motor Weight-bearing Dual-task Intervention in Older Adults[NCT05296551] | 30 participants (Anticipated) | Interventional | 2022-03-03 | Recruiting | |||
| Neural Mechanisms of CBT for Anxiety in Children With Autism: Randomized Controlled Trial[NCT02725619] | 70 participants (Actual) | Interventional | 2016-04-30 | Completed | |||
| Neural Mechanisms of Cognitive-Behavioral Therapy for Anxiety in Children With Autism Spectrum Disorder: A Pilot Study[NCT02225808] | 10 participants (Actual) | Interventional | 2014-08-31 | Completed | |||
| Effects of the Transcranial Direct Current Stimulation on Prevention of Cognitive Dysfunction in Elderly Patients Submitted to Cardiac Surgeries: Prospective, Randomized and Double-blind Study[NCT02549560] | 138 participants (Anticipated) | Interventional | 2021-07-08 | Recruiting | |||
| Open-label Conditioning Therapy for Peri-operative Pain Management in Head and Neck Cancer Patients[NCT04973748] | 62 participants (Anticipated) | Interventional | 2023-02-07 | Recruiting | |||
| Open-Label Placebo Treatment of Women With Premenstrual Syndrome: A Randomized Controlled Trial[NCT03547661] | 150 participants (Actual) | Interventional | 2018-08-02 | Completed | |||
| Functional Neuroimaging of Acute Concerta Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD): Differences Across Development[NCT00778310] | Phase 4 | 76 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| Added Value of the Oculomotor and Cognitive Examination in the Management of Patients With Attention Deficit Disorder With or Without Hyperactivity. Interventional Study to Evaluate Current Care[NCT03411434] | 90 participants (Anticipated) | Interventional | 2014-02-17 | Recruiting | |||
| Hyperactivity Assessment in Children With Attention-deficit Hyperactivity Disorder[NCT05810636] | 200 participants (Anticipated) | Observational [Patient Registry] | 2022-02-16 | Enrolling by invitation | |||
| A Phase III, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled, Dose Optimization Study, Designed to Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) vs. CONCERTA® in Pediatric Patients Aged 6-12 With A[NCT00444574] | Phase 3 | 282 participants (Actual) | Interventional | 2004-09-30 | Completed | ||
| A Randomized Controlled Trial Into the Effectiveness of a Behavioral Teacher Program Targeting ADHD Symptoms[NCT02518711] | 114 participants (Actual) | Interventional | 2011-09-30 | Completed | |||
| Methylphenidate Treatment of ADHD in Children With Tourette Syndrome[NCT00441649] | 71 participants | Interventional | 2000-02-29 | Completed | |||
| Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)[NCT02202551] | Phase 3 | 223 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| A Parallel-group, Double-blind, Placebo-controlled Study of Methylphenidate as an Add on Therapy for Mirtazapine in the Treatment of Major Depressive Disorder in Cancer Patients Under Palliative Care[NCT01497548] | Phase 3 | 120 participants (Anticipated) | Interventional | 2011-03-31 | Recruiting | ||
| Transcranial Photobiomodulation Therapy for the Treatment of Autistic Traits in Children and Adolescents With Attention Deficit Hyperactivity Disorder[NCT04569058] | 60 participants (Anticipated) | Interventional | 2021-01-14 | Recruiting | |||
| Comparative Crossover Study of OROS (Methylphenidate HCl), Ritalin, and Placebo in Children With ADHD[NCT00269789] | Phase 3 | 0 participants | Interventional | 1998-03-31 | Completed | ||
| Multicenter Study Comparing the Efficacy and Safety of OROS (Methylphenidate HCl), Ritalin, and Placebo in Children With ADHD[NCT00269802] | Phase 3 | 0 participants | Interventional | Completed | |||
| Pharmacological Treatment of Rett Syndrome by Stimulation of Synaptic Maturation With Recombinant Human IGF-1(Mecasermin [rDNA] Injection)[NCT01777542] | Phase 2 | 30 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| Atomoxetine for Attention Deficits in Adults With Mild HD: A Randomized, Placebo-Controlled Crossover Study[NCT00368849] | Phase 2 | 20 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| Galantamine Versus Placebo in Childhood Autism[NCT00252603] | Phase 3 | 20 participants | Interventional | 2004-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To determine whether RT2CK17 + escitalopram results in greater consistency of adherence relative to placebo + escitalopram as measured by percentage of doses taken on schedule within 25% of the expected time interval, defined as +/- 6 hours from the participant's breakfast time (NCT03388164)
Timeframe: 8 weeks
| Intervention | percentage of pills taken on time (Mean) |
|---|---|
| Escitalopram + RT2CK17 | 89.8 |
| Escitalopram + Placebo | 93.6 |
To determine whether RT2CK17 + escitalopram results in higher rates of medication adherence relative to placebo + escitalopram as measured by percentage pill count (NCT03388164)
Timeframe: 8 weeks
| Intervention | percentage of pills taken (Mean) |
|---|---|
| Escitalopram + RT2CK17 | 93.5 |
| Escitalopram + Placebo | 97.6 |
"To evaluate maintenance of treatment effects of PR OROS MPH vs. placebo as measured on CAARS.~CAARS assesses ADHD symptoms and behaviors in adults. best value: 0 worst value: 54~Endpoint: last available post-baseline assessment." (NCT00307684)
Timeframe: DB baseline, DB endpoint
| Intervention | units on a scale (Mean) |
|---|---|
| Active | 4.0 |
| Placebo | 6.5 |
Evaluation of treatment effects as rated by the subjects on the CAARS-S:S. best score: 0 worst score: 104 (NCT00307684)
Timeframe: DB baseline, DB endpoint
| Intervention | units on a scale (Mean) |
|---|---|
| Active | 4.4 |
| Placebo | 4.0 |
evaluation of treatment effects as rated by the investigator on the CGI-S scale. CGI-S is used to rate the severity of a subject's illness on a 7- point scale ranging from 1 (not ill) to 7 (extremely severe). (NCT00307684)
Timeframe: DB baseline, DB endpoint
| Intervention | units on a scale (Mean) |
|---|---|
| Active | 0.6 |
| Placebo | 1.0 |
Assessment of the long term effect on overall functioning measured by CGI-S best score: 1 worst score: 7 (NCT00307684)
Timeframe: OL baseline, OL endpoint
| Intervention | units on a scale (Mean) |
|---|---|
| Open Label PR OROS MPH | -0.3 |
Quality of life measured by Q-LES-Q best score: 100 worst score: 0 (NCT00307684)
Timeframe: OL baseline, OL endpoint
| Intervention | units on a scale (Mean) |
|---|---|
| Open Label PR OROS MPH | 1.4 |
"Long term efficacy of PR OROS MPH as assessed by investigator-rated CAARS total score, hyperactivity/impulsivity subscale score and inattention subscale score.~Subscale scores: best value: 0, worst value: 27" (NCT00307684)
Timeframe: OL baseline, OL endpoint
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| change from baseline to endpoint in total score | change from baseline to endpoint in inattention | change from baseline to endpoint in hyperactivity | |
| Open Label PR OROS MPH | -1.9 | -1.0 | -0.9 |
To evaluate the long term safety and tolerability of PR OROS MPH (18, 36, 54, 72 and 90 mg/day) in adults with Attention Deficit Hyperactivity Disorder (ADHD) (NCT00307684)
Timeframe: Treatment duration for OL extended from 52 wks to 72 wks (International Amendment 2) or 108 wks in Germany. Treatment duration for double-blind (DB) randomized withdrawal: 4 weeks
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| at least one AE | at least one SAE | at least one severe AE | at least one AE leading to permanent stop | at least one AE leading to temporary stop | at least one AE with concomitant therapy | at least one AE at least possibly related | |
| Active | 7 | 0 | 0 | 0 | 0 | 0 | 3 |
| Open Label PR OROS MPH | 126 | 12 | 27 | 15 | 23 | 93 | 62 |
| Placebo | 8 | 1 | 3 | 0 | 2 | 4 | 5 |
"Attention-Deficit/Hyperactivity Disorder Rating Scale (DSM-IV ADHD RS) total score consists of 18 items directly adapted from the ADHD symptom list according to the DSM-IV. The DSM-IV ADHD RS total score was calculated as the sum of the Inattentive and the Hyperactive-Impulsive subscores. The 18 items are rated from 0 (rarely or never) to 3 (Very often). The total score ranges from 0 to 54. Decrease in the DSM-IV ADHD RS total score indicates improvement, therefore a greater decrease (change at Final Visit compared to baseline) indicates a greater improvement in ADHD symptoms. Last Observation Carried Forward (LOCF) applied for each patient with data in extension period. If no post-baseline is available, it is considered as missing." (NCT01338818)
Timeframe: week 40 - week 66
| Intervention | scores on a scale (Mean) |
|---|---|
| Ritalin LA | -7.2 |
SDS,5-self-rated questionnaire to measure the extent a pt's disability due to an illness/health problem interferes with work/school,social life/leisure,family life/home. First 3 items, pts are asked how their symptoms disrupted their regular activities over the past 7d in each using a scale from 0(not at all)-10(extremely) Each subscale(work disability, social life disability, family life disability)can be scored independently or combined into a total score(sum of the non-missing responses for items 1-3)from 0-30,higher scores indicate significant functional impairment. Subscale scores>5 suggest impairment in that subscale area. Final 2 items ask pts about the # of days their symptoms caused them to miss school/work and # of days their symptoms caused them to be underproductive at school/work.(These items were not included in the total score.) Before responding to SDS items 1-3, pts were verbally instructed to recall the past 7d, items 4-5 refer to the last week w/in the item wording. (NCT01338818)
Timeframe: week 40 - week 66
| Intervention | Scores on a scale (Mean) |
|---|---|
| Ritalin LA | -4.8 |
Adverse Events, Serious Adverse Events and Deaths were monitored from week 40 to week 66. (NCT01338818)
Timeframe: Week 40 - Week 66
| Intervention | participants (Number) | ||
|---|---|---|---|
| Adverse Events (Serious and Non Serious) | Serious Adverse Events | Deaths | |
| Ritalin LA | 208 | 2 | 0 |
TASS was completed at the end of waking hours (14 - 16 hours post-dosing) at Month-2 after baseline visit. TASS was developed to capture the change in ADHD symptoms over the course of a day and consists of 18 items that directly correspond to the 18 ADHD symptom domains listed in the DSM-5. Each item is scored on a 4-point scale as follows: 0 (none), 1 (mild), 2 (moderate), and 3 (severe); the maximum total score is 54. A higher total score corresponds to worse ADHD severity. (NCT04507204)
Timeframe: Month-2
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Adhansia XR | 20.2 |
| Concerta | 22.1 |
Used to assess health-related quality of life for adult patients. The AAQoL yields a total score based on 29 items. The raw scores are transformed to a 0 to 100 scale with higher scores indicating a better quality of life. (NCT04507204)
Timeframe: Baseline, Months -1, -2, -3, -4, -5 and -6
| Intervention | score on a scale (Least Squares Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Total Score at Baseline | Total Score at Month 1 | Total Score at Month 2 | Total Score at Month 3 | Total Score at Month 4 | Total Score at Month 5 | Total Score at Month 6 | |
| Adhansia XR | 41.1 | 55.5 | 63.0 | 63.4 | 64.7 | 66.3 | 67.4 |
| Concerta | 41.1 | 55.0 | 59.1 | 60.9 | 61.8 | 60.2 | 63.6 |
The CGI-I measures global improvement prior to and after initiating the study medication. The CGI-I scale is 1 question, and rates improvement compared with the baseline visit using a 7-point scale. The range of responses are from 1 (very much improved) through 7 (very much worse). A higher score corresponds to higher ADHD severity. (NCT04507204)
Timeframe: Month-2, Month-4, and Month-6
| Intervention | score on a scale (Least Squares Mean) | ||
|---|---|---|---|
| Month 2 | Month 4 | Month 6 | |
| Adhansia XR | 2.3 | 2.0 | 2.0 |
| Concerta | 2.3 | 2.2 | 2.3 |
The CGI-S rates symptoms from 1 (not ill) to 7 (extremely ill). A higher score corresponds to higher ADHD severity. (NCT04507204)
Timeframe: Baseline, Month-2, Month-4, and Month-6
| Intervention | score on a scale (Least Squares Mean) | |||
|---|---|---|---|---|
| Baseline | Month 2 | Month 4 | Month 6 | |
| Adhansia XR | 4.6 | 3.1 | 2.7 | 2.7 |
| Concerta | 4.6 | 3.2 | 3.0 | 3.1 |
"The Treatment Satisfaction Questionnaire for Medications (TSQM) measures a patient's level of satisfaction or dissatisfaction with the study medication. It assesses perceptions of effectiveness, side effects and convenience of the medication and consists of 14 items that evaluate these three domains and one global scale item (ie, global satisfaction). Scores for each domain are computed by adding the TSQM items in each domain and then transforming the composite score into a value ranging from 0 to 100.~A lower score indicates a lower satisfaction with treatment." (NCT04507204)
Timeframe: Month-1, Month-2, and Month-6
| Intervention | score on a scale (Least Squares Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Global Satisfaction at Month 1 | Global Satisfaction at Month 2 | Global Satisfaction at Month 6 | Effectiveness at Month 1 | Effectiveness at Month 2 | Effectiveness at Month 6 | Side Effects at Month 1 | Side Effects at Month 2 | Side Effects at Month 6 | Convenience at Month 1 | Convenience at Month 2 | Convenience at Month 6 | |
| Adhansia XR | 84.8 | 85.2 | 86.2 | 51.3 | 61.1 | 63.9 | 74.0 | 72.0 | 70.7 | 58.9 | 57.0 | 59.7 |
| Concerta | 84.3 | 82.8 | 84.3 | 52.4 | 58.8 | 61.9 | 69.6 | 67.6 | 74.1 | 59.2 | 58.7 | 57.0 |
The ADHD-RS-5 assesses the frequency and severity of each of the 18 ADHD symptoms among adults based on DSM-5 criteria. Each of the 18 DSM-5 symptoms are rated on a 4 point scale from 0 (never or rarely) to 3 (very often), yielding a total score of 0 to 54. A higher score corresponds to worse ADHD severity. (NCT04507204)
Timeframe: Baseline to Month-2
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Total Score at baseline | Total Score at Month 2 | |
| Adhansia XR | 34.6 | 18.7 |
A comparison of the frequency of health care encounters between the 2 treatment groups. Healthcare resource utilization were evaluated monthly by comparing the frequency of clinic visits (outpatient), inpatient/hospitalizations (and length of stay), and emergency department visits between the 2 treatment groups. (NCT04507204)
Timeframe: Baseline (past 6 months) Months -2, -4, and -6
| Intervention | Visits or Inpatient Admissions (Least Squares Mean) | |||
|---|---|---|---|---|
| Baseline (past 6 months) Overall Total Visits or Inpatient Admissions | Month 2 - Overall Total Visits or Inpatient Admissions | Month 4 - Overall Total Visits or Inpatient Admissions | Month 6 - Overall Total Visits or Inpatient Admissions | |
| Adhansia XR | 2.14 | 2.26 | 1.67 | 1.34 |
| Concerta | 2.93 | 2.43 | 1.73 | 1.85 |
"The PSQI is an instrument used to measure the quality and patterns of sleep; It differentiates poor from good sleep. It is filled out by the caregiver or the patient and the global sum score ranges from 0 to 21, with higher scores indicating worse sleep quality." (NCT04507204)
Timeframe: Baseline and Months -2, -4, and -6
| Intervention | score on a scale (Least Squares Mean) | |||
|---|---|---|---|---|
| Global PSQI - Baseline | Global PSQI - Month 2 | Global PSQI - Month 4 | Global PSQI - Month 6 | |
| Adhansia XR | 9.68 | 7.92 | 8.11 | 7.92 |
| Concerta | 9.59 | 9.59 | 7.76 | 7.80 |
The WPAI questionnaire is designed to measure the effect of general health and symptom severity on work productivity and regular activities during the past 7 days. It consists of 4 domains [absenteeism (missing work), presenteeism (impaired productivity at work), overall work performance (combined absenteeism and presenteeism), and non-work activities (activity impairment)]. WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity. (NCT04507204)
Timeframe: Baseline, Months -2, -3, -4, -5, and -6
| Intervention | percentage of impairment (Least Squares Mean) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percent work time missed due to health (Absenteeism) - Baseline | Percent work time missed due to health (Absenteeism) - Month 2 | Percent work time missed due to health (Absenteeism) - Month 3 | Percent work time missed due to health (Absenteeism) - Month 4 | Percent work time missed due to health (Absenteeism) - Month 5 | Percent work time missed due to health (Absenteeism) - Month 6 | Percent impairment while working due to health (Presenteeism) - Baseline | Percent impairment while working due to health (Presenteeism) - Month 2 | Percent impairment while working due to health (Presenteeism) - Month 3 | Percent impairment while working due to health (Presenteeism) - Month 4 | Percent impairment while working due to health (Presenteeism) - Month 5 | Percent impairment while working due to health (Presenteeism) - Month 6 | Percent overall work impairment due to health - Baseline | Percent overall work impairment due to health - Month 2 | Percent overall work impairment due to health - Month 3 | Percent overall work impairment due to health - Month 4 | Percent overall work impairment due to health - Month 5 | Percent overall work impairment due to health - Month 6 | Percent activity impairment due to health - Baseline | Percent activity impairment due to health - Month 2 | Percent activity impairment due to health - Month 3 | Percent activity impairment due to health - Month 4 | Percent activity impairment due to health - Month 5 | Percent activity impairment due to health - Month 6 | |
| Adhansia XR | 5.4 | 4.2 | 3.0 | 2.4 | 4.8 | 2.9 | 32.0 | 19.7 | 20.1 | 13.5 | 17.8 | 15.9 | 34.1 | 22.4 | 21.8 | 15.8 | 19.7 | 18.4 | 39.7 | 26.1 | 26.1 | 19.5 | 23.6 | 21.9 |
| Concerta | 5.6 | 3.7 | 3.2 | 4.7 | 4.9 | 4.1 | 33.3 | 24.2 | 25.0 | 24.6 | 18.3 | 17.6 | 35.5 | 27.2 | 26.4 | 25.3 | 19.5 | 18.9 | 40.9 | 30.1 | 27.1 | 28.6 | 26.3 | 23.5 |
Dose of medication reported in mg/kg/day (NCT02039908)
Timeframe: End of Phase 2 School Year
| Intervention | Mg/kg/day (Mean) |
|---|---|
| Methylphenidate 7-day Dosing | 1.30 |
| Methylphenidate 5-day Dosing | 1.24 |
Monthly evaluations of medication efficacy will be used to determine whether dose adjustments are needed due to anticipated tolerance effects. (NCT02039908)
Timeframe: 10 months
| Intervention | Number of Increases (Mean) |
|---|---|
| Methylphenidate 7-day Dosing | 1.79 |
| Methylphenidate 5-day Dosing | 1.61 |
The amount of time elapsed before a child requires a dose increase during the school year will be measured in months. (NCT02039908)
Timeframe: 10 months
| Intervention | Months (Mean) |
|---|---|
| Methylphenidate 7-day Dosing | 3.8 |
| Methylphenidate 5-day Dosing | 4.1 |
"The primary clinical efficacy variable for treatment was the ADHD-RS-IV (Attention-Deficit/Hyperactivity Disorder Rating Scale) Total Score and two sub-scales (Inattentive and Hyperactive-Impulsive ).~The rating scale has 18 questions with answer options: None (0), Mild (1), Moderate (2) and Severe (3). Min 0; max 3.~Scores are obtained by summing each item; The higher the score, the worse the outcome.~Total score range: 0-54 Total Inattentive score range: 0-27 Total Hyperactive/Impulsive score range: 0-27" (NCT00429273)
Timeframe: Measured at baseline Week 4 and Week 8
| Intervention | units on a scale (Least Squares Mean) | ||
|---|---|---|---|
| Total ADHD-RS Score | Inattentive Subscale | Hyperactive Impulsive Subscale | |
| Estimated Difference Between DMPH and Placebo | -7.99 | -4.10 | -4.0 |
| Estimated Difference Between Guan and Placebo | -7.77 | -4.14 | -3.73 |
| Estimated Difference Between Placebo and Combo | -10.66 | -5.89 | -5.10 |
sum of score on 10 item IOWA Conners with range from 0 to 30 and higher values indicating more symptoms. Collected at end point or last assessment point. (NCT01109849)
Timeframe: at month 30 or last collected assessment point
| Intervention | units on a scale (Mean) |
|---|---|
| Behavior Therapy | 15.6 |
| ER Stimulant | 15.2 |
sum of items on 10 item IOWA Conners with range from 0-30 and larger values indicating greater symptoms. Collected at endpoint or last assessment point. (NCT01109849)
Timeframe: month 30 or last assessment point
| Intervention | units on a scale (Mean) |
|---|---|
| Behavior Therapy | 14.5 |
| ER Stimulant | 13.8 |
measures change in BMI z score from baseline to last assessment with participants grouped based on actual medication usage versus randomly assigned group since participants were allowed to cross treatment arms after 6 months and not all participants assigned to medication used it consistently. The rarely med group (n=44) used med <12.5% of the study duration (with most using not at all). The consistent med group (N=38 used med for at least 87.5% of their time in the study with most using the entire time). The inconsistent med group (N=111, 27.5% used medication 45% of the time in the study. The other 37 participants did not have one year of growth data so were excluded from this analysis. Z scores used to account for differences in age and gender between groups. Higher values represent a larger BMI (NCT01109849)
Timeframe: baseline to month 30 or last assessment point
| Intervention | Z score (Mean) |
|---|---|
| Consistent Medication | -0.554 |
| Inconsistent Medication Group | -0.170 |
| Rare Medication Group | 0.036 |
"difference in height z score from entry into weight recovery phase to exit from that phase (exact duration varied by participant). Randomization could not occur before month 6 (so max of 24 month duration) but could start as late as month 29 (equaling a 1 month duration) based on the pattern of zBMI change. In this post hoc analysis we grouped participants by what they did (caloric supplementation, drug holiday or monitoring) not what they were randomly assigned to. The most common change was from drug holiday to monitoring for participants who were not using medication on weekends before assignment to drug holiday (family stopped weekend med by own accord prior to 2nd randomization) so assignment to drug holiday did not alter actual frequency of use as was designed to.Therefore they were reclassified as monitoring as frequency of med use did not change.~Z score used to account for differences in age and gender between groups. Higher values reflect greater incremental BMI increase." (NCT01109849)
Timeframe: between 1 month and 24 months
| Intervention | Z score (Mean) |
|---|---|
| Caloric Supplementation | 0.248 |
| Drug Holiday | 0.496 |
| Monitoring | 0.260 |
measures change in height z score from baseline to last assessment with participants grouped based on actual medication usage versus randomly assigned group since participants were allowed to cross treatment arms after 6 months and not all participants assigned to medication used it consistently. The rarely med group (n=44) used med <12.5% of the study duration (with most using not at all). The consistent med group (N=38 used) med for at least 87.5% of their time in the study with most using the entire time. The inconsistent med group (N=111), used medication between 12.5 to 87.5 of the time (mean time on med was 45% of the time in the study) The other 37 participants did not have one year of growth data so were excluded from this analysis. Z scores used to account for differences in age and gender between groups. More negative values reflecting a smaller incremental height gain. (NCT01109849)
Timeframe: baseline to month 30 or last assessment point
| Intervention | Z score (Mean) |
|---|---|
| Consistent Medication | -0.248 |
| Inconsistent Medication Group | -0.113 |
| Rare Medication Group | 0.042 |
"difference in height z score from entry into weight recovery phase to exit from weight recovery phase (exact duration varied by participant). Randomization could not occur before month 6 (equaling a 24 month duration) but could start as late as month 29 (equaling a 1 month duration) of treatment based on the pattern of zBMI change by the individual participant.~Z scores used to account for differences in age and gender. More negative values reflecting less incremental height gain." (NCT01109849)
Timeframe: between 1 month and 24 months
| Intervention | Z score (Mean) |
|---|---|
| Caloric Supplementation | -0.185 |
| Drug Holiday | -0.030 |
| Monitoring | -0.168 |
measures change in weight z score from baseline to last assessment with participants grouped based on actual medication usage versus randomly assigned group since participants were allowed to cross treatment arms after 6 months and not all participants assigned to medication used it consistently. The rarely med group (n=44) used med <12.5% of the study duration (with most using not at all). The consistent med group (N=38 used med for at least 87.5% of their time in the study with most using the entire time). The inconsistent med group (N=111, 27.5% used medication 45% of the time in the study. The other 37 participants did not have one year of growth data so were excluded from this analysis. Z scores used to account for differences in age and gender between groups. Higher values represent a greater incremental weight gain. (NCT01109849)
Timeframe: baseline to month 30 or last assessment point
| Intervention | Z score (Mean) |
|---|---|
| Consistent Medication | -0.507 |
| Inconsistent Medication Group | -0.177 |
| Rare Medication Group | 0.112 |
"difference in weight z score from entry into weight recovery phase to exit from weight recovery phase (exact duration varied by participant). Randomization could not occur before month 6 (equaling a 24 month duration) but could start as late as month 29 (equaling a 1 month duration) of treatment based on the pattern of zBMI change by the individual participant.~Z scores used to account for differences in age and gender. Larger values reflect a greater incremental weight gain." (NCT01109849)
Timeframe: 1 to 24 months duration
| Intervention | Z score (Mean) |
|---|---|
| Caloric Supplementation | 0.050 |
| Drug Holiday | 0.262 |
| Monitoring | 0.062 |
"difference in height z score from entry into weight recovery phase to exit from that phase (exact duration varied by participant). Randomization could not occur before month 6 (so max of 24 month duration) but could start as late as month 29 (equaling a 1 month duration) based on the pattern of zBMI change. In this post hoc analysis we grouped participants by what they did (caloric supplementation, drug holiday or monitoring) not what they were randomly assigned to. The most common change was from drug holiday to monitoring for participants who were not using medication on weekends before assignment to drug holiday (family stopped weekend med by own accord prior to 2nd randomization) so assignment to drug holiday did not alter actual frequency of use as was designed to.Therefore they were reclassified as monitoring as frequency of med use did not change.~Z score used to account for differences in age and gender between groups. Higher values reflect greater incremental weight gain." (NCT01109849)
Timeframe: between 1 month and 24 months
| Intervention | zscore (Mean) |
|---|---|
| Caloric Supplementation | 0.055 |
| Drug Holiday | 0.299 |
| Monitoring | 0.084 |
BMI will be calculated at endpoint (month 30). Difference between baseline and endpoint (month 30 or last assessment point if did not finish study). Measured as a zscore with more negative units reflecting less BMI gain. Z units used to account for differences between groups in gender and age with both impact BMI at a fixed time. (NCT01109849)
Timeframe: baseline to month 30 or last assessment point
| Intervention | Z score (Mean) |
|---|---|
| Behavior Therapy | -.06 |
| ER Stimulant | -.21 |
"difference in BMI z score from entry into weight recovery phase to exit from weight recovery phase (exact duration varied by participant). Randomization could not occur before month 6 (equaling a 24 month duration) but could start as late as month 29 (equaling a 1 month duration) of treatment based on the pattern of zBMI change by the individual participant.~Z scores used to account for differences in age and gender. Larger values reflecting a greater incremental BMI gain." (NCT01109849)
Timeframe: between 1 month and 24 months
| Intervention | Z score (Mean) |
|---|---|
| Caloric Supplementation | 0.243 |
| Drug Holiday | 0.443 |
| Monitoring | 0.247 |
difference between baseline and endpoint (month 30 or last assessment point if did not finish study). Measured as a zscore with more negative units reflecting lesser weight gain. Z units used to account for differences between groups in gender and age with both impact weight at a fixed time. (NCT01109849)
Timeframe: baseline to month 30 or to last assessment point
| Intervention | Z score (Mean) |
|---|---|
| Behavior Therapy | -.01 |
| ER Stimulant | -.19 |
"The primary endpoint will be change in z-height at month 30 which is study endpoint.~Measured as a zscore with more negative units reflecting smaller incremental height gain. Z units used to account for differences between groups in gender and age with both impact height at a fixed time." (NCT01109849)
Timeframe: month 30 or last assessment point
| Intervention | Z score (Mean) |
|---|---|
| Behavior Therapy | -.04 |
| ER Stimulant | -.11 |
"in addition to the primary outcome of height at month 30, change in z-height from baseline to study month 6 post is also reported. Subjects who were still moderately impaired after 6 months in their initial treatment arm were allowed to cross over and receive the treatments in the other arm so prior to month 6 no participants randomized to behavior arm were prescribed study medication.~This outcome includes all participants with 2+ growth assessments from the behavior therapy and ER stimulant arms. Doesn't include adaptive randomization arms (drug holiday, cal supplement, monitoring) as they didn't exist until 2nd randomization which did not occur until after this assessment period was over.~Height converted to z score to account for differences in age and gender. More negative values reflecting smaller incremental height gain.~If participant dropped out prior to month 6, then the last assessment point was used." (NCT01109849)
Timeframe: baseline to month 6
| Intervention | Z score (Mean) |
|---|---|
| Behavior Therapy | 0.00 |
| ER Stimulant | -0.035 |
"difference in height z score from entry into weight recovery phase to exit from that phase (exact duration varied by participant). Randomization could not occur before month 6 (so max of 24 month duration) but could start as late as month 29 (equaling a 1 month duration) based on the pattern of zBMI change. In this post hoc analysis we grouped participants by what they did (caloric supplementation, drug holiday or monitoring) not what they were randomly assigned to. The most common change was from drug holiday to monitoring for participants who were not using medication on weekends before assignment to drug holiday (family stopped weekend med by own accord prior to 2nd randomization) so assignment to drug holiday did not alter actual frequency of use as was designed to.Therefore they were reclassified as monitoring as frequency of med use did not change.~Z score used to account for differences in age and gender between groups. Larger values reflect greater height change." (NCT01109849)
Timeframe: between 1 month and 24 months
| Intervention | Z score (Mean) |
|---|---|
| Caloric Supplementation | -0.184 |
| Drug Holiday | -0.095 |
| Monitoring | -0.105 |
% of study days that study ADHD medication was taken when prescribed to be taken; behavior group could be prescribed medication if moderately impaired still after month 6. Once prescribed, all medication was prescribed to be taken 7 days a week except for in the drug holiday weight recovery arm. (NCT01109849)
Timeframe: denominator is number of days in study for which study med was prescribed
| Intervention | % of days dose taken as prescribed (Number) |
|---|---|
| Behavior Therapy | 68.1 |
| ER Stimulant | 71.1 |
Raw number of behavior therapy sessions attended; participants could cross over to other treatment arm if moderately impaired after 6 months in initial randomly assigned arm (NCT01109849)
Timeframe: months 0 through 30
| Intervention | sessions attended (Mean) |
|---|---|
| Behavior Therapy | 8.1 |
| ER Stimulant | 8.1 |
percent of days caloric supplement were taken versus prescribed in caloric supplement arm (NCT01109849)
Timeframe: from entry to exit of caloric supplement arm
| Intervention | percentage of days (Mean) |
|---|---|
| Weight Promotion Treatment- Caloric Supplement | 70 |
The PREMB-R is an 11-item rating scale designed to assess at-home functional impairments in children with ADHD during both early morning (AM) and late afternoon/evening (PM) time periods. With demonstrated validity and reliablility (Faraone et al., 2015), the AM subscale total score (sum of items 1 to 3) was designated in this study as a key secondary endpoint. Items are scored from 0 (none) to 3 (a lot), with higher scores signifying greater impairment of function. The PREMB-R rating scale was completed by parents during the 2-days prior to study visits at the beginning and end of the open-label period (Visits 2 and 8, respectively), as well as at the end of the randomized, double-blind period (Visit 9). At each visit, these ratings were used only for review by the clinician (MD, PhD, DO, licensed social worker, or any trained mental health professional approved by the sponsor) as part of a structured interview to enable collection of a clinician-rated PREMB-R AM subscale score. (NCT02493777)
Timeframe: PREMB-R AM mean subscale score for the 2-days prior to Visit 9.
| Intervention | PREMB-R AM subscale total score (Least Squares Mean) |
|---|---|
| HLD200 (Methylphenidate) | 0.9 |
| Placebo | 2.7 |
The SKAMP is a validated, 13-item, observer-rated scale designed to assess the level of impairment of classroom-observed behaviors (Wigal and Wigal, 2006). Items 1 through 4 assess subject attention; items 5 through 8 assess deportment; items 9 through 11 assess quality of work; while items 12 and 13 assess subject compliance with teacher/classroom rules. Each individual item is rated on a 7-point scale from 0 (normal, no impairment) to 6 (maximal impairment). When all individual item scores are summed together, they produce a 13-item combined score that ranges from 0 to 78, with higher scores signifying greater impairment. In the present study, the SKAMP rating scale was utilized across 9 sessions occuring at 8:00 am, 9:00 am, 10:00 am, 12:00 pm, 2:00 pm, 4:00 pm, 6:00 pm, 7:00 pm, and 8:00 pm of the laboratory classroom day. Successful training of qualified individuals on the SKAMP scale was required before raters were allowed to perform study assessments. (NCT02493777)
Timeframe: 12-hours from 8:00 am to 8:00 pm
| Intervention | SKAMP CS (12-hour average) (Least Squares Mean) |
|---|---|
| HLD200 (Methylphenidate) | 14.8 |
| Placebo | 20.7 |
Participants were monitored for 4 weeks on treatment (final 2 weeks on stable dose). Clinicians rated subject behavior on the ADHD-5-Rating Scale each week. Primary outcome was based on the final week of treatment. The ADHD-5-RS is an 18-item questionnaire that measures the frequency of ADHD symptoms based on DSM-5 criteria. For each item, clinicians rate how often the behavior is displayed on a scale of 0 (Never or Rarely) to 3 (Very Often). Scores can range from 0 to 54, with lower scores indicating a lower frequency of ADHD symptoms. (NCT02139124)
Timeframe: 4 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| PRC-063 25 mg | 24.2 |
| PRC-063 45 mg | 19.9 |
| PRC-063 70 mg | 24.0 |
| PRC-063 100 mg | 18.7 |
| 0 mg/Day | 26.1 |
The ADHD-RS-IV was developed to measure the behaviors of children with ADHD (DuPaul et al., 1998). The scale consists of 18 items designed to reflect current symptomatology of ADHD. Each item is scored in a range from 0 (reflecting no symptoms or a frequency of never or rarely) to 3 (reflecting severe symptoms or a frequency of almost always), with a range of total scores ranging from 0 to 54. In this study, a site clinican (required to be an MD, PhD, DO, licensed social worker, or any trained mental health professional approved by the sponsor) completed ADHD-RS-IV assessments at each visit using a structured interview format. (NCT02520388)
Timeframe: Last week of 3-week treatment period assessed at Visit 5.
| Intervention | ADHD-RS-IV total score (Least Squares Mean) |
|---|---|
| HLD200 (Methylphenidate) | 24.1 |
| Placebo | 31.2 |
The BSFQ was developed as a hybrid measure completed by a clinician or parent/legal guardian to assess commonly reported areas of morning dysfunction - both behaviors and functions associated with the post-waking, early morning period (from approximately 6:00 am to 9:00 am) - in children and adolescents with ADHD (Wilens et al., 2010; Wilens et al., 2013). Symptom severity and functional impairment were rated from 0 (none) to 3 (severe - different from peers all days, all settings) with total scores ranging from 0 to 60. Ratings were completed by a site clinician (MD, PhD, DO, licensed social worker, or trained mental health professional approved by the sponsor) at Visits 2 through 5 using a structured interview format. (NCT02520388)
Timeframe: Last week of 3-week treatment period assessed at Visit 5.
| Intervention | BSFQ total score (Least Squares Mean) |
|---|---|
| HLD200 (Methylphenidate) | 18.7 |
| Placebo | 28.4 |
PERMP-T measures the number of completed and number of attempted math problems completed during a 10 minute test. The scale ranges from 0 to 800, with a higher score indicating a better outcome. (NCT03618030)
Timeframe: Full-day ALC - 13 hours
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Double-Blind Active Treatment | 302.9 |
| Double-Blind Placebo Treatment | 286.6 |
The SKAMP scale measured the manifestations of attention deficit hyperactivity disorder (ADHD) using an independent observer rating of the participant's impairment in classroom observed behaviors. SKAMP combined score comprised of 13 items (including subscales: attention with items 1-4, deportment with items 5-8, quality of work with items 9-11 and compliance with items 12-13). The SKAMP composite score was obtained by summing up each item score where each item was rated on a 7-point impairment scale (0=normal to 6=maximal impairment) for a total possible combined score of 0 to 78; where higher score signified worst impairment. Average of all post dose SKAMP-combined scores measured at 0.75, 2, 4, 8, 10, 12 and 13 hours post-dose was calculated. (NCT01654250)
Timeframe: 0.75 up to 13 hours post-dose
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo (OL Phase; DB Phase) | 19.1 |
| NWP09 (OL Phase; DB Phase) | 12.1 |
CGI-S scale was used to measure features associated with ADHD. The assessment was performed by the investigator of the study research team. The CGI-S classified the participant's current disease status as: 1 = normal, not at all ill, 2 = borderline ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly ill, 6 = severely ill, and 7 = among the most extremely ill participants. This outcome measure was analyzed during open label phase in entire study population prior to randomization into two treatment groups. (NCT01654250)
Timeframe: Baseline, Day 8, 15, 22, 29, 36, 43
| Intervention | Units on a scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Baseline | Day 8 | Day 15 | Day 22 | Day 29 | Day 36 | Day 43 | |
| Entire Study Population | 4.6 | 3.9 | 3.3 | 2.6 | 2.2 | 2.0 | 2.0 |
The CGI-I measured the participant's disease improvement relative to baseline as followed: 1= very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6= much worse, and 7=very much worse. This outcome measure was analyzed during open label phase in entire study population prior to randomization into two treatment groups. (NCT01654250)
Timeframe: Day 8, 15, 22, 29, 36, 43
| Intervention | Units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Day 8 | Day 15 | Day 22 | Day 29 | Day 36 | Day 43 | |
| Entire Study Population | 3.0 | 2.3 | 1.7 | 1.4 | 1.3 | 1.3 |
CPRS was used to measure features associated with ADHD and was used to compare scores during the dose optimization period i.e. 1-6 weeks. The assessment was performed by parent or guardian. CPRS consisted of 27 questions graded on a scale from 0 (not true at all) to 3 (very much true). Raw scores were converted to t-scores and t-scores have a mean of 50 ± 10 where higher scores are indicative of greater problems. The participant received normalized t-scores on the following scales: oppositional, cognitive problems/inattention, hyperactivity, anxious-shy, perfectionism, social problems, psychosomatic, ADHD index, restless-impulse, emotional liability, conner's global index, inattentive, hyperactive-impulsive and diagnostic and statistical manual of mental disorders IV (DSM-IV). This outcome measure was analyzed during open label phase in entire study population prior to randomization into two treatment groups. (NCT01654250)
Timeframe: Baseline, Day 8, 15, 22, 29, 36, 43
| Intervention | Units on a scale (Mean) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oppositional : Baseline | Cognitive Problems/ Inattention: Baseline | Hyperactivity: Baseline | Anxious-shy: Baseline | Perfectionism: Baseline | Social problems: Baseline | Psychosomatic: Baseline | ADHD index: Baseline | Restless-Impulse: Baseline | Emotional Liability: Baseline | Conner's Global index: Baseline | Inattentive: Baseline | Hyperactive-Impulsive: Baseline | DSM-IV: Baseline | Oppositional: Day 8 | Cognitive Problems/ Inattention: Day 8 | Hyperactivity: Day 8 | Anxious-shy: Day 8 | Perfectionism: Day 8 | Social problems: Day 8 | Psychosomatic: Day 8 | ADHD index: Day 8 | Restless-Impulse: Day 8 | Emotional Liability: Day 8 | Conner's Global index: Day 8 | Inattentive: Day 8 | Hyperactive-Impulsive: Day 8 | DSM-IV: Day 8 | Oppositional: Day 15 | Cognitive Problems/ Inattention: Day 15 | Hyperactivity: Day 15 | Anxious-shy: Day 15 | Perfectionism: Day 15 | Social problems: Day 15 | Psychosomatic: Day 15 | ADHD index: Day 15 | Restless-Impulse: Day 15 | Emotional Liability: Day 15 | Conner's Global index: Day 15 | Inattentive: Day 15 | Hyperactive-Impulsive: Day 15 | DSM-IV: Day 15 | Oppositional: Day 22 | Cognitive Problems/ Inattention: Day 22 | Hyperactivity: Day 22 | Anxious-shy: Day 22 | Perfectionism: Day 22 | Social problems: Day 22 | Psychosomatic: Day 22 | ADHD index: Day 22 | Restless-Impulse: Day 22 | Emotional Liability: Day 22 | Conner's Global index: Day 22 | Inattentive: Day 22 | Hyperactive-Impulsive: Day 22 | DSM-IV: Day 22 | Oppositional: Day 29 | Cognitive Problems/ Inattention: Day 29 | Hyperactivity: Day 29 | Anxious-shy: Day 29 | Perfectionism: Day 29 | Social problems: Day 29 | Psychosomatic: Day 29 | ADHD index: Day 29 | Restless-Impulse: Day 29 | Emotional Liability: Day 29 | Conner's Global index: Day 29 | Inattentive: Day 29 | Hyperactive-Impulsive: Day 29 | DSM-IV: Day 29 | Oppositional: Day 36 | Cognitive Problems/ Inattention: Day 36 | Hyperactivity: Day 36 | Anxious-shy: Day 36 | Perfectionism: Day 36 | Social problems: Day 36 | Psychosomatic: Day 36 | ADHD index: Day 36 | Restless-Impulse: Day 36 | Emotional Liability: Day 36 | Conner's Global index: Day 36 | Inattentive: Day 36 | Hyperactive-Impulsive: Day 36 | DSM-IV: Day 36 | Oppositional: Day 43 | Cognitive Problems/ Inattention: Day 43 | Hyperactivity: Day 43 | Anxious-shy: Day 43 | Perfectionism: Day 43 | Social problems: Day 43 | Psychosomatic: Day 43 | ADHD index: Day 43 | Restless-Impulse: Day 43 | Emotional Liability: Day 43 | Conner's Global index: Day 43 | Inattentive: Day 43 | Hyperactive-Impulsive: Day 43 | DSM-IV: Day 43 | |
| Entire Study Population | 67.3 | 71.1 | 79.3 | 57.3 | 54.9 | 57.1 | 57.1 | 73.8 | 74.6 | 64.8 | 73.6 | 73.8 | 78.0 | 77.8 | 64.0 | 66.5 | 73.5 | 54.9 | 52.7 | 55.5 | 55.2 | 68.8 | 69.7 | 62.1 | 68.9 | 68.3 | 73.1 | 72.1 | 59.5 | 61.8 | 68.0 | 52.5 | 51.1 | 54.0 | 53.2 | 63.3 | 65.2 | 57.0 | 63.6 | 63.0 | 67.4 | 66.2 | 55.5 | 59.1 | 62.8 | 50.5 | 49.3 | 52.6 | 50.6 | 59.7 | 59.6 | 53.3 | 58.4 | 59.5 | 63.5 | 62.3 | 52.8 | 55.7 | 58.2 | 49.8 | 48.3 | 51.2 | 49.7 | 55.7 | 55.9 | 51.0 | 54.8 | 55.6 | 57.8 | 57.1 | 50.5 | 54.7 | 56.0 | 49.0 | 46.6 | 50.1 | 47.9 | 53.8 | 54.3 | 49.8 | 53.3 | 54.7 | 55.2 | 55.4 | 49.8 | 54.0 | 54.4 | 47.9 | 45.9 | 50.5 | 47.2 | 52.9 | 53.2 | 48.9 | 52.1 | 53.8 | 54.3 | 54.3 |
Onset and duration of clinical effect was determined using SKAMP combined rating scale at each post-dose time point. Onset of effect was defined as first assessment time showing statistical significance (i.e. p was less than or equal to [=<] 0.05) between NWP09 and placebo and duration of effect was defined as the as last consecutive time-point at which difference was statistically significant between NWP09 and placebo. SKAMP scale measured the manifestations of ADHD using an independent observer rating of the participant's impairment in classroom observed behaviors. SKAMP combined score was comprised of 13 items [subscales: attention (1-4 items), deportment (5-8 items), quality of work (9-11 items) and compliance (12-13 items)]. SKAMP combined score was obtained by summing up each item score where each item was rated on a 7-point impairment scale (0=normal to 6=maximal impairment) for total possible combined score of 0 to 78; where higher score signified worst impairment. (NCT01654250)
Timeframe: 0.75, 2, 4, 8, 10, 12, 13 hours post-dose
| Intervention | Units on a scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Hour 0.75 | Hour 2 | Hour 4 | Hour 8 | Hour 10 | Hour 12 | Hour 13 | |
| NWP09 (OL Phase; DB Phase) | 10.7 | 8.0 | 8.1 | 12.1 | 14.8 | 17.0 | 17.5 |
| Placebo (OL Phase; DB Phase) | 18.3 | 20.3 | 19.8 | 19.3 | 17.7 | 19.4 | 18.4 |
The PERMP score measured the manifestations of attention deficit hyperactivity disorder. The PERMP is a 10-minute written test, on 80 math problems, performed as seatwork in the classroom. At the end of the 10- minute math test , the PERMP score of the number of math problems attempted plus the number of math problems answered correctly in a 10-minute session was used to measure participant's performance. The total score range from 0-160 with higher scores indicating better performance. (NCT01654250)
Timeframe: 0.75, 2, 4, 8, 10, 12 and 13 post-dose
| Intervention | Units on a scale (Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hour 0.75: Problems attempted | Hour 0.75: Problems corrected | Hour 2: Problems attempted | Hour 2: Problems corrected | Hour 4: Problems attempted | Hour 4: Problems corrected | Hour 8: Problems attempted | Hour 8: Problems corrected | Hour 10: Problems attempted | Hour 10: Problems corrected | Hour 12: Problems attempted | Hour 12: Problems corrected | Hour 13: Problems attempted | Hour 13: Problems corrected | |
| NWP09 (OL Phase; DB Phase) | 128.8 | 123.9 | 140.9 | 136.6 | 140.0 | 135.6 | 129.1 | 124.0 | 113.9 | 107.9 | 111.1 | 103.3 | 115.4 | 101.8 |
| Placebo (OL Phase; DB Phase) | 105.4 | 102.8 | 106.6 | 103.7 | 107.2 | 104.2 | 101.7 | 98.5 | 103.2 | 100.8 | 97.9 | 95.1 | 98.6 | 95.0 |
SKAMP scale measured the manifestations of ADHD using an independent observer rating of the participant's impairment in classroom observed behaviors. The SKAMP subscales were obtained by summing the individual items as follows: Attention (items 1-4) and Deportment (items 5-8), where each item was rated on a 7-point scale (0=normal to 6=maximal impairment). SKAMP attention subscale was reported which evaluates concentration in the classroom and comprises of 4 items, with a total possible score for of 0 to 24; higher score indicates worst impairment. SKAMP deportment subscale was reported which assesses behavior in the classroom and comprises of 4 items, with a total possible score for each sub-scale of 0 to 24; higher score indicates worst impairment. (NCT01654250)
Timeframe: 0.75, 2, 4, 8, 10, 12, 13 hours post-dose
| Intervention | Units on a scale (Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hour 0.75: Attention Subscale | Hour 0.75: Deportment Subscale | Hour 2: Attention Subscale | Hour 2: Deportment Subscale | Hour 4: Attention Subscale | Hour 4: Deportment Subscale | Hour 8: Attention Subscale | Hour 8: Deportment Subscale | Hour 10: Attention Subscale | Hour 10: Deportment Subscale | Hour 12: Attention Subscale | Hour 12: Deportment Subscale | Hour 13: Attention Subscale | Hour 13: Deportment Subscale | |
| NWP09 (OL Phase; DB Phase) | 1.6 | 2.1 | 1.1 | 1.6 | 1.0 | 1.7 | 2.0 | 2.6 | 2.6 | 2.6 | 3.2 | 3.5 | 3.2 | 3.9 |
| Placebo (OL Phase; DB Phase) | 2.9 | 4.6 | 3.4 | 5.4 | 3.2 | 5.4 | 3.5 | 4.3 | 3.4 | 3.9 | 3.4 | 4.2 | 3.8 | 3.7 |
Attention deficit/hyperactivity disorder - hyperactivity/impulsivity (ADHD- H/I). Each item on the 18-item measure is scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms), yielding a possible total score of 0-27. Higher score indicates higher probability of diagnosis. (NCT00183391)
Timeframe: up to 14 weeks
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Block 1 Baseline Week 0 | Block 1 End of Treatment Week 6 | Block 2 Baseline 8 | Blocks 2 End of Treatment Week 14 | |
| Atomoxetine Then Methylphenidate | 16.56 | 7.82 | 13.99 | 6.67 |
| Methylphenidate Then Atomoxetine | 17.31 | 7.24 | 14.80 | 8.87 |
Each item on the 18-item measure is scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms), yielding a possible total score of 0-27. Higher score indicates higher probability of diagnosis. (NCT00183391)
Timeframe: up to 14 weeks
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Block 1 Baseline Week 0 | Block 1 End of Treatment Week 6 | Block 2 Baseline Week 8 | Blocks 2 End of Treatment Week 14 | |
| Atomoxetine Then Methylphenidate | 23.30 | 12.32 | 20.33 | 11.09 |
| Methylphenidate Then Atomoxetine | 22.44 | 10.35 | 18.74 | 13.26 |
ADHD-RS Total Score Attention Deficit Hyperactivity Disorder Rating Scale. Each item on the 18-item measure is scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms), yielding a possible total score of 0-54. Higher score indicates higher probability of diagnosis. (NCT00183391)
Timeframe: up to 14 weeks
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Block 1 Baseline Week 0 | Block 1 End of Treatment Week 6 | Block 2 Baseline Week 8 | Blocks 2 End of Treatment Week 14 | |
| Atomoxetine Then Methylphenidate | 39.58 | 20.03 | 34.32 | 18.08 |
| Methylphenidate Then Atomoxetine | 39.75 | 17.59 | 33.54 | 22.13 |
Affective problems. This scale consists of 8 items, scored 0-3, with 0 representing no problems and 3 representing extreme problems. This analysis presents sum of scores, higher is worse. Full range from 0 to 24. This score does not have psychometrics available. (NCT00183391)
Timeframe: up to 14 weeks
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Block 1 Baseline Week 0 | Block 1 End of Treatment Week 6 | Block 2 Baseline Week 8 | Blocks 2 End of Treatment Week 14 | |
| Atomoxetine Then Methylphenidate | 11.2609 | 10.6889 | 9.7108 | 10.9886 |
| Methylphenidate Then Atomoxetine | 10.6905 | 10.8257 | 10.1400 | 10.9286 |
Measure of conflict within the home over the past 24 hours. The CCI is a validated measure of family conflicts in the home and is completed by parents. It consists of 42 items (for boys) or 36 items (for girls) reflecting attention-seeking and conflictual behavior, as well as negativity and withdrawal. Items are scored as yes (1 point) or no (0 points). Mean score between 0 and 1 reported, with higher score indicating greater conflict. (NCT00183391)
Timeframe: up to 14 weeks
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Block 1 Baseline Week 0 | Block 1 End of Treatment week 6 | Block 1 End of Treatment Week 8 | Blocks 2 End of Treatment Week 14 | |
| Atomoxetine Then Methylphenidate | .3224 | .2386 | .3526 | .2118 |
| Methylphenidate Then Atomoxetine | .3385 | .1978 | .3078 | .2304 |
Children's Sleep Problems Severity, sum of scores, higher is worse.The scale assessed contains 16 items, each scored 0 to 3, with 0 representing no problems and 3 representing daily problems. total range from 0 to 48. This score does not have psychometrics available. (NCT00183391)
Timeframe: up to 14 weeks
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Block 1 Baseline Week 0 | Block 1 End of Treatment Week 6 | Block 2 Baseline Week 8 | Blocks 2 End of Treatment Week 14 | |
| Atomoxetine Then Methylphenidate | 5.14 | 3.20 | 4.75 | 2.94 |
| Methylphenidate Then Atomoxetine | 5.09 | 2.83 | 4.55 | 3.43 |
The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness at the time of rating 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. (NCT00183391)
Timeframe: up to 14 weeks
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Block 1 Baseline Week 0 | Block 1 End of Treatment Week 6 | Block 2 Baseline Week 8 | Blocks 2 End of Treatment Week 14 | |
| Atomoxetine Then Methylphenidate | 5.14 | 3.20 | 4.75 | 2.94 |
| Methylphenidate Then Atomoxetine | 5.09 | 2.83 | 4.55 | 3.43 |
CPT Commissions, impulsive responses, higher score is worse. This scale is based on t-scores and does not have psychometrics available. (NCT00183391)
Timeframe: up to 14 weeks
| Intervention | T-scores (Mean) | |||
|---|---|---|---|---|
| Block 1 Baseline Week 0 | Block 1 End of Treatment Week 6 | Block 2 Baseline Week 8 | Blocks 2 End of Treatment Week 14 | |
| Atomoxetine Then Methylphenidate | 51.3277 | 51.7005 | 59.8788 | 50.0763 |
| Methylphenidate Then Atomoxetine | 52.8976 | 51.1713 | 51.2159 | 49.1616 |
Measure of social skills, higher score is better. This scale is based on t-scores and does not have psychometrics available. (NCT00183391)
Timeframe: up to 14 weeks
| Intervention | t-score (Mean) | |||
|---|---|---|---|---|
| Block 1 Baseline Week 0 | Block 1 End of Treatment Week 6 | Block 2 Baseline Week 8 | Blocks 2 End of Treatment Week 14 | |
| Atomoxetine Then Methylphenidate | 82.71 | 91.07 | 78.58 | 91.07 |
| Methylphenidate Then Atomoxetine | 77.96 | 88.57 | 82.35 | 87.96 |
Modified Yale Global Tic Severity Scale, sum, higher is worse. This score does not have psychometrics available. The Yale Global Tic Severity Scale (YGTSS) is a semistructured clinician-rated instrument that assesses the severity and frequency of motor and phonic tics over the previous week. Five index scores are obtained during the assessment, where higher scores indicate greater frequency or severity. These indices are: Total Motor Tic Score (0-25), Total Phonic Tic Score (0-25), Total Tic Score (0-50) Overall Impairment Rating (0-50). (NCT00183391)
Timeframe: up to 14 weeks
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Block 1 Baseline Week 0 | Block 1 End of Treatment Week 6 | Block 2 Baseline Week 8 | Blocks 2 End of Treatment Week 14 | |
| Atomoxetine Then Methylphenidate | 5.304 | 1.737 | .000 | .500 |
| Methylphenidate Then Atomoxetine | .292 | .132 | .643 | .397 |
Modified Yale Global Tic Severity Scale, sum, higher is worse. This score does not have psychometrics available. The Yale Global Tic Severity Scale (YGTSS) is a semistructured clinician-rated instrument that assesses the severity and frequency of motor and phonic tics over the previous week. Five index scores are obtained during the assessment, where higher scores indicate greater frequency or severity. These indices are: Total Motor Tic Score (0-25), Total Phonic Tic Score (0-25), Total Tic Score (0-50) Overall Impairment Rating (0-50). (NCT00183391)
Timeframe: up to 14 weeks
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Block 1 Baseline Week 0 | Block 1 End of Treatment Week 6 | Block 2 Baseline Week 8 | Blocks 2 End of Treatment Week 14 | |
| Atomoxetine Then Methylphenidate | .196 | .053 | .000 | .160 |
| Methylphenidate Then Atomoxetine | .111 | 1.342 | .214 | .143 |
Modified Yale Global Tic Severity Scale, sum, higher is worse. This score does not have psychometrics available. The Yale Global Tic Severity Scale (YGTSS) is a semistructured clinician-rated instrument that assesses the severity and frequency of motor and phonic tics over the previous week. Five index scores are obtained during the assessment, where higher scores indicate greater frequency or severity. These indices are: Total Motor Tic Score (0-25), Total Phonic Tic Score (0-25), Total Tic Score (0-50) Overall Impairment Rating (0-50). (NCT00183391)
Timeframe: up to 14 weeks
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Block 1 Baseline Week 0 | Block 1 End of Treatment Week 6 | Block 2 Baseline Week 8 | Blocks 2 End of Treatment Week 14 | |
| Atomoxetine Then Methylphenidate | .161 | .018 | .039 | .060 |
| Methylphenidate Then Atomoxetine | .028 | 1.329 | .057 | .016 |
(NCT00183391)
Timeframe: Measured at ends of treatments one and two
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Treatment Preference of ATX | Treatment Preference of MPH | |
| Atomoxetine Then Methylphenidate | 41.8 | 50.5 |
| Methylphenidate Then Atomoxetine | 27.4 | 51.9 |
Diastole blood pressure - blood pressure when the heart muscle is between beats. normal range varies by age, sex, height and weight and can range from 34mm Hg to 90mmHg (NCT00183391)
Timeframe: up to 14 weeks
| Intervention | mm HG (Mean) | |||
|---|---|---|---|---|
| Block 1 Baseline Week 0 | Block 1 End of Treatment Week 6 | Block 2 Baseline Week 8 | Blocks 2 End of Treatment Week 14 | |
| Atomoxetine Then Methylphenidate | 61.78 | 64.58 | 62.33 | 62.82 |
| Methylphenidate Then Atomoxetine | 61.26 | 62.77 | 61.28 | 65.44 |
Heartbeats per minute. Range varies from 50-205 depending on age and level of activity. (NCT00183391)
Timeframe: up to 14 weeks
| Intervention | beats per minute (Mean) | |||
|---|---|---|---|---|
| Block 1 Baseline Week 0 | Block 1 End of Treatment Week 6 | Block 2 Baseline Week 8 | Blocks 2 End of Treatment Week 14 | |
| Atomoxetine Then Methylphenidate | 78.20 | 84.46 | 82.96 | 84.85 |
| Methylphenidate Then Atomoxetine | 77.49 | 82.05 | 81.30 | 84.31 |
Systolic blood pressure - the amount of pressure in arteries during contraction of the heart muscle Normal range varies by age, sex, height and weight and can range from 80mm Hg to 130mmHg (NCT00183391)
Timeframe: up to 14 weeks
| Intervention | mm HG (Mean) | |||
|---|---|---|---|---|
| Block 1 Baseline Week 0 | Block 1 End of Treatment Week 6 | Block 2 Baseline Week 8 | Blocks 2 End of Treatment Week 14 | |
| Atomoxetine Then Methylphenidate | 101.11 | 102.10 | 99.74 | 102.34 |
| Methylphenidate Then Atomoxetine | 101.60 | 103.29 | 101.29 | 102.51 |
The ADHD-RS-IV was developed to measure the behaviors of children with ADHD and is commonly used in clinical studies of ADHD. The ADHD-RS-IV consisted of 18 items designed to reflect current symptomatology of ADHD based on Diagnostic and Statistical Manual of Mental Disorders, 4th Edition-Text Revision (DSM-IV-TR) criteria. Each item was scored on a 4-point scale ranging from 0 (reflecting no symptoms) to 3 (reflecting severe symptoms) with total scores ranging from 0-54, Higher score = more severe symptoms. (NCT01552902)
Timeframe: Baseline, Week 6
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -17 |
| Lisdexamfetamine Dimesylate | -25.4 |
| Methylphenidate | -22.1 |
(NCT01552902)
Timeframe: Baseline, Week 6
| Intervention | Beats per minute (Mean) |
|---|---|
| Placebo | 2.4 |
| Lisdexamfetamine Dimesylate | 6.7 |
| Methylphenidate | 8.2 |
The Clinical Global Impressions Scale permits a global evaluation of the participant's severity of illness and improvement over time. The scale included a severity of illness item and a global improvement item. The investigator performed the CGI-I to rate the improvement of a participant's ADHD symptoms based on a 7-point scale (1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; or 7=very much worse.). Percentage of participants with an improved measurement (response of very much improved and much improved) is reported. (NCT01552902)
Timeframe: Week 6
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 50 |
| Lisdexamfetamine Dimesylate | 81.4 |
| Methylphenidate | 71.3 |
(NCT01552902)
Timeframe: Baseline, Week 6
| Intervention | millimeter of mercury (mmHg) (Mean) | |
|---|---|---|
| Systolic blood pressure | Diastolic blood pressure | |
| Lisdexamfetamine Dimesylate | 1.5 | 3.4 |
| Methylphenidate | 2.4 | 3.5 |
| Placebo | -1 | -0.1 |
An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered as a pharmaceutical product that did not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs were events between first dose of double-blind investigational product and up to 3 days after last dose that were absent before treatment or that worsened relative to pretreatment state. (NCT01552902)
Timeframe: Baseline up to 3 days after last dose (last dose at Week 6)
| Intervention | participants (Number) | |
|---|---|---|
| Participants with TEAEs | Participants with serious TEAEs | |
| Lisdexamfetamine Dimesylate | 145 | 1 |
| Methylphenidate | 129 | 1 |
| Placebo | 49 | 1 |
The ADHD-RS-IV consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54. Higher score indicates more severe symptoms. (NCT01552915)
Timeframe: Baseline and week 8
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -13.4 |
| SPD489 | -25.6 |
| OROS-MPH | -23.5 |
(NCT01552915)
Timeframe: Baseline and up to 8 weeks
| Intervention | mmHg (Mean) |
|---|---|
| Placebo | -1.2 |
| SPD489 | 2.8 |
| OROS-MPH | 2.2 |
(NCT01552915)
Timeframe: Baseline and up to 8 weeks
| Intervention | bpm (Mean) |
|---|---|
| Placebo | 0.3 |
| SPD489 | 4.7 |
| OROS-MPH | 6.0 |
(NCT01552915)
Timeframe: Baseline and up to 8 Weeks
| Intervention | mmHg (Mean) |
|---|---|
| Placebo | -0.8 |
| SPD489 | 2.4 |
| OROS-MPH | 0.4 |
Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale. (NCT01552915)
Timeframe: Week 8
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 34.8 |
| SPD489 | 83.1 |
| OROS-MPH | 81.0 |
A Generalized Estimating Equations(GEE)model which included treatment group, week, site, and treatment by week and site by week interaction effects was used to compare the groups on the DSM-IV ADHD total severity score (18 domains score at severity levels of 0[none]-3[severe]; maximum score 54) as measured at screening/baseline and study weeks 1-4 using the the interviewer-administered DSM-IV checklist and by the severity portion of the National Institute of Mental Health Clinical Global Impression (CGI) scale to rate the severity of the participant's ADHD symptoms. A single severity score ranging from 1 to 7 is yielded by the CGI severity scale. (NCT00253747)
Timeframe: Baseline and Study weeks 1,4,7,9,11
| Intervention | DSM IV ADHD Score (Mean) |
|---|---|
| Osmotic-Release Methylphenidate (OROS-MPH)-Baseline | 38.4 |
| Osmotic-Release Methylphenidate (OROS-MPH) - Placebo-Baseline | 36.6 |
| Osmotic-Release Methylphenidate (OROS-MPH)-Week 11 | 16.4 |
| Osmotic-Release Methylphenidate (OROS-MPH) - Placebo-Week 11 | 24.2 |
| Release Methylphenidate (OROS-MPH)-Week 4 | 20.4 |
| Osmotic-Release Methylphenidate (OROS-MPH) - Placebo-Week 4 | 27.2 |
| Release Methylphenidate (OROS-MPH)-Week 7 | 20 |
| Osmotic-Release Methylphenidate (OROS-MPH) - Placebo-Week 7 | 24 |
| Release Methylphenidate (OROS-MPH)-Week 9 | 17.3 |
| Methylphenidate (OROS-MPH) - Placebo-Week 9 | 23.9 |
A logistic regression including site and treatment group will be used to model rates of achieving point prevalence abstinence as assessed at the final visit of the O-MPH/P-Stnd Smoking Tx phase. Point prevalence abstinence was defined as not smoking in the previous seven days based on self-report using the TLFB method and confirmed with a Carbon Monoxide (CO) level <8 ppm. (NCT00253747)
Timeframe: Week 11
| Intervention | participants (Number) |
|---|---|
| Osmotic-Release Methylphenidate (OROS-MPH) | 24 |
| Osmotic-Release Methylphenidate (OROS-MPH) - Placebo | 26 |
"The smoking quit date was considered the first day of the O-MPH/P-Stnd Smoking Tx phase, which lasted for 6 weeks or more precisely 42 days (i.e., approximately weeks 5-10). The grace period was the first two weeks (i.e., days 1-14) with the remaining four weeks (days 15-42) comprising the period in which the participant must not meet criteria for treatment failure in order to be scored as obtaining prolonged abstinence. Self-report of cigarette use was assessed using a time-line follow-back (TLFB) assessment using carbon monoxide (CO)levels to correct self-reported smoking days. Smoking days were determined by starting with self-reported smoking and non-smoking days and using CO levels measured at weekly visits to modify the self-reports." (NCT00253747)
Timeframe: Weeks 7-10
| Intervention | participants (Number) |
|---|---|
| Osmotic-Release Methylphenidate (OROS-MPH) | 25 |
| Osmotic-Release Methylphenidate (OROS-MPH) - Placebo | 28 |
"Attendtion-deficit hyperactivity disorder (ADHD) Rating Scale-IV is the sum of 18 questions, ranging from 0 (no symptoms) to 54 (worst possible symptoms).~Change from baseline ADHD Rating Scale-IV scores at 8 weeks was calculated as baseline minus 8 weeks." (NCT01912352)
Timeframe: baseline and 8 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Methylphenidate | 14.9 |
"Clinical Global Impression-Improvement (CGI-I) scale is a one-item measure evaluating the change from the initiation of treatment on a seven-point scale: Compared to the patient's condition at baseline [prior to medication initiation], this patient's condition is: 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment.~Clinical Global Impression-Improvement was measured at 8 weeks." (NCT01912352)
Timeframe: baseline and 8 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Methylphenidate | 2.3 |
Number of high-effort selections in the effort-based decision making task from the placebo to the methylphenidate condition. This is a decision-making task where participants make high- or low-effort choices to earn a small financial reward. High-effort selections require 100 button presses with non-dominant hand pinky finger and low-effort selections require 30 button presses with dominant hand index finger (within 15 seconds). The number of high effort selections are summed across 50 trials of the task. This task measures the willingness to perform effort in relation to changing reward magnitude and probability. This is a basic science experiment, the clinical and/or physiological relevance of these results are not established. (NCT02630017)
Timeframe: 1 hour post drug (or placebo) administration for each study session
| Intervention | Number of high-effort selections (Mean) |
|---|---|
| ADHD Subjects, Placebo Condition | 16.4 |
| ADHD Subjects, Methylphenidate Condition | 21.35 |
| Non-ADHD Subjects, Placebo Condition | 20.45 |
| Non-ADHD Subjects, Methylphenidate Condition | 19.8 |
The CGI-I is a 7-point scale that requires the clinician to assess how much the participant's illness has improved or worsened relative to a baseline state at the beginning of the intervention and rated as: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse. (NCT01060150)
Timeframe: Week 12
| Intervention | Units on a scale (Mean) |
|---|---|
| OROS Methylphenidate HCl | 2.14 |
"The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to Normal, not at all ill and a rating of 7 is equivalent to Among the most extremely ill participants. Higher scores indicate worsening." (NCT01060150)
Timeframe: Week 12
| Intervention | Units on a scale (Mean) |
|---|---|
| OROS Methylphenidate HCl | 2.81 |
The K-ARS is a rating scale that is used for the ADHD diagnosis and the assessment of treatment efficacy and comprises 18 items in total on the basis of Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV), each item being rated from 0-3 points. The total score ranges from 0-54 with 0=normal and 54=severe condition. (NCT01060150)
Timeframe: Week 12
| Intervention | Units on a scale (Mean) |
|---|---|
| OROS Methylphenidate HCl | 11.78 |
The LST measures learning ability of student. This scale is composed of 7 sections: self control, participation, task accomplishment, reading, writing, test taking and information processing. It consists of 70 items for middle school student (age 13-15 years) and 80 items for high school student (age 16-18 years). Each item is rated on a 5-point Likert scale ranging from 1 (never) to 5 (always). The total score range is 70-350 for middle school version and 80-400 for high school version where higher score indicates better ability for learning. In result analysis, each sub-score and total score was converted to T-score for normalization. The score range of T-score is from 1 to 100 with a mean of 50. Higher score indicates better ability for learning. (NCT01060150)
Timeframe: Week 12
| Intervention | T-score (Mean) |
|---|---|
| OROS Methylphenidate HCl | 49.61 |
The ADS is composed of 4 factors: omission/missing frequency to measure attention dispersibility; false alarm/commission frequency to measure impulse; mean response/reaction time to measure the speed of task processing; and the response variability/standard deviation of response time to measure the consistency of attention. The total value for both, omission errors and commission errors, ranges from 0-100 errors where high value indicates worsening attention. (NCT01060150)
Timeframe: Baseline and Week 12
| Intervention | Errors (Mean) | |||
|---|---|---|---|---|
| Omission errors: Baseline | Omission errors: Week 12 | Commission errors: Baseline | Commission errors: Week 12 | |
| OROS Methylphenidate HCl | 58.88 | 57.40 | 62.98 | 51.70 |
The ADS is composed of 4 factors: omission/missing frequency to measure attention dispersibility; false alarm/comission frequency to measure impulse; mean response/reaction time to measure the speed of task processing; and the response variability/standard deviation of response time to measure the consistency of attention. The score range for both, reaction time and response variability, is 0-100. High score indicates worsening attention. If one or over factor's score is over 65 point, the participant is resulted in having attention deficit. (NCT01060150)
Timeframe: Baseline and Week 12
| Intervention | Units on scale (Mean) | |||
|---|---|---|---|---|
| Reaction time average: Baseline | Reaction time average: Week 12 | Response variability: Baseline | Response variability: Week 12 | |
| OROS Methylphenidate HCl | 54.32 | 49.73 | 85.77 | 59.42 |
This test measures the executive function of the frontal lobe and is consisted of examinations of category/meaning fluency and letter/phoneme fluency. It consisted of three 60 second word generation trials in which the participant orally generates as many words as possible that begin with target letters F, A and S. Dependent variables included total number of acceptable words generated for each target letter and total number of words generated across all three letter trials. Total score was calculated as sum of acceptable words generated, with higher scores indicating better verbal fluency. (NCT01060150)
Timeframe: Baseline and Week 12
| Intervention | Words (Mean) | |||
|---|---|---|---|---|
| Category/semantic: Baseline | Category/semantic: Week 12 | Letter/phenomic: Baseline | Letter/phenomic: Week 12 | |
| OROS Methylphenidate HCl | 29.71 | 30.62 | 28.71 | 33.78 |
Each participant individually was given a sequence of numbers, with the sequence becoming progressively longer, to repeat the digits in the same sequence, either forwards or backwards. Each sequence length was attempted twice. The test was complete after failure on both trials of any sequence length. 1 point was awarded if the participant passed only 1 trial of a sequence length. 0 points were given if the participant failed both trials. Total score range was 0-16 (forwards) and 0-14 (backwards). A higher score was indicative of better recall and attention. (NCT01060150)
Timeframe: Baseline and Week 12
| Intervention | Units on a scale (Mean) | |||
|---|---|---|---|---|
| Forward: Baseline | Forward: Week 12 | Backward: Baseline | Backward: Week 12 | |
| OROS Methylphenidate HCl | 11.19 | 11.56 | 7.09 | 7.32 |
In FW test, a participant shows memory of a demonstrated visual pattern using a 8x11 inch plastic template containing 9 asymmetrically located holes. The examiner models a given sequence of holes and asks the participant to imitate the sequence by placing his/her finger through the same holes in the correct order. The total number of correct sequences constitutes the total score which ranges from 0-24 (forward FW) and 0-28 (backward FW) with higher score indicating a more favorable health state. (NCT01060150)
Timeframe: Baseline and Week 12
| Intervention | Units on a scale (Mean) | |||
|---|---|---|---|---|
| Forward FW: Baseline | Forward FW: Week 12 | Backward FW: Baseline | Backward FW: Week 12 | |
| OROS Methylphenidate HCl | 18.42 | 19.09 | 15.59 | 17.36 |
This test consists of 3 trials: color trial (simple execution), word trial (middle execution) and word-color interference trial (interfering execution). In simple execution, participants have to read the written color names of the words independent of the color of the ink. In middle execution, participants have to read words written in black letters. In interfering experiment, participants have to say the color of the letters independent of the written word. The total value ranges from 0-24 errors for each execution where high value indicates worsening attention. (NCT01060150)
Timeframe: Baseline and Week 12
| Intervention | Errors (Mean) | |||||
|---|---|---|---|---|---|---|
| Simple execution false reaction: Baseline | Simple execution false reaction: Week 12 | Middle execution false reaction: Baseline | Middle execution false reaction: Week 12 | Interfering execution false reaction: Baseline | Interfering execution false reaction: Week 12 | |
| OROS Methylphenidate HCl | 0.4 | 0.16 | 0.3 | 0.2 | 1.04 | 0.84 |
This test consists of 3 trials: color trial (simple execution), word trial (middle execution) and word-color interference trial (interfering execution). In simple execution, participants have to read the written color names of the words independent of the color of the ink. In middle execution, participants have to read words written in black letters. In interfering experiment, participants have to say the color of the letters independent of the written word. This test estimates spending time for execution. High spending time indicates low ability of suppression of automation. (NCT01060150)
Timeframe: Baseline and Week 12
| Intervention | Seconds (Mean) | |||||
|---|---|---|---|---|---|---|
| Simple execution time: Baseline | Simple execution time: Week 12 | Middle execution time: Baseline | Middle execution time: Week 12 | Interfering execution time: Baseline | Interfering execution time: Week 12 | |
| OROS Methylphenidate HCl | 14.78 | 13.64 | 15.88 | 15.04 | 22.12 | 19.72 |
Ratio interference is calculated by dividing simple execution time by interfering execution time. The score range is 0-1. Higher value indicates better ability of suppression of automation. (NCT01060150)
Timeframe: Baseline and Week 12
| Intervention | Units on a scale (Mean) | |
|---|---|---|
| Baseline | Week 12 | |
| OROS Methylphenidate HCl | 0.70 | 0.72 |
Cigarette smoking was assessed by youth self report using a modified version of the Fagerstrom Tolerance Questionnaire (FTQ) (NCT00181714)
Timeframe: 24 months
| Intervention | percent (Number) |
|---|---|
| OROS-Methylphenidate | 7 |
The ADHD-RS-IV consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54. A decrease in score indicates an improvement in ADHD symptomology. (NCT00763971)
Timeframe: Baseline and up to 7 weeks
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| Lisdexamfetamine Dimesylate (LDX) | -24.3 |
| Methylphenidate Hydrochloride | -18.7 |
| Placebo | -5.7 |
The BPRS-C characterizes psychopathology. A total of 21 items are rated on a scale from 0 (not present) to 6 (extremely severe) with a total score ranging from 0 to 126. A decrease in score indicates a reduction in psychopathology. (NCT00763971)
Timeframe: Baseline and up to 7 weeks
| Intervention | Scores on a scale (Mean) |
|---|---|
| Lisdexamfetamine Dimesylate (LDX) | -9.15 |
| Methylphenidate Hydrochloride | -9.71 |
| Placebo | -2.59 |
The Conner's Parent rating Scale-revised short version (CPRS-R) consists of 27 questions graded on a scale from 0 (not true at all) to 3 (very much true) with a total score ranging from 0 to 81. Higher scores are indicative of increased ADHD. This scale allows parents to respond on the basis of the child's behavior and help assess ADHD and evaluate problem behavior. (NCT00763971)
Timeframe: Baseline and up to 7 weeks
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| Lisdexamfetamine Dimesylate (LDX) | -24.5 |
| Methylphenidate Hydrochloride | -18.4 |
| Placebo | -3.2 |
The CHIP-CE:PRF evaluates health-related quality of life. It is composed of 5 domains (satisfaction, comfort, resilience, avoidance, and achievement) consisting of a total of 76 items. The global score is an average of the scores for the 5 domains. The majority of items assess frequency of events using a 5-point response format. There is no range for a total score. Raw scale scores are used to generate T-scores. Higher scores indicate better health. (NCT00763971)
Timeframe: Baseline and up to 7 weeks
| Intervention | T-scores (Least Squares Mean) |
|---|---|
| Lisdexamfetamine Dimesylate (LDX) | 8.6 |
| Methylphenidate Hydrochloride | 7.1 |
| Placebo | -0.2 |
The WFIRS-P is a 50-item scale with each item scored from 0 (never/not at all) to 3 (very often/very much). Mean scores range from 0 to 3. Higher scores indicate greater functional impairment. (NCT00763971)
Timeframe: Baseline and up to 7 weeks
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| Lisdexamfetamine Dimesylate (LDX) | -0.3 |
| Methylphenidate Hydrochloride | -0.3 |
| Placebo | 0.0 |
Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale. (NCT00763971)
Timeframe: Up to 7 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Lisdexamfetamine Dimesylate (LDX) | 78.0 |
| Methylphenidate Hydrochloride | 60.6 |
| Placebo | 14.4 |
C-SSRS is a 19-item semi-structured interview designed to capture suicide-related thoughts and behaviors. (NCT00763971)
Timeframe: Up to 7 weeks
| Intervention | participants (Number) | |
|---|---|---|
| Suicidal ideation | Non-suicidal self injurious behavior | |
| Lisdexamfetamine Dimesylate (LDX) | 1 | 1 |
| Methylphenidate Hydrochloride | 0 | 0 |
| Placebo | 0 | 0 |
HUI is used to describe health status and to obtain utility scores by collecting data using one or more questionnaires in formats selected to match the specific study design criteria. Scoring ranges from 0.00 (dead) to 1.00 (perfect health). Higher scores represent better health status. (NCT00763971)
Timeframe: Baseline and up to 7 weeks
| Intervention | Scores on a scale (Mean) | |
|---|---|---|
| Baseline | Up to 7 weeks | |
| Lisdexamfetamine Dimesylate (LDX) | 0.811 | 0.878 |
| Methylphenidate Hydrochloride | 0.822 | 0.887 |
| Placebo | 0.806 | 0.843 |
"Attention-Deficit/Hyperactivity Disorder Rating Scale (DSM-IV ADHD RS) total score consists of 18 items directly adapted from the ADHD symptom list according to the DSM-IV. The DSM-IV ADHD RS total score was calculated as the sum of the Inattentive and the Hyperactive-Impulsive subscores. The 18 items are rated from 0 (Never) to 4 (Very often). The total score ranges from 0(least symptomatic) to 72 (most symptomatic). Decrease in the DSM-IV ADHD RS total score indicates improvement, therefore a greater decrease (change at Final Visit compared to baseline) indicates a greater improvement in ADHD symptoms. 30% improvement: 100×(DSM-IV ADHD RS total score during Period 1 - DSM-IV ADHD RS total score at randomization(visit 2))/DSM-IV ADHD RS total score at randomization (visit 2) <= - 30%." (NCT01259492)
Timeframe: Baseline 1 to End of Period 1 (Week 9)
| Intervention | Units on a Scale (Mean) |
|---|---|
| Ritalin LA 40 mg | 16.0 |
| Ritalin LA 60 mg | 14.7 |
| Ritalin LA 80 mg | 16.8 |
| Placebo | 9.7 |
SDS, a 5-self-rated questionnaire to measure the extent a pt's disability due to an illness/health problem interferes with work/school, social life/leisure, family life/home. First 3 items, pts are asked how their symptoms disrupted their reg. activities over the past 7d in ea. using a scale from 0(not at all)-10(extremely) Ea. subscale(work disability, social life disability, family life disability) can be scored independently or combined into a total score(sum of the non-missing responses for items 1-3)from 0-30,higher scores indicate significant functional impairmt. Subscale scores >5 suggest impairment in that subscale area. Final 2 items ask pts about the # of days their symptoms caused them to miss school/work and # of days their symptoms caused them to be underproductive at school/work.(These items were not included in the total score.) Before responding to SDS items 1-3, pts were verbally instructed to recall the past 7d, items 4-5 refer to the last week w/in the item wording. (NCT01259492)
Timeframe: Baseline 1 to End of Period 1 (Week 9)
| Intervention | Units on a Scale (Mean) |
|---|---|
| Ritalin LA 40 mg | 6.4 |
| Ritalin LA 60 mg | 4.7 |
| Ritalin LA 80 mg | 6.1 |
| Placebo | 2.9 |
"The ASRS is a self-rating scale designed to assess ADHD symptoms in adults and is now part of the World Health Organization Composite International Diagnostic Interview. It consists of 18 items written to reflect the DSM-IV diagnostic criteria for ADHD and are rated from 0 (Never) to 4 (Very often). The total score ranges from 0 to 72." (NCT01259492)
Timeframe: Baseline 2 to end of Period 3 (end of withdrawal period 40 weeks)
| Intervention | Units on a scale (Mean) |
|---|---|
| Ritalin LA 40 mg | 3.0 |
| Ritalin LA 60 mg | 3.8 |
| Ritalin LA 80 mg | 3.0 |
| Placebo | 8.0 |
"CAARS is an instrument to assess ADHD symptoms and behaviors in adults. This study utilizes the Observer Short Version (CAARS-O: S), consisting of 26 items and 6 subscales: Inattention/Memory Problems, Hyperactivity/Restlessness, Impulsivity/Emotional Lability, Problems with Self-Concept, ADHD Index (to distinguish ADHD adults from non-clinical adults), and Inconsistency Index (to identify random or careless responding) and is rated by someone close to the patient in their daily life such as a spouse, friend, or coworker. The observer is asked to notice the patient carefully and decide how much or how frequently each of the 26 items of the scale describes the patient recently. The response to every question in increasing order of severity is not at all, never = 0; Just a little, once in a while = 1; Pretty much, often = 2; Very much, very frequently = 3. The total score combined from all the 26 items ranges from 0 to 88." (NCT01259492)
Timeframe: Baseline 2 to end of Period 3 (end of withdrawal period 40 weeks)
| Intervention | Units on a scale (Mean) |
|---|---|
| Ritalin LA 40 mg | -2.7 |
| Ritalin LA 60 mg | 1.7 |
| Ritalin LA 80 mg | -0.2 |
| Placebo | 2.9 |
The ADHD-RS-IV is an 180 item clinician rated scale to assess ADHD by DSM-IV-TR, defined criteria using symptom terminology appropriate for the adult population. Each item pertains to inattention (odd-numbered) or hyperactivity/impulsivity (even-numbered) and is scored on a scale of 0 (no symptoms) to 3 (severe symptoms). A total added score can range from 0-54. (NCT01259492)
Timeframe: Baseline 2 to end of Period 3 (end of withdrawal period 40 weeks)
| Intervention | Units on a Scale (Mean) |
|---|---|
| Ritalin LA 40 mg | 3.0 |
| Ritalin LA 60 mg | 5.1 |
| Ritalin LA 80 mg | 2.6 |
| Placebo | 9.3 |
"The Sheehan Disability Scale (SDS) is a self-rating scale designed to assess the extent to which the patient's work social life/leisure activities and home life are impaired by his or her symptoms. The scale generates 4 scores: a work disability score, a social life disability score, a family life disability score and a total score. To get a total score the 3 individual scores (work: social life: family life) are totaled. The maximum possible score is 30 The higher the score, the more impaired a patient's work, social life, family life is." (NCT01259492)
Timeframe: Baseline 2 to end of Period 3 (end of withdrawal period 40 weeks)
| Intervention | Units on a Scale (Mean) |
|---|---|
| Ritalin LA 40 mg | 2.1 |
| Ritalin LA 60 mg | 2.3 |
| Ritalin LA 80 mg | 2.0 |
| Placebo | 5.0 |
"On the CGI-I scale, a lower score reflects greater improvement between 1 and 3, a score of 4 is no change, scores higher than 4 reflect worsening. The CGI-I consists of 7 ratings that range from 1 = Very much improved to 7 =Very much worse. Improvement on the CGI-I scale is defined as a visit rating of 1 very much improved or 2 much improved on the CGI-I scale." (NCT01259492)
Timeframe: Baseline 2 to end of Period 3 (end of withdrawal period 40 weeks)
| Intervention | participants (Number) |
|---|---|
| Ritalin LA 40 mg | 6 |
| Ritalin LA 60 mg | 13 |
| Ritalin LA 80 mg | 5 |
| Placebo | 21 |
"CGI-S assesses the patient's current illness state. CGI-S consists of 7 ratings that range from 1 = normal, not at all ill , 2 = borderline mentally ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly ill, 6 = severely ill, 7 = among the most extremely ill patients" (NCT01259492)
Timeframe: Baseline 2 to end of Period 3 (end of withdrawal period 40 weeks)
| Intervention | Participants (Number) |
|---|---|
| Ritalin LA 40 mg | 39 |
| Ritalin LA 60 mg | 50 |
| Ritalin LA 80 mg | 35 |
| Placebo | 72 |
"On the CGI-I scale, a lower score reflects greater improvement between 1 and 3, a score of 4 is no change, scores higher than 4 reflect worsening. The CGI-I consists of 7 ratings that range from 1 = Very much improved to 7 =Very much worse. Improvement on the CGI-I scale is defined as a visit rating of 1 very much improved or 2 much improved on the CGI-I scale. Percentage has been calculated from the evaluable patients (N) as Percentage = n/N * 100." (NCT01259492)
Timeframe: Baseline 1 to End of Period 1 (Week 9)
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ritalin LA 40 mg | 56.3 |
| Ritalin LA 60 mg | 54.8 |
| Ritalin LA 80 mg | 57.1 |
| Placebo | 31.7 |
"DSM-IV ADHD RS consists of 18 items directly adapted from the ADHD symptom list according to the DSM-IV. The SDS is a five-item, self-rated questionnaire that has been used widely in clinical trials and observational studies. CAARS-O: S consists of 26 items and 6 subscales: Inattention/Memory Problems, Hyperactivity/Restlessness, Impulsivity/Emotional Lability, Problems with Self-Concept, ADHD Index, and Inconsistency Index and is rated by someone close to the patient in their daily life such as a spouse, friend, or coworker. The Adult Self-Report Scale (ASRS) is a self-rating scale designed to assess Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms. The 18 items are written to reflect the DSM-IV diagnostic criteria for ADHD and are rated from 0 (Never) to 4 (Very often)." (NCT01259492)
Timeframe: Baseline 1 to End of Period 2 (Week 14)
| Intervention | Score on Scale (Mean) | |||
|---|---|---|---|---|
| DSM-IV ADHD RS total score n=494 | SDS total score n=480 | CAARS-O:S total score n=411 | ASRS total score n=490 | |
| ALL Ritalin LA Group | 24.8 | 10.1 | 15.5 | 23.2 |
"CGI-I assesses the overall change of illness relative to baseline. CGI-I consists of 7 ratings that range from 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change from baseline, 5 = minimally worse, 6 = much worse 7 = very much worse" (NCT01259492)
Timeframe: Baseline 1 to End of Period 2 (Week 14)
| Intervention | number of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| very much improved | much improved | minimally improved | no change | minimally worse | much worse | very much worse | |
| ALL Ritalin LA Group | 195 | 230 | 42 | 16 | 7 | 2 | 0 |
"CGI-S assesses the patient's current illness state. CGI-S consists of 7 ratings that range from 1 = normal, not at all ill , 2 = borderline mentally ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly ill, 6 = severely ill, 7 = among the most extremely ill patients" (NCT01259492)
Timeframe: Baseline 1 to End of Period 2 (Week 14)
| Intervention | number of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Normal, not ill at all | borderline mentally ill | mildly ill | moderately ill | markedly ill | severely ill | among the most extremely ill patients | |
| ALL Ritalin LA Group | 91 | 151 | 193 | 50 | 7 | 0 | 0 |
Treatment failure is defined as: 100×(DSM-IV ADHD RS total score during Period 3 - DSM-IV ADHD RS total score at re-randomization (visit 13))/DSM-IV ADHD RS total score at re-randomization (visit 13) >= 30% AND 100×(DSM-IV ADHD RS total score during Period 3 - DSM-IV ADHD RS total score at randomization (visit 2))/DSM-IV ADHD RS total score at randomization (visit 2) > - 30%. The ADHD-RS-IV is an 180item clinician rated scale to assess ADHD by DSM-IV-TR, defined criteria using symptom terminology appropriate for the adult population. Each item pertains to inattention (odd-numbered) or hyperactivity/impulsivity (even-numbered) and is scored on a scale of 0 (no symptoms) to 3 (severe symptoms). A total added score can range from 0-54 (NCT01259492)
Timeframe: Baseline Period 1 (Baseline 1) and Baseline Period 3 (Baseline 2) to End of Week 40
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Without Imputation - Treatment failure | Without Imputation - Not treatment failure | Without Imputation missing failure status | With Imputation - Treatment failure | With Imputation - Not treatment failure | |
| Placebo | 43.5 | 31.3 | 25.2 | 49.6 | 50.4 |
| Ritalin LA 40 mg | 11.8 | 54.5 | 33.6 | 16.4 | 83.6 |
| Ritalin LA 60 mg | 20.3 | 50.0 | 29.7 | 26.6 | 73.4 |
| Ritalin LA 80 mg | 17.5 | 56.1 | 25.4 | 20.2 | 79.8 |
Daily records of percentage of assigned problems completed by children in a 60-minute classroom period. (NCT00050622)
Timeframe: Daily for 45 days
| Intervention | Percentage of Work Completed (Mean) |
|---|---|
| No Treatment | 37 |
| Low Dose Medication Only | 53 |
| Medium Dose Medication Only | 57 |
| Higher Dose Medication Only | 61 |
| Low Intensity BMOD Only | 53 |
| Low Intensity BMOD + Low Dose Medication | 67 |
| Low Intensity BMOD + Medium Dose Medication | 72 |
| Low Intensity BMOD + Higher Dose Medication | 75 |
| High Intensity BMOD Only | 58 |
| High Intensity BMOD + Low Dose Medication | 72 |
| High Intensity BMOD + Medium Dose Medication | 75 |
| High Intensity BMOD + Higher Dose Medication | 76 |
Sum of daily frequency of Verbal Abuse toward staff members, Teasing toward peers, and Cursing/Swearing as defined by a behavioral point system that doubles as an objective measure of children's behavior. All instances of these behaviors were reported and noted as they occur throughout daily activities. (NCT00050622)
Timeframe: Daily for 45 days
| Intervention | Number of Observed Behaviors (Mean) |
|---|---|
| No Treatment | 73.32 |
| Low Dose Medication Only | 45.41 |
| Medium Dose Medication Only | 28.41 |
| Higher Dose Medication Only | 15.08 |
| Low Intensity BMOD Only | 27.06 |
| Low Intensity BMOD + Low Dose Medication | 13.70 |
| Low Intensity BMOD + Medium Dose Medication | 9.27 |
| Low Intensity BMOD + Higher Dose Medication | 4.28 |
| High Intensity BMOD Only | 20.23 |
| High Intensity BMOD + Low Dose Medication | 7.61 |
| High Intensity BMOD + Medium Dose Medication | 4.08 |
| High Intensity BMOD + Higher Dose Medication | 2.49 |
Parent rating of treatment satisfaction with medication, behavioral treatment, and their combination,on a scale of 1 (bad) to 7 (good). (NCT00050622)
Timeframe: End of Treatment
| Intervention | Units on scale (Mean) |
|---|---|
| No Treatment | 1.8 |
| Low Intensity BMOD Only | 2.7 |
| High Intensity BMOD ONly | 3.8 |
| Medication Only | 3.5 |
| Low Intensity BMOD + Med | 4.6 |
| High Intensity BMOD + Medication | 5.6 |
Assesses 18 Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision ADHD diagnosis symptoms/severity in past week. Each item: 0 (none/never, rarely) to 3 (severe/very often). Total score ranges from 0 to 54. Higher total scores indicate greater illness severity. Change scores=Week 8 score-baseline score. Least Squares (LS) Mean Change adjusted for fixed class effects of treatment, pooled investigative site, strata (prior stimulant use status), visit, and treatment*visit interaction, and continuous, fixed effects of baseline score and baseline score*visit interaction. (NCT00922636)
Timeframe: Baseline, 8 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -10.35 |
| LY2216684 (0.1 mg/kg/Day) | -12.20 |
| LY2216684 (0.2 mg/kg/Day) | -16.09 |
| LY2216684 (0.3 mg/kg/Day) | -16.39 |
Assesses 18 Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision ADHD diagnosis symptoms/severity in past week. Each item: 0 (none/never, rarely) to 3 (severe/very often). Total score ranges from 0 to 54. Higher total scores indicate greater illness severity. Change scores=Week 8 score-baseline score. LS Mean Change adjusted for fixed class effects of treatment, pooled investigative site, strata (prior stimulant use status), visit, and treatment*visit interaction, and continuous, fixed effects of baseline score and baseline score*visit interaction. (NCT00922636)
Timeframe: Baseline, 8 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Methylphenidate | -19.46 |
Measures participant's overall ADHD symptom severity. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). Higher scores represent greater illness severity. Change scores=Week 8 score-baseline score. The Least Squares (LS) Mean Change was based on the fixed class effects of treatment, pooled investigative site, strata (prior stimulant use status), visit, and treatment*visit interaction, as well as the continuous, fixed effects of baseline CGI-S score and baseline score*visit interaction. (NCT00922636)
Timeframe: Baseline, 8 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -1.07 |
| LY2216684 (0.1 mg/kg/Day) | -0.96 |
| LY2216684 (0.2 mg/kg/Day) | -1.52 |
| LY2216684 (0.3 mg/kg/Day) | -1.41 |
Measures participant's overall ADHD symptom severity. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). Higher scores represent greater illness severity. Change scores=Week 8 score-baseline score. The Least Squares (LS) Mean Change was based on the fixed class effects of treatment, pooled investigative site, strata (prior stimulant use status), visit, and treatment*visit interaction, as well as the continuous, fixed effects of baseline CGI-S score and baseline score*visit interaction. (NCT00922636)
Timeframe: Baseline, 8 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Methylphenidate | -1.69 |
Assess conduct disorder symptom severity. Individual subscale items: 0 (never/seldom) - 3 (very often/frequently). Total expressed as T-score based on gender/age norms (0-100). Higher T-score=greater conduct disorder. Change scores=Week 8 score-baseline score. Least Squares Mean Change from restricted maximum likelihood-based, mixed model repeated measure analysis; included fixed class effects of treatment, pooled investigative site, strata (prior stimulant use status), visit, and treatment*visit interaction, and continuous, fixed effects of baseline score and baseline score*visit interaction. (NCT00922636)
Timeframe: Baseline, 8 weeks
| Intervention | T-Score (Least Squares Mean) |
|---|---|
| Placebo | -4.64 |
| LY2216684 (0.1 mg/kg/Day) | -2.24 |
| LY2216684 (0.2 mg/kg/Day) | -6.26 |
| LY2216684 (0.3 mg/kg/Day) | -7.62 |
Assess conduct disorder symptom severity. Individual subscale items: 0 (never/seldom) - 3 (very often/frequently). Total expressed as T-score based on gender/age norms (0-100). Higher T-score=greater conduct disorder. Change scores=Week 8 score-baseline score. Least Squares Mean Change from restricted maximum likelihood-based, mixed model repeated measure analysis; included fixed class effects of treatment, pooled investigative site, strata (prior stimulant use status), visit, and treatment*visit interaction, and continuous, fixed effects of baseline score and baseline score*visit interaction. (NCT00922636)
Timeframe: Baseline, 8 weeks
| Intervention | T-Score (Least Squares Mean) |
|---|---|
| Methylphenidate | -7.10 |
Assess depressive symptom severity. Individual subscale items range: 0 (never, seldom) to 3 (very often/frequently). Total expressed as T-score based on gender/age norms (0-100). Higher T-scores=greater depression. Change scores=Week 8 score-baseline score. Least Squares Mean Change from restricted maximum likelihood-based, mixed model repeated measure analysis and included fixed class effects of treatment, pooled investigative site, strata (prior stimulant use status), visit, and treatment*visit interaction, and continuous, fixed effects of baseline score and baseline score*visit interaction. (NCT00922636)
Timeframe: Baseline, 8 weeks
| Intervention | T-Score (Least Squares Mean) |
|---|---|
| Placebo | -10.27 |
| LY2216684 (0.1 mg/kg/Day) | -5.41 |
| LY2216684 (0.2 mg/kg/Day) | -9.58 |
| LY2216684 (0.3 mg/kg/Day) | -13.67 |
Assess depressive symptom severity. Individual subscale items range: 0 (never, seldom) to 3 (very often/frequently). Total expressed as T-score based on gender/age norms (0-100). Higher T-scores=greater depression. Change scores=Week 8 score-baseline score. Least Squares Mean Change from restricted maximum likelihood-based, mixed model repeated measure analysis and included fixed class effects of treatment, pooled investigative site, strata (prior stimulant use status), visit, and treatment*visit interaction, and continuous, fixed effects of baseline score and baseline score*visit interaction. (NCT00922636)
Timeframe: Baseline, 8 weeks
| Intervention | T-Score (Least Squares Mean) |
|---|---|
| Methylphenidate | -1.09 |
Measures manic symptom severity. Individual subscale items range: 0 (never) to 3 (very often). Total score expressed as T-score based on gender/age norms (0-100). Higher T-scores=greater symptom severity. Change scores=Week 8 score-baseline score. Least Squares Mean Change is from a restricted maximum likelihood-based, mixed model repeated measure analysis. Model included fixed class effects of treatment, pooled investigative site, strata (prior stimulant use status), visit, and treatment*visit interaction, and continuous, fixed effects of baseline score and baseline score*visit interaction. (NCT00922636)
Timeframe: Baseline, 8 weeks
| Intervention | T-Score (Least Squares Mean) |
|---|---|
| Methylphenidate | -11.85 |
Measures manic symptom severity. Individual subscale items range: 0 (never) to 3 (very often). Total score expressed as T-score based on gender/age norms (0-100). Higher T-scores=greater symptom severity. Change scores=Week 8 score-baseline score. Least Squares Mean Change is from a restricted maximum likelihood-based, mixed model repeated measure analysis. Model included fixed class effects of treatment, pooled investigative site, strata (prior stimulant use status), visit, and treatment*visit interaction, and continuous, fixed effects of baseline score and baseline score*visit interaction. (NCT00922636)
Timeframe: Baseline, 8 weeks
| Intervention | T-Score (Least Squares Mean) |
|---|---|
| Placebo | -9.35 |
| LY2216684 (0.1 mg/kg/Day) | -5.00 |
| LY2216684 (0.2 mg/kg/Day) | -12.60 |
| LY2216684 (0.3 mg/kg/Day) | -12.41 |
Assess ODD symptom severity. Individual subscale items range from 0 (never) to 3 (very often/frequently). Total is expressed as a T-score based on gender/age norms (range 0-100). Higher T-score=greater ODD. Change scores=Week 8 score-baseline score. Least Squares Mean Change from restricted maximum likelihood-based, mixed model repeated measure analysis. Model included fixed class effects of treatment, pooled investigative site, strata (prior stimulant use status), visit, and treatment*visit interaction, and continuous, fixed effects of baseline score and baseline score*visit interaction. (NCT00922636)
Timeframe: Baseline, 8 weeks
| Intervention | T-Score (Least Squares Mean) |
|---|---|
| Placebo | -7.17 |
| LY2216684 (0.1 mg/kg/Day) | -4.00 |
| LY2216684 (0.2 mg/kg/Day) | -10.18 |
| LY2216684 (0.3 mg/kg/Day) | -12.29 |
Assess ODD symptom severity. Individual subscale items range from 0 (never) to 3 (very often/frequently). Total is expressed as a T-score based on gender/age norms (range 0-100). Higher T-score=greater ODD. Change scores=Week 8 score-baseline score. Least Squares Mean Change from restricted maximum likelihood-based, mixed model repeated measure analysis. Model included fixed class effects of treatment, pooled investigative site, strata (prior stimulant use status), visit, and treatment*visit interaction, and continuous, fixed effects of baseline score and baseline score*visit interaction. (NCT00922636)
Timeframe: Baseline, 8 weeks
| Intervention | T-Score (Least Squares Mean) |
|---|---|
| Methylphenidate | -13.83 |
Measures oppositional defiance disorder symptoms. Total scores range from 0 (not at all) to 3 (very much). Higher total scores represent greater ODD. Change scores=Week 8 score-baseline score. Least Squares Mean Change is from a restricted maximum likelihood-based, mixed model repeated measure (MMRM) analysis. Model included fixed class effects of treatment, pooled investigative site, strata (prior stimulant use status), visit, and treatment*visit interaction, and continuous, fixed effects of baseline total score and baseline score*visit interaction. (NCT00922636)
Timeframe: Baseline, 8 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 0.19 |
| LY2216684 (0.1 mg/kg/Day) | 0.62 |
| LY2216684 (0.2 mg/kg/Day) | -0.04 |
| LY2216684 (0.3 mg/kg/Day) | -0.30 |
Measures oppositional defiance disorder symptoms. Total scores range from 0 (not at all) to 3 (very much). Higher total scores represent greater ODD. Change scores=Week 8 score-baseline score. Least Squares Mean Change is from a restricted maximum likelihood-based, mixed model repeated measure (MMRM) analysis. Model included fixed class effects of treatment, pooled investigative site, strata (prior stimulant use status), visit, and treatment*visit interaction, and continuous, fixed effects of baseline total score and baseline score*visit interaction. (NCT00922636)
Timeframe: Baseline, 8 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Methylphenidate | -0.72 |
Includes Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision ADHD criteria for inattention (items 1-9) and hyperactivity/impulsivity (items 11-19) symptom subsets. Item score: 0 (not at all) to 3 (very much) rating scale. Total score is average of 18 items. Higher total scores=greater ADHD symptoms. Least Squares Mean change is adjusted for fixed class effects of treatment, pooled investigative site, strata (prior stimulant use status), visit, and treatment*visit interaction, and the continuous, fixed effects of baseline score and baseline score*visit interaction. (NCT00922636)
Timeframe: Baseline, 8 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 0.10 |
| LY2216684 (0.1 mg/kg/Day) | 0.35 |
| LY2216684 (0.2 mg/kg/Day) | -0.21 |
| LY2216684 (0.3 mg/kg/Day) | -0.46 |
Includes Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision ADHD criteria for inattention (items 1-9) and hyperactivity/impulsivity (items 11-19) symptom subsets. Item score: 0 (not at all) to 3 (very much) rating scale. Total score is average of 18 items. Higher total scores=greater ADHD symptoms. Least Squares Mean change is adjusted for fixed class effects of treatment, pooled investigative site, strata (prior stimulant use status), visit, and treatment*visit interaction, and the continuous, fixed effects of baseline score and baseline score*visit interaction. (NCT00922636)
Timeframe: Baseline, 8 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Methylphenidate | NA |
A working memory subtest of WISC-IV, a measure of attention; concentration; sequencing; number facility; and auditory short-term memory. Scaled scores range from 1 to 19. Higher scores denote better performance. Least Squares (LS) Mean Change is from a restricted maximum likelihood-based, mixed model repeated measure (MMRM) analysis and included fixed class effects of treatment, pooled investigative site, strata (prior stimulant use status), visit, and treatment*visit interaction, as well as the continuous, fixed effects of baseline Digit Span total score and baseline score*visit interaction. (NCT00922636)
Timeframe: Baseline, 8 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 0.64 |
| LY2216684 (0.1 mg/kg/Day) | 1.22 |
| LY2216684 (0.2 mg/kg/Day) | 0.95 |
| LY2216684 (0.3 mg/kg/Day) | 1.02 |
A working memory subtest of WISC-IV, a measure of attention; concentration; sequencing; number facility; and auditory short-term memory. Scaled scores range from 1 to 19. Higher scores denote better performance. Least Squares (LS) Mean Change is from a restricted maximum likelihood-based, mixed model repeated measure (MMRM) analysis and included fixed class effects of treatment, pooled investigative site, strata (prior stimulant use status), visit, and treatment*visit interaction, as well as the continuous, fixed effects of baseline Digit Span total score and baseline score*visit interaction. (NCT00922636)
Timeframe: Baseline, 8 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Methylphenidate | 0.54 |
Working memory subtest. Task involves sequencing, mental manipulation, attention, short-term memory, visual spatial imaging, and processing speed; consists of 10 items, 3 trials each. Scaled scores range: 1 to 19. Higher scores denote better performance. Least Squares Mean Change from restricted maximum likelihood-based, mixed model repeated measure analysis that included fixed class effects of treatment, pooled investigative site, strata (prior stimulant use status), visit, and treatment*visit interaction, and continuous, fixed effects of baseline score and baseline score*visit interaction. (NCT00922636)
Timeframe: Baseline, 8 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 1.30 |
| LY2216684 (0.1 mg/kg/Day) | 1.36 |
| LY2216684 (0.2 mg/kg/Day) | 1.48 |
| LY2216684 (0.3 mg/kg/Day) | 1.84 |
Working memory subtest. Task involves sequencing, mental manipulation, attention, short-term memory, visual spatial imaging, and processing speed; consists of 10 items, 3 trials each. Scaled scores range: 1 to 19. Higher scores denote better performance. Least Squares Mean Change from restricted maximum likelihood-based, mixed model repeated measure analysis that included fixed class effects of treatment, pooled investigative site, strata (prior stimulant use status), visit, and treatment*visit interaction, and continuous, fixed effects of baseline score and baseline score*visit interaction. (NCT00922636)
Timeframe: Baseline, 8 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Methylphenidate | 1.58 |
Measures difficulty level of 8 common evening behaviors (for example, sit through dinner) from 0 (no difficulty) to 3 (a lot of difficulty). Total score ranges: 0 to 24; higher scores indicate greater difficulty in evening behavior. Least Squares (LS) Mean Change is from restricted maximum likelihood-based, mixed model repeated measure analysis (MMRM) and included fixed class effects of treatment, pooled investigative site, strata (prior stimulant use status), visit, and treatment*visit interaction, and continuous, fixed effects of baseline evening score and baseline score*visit interaction. (NCT00922636)
Timeframe: Baseline, 8 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -3.34 |
| LY2216684 (0.1 mg/kg/Day) | -3.37 |
| LY2216684 (0.2 mg/kg/Day) | -4.77 |
| LY2216684 (0.3 mg/kg/Day) | -5.24 |
Measures difficulty level of 8 common evening behaviors (for example, sit through dinner) from 0 (no difficulty) to 3 (a lot of difficulty). Total score ranges: 0 to 24; higher scores indicate greater difficulty in evening behavior. Least Squares (LS) Mean Change is from restricted maximum likelihood-based, mixed model repeated measure analysis (MMRM) and included fixed class effects of treatment, pooled investigative site, strata (prior stimulant use status), visit, and treatment*visit interaction, and continuous, fixed effects of baseline evening score and baseline score*visit interaction. (NCT00922636)
Timeframe: Baseline, 8 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Methylphenidate | -6.17 |
Measures difficulty level of 3 common morning behaviors (for example, get out of bed) from 0 (no difficulty) to 3 (a lot of difficulty). Total score range is from 0 to 9; a higher score indicates greater difficulty in morning behavior. Least Squares (LS) Mean Change from restricted maximum likelihood-based, mixed model repeated measure (MMRM) analysis and includes fixed class effects of treatment, pooled investigative site, strata (prior stimulant use status), visit, and treatment*visit interaction, and continuous, fixed effects of baseline morning score and baseline score*visit interaction. (NCT00922636)
Timeframe: Baseline, 8 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -1.07 |
| LY2216684 (0.1 mg/kg/Day) | -0.91 |
| LY2216684 (0.2 mg/kg/Day) | -1.53 |
| LY2216684 (0.3 mg/kg/Day) | -2.20 |
Measures difficulty level of 3 common morning behaviors (for example, get out of bed) from 0 (no difficulty) to 3 (a lot of difficulty). Total score range is from 0 to 9; a higher score indicates greater difficulty in morning behavior. Least Squares (LS) Mean Change from restricted maximum likelihood-based, mixed model repeated measure (MMRM) analysis and includes fixed class effects of treatment, pooled investigative site, strata (prior stimulant use status), visit, and treatment*visit interaction, and continuous, fixed effects of baseline morning score and baseline score*visit interaction. (NCT00922636)
Timeframe: Baseline, 8 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Methylphenidate | -0.80 |
Parent-completed 11-item questionnaire (3 morning items, 8 evening items) on a scale of 0 (no difficulty) to 3 (a lot of difficulty). Total score ranges from 0 to 33; higher score=greater difficulty in evening and morning behavior. Least Squares (LS) Mean Change is from a restricted maximum likelihood-based, mixed model repeated measure (MMRM) analysis and includes fixed class effects of treatment, pooled investigative site, strata (prior stimulant use status), visit, and treatment*visit interaction, and continuous, fixed effects of baseline score and baseline score*visit interaction. (NCT00922636)
Timeframe: Baseline, 8 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -4.95 |
| LY2216684 (0.1 mg/kg/Day) | -4.72 |
| LY2216684 (0.2 mg/kg/Day) | -7.08 |
| LY2216684 (0.3 mg/kg/Day) | -8.24 |
Parent-completed 11-item questionnaire (3 morning items, 8 evening items) on a scale of 0 (no difficulty) to 3 (a lot of difficulty). Total score ranges from 0 to 33; higher score=greater difficulty in evening and morning behavior. Least Squares (LS) Mean Change is from a restricted maximum likelihood-based, mixed model repeated measure (MMRM) analysis and includes fixed class effects of treatment, pooled investigative site, strata (prior stimulant use status), visit, and treatment*visit interaction, and continuous, fixed effects of baseline score and baseline score*visit interaction. (NCT00922636)
Timeframe: Baseline, 8 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Methylphenidate | -6.88 |
Measures total improvement (or worsening) of a participant's ADHD symptoms from the beginning of treatment. Scores range from 1 (very much improved) to 7 (very much worsened). Lower scores represent greater improvement. Least Squares (LS) Mean Change for weeks 1-8 is from a restricted maximum likelihood-based, mixed model repeated measure analysis. The model included fixed class effects of treatment, pooled investigative site, strata (prior stimulant use status), visit, and treatment*visit interaction. (NCT00922636)
Timeframe: Weeks 1 through 8
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 3.05 |
| LY2216684 (0.1 mg/kg/Day) | 3.01 |
| LY2216684 (0.2 mg/kg/Day) | 2.54 |
| LY2216684 (0.3 mg/kg/Day) | 2.53 |
Measures total improvement (or worsening) of a participant's ADHD symptoms from the beginning of treatment. Scores range from 1 (very much improved) to 7 (very much worsened). Lower scores represent greater improvement. Least Squares (LS) Mean Change for weeks 1-8 is from a restricted maximum likelihood-based, mixed model repeated measure analysis. The model included fixed class effects of treatment, pooled investigative site, strata (prior stimulant use status), visit, and treatment*visit interaction. (NCT00922636)
Timeframe: Weeks 1 through 8
| Intervention | Total Score (Least Squares Mean) |
|---|---|
| Methylphenidate | 2.31 |
Response rate analysis compared the frequency of response between LY2216684 treatment groups versus placebo for participants who had a final study period II (weeks 1-8) Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version:Investigator-Administered and Scored (ADHD-RS-IV-PV:IR) total score <=60% of their baseline total score. ADHD-RS-IV-PV:IR measures 18 symptoms in Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision (DSM-IV-TR) ADHD diagnosis. Item scores range: 0 (none/never or rarely) to 3 (severe/very often). Total scores range: 0 to 54. (NCT00922636)
Timeframe: Baseline, up to 8 weeks
| Intervention | Participants (Number) |
|---|---|
| Placebo | 22 |
| LY2216684 (0.1 mg/kg/Day) | 19 |
| LY2216684 (0.2 mg/kg/Day) | 34 |
| LY2216684 (0.3 mg/kg/Day) | 28 |
Response rate analysis compared the frequency of response between LY2216684 treatment groups versus placebo for participants who had a final study period II (weeks 1-8) Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version:Investigator-Administered and Scored (ADHD-RS-IV-PV:IR) total score <=60% of their baseline total score. ADHD-RS-IV-PV:IR measures 18 symptoms in Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision (DSM-IV-TR) ADHD diagnosis. Item scores range: 0 (none/never or rarely) to 3 (severe/very often). Total scores range: 0 to 54. (NCT00922636)
Timeframe: Baseline, up to 8 weeks
| Intervention | Participants (Number) |
|---|---|
| Methylphenidate | 14 |
Measures ADHD diagnostic symptoms (0=none/never-3=severe/very often). Inattention=sum odd items; hyperactivity-impulsivity=sum even items (subtotal: 0-27). Total scores: 0-54. High score=greater illness severity. Missing data-imputation in manual was applied. Least Squares Mean Change from restricted maximum likelihood-based, mixed model repeated measure analysis; included fixed class effects of treatment, pooled investigative site, strata (prior stimulant use status), visit, and treatment*visit interaction, and continuous, fixed effects of baseline score and baseline score*visit interaction. (NCT00922636)
Timeframe: Baseline, 8 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| Hyperactivity-Impulsivity Score | Inattention Score | |
| Methylphenidate | -9.00 | -10.46 |
Measures ADHD diagnostic symptoms (0=none/never-3=severe/very often). Inattention=sum odd items; hyperactivity-impulsivity=sum even items (subtotal: 0-27). Total scores: 0-54. High score=greater illness severity. Missing data-imputation in manual was applied. Least Squares Mean Change from restricted maximum likelihood-based, mixed model repeated measure analysis; included fixed class effects of treatment, pooled investigative site, strata (prior stimulant use status), visit, and treatment*visit interaction, and continuous, fixed effects of baseline score and baseline score*visit interaction. (NCT00922636)
Timeframe: Baseline, 8 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| Hyperactivity-Impulsivity Score (n=63, 58,60,59) | Inattention Score (n=63, 59, 60, 59) | |
| LY2216684 (0.1 mg/kg/Day) | -5.94 | -6.23 |
| LY2216684 (0.2 mg/kg/Day) | -7.53 | -8.58 |
| LY2216684 (0.3 mg/kg/Day) | -7.32 | -9.09 |
| Placebo | -4.88 | -5.55 |
76-item parent-rated assessment of child's health status/functioning level. Most items assess frequency of activities/feelings (1=never, 5=always). Standard scores (T-scores) were calculated for all domains by adjusting raw scores based on an established reference group mean and standard deviation (T-scores mean=50, standard deviation=10). Higher scores denote improvement. Least Squares (LS) Mean Change is from an analysis of covariance model that included fixed class effects of treatment, pooled investigative site, strata (prior stimulant use status), and baseline domain score. (NCT00922636)
Timeframe: Baseline, 8 weeks
| Intervention | T-Score (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Achievement Standardized Score (n=27,14,19,26) | Comfort Standardized Score (n=28,16,19,29) | Resilience Standardized Score (n=28,16,19,29) | Risk Avoidance Standardized Score (n=28,16,19,29) | Satisfaction Standardized Score(n=28,16,19,29) | |
| LY2216684 (0.1 mg/kg/Day) | 3.45 | 2.96 | 0.60 | 1.81 | -2.07 |
| LY2216684 (0.2 mg/kg/Day) | 2.96 | 3.50 | 0.19 | 5.77 | -1.24 |
| LY2216684 (0.3 mg/kg/Day) | 3.81 | 7.82 | 4.75 | 4.75 | 3.63 |
| Placebo | 3.82 | 8.24 | 4.07 | 6.06 | 1.19 |
76-item parent-rated assessment of child's health status/functioning level. Most items assess frequency of activities/feelings (1=never, 5=always). Standard scores (T-scores) were calculated for all domains by adjusting raw scores based on an established reference group mean and standard deviation (T-scores mean=50, standard deviation=10). Higher scores denote improvement. Least Squares (LS) Mean Change is from an analysis of ANCOVA model that included fixed class effects of treatment, pooled investigative site, strata (prior stimulant use status), and baseline domain score. (NCT00922636)
Timeframe: Baseline, 8 weeks
| Intervention | T-Score (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Achievement Standardized Score (n=17) | Comfort Standardized Score (n=18) | Resilience Standardized Score (n=18) | Risk Avoidance Standardized Score (n=18) | Satisfaction Standardized Score(n=18) | |
| Methylphenidate | 5.21 | 4.06 | 5.10 | 6.97 | 1.90 |
Assesses adolescent's health status/functioning level. Domains: Achievement, Satisfaction, Comfort, Risk Avoidance, Resilience. Items assess frequency of activities/feelings (1=never, 5=always). Standard scores (T-scores) calculated for all domains by adjusting raw scores based on established reference group mean, standard deviation (T-scores mean=50, standard deviation=10). Higher scores=better health. Least Squares (LS) Mean Change from analysis of covariance model included fixed class effects of treatment, pooled investigative site, strata (prior stimulant use status), and baseline score. (NCT00922636)
Timeframe: Baseline, 8 weeks
| Intervention | T-Score (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Achievement Section (n=3,3,4,3) | Discomfort Section (n=30,31,32,26) | Resilience Section (n=30,30,31,26) | Risks Section (n=30,30,31,26) | Satisfaction Section (n=30,32,32,26) | |
| LY2216684 (0.1 mg/kg/Day) | 301.79 | 0.99 | 0.21 | -0.28 | -0.05 |
| LY2216684 (0.2 mg/kg/Day) | -12.42 | 1.10 | 1.62 | 2.18 | 2.95 |
| LY2216684 (0.3 mg/kg/Day) | 64.55 | 2.39 | 1.28 | 0.74 | 0.72 |
| Placebo | -339.71 | -1.29 | 1.90 | -0.08 | -0.12 |
Assesses adolescent's health status/functioning level. Domains: Achievement, Satisfaction, Comfort, Risk Avoidance, Resilience. Items assess frequency of activities/feelings (1=never, 5=always). Standard scores (T-scores) calculated for all domains by adjusting raw scores based on established reference group mean, standard deviation (T-scores mean=50, standard deviation=10). Higher scores=better health. Least squares (LS) mean of the change from baseline to endpoint (week 8) is from an ANCOVA model. The model included fixed class effects of treatment, pooled investigative site, strata (prior stimulant use status), and baseline CHIP-AE domain score. (NCT00922636)
Timeframe: Baseline, 8 weeks
| Intervention | T-Score (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Achievement Section (n=1) | Discomfort Section (n=6) | Resilience Section (n=6) | Risks Section (n=6) | Satisfaction Section (n=6) | |
| Methylphenidate | NA | -1.97 | -4.06 | 2.01 | 2.19 |
Measures ADHD symptom severity. Individual items on each subscale are scored from 0 (never) to 3 (very often). Total score expressed as T-score based on gender/age norms. Subscale total T-scores (0-100); higher T-scores=greater symptom severity. Least Squares Mean Change is from restricted maximum likelihood-based, mixed model repeated measure analysis. Model included fixed class effects of treatment, pooled investigative site, strata (prior stimulant use status), visit, and treatment*visit interaction, and continuous, fixed effects of baseline total score and baseline score*visit interaction. (NCT00922636)
Timeframe: Baseline, 8 weeks
| Intervention | T-Score (Least Squares Mean) | |
|---|---|---|
| Predominantly Hyperactive-Impulsive Type Total | Predominantly Inattentive Type Total Scale | |
| LY2216684 (0.1 mg/kg/Day) | -6.30 | -8.32 |
| LY2216684 (0.2 mg/kg/Day) | -12.94 | -10.99 |
| LY2216684 (0.3 mg/kg/Day) | -15.69 | -16.99 |
| Placebo | -8.70 | -10.71 |
Assess anxiety symptom severity. Individual subscale items: 0 (never, seldom) - 3 (very often/frequently). Total score expressed as T-score based on gender/age norms (0-100). Higher T-scores=greater anxiety. Change scores=Week 8 score-baseline score. Least Squares Mean Change from restricted maximum likelihood-based, mixed model repeated measure analysis. Model included fixed class effects of treatment, pooled investigative site, strata (prior stimulant use status), visit, and treatment*visit interaction, and continuous, fixed effects of baseline score and baseline score*visit interaction. (NCT00922636)
Timeframe: Baseline, 8 weeks
| Intervention | T-Score (Least Squares Mean) | |
|---|---|---|
| CBRS Generalized Anxiety Disorder T-score | CBRS Separation Anxiety Disorder Scale T-score | |
| LY2216684 (0.1 mg/kg/Day) | -5.34 | -1.13 |
| LY2216684 (0.2 mg/kg/Day) | -11.07 | -5.88 |
| LY2216684 (0.3 mg/kg/Day) | -15.39 | -8.60 |
| Placebo | -9.09 | -6.71 |
Assess anxiety symptom severity. Individual subscale items: 0 (never, seldom) - 3 (very often/frequently). Total score expressed as T-score based on gender/age norms (0-100). Higher T-scores=greater anxiety. Change scores=Week 8 score-baseline score. Least Squares Mean Change from restricted maximum likelihood-based, mixed model repeated measure analysis. Model included fixed class effects of treatment, pooled investigative site, strata (prior stimulant use status), visit, and treatment*visit interaction, and continuous, fixed effects of baseline score and baseline score*visit interaction. (NCT00922636)
Timeframe: Baseline, 8 weeks
| Intervention | T-Score (Least Squares Mean) | |
|---|---|---|
| CBRS Generalized Anxiety Disorder T-score | CBRS Separation Anxiety Disorder Scale T-score | |
| Methylphenidate | -8.78 | -2.91 |
The CP-CBRS academic difficulties total/language/math subscale score is a measure of academic performance. Each subscale item score ranges from 0 (never, seldom) to 3 (very often, very frequently). Total score is expressed as T-score based on gender/age norms. Academic difficulties T-score range: 0-100. Higher T-scores denote greater academic difficulties. Change scores=Week 8 score-baseline score. Least Squares Mean Change is from a restricted maximum likelihood-based, mixed model repeated measure (MMRM) analysis adjusted for fixed class effects of treatment, pooled investigative site, strata (prior stimulant use status), visit, and treatment*visit interaction, and continuous, fixed effects of baseline total score and baseline score*visit interaction. (NCT00922636)
Timeframe: Baseline, 8 weeks
| Intervention | T-Score (Least Squares Mean) | ||
|---|---|---|---|
| Total Score | Language Subscale Score | Math Subscales Score | |
| LY2216684 (0.1 mg/kg/Day) | -6.13 | -6.75 | -3.8 |
| LY2216684 (0.2 mg/kg/Day) | -5.93 | -6.07 | -2.85 |
| LY2216684 (0.3 mg/kg/Day) | -12.53 | -12.5 | -7.78 |
| Placebo | -6.09 | -5.87 | -4.63 |
The CP-CBRS academic difficulties total/language/math subscale score is a measure of academic performance. Each subscale item score ranges from 0 (never, seldom) to 3 (very often, very frequently). Total score is expressed as T-score based on gender/age norms. Academic difficulties T-score range: 0-100. Higher T-scores denote greater academic difficulties. Change scores=Week 8 score-baseline score. Least Squares Mean Change is adjusted for fixed class effects of treatment, pooled investigative site, strata (prior stimulant use status), visit, and treatment*visit interaction, and continuous, fixed effects of baseline total score and baseline score*visit interaction. (NCT00922636)
Timeframe: Baseline, 8 weeks
| Intervention | T-Score (Least Squares Mean) | ||
|---|---|---|---|
| Total Score | Language Subscale Score | Math Subscales Score | |
| Methylphenidate | -12.14 | -12.24 | -7.11 |
Assess aggressive behaviors, academic difficulties, social problems, violence potential. Individual subscale items range: 0=never to 3=very often. Total expressed as T-score based on gender/age norms (0-100). Change scores=Week 8 score-baseline score. Least Squares (LS) Mean Change from restricted maximum likelihood-based, mixed model repeated measure (MMRM) analysis; included fixed class effects of treatment, pooled investigative site, strata (prior stimulant use status), visit, and treatment*visit interaction, and continuous, fixed effects of baseline score, baseline score*visit interaction. (NCT00922636)
Timeframe: Baseline, 8 weeks
| Intervention | T-Score (Least Squares Mean) | ||
|---|---|---|---|
| Aggressive Behaviors Scale Score | Social Problems T-score | Violence Potential T-score | |
| LY2216684 (0.1 mg/kg/Day) | -3.32 | -3.33 | -4.22 |
| LY2216684 (0.2 mg/kg/Day) | -8.09 | -5.19 | -7.95 |
| LY2216684 (0.3 mg/kg/Day) | -11.01 | -12.06 | -11.88 |
| Placebo | -5.52 | -6.77 | -6.97 |
Assess aggressive behaviors, academic difficulties, social problems, violence potential. Individual subscale items range: 0=never to 3=very often. Total expressed as T-score based on gender/age norms (0-100). Change scores=Week 8 score-baseline score. Least Squares (LS) Mean Change from restricted maximum likelihood-based, mixed model repeated measure (MMRM) analysis; included fixed class effects of treatment, pooled investigative site, strata (prior stimulant use status), visit, and treatment*visit interaction, and continuous, fixed effects of baseline score, baseline score*visit interaction. (NCT00922636)
Timeframe: Baseline, 8 weeks
| Intervention | T-Score (Least Squares Mean) | ||
|---|---|---|---|
| Aggressive Behaviors Scale Score | Social Problems T-score | Violence Potential T-score | |
| Methylphenidate | -10.96 | -2.12 | -9.58 |
Rates schoolwork/grades, friendships/relationships, home life functioning (0=never to 3=very often). Total score expressed as a T-score based on gender/age norms (range 0-100). Higher T-score=greater symptom severity. Change scores=Week 8 score-baseline score. Least Squares Mean Change from restricted maximum likelihood-based, mixed model repeated measure analysis; included fixed class effects of treatment, pooled investigative site, strata (prior stimulant use status), visit, and treatment*visit interaction, and continuous, fixed effects of baseline score and baseline score*visit interaction. (NCT00922636)
Timeframe: Baseline, 8 weeks
| Intervention | T-Score (Least Squares Mean) | ||
|---|---|---|---|
| Schoolwork/Grades Score | Friendships/Relationships Score | Home Life Score | |
| LY2216684 (0.1 mg/kg/Day) | -0.35 | -0.00 | -0.08 |
| LY2216684 (0.2 mg/kg/Day) | -0.53 | -0.22 | -0.44 |
| LY2216684 (0.3 mg/kg/Day) | -0.81 | -0.65 | -0.73 |
| Placebo | -0.49 | -0.43 | -0.40 |
Rates schoolwork/grades, friendships/relationships, home life functioning (0=never to 3=very often). Total score expressed as a T-score based on gender/age norms (range 0-100). Higher T-score=greater symptom severity. Change scores=Week 8 score-baseline score. Least Squares Mean Change from restricted maximum likelihood-based, mixed model repeated measure analysis; included fixed class effects of treatment, pooled investigative site, strata (prior stimulant use status), visit, and treatment*visit interaction, and continuous, fixed effects of baseline score and baseline score*visit interaction. (NCT00922636)
Timeframe: Baseline, 8 weeks
| Intervention | T-Score (Least Squares Mean) | ||
|---|---|---|---|
| Schoolwork/Grades Score | Friendships/Relationships Score | Home Life Score | |
| Methylphenidate | -0.65 | -0.28 | -0.44 |
Measures ADHD symptom severity. Individual items on each subscale are scored from 0 (never) to 3 (very often). Total score expressed as T-score based on gender/age norms. Subscale total T-scores (0-100); higher T-scores=greater symptom severity. Least Squares Mean Change is from restricted maximum likelihood-based, mixed model repeated measure analysis. Model included fixed class effects of treatment, pooled investigative site, strata (prior stimulant use status), visit, and treatment*visit interaction, and continuous, fixed effects of baseline total score and baseline score*visit interaction. (NCT00922636)
Timeframe: Baseline, 8 weeks
| Intervention | T-Score (Least Squares Mean) | |
|---|---|---|
| Predominantly Hyperactive-Impulsive Type Total | Predominantly Inattentive Type Total Scale | |
| Methylphenidate | -12.41 | -18.28 |
Assesses ability to accurately and rapidly recognize and name visual symbols. The tests consist of rapid automatized naming tests (that is, Letters, Numbers, Objects, Colors) and 2 rapid alternating stimulus tests (that is, 2-Set Letters and Numbers; 3-Set Letters, Numbers, and Colors). Scores are based on the amount of time required to name all the stimulus items in each test section. Raw scores were converted to standard scores based on participant's age and conversion tables from manual (mean=100, standard deviation=15). Higher scores=better ability. Least Squares (LS) Mean Change from restricted maximum likelihood-based, mixed model repeated measure analysis. Model included fixed class effects of treatment, pooled investigative site, strata (prior stimulant use status), visit, and treatment*visit interaction, and continuous, fixed effects of baseline score and baseline score*visit interaction. (NCT00922636)
Timeframe: Baseline, 8 weeks
| Intervention | units on a scale (Least Squares Mean) | |||||
|---|---|---|---|---|---|---|
| Objects (n=21,18,18,11) | Colors (n=25, 21, 26, 16) | Numbers (n=28, 26, 30, 23) | Letters (n=27,24,27,22) | 2-set Letters and Numbers (n=27, 23, 28, 19) | 3-set Letters, Numbers, and Colors (n=26,24,28,21) | |
| LY2216684 (0.1 mg/kg/Day) | 6.45 | 4.86 | 2.85 | 2.84 | 3.21 | 3.86 |
| LY2216684 (0.2 mg/kg/Day) | 11.70 | 3.30 | 2.99 | 3.62 | 6.38 | 6.47 |
| LY2216684 (0.3 mg/kg/Day) | 5.64 | 2.98 | 2.38 | 2.22 | 4.69 | 1.56 |
| Placebo | -0.56 | 2.85 | 3.44 | 1.16 | 5.23 | 7.89 |
Assesses ability to accurately and rapidly recognize and name visual symbols. The tests consist of rapid automatized naming tests (that is, Letters, Numbers, Objects, Colors) and 2 rapid alternating stimulus tests (that is, 2-Set Letters and Numbers; 3-Set Letters, Numbers, and Colors). Scores are based on the amount of time required to name all the stimulus items in each test section. Raw scores were converted to standard scores based on participant's age and conversion tables from manual (mean=100, standard deviation=15). Higher scores=better ability. Least Squares (LS) Mean Change from restricted maximum likelihood-based, mixed model repeated measure analysis. Model included fixed class effects of treatment, pooled investigative site, strata (prior stimulant use status), visit, and treatment*visit interaction, and continuous, fixed effects of baseline score and baseline score*visit interaction. (NCT00922636)
Timeframe: Baseline, 8 weeks
| Intervention | units on a scale (Least Squares Mean) | |||||
|---|---|---|---|---|---|---|
| Objects (n=9) | Colors (n=11) | Numbers (n=14) | Letters (n=11) | 2-set Letters and Numbers (n=12) | 3-set Letters, Numbers, and Colors (n=12) | |
| Methylphenidate | 0.65 | 3.37 | 6.60 | 7.81 | 6.65 | 4.82 |
Measures attention, concentration, sequencing, number facility, and auditory short-term memory. Digit forward and digit backward subscales each comprise 2 trials and 8 items. Scaled scores range from 1 to 19. Higher scores denote better performance. Least Squares Mean Change is from a restricted maximum likelihood-based, mixed model repeated measure analysis. Model included fixed class effects of treatment, pooled investigative site, strata (prior stimulant use status), visit, and treatment*visit interaction, and continuous, fixed effects of baseline score and baseline score*visit interaction. (NCT00922636)
Timeframe: Baseline, 8 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| Digit Span Forward: Scaled Process Score | Digit Span Backward: Scaled Process Score | |
| LY2216684 (0.1 mg/kg/Day) | 0.97 | 0.98 |
| LY2216684 (0.2 mg/kg/Day) | 0.56 | 1.04 |
| LY2216684 (0.3 mg/kg/Day) | 0.61 | 0.74 |
| Placebo | 0.43 | 0.77 |
Measures attention, concentration, sequencing, number facility, and auditory short-term memory. Digit forward and digit backward subscales each comprise 2 trials and 8 items. Scaled scores range from 1 to 19. Higher scores denote better performance. Least Squares Mean Change is from a restricted maximum likelihood-based, mixed model repeated measure analysis. Model included fixed class effects of treatment, pooled investigative site, strata (prior stimulant use status), visit, and treatment*visit interaction, and continuous, fixed effects of baseline score and baseline score*visit interaction. (NCT00922636)
Timeframe: Baseline, 8 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| Digit Span Forward: Scaled Process Score | Digit Span Backward: Scaled Process Score | |
| Methylphenidate | 0.53 | 0.36 |
"Captures occurrence, severity, and frequency of suicide-related thoughts and behaviors. Number of participants with suicidal behaviors, ideations, and acts are provided. Suicidal behavior: a yes answer to any of 3 suicidal behavior questions: preparatory acts or behavior, aborted attempt, and interrupted attempt. Suicidal ideation: yes answer to any one of 5 suicidal ideation questions, which includes wish to be dead, and 4 different categories of active suicidal ideation. Suicidal act: a yes answer to actual attempt or completed suicide, nonfatal suicide attempt, and completed suicide." (NCT00922636)
Timeframe: 8 weeks
| Intervention | Participants (Number) | ||
|---|---|---|---|
| Suicidal Ideation | Suicidal Behavior | Suicidal Acts | |
| LY2216684 (0.1 mg/kg/Day) | 1 | 0 | 0 |
| LY2216684 (0.2 mg/kg/Day) | 5 | 0 | 0 |
| LY2216684 (0.3 mg/kg/Day) | 2 | 0 | 0 |
| Placebo | 1 | 0 | 0 |
"Captures occurrence, severity, and frequency of suicide-related thoughts and behaviors. Number of participants with suicidal behaviors, ideations, and acts are provided. Suicidal behavior: a yes answer to any of 3 suicidal behavior questions: preparatory acts or behavior, aborted attempt, and interrupted attempt. Suicidal ideation: yes answer to any one of 5 suicidal ideation questions, which includes wish to be dead, and 4 different categories of active suicidal ideation. Suicidal act: a yes answer to actual attempt or completed suicide, nonfatal suicide attempt, and completed suicide." (NCT00922636)
Timeframe: 8 weeks
| Intervention | Participants (Number) | ||
|---|---|---|---|
| Suicidal Ideation | Suicidal Behavior | Suicidal Acts | |
| Methylphenidate | 1 | 0 | 0 |
"Comparison of Swanson, Kotkin, Alger, M-Flynn and Pelham (SKAMP) Combined, Attention, and Deportment Scales following drug dose versus placebo.~The SKAMP scale is a validated rating scale that assesses behavioral symptoms of ADHD in a classroom setting using a 7-point impairment scale (0 = none through 6 = maximal impairment). The SKAMP total score comprises 13 items, with individual total scores ranging from 0 to 78 (lower scores mean better outcome). The SKAMP-D subscale evaluates deportment, including interacting with other children, interacting with adults, remaining quiet according to classroom rules, and staying seated according to classroom rules. The SKAMP-A subscale is a measure of attention and evaluates getting started on assignments, sticking with tasks, attending to an activity, and making activity transitions. The SKAMP quality of work subscale includes 3 items: completing assigned work, performing work accurately, and being careful and neat while writing or drawing." (NCT01269463)
Timeframe: Average over all post-dose time points (1.0, 2.0, 3.0, 4.5, 6.0, 7.5, 9.0, 10.5, and 12 hours)
| Intervention | units on a scale (Mean) |
|---|---|
| Methylphenidate HCl ER Capsules | 1.46 |
| Capsule Without Active Drug | 2.03 |
"Comparison of PERMP measurement scores following drug dose versus placebo (math-correct).~The Permanent Product Measure of Performance (PERMP), is a 5-page test consisting of 80 math problems per page (total of 400 problems) and evaluates effortful performance in the classroom as a measure of efficacy. Participants are instructed to work at their seats and to complete as many problems as possible in 10 minutes. The appropriate level of difficulty for each student was determined previously based on results of a math pretest administered at screening. Performance was evaluated using PERMP-A) and PERMP-C scores.~Measures obtained from these tests include the number of problems attempted (Math-Attempted; PERMP-A) and the number of problems answered correctly (Math-Correct; PERMP-C). Higher scores are better. The responses are reviewed by comparing them to an answer template, and they are triple-checked for accuracy" (NCT01269463)
Timeframe: 12 hours post-dose
| Intervention | Number of Problems (Least Squares Mean) | |
|---|---|---|
| PERMP-A | PERMP-C | |
| Capsule Without Active Drug | 80.30 | 74.80 |
| Methylphenidate HCl ER Capsules | 92.85 | 86.85 |
"The questionnaire includes two a sections, a clinician rated 20-item scale and a 14-item self-report section completed collaboratively by child and parent/guardian.~Units on the clinician rated scale range from 0-3 on a scale of severity, with 0 being the least severe item score and 3 being the most severe. Units on the self-report section ranged from 0-2 on a scale of severity, with 0 being the least severe item score and 2 being the most severe. The possible range of scores for the questionnaire is 88" (NCT00586157)
Timeframe: Baseline and 4 weeks
| Intervention | Units on a scale (Mean) |
|---|---|
| MTS (Drug A) | 12.76 |
| Placebo | 31.37 |
Units on a scale range from 0-3 on a scale of severity, with 0 being the least severe item score and 3 being the most severe. The possible range of scores for the scale is 0 (least severe) to 54 (most severe). (NCT00586157)
Timeframe: Baseline and 4 weeks
| Intervention | Units on a scale (Mean) |
|---|---|
| MTS (Drug A) | 10.03 |
| Placebo | 23.22 |
Units on a scale range from 0-3 on a scale of severity, with 0 being the least severe item score and 3 being the most severe. The possible range of scores for the scale is 0 (least severe) to 54 (most severe). (NCT00586157)
Timeframe: Baseline and 4 weeks
| Intervention | Units on a scale (Mean) |
|---|---|
| MTS (Drug A) | 14.76 |
| Placebo | 28.33 |
"Change in ADHD-RS-IV Total Score from Baseline (Visit 2) to end of Double Blind Phase (Visit 3); [Calculations of baseline values (Visit 2) minus end of Double Blind values (Visit 3), higher differences means better outcomes].~Attention Deficit Hyperactivity Disorder Rating Scale-IV (ADHD-RS-IV): The home version of the ADHD-RS-IV comprising symptoms of ADHD was used. This 18-item scale incorporates each of the ADHD symptoms regardless of assigned subtype. Trained clinicians administered questionnaire to parents. Scoring was based on symptom severity on a 4-point scale: 0=never or rarely, 1=sometimes, 2=often, and 3=very often. The Total Score is the sum of the scores for all 18 items, and could range from 0 (no impairment) to 54 (maximal impairment)." (NCT01239030)
Timeframe: From baseline (visit 2) to end of of Double-Blind phase (visit 3)
| Intervention | units on a scale (Mean) |
|---|---|
| 10 mg | 9.3 |
| 15 mg | 11.2 |
| 20 mg | 12.3 |
| 40 mg | 13.2 |
| Placebo | 5.1 |
ADHD-RS-IV consists of 18 items scored on a 4-point scale from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54. A decrease in score indicates an improvement in ADHD symptomology. (NCT01106430)
Timeframe: Baseline and 9 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Lisdexamfetamine Dimesylate | -26.1 |
| Atomoxetine Hydrochloride | -19.7 |
The BPRS-C characterizes psychopathology. A total of 21 items are rated on a scale from 0 (not present) to 6 (extremely severe) with a total score ranging from 0 to 126. A decrease in score indicates a reduction in psychopathology. (NCT01106430)
Timeframe: Baseline and up to 9 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Lisdexamfetamine Dimesylate | -10.7 |
| Atomoxetine Hydrochloride | -7.9 |
The WFIRS-P is a 50-item scale with each item scored from 0 (never/not at all) to 3 (very often/very much). Mean scores range from 0 to 3. Higher scores indicate greater functional impairment. (NCT01106430)
Timeframe: Baseline and up to 9 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Lisdexamfetamine Dimesylate | -0.35 |
| Atomoxetine Hydrochloride | -0.27 |
HUI is used to describe health status and to obtain utility scores by collecting data using one or more questionnaires in formats selected to match the specific study design criteria. Scoring ranges from 0.00 (dead) to 1.00 (perfect health). Higher scores represent better health status. (NCT01106430)
Timeframe: up to 9 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Lisdexamfetamine Dimesylate | 0.920 |
| Atomoxetine Hydrochloride | 0.922 |
Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale. (NCT01106430)
Timeframe: 9 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Lisdexamfetamine Dimesylate | 81.7 |
| Atomoxetine Hydrochloride | 63.6 |
Time to first response was defined as a Clinical Global Impression-Improvement (CGI-I) value of 1 (very much improved) or 2 (much improved) first recorded following first dose of investigational product. CGI-I consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). (NCT01106430)
Timeframe: 9 weeks
| Intervention | Days (Median) |
|---|---|
| Lisdexamfetamine Dimesylate | 12.0 |
| Atomoxetine Hydrochloride | 21.0 |
C-SSRS is a semi-structured interview that captures the occurence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The assessment is done by the nature of the responses, not by a numbered scale. (NCT01106430)
Timeframe: 9 weeks
| Intervention | participants (Number) | |
|---|---|---|
| Suicidal ideation | Suicidal behavior | |
| Atomoxetine Hydrochloride | 0 | 0 |
| Lisdexamfetamine Dimesylate | 0 | 0 |
UKU-SERS-Clin is composed of 48 items each of which asks about a single side effect. Each side effect is rated based on a 4-point scale ranging from 0 (no or doubtful presence) to 3 (the least favorable rating). The rating is independent of whether the symptom is regarded as related to the investigational product. (NCT01106430)
Timeframe: 9 weeks
| Intervention | participants (Number) | |||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Weight Loss | Reduced Duration of Sleep | Asthenia/Lassitude/Increased Fatigability | Tension/Inner Unrest | Nausea/Vomiting | Sleepiness/Sedation | Reduced Salivation | Headache-Tension Headache | Concentration Difficulties | Failing Memory | Depression | Increased Duration of Sleep | Increased Dream Activity | Emotional Indifference | Dystonia | Rigidity | Hypokinesia/Akinesia | Hyperkinesia Logic | Tremor | Akathisia | Paraesthesias | Accomodation Disturbances | Increased Salivation | Diarrhea | Constipation | Micturition Disturbances | Polyuria/Polydipsia | Orthostatic Dizziness | Palpitations/Tachycardia | Increased Tendency to Sweating | Rash-Morbiliform | Rash-Petechial | Rash-Urticarial | Rash-Cannot be Classified | Pruritus | Weight Gain | Headache-Migraine | Headache-Other Forms | |
| Atomoxetine Hydrochloride | 19 | 16 | 29 | 22 | 26 | 35 | 6 | 17 | 92 | 21 | 10 | 12 | 8 | 10 | 1 | 1 | 0 | 3 | 1 | 2 | 0 | 2 | 2 | 9 | 5 | 1 | 2 | 9 | 5 | 5 | 1 | 0 | 1 | 2 | 7 | 0 | 2 | 10 |
| Lisdexamfetamine Dimesylate | 46 | 29 | 25 | 20 | 19 | 16 | 16 | 15 | 75 | 10 | 6 | 12 | 3 | 12 | 0 | 0 | 1 | 2 | 3 | 0 | 1 | 0 | 1 | 6 | 9 | 0 | 3 | 10 | 1 | 3 | 0 | 1 | 1 | 1 | 4 | 1 | 2 | 11 |
Remission rate in different dosage groups will be accessed to evaluate the relationship between therapeutic effect and dosage. Remission rate is the percentage of participants with total score of IO sub-scale less than or equal to 5 in IOWA Conners measurement scale. (NCT01933880)
Timeframe: Week 12
| Intervention | Percentage of participants (Number) |
|---|---|
| OROS-MPH Group 18 Milligram (mg) | 85.37 |
| OROS-MPH Group 36 mg | 74.07 |
| OROS-MPH Group 54 mg | 100.00 |
Mathematics and language scores will be obtained from their corresponding examinations at school. Scores ranges from 0-100 respectively. Mathematics and language would be summarized separately. (NCT01933880)
Timeframe: Baseline and End of Week 12
| Intervention | scores on a scale (Mean) | |||
|---|---|---|---|---|
| Chinese Achievement: Basline (n=128, 40) | Chinese Achievement: End of Week 12(n=111, 40) | Mathematical Achievement (MA):Baseline (n=128, 40) | MA: End of Week 12 (n=111, 40) | |
| Normal Group | 94.21 | 94.56 | 96.23 | 96.13 |
| OROS-MPH Group | 77.35 | 83.94 | 78.86 | 86.05 |
Completion time of stroop color-word test in different dosage groups will be accessed to evaluate the relationship between therapeutic effect and dosage. This is a psychological test to observe the interference in which disparity between the meaning and color affects reading speed. A participant will be given 3 tasks of recognition: reading the printed colored ink (Color Test), reading color words in black ink (Word Test), and interference, reading color words printed in different colored ink (Word-Color Test). The test will be scored on the number of correct answers. There are 100 items for each of the three categories and if they made it through the 100 words with time remaining, they would repeat the list. Median time of the naming time in the Stroop color word naming test will be accessed. Stroop color word naming test 1 ,2 ,3 and 4 stand for gradually increased difficulty and each test has a corresponding baseline and endpoint. (NCT01933880)
Timeframe: Baseline and End of Week 12
| Intervention | Seconds (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Test 1: Baseline (n=86, 30, 1) | Test 1: Change at End of Week 12 (n=82, 27, 1) | Test 2: Baseline (n=86, 30, 1) | Test 2: Change at End of Week 12 (n=82, 27, 1) | Test 3: Baseline (n=86, 30, 1) | Test 3: Change at End of Week 12 (n=82, 27, 1) | Test 4: Baseline (n=86, 30, 1) | Test 4: Change at End of Week 12 (n=82, 27, 1) | |
| OROS-MPH Group 18 Milligram (mg) | 22.229 | -3.318 | 20.538 | -2.164 | 19.515 | -2.336 | 23.61 | -4.374 |
| OROS-MPH Group 36 mg | 17.7 | -1 | 17.29 | -1.233 | 17.473 | -2.996 | 22.154 | -3.974 |
| OROS-MPH Group 54 mg | 5 | 0 | 9 | 0 | 7 | 3 | 15 | 1 |
The digit span test is mainly used to measure the ability of short-term memory and attention. The participant will be given a string of digits and asked to repeat them forward, and then a second string of digits to repeat backward. The score is the number of correct responses, where the digits were repeated correctly. One point will be given for each correctly repeated string of digits. The maximum subscore in the Digits Forward is 16, and the maximum subscore in the Digits Backward is 14, summed for a total score of 30. A higher score is indicative of better recall and attention. (NCT01933880)
Timeframe: Baseline and Week 12
| Intervention | Scores on a scale (Mean) | |
|---|---|---|
| Baseline | Change at Week 12 | |
| Normal Group | 13.7 | 0.5 |
| OROS-MPH Group | 11.7 | 1 |
IOWA conners behavior rating scale score in different dosage groups will be accessed to evaluate relationship between therapeutic effect and dosage. IOWA Conners Behavior Rating Scale evaluated by parents provides accurate measurement standards for behavioral change and therapeutic response. It includes 2 sub-scales: Inattention/Overactivity (I/O) subscale and Attacks (A), also known as Opposition/Defiant (O/D) sub-scale. IO (primary measurement ) will be assessed using 5-items and all Items will be scored on a 4-point scale (from 0=not at all to 3=very much). Total score range is from 0 to 15. Higher scores indicate worsening. (NCT01933880)
Timeframe: Baseline and End of Week 12
| Intervention | Scores on a scale (Mean) | |
|---|---|---|
| Baseline | Change at End of Week 12 | |
| OROS-MPH Group 18 Milligram (mg) | 10 | -6.8 |
| OROS-MPH Group 36 mg | 10.3 | -5.8 |
| OROS-MPH Group 54 mg | 7 | -4 |
IOWA Conners Behavior Rating Scale evaluated by parents provides accurate measurement standards for behavioral change and therapeutic response. It includes 2 sub-scales: Inattention/Overactivity (I/O) subscale and Attacks (A), also known as Opposition/Defiant (O/D) sub-scale. IO (primary measurement ) will be assessed using 5-items and all Items will be scored on a 4-point scale (from 0=not at all to 3=very much). Total score range is from 0 to 15. Higher scores indicate worsening. (NCT01933880)
Timeframe: Baseline and Week 1
| Intervention | Scores on a scale (Mean) | |
|---|---|---|
| Baseline | Change at Week 1 | |
| OROS-MPH Group | 10 | -2.7 |
IOWA Conners Behavior Rating Scale evaluated by parents provides accurate measurement standards for behavioral change and therapeutic response. It includes 2 sub-scales: Inattention/Overactivity (I/O) subscale and Attacks (A), also known as Opposition/Defiant (O/D) sub-scale. IO (primary measurement ) will be assessed using 5-items and all Items will be scored on a 4-point scale (from 0=not at all to 3=very much). Total score range is from 0 to 15. Higher scores indicate worsening. (NCT01933880)
Timeframe: Baseline and Week 12
| Intervention | Scores on a scale (Mean) | |
|---|---|---|
| Baseline | Change at Week 12 | |
| OROS-MPH Group | 10 | -6.2 |
IOWA Conners Behavior Rating Scale evaluated by parents provides accurate measurement standards for behavioral change and therapeutic response. It includes 2 sub-scales: Inattention/Overactivity (I/O) subscale and Attacks (A), also known as Opposition/Defiant (O/D) sub-scale. IO (primary measurement ) will be assessed using 5-items and all Items will be scored on a 4-point scale (from 0=not at all to 3=very much). Total score range is from 0 to 15. Higher scores indicate worsening. (NCT01933880)
Timeframe: Baseline and Week 2
| Intervention | Scores on a scale (Mean) | |
|---|---|---|
| Baseline | Change at Week 2 | |
| OROS-MPH Group | 10 | -4.1 |
IOWA Conners Behavior Rating Scale evaluated by parents provides accurate measurement standards for behavioral change and therapeutic response. It includes 2 sub-scales: Inattention/Overactivity (I/O) subscale and Attacks (A), also known as Opposition/Defiant (O/D) sub-scale. IO (primary measurement ) will be assessed using 5-items and all Items will be scored on a 4-point scale (from 0=not at all to 3=very much). Total score range is from 0 to 15. Higher scores indicate worsening. (NCT01933880)
Timeframe: Baseline and Week 3
| Intervention | Scores on a scale (Mean) | |
|---|---|---|
| Baseline | Change at Week 3 | |
| OROS-MPH Group | 10 | -5 |
IOWA Conners Behavior Rating Scale evaluated by parents provides accurate measurement standards for behavioral change and therapeutic response. It includes 2 sub-scales: Inattention/Overactivity (I/O) subscale and Attacks (A), also known as Opposition/Defiant (O/D) sub-scale. IO (primary measurement ) will be assessed using 5-items and all Items will be scored on a 4-point scale (from 0=not at all to 3=very much). Total score range is from 0 to 15. Higher scores indicate worsening. (NCT01933880)
Timeframe: Baseline and Week 7
| Intervention | Scores on a scale (Mean) | |
|---|---|---|
| Baseline | Change at Week 7 | |
| OROS-MPH Group | 10 | -5.8 |
The digit span test total score will be accessed in different dosage groups to evaluate the relationship between therapeutic effect and dosage. The digit span test is mainly used to measure the ability of short-term memory and attention. The participant will be given a string of digits and asked to repeat them forward, and then a second string of digits to repeat backward. The score is the number of correct responses, where the digits were repeated correctly. One point will be given for each correctly repeated string of digits. The maximum subscore in the Digits Forward is16, and the maximum subscore in the Digits Backward is 14, for a total score of 30. A higher score was indicative of better recall and attention. (NCT01933880)
Timeframe: Baseline and End of Week 12
| Intervention | Scores on a scale (Mean) | |
|---|---|---|
| Baseline | Change at End of Week 12 | |
| OROS-MPH Group 18 Milligram (mg) | 11.7 | 1.2 |
| OROS-MPH Group 36 mg | 11.3 | 0.8 |
| OROS-MPH Group 54 mg | 15 | 0 |
The coding Test is a common test indicator for perceptual speed. The test presents a series of corresponding relationship between graphics and symbols to the participant, and then participants will be required to fill out the appropriate symbol following single symbol in the test part. The test is limited within 150 seconds and evaluated the number of symbols been replaced correctly by the participants. (NCT01933880)
Timeframe: Baseline and End of Week 12
| Intervention | Number of symbols correctly replaced (Mean) | |
|---|---|---|
| Baseline (n=128, 40) | End of Week 12 (n=111, 40) | |
| Normal Group | 77.4 | 83.1 |
| OROS-MPH Group | 63.4 | 73.2 |
Number of Participants who are Compliant with Treatment will be accessed. Less than 80 percent and more than 120 percent compliance signifies bad compliance, 80 to 120 percent compliance signifies good compliance . The compliance was calculated by the percentage of dose (actual dose multiplied by 100/theoretical dose).The theoretical dose means the dose prescribed by the Investigator. (NCT01933880)
Timeframe: End of Week 12
| Intervention | participants (Number) | ||
|---|---|---|---|
| Less than 80 percent | Between 80 to 120 percent | More than 120 percent | |
| OROS-MPH Group | 17 | 110 | 0 |
CGI is an overall rating scale. Clinical Global Impression (Improvement of Diseases) is divided into seven grades: 1=very significant improvement, 24=significant improvement or advanced, 3=improvement or slightly advanced, 4=no change, 5=slight aggravation, 6=significant aggravation, and 7=very significant aggravation or seriously aggravated. Number of participants in each category of grade were assessed. (NCT01933880)
Timeframe: End of Week 1, 2, 3, 7 and 12
| Intervention | Participants (Number) | ||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Significantly Advanced: End of Week 1 | Significantly Advanced: End of Week 2 | Significantly Advanced: End of Week 3 | Significantly Advanced: End of Week 7 | Significantly Advanced: End of Week 12 | Advanced: End of Week 1 | Advanced: End of Week 2 | Advanced: End of Week 3 | Advanced: End of Week 7 | Advanced: End of Week 12 | Slightly Advanced: End of Week 1 | Slightly Advanced: End of Week 2 | Slightly Advanced: End of Week 3 | Slightly Advanced: End of Week 7 | Slightly Advanced: End of Week 12 | No Change: End of Week 1 | No Change: End of Week 2 | No Change: End of Week 3 | No Change: End of Week 7 | No Change: End of Week 12 | Slightly Aggravated: End of Week 1 | Slightly Aggravated: End of Week 2 | Slightly Aggravated: End of Week 3 | Slightly Aggravated: End of Week 7 | Slightly Aggravated: End of Week 12 | Aggravated: End of Week 1 | Aggravated: End of Week 2 | Aggravated: End of Week 3 | Aggravated: End of Week 7 | Aggravated: End of Week 12 | Seriously Aggravated: End of Week 1 | Seriously Aggravated: End of Week 2 | Seriously Aggravated: End of Week 3 | Seriously Aggravated: End of Week 7 | Seriously Aggravated: End of Week 12 | |
| OROS-MPH Group | 20 | 28 | 29 | 35 | 36 | 59 | 53 | 44 | 41 | 46 | 33 | 28 | 33 | 28 | 25 | 15 | 10 | 11 | 7 | 3 | 0 | 2 | 0 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Remission rate is the percentage of participants with total score of IO sub-scale less than or equal to 5 in IOWA Conners measurement scale (NCT01933880)
Timeframe: End of Week 1, 2, 3, 7 and 12
| Intervention | Percentage of Participants (Number) | ||||
|---|---|---|---|---|---|
| End of Week 1 | End of Week 2 | End of Week 3 | End of Week 7 | End of Week 12 | |
| OROS-MPH Group | 25.98 | 51.97 | 66.93 | 78.74 | 81.10 |
This is a psychological test to observe the interference in which disparity between the meaning and color affects reading speed. A participant will be given 3 tasks of recognition: reading the printed colored ink (Color Test), reading color words in black ink (Word Test), and interference, reading color words printed in different colored ink (Word-Color Test). The test is scored on the number of correct answers. There are 100 items for each of the three categories and if they made it through the 100 words with time remaining, they would repeat the list. Median naming time in the Stroop color word naming test will be assessed. Stroop color word naming test 1 ,2 ,3 and 4 stand for gradually increased difficulty and each test has a corresponding baseline and endpoint. (NCT01933880)
Timeframe: Baseline and End of Week 12
| Intervention | Seconds (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Test 1: Baseline (n=128, 40) | Test 1: End of Week 12 (n=111, 40) | Test 2: Baseline (n=128, 40) | Test 2: End of Week 12 (n=111, 40) | Test 3: Baseline (n=128, 40) | Test 3: End of Week 12 (n=111, 40) | Test 4: Baseline (n=128, 40) | Test 4: End of Week 12 (n=111, 40) | |
| Normal Group | 6.213 | 5.7 | 7.15 | 6.675 | 6.875 | 6.513 | 11.763 | 10.488 |
| OROS-MPH Group | 20.561 | 18.961 | 19.32 | 18.281 | 18.652 | 16.946 | 22.868 | 19.388 |
WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. In completed categoriies, number of categories completed out of 6 sorting categories after the test was evaluated. Ranges from 0 to 6. The more the number of categories completed the better is the response. (NCT01933880)
Timeframe: Baseline and End of Week 12
| Intervention | Nunber of Categories Completed (Mean) | |
|---|---|---|
| Baseline (n=128, 40) | End of Week 12 (n=111, 40) | |
| Normal Group | 3.3 | 4 |
| OROS-MPH Group | 3.2 | 4.1 |
WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. The number of correct responses which meets all the requirements according to the response principles was evaluated. Ranges from 0-116, the more the better. (NCT01933880)
Timeframe: Baseline and End of Week 12
| Intervention | number of correct responses (Mean) | |
|---|---|---|
| Baseline (n=128, 40) | End of Week 12 (n=111, 40) | |
| Normal Group | 77.9 | 84.7 |
| OROS-MPH Group | 72.9 | 80.3 |
WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. Number of error responses which did not comply with the response principles was evaluated. Ranges from 0 to 128, the less the better. (NCT01933880)
Timeframe: Baseline and End of Week 12
| Intervention | number of error responses (Mean) | |
|---|---|---|
| Baseline (n=128, 40) | End of Week 12 (n= 111, 40) | |
| Normal Group | 42.9 | 32.3 |
| OROS-MPH Group | 52.3 | 36.1 |
WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. The frequency (number of times) of responses completed with 5 to 9 continuous correct was evaluated. Ranges from 0 to 26 and was not linear (cannot be considered to be good or bad just judged by the number, analyzed with other factors case by case). (NCT01933880)
Timeframe: Baseline and End of Week 12
| Intervention | number of times (Mean) | |
|---|---|---|
| Baseline (n=128, 40) | End of Week 12 (n=111, 40) | |
| Normal Group | 2.3 | 2.5 |
| OROS-MPH Group | 1.7 | 2 |
WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. Number of responses needed to complete the first color classification was evaluated. Ranges from 9 to 128, the lesser the better. (NCT01933880)
Timeframe: Baseline and End of Week 12
| Intervention | number of first responses (Mean) | |
|---|---|---|
| Baseline (n=128,40) | End of Week 12 (n=111, 40) | |
| Normal Group | 25.2 | 26.5 |
| OROS-MPH Group | 22.6 | 23.4 |
"WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. Learning to learn indicator was a measure of decrement in the number of responses needed to achieve each successive category. The raw score ranged from 0 to 100. The high, negative value suggests the participants could not effectively learn the task presented by the WCST. Only calculated in those completed 3 or more categories and not linear (cannot be considered to be good or bad just judged by the number, analyzed with other factors case by case)." (NCT01933880)
Timeframe: Baseline and End of Week 12
| Intervention | number of responses (Mean) | |
|---|---|---|
| Baseline (n=128, 40) | End of Week 12 (n=111, 40) | |
| Normal Group | -2.37 | -1.34 |
| OROS-MPH Group | -2.49 | -1.87 |
WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. Non perseverative error responses are the errors remaining after subtracting persistent errors from total errors. Ranges from 0 to 128 and was not linear (cannot be considered to be good or bad just judged by the number, analyzed with other factors case by case). (NCT01933880)
Timeframe: Baseline and End of Week 12
| Intervention | number of non-persistent error responses (Mean) | |
|---|---|---|
| Baseline (n=128, 40) | End of Week 12 (n=111, 40) | |
| Normal Group | 19.98 | 15.8 |
| OROS-MPH Group | 23.54 | 16.75 |
WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. Percentage of the responses completed with 3-10 continuous correct during the entire measuring process was evaluated. Ranges from 0 to 100%, the more the better. (NCT01933880)
Timeframe: Baseline and End of Week 12
| Intervention | percentage of conceptual level responses (Mean) | |
|---|---|---|
| Baseline (n=128, 40) | End of Week 12 (n=111, 40) | |
| Normal Group | 54.73 | 65 |
| OROS-MPH Group | 46.36 | 61.07 |
WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. Percentage of correct responses which meets all the requirements according to the response principles was evaluated. Ranges from 0 to 100 percent (%), the more the better. (NCT01933880)
Timeframe: Baseline and End of Week 12
| Intervention | Percentage of correct responses (Mean) | |
|---|---|---|
| Baseline (n=128, 40) | End of Week 12 (n=111, 40) | |
| Normal Group | 65.52 | 73.34 |
| OROS-MPH Group | 58.678 | 70.096 |
WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative (pvt) errors; nonperseverative errors; failure to maintain set; learning to learn. Percentage of persistent errors out of total number of responses was evaluated. Ranges from 0 to 100%, the less the better. (NCT01933880)
Timeframe: Baseline and End of Week 12
| Intervention | Percentage of pvt error responses (Mean) | |
|---|---|---|
| Baseline (n=128, 40) | End of Week 12 (n=111, 40) | |
| Normal Group | 18.45 | 13.59 |
| OROS-MPH Group | 22.67 | 16.07 |
WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. Perseverative error responses are the number of responses which applied continuity principle for matching answers and also had the wrong answer was evaluated. Ranges from 0 to 128, the less the better. (NCT01933880)
Timeframe: Baseline and End of Week 12
| Intervention | number of perseverative error responses (Mean) | |
|---|---|---|
| Baseline (n=128, 40) | End of Week 12 (n=111, 40) | |
| Normal Group | 23 | 16.4 |
| OROS-MPH Group | 28.7 | 19.4 |
WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. Number of perseverative responses were the responses which applied continuity principle for matching answers was evaluated. Ranges from 0 to 100, the less the better. (NCT01933880)
Timeframe: Baseline and End of Week 12
| Intervention | number of perseverative responses (Mean) | |
|---|---|---|
| Baseline (n=128, 40) | End of Week 12 (n=111, 40) | |
| Normal Group | 26.5 | 18.6 |
| OROS-MPH Group | 33.7 | 22 |
WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. During number of trials administered or administered responses, participants were administered 128 cards and asked to sort the cards until all the 6 sorting categories was completed. Response number used to complete all 6 categories ranges from 50 to 128, lesser the better. (NCT01933880)
Timeframe: Baseline and End of Week 12
| Intervention | Responses (Mean) | |
|---|---|---|
| Baseline (n=128, 40) | End of Week 12 (n=111, 40) | |
| Normal Group | 120.8 | 117.1 |
| OROS-MPH Group | 125.1 | 116.4 |
Measures the DSM based ADHD criteria of Inattention and Hyperactivity/Impulsivity. There are 30 items scored 0-3 for a minimum score of 0 (no symptoms) and a maximum score of 90 worst possible symptoms. (NCT00506285)
Timeframe: Double-blind endpoints for MTS and placebo arms
| Intervention | units on a scale (Mean) |
|---|---|
| Scores in MTS Arm | 30.8 |
| Scores in Placebo Arm | 49.5 |
This scale measures the 7 domains of the Utah Criteria for Adult ADHD. Total scores run from 0 to 28. Normative samples average below 5. The worst possible score is 28. (NCT00506285)
Timeframe: Double-blind endpoints during MTS and placebo arms
| Intervention | units on a scale (Mean) |
|---|---|
| Scores in MTS Arm | 11.0 |
| Scores in Placebo Arm | 17.9 |
Duration of effect was defined as the last time point at which NT0102 separates from placebo on SKAMP-Combined scores. A separation was defined as a statistically significant difference at the 5% level of active drug over placebo. Data was collected separately for NT0102 and Placebo arms, and is reported as a comparison analysis of the two arms. This assessment was collected on the full classroom day, Visit 8. (NCT01835548)
Timeframe: Visit 8 (Day 42) at 1 hour (h), 3 h, 5 h, 7 h, 10 h, 12 h and 13 h
| Intervention | hour (Number) |
|---|---|
| All Participants | 12 |
An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. (NCT01835548)
Timeframe: Visit 9 (Day 43)
| Intervention | Participants (Count of Participants) |
|---|---|
| Dose Optimization/Stabilization Phase | 70 |
| Double-Blind Phase: Placebo | 10 |
| Double-Blind Phase: NT0102 | 11 |
Onset of effect was defined as the first time point at which NT0102 separates from placebo on SKAMP-Combined scores. A separation was defined as a statistically significant difference at the 5% level of active drug over placebo. Data was collected separately for NT0102 and Placebo arms and is reported as a comparison analysis of the two arms. This assessment was collected on the full classroom day, Visit 8. (NCT01835548)
Timeframe: Visit 8 (Day 42) at 1 hour (h), 3 h, 5 h, 7 h, 10 h, 12 h and 13 h
| Intervention | hour (Number) |
|---|---|
| All Participants | 1 |
The primary efficacy endpoint was derived from the SKAMP-Combined score calculated as the total score of all 13 items of the SKAMP-Combined score. The SKAMP-Combined score was obtained by summing up each item score where each item is rated on a 7-point impairment scale (0=normal to 6=maximal impairment) for a total possible score of 0 to 78. A lower score indicates less symptomatology (i.e., is better). The SKAMP was a rating scale that specifically measures the classroom manifestations of ADHD. The SKAMP ratings were completed for all subjects at baseline (pre-dose) and at 1, 3, 5, 7, 10, 12, and 13 hours post-dose on the classroom testing day (Visit 8). The primary analysis time point for the primary efficacy endpoint was the average of all post-dose SKAMP scores during the 13-hour period. (NCT01835548)
Timeframe: Visit 8 (Day 42)
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | 24.3 |
| NT0102 | 17.3 |
"The PERMP consisted of 400 math problems and was graded as number of problems Attempted (PERMP-A) and number of problems Correct. (PERMP-C). It was an objective measure of performance during the classroom testing day." (NCT01835548)
Timeframe: Visit 8 (Day 42)
| Intervention | number of problems attempted (Mean) |
|---|---|
| Placebo | 82.0 |
| NT0102 | 107.5 |
"The PERMP consisted of 400 math problems and was graded as number of problems Attempted (PERMP-A) and number of problems Correct. (PERMP-C). It was an objective measure of performance during the classroom testing day." (NCT01835548)
Timeframe: Visit 8 (Day 42)
| Intervention | number of problems correct (Mean) |
|---|---|
| Placebo | 78.6 |
| NT0102 | 104.1 |
"The SKAMP Rating Scale was comprised of 2 behavioral subscales, including the Attention subscale (4 items). The SKAMP-Attention subscore evaluates concentration in the classroom and is obtained by summing up each item score where each item is rated on a 7-point impairment scale (0=normal to 6=maximal impairment) for total possible combined score of 0 to 24. A lower score indicates less symptomatology (i.e. is better). The SKAMP-Attention subscores were derived from 20 minutes of direct observations of participant behavior. Ratings were based on the frequency and quality of behaviors." (NCT01835548)
Timeframe: Visit 8 (Day 42)
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | 12.2 |
| NT0102 | 9.4 |
"The SKAMP Rating Scale is comprised of 2 behavioural subscales, including the Deportment subscale (4 items). The SKAMP-Deportment subscore evaluates behaviour in the classroom and is obtained by summing up each item score where each item is rated on a 7-point impairment scale (0=normal to 6=maximal impairment) for total possible combined score of 0 to 24. A lower score indicates less symptomatology (i.e. is better). The SKAMP-Attention subscores were derived from 20 minutes of direct observations of participant behaviour. Ratings were based on the frequency and quality of behaviours." (NCT01835548)
Timeframe: Visit 8 (Day 42)
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | 12.5 |
| NT0102 | 7.9 |
The Adult ADHD Self-Report Scale (ASRS) assesses 18 core ADHD symptoms corresponding to the DSM-IV diagnostic symptoms for adult subjects based on the subject's own rating for each of the symptoms using a four point scale (0=None, 1=Mild, 2=Moderate, and 3=Severe). If a single item is missing the score is imputed and if more than one item is missing, the total score is treated as missing. The ASRS total score is derived by summing the score assigned to each of the 18 symptoms (low=0, high=54, a higher score signifies a greater severity of symptoms). (NCT00937040)
Timeframe: Baseline, endpoint (42 days or early discontinuation)
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline (N=167, 166) | Endpoint (N=171,167) | Change from baseline at endpoint (N=166, 165) | |
| OROS MPH | 51.6 | 32.6 | -19.4 |
| PLACEBO | 49.8 | 37.5 | -12.1 |
The Adult ADHD Investigator Symptom Rating Score (AISRS) assesses 18 core ADHD symptoms corresponding to the DSM-IV diagnostic symptoms for adult subjects based on the investigator's rating for each of the symptoms using a four point scale (0=None, 1=Mild, 2=Moderate, and 3=Severe). If a single item is missing the score is imputed and if more than one item is missing, the total score is treated as missing. The AISRS total score is derived by summing the score assigned to each of the 18 symptoms (low=0, high=54, a higher score signifies a greater severity of symptoms). (NCT00937040)
Timeframe: Baseline, endpoint (42 days or early discontinuation)
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Endpoint | Change from baseline at endpoint | |
| OROS MPH | 37.8 | 20.7 | -17.1 |
| PLACEBO | 37.0 | 25.2 | -11.7 |
"The Clinical Global Impression - Severity of Illness (CGI-S) is a clinician-rated subscale (low=0, high=7, higher score indicates increasing illness). The clinician rates the severity of the ADHD symptoms in relation to the clinician's total experience with ADHD subjects using a 7-point scale (1=normal, not at all ill, 2= borderline ill, 3= mildly ill, 4=moderately ill, 5= markedly ill, 6= severely ill, 7= among the most extremely ill subjects) in response to the question Considering your total clinical experience with this particular population, how ill is the subject at this time?." (NCT00937040)
Timeframe: Baseline, endpoint (42 days or early discontinuation)
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Endpoint (N=160,158) | Change from baseline at endpoint (N=160,158) | |
| OROS MPH | 4.7 | 3.0 | -1.7 |
| PLACEBO | 4.6 | 3.5 | -1.1 |
The Stroop Test is a computerized measure of inhibition/disinhibition, executive function, reaction time, and information processing. The SAT is a computerized measure of the ability to shift from one instruction set to another quickly and accurately. The scores generated by the SAT are: correct matches, errors, and response time. The testing score is a measure of cognitive flexibility. Cognitive Flexibility Domain Score = SAT Correct Responses - SAT Errors - Stroop Commission Errors. Higher scores indicate better accuracy. (NCT00937040)
Timeframe: Baseline, 4 hour timepoint for extended days or last non-missing value for non-extended days on day 42 or early discontinuation (endpoint)
| Intervention | correct responses (Mean) | ||
|---|---|---|---|
| Baseline (N=140,132) | Endpoint (N=108,114) | Change from baseline at endpoint (N=103,101) | |
| OROS MPH | 31.5 | 46.6 | 13.9 |
| PLACEBO | 34.0 | 45.9 | 11.3 |
The BRIEF-A, as completed by the DO, is a measure (low=61, high=225, lower scores indicate higher executive functioning) capturing views of an adult informant familiar with the subject's functioning. The BRIEF-A contains 75 scored items (1=never, 2=sometimes, 3=often) in nine non-overlapping clinical scales (Inhibit, Shift, Emotional Control, Self-Monitor, Initiate, Working Memory, Plan/Organize, Task Monitor, and Organization of Materials). The Behavioral Regulation Index (BRI), Metacognition Index (MI), and Global Executive Composite (GEC) are then derived. (NCT00937040)
Timeframe: Baseline, endpoint (42 days or early discontinuation)
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline (N=66,58) | Endpoint (N=55,52) | Change from baseline at endpoint (N=44,39) | |
| OROS MPH | 144.1 | 127.3 | -20.1 |
| PLACEBO | 139.3 | 133.3 | -10.3 |
The Dyadic Adjustment Scale (DAS) completed by DOs who were spouses or significant others assesses the relationship satisfaction or adjustment of partners in committed couple relationships. The 32-question DAS includes 4 empirically validated subscales that measure: dyadic satisfaction, dyadic consensus, dyadic cohesion and affectional expression. Possible responses include 5-, 6-, and 7-point Likert-scale questions and two yes/no items. The 10-question DAS subset, the Dyadic Satisfaction Subscale, was used in this study (low=0, high=50, higher score means better relationship satisfaction). (NCT00937040)
Timeframe: Baseline, endpoint (42 days or early discontinuation)
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline (N=44,43) | Endpoint (N=43,38) | Change from baseline at endpoint (N=31,31) | |
| OROS MPH | 35.8 | 37.2 | 1.5 |
| PLACEBO | 36.2 | 37.5 | 0.6 |
The satisfaction with treatment questionnaire (low=0, high=20, a lower score indicates lower satisfaction with treatment) requires the subject's DO to answer 4 questions related to how much the subject's ADHD symptoms have changed since starting the medication, how much benefit was received from the medication, the extent, if any, the advantages outweighed the disadvantages, and overall satisfaction with the medication. Responses vary from extremely satisfied, very satisfied, satisfied, neutral, mildly dissatisfied, dissatisfied, very dissatisfied, or extremely dissatisfied. (NCT00937040)
Timeframe: Endpoint (42 days or early discontinuation)
| Intervention | Participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Extremely Dissatisfied | Very Dissatisfied | Dissatisfied | Neither Dissatisfied or Satisfied | Satisfied | Very Satisfied | Extremely Satisfied | Missing/Unknown | |
| OROS MPH | 2 | 2 | 6 | 9 | 10 | 3 | 0 | 44 |
| PLACEBO | 5 | 4 | 8 | 19 | 5 | 6 | 0 | 33 |
The Epworth Sleepiness Scale (ESS) is an 8-item self-rated questionnaire designed to assess the overall level of daytime sleepiness. Each item describes normal daily situations (i.e., watching TV, lying down in the afternoon, sitting inactive in a public place) and subjects rate the likelihood of dozing off or falling asleep in each situation. Responses use a 4-point rating scale (0=would never doze, 1=slight chance of dozing, 2=moderate chance of dozing, 3=high chance of dozing). Item scores are summed to produce a total score (range of 0-24) with lower score suggesting more alertness. (NCT00937040)
Timeframe: Baseline, endpoint (42 days or early discontinuation)
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline (N=167,166) | Endpoint (N=157,155) | Change from baseline at endpoint (N=152,153) | |
| OROS MPH | 9.5 | 7.0 | -2.5 |
| PLACEBO | 9.1 | 8.0 | -1.0 |
The BRIEF-A is a self-reported measure (low=61, high=225, lower scores indicate higher executive functioning) capturing views of the subject's own functioning in the everyday environment. The BRIEF-A contains 75 scored items (1=never, 2=sometimes, 3=often) in 9 non-overlapping clinical scales (Inhibit, Shift, Emotional Control, Self-Monitor, Initiate, Working Memory, Plan/Organize, Task Monitor, and Organization of Materials). The Behavioral Regulation Index (BRI), Metacognition Index (MI), and GEC are then derived. (NCT00937040)
Timeframe: Baseline, endpoint (42 days or early discontinuation)
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline (N=168,166) | Endpoint (N=157,155) | Change from baseline at endpoint (N=153,153) | |
| OROS MPH | 153.7 | 128.4 | -25.8 |
| PLACEBO | 153.3 | 137.9 | -14.5 |
The AIM-A is a subject-reported measure (low=0, high=100, a higher score is more favorable) to assess the overall impact and role that ADHD may have in the conduct of tasks that are expected of adults. The AIM-A is comprised of four global quality of life items, five economic impact items, and five multi-item scales that describe important concepts. Items include: Living with ADHD; General Well-Being; Work, Home and School Performance and Daily Functioning; Relationships; and Communication; and Impact of Symptoms (emotional, degree of daily interference). (NCT00937040)
Timeframe: Baseline, endpoint (42 days or early discontinuation)
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline (N=168,166) | Endpoint (N=157,155) | Change from baseline at endpoint (N=153,153) | |
| OROS MPH | 31.9 | 59.4 | 27.5 |
| PLACEBO | 36.0 | 48.5 | 12.7 |
The PSQI discriminates between good and poor sleepers. The self-administered scale contains 15 multiple-choice items concerning frequency of sleep disturbances and subjective sleep quality and 4 write-in items that inquire about typical bedtime, wake-up time, sleep latency, and sleep duration over the past month. The PSQI generates 7 scores corresponding to the different sleep domains. Each component score ranges from 0 to 3. Total sleep index is calculated by adding up the 7 component scores (low=0, high=21, the lower the score, the better in sleep quality). (NCT00937040)
Timeframe: Baseline, endpoint (42 days or early discontinuation)
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline (N=167, 166) | Endpoint (N=157, 155) | Change from baseline at endpoint (N=152, 153) | |
| OROS MPH | 9.1 | 8.4 | -0.8 |
| PLACEBO | 8.8 | 8.5 | -0.4 |
The Symbol Digit Modalities Test (SDMT) is a computerized variant of the Wechsler Digit Symbol Substitution Test (DSST), but the position of symbols and digits is reversed. Scoring is the number of correct responses generated in 2 minutes. Processing Speed Domain = SDMT correct responses - SDMT errors. Higher scores indicate better functioning (i.e. information processing). (NCT00937040)
Timeframe: Baseline, endpoint (42 days or early discontinuation)
| Intervention | acccurate responses per minute (Mean) | ||
|---|---|---|---|
| Baseline (N=140,132) | Endpoint (N=109,114) | Change from baseline at endpoint (N=104,101) | |
| OROS MPH | 52.8 | 58.8 | 4.9 |
| PLACEBO | 53.9 | 59.7 | 5.9 |
"Stroop Test is a computerized measure of inhibition/disinhibition, executive function, reaction time, and information processing. The 1st part generates basic reaction time to colors. The 2nd part generates complex reaction time score to matching color names and font color. The 3rd part establishes a Stroop reaction time and an error score to unmatched color names/fonts. Reaction Time Domain Score = (Stroop Complex Reaction Time Correct + Stroop Reaction Time Correct)/2. Lower scores indicate better functioning (i.e. reaction time)." (NCT00937040)
Timeframe: Baseline, 4 hour timepoint for extended days or last non-missing value for non-extended days on day 42 or early discontinuation (endpoint)
| Intervention | milliseconds (msec) (Mean) | ||
|---|---|---|---|
| Baseline (N=140,132) | Endpoint (N=108,114) | Change from baseline at endpoint (N=103,101) | |
| OROS MPH | 700.3 | 645.2 | -51.2 |
| PLACEBO | 708.0 | 653.2 | -39.8 |
AISRS responder rate is defined as the percentage of subjects with AISRS < 18 at endpoint. (NCT00937040)
Timeframe: Endpoint (42 days or early discontinuation)
| Intervention | Percent of participants (Number) | |
|---|---|---|
| Responder | Non-responder | |
| OROS MPH | 45.0 | 55.0 |
| PLACEBO | 30.8 | 69.2 |
The ADHD Rating Scale-IV (Significant Other) is an 18-item list of core ADHD symptoms corresponding to the DSM-IV diagnostic symptoms. Each item is rated on a four point Likert type scale (0 = never or rarely, 1 = sometimes, 2 = often, and 3 = very often). The subject's designated observer will complete this scale, with baseline assessment based on the subject's usual functioning when not on medication. The total score is derived by summing the score assigned to each of the 18 symptoms (low=0, high=54, a higher score signifies a greater severity of symptoms). (NCT00937040)
Timeframe: Baseline, endpoint (42 days or early discontinuation)
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline (N=51,40) | Endpoint (N=40,35) | Change from baseline at endpoint (N=35,28) | |
| OROS MPH | 29.2 | 21.7 | -8.3 |
| PLACEBO | 29.9 | 27.3 | -1.7 |
The Dyadic Adjustment Scale (DAS) assesses the relationship satisfaction or adjustment of partners in committed couple relationships. The 32-question DAS includes 4 empirically validated subscales that measure: dyadic satisfaction, dyadic consensus, dyadic cohesion and affectional expression. The response format varies across the entire scale and includes 5-, 6-, and 7-point Likert-scale questions and two yes/no items. The 10-question subset of the DAS, the Dyadic Satisfaction Subscale, was used in this study (low=0, high=50, higher score means better relationship satisfaction). (NCT00937040)
Timeframe: Baseline, endpoint (42 days or early discontinuation)
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline (N=65,80) | Endpoint (N=66,68) | Change from baseline at endpoint (N=46,52) | |
| OROS MPH | 31.4 | 33.3 | 1.4 |
| PLACEBO | 32.3 | 32.5 | 0.0 |
The EWPS provides a measure of the subject's report of their overall productivity (low=0, high=100, a higher score indicates worsening work productivity and efficiency). There are 25 items (questions 15-39) on the scale that describe types of behaviors/ subjective feelings that are highly likely to reduce work productivity/efficiency. These 25 items are rated on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=often, to 4=almost always) indicating how often the behavior, feeling or attitude has been manifested in the past week. The total score is the sum of the 25 items. (NCT00937040)
Timeframe: Baseline, endpoint (42 days or early discontinuation)
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline (N=129,141) | Endpoint (N=126,124) | Change from baseline at endpoint (N=104,115) | |
| OROS MPH | 46.2 | 27.6 | -18.0 |
| PLACEBO | 44.7 | 33.3 | -9.7 |
The satisfaction with treatment questionnaire (low=0, high=20, a lower score indicates lower satisfaction with treatment) requires subjects to answer 4 questions related to how much their ADHD symptoms have changed since starting the medication, how much benefit they received from the medication, the extent, if any, the advantages outweighed the disadvantages, and overall satisfaction with the medication. The responses for this question vary with range of satisfaction (e.g. extremely satisfied, very satisfied, satisfied, neutral, dissatisfied, very dissatisfied, or extremely dissatisfied). (NCT00937040)
Timeframe: Endpoint (42 days or early discontinuation)
| Intervention | Participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Extremely Dissatisfied | Very Dissatisfied | Dissatisfied | Neither Dissatisfied or Satisfied | Satisfied | Very Satisfied | Extremely Satisfied | |
| OROS MPH | 14 | 17 | 7 | 36 | 40 | 28 | 13 |
| PLACEBO | 39 | 18 | 24 | 38 | 16 | 15 | 7 |
The Stroop Test is a computerized measure of inhibition/disinhibition, executive function, reaction time, and information processing. The Shifting Attention Test (SAT) a computerized measure of the ability to shift from one instruction set to another quickly and accurately. The Continuous Performance Test (CPT) is a computerized measure of vigilance or sustained attention/attention over time. Vigilance Domain (Complex Attention) Score = Stroop Commission Errors + SAT Errors + CPT Commission Errors + CPT Omission Errors. Lower scores indicate better functioning (i.e. sustained attention). (NCT00937040)
Timeframe: Baseline, endpoint (42 days or early discontinuation)
| Intervention | errors (Mean) | ||
|---|---|---|---|
| Baseline (N=140,132) | Endpoint (N=108,114) | Change from baseline at endpoint (N=103,101) | |
| OROS MPH | 35.7 | 23.9 | -10.4 |
| PLACEBO | 28.2 | 27.2 | -0.2 |
ADHD severity was measured by the Swanson, Nolan, and Pelham Rating Scale (SNAP)-IV-ADHD consists of 18 items that closely parallel in wording the diagnostic symptoms for ADHD as they appear in the DSM-IV. The range of scores are from 0 to 54. Higher scores indicate greater ADHD severity . The blinded assessors (Clinicians) used clinical judgement to provide an overall rating, based on all available information from the parents, teachers, and the assessors' own direct interactions with the child on the day of the assessment. (NCT01542528)
Timeframe: End of intervention is at a maximum of 15 weeks from baseline.
| Intervention | units on a scale (Mean) |
|---|---|
| IBBS | 3.0 |
| Treatment as Usual (TAU) | 3.2 |
Clinical Global Improvement Scale (CGI-I) - responders vs. non-responders. CGI is a seven point scale with the following anchor point: 1=Very Much Improved, 2=Much Improved, 3=Improved, 4=No change, 5=Minimally worse, 6=Much worse, 7=Very much worse. Participants with a score of 1, 2, or 3 at Endpoint were considered Responders; all others were considered non-responders. (NCT01542528)
Timeframe: 15 weeks for a total of 60 IBBS sessions vs. treatment as usual (TAU)
| Intervention | Percentage of participants (Number) |
|---|---|
| IBBS | 60.8 |
| Treatment as Usual (TAU) | 59.6 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | percentage of weight change (Mean) |
|---|---|
| Ziprasidone | 11.58 |
| Aripiprazole, Quetiapine, Risperidone | 5.66 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | BMI percentile (Mean) | |
|---|---|---|
| baseline | week 12 (n=1, n=2) | |
| Aripiprazole, Quetiapine, Risperidone | 37.67 | 62.5 |
| Ziprasidone | 32 | 59 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | BMI z-score (Mean) | |
|---|---|---|
| baseline | week 12 (n=1, n=2) | |
| Aripiprazole, Quetiapine, Risperidone | -0.37 | 0.38 |
| Ziprasidone | -0.51 | 0.22 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | lbs (Mean) | |
|---|---|---|
| baseline | week 12 (n=1,2) | |
| Aripiprazole, Quetiapine, Risperidone | 118.5 | 141 |
| Ziprasidone | 120.5 | 151 |
Children's Global Assessment Scale (C-GAS) is designed to assess overall functioning across settings. The scale is rated from 1 to 100, with lower scores reflecting poorer adjustment. Change from baseline is reported. (NCT00257725)
Timeframe: week 5
| Intervention | score on a scale (Mean) |
|---|---|
| ADHD Treatment Group | 10.55 |
"CGI-S is designed to assess severity of illness on a seven-point scale: 1 = normal (not at ll ill) to 7 = among the most extremely ill patients.~Range: 0-7, higher score means worse outcome. Change from baseline is reported." (NCT00257725)
Timeframe: week 5
| Intervention | score on a scale (Mean) |
|---|---|
| ADHD Treatment Group | -1.64 |
"The SNAP-IV Rating Scale is a revision of the Swanson, Nolan and Pelham (SNAP) Questionnaire (Swanson et al, 1983). The SNAP-IV is based on a 0 to 3 rating scale: Not at All = 0, Just A Little = 1, Quite A Bit = 2, and Very Much = 3. Subscale scores on the SNAP-IV are calculated by summing the scores on the items in the subset and dividing by the number of items in the subset. The score for any subset is expressed as the Average Rating-Per-Item, as shown for ratings on the ADHD-Inattentive (ADHD-I) subset.~Sub scale ranges from 0-3. Higher scores mean better outcome. Change score from baseline is reported." (NCT00257725)
Timeframe: week 5
| Intervention | score on a scale (Mean) |
|---|---|
| ADHD Treatment Group | -1.09 |
The Conner's Parent Rating Scale-revised short version (CPRS-R) consists of 27 questions graded on a scale from 0 (not true at all) to 3 (very much true) with a total score ranging from 0 to 81. Higher scores are indicative of increased ADHD. This scale allows parents to respond on the basis of the child's behavior and help assess ADHD and evaluate problem behavior. (NCT00151996)
Timeframe: Baseline and 6 weeks
| Intervention | Units on a Scale (Mean) |
|---|---|
| Methylphenidate + SPD503 | -22.18 |
| Amphetamine + SPD503 | -16.28 |
Change in the Attention Deficit Hyperactivity Disorder Rating Scale-fourth edition (ADHD-RS-IV) total score from baseline. The ADHD-RS-IV consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54. (NCT00151996)
Timeframe: Baseline and 6 weeks
| Intervention | Units on a Scale (Mean) |
|---|---|
| Methylphenidate + SPD503 | -17.8 |
| Amphetamine + SPD503 | -13.8 |
Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale. (NCT00151996)
Timeframe: 6 weeks
| Intervention | Participants (Number) |
|---|---|
| Methylphenidate + SPD503 | 28 |
| Amphetamine + SPD503 | 18 |
Parent Global Assessment (PGA) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). The PGA is designed to capture parent's opinions of their child's disease (ADHD) severity and improvement. Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale. (NCT00151996)
Timeframe: 6 weeks
| Intervention | Participants (Number) |
|---|---|
| Methylphenidate + SPD503 | 32 |
| Amphetamine + SPD503 | 21 |
The Child Health Questionnaire-Parent Form (CHQ-PF50) was developed to measure the physical and psychosocial well-being of children aged 5 years of age and older. Total scoring ranges from 0-100 for each. Increases in scores represent improved well-being in subjects as assessed by their parents. (NCT00151996)
Timeframe: Baseline and 6 weeks
| Intervention | Units on a scale (Mean) | |
|---|---|---|
| Physical Summary Score | Psychosocial Summary Score | |
| Amphetamine + SPD503 | 0.22 | 11.56 |
| Methylphenidate + SPD503 | -0.38 | 8.98 |
(NCT00499863)
Timeframe: Baseline and endpoint (up to 7 weeks)
| Intervention | mmHg (Mean) |
|---|---|
| Methylphenidate Transdermal System | 1.9 |
| Placebo (PTS) | 1.1 |
QTcF is the QT interval using Fridericia's correction formula. QT interval is a measure of time between the start of the Q wave and the end of the T wave and is dependent on the heart rate(e.g., the faster the heart rate, the shorter the QT interval). The QT interval has to be corrected in order to aid interpretation. (NCT00499863)
Timeframe: Baseline and endpoint (up to 7 weeks)
| Intervention | msec (Mean) |
|---|---|
| Methylphenidate Transdermal System | -1.3 |
| Placebo (PTS) | -0.8 |
(NCT00499863)
Timeframe: Baseline and endpoint (up to 7 weeks)
| Intervention | bpm (Mean) |
|---|---|
| Methylphenidate Transdermal System | 6.5 |
| Placebo (PTS) | -1.4 |
(NCT00499863)
Timeframe: Baseline and endpoint (up to 7 weeks)
| Intervention | mmHg (Mean) |
|---|---|
| Methylphenidate Transdermal System | 2.0 |
| Placebo (PTS) | -0.4 |
The Attention Deficit Hyperactivity Disorder Rating Scale-fourth edition (ADHD-RS-IV) consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54. (NCT00499863)
Timeframe: baseline and endpoint (up to 7 weeks)
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| Methylphenidate Transdermal System | -18.8 |
| Placebo (PTS) | -8.8 |
The Conner's Parent rating Scale-revised short version (CPRS-R) consists of 27 questions graded on a scale from 0 (not true at all) to 3 (very much true). (NCT00499863)
Timeframe: Baseline and endpoint (up to 7 weeks)
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| Methylphenidate Transdermal System | -20.9 |
| Placebo (PTS) | -7.5 |
(NCT00499863)
Timeframe: Baseline and endpoint (up to 7 weeks)
| Intervention | lbs (Mean) |
|---|---|
| Methylphenidate Transdermal System | -1.9 |
| Placebo (PTS) | 1.77 |
The Youth Quality of Life Instrument-research version (YQOL-R) is a validated 56-item generic instrument for comparing quality of life of adolescents across condition groups that scores each question on a scale from 0 (never) to 4 (very often). (NCT00499863)
Timeframe: Baseline and endpoint (up to 7 weeks)
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| Methylphenidate Transdermal System | 3.3 |
| Placebo (PTS) | 1.3 |
Mean dermal reaction scores were graded on a scale ranging from 0 (no irritation) to 7 (strong reaction) for observed findings of erythema, edema, papules, and vesicles. (NCT00499863)
Timeframe: up to 7 weeks
| Intervention | scores on a scale (Mean) |
|---|---|
| Methylphenidate Transdermal System | 0.6 |
| Placebo (PTS) | 0.2 |
Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement includes a score of 1 (very much improved) or 2 (much improved) on the scale. (NCT00499863)
Timeframe: up to 7 weeks
| Intervention | Participants (Number) |
|---|---|
| Methylphenidate Transdermal System | 93 |
| Placebo (PTS) | 22 |
Parent Global Assessment (PGA) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement includes a score of 1 (very much improved) or 2 (much improved) on the scale. (NCT00499863)
Timeframe: up to 7 weeks
| Intervention | Participants (Number) |
|---|---|
| Methylphenidate Transdermal System | 76 |
| Placebo (PTS) | 15 |
Post Sleep Questionnaire (PSQ) overall rating of quality of sleep. There are 5 rating responses ranging from very poor to very good. No numbers are associated with the rating responses. (NCT00499863)
Timeframe: up to 7 weeks
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Very poor | Poor | Average | Good | Very good | |
| Methylphenidate Transdermal System | 2 | 14 | 27 | 47 | 31 |
| Placebo (PTS) | 2 | 7 | 13 | 18 | 18 |
Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale. (NCT00501293)
Timeframe: 6 months
| Intervention | Participants (Number) |
|---|---|
| Antecedent Methylphenidate Transdermal System (MTS) | 81 |
| Antecedent Placebo | 39 |
Parent Global Assessment (PGA) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale. (NCT00501293)
Timeframe: 6 months
| Intervention | Participants (Number) |
|---|---|
| Antecedent Methylphenidate Transdermal System (MTS) | 69 |
| Antecedent Placebo | 31 |
The ADHD-RS-IV consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54. (NCT00501293)
Timeframe: Baseline and 6 months
| Intervention | Units on a scale (Mean) | ||
|---|---|---|---|
| Baseline measure | 6 months | Change from baseline at 6 months | |
| Antecedent Methylphenidate Transdermal System (MTS) | 16.0 | 13.5 | -2.6 |
| Antecedent Placebo | 27.4 | 14.5 | -12.9 |
The Conner's Parent rating Scale-revised short version (CPRS-R) consists of 27 questions graded on a scale from 0 (not true at all) to 3 (very much true) with a total score ranging from 0 to 81. Higher scores are indicative of increased ADHD. This scale allows parents to respond on the basis of the child's behavior and help assess ADHD and evaluate problem behavior. (NCT00501293)
Timeframe: Baseline and 6 months
| Intervention | Units on a scale (Mean) | ||
|---|---|---|---|
| Baseline measure | 6 months | Change from baseline at 6 months | |
| Antecedent Methylphenidate Transdermal System (MTS) | 26.5 | 22.5 | -3.9 |
| Antecedent Placebo | 42.3 | 24.6 | -17.7 |
The Youth Quality of Life-research version (YQOL-R) is a validated 56-item generic instrument for comparing quality of life of adolescents across condition groups that scores each question on a scale from 0 (never) to 4 (very often). The YQOL scores are transformed to a 0-100 scale for easy interpretability. Higher scores indicate better quality of life. (NCT00501293)
Timeframe: Baseline and 6 months
| Intervention | Units on a scale (Mean) | ||
|---|---|---|---|
| Baseline measure | 6 months | Change from baseline at 6 months | |
| Antecedent Methylphenidate Transdermal System (MTS) | 82.4 | 85.0 | 1.9 |
| Antecedent Placebo | 80.9 | 84.6 | 2.7 |
Dermal reactions were graded on a scale ranging from 0 (no irritation) to 7 (strong reaction) for observed findings of erythema, edema, papules, and vesicles. (NCT00501293)
Timeframe: 6 months
| Intervention | Participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 0 (No evidence of irritation) | 1 (Minimal erythema) | 2 (Definite erythema) | 3 (Erythema and papules) | 4 (Definite edema) | 5 (Erythema, edema, and papules) | 6 (Vesicular eruption) | 7 (Strong reaction beyond test site) | No dermal evaluation | |
| Antecedent MTS and Antecedent Placebo | 23 | 42 | 82 | 6 | 0 | 4 | 0 | 0 | 5 |
(NCT00501293)
Timeframe: Baseline and 6 months
| Intervention | mmHg (Mean) | |
|---|---|---|
| Baseline measure | 6 months | |
| Antecedent Methylphenidate Transdermal System (MTS) | 69.4 | 67.9 |
| Antecedent Placebo | 67.2 | 68.9 |
QTcF is the QT interval using Fridericia's correction formula. QT interval is a measure of time between the start of the Q wave and the end of the T wave and is dependent on the heart rate(e.g., the faster the heart rate, the shorter the QT interval). The QT interval has to be corrected in order to aid interpretation. (NCT00501293)
Timeframe: Baseline and 6 months
| Intervention | msec (Mean) | |
|---|---|---|
| Baseline measure | 6 months | |
| Antecedent Methylphenidate Transdermal System (MTS) | 391.8 | 395.3 |
| Antecedent Placebo | 393.2 | 393.5 |
Post Sleep Questionnaire (PSQ) overall rating of quality of sleep. There are 5 rating responses ranging from very poor to very good. No numbers are associated with the rating responses. (NCT00501293)
Timeframe: 6 months
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Very poor | Poor | Average | Good | Very Good | |
| Antecedent Methylphenidate Transdermal System (MTS) | 1 | 6 | 34 | 27 | 23 |
| Antecedent Placebo | 1 | 3 | 10 | 15 | 9 |
(NCT00501293)
Timeframe: Baseline and 6 months
| Intervention | beats per minute (Mean) | |
|---|---|---|
| Baseline measure | 6 months | |
| Antecedent Methylphenidate Transdermal System (MTS) | 80.4 | 81.7 |
| Antecedent Placebo | 74.3 | 78.9 |
(NCT00501293)
Timeframe: Baseline and 6 months
| Intervention | mmHg (Mean) | |
|---|---|---|
| Baseline measure | 6 months | |
| Antecedent Methylphenidate Transdermal System (MTS) | 113.4 | 115.3 |
| Antecedent Placebo | 113.0 | 115.9 |
(NCT00501293)
Timeframe: Baseline and 6 months
| Intervention | lb (Mean) | |
|---|---|---|
| Baseline measure | 6 months | |
| Antecedent Methylphenidate Transdermal System (MTS) | 127.05 | 134.55 |
| Antecedent Placebo | 131.95 | 124.78 |
Number of subject who self report no smoking in the last 7 days (7-day point prevalence)at the end of study (week 24) and are biochemically confirmed (expired carbon monoxide <= 8 ppm) (NCT00549640)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Methylphenidate | 4 |
| Placebo | 3 |
Number of subject who self report no smoking in the last 7 days (7-day point prevalence)at the end of the medication phase (week 8) and are biochemically confirmed (expired carbon monoxide <= 8 ppm) (NCT00549640)
Timeframe: 8 weeks
| Intervention | participants (Number) |
|---|---|
| Methylphenidate | 1 |
| Placebo | 4 |
The average composite nicotine withdrawal score (using Minnesota Nicotine Withdrawal Scale) change from baseline for the first 14 days following target quit date. Scale scores range from 0 (none) to 4 (severe). (NCT00549640)
Timeframe: baseline and 14 days
| Intervention | units on a scale (Mean) |
|---|---|
| Methylphenidate | 0.28 |
| Placebo | 0.24 |
"This task, presented once during a laboratory school day, was designed to index attention to detail by determining how many grammatical mistakes each child could identify and circle in a brief paragraph. The errors were not difficult to identify and were designed to show attention to task, not comprehension. A higher number of errors identified, of those possible, was indicative of better attention - identification of grammatical errors(range: 0, 1 represents correct responses divided by the number of possible responses)." (NCT00799409)
Timeframe: Hour 3.0 of the Lab School Day During the Double-Blind Assessment Period
| Intervention | Units on a scale (Mean) |
|---|---|
| Placebo | 0.241 |
| Concerta | 0.327 |
The DIBELS (range: 0, 376), used to assess reading fluency, consists of standardized, individually administered measures of early literacy development. These short (1 minute) fluency measures were developed based upon essential early literacy domains to assess development of phonological awareness, alphabetic understanding, and automaticity and fluency. Only the paragraph fluency component of an age/grade-appropriate DIBELS was used. A higher score indicated better performance, as it represented that the subject orally read a greater number of words correctly within the time allowed. (NCT00799409)
Timeframe: Hour 3.5 of the Lab School Day During the Double-Blind Assessment Period
| Intervention | Units on a scale (Mean) |
|---|---|
| Placebo | 106.2 |
| Concerta | 112.0 |
PERMP (range: 0, 400) is a measure of academic productivity in children up to 14 years of age. These seatwork math tasks provide an objective measure of attention and accuracy in calculations. The level of difficulty is established on a screening math pretest. The subsequent laboratory school day assessments employed a series of 10-minute math tests (5 pages of 80 math problem each for a total of 400 problems available). Children were graded on the number of attempted problems. A higher number of problems attempted was indicative of greater attention to detail (higher score is preferable) (NCT00799409)
Timeframe: Hour 4 of the of the Lab School Day during Double-Blind Assessment Period
| Intervention | Problems attempted (Mean) |
|---|---|
| Placebo | 74.8 |
| Concerta | 103.5 |
PERMP (range: 0, 400) is a measure of academic productivity in children up to 14 years of age. These seatwork math tasks provide an objective measure of attention and accuracy in calculations. The level of difficulty is established on a screening math pretest performed at Visit 2. The subsequent laboratory school day assessments employed a series of 10-minute math tests (5 pages of 80 math problem each for a total of 400 problems available). Children were graded on the number of correct problems. A higher number of problems correct, of those attempted, was indicative of greater accuracy. (NCT00799409)
Timeframe: Hour 4 of the Lab School Day During the Double-Blind Assessment Period
| Intervention | Problems correct (Mean) |
|---|---|
| Placebo | 69.0 |
| Concerta | 97.4 |
The SKAMP scale measures the manifestations of ADHD using an independent observer (teacher) rating of the child's impairment in classroom behavior. The SKAMP-Attention (SKAMP-A) (range: 0, 42) is a sum of the ratings on 7 attention items (getting started, sticking with tasks, attending to an activity, making activity transitions, completing assigned tasks, performing work accurately, and being neat and careful while writing or drawing). Each item was rated on a 7-point impairment scale (0=normal, 6=maximum impairment), with higher scores indicating more severe symptoms. (NCT00799409)
Timeframe: Hour 4 of the Lab School Day During the Double-Blind Assessment Period
| Intervention | Units on a scale (Mean) |
|---|---|
| Placebo | 11.8 |
| Concerta | 6.7 |
The SKAMP scale measures the manifestations of ADHD using an independent observer (teacher) rating of the child's impairment in classroom behavior. A composite score (range: 0, 78) for the SKAMP variable (13 items total) was obtained by summing the SKAMP-D and SKAMP-A subscale scores. A lower score was preferable, as a higher score represented greater behavioral impairment. (NCT00799409)
Timeframe: Hour 4 of the Lab School Day During the Double-Blind Assessment Period
| Intervention | Units on a scale (Mean) |
|---|---|
| Placebo | 20.8 |
| Concerta | 9.9 |
The SKAMP scale measures the manifestations of ADHD using an independent observer (teacher) rating of the child's impairment in classroom behavior. The SKAMP-Deportment (SKAMP-D) (range: 0, 36) is a sum of ratings on 6 deportment items (interacting with other children, interacting with adults, remaining quiet, staying seated, complying with the teacher's directions, and following the classroom rules). Each item was rated on a 7-point impairment scale (0=normal, 6=maximum impairment), with higher scores indicating more severe symptoms. (NCT00799409)
Timeframe: Hour 4 of the Lab School Day During the Double-Blind Assessment Period
| Intervention | Units on a scale (Mean) |
|---|---|
| Placebo | 9.0 |
| Concerta | 3.1 |
The TOVA (range: unbounded) is a computerized, visual continuous performance test providing a measure of attention. The stimulus, presented for 100 milliseconds (ms) at the rate of 30 per minute, is a computer-presented square containing a square hole near the top (target) or bottom (non-target) edge. Higher scores indicate better performance, lower scores indicate worse performance. Clinical interpretation: an ADHD scores of -1.80 or lower (<= -1.80) are considered not within normal limits scores above -1.80 (> -1.80) are considered inconclusive (meaning, neither like-ADHD nor like-normal). (NCT00799409)
Timeframe: Hour 5.5 of the Lab School Day During the Double-Blind Assessment Period
| Intervention | Units on a scale (Mean) |
|---|---|
| Placebo | -4.39 |
| Concerta | -1.34 |
The TOVA (range: unbounded) is a computerized, visual continuous performance test providing a measure of attention. The stimulus, presented for 100 milliseconds (ms) at the rate of 30 per minute, is a computer-presented square containing a square hole near the top (target) or bottom (non-target) edge. Higher scores indicated better performance, lower scores indicate worse performance. Clinical interpretation: scores below 80 are considered abnormal, 80-85 are considered borderline, and scores above 85 are considered within normal limits. (NCT00799409)
Timeframe: Hour 5.5 of the Lab School Day During the Double-Blind Assessment Period
| Intervention | Units on a scale (Mean) |
|---|---|
| Placebo | 86.42 |
| Concerta | 92.58 |
The TOVA (range: unbounded) is a computerized, visual continuous performance test providing a measure of attention. The stimulus, presented for 100 milliseconds (ms) at the rate of 30 per minute, is a computer-presented square containing a square hole near the top (target) or bottom (non-target) edge. Higher scores indicated better performance, lower scores indicate worse performance. Clinical interpretation: scores below 80 are considered abnormal, 80-85 are considered borderline, and scores above 85 are considered within normal limits. (NCT00799409)
Timeframe: Hour 5.5 of the Lab School Day During the Double-Blind Assessment Period
| Intervention | Units on a scale (Mean) |
|---|---|
| Placebo | 25.98 |
| Concerta | 64.07 |
The TOVA (range: unbounded) is a computerized, visual continuous performance test providing a measure of attention. The stimulus, presented for 100 milliseconds (ms) at the rate of 30 per minute, is a computer-presented square containing a square hole near the top (target) or bottom (non-target) edge. Higher scores indicated better performance, lower scores indicate worse performance. Clinical interpretation: scores below 80 are considered abnormal, 80-85 are considered borderline, and scores above 85 are considered within normal limits. (NCT00799409)
Timeframe: Hour 5.5 of the Lab School Day During the Double-Blind Assessment Period
| Intervention | Units on a scale (Mean) |
|---|---|
| Placebo | 73.80 |
| Concerta | 89.72 |
The TOVA (range: unbounded) is a computerized, visual continuous performance test providing a measure of attention. The stimulus, presented for 100 milliseconds (ms) at the rate of 30 per minute, is a computer-presented square containing a square hole near the top (target) or bottom (non-target) edge. Higher scores indicated better performance, lower scores indicate worse performance. Clinical interpretation: scores below 80 are considered abnormal, 80-85 are considered borderline, and scores above 85 are considered within normal limits. (NCT00799409)
Timeframe: Hour 5.5 of the Lab School Day During the Double-Blind Assessment Period
| Intervention | Units on a scale (Mean) |
|---|---|
| Placebo | 62.87 |
| Concerta | 85.14 |
Each child individually was given a sequence of numbers with the sequence becoming progressively longer. The child was then asked to repeat the digits in the same sequence, either forwards or backwards. Each sequence length was attempted twice. The test was complete after failure on both trials of any sequence length. One point was awarded if the participant passed only 1 trial of a sequence length. Zero points were given if the participant failed both trials. The maximum raw scores were 16 forwards and 14 backwards. A higher score was indicative of better recall and attention (range: 0, 14). (NCT00799409)
Timeframe: Hour 5.5 of the Lab School Day During the Double-Blind Assessment Period
| Intervention | Correct Trials (Mean) |
|---|---|
| Placebo | 5.1 |
| Concerta | 5.4 |
Each child individually was given a sequence of numbers with the sequence becoming progressively longer. The child was then asked to repeat the digits in the same sequence, either forwards or backwards. Each sequence length was attempted twice. The test was complete after failure on both trials of any sequence length. One point was awarded if the participant passed only 1 trial of a sequence length. Zero points were given if the participant failed both trials. The maximum raw scores were 16 forwards and 14 backwards. A higher score was indicative of better recall and attention (range: 0, 16). (NCT00799409)
Timeframe: Hour 5.5 of the Lab School Day During the Double-Blind Assessment Period
| Intervention | Correct Trials (Mean) |
|---|---|
| Placebo | 9.2 |
| Concerta | 9.3 |
WRAML-2 (range: 0, 28) is designed to evaluate a child's ability to learn and to memorize information, consists of 9 subtests from which 4 summary indexes can be calculated: verbal memory index, visual memory index, learning index, and general memory index. During this test the investigator pointed to a longer and longer series of windows on a card at the rate of 1 location per second, and then the child was asked to reproduce the sequence exactly in reverse order. One point was given for each correctly recalled sequence, and the test was discontinued after 3 consecutive errors. (NCT00799409)
Timeframe: Hour 5.5 of the Lab School Day During the Double-Blind Assessment Period
| Intervention | Correct Sequences (Mean) |
|---|---|
| Placebo | 11.2 |
| Concerta | 12.2 |
WRAML-2 (range: 0, 28) is designed to evaluate a child's ability to learn and to memorize information, consists of 9 subtests from which 4 summary indexes can be calculated: verbal memory index, visual memory index, learning index, and general memory index. During this test the investigator pointed to a longer and longer series of windows on a card at the rate of 1 location per second, and then the child was asked to reproduce the sequence exactly. One point was given for each correctly recalled sequence, and the test was discontinued after 3 consecutive errors. (NCT00799409)
Timeframe: Hour 5.5 of the Lab School Day During the Double-Blind Assessment Period
| Intervention | Correct Sequences (Mean) |
|---|---|
| Placebo | 12.9 |
| Concerta | 14.3 |
The THS-R (range: unbounded) is a standardized, untimed assessment designed to evaluate neurosensory integration manifested in manuscript and cursive writing. The test includes subtests: writing from memory or dictation the letters of the alphabet in order, single digit-numbers out of order, selected words, and copying selected letters, words, and sentences. Each subtest was scored from zero (poorly formed letters) to 3 (perfectly formed letters). 100 is the normal mean; scores lower than 100 indicate performance worse than normal, scores above 100 indicate performance better than normal. (NCT00799409)
Timeframe: Hour 7.5 of the Lab School Day During the Double-Blind Assessment Period
| Intervention | Units on a scale (Mean) |
|---|---|
| Placebo | 93.6 |
| Concerta | 98.3 |
Gray Silent Reading Test (GSRT)Reading Quotient is a reliable, validated measure of reading comprehension administered in the group setting during the first half hour of the homework session (range: 0,unbounded). A higher score is preferable as it means more questions were answered correctly. (NCT00799409)
Timeframe: Hour 8.75 of the Lab School Day During the Double-Blind Assessment Period
| Intervention | Units on a scale (Mean) |
|---|---|
| Placebo | 85.9 |
| Concerta | 91.9 |
Packet Activities: Assessment of ability to organize, listen to instructions, initiate task, complete task, and distractibility, by completing a word search, reading a short story for comprehension on a multiple choice test, reading a longer story for comprehension on a true/false test, decoding a mystery sentence, and completing various vocabulary assessments (word choice, homophones; base/root words, alphabetic order) (range: 0, 1 represents correct responses divided by the number of possible responses). (NCT00799409)
Timeframe: Hour 8.75 of the Lab School Day During the Double-Blind Assessment Period
| Intervention | Units on a scale (Mean) |
|---|---|
| Placebo | 0.676 |
| Concerta | 0.676 |
Packet Activities: Assessment of ability to organize, listen to instructions, initiate task, complete task, and distractibility, by completing a word search, reading a short story for comprehension on a multiple choice test, reading a longer story for comprehension on a true/false test, decoding a mystery sentence, and completing various vocabulary assessments (word choice, homophones; base/root words, alphabetic order) (range: 0, 1 represents correct responses divided by the number of possible responses). (NCT00799409)
Timeframe: Hour 8.75 of the Lab School Day During the Double-Blind Assessment Period
| Intervention | Units on a scale (Mean) |
|---|---|
| Placebo | 0.652 |
| Concerta | 0.741 |
Packet Activities: Assessment of ability to organize, listen to instructions, initiate task, complete task, and distractibility, by completing a word search, reading a short story for comprehension on a multiple choice test, reading a longer story for comprehension on a true/false test, decoding a mystery sentence, and completing various vocabulary assessments (word choice, homophones; base/root words, alphabetic order) (range: 0, 1 represents correct responses divided by the number of possible responses). (NCT00799409)
Timeframe: Hour 8.75 of the Lab School Day During the Double-Blind Assessment Period
| Intervention | Units on a scale (Mean) |
|---|---|
| Placebo | 0.960 |
| Concerta | 0.987 |
Packet Activities: Assessment of ability to organize, listen to instructions, initiate task, complete task, and distractibility, by completing a word search, reading a short story for comprehension on a multiple choice test, reading a longer story for comprehension on a true/false test, decoding a mystery sentence, and completing various vocabulary assessments (word choice, homophones; base/root words, alphabetic order) (range: 0, 1 represents correct responses divided by the number of possible responses). (NCT00799409)
Timeframe: Hour 8.75 of the Lab School Day During the Double-Blind Assessment Period
| Intervention | Units on a scale (Mean) |
|---|---|
| Placebo | 0.694 |
| Concerta | 0.795 |
Packet Activities: Assessment of ability to organize, listen to instructions, initiate task, complete task, and distractibility, by completing a word search, reading a short story for comprehension on a multiple choice test, reading a longer story for comprehension on a true/false test, decoding a mystery sentence, and completing various vocabulary assessments (word choice, homophones; base/root words, alphabetic order) (range: 0, 1 represents correct responses divided by the number of possible responses). (NCT00799409)
Timeframe: Hour 8.75 of the Lab School Day During the Double-Blind Assessment Period
| Intervention | Units on a scale (Mean) |
|---|---|
| Placebo | 0.744 |
| Concerta | 0.760 |
Packet Activities: Assessment of ability to organize, listen to instructions, initiate task, complete task, and distractibility, by completing a word search, reading a short story for comprehension on a multiple choice test, reading a longer story for comprehension on a true/false test, decoding a mystery sentence, and completing various vocabulary assessments (word choice, homophones; base/root words, alphabetic order) (range: 0, 1 represents correct responses divided by the number of possible responses). (NCT00799409)
Timeframe: Hour 8.75 of the Lab School Day During the Double-Blind Assessment Period
| Intervention | Units on a scale (Mean) |
|---|---|
| Placebo | 0.609 |
| Concerta | 0.629 |
Packet Activities: Assessment of ability to organize, listen to instructions, initiate task, complete task, and distractibility, by completing a word search, reading a short story for comprehension on a multiple choice test, reading a longer story for comprehension on a true/false test, decoding a mystery sentence, and completing various vocabulary assessments (word choice, homophones; base/root words, alphabetic order) (range: 0, 1 represents correct responses divided by the number of possible responses). (NCT00799409)
Timeframe: Hour 8.75 of the Lab School Day During the Double-Blind Assessment Period
| Intervention | Units on a scale (Mean) |
|---|---|
| Placebo | 0.935 |
| Concerta | 0.979 |
"Remission is defined by all of the following criteria; 1) K-ARS Total score of 18 or less. 2) Very much improved or Much improved in CGI-I. K-ARS total score ranges from 0 (no symptoms) to 54 (highly symptomatic), higher score indicates worsening of condition. CGI-I is a 7-point scale ranging from 1 to 7, where 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse, higher score indicates worsening of condition." (NCT01012622)
Timeframe: Week 12
| Intervention | participants (Number) |
|---|---|
| Osmotic Release Oral System (OROS) Methylphenidate HCL | 99 |
Response is defined as at least 25 percent (%) decrease in total score of K-ARS compared to baseline. K-ARS measures the 18 symptoms based on DSM-IV (1994). Individual item scores range from 0 (none/never or rarely) to 3 (severe/very often), whereas the rating of 2 points or more was regarded as abnormal. Total scores range from 0 (no symptoms) to 54 (highly symptomatic), higher score indicates worsening of condition. (NCT01012622)
Timeframe: Week 12
| Intervention | participants (Number) |
|---|---|
| Osmotic Release Oral System (OROS) Methylphenidate HCL | 118 |
APRS scale measures four factors in elementary school children such as learning ability, academic performance, impulse control, and social withdrawal. In particular, it is excellent in assessing drug effect on the academic performance not measured by other scales. Score ranges from 19 to 95, higher score means better academic performance. (NCT01012622)
Timeframe: Baseline and Week 12
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Change at Week 12 | |
| Osmotic Release Oral System (OROS) Methylphenidate HCL | 55.46 | 7.40 |
CAT was developed to properly reflect brain function in childhood. It provided measurement of simple auditory selective attention in terms of omission (number of missing response to target stimulus [0-150], higher score indicate greater omission), false alarm (number of response to non-target stimulus [0-150], higher score indicate greater false alarm), response mean (average time spent to response to target stimulus [200-1100, low score means faster response to target stimulus]), Response (consistency of response time to target stimulus [30-650, Low score means good consistency of response]). (NCT01012622)
Timeframe: Baseline and Week 12
| Intervention | units on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Omission:Baseline | Omission:Change at Week 12 | False alarm:Baseline | False alarm:Change at Week 12 | Response mean:Baseline | Response mean:Change at Week 12 | Response:Baseline | Response:Change at Week 12 | |
| Osmotic Release Oral System (OROS) Methylphenidate HCL | 10.31 | -6.27 | 12.07 | -3.61 | 623.95 | -55.34 | 265.69 | -63.76 |
Beck Depression Inventory (BDI) consisted of 21 items for measuring the subjective severity of depression and emotional, cognitive, motivational, physiological symptoms of depression. Each question has a set of 4 possible answer choices, ranging in intensity, each answer being scored on a scale value of 0 (no symptom) to 3 (the most severe symptom). Accordingly, the total score ranges from 0 (no symptom) to 63 (the most severe symptom) for 21 questions. (NCT01012622)
Timeframe: Baseline and Week 12
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Change at Week 12 | |
| Osmotic Release Oral System (OROS) Methylphenidate HCL | 11.69 | -1.89 |
CHIP was designed to assess the physical, psychological health conditions and functional well-being of children. The instrument has sub-domains such satisfaction (11 items) ranges from 0 to 44, stability (22 items) ranges from 0 to 88, elasticity (19 items) ranges from 0 to 76, risk aversion (14 items) ranges from 0 to 56, achievement (10 items) ranges from 0 to 40. Good health is in the range from 44 to 56 points for all sub-domains. A score of 43 or below indicates poor health in that domain. A score of 57 or higher indicates excellent health. The total score is an average of the scores for the 5 domains and ranges from 0 to 304. Higher total score indicates better health. (NCT01012622)
Timeframe: Baseline and Week 12
| Intervention | units on a scale (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Score:Baseline (n=126) | Total Score:Change at Week 12 (n=126) | Satisfaction:Baseline (n=132) | Satisfaction:Change at Week 12 (n=132) | Stability:Baseline (n=129) | Stability:Change at Week 12 (n=129) | Elasticity:Baseline (n=132) | Elasticity:Change at Week 12 (n=132) | Risk aversion:Baseline (n=132) | Risk aversion:Change at Week 12 (n=132) | Achievement:Baseline (n=133) | Achievement:Change at Week 12 (n=133) | |
| Osmotic Release Oral System (OROS) Methylphenidate HCL | 207.85 | 18.08 | 26.17 | 2.27 | 82.13 | 4.47 | 38.30 | 2.53 | 40.67 | 5.73 | 21.00 | 2.45 |
"The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to Normal, not at all ill and a rating of 7 is equivalent to Among the most extremely ill participants. Higher change scores indicate worsening." (NCT01012622)
Timeframe: Baseline and Week 12
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Change at Week 12 | |
| Osmotic Release Oral System (OROS) Methylphenidate HCL | 5.14 | -2.51 |
CAT was developed to properly reflect brain function in childhood. It provided measurement of simple divided attention in terms of omission(number of missing response to target stimulus[0-150], higher score indicate greater omission), false alarm(number of response to non-target stimulus[0-150], higher score indicate greater false alarm), response mean (average time spent to response to target stimulus [200-1100, low score means faster response to target stimulus]), Response (consistency of response time to target stimulus [30-650, Low score means good consistency of response]). (NCT01012622)
Timeframe: Baseline and Week 12
| Intervention | units on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Omission:Baseline | Omission:Change at Week 12 | False alarm:Baseline | False alarm:Change at Week 12 | Response mean:Baseline | Response mean:Change at Week 12 | Response:Baseline | Response:Change at Week 12 | |
| Osmotic Release Oral System (OROS) Methylphenidate HCL | 16.05 | -4.07 | 16.03 | -4.73 | 749.01 | -27.14 | 349.60 | -43.90 |
CAT was developed to properly reflect brain function in childhood. It provided measurement of simple inhibition-sustained attention in terms of omission(number of missing response to target stimulus [0-150], higher score indicate greater omission), false alarm(number of response to non-target stimulus [0-150], higher score indicate greater false alarm), response mean (average time spent to response to target stimulus [200-1100, low score means faster response to target stimulus]), Response (consistency of response time to target stimulus [30-650, Low score means good consistency of response]). (NCT01012622)
Timeframe: Baseline and Week 12
| Intervention | units on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Omission:Baseline | Omission:Change at Week 12 | False alarm:Baseline | False alarm:Change at Week 12 | Response mean:Baseline | Response mean:Change at Week 12 | Response:Baseline | Response:Change at Week 12 | |
| Osmotic Release Oral System (OROS) Methylphenidate HCL | 35.78 | -20.39 | 27.73 | -7.54 | 576.55 | -34.44 | 273.78 | -66.85 |
CAT was developed to properly reflect brain function in childhood. It provided measurement of simple interference-selective attention in terms of omission(number of missing response to target stimulus[0-150], higher score indicate greater omission), false alarm(number of response to non-target stimulus[0-150], higher score indicate greater false alarm), response mean (average time spent to response to target stimulus [200-1100, low score means faster response to target stimulus]), Response (consistency of response time to target stimulus [30-650, Low score means good consistency of response]). (NCT01012622)
Timeframe: Baseline and Week 12
| Intervention | units on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Omission:Baseline | Omission:Change at Week 12 | False alarm:Baseline | False alarm:Change at Week 12 | Response mean:Baseline | Response mean:Change at Week 12 | Response:Baseline | Response:Change at Week 12 | |
| Osmotic Release Oral System (OROS) Methylphenidate HCL | 20.39 | -10.83 | 26.03 | -6.14 | 648.48 | -54.35 | 276.74 | -72.18 |
K-ARS measures the 18 symptoms based on Diagnostic and Statistical Manual of Mental Disorders-forth edition (DSM-IV 1994). Individual item scores range from 0 (none/never or rarely) to 3 (severe/very often), whereas the rating of 2 points or more was regarded as abnormal. Total scores range from 0 (no symptoms) to 54 (highly symptomatic), higher score indicates worsening of condition. (NCT01012622)
Timeframe: Baseline and Week 12
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Change at Week 12 | |
| Osmotic Release Oral System (OROS) Methylphenidate HCL | 33.37 | -20.43 |
"Parenting Stress Index (PSI) was designed to assess parent or guardian child-rearing stress index on a 5-rating scale from never to very truly. Out of 30 items, 20 items are scored, being consisted of 8 child characteristics-related stress items; 9 parent-child interaction-related stress items; and 3 achievement expectation-related stress items. A possible total score ranges from 20 to 100; Increase in score indicates higher stress perceived by the parent." (NCT01012622)
Timeframe: Baseline and Week 12
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Change at Week 12 | |
| Osmotic Release Oral System (OROS) Methylphenidate HCL | 58.20 | -5.25 |
CAT was developed to properly reflect brain function in childhood. It provided measurement of simple visual selective attention in terms of omission (number of missing response to target stimulus [0-150], higher score indicate greater omission), false alarm (number of response to non-target stimulus [0-150], higher score indicate greater false alarm), response mean (average time spent to response to target stimulus [200-1100, low score means faster response to target stimulus]), Response (consistency of response time to target stimulus [30-650, Low score means good consistency of response]). (NCT01012622)
Timeframe: Baseline and Week 12
| Intervention | units on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Omission:Baseline | Omission:Change at Week 12 | False alarm:Baseline | False alarm:Change at Week 12 | Response mean:Baseline | Response mean:Change at Week 12 | Response:Baseline | Response:Change at Week 12 | |
| Osmotic Release Oral System (OROS) Methylphenidate HCL | 8.79 | -4.53 | 17.42 | -5.03 | 501.32 | -37.41 | 201.05 | -48.36 |
CAT was developed to properly reflect brain function in childhood. The test battery provided a comprehensive measurement of simple visual auditory attention, interventional visual-auditory selective attention, divided attention, continuous attention, and operational memory. Working memory forward was measured in terms of width of space and number of correct responses ranging from 0 to 10. For width of space boxes were presented on the screen and participants remembered the order of presented box. Participants pressed the box using mouse in the backward order. Maximum number that participants correctly memorized box in the screen in the respective order was reported and overall number of times a participant responded correctly was also reported. (NCT01012622)
Timeframe: Baseline and Week 12
| Intervention | correct responses (Mean) | |||
|---|---|---|---|---|
| Baseline:Number of correct responses | Change at Week 12:Number of correct responses | Baseline:Spatial span | Change at Week 12:Spatial span | |
| Osmotic Release Oral System (OROS) Methylphenidate HCL | 4.22 | 1.86 | 3.63 | 1.24 |
CAT was developed to properly reflect brain function in childhood. The test battery provided a comprehensive measurement of simple visual auditory attention, interventional visual-auditory selective attention, divided attention, continuous attention, and operational memory. Working memory forward was measured in terms of width of space and number of correct responses ranging from 0 to 10. For width of space boxes were presented on the screen and participants remembered the order of presented box. Participants pressed the box using mouse in the forward order. Maximum number that participants correctly memorized box in the screen in the respective order was reported and overall number of times a participant responded correctly was also reported. (NCT01012622)
Timeframe: Baseline and Week 12
| Intervention | correct responses (Mean) | |||
|---|---|---|---|---|
| Baseline:Number of correct responses | Change at Week 12:Number of correct responses | Baseline:Width of space | Change at Week 12:Width of space | |
| Osmotic Release Oral System (OROS) Methylphenidate HCL | 5.76 | 0.63 | 4.46 | 0.25 |
The CGI-I is a 7-point scale that requires the clinician to assess how much the participant's illness has improved or worsened relative to a baseline state at the beginning of the intervention and rated as: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse. Improved very much, Improved much and Improved a little are defined as improvement and No change, Aggravated a little, Aggravated much and Aggravated very much were defined as aggravation. (NCT01012622)
Timeframe: Week 12
| Intervention | participants (Number) | |
|---|---|---|
| Improvement | Aggravation | |
| Osmotic Release Oral System (OROS) Methylphenidate HCL | 122 | 7 |
DSM IV ADHD Rating Scale (ADHD-RS) adolescent informant, ascertained at baseline and weekly throughout the 16 week study. This scale is an 18-item symptom checklist of self-reported adolescent ADHD symptoms. Symptoms are scored as None (0), Mild (1), Moderate (2), and Severe (3), with a summary total of scores for the 18 symptoms. Possible scores range from 0 to 54, with higher scores indicating greater severity. Outcome is measured as the decrease in total severity score over time. (NCT00264797)
Timeframe: baseline and 20 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Methylphenidate | -20.6 |
| Methylphenidate (Placebo) | -21.8 |
Assessed by pill counts in conjunction with weekly review of subjects' medication diaries and self-reported medication compliance. (NCT00264797)
Timeframe: 20 weeks
| Intervention | pills (Mean) |
|---|---|
| Methylphenidate | 15.4 |
| Methylphenidate (Placebo) | 9.7 |
The change in number of days of substance use from baseline to end of the trial. The number of days of non-tobacco drug/alcohol ascertained using standard timeline follow back (TLFB) procedures. (NCT00264797)
Timeframe: 20 weeks
| Intervention | days (Mean) |
|---|---|
| Methylphenidate | -5.7 |
| Methylphenidate (Placebo) | -5.2 |
The mean number of negative urine drug screens (UDS). (NCT00264797)
Timeframe: 20 weeks
| Intervention | negative UDS (Mean) |
|---|---|
| Methylphenidate | 3.8 |
| Methylphenidate (Placebo) | 2.8 |
"Parent and teacher Vanderbilt ADHD Rating Scales - Attention Deficit / Hyperactivity Disorder Total sum score of all 18 ADHD symptom items - range equals 0-54~O - No ADHD symptoms 54 - Highest ADHD symptoms" (NCT01238822)
Timeframe: end of first week, end of second week, end of third week, end of fourth week. Total of 4 weeks.
| Intervention | Score (Mean) |
|---|---|
| Placebo | 26.54 |
| Low Dosage | 25 |
| Medium Dosage | 18.94 |
| High Dosage | 18.46 |
Measure by daily subject sleep diary (NCT00989950)
Timeframe: 9 weeks
| Intervention | minutes (Mean) |
|---|---|
| 9 hr Wear | 34 |
| 10 hr Wear | 34 |
| 11 hr Wear | 32 |
| 12 hr Wear | 34 |
The CGI-S scale summarizes the clinician's impression of the participant's symptom severity and ranges from 1-7 with 1 representing normal (not at all ill) and 7 representing extremely ill. (NCT00393042)
Timeframe: 8-10 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Adderall XR - Placebo | 4.26 |
| Adderall XR - 10 mg | 4.09 |
| Adderall XR - 20 mg | 3.48 |
| Adderall XR - 25/30 mg | 3.56 |
| Focalin XR - Placebo | 4.24 |
| Focalin - 10 mg | 4.24 |
| Focalin XR - 20 mg | 3.63 |
| Focalin XR - 25/30 mg | 3.55 |
Actigraphs (AW64 series) were worn each night and were used to assess participant's sleep patterns in their natural home environment. These computerized wristwatch-like devices collect data generated by movements. They are minimally invasive and allow sleep to be recorded reliably without interfering with the family's routine. One-minute epochs were used to analyze actigraphic sleep sata. Bedtimes and wake times were reported for each participant using sleep logs, and these times were used as the start and end times for the analyses. For each 1-min epoch, the total sum of activity counts were computed. If they exceeded a threshold (threshold sensitivity value = mean score in active period/45), then the epoch was considered waking. If it fell below that threshold, then it was considered sleep.The data for Adderall XR and Focalin XR was combined to look at the cumulative effects that medication has on sleep. (NCT00393042)
Timeframe: 8-10 weeks
| Intervention | minutes (Mean) |
|---|---|
| Placebo | 459.6 |
| 10mg of Either Focalin XR or Adderall XR | 446.7 |
| 20 mg of Either Focalin XR or Adderall XR | 432.17 |
| 25/30mg of Either Focalin XR or Adderall XR | 425.5 |
| Adderall XR All Dose Levels | 438.82 |
| Focalin XR All Dose Levels | 443.2 |
Measures the severity of Total ADHD symptoms, Inattention and Hyperactivity/Impulsive symptoms. The Inattention and Hyperactivity/Impulsive symptoms can range from 0 to 27 each, with a higher score reflecting more severe ADHD symptoms. The total score is calculated by summing the inattention and Hyperactivity/Impulsive subscales. The total score can range from 0 to 54 with a higher score reflecting more severe ADHD symptoms. (NCT00393042)
Timeframe: completed weekly over 8-10 weeks
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Inattention Symptom Subscale Scores | Hyperactivity/Impulsivity Symptom subscale scores | Total Symptoms scores | |
| Adderall XR - 10 mg | 6.40 | 10.78 | 27.15 |
| Adderall XR - 20 mg | 12.2 | 7.92 | 20.12 |
| Adderall XR - 25/30mg | 12.74 | 7.67 | 20.40 |
| Adderall XR - Placebo | 16.61 | 11.41 | 28.02 |
| Focalin XR - 10 mg | 17.51 | 10.84 | 28.35 |
| Focalin XR - 20 mg | 13.33 | 8.49 | 21.82 |
| Focalin XR - 25/30mg | 12.11 | 8.49 | 20.41 |
| Focalin XR - Placebo | 17.31 | 13.24 | 30.58 |
Three variations of the DAT 1 gene were observed, the 9/9 allele, the 9/10 allele and the 10/10 allele. The ADHD Rating Scale (ADHD-RS) and Clinical Global Impressions - Severity (CGI-S) measures were used to evaluate how the DAT 1 gene allele type altered the efficacy of the medication. The DAT 1 genotype did not predict differential response to Focalin XR or Adderall XR so the dose levels of each drug was combined to examine how the genotype interacted with the dose level. The ADHD-RS evaluates the severity of the participant's ADHD symptoms and includes two subscales: Inattention and Hyperactivity/Impulsivity. Both subscale scores range from 0 to 27 with a higher score representing more severe symptoms. The subscales are summed to calculate the total score which can range from 0 to 54. The CGI-S scale summarizes the clinician's impression of the participant's symptom severity and ranges from 1-7 with 1 representing normal (not at all ill) and 7 representing extremely ill. (NCT00393042)
Timeframe: 8-10 weeks
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| ADHD-RS Inattention subscale score | ADHD-RS Hyperactivity/Impulsivity subscale score | ADHD-RS total score | CGI-S score | |
| 10/10 Allele: 10 mg of Adderall XR | 16.13 | 9.63 | 25.77 | 4.07 |
| 10/10 Allele: 10 mg of Focalin XR | 16.56 | 10.63 | 27.19 | 4.19 |
| 10/10 Allele: 20 mg of Adderall XR | 9.36 | 7.07 | 16.43 | 3.21 |
| 10/10 Allele: 20 mg of Focalin XR | 12.56 | 8.41 | 20.96 | 3.52 |
| 10/10 Allele: 25/30 mg of Adderall XR | 11.96 | 7.50 | 19.46 | 3.54 |
| 10/10 Allele: 25/30mg of Focaling XR | 11.15 | 8.65 | 19.81 | 3.31 |
| 10/10 Allele: Placebo of Adderall XR | 15.07 | 11.87 | 26.93 | 4.17 |
| 10/10 Allele: Placebo of Focalin XR | 16.44 | 13.74 | 30.19 | 4.15 |
| 9/10 Allele: 10 mg of Adderall XR | 16.27 | 10.67 | 26.80 | 4.07 |
| 9/10 Allele: 10 mg of Focalin XR | 16.93 | 8.27 | 25.20 | 4.27 |
| 9/10 Allele: 20 mg of Adderall XR | 15.86 | 8.36 | 24.21 | 3.71 |
| 9/10 Allele: 20 mg of Focalin XR | 13.36 | 6.73 | 20.09 | 3.58 |
| 9/10 Allele: 25/30 mg of Adderall XR | 13.43 | 6.43 | 19.86 | 3.50 |
| 9/10 Allele: 25/30 mg of Focalin XR | 13.70 | 7.00 | 20.70 | 3.90 |
| 9/10 Allele: Placebo of Adderall XR | 18.64 | 9.36 | 28.00 | 4.36 |
| 9/10 Allele: Placebo of Focalin XR | 18.08 | 8.92 | 27.08 | 4.31 |
| 9/9 Allele: 10 mg of Adderall XR | 18.83 | 18.33 | 37.17 | 4.33 |
| 9/9 Allele: 10 mg of Focalin XR | 22.20 | 17.40 | 39.60 | 4.60 |
| 9/9 Allele: 20 mg Adderall XR | 19.00 | 14.80 | 33.80 | 4.80 |
| 9/9 Allele: 20 mg of Focalin XR | 16.75 | 14.00 | 30.75 | 4.50 |
| 9/9 Allele: 25/30 mg of Focalin XR | 12.50 | 9.00 | 24.00 | 4.00 |
| 9/9 Allele: 25/30mg of Adderall XR | 15.40 | 10.40 | 25.80 | 4.00 |
| 9/9 Allele: Placebo of Adderall XR | 18.60 | 12.80 | 31.40 | 4.40 |
| 9/9 Allele: Placebo of Focalin XR | 19.33 | 17.33 | 36.67 | 4.67 |
Actigraphs (AW64 series) were worn each night and were used to assess participant's sleep patterns in their natural home environment. These computerized wristwatch-like devices collect data generated by movements. They are minimally invasive and allow sleep to be recorded reliably without interfering with the family's routine. One-minute epochs were used to analyze actigraphic sleep sata. Bedtimes and wake times were reported for each participant using sleep logs, and these times were used as the start and end times for the analyses. For each 1-min epoch, the total sum of activity counts were computed. If they exceeded a threshold (threshold sensitivity value = mean score in active period/45), then the epoch was considered waking. If it fell below that threshold, then it was considered sleep. The data for Adderall XR and Focalin XR was combined to look at the cumulative effects that medication has on sleep. (NCT00393042)
Timeframe: 8-10 weeks
| Intervention | HHMM.SS (Mean) | |
|---|---|---|
| Sleep start time | Sleep End time | |
| 10mg of Either Focalin XR or Adderall XR | 2304 | 0728 |
| 20mg of Either Focalin XR or Adderall XR | 2319 | 0735 |
| 25/30mg of Either Focalin XR or Adderall XR | 2325 | 0732 |
| Adderall XR All Dose Levels | 2309 | 0735 |
| Focalin XR All Dose Levels | 2309 | 0734 |
| Placebo | 2249 | 0742 |
The WFIRS consists of 50 questions where respondents are asked to rate their child's functional impairment. The items of the WFIRS are scored on a four point Likert-type rating scale: 0 (never or not at all), 1 (sometimes or somewhat), 2 (often or much) or 3 (very often or very much) and aggregated to produce six domain scores: Family (ranges between 0-24), Learning or School (ranges between 0-33), Self-Concept (ranges between 0-15), Social Activities (ranges between 0-27), Life Skills (ranges between 0-36), and Risky Activities (ranges between 0-42). The subscales are scored by summing the responses in the subsection. The Total score is the sum of all the responses and it ranges between 0-150. The higher the score in each of the subscales the more impairment is recorded, this is also true for the total score. (NCT00393042)
Timeframe: 8-10 weeks
| Intervention | units on a scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Family subscale score | Learning subscale score | Life skills subscale score | Self-concept subscale score | Social activities subscale score | Risky activities subscale score | Total score | |
| Adderall XR - 10 mg | 7.02 | 8.75 | 7.91 | 1.59 | 3.91 | 1.94 | 31.06 |
| Adderall XR - 20 mg | 6.35 | 6.86 | 7.44 | 1.42 | 2.98 | 2.24 | 27.32 |
| Adderall XR - 25/30mg | 6.70 | 6.21 | 7.34 | 1.06 | 3.06 | 1.68 | 26.23 |
| Adderall XR - Placebo | 6.72 | 6.74 | 7.43 | 1.11 | 3.51 | 2.19 | 27.70 |
| Focalin XR - 10 mg | 7.35 | 9.25 | 7.65 | 1.19 | 3.85 | 1.96 | 31.13 |
| Focalin XR - 20 mg | 6.50 | 7.54 | 8.30 | 1.33 | 3.54 | 1.78 | 29.20 |
| Focalin XR - 25/30mg | 6.50 | 7.39 | 7.60 | 1.31 | 3.17 | 1.67 | 27.45 |
| Focalin XR - Placebo | 7.39 | 9.30 | 8.30 | 1.25 | 3.73 | 1.91 | 20.91 |
"Baseline values for all treatment groups are equal because~the constrained longitudinal data analysis (cLDA) model was used~(Liang and Zeger, 2000, Sankhyā: The Indian Journal of Statistics, Series B 62, 134-148)." (NCT00475735)
Timeframe: Baseline
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| MK-0249 | 34.6 |
| Concerta | 34.6 |
| Placebo | 34.6 |
The AISRS total score consists of 18 items from the original Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS) which were derived based on Diagnostic and Statistical Manual-4 (DSM-IV) criteria for ADHD. The ADHD-RS include 9 items that address symptoms of inattention and 9 items that address symptoms of impulsivity and hyperactivity. Each item is rated from 0 to 3. The AISRS total score can range from 0 to 54. A higher score corresponds to a worse severity of ADHD. (NCT00475735)
Timeframe: after 4 weeks of treatment
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| MK-0249 | -9.8 |
| Concerta | -15.3 |
| Placebo | -7.6 |
"Permanent Product Measure of Performance of Measurement (PERMP) is an age-adjusted, paper-and-pencil math test consisting of 5 pages of 80 math problems each presented in ascending order of difficulty (requiring addition, subtraction, multiplication, and division computations, respectively) during a 10-minute time period. At the end of the 10-minute math test, papers are collected and scored; the number of problems attempted and the number of problems correctly answered are generated as objective measures related to academic productivity. A positive score indicates improvement." (NCT00776009)
Timeframe: Pre-dose to 10, 11, and 12 hours post-dose
| Intervention | Number attempted (Least Squares Mean) |
|---|---|
| Dex-Methylphenidate Hydrochloride (Focalin XR) 20 mg | 18.76 |
| Dex-Methylphenidate Hydrochloride (Focalin XR) 30 mg | 28.03 |
| Placebo | -0.23 |
"Permanent Product Measure of Performance of Measurement (PERMP) is an age-adjusted, paper-and-pencil math test consisting of 5 pages of 80 math problems each presented in ascending order of difficulty (requiring addition, subtraction, multiplication, and division computations, respectively) during a 10-minute time period. At the end of the 10-minute math test, papers are collected and scored; the number of problems attempted and the number of problems correctly answered are generated as objective measures related to academic productivity. A positive score indicates improvement." (NCT00776009)
Timeframe: Pre-dose to 10, 11, and 12 hours post-dose
| Intervention | Number correct (Least Squares Mean) |
|---|---|
| Dex-Methylphenidate Hydrochloride (Focalin XR) 20 mg | 18.45 |
| Dex-Methylphenidate Hydrochloride (Focalin XR) 30 mg | 28.02 |
| Placebo | -4.30 |
SKAMP is a 13-item rating scale consisting of 2 subscales (7-items for Attention and 6-items for Deportment) that measures classroom manifestations of ADHD. SKAMP was used to generate a score on the Attention subscale at Hours 10, 11, and 12 on Day 7 of Weeks 1, 2, and 3. The rating scale is 0 (normal, no impairment) to 6 (maximum impairment) for a total possible combined score of 0 to 42 for the Attention subscale. The reported measure is the difference from baseline of the subscore averaged over Hours 10, 11, and 12. A negative score indicates improvement. (NCT00776009)
Timeframe: Pre-dose to 10, 11, and 12 hours post-dose
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| Dex-Methylphenidate Hydrochloride (Focalin XR) 20 mg | -1.33 |
| Dex-Methylphenidate Hydrochloride (Focalin XR) 30 mg | -2.62 |
| Placebo | 0.94 |
SKAMP is a 13-item rating scale that measures classroom manifestations of ADHD consisting of 2 subscales (7 items for Attention and 6 items for Deportment) used to generate a score at Hours 10, 11 and 12 on Day 7 of Weeks 1, 2 and 3. The ratings were based on both frequency and quality of specific behaviors. The rating scale is 0 (normal, no impairment) to 6 (maximum impairment) for a total possible combined score of 0 to 78. The reported measure is the difference from baseline of the 2 combined subscores averaged over Hours 10, 11 and 12. A negative score indicates improvement. (NCT00776009)
Timeframe: Pre-dose to 10, 11, and 12 hours post-dose
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| Dex-Methylphenidate Hydrochloride (Focalin XR) 20 mg | -2.02 |
| Dex-Methylphenidate Hydrochloride (Focalin XR) 30 mg | -4.47 |
| Placebo | 4.50 |
SKAMP is a 13-item rating scale consisting of 2 subscales (7-items for Attention and 6-items for Deportment) that measures classroom manifestations of ADHD. SKAMP was used to generate a score on the Deportment subscale at Hours 10, 11, and 12 on Day 7 of Weeks 1, 2, and 3. The rating scale is 0 (normal, no impairment) to 6 (maximum impairment) for a total possible combined score of 0 to 36 for the Deportment subscale. The reported measure is the difference from baseline of the subscore averaged over Hours 10, 11, and 12. A negative score indicates improvement. (NCT00776009)
Timeframe: Pre-dose to 10, 11, and 12 hours post-dose
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| Dex-Methylphenidate Hydrochloride (Focalin XR) 20 mg | -0.39 |
| Dex-Methylphenidate Hydrochloride (Focalin XR) 30 mg | -1.49 |
| Placebo | 2.95 |
The SKAMP scale measures the manifestations of attention deficit hyperactivity disorder (ADHD) using an independent observer rating of the participant's impairment in classroom observed behaviors. SKAMP combined score is comprised of 13 items (including subscales: attention with items 1-4, deportment with items 5-8, quality of work with items 9-11 and compliance with items 12-13). The SKAMP composite score was obtained by summing up each item score where each item is rated on a 7-point impairment scale (0=normal to 6=maximal impairment) for a total possible combined score of 0 to 78; where higher score signified worst impairment. (NCT00904670)
Timeframe: Hour 4 post-dose
| Intervention | units on a scale (Mean) |
|---|---|
| NWP06 | 7.1 |
| Placebo | 19.3 |
Onset and duration is determined using SKAMP combined rating scale at each post-dose time point. Onset of effect is defined as first assessment time showing statistical significance (i.e. p is less than or equal to [=<] 0.05) between NWP06 and placebo and duration of effect is defined as the as last consecutive time-point at which difference is still statistically significant between NWP06 and placebo. SKAMP scale measures the manifestations of ADHD using an independent observer rating of the participant's impairment in classroom observed behaviors. SKAMP combined score is comprised of 13 items [subscales: attention (1-4 items), deportment (5-8 items), quality of work (9-11 items) and compliance (12-13 items)]. SKAMP combined score is obtained by summing up each item score where each item is rated on a 7-point impairment scale (0=normal to 6=maximal impairment) for total possible combined score of 0 to 78; where higher score signified worst impairment. (NCT00904670)
Timeframe: 0.75, 2, 8, 10, 12 hours post-dose
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Hour 0.75 | Hour 2 | Hour 8 | Hour 10 | Hour 12 | |
| NWP06 | 9.5 | 7.2 | 10.8 | 14.0 | 15.1 |
| Placebo | 15.8 | 16.9 | 20.0 | 17.7 | 19.8 |
The PERMP is a 10-minute written test, on 80 math problems, performed as seatwork in the classroom. At the end of the 10-minute math test , the PERMP score of the number of math problems attempted plus the number of math problems answered correctly in a 10-minute session was used to measure a participant's performance. The total score range from 0-160 with higher scores indicating better performance. (NCT00904670)
Timeframe: 0.75, 2, 4, 8, 10, 12 hours post-dose
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Hour 0.75 | Hour 2 | Hour 4 | Hour 8 | Hour 10 | Hour 12 | |
| NWP06 | 111.1 | 118.2 | 119.2 | 105.2 | 95.6 | 94.0 |
| Placebo | 85.5 | 82.4 | 75.5 | 72.1 | 82.7 | 78.1 |
SKAMP scale measures the manifestations of ADHD using an independent observer rating of the participant's impairment in classroom observed behaviors. SKAMP combined score is comprised of 13 items [subscales: attention (1-4 items), deportment (5-8 items), quality of work (9-11 items) and compliance (12-13 items)]. SKAMP combined score is obtained by summing up each item score where each item is rated on a 7-point impairment scale (0=normal to 6=maximal impairment) for total possible combined score of 0 to 78; where higher score signified worst impairment. SKAMP attention subscale is reported which evaluates concentration in the classroom and comprises of 4 items, with a total possible score for of 0 to 24; higher score indicates worst impairment. (NCT00904670)
Timeframe: 0.75, 2, 4, 8, 10, 12 hours post-dose
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Hour 0.75 | Hour 2 | Hour 4 | Hour 8 | Hour 10 | Hour 12 | |
| NWP06 | 1.3 | 1.1 | 0.9 | 1.2 | 2.5 | 2.4 |
| Placebo | 2.5 | 2.6 | 3.1 | 2.7 | 3.0 | 3.4 |
SKAMP scale measures the manifestations of ADHD using an independent observer rating of the participant's impairment in classroom observed behaviors. SKAMP composite score is comprised of 13 items [subscales: attention (1-4 items), deportment (5-8 items), quality of work (9-11 items) and compliance (12-13 items)]. SKAMP composite score is obtained by summing up each item score where each item is rated on a 7-point impairment scale (0=normal to 6=maximal impairment) for total possible combined score of 0 to 78; where higher score signified worst impairment. SKAMP compliance subscale is reported which comprises of 2 items, with a total possible score of 0 to 12; higher score indicates worst impairment. (NCT00904670)
Timeframe: 0.75, 2, 4, 8, 10, 12 hours post-dose
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Hour 0.75 | Hour 2 | Hour 4 | Hour 8 | Hour 10 | Hour 12 | |
| NWP06 | 1.9 | 1.2 | 1.3 | 2.1 | 2.7 | 3.5 |
| Placebo | 3.5 | 4.1 | 4.7 | 4.8 | 4.4 | 4.6 |
SKAMP scale measures the manifestations of ADHD using an independent observer rating of the participant's impairment in classroom observed behaviors. SKAMP combined score is comprised of 13 items [subscales: attention (1-4 items), deportment (5-8 items), quality of work (9-11 items) and compliance (12-13 items)]. SKAMP combined score is obtained by summing up each item score where each item is rated on a 7-point impairment scale (0=normal to 6=maximal impairment) for total possible combined score of 0 to 78; where higher score signified worst impairment. SKAMP deportment subscale is reported which assesses behavior in the classroom and comprises of 4 items, with a total possible score for each sub-scale of 0 to 24; higher score indicates worst impairment. (NCT00904670)
Timeframe: 0.75, 2, 4, 8, 10, 12 hours post-dose
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Hour 0.75 | Hour 2 | Hour 4 | Hour 8 | Hour 10 | Hour 12 | |
| NWP06 | 1.7 | 1.0 | 1.2 | 2.1 | 2.4 | 2.7 |
| Placebo | 3.3 | 3.6 | 4.2 | 4.5 | 3.7 | 4.2 |
SKAMP scale measures the manifestations of ADHD using an independent observer rating of the participant's impairment in classroom observed behaviors. SKAMP composite score is comprised of 13 items [subscales: attention (1-4 items), deportment (5-8 items), quality of work (9-11 items) and compliance (12-13 items)]. SKAMP composite score is obtained by summing up each item score where each item is rated on a 7-point impairment scale (0=normal to 6=maximal impairment) for total possible combined score of 0 to 78; where higher score signified worst impairment. SKAMP quality of work subscale is reported which comprises of 3 items, with a total possible score of 0 to 18; higher score indicates worst impairment. (NCT00904670)
Timeframe: 0.75, 2, 4, 8, 10, 12 hours post-dose
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Hour 0.75 | Hour 2 | Hour 4 | Hour 8 | Hour 10 | Hour 12 | |
| NWP06 | 4.6 | 3.8 | 3.6 | 5.5 | 6.4 | 6.5 |
| Placebo | 6.5 | 6.6 | 7.3 | 7.9 | 6.7 | 7.6 |
To compare the white matter volume of patients with those of sibling controls using MRI results captured between -1.8 and 42.36 months from study enrollment. Existing MRIs very close to enrollment were permissable for inclusion in this study. (NCT00576472)
Timeframe: Enrollment to evaluation of MRI, on average 12.8 months.
| Intervention | percentage (Mean) |
|---|---|
| Patients | 27 |
| Siblings | 30.3 |
To compare the white matter volume of Acute Lymphoblastic Leukemia (ALL) patients with those of patients with malignant brain tumors using MRI results captured between -1.8 and 42.36 months from study enrollment. Existing MRIs very close to enrollment were permissable for inclusion in this study. (NCT00576472)
Timeframe: Enrollment to evaluation of MRI, on average 12.8 months.
| Intervention | percentage (Mean) |
|---|---|
| Patients With ALL | 28.4 |
| Patients With Brain Tumors | 25.5 |
To compare the white matter volume of patients by treatment intensity groups (mild, moderate, and high) and sibling controls using MRI results captured between -1.8 and 42.36 months from study enrollment. Existing MRIs very close to enrollment were permissable for inclusion in this study. (NCT00576472)
Timeframe: Enrollment to evaluation of MRI, on average 12.8 months.
| Intervention | percentage (Mean) |
|---|---|
| Siblings | 30.3 |
| Mild Treatment Intensity | 28.8 |
| Moderate Treatment Intensity | 25.9 |
| High Treatment Intensity | 25.4 |
The Conners' Teacher Rating Scale- Revised (S) is a measure of the observed frequency of behaviors associated with ADHD. Twenty-seven questions are rated on a scale from 0 (not true at all) to 3 (very much true). Raw scores are converted to T scores using age and gender normative data. T scores have a mean of 50 ± 10 where higher scores are indicative of greater problems. Assessments were performed prior to beginning the Home Therapy Phase (baseline) and upon completion of the phase. Phase completion ranged between 11.44 to 24.36 months (NCT00576472)
Timeframe: From beginning and at completion of home maintenance phase, on average 16.3 months.
| Intervention | T-score (Mean) |
|---|---|
| Overall | -9.56 |
The Conners' Teacher Rating Scale- Revised (S) is a measure of the observed frequency of behaviors associated with ADHD. Twenty-seven questions are rated on a scale from 0 (not true at all) to 3 (very much true). Raw scores are converted to T scores using age and gender normative data. T scores have a mean of 50 ± 10 where higher scores are indicative of greater problems. Assessments were performed prior to beginning the Home Therapy Phase (baseline) and upon completion of the phase. Phase completion ranged between 11.44 and 24.36 months. (NCT00576472)
Timeframe: From beginning and at completion of home maintenance phase, on average 16.3 months.
| Intervention | T-score (Mean) |
|---|---|
| Overall | -8.74 |
The Conners' Teacher Rating Scale- Revised (S) is a measure of the observed frequency of behaviors associated with ADHD. Twenty-eight questions are rated on a scale from 0 (not true at all) to 3 (very much true). Raw scores are converted to T scores using age and gender normative data. T scores have a mean of 50 ± 10 where higher scores are indicative of greater problems. Assessments were performed prior to beginning the Home Therapy Phase (baseline) and upon completion of the phase. Phase completion ranged between 11.44 to 24.36 months (NCT00576472)
Timeframe: From beginning and at completion of home maintenance phase, on average 16.3 months.
| Intervention | T-score (Mean) |
|---|---|
| Overall | -3.34 |
The Social Skills Rating System- Parent Version (SSRS-P) is a parent rating scale of social behaviors in reference to typically developing children. Thirty eight questions are rated 0 (Never) to 3 (very often). The social skills score is norm-referenced with a mean of 100±15 where a higher score is indicative of better skills. Assessments were performed prior to beginning the Home Therapy Phase (baseline) and upon completion of the phase. Phase completion ranged between 11.44 to 24.36 months (NCT00576472)
Timeframe: From beginning and at completion of home maintenance phase, on average 16.3 months.
| Intervention | T-score (Mean) |
|---|---|
| Overall | 7.99 |
The Wechsler Individual Achievement Test is an examiner administered measure of academic skills. The Math Composite score assesses the child's ability to solve calculation problems (Numerical Operations) and solve applied, word problems (Math Reasoning). Raw scores are converted to standard scores with a mean of 100±15 where higher scores indicate better performance. Assessments were performed prior to beginning the Home Therapy Phase (baseline) and upon completion of the phase. Phase completion ranged between 11.44 to 24.36 months (NCT00576472)
Timeframe: From beginning and after completion of home maintenance phase, on average 16.3 months.
| Intervention | T-score (Mean) |
|---|---|
| Overall | 0.22 |
The Wechsler Individual Achievement Test is an examiner administered measure of academic skills. The Reading Composite consists of Basic Reading (single word reading) and Reading Comprehension. Raw scores are converted to standard scores with a mean of 100±15 where higher scores indicate better performance. Assessments were performed prior to beginning the Home Therapy Phase (baseline) and upon completion of the phase. Phase completion ranged between 11.44 to 24.36 months (NCT00576472)
Timeframe: From beginning and at completion of home maintenance phase, on average 16.3 months.
| Intervention | T-score (Mean) |
|---|---|
| Overall | -0.21 |
The Wechsler Individual Achievement Test is an examiner administered measure of academic skills. The Spelling score assesses the child's ability to spell words to dictation. Raw scores are converted to standard scores with a mean of 100±15 where higher scores indicate better performance. Assessments were performed prior to beginning the Home Therapy Phase (baseline) and upon completion of the phase. Phase completion ranged between 11.44 to 24.36 months (NCT00576472)
Timeframe: From beginning and after completion of home maintenance phase, on average 16.3 months.
| Intervention | T-score (Mean) |
|---|---|
| Overall | -2.41 |
The Conners' Teacher Rating Scale- Revised (S) is a measure of the observed frequency of behaviors associated with ADHD. Twenty-eight questions are rated on a scale from 0 (not true at all) to 3 (very much true). Raw scores are converted to T scores using age and gender normative data. T scores have a mean of 50 ± 10 where higher scores are indicative of greater problems. Assessments were performed prior to beginning the Methylphenidate (MPH) Home Maintenance Phase(baseline) and upon completion of the phase. Phase completion ranged between 11.44 and 24.36 months. (NCT00576472)
Timeframe: From beginning and at completion of Methylphenidate (MPH) Home Maintenance Phase, on average 16.3 months.
| Intervention | T-score (Mean) |
|---|---|
| Overall | -7.17 |
The SSRS assesses social skills for children and adolescents at preschool, elementary and secondary developmental levels. The SSRS is 40 to 57 items, depending on age, completed separately by parents (SSRS-P) and teachers (SSRS-T). Respondents rate the frequency of occurrence for each item ranging from 0 to 2 (0-never, 1-sometimes, 2-very often). The raw scores for the SSRS-P and SSRS-T Social Skills Scales and the SSRS-P and SSRS-T Problem Behaviors Scales have different ranges that are dependent upon age. Raw scores obtained from the SSRS Scales cannot be used to directly interpret social skills or problem behaviors as raw scores vary in meaning based on scale, informant form and developmental level. Raw scores are converted to standard scores with a mean of 100 ± 15. For the Social Skills Scale, a higher score is indicative of better social functioning, and for the Problem Behaviors Scale, a higher score is indicative of greater behavior problems. (NCT00576472)
Timeframe: Evaluated at the end of each medication week during the Home Therapy Phase- placebo, low dose and moderate dose weeks.
| Intervention | Estimated Standard Score (Mean) |
|---|---|
| Placebo | 97.4890 |
| Low Dose | 97.0891 |
| Moderate Dose | 97.5709 |
The SSRS assesses social skills for children and adolescents at preschool, elementary and secondary developmental levels. The SSRS is 40 to 57 items, depending on age, completed separately by parents (SSRS-P) and teachers (SSRS-T). Respondents rate the frequency of occurrence for each item ranging from 0 to 2 (0-never, 1-sometimes, 2-very often). The raw scores for the SSRS-P and SSRS-T Social Skills Scales and the SSRS-P and SSRS-T Problem Behaviors Scales have different ranges that are dependent upon age. Raw scores obtained from the SSRS Scales cannot be used to directly interpret social skills or problem behaviors as raw scores vary in meaning based on scale, informant form and developmental level. Raw scores are converted to standard scores with a mean of 100 ± 15. For the Social Skills Scale, a higher score is indicative of better social functioning, and for the Problem Behaviors Scale, a higher score is indicative of greater behavior problems. (NCT00576472)
Timeframe: Evaluated at the end of each medication week during the Home Therapy Phase- placebo, low dose and moderate dose weeks.
| Intervention | Estimated Standard Score (Mean) |
|---|---|
| Placebo | 99.4412 |
| Low Dose | 101.5457 |
| Moderate Dose | 101.8999 |
The SSRS assesses social skills for children and adolescents at preschool, elementary and secondary developmental levels. The SSRS is 40 to 57 items, depending on age, completed separately by parents (SSRS-P) and teachers (SSRS-T). Respondents rate the frequency of occurrence for each item ranging from 0 to 2 (0-never, 1-sometimes, 2-very often). The raw scores for the SSRS-P and SSRS-T Social Skills Scales and the SSRS-P and SSRS-T Problem Behaviors Scales have different ranges that are dependent upon age. Raw scores obtained from the SSRS Scales cannot be used to directly interpret social skills or problem behaviors as raw scores vary in meaning based on scale, informant form and developmental level. Raw scores are converted to standard scores with a mean of 100 ± 15. For the Social Skills Scale, a higher score is indicative of better social functioning, and for the Problem Behaviors Scale, a higher score is indicative of greater behavior problems. (NCT00576472)
Timeframe: Evaluated at the end of each medication week during the Home Therapy Phase- placebo, low dose and moderate dose weeks.
| Intervention | Estimated Standard Score (Mean) |
|---|---|
| Placebo | 100.6084 |
| Low Dose | 98.6610 |
| Moderate Dose | 97.3103 |
The SSRS assesses social skills for children and adolescents at preschool, elementary and secondary developmental levels. The SSRS is 40 to 57 items, depending on age, completed separately by parents (SSRS-P) and teachers (SSRS-T). Respondents rate the frequency of occurrence for each item ranging from 0 to 2 (0-never, 1-sometimes, 2-very often). The raw scores for the SSRS-P and SSRS-T Social Skills Scales and the SSRS-P and SSRS-T Problem Behaviors Scales have different ranges that are dependent upon age. Raw scores obtained from the SSRS Scales cannot be used to directly interpret social skills or problem behaviors as raw scores vary in meaning based on scale, informant form and developmental level. Raw scores are converted to standard scores with a mean of 100 ± 15. For the Social Skills Scale, a higher score is indicative of better social functioning, and for the Problem Behaviors Scale, a higher score is indicative of greater behavior problems. (NCT00576472)
Timeframe: Evaluated at the end of each medication week during the Home Therapy Phase- placebo, low dose and moderate dose weeks.
| Intervention | Estimated Standard Score (Mean) |
|---|---|
| Placebo | 97.6171 |
| Low Dose | 100.6957 |
| Moderate Dose | 102.5281 |
The Conners' Parent Rating Scale- Revised (S) is a measure of the observed frequency of behaviors associated with ADHD. Three scales are reported: Cognitive Problems/Inattention (assesses the ability to learn at the same pace as peers, organize and complete work, and concentrate for sustained periods of time), Hyperactivity (assesses the ability to sit still to complete tasks, and impulsivity) and ADHD Index (assesses risk for ADHD disorder to be corroborated by other clinical information). Raw scores are converted to T scores using age and gender normative data. T scores have a mean of 50 ± 10 where higher scores are indicative of greater problems. Assessments were performed at the end of each medication week during the Home Therapy Phase- placebo, low dose and moderate dose weeks. (NCT00576472)
Timeframe: Evaluated at the end of each medication week during the Home Therapy Phase- placebo, low dose and moderate dose weeks.
| Intervention | Estimated T Score (Mean) |
|---|---|
| Placebo | 57.5805 |
| Low Dose | 54.4226 |
| Moderate Dose | 53.5317 |
The Conners' Parent Rating Scale- Revised (S) is a measure of the observed frequency of behaviors associated with ADHD. Three scales are reported: Cognitive Problems/Inattention (assesses the ability to learn at the same pace as peers, organize and complete work, and concentrate for sustained periods of time), Hyperactivity (assesses the ability to sit still to complete tasks, and impulsivity) and ADHD Index (assesses risk for ADHD disorder to be corroborated by other clinical information). Raw scores are converted to T scores using age and gender normative data. T scores have a mean of 50 ± 10 where higher scores are indicative of greater problems. Assessments were performed at the end of each medication week during the Home Therapy Phase- placebo, low dose and moderate dose weeks. (NCT00576472)
Timeframe: Evaluated at the end of each medication week during the Home Therapy Phase- placebo, low dose and moderate dose weeks.
| Intervention | Estimated T Score (Mean) |
|---|---|
| Placebo | 57.6595 |
| Low Dose | 54.6491 |
| Moderate Dose | 52.9854 |
The Conners' Parent Rating Scale- Revised (S) is a measure of the observed frequency of behaviors associated with ADHD. Three scales are reported: Cognitive Problems/Inattention (assesses the ability to learn at the same pace as peers, organize and complete work, and concentrate for sustained periods of time), Hyperactivity (assesses the ability to sit still to complete tasks, and impulsivity) and ADHD Index (assesses risk for ADHD disorder to be corroborated by other clinical information). Raw scores are converted to T scores using age and gender normative data. T scores have a mean of 50 ± 10 where higher scores are indicative of greater problems. Assessments were performed at the end of each medication week during the Home Therapy Phase- placebo, low dose and moderate dose weeks. (NCT00576472)
Timeframe: Evaluated at the end of each medication week during the Home Therapy Phase- placebo, low dose and moderate dose weeks.
| Intervention | Estimated T Score (Mean) |
|---|---|
| Placebo | 54.2138 |
| Low Dose | 52.2771 |
| Moderate Dose | 51.5143 |
The Conners' Teacher Rating Scale-Revised (S) is a measure of the observed frequency of behaviors associated with ADHD. Three scales are reported: Cognitive Problems/Inattention (assesses the ability to learn at the same pace as peers, organize and complete work, and concentrate for sustained periods of time), Hyperactivity (assesses the ability to sit still to complete tasks, and impulsivity) and ADHD Index (assesses risk for ADHD disorder to be corroborated by other clinical information). Raw scores are converted to T scores using age and gender normative data. T scores have a mean of 50 ± 10 where higher scores are indicative of greater problems. Assessments were performed at the end of each medication week during the Home Therapy Phase- placebo, low dose and moderate dose weeks. (NCT00576472)
Timeframe: Evaluated at the end of each medication week during the Home Therapy Phase- placebo, low dose and moderate dose weeks
| Intervention | Estimated T Score (Mean) |
|---|---|
| Placebo | 58.7691 |
| Low Dose | 54.7438 |
| Moderate Dose | 54.1974 |
The Conners' Teacher Rating Scale-Revised (S) is a measure of the observed frequency of behaviors associated with ADHD. Three scales are reported: Cognitive Problems/Inattention (assesses the ability to learn at the same pace as peers, organize and complete work, and concentrate for sustained periods of time), Hyperactivity (assesses the ability to sit still to complete tasks, and impulsivity) and ADHD Index (assesses risk for ADHD disorder to be corroborated by other clinical information). Raw scores are converted to T scores using age and gender normative data. T scores have a mean of 50 ± 10 where higher scores are indicative of greater problems. Assessments were performed at the end of each medication week during the Home Therapy Phase- placebo, low dose and moderate dose weeks. (NCT00576472)
Timeframe: Evaluated at the end of each medication week during the Home Therapy Phase- placebo, low dose and moderate dose weeks.
| Intervention | Estimated T Score (Mean) |
|---|---|
| Placebo | 62.7053 |
| Low Dose | 59.3272 |
| Moderate Dose | 59.6638 |
The Conners' Teacher Rating Scale-Revised (S) is a measure of the observed frequency of behaviors associated with ADHD. Three scales are reported: Cognitive Problems/Inattention (assesses the ability to learn at the same pace as peers, organize and complete work, and concentrate for sustained periods of time), Hyperactivity (assesses the ability to sit still to complete tasks, and impulsivity) and ADHD Index (assesses risk for ADHD disorder to be corroborated by other clinical information). Raw scores are converted to T scores using age and gender normative data. T scores have a mean of 50 ± 10 where higher scores are indicative of greater problems. Assessments were performed at the end of each medication week during the Home Therapy Phase- placebo, low dose and moderate dose weeks. (NCT00576472)
Timeframe: Evaluated at the end of each medication week during the Home Therapy Phase- placebo, low dose and moderate dose weeks.
| Intervention | Estimated T Score (Mean) |
|---|---|
| Placebo | 55.7638 |
| Low Dose | 52.1765 |
| Moderate Dose | 52.6495 |
Patients were randomized into two sequence groups: 1) P/M: placebo followed by MPH; 2) M/P: MPH followed by placebo. We are interested in testing the difference of effects of MPH and placebo, not in testing the difference of two sequence groups. We will use the Stroop Word-Color Association Test (Stroop) to estimate the effectiveness of MPH on laboratory measures of interference, impulsivity, cognitive flexibility, and selective attention. Stroop T scores for Color Naming Time have a mean of 50 and a standard deviation of 10. (NCT00576472)
Timeframe: Subjects were tested in both the drug and placebo groups before and after taking either MPH or placebo.
| Intervention | Estimated T Score (Mean) |
|---|---|
| MPH (Methylphenidate) | 40.7031 |
| Placebo | 39.8889 |
| MPH Versus Placebo | 0.8142 |
Patients were randomized into two sequence groups: 1) P/M: placebo followed by MPH; 2) M/P: MPH followed by placebo. We are interested in testing the difference of effects of MPH and placebo, not in testing the difference of two sequence groups. We will use the Stroop Word-Color Association Test (Stroop) to estimate the effectiveness of MPH on laboratory measures of interference, impulsivity, cognitive flexibility, and selective attention. Stroop T scores for Ink Color Naming Time have a mean of 50 and a standard deviation of 10. (NCT00576472)
Timeframe: Subjects were tested in both the drug and placebo groups before and after taking either MPH or placebo.
| Intervention | Estimated T Score (Mean) |
|---|---|
| MPH (Methylphenidate) | 45.1094 |
| Placebo | 41.7937 |
| MPH Versus Placebo | 3.3157 |
Patients were randomized into two sequence groups: 1) P/M: placebo followed by MPH; 2) M/P: MPH followed by placebo. We are interested in testing the difference of effects of MPH and placebo, not in testing the difference of two sequence groups. We will use the Stroop Word-Color Association Test (Stroop) to estimate the effectiveness of MPH on laboratory measures of interference, impulsivity, cognitive flexibility, and selective attention. Stroop T scores for Interference Score have a mean of 50 and a standard deviation of 10. (NCT00576472)
Timeframe: Subjects were tested in both the drug and placebo groups before and after taking either MPH or placebo.
| Intervention | Estimated T Score (Mean) |
|---|---|
| MPH (Methylphenidate) | 52.6875 |
| Placebo | 50.6349 |
| MPH Versus Placebo | 2.0526 |
Patients were randomized into two sequence groups: 1) P/M: placebo followed by MPH; 2) M/P: MPH followed by placebo. We are interested in testing the difference of effects of MPH and placebo, not in testing the difference of two sequence groups. We will use the Stroop Word-Color Association Test (Stroop) to estimate the effectiveness of MPH on laboratory measures of interference, impulsivity, cognitive flexibility, and selective attention. Stroop T scores for Word Naming Time have a mean of 50 and a standard deviation of 10. (NCT00576472)
Timeframe: Subjects were tested in both the drug and placebo groups before and after taking either MPH or placebo.
| Intervention | Estimated T Score (Mean) |
|---|---|
| MPH (Methylphenidate) | 39.0156 |
| Placebo | 37.8571 |
| MPH Versus Placebo | 1.1585 |
Patients were randomized into two sequence groups: 1) P/M: placebo followed by MPH; 2) M/P: MPH followed by placebo. We are interested in testing the difference of effects of MPH and placebo, not in testing the difference of two sequence groups. We will use the California Verbal Learning Test (CVLT) to estimate the effectiveness of MPH on laboratory measures of learning and recall. CVLT Z Score for Long Delay Free Recall has a mean of 0 and a standard deviation of 1. (NCT00576472)
Timeframe: Subjects were tested in both the drug and placebo groups before and after taking either MPH or placebo.
| Intervention | Estimated Z Score (Mean) |
|---|---|
| MPH (Methylphenidate) | -0.3692 |
| Placebo | -0.2090 |
| MPH Versus Placebo | -0.1603 |
Patients were randomized into two sequence groups: 1) P/M: placebo followed by MPH; 2) M/P: MPH followed by placebo. We are interested in testing the difference of effects of MPH and placebo, not in testing the difference of two sequence groups. We will use the California Verbal Learning Test (CVLT) to estimate the effectiveness of MPH on laboratory measures of learning and recall. CVLT Z Score for Short Delay Free Recall has a mean of 0 and a standard deviation of 1. (NCT00576472)
Timeframe: Subjects were tested in both the drug and placebo groups before and after taking either MPH or placebo.
| Intervention | Estimated Z Score (Mean) |
|---|---|
| MPH (Methylphenidate) | -0.3636 |
| Placebo | -0.3358 |
| MPH Versus Placebo | -0.0278 |
Patients were randomized into two sequence groups: 1) P/M: placebo followed by MPH; 2) M/P: MPH followed by placebo. We are interested in testing the difference of effects of MPH and placebo, not in testing the difference of two sequence groups. We will use the California Verbal Learning Test (CVLT) to estimate the effectiveness of MPH on laboratory measures of learning and recall. CVLT Trials 1-5 have a mean T Score of 50 and Standard Deviation of 10. (NCT00576472)
Timeframe: Subjects were tested in both the drug and placebo groups before and after taking either MPH or placebo.
| Intervention | Estimated T Score (Mean) |
|---|---|
| MPH (Methylphenidate) | 44.6970 |
| Placebo | 45.9403 |
| MPH Versus Placebo | -1.2433 |
Change in raw scores for the shortened version of the Conner's CPT from Baseline to Post-dose. The continuous performance test used during the in-lab trial was developed in house using SuperLab Pro v2.0 (Cedrus Corp., Phoenix, AZ). The test was modeled after Conners' CPT, but was shortened for ease of administration and evaluation of short-form sensitivity. The test is one-sixth the length of the Conners' CPT, lasting 2.33 min with 54 total targets and six nontargets (10% of trials). Similar to the Conners' CPT, the interstimulus intervals also varied by trial blocks with lengths of 1, 2, or 4 s. D' and β are derived variables from signal detection theory. β is a measure of response tendency; higher scores indicate a more conservative response pattern. β was calculated using the formula = -d'*.5*(NORMSINV(hits)-NORMSINV(false alarms)). In the case where the false alarm rate = 0 or the hit rate = 1.0, we used the standard correction of 1/2N and 1- 1/2N, respectively. (NCT00576472)
Timeframe: Subjects were tested in both the drug and placebo groups before and after taking either MPH or placebo.
| Intervention | Estimated raw score (Mean) |
|---|---|
| MPH (Methylphenidate) | 0.2300 |
| Placebo | 0.2647 |
| MPH Versus Placebo | -0.0346 |
Change in raw scores for the shortened version of the Conner's CPT from Baseline to Post-dose. The continuous performance test used during the in-lab trial was developed in house using SuperLab Pro v2.0 (Cedrus Corp., Phoenix, AZ). The test was modeled after Conners' CPT, but was shortened for ease of administration and evaluation of short-form sensitivity. The test is one-sixth the length of the Conners' CPT, lasting 2.33 min with 54 total targets and six nontargets (10% of trials). Similar to the Conners' CPT, the interstimulus intervals also varied by trial blocks with lengths of 1, 2, or 4 s. Commission errors are the raw score for the numbers of nontargets presented where the subject incorrectly responded. Accordingly, the range for this variable is 0-6 with a higher score indicative of worse performance or impulsivity. (NCT00576472)
Timeframe: Subjects were tested in both the drug and placebo groups before and after taking either MPH or placebo.
| Intervention | Estimated raw score (Mean) |
|---|---|
| MPH (Methylphenidate) | 3.6984 |
| Placebo | 3.5970 |
| MPH Versus Placebo | 0.1014 |
Change in raw scores for the shortened version of the Conner's CPT from Baseline to Post-dose. The continuous performance test used during the in-lab trial was developed in house using SuperLab Pro v2.0 (Cedrus Corp., Phoenix, AZ). The test was modeled after Conners' CPT, but was shortened for ease of administration and evaluation of short-form sensitivity. The test is one-sixth the length of the Conners' CPT, lasting 2.33 min with 54 total targets and six nontargets (10% of trials). Similar to the Conners' CPT, the interstimulus intervals also varied by trial blocks with lengths of 1, 2, or 4 s. D' and β are derived variables from signal detection theory. D' is a measure of sensitivity of a person to the signal or target; a higher score is indicative of better performance or better sustained attention. D' was calculated as z(hit) - z(commission). Z-scores were calculated using the NORMSINV function in Microsoft Excel. (NCT00576472)
Timeframe: Subjects were tested in both the drug and placebo groups before and after taking either MPH or placebo.
| Intervention | Estimated raw score (Mean) |
|---|---|
| MPH (Methylphenidate) | 1.6809 |
| Placebo | 1.7972 |
| MPH Versus Placebo | -0.1163 |
Change in raw scores for the shortened version of the Conner's CPT from Baseline to Post-dose. The continuous performance test used during the in-lab trial was developed in house using SuperLab Pro v2.0 (Cedrus Corp., Phoenix, AZ). The test was modeled after Conners' CPT, but was shortened for ease of administration and evaluation of short-form sensitivity. The test is one-sixth the length of the Conners' CPT, lasting 2.33 min with 54 total targets and six nontargets (10% of trials). Similar to the Conners' CPT, the interstimulus intervals also varied by trial blocks with lengths of 1, 2, or 4 s. Hit reaction time is average reaction time in milliseconds for all correct responses when targets were presented. There is no pre-defined range for reaction time; higher score is indicative of slower processing speed. (NCT00576472)
Timeframe: Subjects were tested in both the drug and placebo groups before and after taking either MPH or placebo.
| Intervention | Estimated raw score (Mean) |
|---|---|
| MPH (Methylphenidate) | 350.0590 |
| Placebo | 354.8515 |
| MPH Versus Placebo | -4.7925 |
Change in raw scores for the shortened version of the Conner's CPT from Baseline to Post-dose. The continuous performance test used during the in-lab trial was developed in house using SuperLab Pro v2.0 (Cedrus Corp., Phoenix, AZ). The test was modeled after Conners' CPT, but was shortened for ease of administration and evaluation of short-form sensitivity. The test is one-sixth the length of the Conners' CPT, lasting 2.33 min with 54 total targets and six nontargets (10% of trials). Similar to the Conners' CPT, the interstimulus intervals also varied by trial blocks with lengths of 1, 2, or 4 s. Omission errors are the raw score for the number of targets presented where the subject did not respond. Accordingly, the range for this variable is 0-54 with a higher score indicative of worse performance or problems with sustained attention. (NCT00576472)
Timeframe: Subjects were tested in both the drug and placebo groups before and after taking either MPH or placebo.
| Intervention | Estimated raw score (Mean) |
|---|---|
| MPH (Methylphenidate) | 1.8889 |
| Placebo | 1.6269 |
| MPH Versus Placebo | 0.2620 |
The Conners' Teacher Rating Scale- Revised (S) is a measure of the observed frequency of behaviors associated with ADHD. Twenty-seven questions are rated on a scale from 0 (not true at all) to 3 (very much true). Raw scores are converted to T scores using age and gender normative data. T scores have a mean of 50 ± 10 where higher scores are indicative of greater problems. Assessments were done weekly during the 3-week Home Crossover Period with the best response being used as the measurement for the test. (NCT00576472)
Timeframe: weekly during 3-week home crossover phase
| Intervention | T score (Mean) | |||
|---|---|---|---|---|
| Oppositional T Score | Cognitive Problems/Inattention T Score | Hyperactivity T Score | Adhd T Score | |
| Low Dose | 50.87 | 53.14 | 51.14 | 53.08 |
| Moderate Dose | 50.44 | 51.72 | 50.63 | 52.23 |
| Placebo | 49.49 | 55.64 | 51.96 | 55.45 |
Academic performance will be measured by student report cards, and converted to a standardized scale (NCT02094612)
Timeframe: Baseline and Six Months
| Intervention | () |
|---|---|
| Usual Care | 0 |
| Usual Care Plus Assessment | 0 |
"Update: Outcome reported is number of participants taking medication as prescribed at all study follow up visits.~Sustained use of ADHD medication" (NCT02094612)
Timeframe: Baseline to six months
| Intervention | Participants (Count of Participants) |
|---|---|
| Usual Care | 18 |
| Usual Care Plus Assessment | 17 |
Outcome measure reported is the number of participants with at least one 25% reduction in SNAP between visits. In treatment of ADHD, the therapeutic dose is defined as a 25% reduction in SNAP IV score between consecutive clinic visits. SNAP is itemized rating scale (Swanson, Nolan, and Pelham-IV Questionnaire) designed to measure ADHD symptoms and severity on a 4 point scale. It is based on DSM IV criteria, and is designed to measure attention deficit hyperactivity disorder (ADHD) and oppositional defiant disorder (ODD) symptoms in children and young adults ages 6-18. (NCT02094612)
Timeframe: One month, 3 month and six month follow ups
| Intervention | Participants (Count of Participants) |
|---|---|
| Usual Care | 29 |
| Usual Care Plus Assessment | 23 |
"Update: Outcome measure reported is the # of participants who attended all study follow-up visits.~Use of pediatric health care services" (NCT02094612)
Timeframe: Baseline to Six Months
| Intervention | Participants (Count of Participants) |
|---|---|
| Usual Care | 30 |
| Usual Care Plus Assessment | 25 |
"Update: Outcome measure reported is number of participants who responded very satisfied with their ADHD care on 5-point Likert scale.~Likert scale single item measure of how satisfied the pediatric patient's parent was with care received" (NCT02094612)
Timeframe: Six months
| Intervention | Participants (Count of Participants) |
|---|---|
| Usual Care | 28 |
| Usual Care Plus Assessment | 20 |
"Outcomes reported are average SNAP IV scores at baseline and 6 monhts. ADHD symptomatology is measured by the Swanson, Nolan and Pelham Teacher and Parent Rating Scale (SNAP-IV), developed by James Swanson, Edith Nolan and William Pelham. We used the 18-item self-report inventory designed to measure attention deficit hyperactivity disorder (ADHD) symptoms in children and young adults. Each question measures the frequency of a variety of symptoms or behaviors.The subscales measure Inattention (9 items) and Hyperactivity/impulsivity (9 items), using 0-3 rating, 0=not at all, 1=just a little, 2=quite a bit, or 3=very much. Each 9-item subscale results in a score in range 0-27. The two subscale scores were averaged to create a single score for the 18-item SNAP." (NCT02094612)
Timeframe: 6 months post baseline
| Intervention | Score on a scale (Mean) | |
|---|---|---|
| Average SNAP score at baseline | Average SNAP score at 6 months | |
| Usual Care | 17.4 | 9.0 |
| Usual Care Plus Assessment | 15.0 | 8.6 |
"Update: Outcome measure reported is number of psychiatric and ED visits during the 6 month follow up period.~Use of healthcare services outside of pediatrics, including the emergency room and psychiatric services." (NCT02094612)
Timeframe: Baseline to six months
| Intervention | visits (Number) | |
|---|---|---|
| Number of psych visits | Number of ED visits | |
| Usual Care | 26 | 4 |
| Usual Care Plus Assessment | 22 | 2 |
The CGI-I scale summarizes the clinician's impression of the participant's symptom improvement and ranges from 1-7 with 1 representing very much improved and 7 representing very much worse. (NCT02255565)
Timeframe: once a week for 6 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Very Low Dose Quillivant XR - Week 1 | 3.89 |
| Very Low Dose Quillivant XR - Week 2 | 3.56 |
| Very Low Dose Quillivant XR - Week 3 | 3.44 |
| Very Low Dose Quillivant XR - Week 4 | 3.22 |
| Very Low Dose Quillivant XR - Week 5 | 3.00 |
| Very Low Dose Quillivant XR - Week 6 | 2.89 |
| Low Dose Quillivant XR - Week 1 | 3.78 |
| Low Dose Quillivant XR - Week 2 | 3.00 |
| Low Dose Quillivant XR - Week 3 | 2.22 |
| Low Dose Quillivant XR - Week 4 | 1.63 |
| Low Dose Quillivant XR - Week 5 | 2.13 |
| Low Dose Quillivant XR - Week 6 | 2.00 |
| Moderate Dose Quillivant XR - Week 1 | 3.33 |
| Moderate Dose Quillivant XR - Week 2 | 3.11 |
| Moderate Dose Quillivant XR - Week 3 | 2.67 |
| Moderate Dose Quillivant XR - Week 4 | 2.89 |
| Moderate Dose Quillivant XR - Week 5 | 2.56 |
| Moderate Dose Quillivant XR - Week 6 | 2.22 |
The CGI-S scale summarizes the clinician's impression of the participant's symptom severity and ranges from 1-7 with 1 representing normal (not at all ill) and 7 representing extremely ill. (NCT02255565)
Timeframe: once a week for 6 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Very Low Dose Quillivant XR - Week 1 | 4.78 |
| Very Low Dose Quillivant XR - Week 2 | 4.33 |
| Very Low Dose Quillivant XR - Week 3 | 4.44 |
| Very Low Dose Quillivant XR - Week 4 | 4.33 |
| Very Low Dose Quillivant XR - Week 5 | 4.11 |
| Very Low Dose Quillivant XR - Week 6 | 4.00 |
| Low Dose Quillivant XR - Week 1 | 4.33 |
| Low Dose Quillivant XR - Week 2 | 4.00 |
| Low Dose Quillivant XR - Week 3 | 3.67 |
| Low Dose Quillivant XR - Week 4 | 2.75 |
| Low Dose Quillivant XR - Week 5 | 2.88 |
| Low Dose Quillivant XR - Week 6 | 2.78 |
| Moderate Dose Quillivant XR - Week 1 | 4.89 |
| Moderate Dose Quillivant XR - Week 2 | 4.56 |
| Moderate Dose Quillivant XR - Week 3 | 4.11 |
| Moderate Dose Quillivant XR - Week 4 | 4.00 |
| Moderate Dose Quillivant XR - Week 5 | 3.56 |
| Moderate Dose Quillivant XR - Week 6 | 3.44 |
Measures the severity of Total ADHD symptoms, Inattention and Hyperactivity/Impulsive symptoms. The Inattention and Hyperactivity/Impulsive symptoms can range from 0 to 27 each, with a higher score reflecting more severe ADHD symptoms. The total score is calculated by summing the inattention and Hyperactivity/Impulsive subscales. The total score can range from 0 to 54 with a higher score reflecting more severe ADHD symptoms. (NCT02255565)
Timeframe: once a week for 6 weeks
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Inattention Subscale Score | Hyperactivity Subscale Score | Total Score | |
| Low Dose Quillivant XR - Week 1 | 16.33 | 15.33 | 31.67 |
| Low Dose Quillivant XR - Week 2 | 14.00 | 14.33 | 28.33 |
| Low Dose Quillivant XR - Week 3 | 12.00 | 10.22 | 22.22 |
| Low Dose Quillivant XR - Week 4 | 8.38 | 6.88 | 15.25 |
| Low Dose Quillivant XR - Week 5 | 9.50 | 9.38 | 18.88 |
| Low Dose Quillivant XR - Week 6 | 9.56 | 6.56 | 16.11 |
| Moderate Dose Quillivant XR - Week 1 | 18.11 | 12.78 | 30.89 |
| Moderate Dose Quillivant XR - Week 2 | 14.67 | 11.33 | 26.00 |
| Moderate Dose Quillivant XR - Week 3 | 13.67 | 11.78 | 25.44 |
| Moderate Dose Quillivant XR - Week 4 | 13.56 | 9.67 | 23.22 |
| Moderate Dose Quillivant XR - Week 5 | 13.00 | 9.22 | 22.22 |
| Moderate Dose Quillivant XR - Week 6 | 11.78 | 7.33 | 19.11 |
| Very Low Dose Quillivant XR - Week 1 | 17.89 | 12.44 | 30.33 |
| Very Low Dose Quillivant XR - Week 2 | 16.78 | 10.56 | 27.33 |
| Very Low Dose Quillivant XR - Week 3 | 16.67 | 11.56 | 28.22 |
| Very Low Dose Quillivant XR - Week 4 | 14.33 | 12.33 | 26.67 |
| Very Low Dose Quillivant XR - Week 5 | 14.56 | 9.22 | 23.78 |
| Very Low Dose Quillivant XR - Week 6 | 12.89 | 8.78 | 21.67 |
"The Aberrant Behavior Checklist (ABC) is a symptom checklist for assessing problem behaviors in individuals ages 6 to 54 with mental retardation. The full ABC is a 58-item parent-rating with five factors: Irritability, Social Withdrawal, Stereotypy, Hyperactivity and Inappropriate Speech.~The 16-item Hyperactivity subscale covers over-activity (7 items), impulsiveness (2 items), inattention (3 items) and noncompliance (4 items). It has been used as a primary outcome measure in several trials of children with developmental disabilities. The interpretation of the tool and its sub-scales is that a greater number of items, indicates greater severity. The range of scores is 0 to 48." (NCT01238575)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Extended-release Guanfacine | 34.4 |
| Inactive Placebo | 34.25 |
The Aberrant Behavior Checklist (ABC) is a symptom checklist for assessing problem behaviors in individuals ages 6 to 54 with mental retardation. The full ABC is a 58-item parent-rating with five factors: Irritability, Social Withdrawal, Stereotypy, Hyperactivity and Inappropriate Speech. The 16-item Hyperactivity subscale covers over-activity (7 items), impulsiveness (2 items), inattention (3 items) and noncompliance (4 items). It has been used as a primary outcome measure in several trials of children with developmental disabilities. The interpretation of the tool and its sub-scales is that a greater number of items, indicates greater severity. The range of scores is 0 to 48. (NCT01238575)
Timeframe: Week 8
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Extended-release Guanfacine | 19.3 |
| Inactive Placebo | 29.7 |
The Aberrant Behavior Checklist (ABC) is a symptom checklist for assessing problem behaviors in individuals ages 6 to 54 with mental retardation. The full ABC is a 58-item parent-rating with five factors: Irritability, Social Withdrawal, Stereotypy, Hyperactivity and Inappropriate Speech. It has been used as a primary outcome measure in several trials of children with developmental disabilities. The interpretation of the tool and its sub-scales is that a greater number of items, indicates greater severity. This subscale's scores can range from 0 to 12. (NCT01238575)
Timeframe: 8 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Extended-release Guanfacine | 4.2 |
| Inactive Placebo | 5.99 |
The Aberrant Behavior Checklist (ABC) is a symptom checklist for assessing problem behaviors in individuals ages 6 to 54 with mental retardation. The full ABC is a 58-item parent-rating with five factors: Irritability, Social Withdrawal, Stereotypy, Hyperactivity and Inappropriate Speech. It has been used as a primary outcome measure in several trials of children with developmental disabilities. The interpretation of the tool and its sub-scales is that a greater number of items, indicates greater severity. This subscale's scores can range from 0 to 12. (NCT01238575)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Extended-release Guanfacine | 6.33 |
| Inactive Placebo | 6.84 |
The Aberrant Behavior Checklist (ABC) is a symptom checklist for assessing problem behaviors in individuals ages 6 to 54 with mental retardation. It is a 58 item checklist which takes about 10 - 15 minutes to complete. There are five subscales: a) Irritability and Agitation b) Lethargy and Social Withdrawal c) Stereotypic Behavior d) Hyperactivity and Noncompliance and e) Inappropriate Speech. The higher the number of items (score), the greater the amount of symptoms. Scores can range from 0 to 45. (NCT01238575)
Timeframe: 8 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Extended-release Guanfacine | 13.5 |
| Inactive Placebo | 16.1 |
The Aberrant Behavior Checklist (ABC) is a symptom checklist for assessing problem behaviors in individuals ages 6 to 54 with mental retardation. The full ABC is a 58-item parent-rating with five factors: Irritability, Social Withdrawal, Stereotypy, Hyperactivity and Inappropriate Speech. It has been used as a primary outcome measure in several trials of children with developmental disabilities. The interpretation of the tool and its sub-scales is that a greater number of items, indicates greater severity. Scores for this subscale can range from 0 to 45. (NCT01238575)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Extended-release Guanfacine | 20.3 |
| Inactive Placebo | 18.06 |
The Aberrant Behavior Checklist (ABC) is a symptom checklist for assessing problem behaviors in individuals ages 6 to 54 with mental retardation. The full ABC is a 58-item parent-rating with five factors: Irritability, Social Withdrawal, Stereotypy, Hyperactivity and Inappropriate Speech. It has been used as a primary outcome measure in several trials of children with developmental disabilities. The interpretation of the tool and its sub-scales is that a greater number of items, indicates greater severity. This subscale's scores can range from 0 to 48. (NCT01238575)
Timeframe: 8 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Extended-release Guanfacine | 9.8 |
| Inactive Placebo | 8.6 |
The Aberrant Behavior Checklist (ABC) is a symptom checklist for assessing problem behaviors in individuals ages 6 to 54 with mental retardation. The full ABC is a 58-item parent-rating with five factors: Irritability, Social Withdrawal, Stereotypy, Hyperactivity and Inappropriate Speech. It has been used as a primary outcome measure in several trials of children with developmental disabilities. The interpretation of the tool and its sub-scales is that a greater number of items, indicates greater severity. This subscale's scores can range from 0 to 48. (NCT01238575)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Extended-release Guanfacine | 13.6 |
| Inactive Placebo | 12.06 |
The Aberrant Behavior Checklist (ABC) is a symptom checklist for assessing problem behaviors in individuals ages 6 to 54 with mental retardation. The full ABC is a 58-item parent-rating with five factors: Irritability, Social Withdrawal, Stereotypy, Hyperactivity and Inappropriate Speech. It has been used as a primary outcome measure in several trials of children with developmental disabilities. The interpretation of the tool and its sub-scales is that a greater number of items, indicates greater severity. This subscale's scores can range from 0 to 21. (NCT01238575)
Timeframe: 8 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Extended-release Guanfacine | 3.6 |
| Inactive Placebo | 5.9 |
The Aberrant Behavior Checklist (ABC) is a symptom checklist for assessing problem behaviors in individuals ages 6 to 54 with mental retardation. The full ABC is a 58-item parent-rating with five factors: Irritability, Social Withdrawal, Stereotypy, Hyperactivity and Inappropriate Speech. It has been used as a primary outcome measure in several trials of children with developmental disabilities. The interpretation of the tool and its sub-scales is that a greater number of items, indicates greater severity. This subscale's scores can range from 0 to 21. (NCT01238575)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Extended-release Guanfacine | 8.53 |
| Inactive Placebo | 9.31 |
The ADHD Rating Scale (ADHD-RS) is an 18-item scale directly derived from DSM-IV criteria for Attention Deficit Hyperactivity Disorder with established reliability, validity and sensitivity to change. The ADHD Rating Scale-IV is completed independently by the parent and scored by a clinician. The scale consists of 2 subscales: inattention (9 items) and hyperactivity-impulsivity (9 items). If 3 or more items are skipped, the clinician should use extreme caution in interpreting the scale. Results from this rating scale alone should not be used to make a diagnosis. This subscale can range from 0 to 27 for scoring, with a higher score indicating greater severity. (NCT01238575)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Extended-release Guanfacine | 19.00 |
| Inactive Placebo | 19.5 |
The ADHD Rating Scale (ADHD-RS) is an 18-item scale directly derived from DSM-IV criteria for Attention Deficit Hyperactivity Disorder with established reliability, validity and sensitivity to change. The ADHD Rating Scale-IV is completed independently by the parent and scored by a clinician. The scale consists of 2 subscales: inattention (9 items) and hyperactivity-impulsivity (9 items). If 3 or more items are skipped, the clinician should use extreme caution in interpreting the scale. Results from this rating scale alone should not be used to make a diagnosis. This subscale can range from 0 to 27 for scoring,with a higher score indicating greater severity. (NCT01238575)
Timeframe: 8 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Extended-release Guanfacine | 10.6 |
| Inactive Placebo | 18.7 |
The ADHD Rating Scale (ADHD-RS) is an 18-item scale directly derived from DSM-IV criteria for Attention Deficit Hyperactivity Disorder with established reliability, validity and sensitivity to change. The ADHD Rating Scale-IV is completed independently by the parent and scored by a clinician. The scale consists of 2 subscales: inattention (9 items) and hyperactivity-impulsivity (9 items). If 3 or more items are skipped, the clinician should use extreme caution in interpreting the scale. Results from this rating scale alone should not be used to make a diagnosis. This subscale can range from 0 to 27 for scoring, with a higher score indicating greater severity. (NCT01238575)
Timeframe: 8 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Extended-release Guanfacine | 14.7 |
| Inactive Placebo | 19.5 |
The ADHD Rating Scale (ADHD-RS) is an 18-item scale directly derived from DSM-IV criteria for Attention Deficit Hyperactivity Disorder with established reliability, validity and sensitivity to change. The ADHD Rating Scale-IV is completed independently by the parent and scored by a clinician. The scale consists of 2 subscales: inattention (9 items) and hyperactivity-impulsivity (9 items). If 3 or more items are skipped, the clinician should use extreme caution in interpreting the scale. Results from this rating scale alone should not be used to make a diagnosis. This subscale can range from 0 to 27 for scoring, with a higher score indicating greater severity. (NCT01238575)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Extended-release Guanfacine | 20.53 |
| Inactive Placebo | 20.41 |
The ADHD Rating Scale (ADHD-RS) is an 18-item scale directly derived from DSM-IV criteria for Attention Deficit Hyperactivity Disorder with established reliability, validity and sensitivity to change. The ADHD Rating Scale-IV is completed independently by the parent and scored by a clinician. The scale consists of 2 subscales: inattention (9 items) and hyperactivity-impulsivity (9 items). If 3 or more items are skipped, the clinician should use extreme caution in interpreting the scale. Results from this rating scale alone should not be used to make a diagnosis. The total score can range from 0 to 54, with a higher score indicating greater severity. (NCT01238575)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Extended-release Guanfacine | 39.53 |
| Inactive Placebo | 39.91 |
The ADHD Rating Scale (ADHD-RS) is an 18-item scale directly derived from DSM-IV criteria for Attention Deficit Hyperactivity Disorder with established reliability, validity and sensitivity to change. The ADHD Rating Scale-IV is completed independently by the parent and scored by a clinician. The scale consists of 2 subscales: inattention (9 items) and hyperactivity-impulsivity (9 items). If 3 or more items are skipped, the clinician should use extreme caution in interpreting the scale. Results from this rating scale alone should not be used to make a diagnosis. The total score can range from 0 to 54, with a higher score indicating greater severity. (NCT01238575)
Timeframe: Week 8
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Extended-release Guanfacine | 25.2 |
| Inactive Placebo | 38.0 |
"Scans will be analyzed for task-related prefrontal activation~Difference Score: Percent Signal Change in Regions of Interest (ketamine - saline)" (NCT01600885)
Timeframe: Within 4 hours of dose administration, after up to 1.25 hours of ketamine infusion
| Intervention | percent change in saline signal (Mean) |
|---|---|
| Guanfacine | -0.17 |
| Placebo | -0.094 |
Difference Score: Percent Signal Change in Regions of Interest (ketamine - saline) (NCT01600885)
Timeframe: Within 4 hours of dose administration, after up to 1.25 hours of ketamine infusion
| Intervention | percent change in saline signal (Mean) |
|---|---|
| Guanfacine | -0.1 |
| Placebo | 0.052 |
Difference Score: Percent Signal Change in Regions of Interest (ketamine - saline) (NCT01600885)
Timeframe: Within 4 hours of dose administration, after up to 1.25 hours of ketamine infusion
| Intervention | percent change in saline signal (Mean) |
|---|---|
| Guanfacine | -0.134 |
| Placebo | -0.086 |
Each subject viewed shapes and faces on multiple trials. The subject matched faces or shapes on each trial. BOLD activity during shape trials was subtracted from BOLD activity during Face trials and this value was compared on drug vs. placebo trials. (NCT00778310)
Timeframe: Placebo and Drug day, 1-2 weeks apart
| Intervention | Face-Shape BOLD signal difference (Mean) | |
|---|---|---|
| Amygdala | Fusiform Gyrus | |
| Adults Drug Condition | 1.79 | 1.46 |
| Adults Placebo Condition | 0.58 | 1.64 |
| Children Drug Condition | 1.43 | 1.99 |
| Children Placebo Condition | 0.77 | 1.06 |
"To evaluate clinical progression of PD as assessed by the MDS-UPDRS, combined score, Parts I, II, and III.~Part I - non-motor experiences of daily living; Part II - motor experiences of daily living; Part III - motor examination. Parts I and II each contain 13 questions measured on a 5-point scale (0-4). Part III contains 18 objective rater assessments of the motor signs of PD measured on a 5-point scale (0-4).~Total range for combined score (Part I-III) is = 0-176. Generally for MDS-UPDRS scores and sub-scores, the lower the score, the better.~Parts I, II, and III are summed to make the total score." (NCT02202551)
Timeframe: Up to 101 weeks. MDS-UPDRS was performed at the following visits: Screening, Week 8, Week 16, Week 28, Week 40, Week 52, Week 64, Week 76, Week 88, Week 100 (or ET).
| Intervention | units on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change from Baseline at Week 8 | Change from Baseline at Week 16 | Change from Baseline at Week 28 | Change from Baseline at Week 40 | Change from Baseline at Week 52 | Change from Baseline at Week 64 | Change from Baseline at Week 76 | Change from Baseline at Week 88 | Change from Baseline at Week 100 | |
| ADS-5102 1A | 41.8 | 1.2 | 1.6 | 4.8 | 7.5 | 13.2 | 8.8 | 11.7 | 11.3 | 11.4 |
| ADS-5102 Group 1P | 45.6 | -2.8 | -1.4 | 1.5 | -0.4 | 2.6 | 2.6 | 7.3 | 3.7 | 3.7 |
| ADS-5102 Group 2 | 52.8 | 0.8 | 5.7 | 6.5 | 1.6 | 6.1 | 6.1 | 9.4 | 6.4 | 6.5 |
| ADS-5102 Group 3 | 52.4 | -5.3 | -5.2 | -5.3 | -4.8 | -4.6 | -4.6 | -4.9 | 0.9 | 4.1 |
"This component (Questions 4.1 - 4.6) includes time spent with dyskinesia, functional impact of dyskinesia, time spent in OFF state, functional impact of fluctuations, complexity of motor fluctuations, painful OFF-state dystonia. Questions 4.1-4.6 are summed to make the Part IV score.~Generally for MDS-UPDRS scores and sub-scores, the lower the score, the better. Total range for Part IV is = 0-24" (NCT02202551)
Timeframe: 100 Weeks. MDS-UPDRS was performed at the following visits: Screening, Week 8, Week 16, Week 28, Week 40, Week 52, Week 64, Week 76, Week 88, Week 100 (or ET).
| Intervention | units on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change in Baseline from Week 8 | Change in Baseline from Week 16 | Change from Baseline at Week 28 | Change from Baseline at Week 40 | Change from Baseline at Week 52 | Change from Baseline at Week 64 | Change from Baseline at Week 76 | Change from Baseline at Week 88 | Change from Baseline at Week 100 | |
| Group 1a | 6.5 | -0.2 | -0.8 | -0.3 | 0.0 | 0.2 | 0.4 | 0.9 | 0.4 | 0.4 |
| Group 1P | 9.6 | -3.4 | -3.2 | -3.3 | -2.8 | -2.9 | -3.3 | -2.9 | -2.8 | -2.4 |
| Group 2 | 9.8 | -3.6 | -1.1 | -1.4 | -2.9 | -2.5 | -1.9 | -2.7 | -3.7 | -3.6 |
| Group 3 | 10.4 | -4.0 | -3.9 | -4.4 | -4.7 | -3.6 | -2.5 | -3.7 | -4.3 | -3.6 |
The primary objective of the study was to evaluate the safety and tolerability of ADS-5102 oral capsules, an extended release (ER) formulation of amantadine, administered at a dose of 340 mg once daily at bedtime for the treatment of levodopa-induced dyskinesia (LID) in subjects with Parkinson's disease (PD). (NCT02202551)
Timeframe: Up to 101 weeks
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| AE | Study drug-related AE | SAEs | Permanent discontinuation due to AE | Permanent discontinuation due to drug-related AE | Mild AEs | Moderate AEs | Mild drug-related AE | Moderate drug-related AE | Severe drug-related AE | |
| Group 1a | 57 | 31 | 16 | 12 | 4 | 12 | 25 | 16 | 12 | 3 |
| Group 1P | 70 | 45 | 21 | 21 | 15 | 13 | 36 | 15 | 23 | 7 |
| Group 2 | 23 | 16 | 6 | 6 | 4 | 3 | 13 | 3 | 12 | 1 |
| Group 3 | 55 | 32 | 17 | 10 | 8 | 11 | 26 | 5 | 22 | 5 |
"The ABC-C is a global behavior checklist implemented for the measurement of drug and other treatment effects in populations with intellectual disability. Behavior based on 58 items that describe various behavioral problems.~Each item is rated on the parents perceived severity of the behavior. The answer options for each item are:~0 = Not a problem~= Problem but slight in degree~= Moderately serious problem~= Severe in degree~The measure is broken down into the following subscales with individual ranges as follows:~Subscale I (Irritability): 15 items, score range = 0-45 Subscale II (Lethargy): 16 items, score range = 0-48 Subscale III (Stereotypy): 7 items, score range = 0-21 Subscale IV (Hyperactivity): 16 items, score range = 0-48 Subscale V (Inappropriate Speech) was not included in the breakdown because it was not applicable (no participants in the study had verbal language)." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention: Subscale I | Visit 3 - First Intervention: Subscale I | Visit 5 - First Intervention: Subscale I | Visit 6 - Second Intervention: Subscale I | Visit 8 - Second Intervention: Subscale I | Visit 10 - Second Intervention: Subscale I | Follow-up: Subscale I (Irritability) | Visit 1 - First Intervention: Subscale II | Visit 3 - First Intervention: Subscale II | Visit 5 - First Intervention: Subscale II | Visit 6 - Second Intervention: Subscale II | Visit 8 - Second Intervention: Subscale II | Visit 10 - Second Intervention: Subscale II | Follow-up: Subscale II (Lethargy) | Visit 1 - First Intervention: Subscale III | Visit 3 - First Intervention: Subscale III | Visit 5 - First Intervention: Subscale III | Visit 6 - Second Intervention: Subscale III | Visit 8 - Second Intervention: Subscale III | Visit 10 - Second Intervention: Subscale III | Follow-up: Subscale III (Stereotypy) | Visit 1 - First Intervention: Subscale IV | Visit 3 - First Intervention: Subscale IV | Visit 5 - First Intervention: Subscale IV | Visit 6 - Second Intervention: Subscale IV | Visit 8 - Second Intervention: Subscale IV | Visit 10 - Second Intervention: Subscale IV | Follow-up: Subscale IV (Hyperactivity) | |
| Placebo First, Then rhIGF-1 | 9.00 | 9.00 | 7.00 | 7.00 | 4.00 | 5.00 | 3.00 | 13.00 | 11.00 | 9.00 | 11.00 | 8.00 | 6.00 | 6.00 | 13.00 | 10.00 | 11.00 | 11.00 | 10.00 | 8.00 | 8.00 | 13.00 | 12.00 | 11.00 | 11.00 | 7.00 | 10.00 | 9.00 |
| rhIGF-1 First, Then Placebo | 6.00 | 4.00 | 2.00 | 4.00 | 3.00 | 5.00 | 2.00 | 8.00 | 7.00 | 6.00 | 5.00 | 5.00 | 4.00 | 5.00 | 12.00 | 10.00 | 9.00 | 11.00 | 9.00 | 9.00 | 9.00 | 8.00 | 8.00 | 6.00 | 7.00 | 4.00 | 5.00 | 5.00 |
"Remaining subscales of the ADAMS that are not primary outcome measures include: Manic/hyperactive, Depressed mood, General anxiety, Obsessive/compulsive behavior.~The range for each subscale is as follows:~Manic/Hyperactive Behavior: 0-15 Depressed Mood: 0-21 General Anxiety: 0-21 Obsessive/Compulsive Behavior: 0-9~The higher the score for each subscale, the more problematic the behavior." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | |||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1- First Intervention: Manic/Hyperactive | Visit 2- First Intervention: Manic/Hyperactive | Visit 3- First Intervention: Manic/Hyperactive | Visit 4- First Intervention: Manic/Hyperactive | Visit 5- First Intervention: Manic/Hyperactive | Visit 6- Second Intervention: Manic/Hyperactive | Visit 7- Second Intervention: Manic/Hyperactive | Visit 8- Second Intervention: Manic/Hyperactive | Visit 9- Second Intervention: Manic/Hyperactive | Visit 10- First Intervention: Manic/Hyperactive | Follow-up: Manic/Hyperactive Subscale | Visit 1- First Intervention: Depressed Mood | Visit 2- First Intervention: Depressed Mood | Visit 3- First Intervention: Depressed Mood | Visit 4- First Intervention: Depressed Mood | Visit 5- First Intervention: Depressed Mood | Visit 6- Second Intervention: Depressed Mood | Visit 7- Second Intervention: Depressed Mood | Visit 8- Second Intervention: Depressed Mood | Visit 9- Second Intervention: Depressed Mood | Visit 10- Second Intervention: Depressed Mood | Follow-up: Depressed Mood Subscale | Visit 1- First Intervention: General Anxiety | Visit 2- First Intervention: General Anxiety | Visit 3- First Intervention: General Anxiety | Visit 4- First Intervention: General Anxiety | Visit 5- First Intervention: General Anxiety | Visit 6- Second Intervention: General Anxiety | Visit 7- Second Intervention: General Anxiety | Visit 8- Second Intervention: General Anxiety | Visit 9- Second Intervention: General Anxiety | Visit 10- Second Intervention: General Anxiety | Follow-up: General Anxiety Subscale | Visit 1- First Intervention: Obsessive Compulsive | Visit 2- First Intervention: Obsessive Compulsive | Visit 3- First Intervention: Obsessive Compulsive | Visit 4- First Intervention: Obsessive Compulsive | Visit 5- First Intervention: Obsessive Compulsive | Visit 6- Second Intervention: Obsessive Compulsive | Visit 7- Second Intervention: Obsessive Compulsive | Visit 8- Second Intervention: Obsessive Compulsive | Visit 9- Second Intervention: Obsessive Compulsive | Visit 10- First Intervention: Obsessive Compulsive | Follow-up: Obsessive Compulsive Behavior Subscale | |
| Placebo First, Then rhIGF-1 | 8.00 | 7.00 | 7.00 | 7.00 | 7.00 | 8.00 | 6.50 | 6.00 | 6.00 | 5.00 | 5.00 | 2.00 | 4.00 | 3.00 | 2.00 | 2.00 | 2.00 | 3.00 | 2.00 | 3.00 | 2.00 | 2.00 | 8.00 | 6.00 | 6.00 | 5.00 | 5.00 | 6.00 | 6.00 | 6.00 | 4.00 | 4.00 | 5.50 | 4.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | 3.50 |
| rhIGF-1 First, Then Placebo | 7.00 | 7.00 | 6.00 | 5.00 | 4.00 | 6.00 | 5.00 | 5.00 | 4.00 | 4.50 | 5.00 | 4.00 | 5.00 | 3.00 | 3.00 | 4.00 | 4.00 | 3.00 | 3.00 | 2.00 | 3.00 | 3.50 | 6.00 | 7.00 | 6.00 | 5.00 | 5.00 | 7.00 | 5.00 | 4.00 | 3.00 | 4.00 | 4.00 | 3.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | 2.50 | 3.00 |
"The ADAMS is completed by the parent/caregiver/LAR and consists of 29 items which are scored on a 4-point rating scale that combines frequency and severity ratings. The instructions ask the rater to describe the individual's behavior over the last six months on the following scale: 0 if the behavior has not occurred, 1 if the behavior occurs occasionally or is a mild problem, 2 if the behavior occurs quite often or is moderate problem, or 3 if the behavior occurs a lot or is a severe problem.~The Social Avoidance subscale of the ADAMS will be used as a primary outcome measure for this trial. The range for this subscale is 0-21. The higher the subscale score, the more problematic the behavior." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 6.00 | 5.00 | 5.00 | 6.00 | 5.00 | 4.00 | 4.00 | 4.00 | 3.00 | 3.50 | 4.00 |
| rhIGF-1 First, Then Placebo | 4.00 | 5.00 | 4.00 | 4.00 | 3.00 | 4.00 | 4.00 | 4.00 | 3.00 | 3.50 | 3.00 |
"Each time the patient was seen after the study intervention was initiated, the clinician compared the patient's overall clinical condition to the CGI-S score obtained at the baseline (visit 1) visit. Based on information collected, the clinician determined if any improvement occurred on the following 7-point scale: 1=Very much improved since the initiation of treatment; 2=Much improved; 3=Minimally improved; 4=No change from baseline (the initiation of treatment); 5=Minimally worse; 6=Much worse; 7=Very much worse since the initiation of treatment.~The possible range for reported scores is 1-7." (NCT01777542)
Timeframe: Every 10 weeks during each of the two 20-week treatment periods
| Intervention | units on a scale (Median) | ||||
|---|---|---|---|---|---|
| Visit 3 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 8 - Second Intervention | Visit 10 - Second Intervention | |
| Placebo First, Then rhIGF-1 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
| rhIGF-1 First, Then Placebo | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
"This scale is used to judge the severity of the subject's disease prior to entry into the study. The clinician will rate the severity of behavioral symptoms at baseline on a 7-point scale from not impaired to the most impaired.~The scores that correspond to each possible grouping are as follows: 1=Normal, not at all impaired; 2=Borderline impaired; 3=Mildly impaired; 4=Moderately impaired; 5=Markedly impaired; 6=Severely impaired; 7=The most impaired.~The possible range for reported scores is 1-7." (NCT01777542)
Timeframe: Every 10 weeks during each of the two 20-week treatment periods
| Intervention | units on a scale (Median) | |||||
|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 3 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 8 - Second Intervention | Visit 10 - Second Intervention | |
| Placebo First, Then rhIGF-1 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
| rhIGF-1 First, Then Placebo | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.50 |
"The CSBS-DP was designed to measure early communication and symbolic skills in infants and young children (that is, functional communication skills of 6 month to 2 year olds). The CSBS-DP measures skills from three composites: (a) Social (emotion, eye gaze, and communication); (b) Speech (sounds and words); and (c) Symbolic (understanding and object use) and asks about developmental milestones. The data reported are the composite scores for these three categories.~The possible scores for the three composite categories are as follows:~Social Composite = 0-48; Speech Composite = 0-40; Symbolic Composite = 0-51.~A higher score indicates more advanced abilities in that area." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention: Social | Visit 2: Social Composite Score | Visit 3: Social Composite Score | Visit 4: Social Composite Score | Visit 5: Social Composite Score | Visit 6 - Second Intervention: Social | Visit 7 - Second Intervention: Social | Visit 8 - Second Intervention: Social | Visit 9 - Second Intervention: Social | Visit 10 - Second Intervention: Social | Follow-up: Social Composite Score | Visit 1 - First Intervention: Speech | Visit 2 - First Intervention: Speech | Visit 3 - First Intervention: Speech | Visit 4 - First Intervention: Speech | Visit 5 - First Intervention: Speech | Visit 6 - Second Intervention: Speech | Visit 7 - Second Intervention: Speech | Visit 8 - Second Intervention: Speech | Visit 9 - Second Intervention: Speech | Visit 10 - Second Intervention: Speech | Follow-up: Speech Composite Score | Visit 1 - First Intervention: Symbolic | Visit 2 - First Intervention: Symbolic | Visit 3 - First Intervention: Symbolic | Visit 4 - First Intervention: Symbolic | Visit 5 - First Intervention: Symbolic | Visit 6 - Second Intervention: Symbolic | Visit 7 - Second Intervention: Symbolic | Visit 8 - Second Intervention: Symbolic | Visit 9 - Second Intervention: Symbolic | Visit 10 - Second Intervention: Symbolic | Follow-up: Symbolic Composite Score | |
| Placebo First, Then rhIGF-1 | 19.00 | 20.00 | 18.00 | 18.00 | 20.00 | 18.00 | 20.00 | 21.00 | 21.00 | 22.50 | 22.50 | 4.00 | 3.00 | 5.00 | 5.50 | 6.50 | 4.00 | 4.00 | 5.00 | 5.00 | 5.00 | 6.00 | 9.50 | 10.50 | 10.50 | 12.00 | 11.50 | 13.00 | 10.25 | 11.50 | 11.50 | 13.75 | 14.25 |
| rhIGF-1 First, Then Placebo | 22.00 | 24.00 | 24.00 | 24.00 | 23.00 | 28.00 | 25.00 | 27.00 | 29.00 | 27.00 | 28.00 | 7.00 | 5.00 | 8.00 | 5.00 | 8.00 | 8.50 | 7.00 | 6.50 | 5.00 | 7.25 | 6.00 | 14.00 | 14.50 | 15.00 | 14.00 | 16.50 | 18.50 | 17.00 | 17.00 | 18.00 | 17.00 | 18.00 |
"The Kerr clinical severity scale (Kerr scale) is a quantitative measure of global disease severity. The Kerr scale is a summation of individual items related to Rett syndrome phenotypic characteristics. The items are based on the severity or degree of abnormality of each characteristic on a discrete scale (0, 1, 2) with the highest level corresponding to the most severe or most abnormal presentations.~The possible range of scores is 0-48. The higher the score, the more severe the symptoms." (NCT01777542)
Timeframe: At the start and end of each 20-week treatment period
| Intervention | units on a scale (Median) | |||
|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 10 - Second Intervention | |
| Placebo First, Then rhIGF-1 | 16.50 | 15.00 | 15.00 | 14.00 |
| rhIGF-1 First, Then Placebo | 18.00 | 18.00 | 19.00 | 20.00 |
"The MSEL is a standardized developmental test for children ages 3 to 68 months consisting of five subscales: gross motor, fine motor, visual reception, expressive language, and receptive language.~The raw score is reported for each subscale domain. The potential score ranges are as follows:~Visual Reception: 33 items, score range=0-50, Fine Motor: 30 items, score range= 0-49, Receptive Language: 33 items, score range= 0-48, Expressive Language: 28 items, score range= 0-50. The gross motor subscale was not included in this population.~A higher raw score indicates more advanced abilities in that section." (NCT01777542)
Timeframe: At the start and end of each 20-week treatment period
| Intervention | units on a scale (Median) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1- First Intervention: Visual Reception | Visit 5- First Intervention: Visual Reception | Visit 6- Second Intervention: Visual Reception | Visit 10: Visual Reception Raw Score | Visit 1- First Intervention: Fine Motor | Visit 5- First Intervention: Fine Motor | Visit 6- Second Intervention: Fine Motor | Visit 10- Second Intervention: Fine Motor | Visit 1- First Intervention: Receptive Language | Visit 5- First Intervention: Receptive Language | Visit 6- Second Intervention: Receptive Language | Visit 10- Second Intervention: Receptive Language | Visit 1- First Intervention: Expressive Language | Visit 5- First Intervention: Expressive Language | Visit 6- Second Intervention: Expressive Language | Visit 10- Second Intervention: Expressive Language | |
| Placebo First, Then rhIGF-1 | 17.00 | 26.00 | 23.00 | 28.00 | 10.00 | 9.00 | 11.00 | 9.00 | 20.00 | 30.00 | 31.00 | 31.00 | 8.00 | 9.00 | 6.00 | 8.00 |
| rhIGF-1 First, Then Placebo | 26.00 | 39.50 | 42.00 | 44.00 | 7.00 | 7.00 | 10.00 | 8.50 | 25.50 | 32.00 | 38.00 | 36.50 | 9.00 | 8.00 | 10.00 | 8.00 |
"The parent or caretaker identifies the three most troublesome, RTT-specific, target symptoms, such as inattention or breath-holding. This allows the problems that are of concern to parents and the family to be targeted in the trial. In this study the caregiver will choose three target symptoms at baseline and then rate changes in severity of each target symptom on a visual analog scale (VAS).~The VAS is a 10 cm line, where a target symptom is anchored on one end with the description the best it has ever been and on the other with the description the worst it has ever been. The parent was asked to marked on the line where they felt their child's symptoms currently fit best. This mark was measured as recorded as a numeric value from 0.00-10.00 cm. The higher the value, the worse the symptom." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 6.50 | 4.70 | 5.65 | 5.05 | 4.80 | 4.95 | 4.55 | 5.65 | 4.15 | 4.80 | 5.60 |
| rhIGF-1 First, Then Placebo | 8.80 | 4.80 | 5.35 | 5.10 | 5.15 | 5.20 | 4.65 | 5.00 | 5.15 | 5.05 | 5.08 |
"The parent or caretaker identifies the three most troublesome, RTT-specific, target symptoms, such as inattention or breath-holding. This allows the problems that are of concern to parents and the family to be targeted in the trial. In this study the caregiver will choose three target symptoms at baseline and then rate changes in severity of each target symptom on a visual analog scale (VAS).~The VAS is a 10 cm line, where a target symptom is anchored on one end with the description the best it has ever been and on the other with the description the worst it has ever been. The parent was asked to marked on the line where they felt their child's symptoms currently fit best. This mark was measured as recorded as a numeric value from 0.00-10.00 cm. The higher the value, the worse the symptom." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 7.75 | 4.50 | 5.85 | 5.00 | 5.00 | 5.35 | 5.50 | 5.15 | 3.80 | 4.90 | 5.15 |
| rhIGF-1 First, Then Placebo | 6.35 | 5.25 | 5.95 | 5.40 | 5.45 | 7.10 | 5.85 | 5.00 | 5.13 | 4.95 | 5.20 |
"The parent or caretaker identifies the three most troublesome, RTT-specific, target symptoms, such as inattention or breath-holding. This allows the problems that are of concern to parents and the family to be targeted in the trial. In this study the caregiver will choose three target symptoms at baseline and then rate changes in severity of each target symptom on a visual analog scale (VAS).~The VAS is a 10 cm line, where a target symptom is anchored on one end with the description the best it has ever been and on the other with the description the worst it has ever been. The parent was asked to marked on the line where they felt their child's symptoms currently fit best. This mark was measured as recorded as a numeric value from 0.00-10.00 cm. The higher the value, the worse the symptom." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 7.85 | 4.70 | 5.65 | 4.15 | 5.00 | 6.20 | 4.80 | 4.85 | 4.60 | 4.13 | 4.55 |
| rhIGF-1 First, Then Placebo | 5.70 | 5.00 | 5.20 | 5.35 | 5.10 | 5.35 | 4.95 | 5.15 | 5.25 | 4.55 | 5.10 |
"As part of each visit after the study intervention was initiated, the parent/caregiver was asked to compare the patient's overall clinical condition to the score obtained at the baseline (visit 1) visit. Based on information collected, the clinician determined if any improvement occurred on the following 7-point scale: 1=Very much improved since the initiation of treatment; 2=Much improved; 3=Minimally improved; 4=No change from baseline (the initiation of treatment); 5=Minimally worse; 6=Much worse; 7=Very much worse since the initiation of treatment.~The possible range for reported scores is 1-7." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 4.00 | 3.00 | 3.00 | 3.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
| rhIGF-1 First, Then Placebo | 4.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
"The PGI-S is the parent version of the CGI-S. Parents/caregivers/LAR are asked to rate the severity of their child's symptoms at baseline on a 7-point scale from not at all impaired to the most impaired. The parents/caregivers/LAR will complete the PGI-S at each study visit.~The scores that correspond to each possible grouping are as follows:~1=Normal, not at all impaired; 2=Borderline impaired; 3=Mildly impaired; 4=Moderately impaired; 5=Markedly impaired; 6=Severely impaired; 7=The most impaired.~The possible range for reported scores is 1-7." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
| rhIGF-1 First, Then Placebo | 6.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 6.00 | 6.00 | 5.00 | 4.00 |
"Respiratory data was collected using non-invasive respiratory inductance plethysmography from a BioCapture® recording device. BioCapture® is a child-friendly measurement device that can record from 1 to 12 physiological signal transducers in a time-locked manner. It can be configured with the pediatric chest and abdominal plethysmography bands and the 3 lead ECG signals we plan to use for monitoring cardiac safety throughout the study. Each transducer is placed on the patient independently to provide a customized fit that yields the highest signal quality for each patient irrespective of body shape and proportion. The transducer signals captured by the BioCapture® are transmitted wirelessly to a laptop computer where all signals are displayed in real-time.~The apnea index is given as apneas/hour. Data on apneas greater than or equal to 10 seconds are displayed below. The higher the frequency of apnea, the more severe the breathing abnormality." (NCT01777542)
Timeframe: Every 10 weeks during each of the two 20-week treatment periods
| Intervention | Apneas/Hour (Median) | |||||
|---|---|---|---|---|---|---|
| Visit 1 - First Intervention: Apnea Index | Visit 3 - First Intervention: Apnea Index | Visit 5 - First Intervention: Apnea Index | Visit 6 - Second Intervention: Apnea Index | Visit 8 - Second Intervention: Apnea Index | Visit 10 - Second Intervention: Apnea Index | |
| Placebo First, Then rhIGF-1 | 7.58 | 4.80 | 6.93 | 7.90 | 7.28 | 8.91 |
| rhIGF-1 First, Then Placebo | 4.05 | 3.48 | 3.07 | 3.62 | 5.55 | 5.56 |
"The RSBQ is a parent-completed measure of abnormal behaviors typically observed in individuals with RTT. Each item, grouped into eight subscales, is scored on a Likert scale of 0-2, according to how well the item describes the individual's behavior. A score of 0 indicates the described item is not true, a score of 1 indicates the described item is somewhat or sometimes true, and a score of 2 indicates the described item is very true or often true.~The total sum of each subscale is reported. The higher the score, the more severe the symptoms of that subscale in the participant.~The range for each subscale is as follows:~General Mood: 0-16 Body rocking and expressionless face: 0-14 Hand behaviors: 0-12 Breathing Problems: 0-10 Repetitive Face Movements: 0-8 Night-time behaviors: 0-6 Walking Standing: 0-4~The fear/anxiety subscale was used as a primary outcome measure in this study and results can be found in that section." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1- First Intervention: General Mood | Visit 2- First Intervention: General Mood | Visit 3- First Intervention: General Mood | Visit 4- First Intervention: General Mood | Visit 5- First Intervention: General Mood | Visit 6- Second Intervention: General Mood | Visit 7- Second Intervention: General Mood | Visit 8- Second Intervention: General Mood | Visit 9- Second Intervention: General Mood | Visit 10- Second Intervention: General Mood | Follow-up: General Mood | Visit 1- First Intervention: Body Rocking | Visit 2- First Intervention: Body Rocking | Visit 3- First Intervention: Body Rocking | Visit 4- First Intervention: Body Rocking | Visit 5- First Intervention: Body Rocking | Visit 6- Second Intervention: Body Rocking | Visit 7- Second Intervention: Body Rocking | Visit 8- Second Intervention: Body Rocking | Visit 9- Second Intervention: Body Rocking | Visit 10- Second Intervention: Body Rocking | Followup: Body Rocking | Visit 1- First Intervention: Hand Behaviors | Visit 2- First Intervention: Hand Behaviors | Visit 3- First Intervention: Hand Behaviors | Visit 4- First Intervention: Hand Behaviors | Visit 5- First Intervention: Hand Behaviors | Visit 6- Second Intervention: Hand Behaviors | Visit 7- Second Intervention: Hand Behaviors | Visit 8- Second Intervention: Hand Behaviors | Visit 9- Second Intervention: Hand Behaviors | Visit 10- Second Intervention: Hand Behaviors | Follow-up: Hand Behaviors | Visit 1- First Intervention: Breathing Problems | Visit 2- First Intervention: Breathing Problems | Visit 3- First Intervention: Breathing Problems | Visit 4- First Intervention: Breathing Problems | Visit 5- First Intervention: Breathing Problems | Visit 6- Second Intervention: Breathing Problems | Visit 7- Second Intervention: Breathing Problems | Visit 8- Second Intervention: Breathing Problems | Visit 9- Second Intervention: Breathing Problems | Visit 10- Second Intervention: Breathing Problems | Follow-up: Breathing Problems | Visit 1- First Intervention: Repetitive Face Movem | Visit 2- First Intervention: Repetitive Face Movem | Visit 3- First Intervention: Repetitive Face Movem | Visit 4- First Intervention: Repetitive Face Movem | Visit 5- First Intervention: Repetitive Face Movem | Visit 6- Second Intervention: Repetitive Face Mov | Visit 7- Second Intervention: Repetitive Face Mov | Visit 8- Second Intervention: Repetitive Face Mov | Visit 9- Second Intervention: Repetitive Face Mov | Visit 10- Second Intervention: Repetitive Face Mov | Follow-up: Repetitive Face Movements | Visit 1- First Intervention: Night time Behaviors | Visit 2- First Intervention: Night time Behaviors | Visit 3- First Intervention: Night time Behaviors | Visit 4- First Intervention: Night time Behaviors | Visit 5- First Intervention: Night time Behaviors | Visit 6- Second Intervention: Night time Behavior | Visit 7- Second Intervention: Night time Behavior | Visit 8- Second Intervention: Night time Behavior | Visit 9- Second Intervention: Night time Behavior | Visit 10- Second Intervention: Night time Behavior | Follow-up: Night time Behaviors | Visit 1- First Intervention: Walking/Standing | Visit 2- First Intervention: Walking/Standing | Visit 3- First Intervention: Walking/Standing | Visit 4- First Intervention: Walking/Standing | Visit 5- First Intervention: Walking/Standing | Visit 6- Second Intervention: Walking/Standing | Visit 7- Second Intervention: Walking/Standing | Visit 8- Second Intervention: Walking/Standing | Visit 9- Second Intervention: Walking/Standing | Visit 10- Second Intervention: Walking/Standing | Follow-up: Walking/Standing | |
| Placebo First, Then rhIGF-1 | 7.00 | 5.00 | 6.00 | 5.00 | 5.00 | 4.00 | 5.50 | 5.00 | 6.00 | 4.00 | 5.50 | 6.00 | 5.00 | 5.00 | 6.00 | 5.00 | 4.00 | 5.00 | 5.00 | 4.00 | 5.00 | 4.50 | 8.00 | 9.00 | 8.00 | 8.00 | 8.00 | 9.00 | 8.00 | 8.00 | 8.00 | 7.00 | 7.50 | 6.00 | 4.00 | 5.00 | 5.00 | 5.00 | 6.00 | 4.50 | 6.00 | 5.00 | 6.00 | 5.00 | 2.00 | 2.00 | 3.00 | 2.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 0.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 3.00 | 1.50 | 2.00 |
| rhIGF-1 First, Then Placebo | 4.00 | 3.00 | 2.00 | 2.00 | 3.00 | 4.00 | 2.00 | 2.00 | 1.00 | 2.50 | 2.00 | 4.00 | 4.00 | 3.00 | 4.00 | 4.00 | 4.00 | 3.00 | 4.00 | 3.00 | 4.00 | 4.00 | 8.00 | 8.00 | 8.00 | 9.00 | 9.00 | 8.00 | 9.00 | 9.00 | 7.00 | 9.00 | 8.50 | 4.00 | 4.00 | 4.00 | 5.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 4.00 | 3.00 | 2.00 | 2.00 | 3.00 | 2.00 | 2.00 | 3.00 | 2.00 | 2.00 | 2.00 | 1.50 | 2.00 | 1.00 | 1.00 | 0.00 | 0.00 | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
"The RSBQ is an informant/parent-completed measure of abnormal behaviors typically observed in individuals with RTT, which is completed by a parent/caregiver/LAR. Each item, grouped into eight domains/factors: General mood, Breathing problems, Body rocking and expressionless face, Hand behaviors, Repetitive face movements, Night-time behaviors, Fear/anxiety and Walking/standing), is scored on a Likert scale of 0-2, according to how well the item describes the individual's behavior. A score of 0 indicates the described item is not true, a score of 1 indicates the described item is somewhat or sometimes true, and a score of 2 indicates the described item is very true or often true.~The total sum of items in each subscale is reported.~For the fear/anxiety subscale, the sum total could be between 0-8. The higher the sum total score, the greater the frequency of fear/anxiety behaviors." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 4.00 | 5.00 | 4.00 | 4.00 | 3.00 | 4.00 | 4.00 | 3.00 | 3.00 | 4.00 | 3.50 |
| rhIGF-1 First, Then Placebo | 5.00 | 3.00 | 3.00 | 3.00 | 3.00 | 4.00 | 3.00 | 4.00 | 3.00 | 3.00 | 3.50 |
"The VABS-II is a survey designed to assess personal and social functioning. Within each domain (Communication, Daily Living Skills, Socialization, and Motor Skills), items can given a score of 2 if the participant successfully performs the activity usually; a 1 if the participant successfully performs the activity sometimes, or needs reminders; a 0 if the participant never performs the activity, and a DK if the parent/caregiver is unsure of the participant's ability for an item.~The raw scores in each sub-domain are reported and the ranges for these are as follows: [Communication Domain], Receptive Language=0-40, Expressive Language=0-108, Written Language=0-50; [Daily Living Skills Domain], Personal=0-82, Domestic=0-48, Community=0-88; [Socialization Domain], Interpersonal Relationships=0-76, Play and Leisure Time=0-62, Coping Skills=0-60; [Motor Skills Domain]: Gross Motor Skills=0-80, Fine Motor Skills=0-72.~A higher score indicates more advanced abilities." (NCT01777542)
Timeframe: At the start and end of each 20-week treatment period
| Intervention | units on a scale (Median) | |||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention: Receptive | Visit 5 - First Intervention: Receptive | Visit 6 - Second Intervention: Receptive Language | Visit 10 - Second Intervention: Receptive Language | Visit 1 - First Intervention: Expressive | Visit 5 - First Intervention: Expressive | Visit 6 - Second Intervention: Expressive Lang. | Visit 10 - Second Intervention: Expressive Lang. | Visit 1 - First Intervention: Written | Visit 5 - First Intervention: Written | Visit 6: - Second Intervention Written Language | Visit 10 - Second Intervention: Written Language | Visit 1 - First Intervention: Personal | Visit 5 - First Intervention: Personal | Visit 6 - Second Intervention: Personal | Visit 10 - Second Intervention: Personal | Visit 1 - First Intervention: Domestic | Visit 5 - First Intervention: Domestic | Visit 6 - Second Intervention: Domestic | Visit 10 - Second Intervention: Domestic | Visit 1 - First Intervention: Community | Visit 5 - First Intervention: Community | Visit 6 - Second Intervention: Community | Visit 10 - Second Intervention: Community | Visit 1 - First Intervention: Interpersonal Rel. | Visit 5 - First Intervention: Interpersonal Rel. | Visit 6 - Second Intervention: Interpersonal Rel. | Visit 10 - Second Intervention: Interpersonal Rel. | Visit 1 - First Intervention: Play and Leisure | Visit 5 - First Intervention: Play and Leisure | Visit 6 - Second Intervention: Play and Leisure | Visit 10 - Second Intervention: Play and Leisure | Visit 1 - First Intervention: Coping Skills | Visit 5 - First Intervention: Coping Skills | Visit 6 - Second Intervention: Coping Skills | Visit 10 - Second Intervention: Coping Skills | Visit 1 - First Intervention: Gross Motor | Visit 5 - First Intervention: Gross Motor | Visit 6 - Second Intervention: Gross Motor | Visit 10 - Second Intervention: Gross Motor | Visit 1 - First Intervention: Fine Motor | Visit 5 - First Intervention: Fine Motor | Visit 6 - Second Intervention: Fine Motor | Visit 10 - Second Intervention: Fine Motor | |
| Placebo First, Then rhIGF-1 | 13.00 | 15.00 | 18.00 | 20.00 | 16.00 | 17.00 | 18.00 | 20.00 | 0.00 | 0.00 | 4.00 | 6.00 | 9.00 | 10.00 | 9.00 | 10.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 1.00 | 2.00 | 18.00 | 18.00 | 19.00 | 20.00 | 8.00 | 11.00 | 12.00 | 11.00 | 3.00 | 2.00 | 3.00 | 4.00 | 31.00 | 34.00 | 27.00 | 27.00 | 6.00 | 6.00 | 7.00 | 5.00 |
| rhIGF-1 First, Then Placebo | 18.00 | 21.00 | 22.00 | 24.50 | 18.00 | 22.00 | 25.00 | 24.00 | 4.00 | 5.00 | 7.00 | 7.00 | 8.00 | 9.00 | 8.50 | 9.50 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00 | 3.00 | 5.00 | 5.00 | 21.00 | 22.00 | 21.00 | 22.50 | 13.00 | 12.00 | 13.00 | 12.50 | 3.00 | 4.00 | 6.00 | 4.50 | 10.00 | 10.00 | 11.50 | 10.50 | 2.00 | 3.00 | 4.00 | 4.00 |
The attention composite comprises performance on Wechsler Adult Intelligence Scale III Symbol-Digit and Letter Number Sequencing Subtests, Trail Making Test Part A, computerized simple-choice reaction time, and computerized working memory (i.e., 2-Back). The composite score is the average combined z score for each test. Higher, positive values indicate better than average performance and negative and lower values indicate worse than average. The outcome reported was change in score from baseline for each treatment arm. (NCT00368849)
Timeframe: There are two time points for this measure: baseline and after 4 weeks of treatment
| Intervention | Units on a scale (Mean) |
|---|---|
| Atomoxetine | -0.13 |
| Placebo | 0.02 |
The Conners' Adult Attention Rating Scale (CAARS) is one of the most frequently used self-rating measures for adult Attention Deficit Hyperactivity Disorder (ADHD) and was given as a self-report measure of attention. It has 66 items with each item ranging from 0 to 3 points. Higher total scores represent greater impairment. The outcome reported was change in score from baseline for each treatment arm. (NCT00368849)
Timeframe: There are two time points for this measure: baseline and after 4 weeks of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Atomoxetine | -2.88 |
| Placebo | -2.24 |
The executive composite comprises performance on Trail Making Test Part B, Stroop Color and Word Test, and the Controlled Oral Word Association Test (i.e., Verbal Fluency). The composite score is the average combined z score for each test. Positive values indicate better than average performance and negative values worse than average. The outcome reported was change in score from baseline for each treatment arm. (NCT00368849)
Timeframe: There are two time points for this measure: baseline and after 4 weeks of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Atomoxetine | -1.68 |
| Placebo | -2.94 |
Psychiatric symptoms were evaluated with the Symptom Checklist-90-Revised, a self report measure of psychiatric symptoms. The measure produces raw scores and normed scores (T scores Mean = 50), with higher values representing greater impairment. The outcome reported was change in score from baseline for each treatment arm. (NCT00368849)
Timeframe: There are two time points for this measure: baseline and after 4 weeks of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Atomoxetine | -4.20 |
| Placebo | -4.64 |
Although changes in motor symptoms were not hypothesized, the Unified Huntington Disease Rating Scale motor examination was administered at every visit. An experienced motor rater completes a motor examination and rates the participant on several motor tasks. Total score ranges from 0 - 124, with higher scores indicating a worse outcome. The outcome reported was change in score from baseline for each treatment arm. (NCT00368849)
Timeframe: There are two time points for this measure: baseline and after 4 weeks of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Atomoxetine | 0.42 |
| Placebo | -0.35 |
600 reviews available for methylphenidate and ADDH
| Article | Year |
|---|---|
Meta-analysis: Dose-Dependent Effects of Methylphenidate on Neurocognitive Functioning in Children With Attention-Deficit/Hyperactivity Disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2022 |
Headache in ADHD as comorbidity and a side effect of medications: a systematic review and meta-analysis.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2022 |
Association between central nervous system stimulants used to treat attention deficit hyperactivity disorder (ADHD) and Raynaud's phenomenon: A scoping review.
Topics: Adolescent; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central | 2021 |
Clinical trials were missing from regulatory documents of extended-release methylphenidate for ADHD in adults: a case study of public documents.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Delayed-Act | 2022 |
Noradrenergic genes polymorphisms and response to methylphenidate in children with ADHD: A systematic review and meta-analysis.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Met | 2021 |
The effects of stimulant dose and dosing strategy on treatment outcomes in attention-deficit/hyperactivity disorder in children and adolescents: a meta-analysis.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2022 |
Evidence of methylphenidate effect on mitochondria, redox homeostasis, and inflammatory aspects: Insights from animal studies.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Homeostas | 2022 |
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2022 |
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2022 |
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2022 |
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2022 |
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2022 |
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2022 |
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2022 |
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2022 |
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2022 |
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2022 |
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2022 |
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2022 |
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2022 |
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2022 |
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2022 |
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2022 |
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2022 |
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2022 |
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2022 |
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2022 |
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2022 |
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2022 |
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2022 |
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2022 |
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2022 |
Understanding the Impact of Stimulants on Sleep in ADHD: Evidence from Systematic Assessment of Sleep in Adults.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Met | 2022 |
The effects of psychostimulants on cognitive functions in individuals with attention-deficit hyperactivity disorder: A systematic review.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cognition; Humans; | 2022 |
The Benefits and Limitations of Stimulants in Treating ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Methylphen | 2022 |
Current Pharmacological Treatments for ADHD.
Topics: Adolescent; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central | 2022 |
New Drugs to Treat ADHD: Opportunities and Challenges in Research and Development.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Methylphen | 2022 |
Stimulants.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Delayed-Action Pre | 2022 |
The Pharmacokinetics and Pharmacogenomics of Psychostimulants.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Methylphen | 2022 |
Addressing the Treatment and Service Needs of Young Adults with Attention Deficit Hyperactivity Disorder.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2022 |
Do Treatments for Adult ADHD Improve Emotional Behavior? A Systematic Review and Analysis.
Topics: Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2022 |
Treatments for child and adolescent attention deficit hyperactivity disorder in low and middle-income countries: A narrative review.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2022 |
[Formula: see text] The influence of methylphenidate on sustained attention in paediatric acquired brain injury: a meta-analytical review.
Topics: Attention Deficit Disorder with Hyperactivity; Brain Injuries; Central Nervous System Stimulants; Ch | 2023 |
Therapeutic Approaches for ADHD by Developmental Stage and Clinical Presentation.
Topics: Adolescent; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central | 2022 |
NLS-3 (Levophacetoperane or (
Topics: Adolescent; Amphetamine; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimu | 2024 |
Efficacy and Safety of PRC-063 for Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-analysis From Randomized Controlled Trials.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2023 |
Attention-Deficit/Hyperactivity Disorder Across the Spectrum: From Childhood to Adulthood.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2023 |
Animal Models of Childhood Exposure to Lead or Manganese: Evidence for Impaired Attention, Impulse Control, and Affect Regulation and Assessment of Potential Therapies.
Topics: Adolescent; Animals; Attention; Attention Deficit Disorder with Hyperactivity; Chelating Agents; Chi | 2023 |
Treatment with methylphenidate and the risk of fractures among children and young people: A systematic review and self-controlled case series study.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cohort Studies; Hu | 2023 |
Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2023 |
Brain-derived neurotrophic factor (BDNF) levels in children and adolescents before and after stimulant use a systematic review and metanalysis.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Brain-Derived Neurotrophic Factor; Centra | 2023 |
Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents.
Topics: Adolescent; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; C | 2023 |
Efficacy and safety of selegiline across different psychiatric disorders: A systematic review and meta-analysis of oral and transdermal formulations.
Topics: Attention Deficit Disorder with Hyperactivity; Depressive Disorder, Major; Humans; Methylphenidate; | 2023 |
Experiences of children and adolescents with attention-deficit/hyperactivity disorder taking methylphenidate.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2023 |
[Many sources of bias in medical research: experience from systematic reviews].
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Biomedical Research; Humans; Infant, Newborn; | 2023 |
The co-use of nicotine and prescription psychostimulants: A review of their behavioral and neuropharmacological interactions.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Dextroamphetamine; | 2023 |
Predicting the Response of Children and Adolescents With ADHD to Methylphenidate: A Systematic Review.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2023 |
Association between sleep pattern and pharmacological treatment in children with attention deficit disorder with hyperactivity: a systematic review.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2023 |
Molecular Mechanisms Underlying NMDARs Dysfunction and Their Role in ADHD Pathogenesis.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; Me | 2023 |
Attention Deficit Hyperactivity Disorder Medication Management: Where to Begin?
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child Welfa | 2019 |
Neurological and psychiatric adverse effects of long-term methylphenidate treatment in ADHD: A map of the current evidence.
Topics: Attention Deficit Disorder with Hyperactivity; Brain Diseases; Central Nervous System Stimulants; Hu | 2019 |
Practical considerations for the evaluation and management of Attention Deficit Hyperactivity Disorder (ADHD) in adults.
Topics: Adult; Aging; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Huma | 2020 |
Therapeutic effects of methylphenidate for attention-deficit/hyperactivity disorder in children with borderline intellectual functioning or intellectual disability: A systematic review and meta-analysis.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Int | 2019 |
Drugs for ADHD.
Topics: Adrenergic alpha-2 Receptor Agonists; Amphetamines; Attention Deficit Disorder with Hyperactivity; B | 2020 |
Relationship Between Treatment Duration and Efficacy of Pharmacological Treatment for ADHD: A Meta-Analysis and Meta-Regression of 87 Randomized Controlled Clinical Trials.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2021 |
DRD4 48 bp multiallelic variants as age-population-specific biomarkers in attention-deficit/hyperactivity disorder.
Topics: Adult; Alleles; Attention Deficit Disorder with Hyperactivity; Biomarkers; Child; Genome-Wide Associ | 2020 |
[Pharmacotherapy of attention deficit hyperactivity disorder in adults].
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Germany; Hu | 2020 |
[Attention deficit hyperactivity disorder in childhood and adolescence : Current state of research].
Topics: Adolescent; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central | 2020 |
Movement disorders and use of risperidone and methylphenidate: a review of case reports and an analysis of the WHO database in pharmacovigilance.
Topics: Attention Deficit Disorder with Hyperactivity; Combined Modality Therapy; Comorbidity; Conduct Disor | 2021 |
Clinical guidance on pharmacotherapy for the treatment of attention-deficit hyperactivity disorder (ADHD) for people with intellectual disability.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Clonidi | 2020 |
An update on the clinical pharmacology of methylphenidate: therapeutic efficacy, abuse potential and future considerations.
Topics: Abuse-Deterrent Formulations; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous | 2020 |
Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autism Spectru | 2021 |
Pharmacologic Treatment of Attention Deficit-Hyperactivity Disorder.
Topics: Adolescent; Adult; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperact | 2020 |
The female side of pharmacotherapy for ADHD-A systematic literature review.
Topics: Adolescent; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central | 2020 |
The stress-Wnt-signaling axis: a hypothesis for attention-deficit hyperactivity disorder and therapy approaches.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2020 |
Long term methylphenidate exposure and growth in children and adolescents with ADHD. A systematic review and meta-analysis.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Body Weight; Central Nervous System Stimu | 2021 |
Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis.
Topics: Adult; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bayes | 2020 |
Systematic Review: Medication Effects on Brain Intrinsic Functional Connectivity in Patients With Attention-Deficit/Hyperactivity Disorder.
Topics: Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Brain; Central Nerv | 2021 |
Functional validation of CHMP7 as an ADHD risk gene.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Brain; Child; Clustered Regularly Interspace | 2020 |
The Effects of Drugs used for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) on Pregnancy Outcome and Breast-feeding: A Critical Review.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Breast Feeding; Central Nervous System Stimula | 2021 |
Pharmacotherapy of attention deficit/hyperactivity disorder in individuals with autism spectrum disorder: A systematic review of the literature.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; | 2021 |
Methylphenidate for attention problems in epilepsy patients: Safety and efficacy.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Double-Blin | 2021 |
Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety; Attention Deficit Disorder with Hyperactiv | 2021 |
Attention deficit/hyperactivity disorder and epilepsy.
Topics: Attention Deficit Disorder with Hyperactivity; Comorbidity; Epilepsy; Humans; Methylphenidate; Paren | 2021 |
The Efficacy of Acupuncture Treatment for Attention Deficit Hyperactivity Disorder: A Systematic Review and Meta-Analysis.
Topics: Acupuncture Therapy; Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous Syst | 2021 |
Parental ADHD in pregnancy and the postpartum period - A systematic review.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Fema | 2021 |
ADHD and accidents over the life span - A systematic review.
Topics: Accidents; Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System | 2021 |
Systematic Review: Attention-Deficit/Hyperactivity Disorder and Instrumental Learning.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Conditioning, Operant; Humans; Learning; Methy | 2021 |
[ADHD during childhood and subsequent psychotic disorder: A link?]
Topics: Attention Deficit Disorder with Hyperactivity; Comorbidity; Humans; Infant, Newborn; Methylphenidate | 2021 |
Topics: Adolescent; Africa; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants | 2021 |
Clinical practice guideline on pharmacological and psychological management of adult patients with attention deficit and hyperactivity disorder and comorbid substance use.
Topics: Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2022 |
Evidence-based pharmacological treatment options for ADHD in children and adolescents.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2022 |
"Real-world" effectiveness of methylphenidate in improving the academic achievement of Attention-Deficit Hyperactivity Disorder diagnosed students-A systematic review.
Topics: Academic Success; Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System | 2022 |
A Practical, Evidence-informed Approach to Managing Stimulant-Refractory Attention Deficit Hyperactivity Disorder (ADHD).
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Atten | 2021 |
Editorial: Accumulating Evidence for the Benefit of Micronutrients for Children With Attention-Deficit/Hyperactivity Disorder.
Topics: Adolescent; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; | 2022 |
Methylphenidate for attention-deficit/hyperactivity disorder in adults: a narrative review.
Topics: Adult; Anxiety; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Do | 2021 |
[The effect of methylphenidate on appetite and weight].
Topics: Adolescent; Adult; Appetite; Appetite Depressants; Attention Deficit Disorder with Hyperactivity; Bo | 2017 |
Safety of Treatments for ADHD in Adults: Pairwise and Network Meta-Analyses.
Topics: Adrenergic Uptake Inhibitors; Adult; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disor | 2019 |
Impaired oral absorption of methylphenidate after Roux-en-Y gastric bypass.
Topics: Administration, Oral; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulan | 2017 |
Contribution of Clinical Neuroimaging to the Understanding of the Pharmacology of Methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; Dopamine Up | 2017 |
Risks of Stimulant Use for Attention Deficit Hyperactivity Disorder on the Developing Brain: Primum non nocere.
Topics: Adolescent; Amphetamines; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous Syst | 2017 |
Gastrointestinal adverse events during methylphenidate treatment of children and adolescents with attention deficit hyperactivity disorder: A systematic review with meta-analysis and Trial Sequential Analysis of randomised clinical trials.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2017 |
Discontinuation of pharmacological treatment of children and adolescents with attention deficit hyperactivity disorder: meta-analysis of 63 studies enrolling 11,788 patients.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2017 |
Effects of stimulants and atomoxetine on emotional lability in adults: A systematic review and meta-analysis.
Topics: Adult; Affective Symptoms; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; | 2017 |
Brief psychosis induced by methylphenidate in a child with attention deficit disorder: a case report and literature review.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Mal | 2017 |
Risk of Irritability With Psychostimulant Treatment in Children With ADHD: A Meta-Analysis.
Topics: Amphetamine; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child | 2017 |
A clinician's guide to ADHD treatment options.
Topics: Adolescent; Amphetamines; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2017 |
Pharmacotherapy of emotional dysregulation in adults with ADHD: A systematic review and meta-analysis.
Topics: Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Emotions; Hu | 2018 |
Impaired reproduction after exposure to ADHD drugs: Systematic review of animal studies.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Clonidine; Female; Male; Methylphenidate; Re | 2017 |
[Regional differences of ADHD diagnosis rates in health insurance data from 2005 to 2015 : Methodological considerations and results].
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Cross-Sec | 2017 |
Methylphenidate for children and adolescents with autism spectrum disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Central Nervous | 2017 |
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Comorbidity | 2017 |
SLC6A3 polymorphism and response to methylphenidate in children with ADHD: A systematic review and meta-analysis.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Biomarkers, Pharmacological; Child; Dopam | 2018 |
Pharmacogenetics predictors of methylphenidate efficacy in childhood ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Biomarkers, Pharmacological; Catechol O-Methyltransfe | 2018 |
Autism spectrum disorder: Consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology.
Topics: Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autism Spectrum D | 2018 |
A case report and literature review of autism and attention deficit hyperactivity disorder in paediatric chronic pain.
Topics: Acceptance and Commitment Therapy; Asperger Syndrome; Attention Deficit Disorder with Hyperactivity; | 2018 |
Does methylphenidate improve academic performance? A systematic review and meta-analysis.
Topics: Academic Performance; Achievement; Attention Deficit Disorder with Hyperactivity; Central Nervous Sy | 2019 |
Association analysis of norepinephrine transporter polymorphisms and methylphenidate response in ADHD patients.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Central Nervous Syst | 2018 |
Clinical trials in autism spectrum disorder: evidence, challenges and future directions.
Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Aggression; Antipsychotic Agents; Aripipraz | 2018 |
The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities.
Topics: Adrenergic Uptake Inhibitors; Amphetamine; Animals; Attention Deficit Disorder with Hyperactivity; B | 2018 |
[Side effects of methylphenidate in children and the young].
Topics: Adolescent; Anorexia; Attention Deficit Disorder with Hyperactivity; Bone Diseases, Developmental; C | 2018 |
Stimulant Use in the Management of Mild Traumatic Brain Injury: A Qualitative Literature Review.
Topics: Attention Deficit Disorder with Hyperactivity; Brain Concussion; Central Nervous System Stimulants; | 2020 |
Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2018 |
Neurocognitive effects of methylphenidate in adults with attention-deficit/hyperactivity disorder: A meta-analysis.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; | 2018 |
The Effects of Long-Acting Stimulant and Nonstimulant Medications in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Meta-Analysis of Randomized Controlled Trials.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2018 |
Lisdexamfetamine Dimesylate: A Review in Paediatric ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Dextroamphe | 2018 |
Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2018 |
Risk of Bias and Quality of Evidence for Treatment of ADHD With Stimulant Medication.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2018 |
Management of Attention Deficit Hyperactivity Disorder During Pregnancy.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cognitive B | 2018 |
Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Adult; Attention Deficit Disorder with Hyperactivi | 2018 |
Efficacy, Acceptability, and Tolerability of Lisdexamfetamine, Mixed Amphetamine Salts, Methylphenidate, and Modafinil in the Treatment of Attention-Deficit Hyperactivity Disorder in Adults: A Systematic Review and Meta-analysis.
Topics: Adult; Amphetamine; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants | 2019 |
Are the effects of methylphenidate uncertain?
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Meta-Analy | 2018 |
The Effect of Methylphenidate and Atomoxetine on Heart Rate and Systolic Blood Pressure in Young People and Adults with Attention-Deficit Hyperactivity Disorder (ADHD): Systematic Review, Meta-Analysis, and Meta-Regression.
Topics: Adolescent; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Blood P | 2018 |
The effectiveness of methylphenidate in the management of Attention Deficit Hyperactivity Disorder (ADHD) in people with intellectual disabilities: A systematic review.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Int | 2018 |
Effects of neurofeedback versus methylphenidate for the treatment of attention-deficit/hyperactivity disorder protocol for a systematic review and meta-analysis of head-to-head trials.
Topics: Adolescent; Adult; Age Factors; Attention Deficit Disorder with Hyperactivity; Central Nervous Syste | 2018 |
Light up ADHD: II. Neuropharmacological effects measured by near infrared spectroscopy: is there a biomarker?
Topics: Aging; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Biomarkers; Humans; | 2019 |
Drug Regimen Individualization for Attention-Deficit/Hyperactivity Disorder: Guidance for Methylphenidate and Dexmethylphenidate Formulations.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Delayed-Action Pre | 2019 |
Pharmacological treatment of attention-deficit hyperactivity disorder comorbid with an anxiety disorder: a systematic review.
Topics: Adolescent; Adult; Anxiety Disorders; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyp | 2019 |
New stimulant formulations for pediatric attention-deficit/hyperactivity disorder: a case-based approach for the primary care provider.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Met | 2019 |
Maternal and neonatal outcomes after exposure to ADHD medication during pregnancy: A systematic review and meta-analysis.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cohort Studies; Fe | 2019 |
Pharmacological treatment of attention-deficit/hyperactivity disorder in children and adolescents with epilepsy.
Topics: Adolescent; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Central Nervous System A | 2019 |
Massage therapy for the treatment of attention deficit/hyperactivity disorder (ADHD) in children and adolescents: A systematic review and meta-analysis.
Topics: Adolescent; Adolescent Behavior; Attention Deficit Disorder with Hyperactivity; Child; Child Behavio | 2019 |
Attention-deficit/hyperactivity disorder and task-related heart rate variability: A systematic review and meta-analysis.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior; Central Nervous System Stimulants; Heart Ra | 2019 |
Systematic review and meta-analysis of the behavioral effects of methylphenidate in the spontaneously hypertensive rat model of attention-deficit/hyperactivity disorder.
Topics: Animals; Attention; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Central Nervous | 2019 |
Methodological advantages and disadvantages of parallel and crossover randomised clinical trials on methylphenidate for attention deficit hyperactivity disorder: a systematic review and meta-analyses.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2019 |
PharmGKB summary: methylphenidate pathway, pharmacokinetics/pharmacodynamics.
Topics: Attention Deficit Disorder with Hyperactivity; Carboxylic Ester Hydrolases; Dopamine Plasma Membrane | 2019 |
New Formulations of Stimulants: An Update for Clinicians.
Topics: Amphetamine; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child | 2019 |
How does methylphenidate affect default mode network? A systematic review.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Methylphen | 2019 |
Using Cell Cultures for the Investigation of Treatments for Attention Deficit Hyperactivity Disorder: A Systematic Review.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cell Culture Techniques; C | 2019 |
Sleep-Associated Adverse Events During Methylphenidate Treatment of Attention-Deficit/Hyperactivity Disorder: A Meta-Analysis.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Child; Controlled C | 2019 |
Evaluation of Methylphenidate Safety and Maximum-Dose Titration Rationale in Attention-Deficit/Hyperactivity Disorder: A Meta-analysis.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Dose-Respon | 2019 |
Nootropic drugs: Methylphenidate, modafinil and piracetam - Population use trends, occurrence in the environment, ecotoxicity and removal methods - A review.
Topics: Attention Deficit Disorder with Hyperactivity; Brain; Environmental Pollutants; Humans; Memory; Meth | 2019 |
Effects of neurofeedback versus methylphenidate for the treatment of ADHD: systematic review and meta-analysis of head-to-head trials.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Methylphen | 2019 |
[Adult attention deficit hyperactivity disorder (ADHD) with comorbid addictive disorder. Therapeutic challenges using the example of a survey of clinical practice].
Topics: Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2019 |
Jornay PM -- evening-dosed methylphenidate for ADHD.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Dela | 2019 |
Toward quality care in ADHD: defining the goals of treatment.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2015 |
Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009-2011: focus on clinical efficacy and safety.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with | 2014 |
[Bases for the selection of pharmacological treatment in attention deficit hyperactivity disorder].
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2013 |
Systematic review and meta-analysis of pharmacological treatment of the symptoms of attention-deficit/hyperactivity disorder in children with pervasive developmental disorders.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention; Attention Deficit Disorder with Hyperactivity; Cen | 2013 |
Abuse and dependence liability analysis of methylphenidate in the spontaneously hypertensive rat model of attention-deficit/hyperactivity disorder (ADHD): what have we learned?
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Addictive; Behavior, Animal; Blood | 2013 |
Interventions for preschool children at high risk for ADHD: a comparative effectiveness review.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; | 2013 |
Interventions for preschool children at high risk for ADHD: a comparative effectiveness review.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; | 2013 |
Interventions for preschool children at high risk for ADHD: a comparative effectiveness review.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; | 2013 |
Interventions for preschool children at high risk for ADHD: a comparative effectiveness review.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; | 2013 |
[Methylphenidate in Brazil: a decade of publications].
Topics: Attention Deficit Disorder with Hyperactivity; Brazil; Central Nervous System Stimulants; Humans; Me | 2013 |
Meta-analysis of the association between dopamine transporter genotype and response to methylphenidate treatment in ADHD.
Topics: 3' Untranslated Regions; Attention Deficit Disorder with Hyperactivity; Dopamine Plasma Membrane Tra | 2014 |
Methylphenidate use in pregnancy and lactation: a systematic review of evidence.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Breast Feeding; Child Development; Female | 2014 |
Is the treatment with psychostimulants in children and adolescents with attention deficit hyperactivity disorder harmful for the dopaminergic system?
Topics: Amphetamine; Animals; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System S | 2013 |
Comparison of the pharmacokinetics and clinical efficacy of new extended-release formulations of methylphenidate.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Delayed-Action Preparations; Human | 2013 |
Neuroimaging markers for the prediction of treatment response to Methylphenidate in ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Databases, Factual | 2013 |
Attention deficit hyperactivity disorder in the European adult population: prevalence, disease awareness, and treatment guidelines.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hype | 2013 |
[The practice and problem of therapeutic agents for AD/HD].
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2010 |
[Adult attention deficit/hyperactivity disorder, associated symptoms and comorbid psychiatric disorders: diagnosis and pharmacological treatment].
Topics: Adult; Anxiety; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Co | 2013 |
[Autism and attention deficit hyperactivity disorder: pharmacological intervention].
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivi | 2013 |
Are motivation deficits underestimated in patients with ADHD? A review of the literature.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Dopamine Uptake Inhibitors; Functio | 2013 |
ADHD interventions in children younger than six years.
Topics: Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; | 2013 |
The use of methylphenidate hydrochloride extended-release oral suspension for the treatment of ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Delayed-Action Pre | 2013 |
Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Delayed-Act | 2013 |
Methylphenidate and the juvenile brain: enhancement of attention at the expense of cortical plasticity?
Topics: Adolescent; Age Factors; Animals; Attention Deficit Disorder with Hyperactivity; Child; Humans; Meth | 2013 |
Neurobiology of ADHD From Childhood to Adulthood: Findings of Imaging Methods.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Brain; Brain Mapping; Cerebellum; Child; Femal | 2015 |
Effect of psychostimulants on brain structure and function in ADHD: a qualitative literature review of magnetic resonance imaging-based neuroimaging studies.
Topics: Adolescent; Adult; Amphetamine; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervou | 2013 |
FPIN's clinical inquiries: Management of ADHD in preschool-aged children.
Topics: Amphetamines; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous Syste | 2013 |
Current pharmacotherapy of attention deficit hyperactivity disorder.
Topics: Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Behavior The | 2013 |
Effects of methylphenidate on cognitive functions in children and adolescents with attention-deficit/hyperactivity disorder: evidence from a systematic review and a meta-analysis.
Topics: Age Factors; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cogni | 2014 |
[Substance use disorders and ADHD: an overview of recent Dutch research].
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Comorbidity; Human | 2013 |
A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD).
Topics: Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Drug Interac | 2014 |
A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD).
Topics: Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Drug Interac | 2014 |
A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD).
Topics: Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Drug Interac | 2014 |
A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD).
Topics: Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Drug Interac | 2014 |
The use of actigraphy in the monitoring of methylphenidate versus placebo in ADHD: a meta-analysis.
Topics: Actigraphy; Attention Deficit Disorder with Hyperactivity; Humans; Methylphenidate; Randomized Contr | 2014 |
Methylphenidate treatment of attention deficit hyperactivity disorder in young people with learning disability and difficult-to-treat epilepsy: evidence of clinical benefit.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2013 |
Bulimia nervosa patient diagnosed with previously unsuspected ADHD in adulthood: clinical case report, literature review, and diagnostic challenges.
Topics: Attention Deficit Disorder with Hyperactivity; Bulimia Nervosa; Comorbidity; Delayed Diagnosis; Fema | 2014 |
Effects of stimulants on brain function in attention-deficit/hyperactivity disorder: a systematic review and meta-analysis.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; | 2014 |
Genetic targeting of the amphetamine and methylphenidate-sensitive dopamine transporter: on the path to an animal model of attention-deficit hyperactivity disorder.
Topics: Amphetamine; Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulan | 2014 |
Disordered sleep in pediatric patients with attention deficit hyperactivity disorder: an overview.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Met | 2013 |
Transdermal therapy for attention-deficit hyperactivity disorder with the methylphenidate patch (MTS).
Topics: Administration, Cutaneous; Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2014 |
Clinical practice. Attention deficit-hyperactivity disorder in children and adolescents.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System | 2014 |
Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with | 2014 |
Pharmacological and psychosocial treatments for adolescents with ADHD: an updated systematic review of the literature.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Behavior Thera | 2014 |
Attention-deficit hyperactivity disorder (ADHD): an updated review of the essential facts.
Topics: Attention Deficit Disorder with Hyperactivity; Brain; Child; Child Behavior Disorders; Child Develop | 2014 |
Safety of medicines used for ADHD in children: a review of published prospective clinical trials.
Topics: Adolescent; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; | 2014 |
Changing Epidemiology of Methylphenidate Prescriptions in the Community: A Multifactorial Model.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2017 |
An evaluation of the pharmacokinetics of methylphenidate for the treatment of attention-deficit/ hyperactivity disorder.
Topics: Adolescent; Animals; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System St | 2014 |
Methylphenidate and dexmethylphenidate formulations for children with attention-deficit/hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Capsules; Central Nervous System Stimulants; Child; D | 2014 |
Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children.
Topics: Adrenergic Uptake Inhibitors; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder wi | 2014 |
[Analysis of dopamine transporter knockout mice as an animal model of AD/HD].
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Disease Models, Animal; Dopamine Plasma Memb | 2013 |
A review of OROS methylphenidate (Concerta(®)) in the treatment of attention-deficit/hyperactivity disorder.
Topics: Administration, Oral; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulan | 2014 |
Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder: an update.
Topics: Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Blood Pressu | 2014 |
Assessment of potential cardiovascular risks of methylphenidate in comparison with sibutramine: do we need a SCOUT (trial)?
Topics: Adolescent; Adult; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Blood Press | 2015 |
Should we keep on? Looking into pharmacogenomics of ADHD in adulthood from a different perspective.
Topics: Attention Deficit Disorder with Hyperactivity; Databases, Genetic; Dopamine Plasma Membrane Transpor | 2014 |
Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2014 |
Prediction of methylphenidate treatment outcome in adults with attention-deficit/hyperactivity disorder (ADHD).
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Methylphen | 2014 |
Tricyclic antidepressants for attention deficit hyperactivity disorder (ADHD) in children and adolescents.
Topics: Adolescent; Antidepressive Agents, Tricyclic; Attention Deficit Disorder with Hyperactivity; Central | 2014 |
Brain abnormalities in attention-deficit hyperactivity disorder: a review.
Topics: Adolescent; Adult; Atomoxetine Hydrochloride; Attention Deficit and Disruptive Behavior Disorders; A | 2014 |
The potential for misuse and abuse of medications in ADHD: a review.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic Uptake Inhibitors; Amphetamine-Related Disorders; A | 2014 |
Long-Term Efficacy of Methylphenidate Immediate-Release for the Treatment of Childhood ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Drug Admini | 2017 |
Current evidence and future directions for research with omega-3 fatty acids and attention deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child Nutri | 2015 |
[Summary of the Dutch College of General Practitioners' (NHG) practice guideline 'ADHD in children'].
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; | 2015 |
Predicted effect size of lisdexamfetamine treatment of attention deficit/hyperactivity disorder (ADHD) in European adults: Estimates based on indirect analysis using a systematic review and meta-regression analysis.
Topics: Adult; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2015 |
Drugs for ADHD.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Delayed-A | 2015 |
Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with | 2015 |
Childhood attention-deficit/hyperactivity disorder.
Topics: Adolescent; Age Factors; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimu | 2015 |
Methylphenidate use in children with attention deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Brazil; Central Nervous System Stimulants; Child; Hum | 2015 |
Methylphenidate in Adults with Attention Deficit Hyperactivity Disorder and Substance Use Disorders.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Comorbidity | 2015 |
Aptensio XR--another long-acting methylphenidate.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Delayed-A | 2015 |
Meta-Analysis: Risk of Tics Associated With Psychostimulant Use in Randomized, Placebo-Controlled Trials.
Topics: Adolescent; Amphetamine; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimu | 2015 |
[Methylphenidate].
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; J | 2015 |
Long-Term Pharmacotherapy of Adults With Attention Deficit Hyperactivity Disorder: A Literature Review and Clinical Study.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hype | 2016 |
Recent Trends in Stimulant Usage.
Topics: Adolescent; Adult; Age Distribution; Amphetamines; Attention Deficit Disorder with Hyperactivity; Ce | 2016 |
Are there any potentially dangerous pharmacological effects of combining ADHD medication with alcohol and drugs of abuse? A systematic review of the literature.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Alcohol Drinking; Atomoxetine Hydrochloride; Attention Def | 2015 |
Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2015 |
Psychopharmacology of Attention-Deficit Hyperactivity Disorder: Effects and Side Effects.
Topics: Attention Deficit Disorder with Hyperactivity; Humans; Methylphenidate; Psychopharmacology | 2016 |
Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: Cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trials.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2015 |
Examining why patients with attention-deficit/hyperactivity disorder lack adherence to medication over the long term: a review and analysis.
Topics: Adolescent; Amphetamines; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2015 |
[Substitution therapy tested against amphetamine dependence].
Topics: Amphetamine-Related Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System | 2016 |
Pharmacotherapy for mental health problems in people with intellectual disability.
Topics: Aggression; Anticonvulsants; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Ce | 2016 |
From Clinical Application to Cognitive Enhancement: The Example of Methylphenidate.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cognition | 2016 |
A network meta-analysis of atomoxetine and osmotic release oral system methylphenidate in the treatment of attention-deficit/hyperactivity disorder in adult patients.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hype | 2016 |
Effects of methylphenidate on executive functioning in attention-deficit/hyperactivity disorder across the lifespan: a meta-regression analysis.
Topics: Adolescent; Adult; Age Factors; Attention Deficit Disorder with Hyperactivity; Central Nervous Syste | 2016 |
To meta-analyze or not to meta-analyze? A combined meta-analysis of N-of-1 trial data with RCT data on amphetamines and methylphenidate for pediatric ADHD.
Topics: Adolescent; Amphetamine; Attention Deficit Disorder with Hyperactivity; Biomedical Research; Child; | 2016 |
N-of-1 trials can be aggregated to generate group mean treatment effects: a systematic review and meta-analysis.
Topics: Adolescent; Amphetamine; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Fem | 2016 |
Treatment of Attention-Deficit/Hyperactivity Disorder in Adolescents: A Systematic Review.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Amphetamines; Atomoxetine Hydrochloride; Attention | 2016 |
Attention-deficit hyperactivity disorder in adults: A systematic review and meta-analysis of genetic, pharmacogenetic and biochemical studies.
Topics: Adult; Alleles; Attention Deficit Disorder with Hyperactivity; Biomarkers; Docosahexaenoic Acids; Do | 2016 |
WITHDRAWN: Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2016 |
Classics in Chemical Neuroscience: Methylphenidate.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; M | 2016 |
Safety and efficacy considerations due to misuse of extended-release formulations of stimulant medications.
Topics: Amphetamine; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Dosag | 2016 |
Attention Deficit Hyperactive Disorder and Occurrence of Tic Disorders in Children and Adolescents-What is the Verdict.
Topics: Adolescent; Adrenergic alpha-Agonists; Attention Deficit Disorder with Hyperactivity; Child; Comorbi | 2016 |
An Evaluation on the Efficacy and Safety of Treatments for Attention Deficit Hyperactivity Disorder in Children and Adolescents: a Comparison of Multiple Treatments.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Clonidi | 2017 |
A Systematic Review of the Use of Bupropion for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Bupropion; Child; Dopamine Uptake Inhibit | 2017 |
Current and Investigational Medication Delivery Systems for Treating Attention-Deficit/Hyperactivity Disorder.
Topics: Adrenergic Agents; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperact | 2016 |
Optimizing outcomes in ADHD treatment: from clinical targets to novel delivery systems.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic Uptake Inhibitors; Anxiety Disorders; Atomoxetine H | 2016 |
Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: Meta-analysis based on head-to-head trials.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2017 |
New Formulations of Methylphenidate for the Treatment of Attention-Deficit/Hyperactivity Disorder: Pharmacokinetics, Efficacy, and Tolerability.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Delayed-Action Pre | 2017 |
Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine.
Topics: Adolescent; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; | 2017 |
An update on the safety of psychostimulants for the treatment of attention-deficit/hyperactivity disorder.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; Hu | 2017 |
Safety of therapeutic methylphenidate in adults: a systematic review of the evidence.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Evidence-Ba | 2009 |
Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; | 2008 |
Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
Topics: Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nerv | 2008 |
Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Humans; Meta-Analysis as Topic; Methylphenidat | 2009 |
ADHD and the rise in stimulant use among children.
Topics: Adolescent; Amphetamines; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2008 |
Effect of stimulants on height and weight: a review of the literature.
Topics: Amphetamine; Attention Deficit Disorder with Hyperactivity; Body Height; Body Weight; Central Nervou | 2008 |
[Long-acting medications for the treatment of hyperkinetic disorders - a systematic review and European treatment guideline. Part 1: overview and recommendations].
Topics: Amphetamines; Attention Deficit Disorder with Hyperactivity; Biological Availability; Central Nervou | 2008 |
[Long-acting medications for the treatment of hyperkinetic disorders - a systematic review and European treatment guidelines. Part 2: a quantitative evaluation of long-acting medications].
Topics: Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nerv | 2008 |
Attention deficit/hyperactivity disorder: a review and update.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Causality; Central Nervous System S | 2008 |
Medications for adolescents with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Amphetamines; Attention Deficit | 2008 |
Psychopharmacological and other treatments in preschool children with attention-deficit/hyperactivity disorder: current evidence and practice.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child, Preschool; | 2008 |
[Use of psychotropic drugs in children].
Topics: Adolescent; Age Factors; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Anxiety Dis | 2008 |
Evolution of stimulants to treat ADHD: transdermal methylphenidate.
Topics: Administration, Cutaneous; Amphetamine; Attention Deficit Disorder with Hyperactivity; Central Nervo | 2009 |
Attention deficits, Attention-Deficit Hyperactivity Disorder, and intellectual disabilities.
Topics: Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; Child; Chro | 2008 |
Amfetamine for attention deficit hyperactivity disorder in people with intellectual disabilities.
Topics: Amphetamine; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child | 2009 |
Pathophysiology of NSS in ADHD.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Brain Damage, Chronic; Central Nervous Syste | 2009 |
InforMatrix for attention deficit hyperactivity disorder.
Topics: Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hy | 2009 |
Transdermal methylphenidate system: old wine in a new bottle.
Topics: Administration, Cutaneous; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2009 |
ADHD in children and adolescents.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit and Disruptive Behavior Disorders; Attentio | 2008 |
Systematic review of interventions for children with Fetal Alcohol Spectrum Disorders.
Topics: Alcohol-Induced Disorders, Nervous System; Antipsychotic Agents; Attention Deficit Disorder with Hyp | 2009 |
An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Amphetamines; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2009 |
Attention-deficit-hyperactivity disorder: an update.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Amphetamine; Antidepressive Agents, Second-Generati | 2009 |
Attention-deficit disorders and epilepsy in childhood: incidence, causative relations and treatment possibilities.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Agents; Child; | 2009 |
Clinical considerations for the diagnosis and treatment of ADHD in the managed care setting.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivi | 2009 |
The role of pharmacotherapy and managed care pharmacy interventions in the treatment of ADHD.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivi | 2009 |
Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders.
Topics: Adrenergic alpha-Agonists; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; | 2009 |
Neurobiology of ADHD.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Brain; Child; Dopamine; Executive Function; | 2009 |
Illicit methylphenidate use: a review of prevalence, availability, pharmacology, and consequences.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Drug Prescriptions | 2009 |
Drug reinforcement in a rat model of attention deficit/hyperactivity disorder--the Spontaneously Hypertensive Rat (SHR).
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Disease M | 2009 |
[Neuropsychopharmacological effects of methylphenidate].
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; M | 2009 |
OROS methylphenidate for the treatment of adults with attention-deficit/hyperactivity disorder.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Drug Admini | 2009 |
[Attention Deficit Hyperactivity Disorder (ADHD) and road traffic - special considerations for the treatment of adolescents with ADHD].
Topics: Accidents, Traffic; Adolescent; Adrenergic Uptake Inhibitors; Adult; Amphetamines; Atomoxetine Hydro | 2009 |
The neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety.
Topics: Adrenergic Uptake Inhibitors; Amphetamine; Animals; Atomoxetine Hydrochloride; Attention Deficit Dis | 2009 |
Safety of stimulant treatment in attention deficit hyperactivity disorder: Part I.
Topics: Adolescent; Adult; Amphetamine; Attention Deficit Disorder with Hyperactivity; Central Nervous Syste | 2009 |
Treating attention-deficit/hyperactivity disorder beyond symptom control alone in children and adolescents: a review of the potential benefits of long-acting stimulants.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2010 |
Diagnosis and management of ADHD: a new way forward?
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; | 2009 |
Dexmethylphenidate extended release: a review of its use in the treatment of attention-deficit hyperactivity disorder.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2009 |
Prospective follow-up studies found no chromosomal mutagenicity of methylphenidate therapy in ADHD affected children.
Topics: Attention Deficit Disorder with Hyperactivity; Carcinogens; Central Nervous System Stimulants; Child | 2010 |
[Care continuity for patients with attention deficit hyperactivity disorder (ADHD) during transition from childhood to adulthood].
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2010 |
Progress and promise of attention-deficit hyperactivity disorder pharmacogenetics.
Topics: Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Catechol O-Me | 2010 |
Review of medication adherence in children and adults with ADHD.
Topics: Adolescent; Adult; Age Factors; Attention Deficit Disorder with Hyperactivity; Central Nervous Syste | 2010 |
[Methylphenidate. Therapy option for adults with ADHD and comorbid substance use disorder?].
Topics: Adult; Amphetamine-Related Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous | 2010 |
A current update on ADHD pharmacogenomics.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with | 2010 |
[Attention deficit hyperactivity disorder].
Topics: Adolescent; Animals; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System St | 2009 |
Attention deficit and hyperactivity disorder in people with epilepsy: diagnosis and implications to the treatment.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Electroencephalogr | 2010 |
What are the cognitive effects of stimulant medications? Emphasis on adults with attention-deficit/hyperactivity disorder (ADHD).
Topics: Achievement; Adult; Amphetamine; Attention Deficit Disorder with Hyperactivity; Central Nervous Syst | 2010 |
Pharmacogenetic approach for a better drug treatment in children.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Clinica | 2010 |
[Attention deficit disorder and hyperactivity: does the treatment affect the statural growth?].
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cost-Benefit Analy | 2010 |
Attention deficit hyperactivity disorder in adults.
Topics: Adrenergic Uptake Inhibitors; Adult; Age Factors; Amphetamines; Atomoxetine Hydrochloride; Attention | 2010 |
Methylphenidate-induced psychosis in adult attention-deficit/hyperactivity disorder: report of 3 new cases and review of the literature.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Central Nervous System Stimu | 2010 |
Treatment of preschoolers with attention-deficit/hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; | 2010 |
Attention-deficit/Hyperactivity Disorder in the context of Autism spectrum disorders.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child Development Disorders, Pervasive; Execut | 2010 |
Question 2 Should a child with ADHD and epilepsy be given ritalin?
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Epilepsy; E | 2010 |
Role of zinc in the pathogenesis of attention-deficit hyperactivity disorder: implications for research and treatment.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Dietary Supplement | 2010 |
Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder.
Topics: Adrenergic Uptake Inhibitors; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder wi | 2010 |
Core ADHD symptom improvement with atomoxetine versus methylphenidate: a direct comparison meta-analysis.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2011 |
The role of alpha2-adrenergic agonists in attention-deficit/hyperactivity disorder.
Topics: Adrenergic alpha-Agonists; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2010 |
Understanding the effects of stimulant medications on cognition in individuals with attention-deficit hyperactivity disorder: a decade of progress.
Topics: Amphetamine; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimul | 2011 |
Review of pharmacotherapy options for the treatment of attention-deficit/hyperactivity disorder (ADHD) and ADHD-like symptoms in children and adolescents with developmental disorders.
Topics: Adolescent; Amphetamines; Antipsychotic Agents; Atomoxetine Hydrochloride; Attention Deficit Disorde | 2010 |
Pharmacokinetic variability of long-acting stimulants in the treatment of children and adults with attention-deficit hyperactivity disorder.
Topics: Adult; Amphetamines; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulant | 2010 |
The neurobiological basis of ADHD.
Topics: Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Basal Ganglia; Be | 2010 |
Advances in the treatment of attention-deficit/hyperactivity disorder: a guide for pediatric neurologists.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Atten | 2010 |
OROS methylphenidate hydrochloride for adult patients with attention deficit/hyperactivity disorder.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Delayed-Act | 2011 |
Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-regression analysis.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Comorbidity; Delayed-Action Preparations; Diag | 2011 |
Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-regression analysis.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Comorbidity; Delayed-Action Preparations; Diag | 2011 |
Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-regression analysis.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Comorbidity; Delayed-Action Preparations; Diag | 2011 |
Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-regression analysis.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Comorbidity; Delayed-Action Preparations; Diag | 2011 |
Pharmacotherapy for child and adolescent attention-deficit hyperactivity disorder.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Adrenergic Uptake Inhibitors; Amphetamines; Atomox | 2011 |
How oppositionality, inattention, and hyperactivity affect response to atomoxetine versus methylphenidate: a pooled meta-analysis.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit and Disruptive Behavior Disorders; Attentio | 2012 |
Another extended-release α2-agonist for ADHD.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Attention Deficit Disorder with Hyperactivity; Child; | 2011 |
[Towards an understanding of the molecular mechanisms underlying the pharmacological treatments of attention deficit hyperactivity disorder].
Topics: Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nerv | 2011 |
Methylphenidate transdermal system: in attention-deficit hyperactivity disorder in adolescents.
Topics: Administration, Cutaneous; Adolescent; Attention Deficit Disorder with Hyperactivity; Clinical Trial | 2011 |
Cognitive and emotional behavioural changes associated with methylphenidate treatment: a review of preclinical studies.
Topics: Adolescent; Animals; Attention Deficit Disorder with Hyperactivity; Behavior; Brain; Central Nervous | 2012 |
Pharmacological treatment of ADHD and the short and long term effects on sleep.
Topics: Actigraphy; Adolescent; Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous Syst | 2011 |
Catecholamine influences on dorsolateral prefrontal cortical networks.
Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Animals; Arousal; Atomoxetine Hydrochloride | 2011 |
The challenges to demonstrating long-term effects of psychostimulant treatment for attention-deficit/hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Dextroamphetamine; | 2011 |
Efficacy and safety of methylphenidate in treating ADHD symptoms in children and adolescents with uncontrolled seizures: a Brazilian sample study and literature review.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Brazil; Central Nervous System Stimulants | 2011 |
[Effectiveness and safety of methylphenidate and atomoxetine for attention deficit hyperactivity disorder: a systematic review].
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Delayed-Action Preparation | 2011 |
Cognitive enhancers for the treatment of ADHD.
Topics: Adult; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; | 2011 |
[Stimulant and non-stimulant medication in current and future therapy for ADHD].
Topics: Adrenergic alpha-2 Receptor Agonists; Adult; Amphetamines; Atomoxetine Hydrochloride; Attention Defi | 2012 |
ADHD in children and adolescents.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit and Disruptive Behavior Disorders; Attentio | 2011 |
Utility of the electroencephalogram in attention deficit hyperactivity disorder.
Topics: Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Brain Waves; Central Nervous System | 2011 |
Brain processes in discounting: consequences of adolescent methylphenidate exposure.
Topics: Adolescent; Animals; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System St | 2012 |
Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2011 |
[Efficacy and safety of stimulants and non-stimulants in adults with attention deficit hyperactivity disorder (ADHD)].
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Agents; Central Nervous | 2011 |
Methylphenidate transdermal system: clinical applications for attention-deficit/hyperactivity disorder.
Topics: Administration, Cutaneous; Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous S | 2011 |
Population pharmacodynamic modeling of various extended-release formulations of methylphenidate in children with attention deficit hyperactivity disorder via meta-analysis.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Delayed-Action Preparations; Female; Humans; M | 2012 |
Attention-deficit/hyperactivity disorder, stimulant therapy, and the patient with congenital heart disease: evidence and reason.
Topics: Amphetamines; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Coro | 2012 |
The genetic toxicity of methylphenidate: a review of the current literature.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Dopamine Uptake Inhibitors; Humans; Methylph | 2012 |
[Deficient adaptive regulation of emotion in children with ADHD].
Topics: Adaptation, Psychological; Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2012 |
[Diagnosis and treatment of attention deficit hyperactivity disorder in adults].
Topics: Adult; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autom | 2012 |
[Attention deficit hyperactivity disorder and epilepsy in childhood].
Topics: Adolescent; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Causality; Child; Child, | 2012 |
[Methylphenidate misuse].
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cross-Sectional St | 2012 |
[Diagnostic validity of attention deficit/hyperactivity disorder: from phenomenology to neurobiology (II)].
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Brain; Brain Mapping; Cognition; Diagnosti | 2012 |
Metabolic, toxicological, and safety considerations for drugs used to treat ADHD.
Topics: Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nerv | 2012 |
Revisiting clonidine: an innovative add-on option for attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adrenergic alpha-Agonists; Amphetamine; Attention Deficit Disorder with Hyperactivity; B | 2012 |
Comorbid attention deficit/hyperactivity disorder and substance use disorder: treatment considerations.
Topics: Adolescent; Adult; Age Factors; Attention Deficit Disorder with Hyperactivity; Central Nervous Syste | 2012 |
Adderall abuse on college campuses: a comprehensive literature review.
Topics: Amphetamine-Related Disorders; Amphetamines; Attention Deficit Disorder with Hyperactivity; Central | 2012 |
Pharmacogenetics of response to methylphenidate in adult patients with Attention-Deficit/Hyperactivity Disorder (ADHD): a systematic review.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; Dopa | 2013 |
Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options.
Topics: Amphetamine; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child | 2012 |
Attention-deficit hyperactivity disorder and cardiac vagal control: a systematic review.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Emotions; Heart; H | 2012 |
Question 3. Should stimulants be administered to manage difficulties with attention, hyperactivity and impulsivity following paediatric acquired brain injury?
Topics: Accidents, Traffic; Attention Deficit Disorder with Hyperactivity; Brain Injuries; Central Nervous S | 2012 |
Long-term efficacy and safety of treatment with stimulants and atomoxetine in adult ADHD: a review of controlled and naturalistic studies.
Topics: Adrenergic Uptake Inhibitors; Adult; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disor | 2013 |
Evolution of the Study of Methylphenidate and Its Actions on the Adult Versus Juvenile Brain.
Topics: Adult; Age Factors; Animals; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous S | 2015 |
Does a normalizing electroencephalogram in benign childhood epilepsy with centrotemporal spikes abort attention deficit hyperactivity disorder?
Topics: Age of Onset; Anticonvulsants; Attention; Attention Deficit Disorder with Hyperactivity; Central Ner | 2012 |
[Clinical use of 30:70 controlled-release methylphenidate in the treatment of attention deficit hyperactivity disorder].
Topics: Attention Deficit Disorder with Hyperactivity; Dopamine Uptake Inhibitors; Drug Administration Sched | 2012 |
Treatment discontinuation with methylphenidate in adults with attention deficit hyperactivity disorder: a meta-analysis of randomized clinical trials.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Chi-Square | 2013 |
[Effects of methylphenidate on anxiety].
Topics: Adolescent; Adult; Age Factors; Animals; Anti-Anxiety Agents; Anxiety; Anxiety Disorders; Attention | 2012 |
First trimester in utero exposure to methylphenidate.
Topics: Adult; Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Fe | 2013 |
Efficacy and adverse effects of venlafaxine in children and adolescents with ADHD: a systematic review of non-controlled and controlled trials.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2013 |
MR imaging of the effects of methylphenidate on brain structure and function in attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adolescent Behavior; Adolescent Development; Animals; Attention Deficit Disorder with Hy | 2013 |
Pharmacological and clinical dilemmas of prescribing in co-morbid adult attention-deficit/hyperactivity disorder and addiction.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hype | 2014 |
Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Blood Pressure | 2013 |
MethyPatch Noven.
Topics: Administration, Cutaneous; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2002 |
Dexmethylphenidate.
Topics: Absorption; Attention Deficit Disorder with Hyperactivity; Child; Dexmethylphenidate Hydrochloride; | 2002 |
Attention deficit hyperactivity disorder in children.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; | 2002 |
Comparative efficacy of Adderall and methylphenidate in attention-deficit/hyperactivity disorder: a meta-analysis.
Topics: Adolescent; Amphetamines; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2002 |
Extended-release methylphenidate (Ritalin LA).
Topics: Administration, Oral; Adult; Attention Deficit Disorder with Hyperactivity; Child; Delayed-Action Pr | 2002 |
Controversies in ADHD. Fundamental questions being answered slowly, but scientifically.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Biofeedback, Psychology; Central Ne | 2002 |
Attention deficit/hyperactivity disorder and methylphenidate. A review of height/weight, cardiovascular, and somatic complaint side effects.
Topics: Attention Deficit Disorder with Hyperactivity; Blood Pressure; Body Height; Body Weight; Central Ner | 2002 |
Dexmethylphenidate--Novartis/Celgene. Focalin, D-MPH, D-methylphenidate hydrochloride, D-methylphenidate, dexmethylphenidate, dexmethylphenidate hydrochloride.
Topics: Attention Deficit Disorder with Hyperactivity; Clinical Trials as Topic; Dexmethylphenidate Hydrochl | 2002 |
Role of dopamine in the therapeutic and reinforcing effects of methylphenidate in humans: results from imaging studies.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Brain; Dopamine; Dopamine Plasma Membrane Tr | 2002 |
Ritalin revisited: does it really help in neurological injury?
Topics: Attention Deficit Disorder with Hyperactivity; Brain Injuries; Brain Neoplasms; Central Nervous Syst | 2002 |
Management of ADHD in adults.
Topics: Adolescent; Adult; Age Factors; Amphetamines; Antidepressive Agents; Antihypertensive Agents; Attent | 2002 |
Management of ADHD in adults.
Topics: Adolescent; Adult; Age Factors; Amphetamines; Antidepressive Agents; Antihypertensive Agents; Attent | 2002 |
Management of ADHD in adults.
Topics: Adolescent; Adult; Age Factors; Amphetamines; Antidepressive Agents; Antihypertensive Agents; Attent | 2002 |
Management of ADHD in adults.
Topics: Adolescent; Adult; Age Factors; Amphetamines; Antidepressive Agents; Antihypertensive Agents; Attent | 2002 |
Psychosocial treatments for attention-deficit/hyperactivity disorder in children.
Topics: Adolescent; Adult; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Behavior Th | 2002 |
Attention deficit hyperactivity disorder in children.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; | 2002 |
Attention-deficit/hyperactivity disorder: current aspects on pharmacogenetics.
Topics: Attention Deficit Disorder with Hyperactivity; DNA-Binding Proteins; Dopamine Plasma Membrane Transp | 2003 |
Forty years of methylphenidate treatment in Attention-Deficit/ Hyperactivity Disorder.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2002 |
Longer term effects of stimulant treatments for Attention-Deficit/Hyperactivity Disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; | 2002 |
Responses to methylphenidate in Attention-Deficit/Hyperactivity Disorder and normal children: update 2002.
Topics: Adolescent; Adult; Arousal; Attention Deficit Disorder with Hyperactivity; Central Nervous System St | 2002 |
Guidelines and algorithms for the use of methylphenidate in children with Attention-Deficit/ Hyperactivity Disorder.
Topics: Adolescent; Algorithms; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimul | 2002 |
[Behavioral and pharmacological studies of juvenile stroke-prone spontaneously hypertensive rats as an animal model of attention-deficit/hyperactivity disorder].
Topics: Animals; Anxiety; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2003 |
Clinical inquiries. Does increasing methylphenidate dose aid symptom control in ADHD?
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Dose-Respon | 2003 |
Attention deficit and hyperactivity disorder: review of genetic association studies.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; DNA-Binding | 2003 |
A review of the biological bases of ADHD: what have we learned from imaging studies?
Topics: Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; Cognition D | 2003 |
Attention deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Clonidine; Combined Modality Therapy; Dextroam | 2003 |
Attention deficit hyperactivity disorder in sport: a review.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Clinical Trials as | 2003 |
Primary pulmonary hypertension after amfepramone (diethylpropion) with BMPR2 mutation.
Topics: Adult; Appetite Depressants; Attention Deficit Disorder with Hyperactivity; Bone Morphogenetic Prote | 2003 |
Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient.
Topics: Adult; Animals; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimula | 2003 |
[Basics of the drug therapy for attention deficit hyperactivity disorders in adolescents].
Topics: Adolescent; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Brain; Central Ner | 2003 |
Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: focus on methylphenidate formulations.
Topics: Attention Deficit Disorder with Hyperactivity; Delayed-Action Preparations; Dopamine Uptake Inhibito | 2003 |
Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Brain; Cocaine; Delayed-Action Preparations; Dopamine | 2003 |
Serum and brain concentrations of methylphenidate: implications for use and abuse.
Topics: Administration, Oral; Adolescent; Attention Deficit Disorder with Hyperactivity; Brain; Brain Chemis | 2003 |
[Attention deficit/hyperactivity disorder].
Topics: Antidepressive Agents, Tricyclic; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2003 |
[Conduct disorder, unsocialized and socialized].
Topics: Antipsychotic Agents; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nerv | 2003 |
Long-term use of stimulants in children with attention deficit hyperactivity disorder: safety, efficacy, and long-term outcome.
Topics: Adolescent; Adolescent Behavior; Attention Deficit Disorder with Hyperactivity; Central Nervous Syst | 2003 |
Stimulant therapy in attention deficit/hyperactivity disorder.
Topics: Amphetamines; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Chil | 2003 |
[Medical treatments of hyperactive child].
Topics: Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Beh | 2004 |
Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Humans; Methylphenidate; Treatment Outcome | 2004 |
Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder.
Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents; Antidepressiv | 2004 |
Recent developments in direct consumer advertising of attention disorder stimulants and creating limits to withstand constitutional scrutiny.
Topics: Advertising; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Const | 2003 |
Methylphenidate treatment of attention-deficit/hyperactivity disorder secondary to traumatic brain injury: a critical appraisal of treatment studies.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Brain Injuries; Central Nervous Sy | 2004 |
Evaluation of risks associated with short- and long-term psychostimulant therapy for treatment of ADHD in children.
Topics: Appetite; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; D | 2004 |
Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Biological Availability; Central Nervous System Stimu | 2004 |
Polymorphisms of the dopamine transporter gene: influence on response to methylphenidate in attention deficit-hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Dopamine Plasma Membrane Transport Proteins; D | 2004 |
Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects.
Topics: Adult; Animals; Attention Deficit Disorder with Hyperactivity; Behavior; Brain Injuries; Central Ner | 2004 |
Pharmacological management of attention-deficit hyperactivity disorder.
Topics: Adrenergic alpha-Agonists; Amphetamines; Antidepressive Agents; Atomoxetine Hydrochloride; Attention | 2004 |
Cost-effectiveness of dexamphetamine and methylphenidate for the treatment of childhood attention deficit hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Australia; Central Nervous System Stimula | 2004 |
Clinical inquiries. Is methylphenidate useful for treating adolescents with ADHD?
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Delaye | 2004 |
Experimental investigations on dopamine transmission can provide clues on the mechanism of the therapeutic effect of amphetamine and methylphenidate in ADHD.
Topics: Amphetamine; Animals; Attention Deficit Disorder with Hyperactivity; Disease Models, Animal; Dopamin | 2004 |
Neuronal network models of ADHD -- lateralization with respect to interhemispheric connectivity reconsidered.
Topics: Agenesis of Corpus Callosum; Attention Deficit Disorder with Hyperactivity; Central Nervous System S | 2004 |
[Neurofeedback for the treatment of attention-deficit/hyperactivity disorder (ADHD) in childhood and adolescence].
Topics: Adolescent; Arousal; Attention Deficit Disorder with Hyperactivity; Biofeedback, Psychology; Central | 2004 |
When the child with ADHD grows up.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2004 |
[The relationship between attention deficit hyperactivity disorder and sleep-alertness problems].
Topics: Adrenergic Uptake Inhibitors; Attention Deficit Disorder with Hyperactivity; Child; Dopamine Agents; | 2004 |
[The effectiveness of stimulants of retard forms in children and adolescents with ADHD--a systematic overview].
Topics: Adolescent; Amphetamines; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2004 |
New drugs for the treatment of attention-deficit/hyperactivity disorder.
Topics: Amphetamines; Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hype | 2004 |
New formulations of stimulants for attention-deficit hyperactivity disorder: therapeutic potential.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Clinical Tr | 2004 |
Attention deficit and hyperactivity disorder, methylphenidate, and epilepsy.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Epilepsy; H | 2005 |
Clinical practice. Attention deficit-hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; | 2005 |
Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder.
Topics: Adolescent; Animals; Attention Deficit Disorder with Hyperactivity; Behavior; Central Nervous System | 2005 |
Clinical inquiries. What is the most effective treatment for ADHD in children?
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; | 2005 |
The control of responsiveness in ADHD by catecholamines: evidence for dopaminergic, noradrenergic and interactive roles.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Brain; Catecholamines; Dopamine; Dopamine Pl | 2005 |
Pharmacotherapy of adult ADHD.
Topics: Adolescent; Adult; Age Factors; Amphetamine; Antidepressive Agents; Atomoxetine Hydrochloride; Atten | 2005 |
[Psychiatry].
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Attention Deficit Disorder with Hyperacti | 2005 |
Attention deficit/hyperactivity disorder: working the system for better diagnosis and treatment.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Insurance | 2005 |
Pharmacological management of treatment-induced insomnia in ADHD.
Topics: Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimula | 2005 |
Treatment of attention-deficit/hyperactivity disorder: overview of the evidence.
Topics: Adolescent; Antidepressive Agents, Tricyclic; Atomoxetine Hydrochloride; Attention Deficit Disorder | 2005 |
Methylphenidate HCl: therapy for attention deficit hyperactivity disorder.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Dopamine; Humans; Methylphenidate | 2005 |
Attention-deficit/hyperactivity disorder pharmacogenomics.
Topics: Attention Deficit Disorder with Hyperactivity; Dopamine Agents; Electroencephalography; Genetic Vari | 2005 |
Stimulant actions in rodents: implications for attention-deficit/hyperactivity disorder treatment and potential substance abuse.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Disease M | 2005 |
Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Brain Mapping; Central Nervous System Stimul | 2005 |
Attention-deficit/hyperactivity disorder: advancing on pharmacogenomics.
Topics: Attention Deficit Disorder with Hyperactivity; Dopamine Plasma Membrane Transport Proteins; Dopamine | 2005 |
Dexmethylphenidate extended-release capsules for attention deficit hyperactivity disorder.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Capsules; Delayed-Action Preparations; Dexme | 2005 |
Righting a troubled course. Diagnosing and treating ADHD in adults.
Topics: Adult; Age Factors; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperact | 2005 |
[The effectiveness of atomoxetine in children, adolescents, and adults with ADHD. A systematic overview].
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disord | 2006 |
Attention deficit hyperactivity disorder in children.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Clonidine; Combined | 2005 |
[Attention deficit hyperactivity disorder: pharmacological options that are not "Ritalin"].
Topics: Adrenergic Uptake Inhibitors; Attention Deficit Disorder with Hyperactivity; Central Nervous System | 2005 |
Attention deficit/hyperactivity disorder and psychopharmacologic treatments in the athlete.
Topics: Adolescent; Amphetamines; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2005 |
Regulated expression and function of the somatodendritic catecholamine neurotransmitter transporters.
Topics: Amphetamine; Animals; Attention Deficit Disorder with Hyperactivity; Catecholamines; Central Nervous | 2005 |
Preventing youth violence: an office-based approach.
Topics: Adolescent; Adolescent Behavior; Animal Welfare; Attention Deficit Disorder with Hyperactivity; Chil | 2003 |
Adolescent substance use: brief interventions by emergency care providers.
Topics: Adolescent; Adolescent Behavior; Attention Deficit Disorder with Hyperactivity; Chest Pain; Cocaine- | 2005 |
New methylphenidate formulations for the treatment of attention-deficit/hyperactivity disorder.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Biological Availability; Chemistry, Pharmace | 2005 |
Pharmacotherapy of attention-deficit hyperactivity disorder in children and adolescents: update on new stimulant preparations, atomoxetine, and novel treatments.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2006 |
Attention deficit hyperactivity disorder--a review for family physicians.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central | 2005 |
Attention deficit hyperactivity disorder, tics and Tourette's syndrome: the relationship and treatment implications. A commentary.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivi | 2006 |
Attention deficit hyperactivity disorder, chronic tic disorder, and methylphenidate.
Topics: Adolescent; Age Factors; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimu | 2006 |
Attention deficit/hyperactivity disorder: complexities and controversies.
Topics: Administration, Cutaneous; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with | 2006 |
ADHD in adolescence and adulthood, with a special focus on the dopamine transporter and nicotine.
Topics: Adolescent; Adult; Age Factors; Attention Deficit Disorder with Hyperactivity; Corpus Striatum; Diag | 2006 |
ADHD and the dopamine transporter: are there reasons to pay attention?
Topics: Adult; Animals; Attention Deficit Disorder with Hyperactivity; Base Sequence; Brain; Child; Disease | 2006 |
Pharmacological treatment of attention-deficit/hyperactivity disorder in adults.
Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents, Tricyclic; Atomoxetine Hydrochloride; At | 2006 |
Methylphenidate transdermal system: In attention-deficit hyperactivity disorder in children.
Topics: Administration, Cutaneous; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2006 |
A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child, | 2006 |
Stimulants: Therapeutic actions in ADHD.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Catecholamines; Central Nervous System Stimu | 2006 |
Atomoxetine.
Topics: Administration, Oral; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Dis | 2006 |
Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system.
Topics: Administration, Cutaneous; Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous S | 2006 |
Effectiveness outcomes in attention-deficit/hyperactivity disorder.
Topics: Adult; Algorithms; Amphetamines; Attention Deficit Disorder with Hyperactivity; Child; Clinical Tria | 2006 |
Attention deficit hyperactivity disorder in children.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Clonidine; Combined | 2006 |
The science of stimulant abuse.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; De | 2006 |
Meta-analysis of aggression or hostility events in randomized, controlled clinical trials of atomoxetine for ADHD.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Aged; Aggression; Atomoxetine Hydrochloride; Attention Def | 2007 |
Osmotic, controlled-release methylphenidate for the treatment of ADHD.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2006 |
Methylphenidate controlled-delivery capsules (EquasymXL, Metadate CD): a review of its use in the treatment of children and adolescents with attention-deficit hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Capsules; Central Nervous System Stimulan | 2006 |
[Attention deficit disorder with hyperactivity (ADHD). Continuing symptom control with medium term methylphenidate treatment].
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Delayed-Act | 2006 |
Dexmethylphenidate extended-release capsules for the treatment of attention deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Capsules; Delayed-Action Preparations; Dexmethylpheni | 2006 |
Cognitive effects of immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Cognition; Humans; Methylphe | 2006 |
Optimizing therapy of seizures in children and adolescents with ADHD.
Topics: Adolescent; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Central Nervous System S | 2006 |
Spotlight on methylphenidate controlled-delivery capsules (Equasym XL, Metadate CD) in the treatment of children and adolescents with attention-deficit hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Capsules; Child; Delayed-Action Preparati | 2007 |
Treatment of hyperactivity in children with pervasive developmental disorders.
Topics: Adrenergic alpha-Agonists; Amantadine; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2007 |
Attention deficit hyperactivity disorder across the lifespan: the child, adolescent, and adult.
Topics: Adolescent; Adult; Antidepressive Agents, Tricyclic; Attention Deficit Disorder with Hyperactivity; | 2007 |
Long-acting medications for the hyperkinetic disorders. A note on cost-effectiveness.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cost-Benefit Analy | 2007 |
[My child is so restless].
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivi | 2007 |
[Neuropsychiatric bases of the methylphenidate-therapy of the attention deficit/hyperactivity disorder (ADHD)].
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stim | 2007 |
Update on drugs for hyperactivity in childhood.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivi | 2007 |
ADHD in children, adolescents, and adults.
Topics: Adolescent; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Behavio | 2007 |
Multimodal treatments for childhood attention-deficit/hyperactivity disorder: interpreting outcomes in the context of study designs.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Combined Mo | 2007 |
Children with autism spectrum disorders and intellectual disability.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with | 2007 |
Attention deficit/hyperactivity disorder in adults.
Topics: Adult; Age Factors; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants | 2007 |
Exposure to attention deficit hyperactivity disorder medications during pregnancy.
Topics: Abnormalities, Drug-Induced; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivit | 2007 |
The consequences of attention-deficit/hyperactivity disorder in adults.
Topics: Achievement; Adult; Age Factors; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder | 2007 |
[Off-label use in psychiatry].
Topics: Attention Deficit Disorder with Hyperactivity; Drug Approval; Drug Prescriptions; Drug Utilization; | 2008 |
Beyond methylphenidate: nonstimulant medications for youth with ADHD.
Topics: Anticonvulsants; Antidepressive Agents; Antihypertensive Agents; Antipsychotic Agents; Attention Def | 2007 |
Interaction of attention and graphomotor functions in children with attention deficit hyperactivity disorder.
Topics: Agraphia; Attention; Attention Deficit Disorder with Hyperactivity; Awareness; Biomechanical Phenome | 2007 |
Brief review of available evidence concerning the potential induction of genomic damage by methylphenidate.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; DNA Damag | 2008 |
Psychopharmacological treatment for very young children: contexts and guidelines.
Topics: Algorithms; Amphetamines; Antidepressive Agents; Antipsychotic Agents; Atomoxetine Hydrochloride; At | 2007 |
Use of medication in children with psychiatric disorders.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child Psychiatry; D | 2007 |
Attention-deficit/hyperactivity disorder in pediatric patients with epilepsy: review of pharmacological treatment.
Topics: Adolescent; Adult; Amphetamines; Attention Deficit Disorder with Hyperactivity; Central Nervous Syst | 2008 |
Efficacy of methylphenidate, psychosocial treatments and their combination in school-aged children with ADHD: a meta-analysis.
Topics: Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; | 2008 |
An expert opinion on methylphenidate treatment for attention deficit hyperactivity disorder in pediatric patients with epilepsy.
Topics: Animals; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2008 |
Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature.
Topics: Adolescent; Adult; Amphetamines; Attention Deficit Disorder with Hyperactivity; Central Nervous Syst | 2008 |
ADHD, substance use disorders, and psychostimulant treatment: current literature and treatment guidelines.
Topics: Amphetamine; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child | 2008 |
Has NICE got it right? An international perspective considering the case of Technology Appraisal No. 98 by the National Institute for Health and Clinical Excellence (NICE).
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2008 |
Attention deficit hyperactivity disorder and substance use disorders.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Bupropion; Central Nervous System Stimula | 2008 |
Attention deficit hyperactivity disorder in preschool children.
Topics: Age Factors; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child | 2008 |
Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Appetite; Atomoxetine Hydrochloride; Attention Deficit Dis | 2008 |
Practical management of cutaneous reactions to the methylphenidate transdermal system: recommendations from a dermatology expert panel consensus meeting.
Topics: Administration, Cutaneous; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2008 |
Medication options when treating children and adolescents with ADHD: interpreting the NICE guidance 2006.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with | 2008 |
Beyond the 'typical' patient: treating attention-deficit/hyperactivity disorder in preschoolers and adults.
Topics: Adult; Age Factors; Age of Onset; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperac | 2008 |
New perspectives from microdialysis studies in freely-moving, spontaneously hypertensive rats on the pharmacology of drugs for the treatment of ADHD.
Topics: Amphetamine; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Dise | 2008 |
Catecholamine dysfunction in attention-deficit/hyperactivity disorder: an update.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2008 |
Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Corpus Stri | 2008 |
Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter?
Topics: Adolescent; Adult; Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System St | 2008 |
Does chirality matter? pharmacodynamics of enantiomers of methylphenidate in patients with attention-deficit/hyperactivity disorder.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; Co | 2008 |
[What's new about hyperactivity disorder in children?].
Topics: Adrenergic Uptake Inhibitors; Age Factors; Atomoxetine Hydrochloride; Attention Deficit Disorder wit | 2008 |
ADHD treatment in Latin America and the Caribbean.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Caribbean Region; Central Nervous System | 2008 |
The efficacy of stimulant drug treatment for hyperactivity: a meta-analysis.
Topics: Achievement; Attention; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Body Height; | 1982 |
Stimulant drug effects in developmental disorders and hyperactivity--toward a resolution of disparate findings.
Topics: Amphetamines; Animals; Attention; Attention Deficit Disorder with Hyperactivity; Autistic Disorder; | 1982 |
Medication and hyperactivity: a meta-analysis.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Dextroa | 1983 |
Effects of stimulant drugs on academic performance in hyperactive and learning disabled children.
Topics: Achievement; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimul | 1983 |
[Biological backgrounds of the hyperkinetic syndrome].
Topics: Arousal; Attention Deficit Disorder with Hyperactivity; Brain; Brain Diseases; Catecholamines; Cereb | 1983 |
Stimulant medications in adults with attention deficit disorder.
Topics: Adolescent; Adult; Amitriptyline; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 1984 |
Neuropharmacological basis of stimulant drug action in attention deficit disorder with hyperactivity: a review and synthesis.
Topics: Animals; Attention; Attention Deficit Disorder with Hyperactivity; Brain Chemistry; Central Nervous | 1984 |
Developmental and pharmacological aspects of attention deficit disorder (ADD).
Topics: Aging; Animals; Attention Deficit Disorder with Hyperactivity; Brain Chemistry; Disease Models, Anim | 1983 |
Hyperactivity (attention-deficit disorder).
Topics: Attention Deficit Disorder with Hyperactivity; Child; Dextroamphetamine; Family; Female; Humans; Hyp | 1984 |
Drug treatment for hyperactive children. Therapeutic guidelines.
Topics: Antidepressive Agents, Tricyclic; Attention Deficit Disorder with Hyperactivity; Child; Dextroamphet | 1993 |
Neuroendocrine responses to methylphenidate and d-amphetamine: applications to attention-deficit disorder.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 1991 |
Major treatment considerations for attention-deficit hyperactivity disorder.
Topics: Antidepressive Agents, Tricyclic; Attention Deficit Disorder with Hyperactivity; Child; Dextroamphet | 1995 |
The dual diagnosis of attention-deficit/hyperactivity disorder and substance abuse: case reports and literature review.
Topics: Adult; Alcoholism; Attention Deficit Disorder with Hyperactivity; Comorbidity; Diagnosis, Dual (Psyc | 1995 |
The role of methylphenidate in psychiatry.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Child; Cost-Benefit Analysis; Fema | 1995 |
Disruptive behavior, hyperactivity, and learning disabilities in children with Tourette's syndrome.
Topics: Adolescent; Antidepressive Agents, Tricyclic; Attention Deficit Disorder with Hyperactivity; Child; | 1995 |
Hemispheric processing and methylphenidate effects in attention-deficit hyperactivity disorder.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Cerebral Cortex; Child; Dominance, Cerebra | 1994 |
Therapy for attention-deficit hyperactivity disorder.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Female; H | 1994 |
[Attention deficit disorder with hyperactivity].
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Child, Pr | 1994 |
Methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Drug Intera | 1996 |
Adults with attention deficit hyperactivity disorder: assessment and treatment considerations.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Methylphen | 1996 |
Inhibition and attention deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Brain Mapping; Central Nervous System Stimulants; Chi | 1997 |
Optimizing ADHD therapy with sustained-release methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Delayed-Action Pre | 1997 |
Error patterns on the continuous performance test in non-medicated and medicated samples of children with and without ADHD: a meta-analytic review.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 1996 |
[Methylphenidate (Ritalin) treatment in attention deficit hyperactivity disorder].
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 1997 |
Attention-deficit/hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Lea | 1997 |
Safety issues in the use of methylphenidate. An American perspective.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Controlled | 1997 |
What is so special about special education?
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Combined Modalit | 1997 |
Antidepressants in the treatment of attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adult; Age Factors; Antidepressive Agents; Antidepressive Agents, Tricyclic; Attention D | 1997 |
Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association.
Topics: Adolescent; American Medical Association; Attention Deficit Disorder with Hyperactivity; Central Ner | 1998 |
Attention-deficit/hyperactivity disorder: a life-span perspective.
Topics: Adolescent; Adult; Age Factors; Antidepressive Agents, Tricyclic; Attention Deficit Disorder with Hy | 1998 |
Diagnosing attention-deficit/hyperactivity disorder in children.
Topics: Adolescent; Adult; Age Factors; Attention Deficit Disorder with Hyperactivity; Child; Child, Prescho | 1998 |
Psychopharmacology of ADHD: children and adolescents.
Topics: Adolescent; Age Factors; Amphetamines; Antidepressive Agents, Tricyclic; Attention Deficit Disorder | 1998 |
Adults with attention-deficit/hyperactivity disorder: a controversial diagnosis.
Topics: Adolescent; Adult; Age Factors; Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit | 1998 |
Pharmacotherapy of attention-deficit/hyperactivity disorder in adults.
Topics: Adult; Age Factors; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants | 1998 |
Attention deficit/hyperactivity disorder--from brain dysfunctions to behaviour.
Topics: Adult; Animals; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimula | 1998 |
Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration.
Topics: Adult; Animals; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimula | 1998 |
Anti-hyperactivity medication: methylphenidate and amphetamine.
Topics: Adult; Amino Acid Sequence; Amphetamine; Animals; Attention Deficit Disorder with Hyperactivity; Cen | 1998 |
[Central stimulants in adults with AD/HD. Do they help?].
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Controlled | 1998 |
The use of psychostimulants in the pediatric patient.
Topics: Adolescent; Amphetamines; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 1998 |
A comparative analysis of antidepressants and stimulants for the treatment of adults with attention-deficit hyperactivity disorder.
Topics: Adult; Antidepressive Agents, Tricyclic; Attention Deficit Disorder with Hyperactivity; Central Nerv | 1999 |
Treatment of attention-deficit-hyperactivity disorder.
Topics: Adrenergic alpha-Agonists; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Beh | 1999 |
Stimulants and tic disorders: from dogma to data.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Clinical Trials as | 1999 |
National trends in the prevalence of attention-deficit/hyperactivity disorder and the prescribing of methylphenidate among school-age children: 1990-1995.
Topics: Adolescent; Age Factors; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Dru | 1999 |
Aggressive behavior in patients with attention-deficit/hyperactivity disorder, conduct disorder, and pervasive developmental disorders.
Topics: Adolescent; Aggression; Attention Deficit Disorder with Hyperactivity; Carbamazepine; Child; Child D | 1999 |
Impact of attentional dysfunction in dyscalculia.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 1999 |
[Central nervous system stimulants and their potential risk of abuse in hyperkinetic disorders].
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Dext | 1999 |
Pharmacokinetics and clinical effectiveness of methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Met | 1999 |
In the wake of the MTA: charting a new course for the study and treatment of children with attention-deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; | 1999 |
Treatment of attention-deficit/hyperactivity disorder.
Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents, Tricyclic; Attention Deficit Disorder wi | 1999 |
Are stimulants overprescribed for youths with ADHD?
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2000 |
Attention-deficit/hyperactivity disorder: a neuropsychiatric disorder with childhood onset.
Topics: Age Factors; Antidepressive Agents, Tricyclic; Attention Deficit Disorder with Hyperactivity; Brain; | 2000 |
Methylphenidate: its pharmacology and uses.
Topics: Attention Deficit Disorder with Hyperactivity; Brain Injuries; Central Nervous System Stimulants; De | 2000 |
Methylphenidate: its pharmacology and uses.
Topics: Attention Deficit Disorder with Hyperactivity; Brain Injuries; Central Nervous System Stimulants; De | 2000 |
Methylphenidate: its pharmacology and uses.
Topics: Attention Deficit Disorder with Hyperactivity; Brain Injuries; Central Nervous System Stimulants; De | 2000 |
Methylphenidate: its pharmacology and uses.
Topics: Attention Deficit Disorder with Hyperactivity; Brain Injuries; Central Nervous System Stimulants; De | 2000 |
Attention-deficit/hyperactivity disorder in adults: an overview.
Topics: Adult; Age Factors; Antidepressive Agents, Tricyclic; Attention Deficit Disorder with Hyperactivity; | 2000 |
How high a dose of stimulant medication in adult attention deficit hyperactivity disorder?
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Dose-Respon | 2000 |
Attention deficit/hyperactivity disorder (ADHD) in children: rationale for its integrative management.
Topics: Attention Deficit Disorder with Hyperactivity; Avitaminosis; Central Nervous System Stimulants; Chil | 2000 |
Current concepts and controversies in the diagnosis and treatment of attention deficit hyperactivity disorder.
Topics: Adolescent; Aggression; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Ner | 2000 |
What's all the fuss about Ritalin?
Topics: Age Factors; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child | 2001 |
What does the MTA study tell us about effective psychosocial treatment for ADHD?
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; | 2001 |
Stimulant effects in attention deficit hyperactivity disorder: theoretical and empirical issues.
Topics: Adolescent; Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulant | 2001 |
An auditable protocol for treating attention deficit/hyperactivity disorder.
Topics: Algorithms; Attention Deficit Disorder with Hyperactivity; Child; Clinical Protocols; Clinical Trial | 2001 |
Present and future pharmacotherapeutic options for adult attention deficit/hyperactivity disorder.
Topics: Adult; Amphetamines; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Central N | 2001 |
Managing stimulant medication for attention-deficit/hyperactivity disorder.
Topics: Amphetamines; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Chil | 2001 |
Attention deficit hyperactivity disorder and substance use disorders: Is there a causal link?
Topics: Adolescent; Adult; Age Factors; Attention Deficit Disorder with Hyperactivity; Central Nervous Syste | 2001 |
Stimulant drugs for severe hyperactivity in childhood.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Pres | 2001 |
[Hyperactive behavior in adults; possibly attention deficit/hyperactivity disorder (ADHD)].
Topics: Adult; Alcoholism; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2001 |
Effects of stimulants on the continuous performance test (CPT): implications for CPT use and interpretation.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cognition; Humans; | 2001 |
Psychopharmacology for young children: clinical needs and research opportunities.
Topics: Age Factors; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Humans; Mental | 2001 |
What's new: newly approved drugs for children.
Topics: Adolescent; Age Factors; Albuterol; Androstadienes; Anticonvulsants; Asthma; Atovaquone; Attention D | 2001 |
The Conners' Parent Rating Scales: a critical review of the literature.
Topics: Adrenergic alpha-Agonists; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2001 |
How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis.
Topics: Adolescent; Adult; Age Factors; Anorexia; Attention Deficit Disorder with Hyperactivity; Bias; Centr | 2001 |
Methylphenidate in the treatment of children with attention-deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Drug Utilization; Humans; Methylphenidate; Pat | 2001 |
[Transcranial magnetic stimulation in child and adolescent psychiatry: excitability of the motor system in tic disorders and/or attention deficit hyperactivity disorders].
Topics: Adolescent; Adolescent Psychiatry; Attention Deficit Disorder with Hyperactivity; Central Nervous Sy | 2001 |
ADHD, growth deficits, and relationships to psychostimulant use.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2002 |
Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults.
Topics: Adolescent; Adult; Amphetamines; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervo | 2002 |
Pharmacokinetic and pharmacodynamic properties of stimulants: implications for the design of new treatments for ADHD.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Do | 2002 |
Psychiatric pharmacogenetics: personalizing psychostimulant therapy in attention-deficit/hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Met | 2002 |
Preschool attention deficit hyperactivity disorder: a review of prevalence, diagnosis, neurobiology, and stimulant treatment.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Pres | 2002 |
[ADHD and remedical intervention].
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Carbamazepine; Child; Child, Presch | 2002 |
[Attention deficit hyperactivity disorder].
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Diagnosis | 2002 |
Use, abuse, toxicity, and monitoring of pediatric psychotropic drug therapy: new issues for the new millennium.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Depression; | 2002 |
Abuse and toxicity of methylphenidate.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2002 |
Methylphenidate treatment.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Methylphen | 2002 |
Keep taking the tablets? Evidence-based approaches to AD(H)D. Part 1: The evidence.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Evidence-Ba | 2002 |
Managing stimulant medication for attention-deficit/hyperactivity disorder: an update.
Topics: Amphetamines; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Chem | 2002 |
[Psychotropic drug therapy in children].
Topics: Antidepressive Agents, Tricyclic; Attention Deficit Disorder with Hyperactivity; Autistic Disorder; | 1977 |
Pediatric psychopharmacology. A review with special reference to deanol.
Topics: Adolescent; Adult; Amphetamines; Animals; Antidepressive Agents, Tricyclic; Attention Deficit Disord | 1977 |
MBD: advanced in understanding many bothersome dilemmas.
Topics: Adolescent; Adult; Attention; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool | 1976 |
Minimal brain Dysfunction.
Topics: Attention Deficit Disorder with Hyperactivity; Brain Diseases; Cerebral Palsy; Child; Child, Prescho | 1975 |
Pharmacologic treatment of attention deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Pres | 1992 |
The stimulants.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 1992 |
Psychosis and idiopathic precocious puberty in two 7-year-old boys.
Topics: Attention Deficit Disorder with Hyperactivity; Body Height; Carbamazepine; Child; Developmental Disa | 1992 |
The myth of attention deficit-hyperactivity disorder: symptoms resulting from multiple causes.
Topics: Arousal; Attention Deficit Disorder with Hyperactivity; Child; Child Behavior Disorders; Child, Pres | 1992 |
Attention deficits in school-aged children and adolescents. Current issues and practice.
Topics: Adolescent; Antidepressive Agents, Tricyclic; Attention Deficit Disorder with Hyperactivity; Child; | 1992 |
Clonidine in attention deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Child, Preschool; Clonidine; | 1992 |
Use of medication in pervasive developmental disorders.
Topics: Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Autistic Disorder; Child; Child | 1991 |
[Management of attention deficit and hyperactivity disorder].
Topics: Attention Deficit Disorder with Hyperactivity; Child; Cognitive Behavioral Therapy; Combined Modalit | 1991 |
[Hyperkinetic syndrome in childhood and adolescence. Diagnosis and therapy].
Topics: Amphetamine; Attention Deficit Disorder with Hyperactivity; Child; Combined Modality Therapy; Humans | 1991 |
[Children with attention deficit disorders with hyperactivity; the role of drugs in treatment].
Topics: Antidepressive Agents, Tricyclic; Attention Deficit Disorder with Hyperactivity; Child; Child, Presc | 1991 |
Cognitive training in ADHD children: less to it than meets the eye.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Combined Modality Therapy; D | 1991 |
Stimulant medication and parent training therapies for attention deficit-hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Combined Modality Therapy; D | 1991 |
Effects of stimulant medication on learning in children with ADHD.
Topics: Achievement; Attention Deficit Disorder with Hyperactivity; Child; Dextroamphetamine; Humans; Learni | 1991 |
Treating attention-deficit hyperactivity disorder: medication and behavior management training.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Chronic Disease; | 1991 |
Stimulants for ADHD in child patients with Tourette's syndrome: the issue of relative risk.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Met | 1990 |
Therapies for hyperactive children: comparisons, combinations, and compromises.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Cognitive Behavi | 1991 |
Legal issues in the treatment of children with attention deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Humans; Informed Consent; Legislation as Topic | 1991 |
A possible pathophysiologic substrate of attention deficit hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Corpus Striatum; Dextroamphetamine | 1991 |
Attention-deficit hyperactivity disorder: a clinical review.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Humans; Methylphenidate | 1991 |
Cognitive event-related potentials in attention deficit disorder.
Topics: Adolescent; Adult; Arousal; Attention; Attention Deficit Disorder with Hyperactivity; Cerebral Corte | 1991 |
Attention deficit hyperactivity disorder: does it affect adults too?
Topics: Adolescent; Adult; Age Factors; Attention Deficit Disorder with Hyperactivity; Child; Dextroamphetam | 1990 |
Pharmacologic treatment of psychiatric and neurodevelopmental disorders in children and adolescents (Part 1).
Topics: Adolescent; Aggression; Antidepressive Agents; Antipsychotic Agents; Anxiety, Separation; Attention | 1986 |
Stimulant medication therapy in the treatment of children with attention deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Dextroamphetamine; Dopamine; Growth; Humans; M | 1989 |
Adolescent outcome of hyperactive children treated with stimulants in childhood: a review.
Topics: Achievement; Adolescent; Amphetamine; Antisocial Personality Disorder; Attention Deficit Disorder wi | 1985 |
A review of studies of drug treatment efficacy for attention deficit disorder with hyperactivity in adolescents.
Topics: Adolescent; Adult; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System | 1985 |
Increased medication use in attention-deficit hyperactivity disorder: regressive or appropriate?
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Child; Humans; Methylphenidate; Sc | 1988 |
Use of stimulant medications in children.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Humans; Methylphenidate | 1988 |
Substance abuse in adolescents: diagnostic issues derived from studies of attention deficit disorder with hyperactivity.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Humans; Male; Methylphenidate; Pro | 1988 |
The what, why and how of hyperkinesis: implications for nursing.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Dextroamphetamine; Humans; Methylphenidate; Mo | 1988 |
Psychophysiological effects of methylphenidate (Ritalin).
Topics: Arousal; Attention Deficit Disorder with Hyperactivity; Humans; Methylphenidate | 1987 |
Treating problem children with stimulant drugs.
Topics: Adult; Amphetamine; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants | 1973 |
Drug therapy in minimal brain dysfunction: a commentary.
Topics: Amphetamine; Anticonvulsants; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; | 1972 |
Genetic approaches to the syndrome of minimal brain dysfunction.
Topics: Amphetamine; Attention Deficit Disorder with Hyperactivity; Child; Dextroamphetamine; Diseases in Tw | 1973 |
Minimal brain dysfunction in children. Diagnosis and management.
Topics: Abnormalities, Multiple; Affective Symptoms; Age Factors; Amphetamine; Attention; Attention Deficit | 1973 |
Genetic issues in the syndrome of minimal brain dysfunction.
Topics: Attention Deficit Disorder with Hyperactivity; Dextroamphetamine; Diseases in Twins; Female; Humans; | 1973 |
[The hyperkinetic syndrom in childhood (author's transl)].
Topics: Attention Deficit Disorder with Hyperactivity; Brain Damage, Chronic; Child; Humans; Hyperkinesis; M | 1974 |
The neurologic learning disability syndrome.
Topics: Anorexia Nervosa; Anxiety; Attention; Attention Deficit Disorder with Hyperactivity; Brain Damage, C | 1971 |
1072 trials available for methylphenidate and ADDH
| Article | Year |
|---|---|
Methylphenidate for attention-deficit/hyperactivity disorder in patients with Smith-Magenis syndrome: protocol for a series of N-of-1 trials.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Double-Blind Metho | 2021 |
Outcomes of a 12-week ecologically valid observational study of first treatment with methylphenidate in a representative clinical sample of drug naïve children with ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Family; Fem | 2021 |
Methylphenidate augmentation of escitalopram to enhance adherence to antidepressant treatment: a pilot randomized controlled trial.
Topics: Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Bayes Theorem; Central Nervous | 2021 |
Third-generation cognitive behavioral therapy versus treatment-as-usual for attention deficit and hyperactivity disorder: a multicenter randomized controlled trial.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Cognitive Behavioral Therapy; Humans; Methylph | 2022 |
Dorsal-to-ventral imbalance in the superior longitudinal fasciculus mediates methylphenidate's effect on beta oscillations in ADHD.
Topics: Anisotropy; Attention Deficit Disorder with Hyperactivity; Diffusion Tensor Imaging; Humans; Male; M | 2022 |
Mind-Wandering and Childhood ADHD: Experimental Manipulations across Laboratory and Naturalistic Settings.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Humans; Methylphenidate; Task Perf | 2022 |
Comparing the Effect of Methylphenidate and Anodal tDCS on Inhibitory Control and Working-Memory in Children and Adolescents with Attention Deficit/Hyperactivity Disorder: A Study Protocol for a Randomized, within-Subject Trial.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2022 |
Effectiveness of neurofeedback training, behaviour management including attention enhancement training and medication in children with attention-deficit/hyperactivity disorder - A comparative follow up study.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Follow-Up Studies; Humans; Methylphenidate; Ne | 2022 |
Oral, intranasal, and intravenous abuse potential of serdexmethylphenidate, a novel prodrug of d-methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cross-Over Studies | 2022 |
The effect of stimulant medication on the learning of academic curricula in children with ADHD: A randomized crossover study.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cross-Over | 2022 |
The effect of Rosa canina L. and a polyherbal formulation syrup in patients with attention-deficit/hyperactivity disorder: a study protocol for a multicenter randomized controlled trial.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2022 |
Effects of methylphenidate on subjective sleep parameters in adults with ADHD: a prospective, non-randomized, non-blinded 6-week trial.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Follow-Up S | 2023 |
Methylphenidate remediates aberrant brain network dynamics in children with attention-deficit/hyperactivity disorder: A randomized controlled trial.
Topics: Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; Child; Doub | 2022 |
Randomised controlled trial of the short-term effects of osmotic-release oral system methylphenidate on symptoms and behavioural outcomes in young male prisoners with attention deficit hyperactivity disorder: CIAO-II study.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Delayed-Action Pre | 2023 |
Withdrawing methylphenidate in relation to serum levels of ferritin and zinc in children and adolescents with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2022 |
Analysis of Daily Sleep Diary Measures From Multilayer Extended-Release Methylphenidate (PRC-063) Studies in Children and Adults With ADHD.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Dela | 2022 |
Methylphenidate, Guanfacine, and Combined Treatment Effects on Electroencephalography Correlates of Spatial Working Memory in Attention-Deficit/Hyperactivity Disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Electroence | 2023 |
Electrophysiological and Clinical Predictors of Methylphenidate, Guanfacine, and Combined Treatment Outcomes in Children With Attention-Deficit/Hyperactivity Disorder.
Topics: Adrenergic alpha-2 Receptor Agonists; Attention Deficit Disorder with Hyperactivity; Central Nervous | 2023 |
Effectivity of Saffron Extract (Saffr'Activ) on Treatment for Children and Adolescents with Attention Deficit/Hyperactivity Disorder (ADHD): A Clinical Effectivity Study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2022 |
Methylphenidate for prison inmates with ADHD: yes or no?
Topics: Administration, Oral; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulan | 2023 |
Efficacy and safety of methylphenidate and behavioural parent training for children aged 3-5 years with attention-deficit hyperactivity disorder: a randomised, double-blind, placebo-controlled, and sham behavioural parent training-controlled trial.
Topics: Attention Deficit Disorder with Hyperactivity; Brazil; Central Nervous System Stimulants; Child, Pre | 2022 |
Authors' Reply to Singh and Balasundaram: Comment on "A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder".
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Capsules; Central Nervous System Stimulants; D | 2022 |
Open assessment of the therapeutic and rate-dependent effects of brain balance center® and interactive metronome® exercises on children with attention deficit hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; | 2023 |
Open assessment of the therapeutic and rate-dependent effects of brain balance center® and interactive metronome® exercises on children with attention deficit hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; | 2023 |
Open assessment of the therapeutic and rate-dependent effects of brain balance center® and interactive metronome® exercises on children with attention deficit hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; | 2023 |
Open assessment of the therapeutic and rate-dependent effects of brain balance center® and interactive metronome® exercises on children with attention deficit hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; | 2023 |
Effect of methylphenidate on functional controllability: a preliminary study in medication-naïve children with ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; Child; Cros | 2022 |
Effect of methylphenidate on functional controllability: a preliminary study in medication-naïve children with ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; Child; Cros | 2022 |
Effect of methylphenidate on functional controllability: a preliminary study in medication-naïve children with ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; Child; Cros | 2022 |
Effect of methylphenidate on functional controllability: a preliminary study in medication-naïve children with ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; Child; Cros | 2022 |
The effects of first-dose methylphenidate on the neural signatures of visual selective attention in children with attention-deficit/hyperactivity disorder.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2023 |
Methylphenidate Enhances Spontaneous Fluctuations in Reward and Cognitive Control Networks in Children With Attention-Deficit/Hyperactivity Disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Brain; Child; Cognition; Humans; Methylphenidate; Rew | 2023 |
Is S100B Involved in Attention-Deficit/Hyperactivity Disorder (ADHD)? Comparisons with Controls and Changes Following a Triple Therapy Containing Methylphenidate, Melatonin and ω-3 PUFAs.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Fatty Acids | 2023 |
Contrasting expectancy effects with objective measures in adults with untreated ADHD during QbTest.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Double-Blin | 2023 |
Single and Combined Effects of Multiple Intensities of Behavioral Modification and Methylphenidate for Children with ADHD in the Home Setting.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Met | 2023 |
Brain tissue iron neurophysiology and its relationship with the cognitive effects of dopaminergic modulation in children with and without ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; Child; Cogn | 2023 |
Bayesian dynamical system analysis of the effects of methylphenidate in children with attention-deficit/hyperactivity disorder: a randomized trial.
Topics: Attention Deficit Disorder with Hyperactivity; Bayes Theorem; Brain; Central Nervous System Stimulan | 2023 |
Single-dose effects of methylphenidate and atomoxetine on functional connectivity during an n-back task in boys with ADHD.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Brain; Central | 2023 |
Effects of one single-dose methylphenidate compared to one single-dose placebo on QbTest performance in adults with untreated ADHD: a randomized controlled trial.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cognition; | 2023 |
Exploring the efficacy of dialectical behaviour therapy and methylphenidate on emotional comorbid symptoms in adults with attention Deficit/Hyperactivity disorder: Results of the COMPAS multicentre randomised controlled trial.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Dialectical | 2023 |
Acute blood pressure change with methylphenidate is associated with improvement in attention performance in children with ADHD.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Central Nervous System Sti | 2020 |
A Randomized Controlled Trial of Interventions for Growth Suppression in Children With Attention-Deficit/Hyperactivity Disorder Treated With Central Nervous System Stimulants.
Topics: Attention Deficit Disorder with Hyperactivity; Body Mass Index; Body Weight; Central Nervous System | 2020 |
The effect of methylphenidate on social cognition and oxytocin in children with attention deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Double-Blin | 2020 |
Randomised controlled trial of the short-term effects of OROS-methylphenidate on ADHD symptoms and behavioural outcomes in young male prisoners with attention-deficit/hyperactivity disorder (CIAO-II).
Topics: Administration, Oral; Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Delayed-Acti | 2019 |
The efficacy of zinc augmentation in children with attention deficit hyperactivity disorder under treatment with methylphenidate: A randomized controlled trial.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Double-Blin | 2020 |
Efficacy and Safety of PRC-063, Extended-Release Multilayer Methylphenidate in Adults with ADHD Including 6-Month Open-Label Extension.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Delayed-Act | 2021 |
Therapeutic response in children with ADHD: role of observers and settings.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cross-Over | 2020 |
The Placebo Response in Adult ADHD as Objectively Assessed by the TOVA Continuous Performance Test.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Delayed-Act | 2021 |
Poor performance of the 'child Reading the Mind in the Eyes Test' correlates with poorer social-emotional functioning in children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Age Factors; Attention Deficit Disorder with Hyperactivity; Child; Emotions; Female; Hum | 2020 |
Baseline performance moderates stimulant effects on cognition in youth with ADHD.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2021 |
Differentiating depression and ADHD without depression in adults with processing-speed measures.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2020 |
The Visuo-Motor Attention Test in Boys with Attention Deficit Hyperactivity Disorder (ADHD): Methylphenidate-Placebo Randomized Controlled Trial.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2021 |
Task experience eliminates catecholaminergic effects on inhibitory control - A randomized, double-blind cross-over neurophysiological study.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Brain; Case-Control Studies; Catecholamines; C | 2020 |
Methylphenidate Effects on Cortical Thickness in Children and Adults with Attention-Deficit/Hyperactivity Disorder: A Randomized Clinical Trial.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cerebral Co | 2020 |
Resveratrol adjunct to methylphenidate improves symptoms of attention-deficit/hyperactivity disorder: a randomized, double-blinded, placebo-controlled clinical trial.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Double-Blin | 2021 |
The interactive effects of test-retest and methylphenidate administration on cognitive performance in youth with ADHD: A double-blind placebo-controlled crossover study.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimula | 2020 |
The effect of behavioral parent training on sleep problems of school-age children with ADHD: A parallel randomized controlled trial.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; | 2020 |
Safety Profile of Methylphenidate Under Long-Term Treatment in Adult ADHD Patients - Results of the COMPAS Study.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2020 |
Attention-deficit/hyperactivity disorder and the explore/exploit trade-off.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Met | 2021 |
A Post Hoc Comparison of Prior ADHD Medication Dose and Optimized Delayed-release and Extended-release Methylphenidate Dose in a Pivotal Phase III Trial.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Delayed-Act | 2020 |
Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Methylphenidate in Healthy Adults.
Topics: Administration, Oral; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System S | 2021 |
The "VIP-ADHD trial": Does brain arousal have prognostic value for predicting response to psychostimulants in adult ADHD patients?
Topics: Arousal; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; El | 2021 |
Association between COMT methylation and response to treatment in children with ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Catechol O-Methyltransferase; Central Nervous System | 2021 |
High-gamma oscillations as neurocorrelates of ADHD: A MEG crossover placebo-controlled study.
Topics: Adult; Anxiety; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Do | 2021 |
Do effects of methylphenidate on cognitive performance last beyond treatment? A randomized placebo-controlled trial in boys and men with ADHD.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cogn | 2021 |
Effects of methylphenidate on executive functioning in children and adolescents with ADHD after long-term use: a randomized, placebo-controlled discontinuation study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2021 |
Effect of a Multi-Layer, Extended-Release Methylphenidate Formulation (PRC-063) on Sleep in Adults with ADHD: A Randomized, Double-Blind, Forced-Dose, Placebo-Controlled Trial Followed by a 6-month Open-Label Extension.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Delayed-Act | 2021 |
Effect of a Multi-Layer, Extended-Release Methylphenidate Formulation (PRC-063) on Sleep in Adults with ADHD: A Randomized, Double-Blind, Forced-Dose, Placebo-Controlled Trial Followed by a 6-month Open-Label Extension.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Delayed-Act | 2021 |
Effect of a Multi-Layer, Extended-Release Methylphenidate Formulation (PRC-063) on Sleep in Adults with ADHD: A Randomized, Double-Blind, Forced-Dose, Placebo-Controlled Trial Followed by a 6-month Open-Label Extension.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Delayed-Act | 2021 |
Effect of a Multi-Layer, Extended-Release Methylphenidate Formulation (PRC-063) on Sleep in Adults with ADHD: A Randomized, Double-Blind, Forced-Dose, Placebo-Controlled Trial Followed by a 6-month Open-Label Extension.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Delayed-Act | 2021 |
Clinically Meaningful Improvements in Early Morning and Late Afternoon/Evening Functional Impairment in Children with ADHD Treated with Delayed-Release and Extended-Release Methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Delayed-Act | 2022 |
Adjuvant effects of vitamin A and vitamin D supplementation on treatment of children with attention-deficit/hyperactivity disorder: a study protocol for a randomised, double-blinded, placebo-controlled, multicentric trial in China.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; China; Diet | 2021 |
Effectiveness of Parenting Training on Emotional and Behavioral Problems in First through Fourth Grade Thai Children with ADHD: A Randomized Controlled Study.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Humans; Methylphenidate; Parenting; Parents; P | 2022 |
Personalized at-home neurofeedback compared to long-acting methylphenidate in children with ADHD: NEWROFEED, a European randomized noninferiority trial.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2022 |
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adult Laboratory Classroom Study of the Efficacy and Safety of PRC-063 (Extended-Release Methylphenidate) for the Treatment of ADHD.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Delayed-Act | 2022 |
Selective Effects of Methylphenidate on Attention and Inhibition in 22q11.2 Deletion Syndrome: Results From a Clinical Trial.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; DiGe | 2022 |
Empathy and Facial Expression Recognition in Children With and Without Attention-Deficit/Hyperactivity Disorder: Effects of Stimulant Medication on Empathic Skills in Children with Attention-Deficit/Hyperactivity Disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Central Nervous Sys | 2017 |
Multimodal treatment in children and adolescents with attention-deficit/hyperactivity disorder: a 6-month follow-up.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2017 |
Effect of Pycnogenol® on attention-deficit hyperactivity disorder (ADHD): study protocol for a randomised controlled trial.
Topics: Adjuvants, Immunologic; Antioxidants; Attention Deficit Disorder with Hyperactivity; Belgium; Biomar | 2017 |
The effect of methylphenidate on anxiety and depression symptoms in patients with Asperger syndrome and comorbid attention deficit/hyperactivity disorder.
Topics: Adolescent; Anxiety; Asperger Syndrome; Attention Deficit Disorder with Hyperactivity; Central Nervo | 2017 |
Auditory and Visual Executive Functions in Children and Response to Methylphenidate: A Randomized Controlled Trial.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Double-Blin | 2020 |
Dose-Response Effects of Long-Acting Liquid Methylphenidate in Children with Attention Deficit/Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD): A Pilot Study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Central Nervous | 2017 |
Efficacy and Safety of a Chewable Methylphenidate Extended-Release Tablet in Children with Attention-Deficit/Hyperactivity Disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Delayed-Act | 2017 |
Methylphenidate-Related Improvements in Math Performance Cannot Be Explained by Better Cognitive Functioning or Higher Academic Motivation: Evidence From a Randomized Controlled Trial.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2020 |
Striatal Activation Predicts Differential Therapeutic Responses to Methylphenidate and Atomoxetine.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with | 2017 |
Verbal working memory-related functional connectivity alterations in boys with attention-deficit/hyperactivity disorder and the effects of methylphenidate.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; | 2017 |
Placebo response and its determinants in children with ADHD across multiple observers and settings: A randomized clinical trial.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cross-Over | 2018 |
A Naturalistic Comparison of Methylphenidate and Risperidone Monotherapy in Drug-Naive Youth With Attention-Deficit/Hyperactivity Disorder Comorbid With Oppositional Defiant Disorder and Aggression.
Topics: Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Attention Def | 2017 |
Increased default-mode variability is related to reduced task-performance and is evident in adults with ADHD.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Connectome; | 2017 |
Age-dependent effects of acute methylphenidate on amygdala reactivity in stimulant treatment-naive patients with Attention Deficit/Hyperactivity Disorder.
Topics: Adult; Age Factors; Amygdala; Attention Deficit Disorder with Hyperactivity; Brain Mapping; Central | 2017 |
Methylphenidate, cognition, and epilepsy: A 1-month open-label trial.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cognition D | 2017 |
Methylphenidate Has Superior Efficacy Over Parent-Child Interaction Therapy for Preschool Children with Disruptive Behaviors.
Topics: Adult; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperact | 2018 |
Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder.
Topics: Appetite; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; D | 2017 |
A Randomized Controlled Trial to Examine the Posttreatment Efficacy of Neurofeedback, Behavior Therapy, and Pharmacology on ADHD Measures.
Topics: Analysis of Variance; Attention; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Ce | 2019 |
Exploring longitudinal course and treatment-baseline severity interactions in secondary outcomes of smoking cessation treatment in individuals with attention-deficit hyperactivity disorder.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Double-Blin | 2018 |
The Short-Term Placebo Response in Children With Attention-Deficit Hyperactivity Disorder (ADHD).
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2018 |
l-Carnosine as Adjunctive Therapy in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Carnosine; Central Nervous System Stimula | 2018 |
QTc prolongation after ADHD medication.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Arrhythmias, Cardiac; Atomoxetine Hydrochloride; Attention | 2018 |
A neurocomputational account of reward and novelty processing and effects of psychostimulants in attention deficit hyperactivity disorder.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Central Nervous System S | 2018 |
Virtual Remediation Versus Methylphenidate to Improve Distractibility in Children With ADHD: A Controlled Randomized Clinical Trial Study.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Met | 2020 |
Effectiveness of parental training, methylphenidate treatment, and their combination on academic achievements and behavior at school of children with attention-deficit hyperactivity disorder.
Topics: Academic Success; Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System | 2018 |
Efficacy of Hippotherapy Versus Pharmacotherapy in Attention-Deficit/Hyperactivity Disorder: A Randomized Clinical Trial.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivi | 2018 |
How do stimulant treatments for ADHD work? Evidence for mediation by improved cognition.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child Behav | 2018 |
Interindividual and Intraindividual Variation of Methylphenidate Concentrations in Serum and Saliva of Patients With Attention-Deficit/Hyperactivity Disorder.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2018 |
The effect of methylphenidate on decision making in patients with borderline personality disorder and attention-deficit/hyperactivity disorder.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Borderline Personality Disorder; Central Nervo | 2018 |
Effectiveness of neurofeedback versus medication for attention-deficit/hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Female; Hum | 2018 |
Electroencephalographic biomarkers as predictors of methylphenidate response in attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; | 2018 |
Electroencephalographic biomarkers as predictors of methylphenidate response in attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; | 2018 |
Electroencephalographic biomarkers as predictors of methylphenidate response in attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; | 2018 |
Electroencephalographic biomarkers as predictors of methylphenidate response in attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; | 2018 |
The effect of methylphenidate treatment on psychopathic behavior of patients having attention-deficit hyperactivity disorder with and without oppositional defiant disorder.
Topics: Adolescent; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyp | 2018 |
DRD3 Gene and ADHD: A Pharmaco-Behavioural Genetic Study.
Topics: Alleles; Amino Acid Substitution; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2018 |
A multicentre randomized controlled trial on trans-generational attention deficit/hyperactivity disorder (ADHD) in mothers and children (AIMAC): an exploratory analysis of predictors and moderators of treatment outcome.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child of Impaired Parents; Female; Humans; Met | 2019 |
Population Pharmacokinetic-Pharmacodynamic Modeling of a Novel Methylphenidate Extended-Release Orally Disintegrating Tablet in Pediatric Patients With Attention-Deficit/Hyperactivity Disorder.
Topics: Administration, Oral; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulan | 2018 |
Cognitive Working Memory Training (CWMT) in adolescents suffering from Attention-Deficit/Hyperactivity Disorder (ADHD): A controlled trial taking into account concomitant medication effects.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2018 |
Aripiprazole/Methylphenidate Combination in Children and Adolescents with Disruptive Mood Dysregulation Disorder and Attention-Deficit/Hyperactivity Disorder: An Open-Label Study.
Topics: Adolescent; Antidepressive Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders | 2018 |
The efficacy of Ritalin in ADHD children under neurofeedback training.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Checklist; Child; | 2018 |
Preventive effect of cyproheptadine on sleep and appetite disorders induced by methylphenidate: an exploratory randomised, double-blinded, placebo-controlled clinical trial.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Pres | 2019 |
Early monitoring of fatty acid profile in children with attention deficit and/or hyperactivity disorder under treatment with omega-3 polyunsaturated fatty acids.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2019 |
Comparative Efficacy of Methylphenidate and Atomoxetine on Emotional and Behavioral Problems in Youths with Attention-Deficit/Hyperactivity Disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with | 2019 |
Visual attention in adults with attention-deficit/hyperactivity disorder before and after stimulant treatment.
Topics: Adult; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2019 |
Crocus sativus L. Versus Methylphenidate in Treatment of Children with Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind Pilot Study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2019 |
Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate: Evaluation of Dose Proportionality, Food Effect, Multiple-Dose Modeling, and Comparative Bioavailability with Immediate-Release Methylphenidate in Healthy Adults.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Biological Availability; Central Nervous Syste | 2019 |
Continued Benefits of Methylphenidate in ADHD After 2 Years in Clinical Practice: A Randomized Placebo-Controlled Discontinuation Study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2019 |
Long-term Effects of Multimodal Treatment on Adult Attention-Deficit/Hyperactivity Disorder Symptoms: Follow-up Analysis of the COMPAS Trial.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cognitive B | 2019 |
Efficacy and safety of tipepidine as adjunctive therapy in children with attention-deficit/hyperactivity disorder: Randomized, double-blind, placebo-controlled clinical trial.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2019 |
Methylphenidate and atomoxetine normalise fronto-parietal underactivation during sustained attention in ADHD adolescents.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention; Attention Deficit Di | 2019 |
Personalized at-home neurofeedback compared with long-acting methylphenidate in an european non-inferiority randomized trial in children with ADHD.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimula | 2019 |
Effect of sweet almond syrup versus methylphenidate in children with ADHD: A randomized triple-blind clinical trial.
Topics: Adolescent; Antioxidants; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2019 |
The Effectiveness of Short- and Long-Acting Stimulant Medications for Adolescents With ADHD in a Naturalistic Secondary School Setting.
Topics: Academic Failure; Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System | 2017 |
An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Adults With ADHD.
Topics: Adolescent; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central | 2017 |
The impact of methylphenidate on seizure frequency and severity in children with attention-deficit-hyperactivity disorder and difficult-to-treat epilepsies.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2013 |
Effect of osmotic-release oral system methylphenidate on learning skills in adolescents with attention-deficit/hyperactivity disorder: an open-label study.
Topics: Administration, Oral; Adolescent; Anorexia; Attention Deficit Disorder with Hyperactivity; Child; De | 2013 |
Drug-specific laterality effects on frontal lobe activation of atomoxetine and methylphenidate in attention deficit hyperactivity disorder boys during working memory.
Topics: Adolescent; Analysis of Variance; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperac | 2014 |
Norepinephrine genes predict response time variability and methylphenidate-induced changes in neuropsychological function in attention deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Diagnosis, | 2013 |
Clinical gains from including both dextroamphetamine and methylphenidate in stimulant trials.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2013 |
Motivational incentives and methylphenidate enhance electrophysiological correlates of error monitoring in children with attention deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Central Nervous Sys | 2013 |
Neurofeedback and standard pharmacological intervention in ADHD: a randomized controlled trial with six-month follow-up.
Topics: Adolescent; Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Brain Waves; Centra | 2013 |
A head-to-head randomized clinical trial of methylphenidate and atomoxetine treatment for executive function in adults with attention-deficit hyperactivity disorder.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention; Attention Deficit Disorde | 2013 |
Efficacy and safety of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder and recent methylphenidate use.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cross-Over | 2013 |
Efficacy of lisdexamfetamine dimesylate throughout the day in children and adolescents with attention-deficit/hyperactivity disorder: results from a randomized, controlled trial.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2014 |
Central nervous system stimulants for secondary attention deficit-hyperactivity disorder after paediatric traumatic brain injury: a rationale and protocol for single patient (n-of-1) multiple cross-over trials.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Bayes Theorem; Brain Injuries; Central Ne | 2013 |
Neurofunctional effects of methylphenidate and atomoxetine in boys with attention-deficit/hyperactivity disorder during time discrimination.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Brain; Brain M | 2013 |
ABCB1 c.2677G>T variation is associated with adverse reactions of OROS-methylphenidate in children and adolescents with ADHD.
Topics: Administration, Oral; Adolescent; Age Factors; ATP Binding Cassette Transporter, Subfamily B; ATP Bi | 2013 |
Effects of extended release methylphenidate treatment on ratings of attention-deficit/hyperactivity disorder (ADHD) and associated behavior in children with autism spectrum disorders and ADHD symptoms.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child Devel | 2013 |
A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2013 |
Effects of neurofeedback versus stimulant medication in attention-deficit/hyperactivity disorder: a randomized pilot study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Brain Waves; Central Nervous System Stimu | 2013 |
No significant association between the alpha-2A-adrenergic receptor gene and treatment response in combined or inattentive subtypes of attention-deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Female; Genotype; Humans; Male; Methylphenidat | 2013 |
Attributions and Perception of Methylphenidate Effects in Adolescents With ADHD.
Topics: Achievement; Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimu | 2017 |
Impact of release mechanism on the pharmacokinetic performance of PAUC metrics for three methylphenidate products with complex absorption.
Topics: Absorption; Area Under Curve; Attention Deficit Disorder with Hyperactivity; Chemistry, Pharmaceutic | 2014 |
Baseline severity of parent-perceived inattentiveness is predictive of the difference between subjective and objective methylphenidate responses in children with attention-deficit/hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Delayed-Act | 2013 |
Long-term quality-of-life and functioning comparison of atomoxetine versus other standard treatment in pediatric attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with | 2013 |
A randomised controlled trial of combined EEG feedback and methylphenidate therapy for the treatment of ADHD.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2013 |
Morning and Evening Effects of Guanfacine Extended Release Adjunctive to Psychostimulants in Pediatric ADHD.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Amphetamine; Analysis of Variance; Attention Defic | 2017 |
Methylphenidate does not influence smoking-reinforced responding or attentional performance in adult smokers with and without attention deficit hyperactivity disorder (ADHD).
Topics: Adolescent; Adult; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System | 2013 |
Methylphenidate for attention deficit hyperactivity disorder and drug relapse in criminal offenders with substance dependence: a 24-week randomized placebo-controlled trial.
Topics: Adult; Amphetamine-Related Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous | 2014 |
A randomized controlled multicenter trial on the multimodal treatment of adult attention-deficit hyperactivity disorder: enrollment and characteristics of the study sample.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Clinical Protocols; Combined | 2014 |
Alterations in pain response are partially reversed by methylphenidate (Ritalin) in adults with attention deficit hyperactivity disorder (ADHD).
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Central Nervous System S | 2015 |
A positron emission tomography study of nigro-striatal dopaminergic mechanisms underlying attention: implications for ADHD and its treatment.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Benzamides; Corpus Striatum; Cross-Over Studie | 2013 |
Treatment adherence and persistence in adult ADHD: results from a twenty-four week controlled clinical trial with extended release methylphenidate.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Delayed-Act | 2014 |
Treating nicotine dependence by targeting attention-deficit/ hyperactivity disorder (ADHD) with OROS methylphenidate: the role of baseline ADHD severity and treatment response.
Topics: Administration, Oral; Adult; Attention Deficit Disorder with Hyperactivity; Biological Availability; | 2013 |
Effects of methylphenidate on acute math performance in children with attention-deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cross-Over | 2013 |
Callous-unemotional traits, proactive aggression, and treatment outcomes of aggressive children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Aggression; Antisocial Personality Disorder; Attention Deficit and Disruptive Behavior D | 2013 |
Callous-unemotional traits, proactive aggression, and treatment outcomes of aggressive children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Aggression; Antisocial Personality Disorder; Attention Deficit and Disruptive Behavior D | 2013 |
Callous-unemotional traits, proactive aggression, and treatment outcomes of aggressive children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Aggression; Antisocial Personality Disorder; Attention Deficit and Disruptive Behavior D | 2013 |
Callous-unemotional traits, proactive aggression, and treatment outcomes of aggressive children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Aggression; Antisocial Personality Disorder; Attention Deficit and Disruptive Behavior D | 2013 |
The effect of a skipped dose (placebo) of methylphenidate on the learning and retention of a motor skill in adolescents with Attention Deficit Hyperactivity Disorder.
Topics: Adolescent; Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2014 |
Methylphenidate hydrochloride modified-release in adults with attention deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2014 |
Striatal volume deficits in children with ADHD who present a poor response to methylphenidate.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cerebr | 2014 |
A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of osmotic-controlled release oral delivery system methylphenidate HCl in adults with attention-deficit/hyperactivity disorder in Japan.
Topics: Administration, Oral; Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nerv | 2014 |
Efficacy and Safety of Omega-3/6 Fatty Acids, Methylphenidate, and a Combined Treatment in Children With ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Delayed-Act | 2017 |
Influence of methylphenidate on spatial attention asymmetry in adolescents with attention deficit hyperactivity disorder (ADHD): preliminary findings.
Topics: Adolescent; Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2014 |
OROS-methylphenidate efficacy on specific executive functioning deficits in adults with ADHD: a randomized, placebo-controlled cross-over study.
Topics: Administration, Oral; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System S | 2014 |
Methylphenidate-osmotic-controlled release oral delivery system treatment reduces parenting stress in parents of children and adolescents with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2013 |
Aggregated n-of-1 trials of central nervous system stimulants versus placebo for paediatric traumatic brain injury--a pilot study.
Topics: Adolescent; Adolescent Behavior; Age Factors; Attention; Attention Deficit Disorder with Hyperactivi | 2014 |
Methylphenidate enhances cognitive performance in adults with poor baseline capacities regardless of attention-deficit/hyperactivity disorder diagnosis.
Topics: Adult; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2014 |
The effects of Psychotropic drugs On Developing brain (ePOD) study: methods and design.
Topics: Adolescent; Adult; Animals; Antidepressive Agents; Anxiety Disorders; Attention Deficit Disorder wit | 2014 |
Adaptive multimodal treatment for children with attention-deficit-/hyperactivity disorder: an 18 month follow-up.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; | 2015 |
Minimizing adverse events while maintaining clinical improvement in a pediatric attention-deficit/hyperactivity disorder crossover trial with dextroamphetamine and methylphenidate.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Cross-Over Studies; Dextroamphetam | 2014 |
The beneficial effect of methylphenidate in ADHD with comorbid separation anxiety.
Topics: Adolescent; Adolescent Behavior; Anti-Anxiety Agents; Anxiety, Separation; Attention Deficit Disorde | 2014 |
Catechol-O-methyltransferase Val158-Met polymorphism and a response of hyperactive-impulsive symptoms to methylphenidate: A replication study from South Korea.
Topics: Adolescent; Adolescent Behavior; Attention Deficit Disorder with Hyperactivity; Catechol O-Methyltra | 2014 |
Aerobic exercise and attention deficit hyperactivity disorder: brain research.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cognit | 2015 |
Aerobic exercise and attention deficit hyperactivity disorder: brain research.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cognit | 2015 |
Aerobic exercise and attention deficit hyperactivity disorder: brain research.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cognit | 2015 |
Aerobic exercise and attention deficit hyperactivity disorder: brain research.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cognit | 2015 |
Aerobic exercise and attention deficit hyperactivity disorder: brain research.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cognit | 2015 |
Aerobic exercise and attention deficit hyperactivity disorder: brain research.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cognit | 2015 |
Aerobic exercise and attention deficit hyperactivity disorder: brain research.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cognit | 2015 |
Aerobic exercise and attention deficit hyperactivity disorder: brain research.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cognit | 2015 |
Aerobic exercise and attention deficit hyperactivity disorder: brain research.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cognit | 2015 |
A randomized trial of edivoxetine in pediatric patients with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Attention Deficit Disorder with Hyperactivity; Central Ner | 2014 |
The most effective intervention for attention deficit-hyperactivity disorder: using continuous performance test.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; | 2014 |
Neurocognitive effects of neurofeedback in adolescents with ADHD: a randomized controlled trial.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous | 2014 |
Differential impact of methylphenidate and atomoxetine on sustained attention in youth with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention; Attention Deficit Di | 2015 |
Salivary neurosteroid levels and behavioural profiles of children with attention-deficit/hyperactivity disorder during six months of methylphenidate treatment.
Topics: Administration, Oral; Attention Deficit Disorder with Hyperactivity; Central Nervous System Agents; | 2014 |
Memantine in the Treatment of Executive Function Deficits in Adults With ADHD.
Topics: Administration, Oral; Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nerv | 2017 |
Methylphenidate significantly reduces lapses of attention during on-road highway driving in patients with ADHD.
Topics: Adult; Attention; Attention Deficit Disorder with Hyperactivity; Automobile Driving; Central Nervous | 2014 |
Effect of methylphenidate treatment on appetite and levels of leptin, ghrelin, adiponectin, and brain-derived neurotrophic factor in children and adolescents with attention deficit and hyperactivity disorder.
Topics: Adiponectin; Adolescent; Appetite; Attention Deficit Disorder with Hyperactivity; Brain-Derived Neur | 2014 |
Open-label dose optimization of methylphenidate modified release long acting (MPH-LA): a post hoc analysis of real-life titration from a 40-week randomized trial.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Delayed-Act | 2014 |
Comparative short term efficacy and tolerability of methylphenidate and atomoxetine in attention deficit hyperactivity disorder.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child B | 2014 |
Improvement of facial affect recognition in children and adolescents with attention-deficit/hyperactivity disorder under methylphenidate.
Topics: Adolescent; Affect; Attention Deficit Disorder with Hyperactivity; Child; Cross-Over Studies; Dopami | 2014 |
Long-term (1 year) safety and efficacy of methylphenidate modified-release long-acting formulation (MPH-LA) in adults with attention-deficit hyperactivity disorder: a 26-week, flexible-dose, open-label extension to a 40-week, double-blind, randomised, pla
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Delayed-Action Preparations; Doubl | 2014 |
Instrumental learning in ADHD in a context of reward: intact learning curves and performance improvement with methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Double-Blin | 2015 |
Predicting methylphenidate response in attention deficit hyperactivity disorder: a preliminary study.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimula | 2015 |
Relationships between computer-based testing and behavioral ratings in the assessment of attention and activity in a pediatric ADHD stimulant crossover trial.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimula | 2014 |
Methylphenidate ameliorates depressive comorbidity in ADHD children without any modification on differences in serum melatonin concentration between ADHD subtypes.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2014 |
Cognitive Improvement of Attention and Inhibition in the Late Afternoon in Children With Attention-Deficit Hyperactivity Disorder (ADHD) Treated With Osmotic-Release Oral System Methylphenidate.
Topics: Administration, Oral; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous Syst | 2015 |
An N-of-1 trial as an individualized withdrawal treatment approach to psychological methylphenidate dependence.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cross-Over | 2014 |
A randomized placebo-controlled double-blind study evaluating the time course of response to methylphenidate hydrochloride extended-release capsules in children with attention-deficit/hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Capsules; Central Nervous System Stimulants; Child; C | 2014 |
Effects of behavioral and pharmacological therapies on peer reinforcement of deviancy in children with ADHD-only, ADHD and conduct problems, and controls.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; | 2015 |
Neurocognitive performance and behavioral symptoms in patients with attention-deficit/hyperactivity disorder during twenty-four months of treatment with methylphenidate.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Behavioral Symptoms; Central Nervous Syst | 2015 |
Reliability and Validity of the Before-School Functioning Scale in Children With ADHD.
Topics: Administration, Cutaneous; Attention Deficit Disorder with Hyperactivity; Behavior Rating Scale; Chi | 2018 |
Toward personalized smoking-cessation treatment: Using a predictive modeling approach to guide decisions regarding stimulant medication treatment of attention-deficit/hyperactivity disorder (ADHD) in smokers.
Topics: Administration, Oral; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System S | 2015 |
Altered white matter tract property related to impaired focused attention, sustained attention, cognitive impulsivity and vigilance in attention-deficit/ hyperactivity disorder.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Child; C | 2015 |
Altered white matter tract property related to impaired focused attention, sustained attention, cognitive impulsivity and vigilance in attention-deficit/ hyperactivity disorder.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Child; C | 2015 |
Altered white matter tract property related to impaired focused attention, sustained attention, cognitive impulsivity and vigilance in attention-deficit/ hyperactivity disorder.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Child; C | 2015 |
Altered white matter tract property related to impaired focused attention, sustained attention, cognitive impulsivity and vigilance in attention-deficit/ hyperactivity disorder.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Child; C | 2015 |
Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Capsules; Central Nervous System Stimulan | 2015 |
Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Capsules; Central Nervous System Stimulan | 2015 |
Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Capsules; Central Nervous System Stimulan | 2015 |
Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Capsules; Central Nervous System Stimulan | 2015 |
Ginkgo biloba in the treatment of attention-deficit/hyperactivity disorder in children and adolescents. A randomized, placebo-controlled, trial.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Female; Gin | 2015 |
Neuroimaging-Aided Prediction of the Effect of Methylphenidate in Children with Attention-Deficit Hyperactivity Disorder: A Randomized Controlled Trial.
Topics: Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Central Nervous System Stimulan | 2015 |
Methylphenidate improves the quality of life of children and adolescents with ADHD and difficult-to-treat epilepsies.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2015 |
Predicting Methylphenidate Response in ADHD Using Machine Learning Approaches.
Topics: Age Factors; Attention Deficit Disorder with Hyperactivity; Body Weight; Brain; Central Nervous Syst | 2015 |
Types of adult attention-deficit hyperactivity disorder (ADHD): baseline characteristics, initial response, and long-term response to treatment with methylphenidate.
Topics: Adult; Attention; Attention Deficit Disorder with Hyperactivity; Cross-Over Studies; Double-Blind Me | 2015 |
Functional outcomes from a head-to-head, randomized, double-blind trial of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder and an inadequate response to methylphenidate.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention; Attention Deficit Disorder with Hyperactivity; Cen | 2016 |
The Unique and Combined Effects of Reinforcement and Methylphenidate on Temporal Information Processing in Attention-Deficit/Hyperactivity Disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Combined Mo | 2015 |
Pharmacotherapy of the Preschool ADHD Treatment Study (PATS) Children Growing Up.
Topics: Antipsychotic Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cent | 2015 |
Does intensive multimodal treatment for maternal ADHD improve the efficacy of parent training for children with ADHD? A randomized controlled multicenter trial.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Chil | 2015 |
Effects of Atomoxetine and Osmotic Release Oral System-Methylphenidate on Executive Functions in Patients with Combined Type Attention-Deficit/Hyperactivity Disorder.
Topics: Administration, Oral; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Dis | 2015 |
An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2015 |
Gender Differences in the Behavioral Symptoms and Neuropsychological Performance of Patients with Attention-Deficit/Hyperactivity Disorder Treated with Methylphenidate: A Two-Year Follow-up Study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2015 |
Remission Rate and Functional Outcomes During a 6-Month Treatment With Osmotic-Release Oral-System Methylphenidate in Children With Attention-Deficit/Hyperactivity Disorder.
Topics: Administration, Oral; Adolescent; Asian People; Attention Deficit Disorder with Hyperactivity; Centr | 2015 |
Safety of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): Data from the Italian National ADHD Registry.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with | 2015 |
An application of analyzing the trajectories of two disorders: A parallel piecewise growth model of substance use and attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cognit | 2015 |
Association Between 5-HTTLPR Polymorphism and Tics after Treatment with Methylphenidate in Korean Children with Attention-Deficit/Hyperactivity Disorder.
Topics: Adolescent; Alleles; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulant | 2015 |
Effects of Group Psychotherapy, Individual Counseling, Methylphenidate, and Placebo in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2015 |
Effects of Group Psychotherapy, Individual Counseling, Methylphenidate, and Placebo in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2015 |
Effects of Group Psychotherapy, Individual Counseling, Methylphenidate, and Placebo in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2015 |
Effects of Group Psychotherapy, Individual Counseling, Methylphenidate, and Placebo in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2015 |
Anxiety reduction on atomoxetine and methylphenidate medication in children with ADHD.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Anxiety; Atomoxetine Hydrochloride; Attention Deficit Diso | 2016 |
An Open-label, Self-control, Prospective Study on Cognitive Function, Academic Performance, and Tolerability of Osmotic-release Oral System Methylphenidate in Children with Attention-deficit Hyperactivity Disorder.
Topics: Administration, Oral; Attention Deficit Disorder with Hyperactivity; Child; Cognition; Female; Human | 2015 |
A randomized controlled trial into the effects of neurofeedback, methylphenidate, and physical activity on EEG power spectra in children with ADHD.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Brain Waves; Central Nervous System Stimu | 2016 |
A Randomized Controlled Trial Investigating the Effects of Neurofeedback, Methylphenidate, and Physical Activity on Event-Related Potentials in Children with Attention-Deficit/Hyperactivity Disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2016 |
Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
Topics: Administration, Oral; Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention | 2016 |
Factors Associated with Management of Teen Aggression: Child Psychiatric Clinical Decision Making.
Topics: Adolescent; Adult; Aged; Aggression; Antipsychotic Agents; Attention Deficit Disorder with Hyperacti | 2017 |
Medication and creativity in Attention Deficit Hyperactivity Disorder (ADHD).
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Pres | 2016 |
Methylphenidate and emotional-motivational processing in attention-deficit/hyperactivity disorder.
Topics: Adult; Analysis of Variance; Anxiety; Attention Deficit Disorder with Hyperactivity; Central Nervous | 2016 |
Atomoxetine could improve intra-individual variability in drug-naïve adults with attention-deficit/hyperactivity disorder comparably with methylphenidate: A head-to-head randomized clinical trial.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hype | 2016 |
Hot executive control and response to a stimulant in a double-blind randomized trial in children with ADHD.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2017 |
Personality Disorder in Adult Attention-Deficit/Hyperactivity Disorder: Attrition and Change During Long-term Treatment.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Cross-Over Studies; Diagnostic and Statistical | 2016 |
Personality Disorder in Adult Attention-Deficit/Hyperactivity Disorder: Attrition and Change During Long-term Treatment.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Cross-Over Studies; Diagnostic and Statistical | 2016 |
Personality Disorder in Adult Attention-Deficit/Hyperactivity Disorder: Attrition and Change During Long-term Treatment.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Cross-Over Studies; Diagnostic and Statistical | 2016 |
Personality Disorder in Adult Attention-Deficit/Hyperactivity Disorder: Attrition and Change During Long-term Treatment.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Cross-Over Studies; Diagnostic and Statistical | 2016 |
Concordance of actigraphy with polysomnography in children with and without attention-deficit/hyperactivity disorder.
Topics: Actigraphy; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimula | 2016 |
Abnormal response to methylphenidate across multiple fMRI procedures in cocaine use disorder: feasibility study.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Brain; Cocaine-Related Disorders; Cognition; C | 2016 |
Efficacy, Safety, and Tolerability of an Extended-Release Orally Disintegrating Methylphenidate Tablet in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder in the Laboratory Classroom Setting.
Topics: Administration, Oral; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulan | 2017 |
A Single-Dose, Single-Period Pharmacokinetic Assessment of an Extended-Release Orally Disintegrating Tablet of Methylphenidate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
Topics: Administration, Oral; Adolescent; Age Factors; Area Under Curve; Attention Deficit Disorder with Hyp | 2016 |
Agomelatine as a Treatment for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: A Double-Blind, Randomized Clinical Trial.
Topics: Acetamides; Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimul | 2016 |
Sarcosine treatment for oppositional defiant disorder symptoms of attention deficit hyperactivity disorder children.
Topics: Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; | 2016 |
Combined Stimulant and Guanfacine Administration in Attention-Deficit/Hyperactivity Disorder: A Controlled, Comparative Study.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Attention Deficit Disorder with Hyperactivity; Cen | 2016 |
Cognitive Effects of Stimulant, Guanfacine, and Combined Treatment in Child and Adolescent Attention-Deficit/Hyperactivity Disorder.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Attention Deficit Disorder with Hyperactivity; Cen | 2016 |
Effects of d-Methylphenidate, Guanfacine, and Their Combination on Electroencephalogram Resting State Spectral Power in Attention-Deficit/Hyperactivity Disorder.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Attention Deficit Disorder with Hyperactivity; Bra | 2016 |
Meditation or Medication? Mindfulness training versus medication in the treatment of childhood ADHD: a randomized controlled trial.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Clinical Protocols; Female; Humans | 2016 |
Is emotion recognition the only problem in ADHD? effects of pharmacotherapy on face and emotion recognition in children with ADHD.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Case-Control S | 2016 |
Randomized, 6-Week, Placebo-Controlled Study of Treatment for Adult Attention-Deficit/Hyperactivity Disorder: Individualized Dosing of Osmotic-Release Oral System (OROS) Methylphenidate With a Goal of Symptom Remission.
Topics: Administration, Oral; Adult; Attention Deficit Disorder with Hyperactivity; Dose-Response Relationsh | 2017 |
Age-Dependent Effects of Methylphenidate on the Human Dopaminergic System in Young vs Adult Patients With Attention-Deficit/Hyperactivity Disorder: A Randomized Clinical Trial.
Topics: Adult; Age Factors; Attention Deficit Disorder with Hyperactivity; Brain; Child; Corpus Striatum; Do | 2016 |
The role of sleep quality and quantity in moderating the effectiveness of medication in the treatment of children with ADHD.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Child; Delayed-Action Preparations; Double | 2017 |
An Investigation of Stimulant Effects on the EEG of Children With Attention-Deficit/Hyperactivity Disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; Child; Dext | 2017 |
The effect of methylphenidate intake on brain structure in adults with ADHD in a placebo-controlled randomized trial.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; Doub | 2016 |
Association of the GRIN2B rs2284411 polymorphism with methylphenidate response in attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2017 |
Novelty-seeking trait predicts the effect of methylphenidate on creativity.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Creativity; | 2017 |
Behavioral Effects of Neurofeedback Compared to Stimulants and Physical Activity in Attention-Deficit/Hyperactivity Disorder: A Randomized Controlled Trial.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Beta Rhythm; Central Nervous System Stimu | 2016 |
An RCT into the effects of neurofeedback on neurocognitive functioning compared to stimulant medication and physical activity in children with ADHD.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimula | 2017 |
The effect of single-dose methylphenidate on resting-state network functional connectivity in ADHD.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Brain; Brain Mapping; Central Nervous Sys | 2017 |
Effect of Aptensio XR (Methylphenidate HCl Extended-Release) Capsules on Sleep in Children with Attention-Deficit/Hyperactivity Disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Capsules; Central Nervous System Stimulan | 2016 |
The Time Course of Effect of Multilayer-Release Methylphenidate Hydrochloride Capsules: A Randomized, Double-Blind Study of Adults With ADHD in a Simulated Adult Workplace Environment.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Capsules; Central Nervous System Stimulants; D | 2020 |
Acute Stimulant Treatment and Reinforcement Increase the Speed of Information Accumulation in Children with ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cognitive D | 2017 |
Does Methylphenidate Reduce Testosterone Levels in Humans? A Prospective Study in Children with Attention-Deficit/Hyperactivity Disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Female; Humans; Male; Methylphenidate; Prospec | 2017 |
Effectiveness of atomoxetine and methylphenidate for problematic online gaming in adolescents with attention deficit hyperactivity disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with | 2016 |
Learning curves of theta/beta neurofeedback in children with ADHD.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Diagnostic and Statistical Manual | 2017 |
Telephone-assisted self-help for parents of children with attention-deficit/hyperactivity disorder who have residual functional impairment despite methylphenidate treatment: a randomized controlled trial.
Topics: Adult; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperact | 2017 |
Using a Patient-Centered Outcome Measure to Test Methylphenidate Versus Placebo in Children with Autism Spectrum Disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Central Nervous System Stim | 2017 |
Effect of vitamin D supplementation as adjunctive therapy to methylphenidate on ADHD symptoms: A randomized, double blind, placebo-controlled trial.
Topics: Activities of Daily Living; Attention Deficit Disorder with Hyperactivity; Calcifediol; Child; Child | 2018 |
Short-Term Effects of Methylphenidate on Math Productivity in Children With Attention-Deficit/Hyperactivity Disorder are Mediated by Symptom Improvements: Evidence From a Placebo-Controlled Trial.
Topics: Achievement; Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimu | 2017 |
Children with ADHD and symptoms of oppositional defiant disorder improved in behavior when treated with methylphenidate and adjuvant risperidone, though weight gain was also observed - Results from a randomized, double-blind, placebo-controlled clinical t
Topics: Adjuvants, Pharmaceutic; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Diso | 2017 |
Effect of switching drug formulations from immediate-release to extended-release OROS methylphenidate : a chart review of Spanish adults with attention-deficit hyperactivity disorder.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Chemistry, | 2008 |
Reboxetine versus methylphenidate in treatment of children and adolescents with attention deficit-hyperactivity disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Attention Deficit Disorder with Hyperactivity; Central Ner | 2009 |
COMT Val108/158Met polymorphism and the modulation of task-oriented behavior in children with ADHD.
Topics: Amino Acid Substitution; Attention Deficit Disorder with Hyperactivity; Catechol O-Methyltransferase | 2008 |
Unexpected effects of methylphenidate in attention-deficit/hyperactivity disorder reflect decreases in core/secondary symptoms and physical complaints common to all children.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Cross-Over Studies; Dose-Response Relationship | 2008 |
Efficacy and safety of extended-release dexmethylphenidate compared with d,l-methylphenidate and placebo in the treatment of children with attention-deficit/hyperactivity disorder: a 12-hour laboratory classroom study.
Topics: Attention Deficit Disorder with Hyperactivity; Chemistry, Pharmaceutical; Child; Cross-Over Studies; | 2008 |
A randomized, double-blind, crossover study of once-daily dexmethylphenidate in children with attention-deficit hyperactivity disorder: rapid onset of effect.
Topics: Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulan | 2008 |
Factor structure of the restricted academic situation scale: implications for ADHD.
Topics: Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; | 2009 |
Treatment effectiveness of combined medication/behavioural treatment with chinese ADHD children in routine practice.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Combined Modality Therapy; D | 2008 |
[Effectiveness of oral osmotic-methylphenidate in treatment of attention deficit hyperactivity disorder in children].
Topics: Administration, Oral; Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Female; Huma | 2008 |
EEG coherence in girls with attention-deficit/hyperactivity disorder: stimulant effects in good responders.
Topics: Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Central Nervous System Stimulan | 2008 |
Children with attention deficits concentrate better after walk in the park.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2009 |
Pharmacokinetics of methylphenidate transdermal system (MTS): results from a laboratory classroom study.
Topics: Administration, Cutaneous; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2008 |
The effect of methylphenidate and placebo on eye-hand coordination functioning and handwriting of children with attention deficit hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2007 |
Improved odor sensitivity in attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Central Nervous Sys | 2008 |
Single dose of methylphenidate improves cognitive performance in multiple sclerosis patients with impaired attention process.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Central Nervous System S | 2009 |
Methylphenidate improves response inhibition but not reflection-impulsivity in children with attention deficit hyperactivity disorder (ADHD).
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2009 |
Methylphenidate and amphetamine do not induce cytogenetic damage in lymphocytes of children with ADHD.
Topics: Amphetamines; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Chil | 2008 |
Effects of methylphenidate on working memory functioning in children with attention deficit/hyperactivity disorder.
Topics: Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulan | 2009 |
Methylphenidate restores link between stop-signal sensory impact and successful stopping in adults with attention-deficit/hyperactivity disorder.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cerebral Co | 2009 |
Reinforcing and subjective effects of methylphenidate in adults with and without attention deficit hyperactivity disorder (ADHD).
Topics: Administration, Oral; Adult; Area Under Curve; Attention Deficit Disorder with Hyperactivity; Centra | 2009 |
Social information processing in elementary-school aged children with ADHD: medication effects and comparisons with typical children.
Topics: Aggression; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2009 |
The efficacy and tolerability of methylphenidate and behavior modification in children with attention-deficit/hyperactivity disorder and severe mood dysregulation.
Topics: Assertiveness; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous Syst | 2008 |
Effects of MPH-OROS on the organizational, time management, and planning behaviors of children with ADHD.
Topics: Administration, Oral; Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2009 |
Association between homozygosity of a G allele of the alpha-2a-adrenergic receptor gene and methylphenidate response in Korean children and adolescents with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Alleles; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulant | 2009 |
A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Clinical Pr | 2009 |
Efficacy of osmotic-release oral system (OROS) methylphenidate for mothers with attention-deficit/hyperactivity disorder (ADHD): preliminary report of effects on ADHD symptoms and parenting.
Topics: Administration, Oral; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System S | 2008 |
Efficacy of osmotic-release oral system (OROS) methylphenidate for mothers with attention-deficit/hyperactivity disorder (ADHD): preliminary report of effects on ADHD symptoms and parenting.
Topics: Administration, Oral; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System S | 2008 |
Efficacy of osmotic-release oral system (OROS) methylphenidate for mothers with attention-deficit/hyperactivity disorder (ADHD): preliminary report of effects on ADHD symptoms and parenting.
Topics: Administration, Oral; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System S | 2008 |
Efficacy of osmotic-release oral system (OROS) methylphenidate for mothers with attention-deficit/hyperactivity disorder (ADHD): preliminary report of effects on ADHD symptoms and parenting.
Topics: Administration, Oral; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System S | 2008 |
The effect of methylphenidate on postural stability under single and dual task conditions in children with attention deficit hyperactivity disorder - a double blind randomized control trial.
Topics: Analysis of Variance; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous Syst | 2009 |
Long-term effectiveness and safety of dexmethylphenidate extended-release capsules in adult ADHD.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Attention Deficit Disorder with Hyperactivity; Capsu | 2009 |
Neurocognitive effects of switching from methylphenidate-IR to OROS-methylphenidate in children with ADHD.
Topics: Administration, Oral; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulan | 2009 |
Stimulant treatment reduces lapses in attention among children with ADHD: the effects of methylphenidate on intra-individual response time distributions.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2009 |
Medication adherence in the MTA: saliva methylphenidate samples versus parent report and mediating effect of concomitant behavioral treatment.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Behavioral Symptoms; Central Nervou | 2009 |
Medication adherence in the MTA: saliva methylphenidate samples versus parent report and mediating effect of concomitant behavioral treatment.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Behavioral Symptoms; Central Nervou | 2009 |
Medication adherence in the MTA: saliva methylphenidate samples versus parent report and mediating effect of concomitant behavioral treatment.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Behavioral Symptoms; Central Nervou | 2009 |
Medication adherence in the MTA: saliva methylphenidate samples versus parent report and mediating effect of concomitant behavioral treatment.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Behavioral Symptoms; Central Nervou | 2009 |
Medication adherence in the MTA: saliva methylphenidate samples versus parent report and mediating effect of concomitant behavioral treatment.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Behavioral Symptoms; Central Nervou | 2009 |
Medication adherence in the MTA: saliva methylphenidate samples versus parent report and mediating effect of concomitant behavioral treatment.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Behavioral Symptoms; Central Nervou | 2009 |
Medication adherence in the MTA: saliva methylphenidate samples versus parent report and mediating effect of concomitant behavioral treatment.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Behavioral Symptoms; Central Nervou | 2009 |
Medication adherence in the MTA: saliva methylphenidate samples versus parent report and mediating effect of concomitant behavioral treatment.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Behavioral Symptoms; Central Nervou | 2009 |
Medication adherence in the MTA: saliva methylphenidate samples versus parent report and mediating effect of concomitant behavioral treatment.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Behavioral Symptoms; Central Nervou | 2009 |
Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2009 |
Dopamine-related genotypes and the dose-response effect of methylphenidate on eating in attention-deficit/hyperactivity disorder youths.
Topics: Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; Child; Dopa | 2009 |
Cardiovascular effects of longer-term, high-dose OROS methylphenidate in adolescents with attention deficit hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Central Nervous System St | 2009 |
Sex differences in effectiveness of extended-release stimulant medication among adolescents with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Delaye | 2009 |
Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
Topics: Adolescent; Adult; Aged; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Central Nerv | 2009 |
Methylphenidate improves diminished error and feedback sensitivity in ADHD: An evoked heart rate analysis.
Topics: Analysis of Variance; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous Syst | 2009 |
Impulsiveness as a timing disturbance: neurocognitive abnormalities in attention-deficit hyperactivity disorder during temporal processes and normalization with methylphenidate.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; | 2009 |
Effects of application to two different skin sites on the pharmacokinetics of transdermal methylphenidate in pediatric patients with attention-deficit/hyperactivity disorder.
Topics: Administration, Cutaneous; Area Under Curve; Attention Deficit Disorder with Hyperactivity; Biologic | 2009 |
Randomized, placebo-controlled, crossover study of methylphenidate for attention-deficit/hyperactivity disorder symptoms in preschoolers with developmental disorders.
Topics: Age Factors; Attention Deficit Disorder with Hyperactivity; Child Development Disorders, Pervasive; | 2009 |
Randomized, placebo-controlled, crossover study of methylphenidate for attention-deficit/hyperactivity disorder symptoms in preschoolers with developmental disorders.
Topics: Age Factors; Attention Deficit Disorder with Hyperactivity; Child Development Disorders, Pervasive; | 2009 |
Randomized, placebo-controlled, crossover study of methylphenidate for attention-deficit/hyperactivity disorder symptoms in preschoolers with developmental disorders.
Topics: Age Factors; Attention Deficit Disorder with Hyperactivity; Child Development Disorders, Pervasive; | 2009 |
Randomized, placebo-controlled, crossover study of methylphenidate for attention-deficit/hyperactivity disorder symptoms in preschoolers with developmental disorders.
Topics: Age Factors; Attention Deficit Disorder with Hyperactivity; Child Development Disorders, Pervasive; | 2009 |
Efficacy and safety of dexmethylphenidate extended-release capsules administered once daily to children with attention-deficit/hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Capsules; Child; Delayed-Action Preparations; Dexmeth | 2009 |
Methylphenidate normalises activation and functional connectivity deficits in attention and motivation networks in medication-naïve children with ADHD during a rewarded continuous performance task.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System | 2009 |
No correlation between Continuous Performance Test and optimal methylphenidate dosage in ADHD children.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Dose-Response Relationship, Drug; Female; Huma | 2009 |
Effects of methylphenidate on discounting of delayed rewards in attention deficit/hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Choice Beha | 2009 |
Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials.
Topics: Administration, Cutaneous; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2009 |
Ginkgo biloba for attention-deficit/hyperactivity disorder in children and adolescents: a double blind, randomized controlled trial.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2010 |
HRQL and medication satisfaction in children with ADHD treated with the methylphenidate transdermal system.
Topics: Administration, Cutaneous; Algorithms; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2009 |
An open study of adjunct OROS-methylphenidate in children and adolescents who are atomoxetine partial responders: I. Effectiveness.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with | 2009 |
An open study of adjunct OROS-methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with | 2009 |
Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adrenergic alpha-Agonists; Amphetamine; Attention Deficit Disorder with Hyperactivity; C | 2009 |
Effects of clonidine and methylphenidate on family quality of life in attention-deficit/hyperactivity disorder.
Topics: Adrenergic alpha-Agonists; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2009 |
Methylphenidate combined with aripiprazole in children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder: a randomized crossover trial.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit Disorder with Hyperactivity; Bipol | 2009 |
Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy.
Topics: Adolescent; Aggression; Antimanic Agents; Attention Deficit and Disruptive Behavior Disorders; Atten | 2009 |
Construct validity of an attention rating scale for traumatic brain injury.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Attention; Attention Deficit Disorder with Hyperactivity | 2009 |
Depression, anxiety and obsessive-compulsive symptoms and quality of life in children with attention-deficit hyperactivity disorder (ADHD) during three-month methylphenidate treatment.
Topics: Adolescent; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System | 2010 |
Sustained release methylphenidate for the treatment of ADHD in amphetamine abusers: a pilot study.
Topics: Adult; Amphetamine-Related Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous | 2010 |
Stimulant drug response in the predominantly inattentive and combined subtypes of attention-deficit/hyperactivity disorder.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2009 |
The sleep of children with attention deficit hyperactivity disorder on and off methylphenidate: a matched case-control study.
Topics: Arousal; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Central Nervous System | 2010 |
A one year trial of methylphenidate in the treatment of ADHD.
Topics: Adult; Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Central Nervous System S | 2011 |
The effect of OROS methylphenidate on the sleep of children with attention-deficit/hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Cognition; Data Interpretation, Statistical; D | 2010 |
OROS-methylphenidate or placebo for adult smokers with attention deficit hyperactivity disorder: racial/ethnic differences.
Topics: Administration, Cutaneous; Adult; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; C | 2010 |
Methylphenidate enhances prepulse inhibition during processing of task-relevant stimuli in attention-deficit/hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Blinking; Central Nervous System Stimulants; Child; D | 2010 |
Twenty-four-week treatment with extended release methylphenidate improves emotional symptoms in adult ADHD.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Delayed-Act | 2010 |
Methylphenidate and comorbid anxiety disorder in children with both chronic multiple tic disorder and ADHD.
Topics: Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2011 |
Methylphenidate transdermal system in adult ADHD and impact on emotional and oppositional symptoms.
Topics: Administration, Cutaneous; Adult; Attention Deficit and Disruptive Behavior Disorders; Attention Def | 2011 |
Manganese in children with attention-deficit/hyperactivity disorder: relationship with methylphenidate exposure.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Dopamine Uptake Inhibitors; Enviro | 2010 |
Non-specific effects of methylphenidate (Ritalin) on cognitive ability and decision-making of ADHD and healthy adults.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Cognition; Decision Making; Double-Blind Metho | 2010 |
Apnea-hypopnea indices and snoring in children diagnosed with ADHD: a matched case-control study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Central Nervous Sys | 2011 |
Clinical response to methylphenidate in children diagnosed with attention-deficit hyperactivity disorder and comorbid psychiatric disorders.
Topics: Anxiety Disorders; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder w | 2010 |
Impact of attention-deficit/hyperactivity disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers: a randomized, double-blind, placebo-controlled trial.
Topics: Administration, Oral; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System S | 2010 |
A controlled trial of the methylphenidate transdermal system on before-school functioning in children with attention-deficit/hyperactivity disorder.
Topics: Administration, Cutaneous; Attention Deficit Disorder with Hyperactivity; Child; Child Behavior; Cro | 2010 |
Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy.
Topics: Adolescent; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Central Nervous System S | 2010 |
A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Delayed-Action Preparations; Drug Administrati | 2011 |
What can actigraphy add to the concept of labschool design in clinical trials?
Topics: Actigraphy; Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimul | 2010 |
Buspirone versus methylphenidate in the treatment of attention deficit hyperactivity disorder: a double-blind and randomized trial.
Topics: Attention Deficit Disorder with Hyperactivity; Buspirone; Central Nervous System Stimulants; Child; | 2010 |
Methylphenidate transdermal system in adults with past stimulant misuse: an open-label trial.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Amphetamine-Related Disorders; Attention Deficit | 2011 |
The 5-HTTLPR polymorphism of the serotonin transporter gene and short term behavioral response to methylphenidate in children with ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cross-Over | 2010 |
Sex differences in attentional performance and their modulation by methylphenidate in children with attention-deficit/hyperactivity disorder.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2010 |
Dose-response characteristics in adolescents with attention-deficit/hyperactivity disorder treated with OROS methylphenidate in a 4-week, open-label, dose-titration study.
Topics: Adolescent; Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Body Weight; Centra | 2010 |
Molecular imaging genetics of methylphenidate response in ADHD and substance use comorbidity.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Brain; Brain Mapping; Comorbidity; Dopami | 2011 |
A randomized, double-blind, multicenter, parallel-group, placebo-controlled, dose-optimization study of the methylphenidate transdermal system for the treatment of ADHD in adolescents.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Dose-R | 2010 |
Methylphenidate significantly improves declarative memory functioning of adults with ADHD.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cross-Over | 2010 |
OROS methylphenidate in the treatment of adults with ADHD: a 6-month, open-label, follow-up study.
Topics: Affective Symptoms; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder | 2010 |
Impact of long-term treatment of methylphenidate on height and weight of school age children with ADHD.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Body Height; Body Mass Index; Body Weight | 2010 |
Testing tic suppression: comparing the effects of dexmethylphenidate to no medication in children and adolescents with attention-deficit/hyperactivity disorder and Tourette's disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2010 |
Single- and multiple-dose pharmacokinetics of methylphenidate administered as methylphenidate transdermal system or osmotic-release oral system methylphenidate to children and adolescents with attention deficit hyperactivity disorder.
Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Age Factors; Attention Deficit Disorder | 2010 |
A randomized, 3-phase, 34-week, double-blind, long-term efficacy study of osmotic-release oral system-methylphenidate in adults with attention-deficit/hyperactivity disorder.
Topics: Administration, Oral; Adult; Age Factors; Attention Deficit Disorder with Hyperactivity; Delayed-Act | 2010 |
Stimulant-responsive and stimulant-refractory aggressive behavior among children with ADHD.
Topics: Adolescent; Aggression; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimul | 2010 |
Venlafaxine versus methylphenidate in pediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Attention Deficit Disorder with Hyperactivity; | 2010 |
The single-dose pharmacokinetics of NWP06, a novel extended-release methylphenidate oral suspension.
Topics: Administration, Oral; Adult; Aged; Area Under Curve; Attention Deficit Disorder with Hyperactivity; | 2010 |
Does placebo response differ between objective and subjective measures in children with attention-deficit/hyperactivity disorder?
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with | 2010 |
Time course and predictors of health-related quality of life improvement and medication satisfaction in children diagnosed with attention-deficit/hyperactivity disorder treated with the methylphenidate transdermal system.
Topics: Administration, Cutaneous; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2010 |
A 6-month, open-label, extension study of the tolerability and effectiveness of the methylphenidate transdermal system in adolescents diagnosed with attention-deficit/hyperactivity disorder.
Topics: Administration, Cutaneous; Adolescent; Appetite; Attention Deficit Disorder with Hyperactivity; Cent | 2010 |
A double-blind, randomized, placebo/active controlled crossover evaluation of the efficacy and safety of Ritalin ® LA in children with attention-deficit/hyperactivity disorder in a laboratory classroom setting.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2010 |
Genome-wide association study of blood pressure response to methylphenidate treatment of attention-deficit/hyperactivity disorder.
Topics: Administration, Cutaneous; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Central Ne | 2011 |
Brain biochemical effects of methylphenidate treatment using proton magnetic spectroscopy in youth with attention-deficit hyperactivity disorder: a controlled pilot study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Brain; Case-Control Studies; Central Nerv | 2012 |
Multiscale assessment of treatment efficacy in adults with ADHD: a randomized placebo-controlled, multi-centre study with extended-release methylphenidate.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Central Nervous Sy | 2012 |
Atomoxetine and methylphenidate treatment in children with ADHD: the efficacy, tolerability and effects on executive functions.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with | 2011 |
Predictors of treatment outcome in adults with ADHD treated with OROS® methylphenidate.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Delayed-Act | 2011 |
Long-term safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: an open-label, dose-titration, 1-year study.
Topics: Adolescent; Adult; Age Factors; Aged; Attention Deficit Disorder with Hyperactivity; Delayed-Action | 2011 |
Effects of stimulant medication, incentives, and event rate on reaction time variability in children with ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Choice Beha | 2011 |
Methylphenidate for treating tobacco dependence in non-attention deficit hyperactivity disorder smokers: a pilot randomized placebo-controlled trial.
Topics: Adult; Aged; Attention Deficit Disorder with Hyperactivity; Female; Humans; Male; Methylphenidate; M | 2011 |
Are stimulants effective in the treatment of executive function deficits? Results from a randomized double blind study of OROS-methylphenidate in adults with ADHD.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Delayed-Act | 2011 |
Amantadine versus methylphenidate in children and adolescents with attention deficit/hyperactivity disorder: a randomized, double-blind trial.
Topics: Adolescent; Amantadine; Attention Deficit Disorder with Hyperactivity; Child; Dopamine Agents; Dopam | 2010 |
Association of salivary dehydroepiandrosterone levels and symptoms in patients with attention deficit hyperactivity disorder during six months of treatment with methylphenidate.
Topics: Affective Symptoms; Attention Deficit Disorder with Hyperactivity; Central Nervous System Agents; Ch | 2011 |
Cigarette and cannabis use trajectories among adolescents in treatment for attention-deficit/hyperactivity disorder and substance use disorders.
Topics: Administration, Oral; Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2011 |
Ningdong granule: a complementary and alternative therapy in the treatment of attention deficit/hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Complementa | 2011 |
Does the treatment of maternal attention deficit and hyperactivity disorder (ADHD) enhance the efficacy of a behavioural parent training for the treatment of their children's ADHD? Study protocol of a randomized controlled multicentre trail.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Child; Clinical Protocols; Cognitive Behaviora | 2009 |
Tolerability and effects of OROS® MPH (Concerta ®) on functioning, severity of disease and quality of life in children and adolescents with ADHD: results from a prospective, non-interventional trial.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2009 |
Exercise impact on sustained attention of ADHD children, methylphenidate effects.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimula | 2010 |
Reboxetine for ADHD in children non-responders or with poor tolerance to methylphenidate: a prospective long-term open-label study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2010 |
A randomized, rater-blinded, crossover study comparing the clinical efficacy of Ritalin(®) LA (methylphenidate) treatment in children with attention-deficit hyperactivity disorder under different breakfast conditions over 2 weeks.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cross-Over | 2010 |
Effects of OROS methylphenidate on academic, behavioral, and cognitive tasks in children 9 to 12 years of age with attention-deficit/hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Cognition; Cross-Over Studies; Dopamine Uptake | 2011 |
Methylphenidate normalizes fronto-striatal underactivation during interference inhibition in medication-naïve boys with attention-deficit hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Corpus Striatum; Double-Blind Meth | 2011 |
Academic, behavioral, and cognitive effects of OROS® methylphenidate on older children with attention-deficit/hyperactivity disorder.
Topics: Administration, Oral; Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Central | 2011 |
Clinical symptoms and performance on the Continuous Performance Test in children with attention deficit hyperactivity disorder between subtypes: a natural follow-up study for 6 months.
Topics: Aggression; Attention Deficit Disorder with Hyperactivity; Child; Cognition; Diagnostic and Statisti | 2011 |
Relation between therapeutic response and side effects induced by methylphenidate as observed by parents and teachers of children with ADHD.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Attitude to Health; Central Nervous System Sti | 2011 |
Correlation of symptomatic improvements with functional improvements and patient-reported outcomes in adults with attention-deficit/hyperactivity disorder treated with OROS methylphenidate.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Delayed-Act | 2013 |
One-year prospective follow-up of pharmacological treatment in children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with | 2011 |
Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD.
Topics: Adolescent; Adolescent Behavior; Adrenergic alpha-2 Receptor Agonists; Amphetamine; Attention Defici | 2011 |
Effect of osmotic-release oral system methylphenidate on different domains of attention and executive functioning in children with attention-deficit-hyperactivity disorder.
Topics: Activities of Daily Living; Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervo | 2011 |
Methylphenidate increases cigarette smoking in participants with ADHD.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Carbon Monoxide; Central Nervous System Stimul | 2011 |
Divergence by ADHD subtype in smoking cessation response to OROS-methylphenidate.
Topics: Adult; Age Factors; Attention Deficit Disorder with Hyperactivity; Diagnostic and Statistical Manual | 2011 |
Effects of methylphenidate on intelligence and attention components in boys with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Analysis of Variance; Attention; Attention Deficit Disorder with Hyperactivity; Central | 2011 |
Pharmacokinetics and therapeutic effect of OROS methylphenidate under different breakfast conditions in children with attention-deficit/hyperactivity disorder.
Topics: Area Under Curve; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2011 |
Methylphenidate normalizes frontocingulate underactivation during error processing in attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimula | 2011 |
Music and video as distractors for boys with ADHD in the classroom: comparison with controls, individual differences, and medication effects.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Case-Control Studies; Ce | 2011 |
Functional improvement and correlations with symptomatic improvement in adults with attention deficit hyperactivity disorder receiving long-acting methylphenidate.
Topics: Activities of Daily Living; Adolescent; Adult; Aged; Attention Deficit Disorder with Hyperactivity; | 2012 |
Val/Val genotype of brain-derived neurotrophic factor (BDNF) Val⁶⁶Met polymorphism is associated with a better response to OROS-MPH in Korean ADHD children.
Topics: Administration, Oral; Age Factors; Analysis of Variance; Attention Deficit Disorder with Hyperactivi | 2011 |
Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study.
Topics: Adolescent; Appetite; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulan | 2011 |
Comparison of the efficacy of two different modified release methylphenidate preparations for children and adolescents with attention-deficit/hyperactivity disorder in a natural setting: comparison of the efficacy of Medikinet(®) retard and Concerta(®)--a
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2011 |
Long-term efficacy and safety outcomes with OROS-MPH in adults with ADHD.
Topics: Administration, Oral; Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nerv | 2012 |
Prepotent response inhibition predicts treatment outcome in attention deficit/hyperactivity disorder.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2012 |
The impact of a multimodal Summer Camp Training on neuropsychological functioning in children and adolescents with ADHD: an exploratory study.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimula | 2012 |
An exploration of site effects in a multisite trial of OROS-methylphenidate for smokers with attention deficit/hyperactivity disorder.
Topics: Administration, Oral; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System S | 2011 |
Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disorders.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cognit | 2011 |
Major depression and treatment response in adolescents with ADHD and substance use disorder.
Topics: Adolescent; Alcohol-Related Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2012 |
Exploring the impact of once-daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPH.
Topics: Activities of Daily Living; Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervo | 2011 |
Single-dose pharmacokinetics of NWP06, an extended-release methylphenidate suspension, in children and adolescents with ADHD.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2011 |
Effects of long-acting methylphenidate in adults with attention deficit hyperactivity disorder: a study with paired-pulse transcranial magnetic stimulation.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Cerebral Cortex; Combined Modality | 2011 |
Comparative study of OROS-MPH and atomoxetine on executive function improvement in ADHD: a randomized controlled trial.
Topics: Administration, Oral; Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperac | 2012 |
Pharmacogenetic predictors of methylphenidate dose-response in attention-deficit/hyperactivity disorder.
Topics: Alleles; Attention Deficit Disorder with Hyperactivity; Catechol O-Methyltransferase; Central Nervou | 2011 |
Subjective effects, misuse, and adverse effects of osmotic-release methylphenidate treatment in adolescent substance abusers with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2011 |
Sports therapy for attention, cognitions and sociality.
Topics: Age Factors; Attention; Attention Deficit Disorder with Hyperactivity; Catecholamines; Central Nervo | 2011 |
Is response to OROS-methylphenidate treatment moderated by treatment with antidepressants or psychiatric comorbidity? A secondary analysis from a large randomized double blind study of adults with ADHD.
Topics: Administration, Oral; Adult; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; C | 2012 |
Methylphenidate treatment of adult male prison inmates with attention-deficit hyperactivity disorder: randomised double-blind placebo-controlled trial with open-label extension.
Topics: Adult; Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Central Nervous System S | 2012 |
Time course of treatment effect of OROS® methylphenidate in children with ADHD.
Topics: Administration, Oral; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous Syst | 2012 |
Oppositional defiant disorder in adults with ADHD.
Topics: Adult; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperact | 2013 |
Efficacy and safety of prolonged-release OROS methylphenidate in adults with attention deficit/hyperactivity disorder: a 13-week, randomized, double-blind, placebo-controlled, fixed-dose study.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2013 |
Effect of transdermal methylphenidate wear times on sleep in children with attention deficit hyperactivity disorder.
Topics: Administration, Cutaneous; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2011 |
Dose effects and comparative effectiveness of extended release dexmethylphenidate and mixed amphetamine salts.
Topics: Adolescent; Amphetamines; Appetite; Attention Deficit Disorder with Hyperactivity; Central Nervous S | 2011 |
The effect of methylphenidate on prefrontal cognitive functioning, inattention, and hyperactivity in velocardiofacial syndrome.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Catechol O-Met | 2011 |
Naturalistic exploration of the effect of osmotic release oral system-methylphenidate on remission rate and functional improvement in Taiwanese children with attention-deficit-hyperactivity disorder.
Topics: Administration, Oral; Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Delayed-Acti | 2012 |
Methylphenidate-elicited dopamine increases in ventral striatum are associated with long-term symptom improvement in adults with attention deficit hyperactivity disorder.
Topics: Adult; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Basal Ganglia; Brain Map | 2012 |
Heart rate variability and methylphenidate in children with ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Circadian R | 2012 |
A multicenter, open-label trial to evaluate the quality of life in adults with ADHD treated with long-acting methylphenidate (OROS MPH): Concerta Quality of Life (CONQoL) study.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Brazil; Central Nervous Sys | 2013 |
Modulation of attention-deficit/hyperactivity disorder symptoms by short- and long-acting methylphenidate over the course of a day.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Circadian R | 2012 |
Long-acting methylphenidate reduces collision rates of young adult drivers with attention-deficit/hyperactivity disorder.
Topics: Activities of Daily Living; Adolescent; Attention Deficit Disorder with Hyperactivity; Automobile Dr | 2012 |
Using the test of variables of attention to determine the effectiveness of modafinil in children with attention-deficit hyperactivity disorder (ADHD): a prospective methylphenidate-controlled trial.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Case-Con | 2012 |
Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder.
Topics: Administration, Oral; Adolescent; Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; At | 2012 |
Long-term functional outcome in adult prison inmates with ADHD receiving OROS-methylphenidate.
Topics: Administration, Oral; Adult; Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Ce | 2012 |
Long-term functional outcome in adult prison inmates with ADHD receiving OROS-methylphenidate.
Topics: Administration, Oral; Adult; Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Ce | 2012 |
Long-term functional outcome in adult prison inmates with ADHD receiving OROS-methylphenidate.
Topics: Administration, Oral; Adult; Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Ce | 2012 |
Long-term functional outcome in adult prison inmates with ADHD receiving OROS-methylphenidate.
Topics: Administration, Oral; Adult; Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Ce | 2012 |
Remission in children and adolescents diagnosed with attention-deficit/hyperactivity disorder via an effective and tolerable titration scheme for osmotic release oral system methylphenidate.
Topics: Administration, Oral; Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2012 |
Combined ω3 and ω6 supplementation in children with attention-deficit hyperactivity disorder (ADHD) refractory to methylphenidate treatment: a double-blind, placebo-controlled study.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; | 2012 |
Anxiety and methylphenidate in attention deficit hyperactivity disorder: a double-blind placebo-drug trial.
Topics: Anxiety; Attention; Attention Deficit Disorder with Hyperactivity; Child; Double-Blind Method; Human | 2012 |
Methylphenidate in children with ADHD with or without learning disability.
Topics: Administration, Oral; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous Syst | 2014 |
Randomized controlled double-blind trial of optimal dose methylphenidate in children and adolescents with severe attention deficit hyperactivity disorder and intellectual disability.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2013 |
[Zinc in the therapy of the attention-deficit/hyperactivity disorder in children. A preliminar randomized controlled trial].
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2011 |
Nortriptyline for treating enuresis in ADHD--a randomized double-blind controlled clinical trial.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Attention Deficit Disorder with Hyperactivity; Central Ner | 2012 |
Prepulse inhibition of acoustic startle and the influence of methylphenidate in children with ADHD.
Topics: Acoustic Stimulation; Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2014 |
Social-skills and parental training plus standard treatment versus standard treatment for children with ADHD--the randomised SOSTRA trial.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivi | 2012 |
Predictors of placebo response in adults with attention-deficit/hyperactivity disorder: data from 2 randomized trials of osmotic-release oral system methylphenidate.
Topics: Administration, Oral; Adult; Age Factors; Attention Deficit Disorder with Hyperactivity; Central Ner | 2012 |
Bupropion versus methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder: randomized double-blind study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Bupropion; Child; Dopamine Uptake Inhibit | 2012 |
Neurofeedback for the treatment of children and adolescents with ADHD: a randomized and controlled clinical trial using parental reports.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2012 |
Do stimulants reduce the risk for cigarette smoking in youth with attention-deficit hyperactivity disorder? A prospective, long-term, open-label study of extended-release methylphenidate.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Delaye | 2013 |
A pilot study of the efficacy of a computerized executive functioning remediation training with game elements for children with ADHD in an outpatient setting: outcome on parent- and teacher-rated executive functioning and ADHD behavior.
Topics: Ambulatory Care; Attention Deficit Disorder with Hyperactivity; Child; Child Behavior Disorders; Cog | 2014 |
Predictors of treatment response in adolescents with comorbid substance use disorder and attention-deficit/hyperactivity disorder.
Topics: Administration, Oral; Adolescent; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; C | 2013 |
Randomized controlled study of the histamine H3 inverse agonist MK-0249 in adult attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Biological Availability; Cross-Ove | 2012 |
A randomized, double-blind study of 30 versus 20 mg dexmethylphenidate extended-release in children with attention-deficit/hyperactivity disorder: late-day symptom control.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cross-Over | 2012 |
Methylphenidate transdermal system in attention-deficit hyperactivity disorder in adolescents: profile report.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Double-Blind Method; Humans; Methylphenid | 2012 |
Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivi | 2012 |
Osmotic release oral system methylphenidate prevents weight gain during a smoking-cessation attempt in adults with ADHD.
Topics: Administration, Oral; Adult; Attention Deficit Disorder with Hyperactivity; Female; Humans; Male; Me | 2013 |
Shared and drug-specific effects of atomoxetine and methylphenidate on inhibitory brain dysfunction in medication-naive ADHD boys.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Analysis of Variance; Atomoxetine Hydrochloride; Attention | 2014 |
Genetic evidence for the association of the hypothalamic-pituitary-adrenal (HPA) axis with ADHD and methylphenidate treatment response.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child Behavior Disorders; Dexamethasone; Doubl | 2013 |
A randomized controlled multicentre trial on the treatment for ADHD in mothers and children: enrolment and basic characteristics of the study sample.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Child; Clinical Protocols; Cognitive Behaviora | 2013 |
The effects of methylphenidate on cognitive function in children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimula | 2012 |
The novel use of objective laboratory school tasks to measure stress responses in children with ADHD.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2012 |
Efficacy of Polyunsaturated Fatty Acids (PUFA) in the Treatment of Attention Deficit Hyperactivity Disorder.
Topics: Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulan | 2017 |
Parents' attitudes toward methylphenidate using n-of-1 trial: a pilot study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Attitude to Health; Child; Double-Blind M | 2013 |
Do Stimulants Reduce the Risk for Alcohol and Substance Use in Youth With ADHD? A Secondary Analysis of a Prospective, 24-Month Open-Label Study of Osmotic-Release Methylphenidate.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2017 |
Differential Response to Methylphenidate in Inattentive and Combined Subtype ADHD.
Topics: Adolescent; Analysis of Variance; Attention; Attention Deficit Disorder with Hyperactivity; Behavior | 2017 |
NWP06, an extended-release oral suspension of methylphenidate, improved attention-deficit/hyperactivity disorder symptoms compared with placebo in a laboratory classroom study.
Topics: Administration, Oral; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulan | 2013 |
Buspirone versus methylphenidate in the treatment of children with attention- deficit/ hyperactivity disorder: randomized double-blind study.
Topics: Adolescent; Algorithms; Attention Deficit Disorder with Hyperactivity; Buspirone; Central Nervous Sy | 2012 |
European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adolescent Behavior; Appetite Regulation; Attention Deficit Disorder with Hyperactivity; | 2013 |
Risk of methylphenidate-induced prehypertension in normotensive adult smokers with attention deficit hyperactivity disorder.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Body Weight; Central Nervous S | 2013 |
Methylphenidate normalizes resting-state brain dysfunction in boys with attention deficit hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Brain; Case-Control Studies; Central Nerv | 2013 |
Two different solicitation methods for obtaining information on adverse events associated with methylphenidate in adolescents: a 12-week multicenter, open-label study.
Topics: Adolescent; Adolescent Behavior; Adverse Drug Reaction Reporting Systems; Attention Deficit Disorder | 2013 |
Predictors and impact of non-adherence in adults with attention-deficit/hyperactivity disorder receiving OROS methylphenidate: results from a randomized, placebo-controlled trial.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Delayed-Act | 2013 |
Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial.
Topics: Adolescent; Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hypera | 2002 |
Efficacy of Adderall and methylphenidate in attention deficit hyperactivity disorder: a drug-placebo and drug-drug response curve analysis of a naturalistic study.
Topics: Amphetamines; Attention Deficit Disorder with Hyperactivity; Behavior; Central Nervous System Stimul | 2002 |
An experimental comparison of Pycnogenol and methylphenidate in adults with Attention-Deficit/Hyperactivity Disorder (ADHD).
Topics: Adjuvants, Immunologic; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System | 2002 |
Effects of methylphenidate on functional magnetic resonance relaxometry of the cerebellar vermis in boys with ADHD.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Cerebellum; Child; Dose-Response Relations | 2002 |
A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder: preliminary findings.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Confidence Intervals; Cross-Over S | 2002 |
Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2002 |
Effect of food on early drug exposure from extended-release stimulants: results from the Concerta, Adderall XR Food Evaluation (CAFE) Study.
Topics: Absorption; Administration, Oral; Adult; Amphetamines; Analysis of Variance; Area Under Curve; Atten | 2002 |
Efficacy of a new pattern of delivery of methylphenidate for the treatment of ADHD: effects on activity level in the classroom and on the playground.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cross-Over | 2002 |
The effects of methylphenidate on prepulse inhibition during attended and ignored prestimuli among boys with attention-deficit hyperactivity disorder.
Topics: Arousal; Attention; Attention Deficit Disorder with Hyperactivity; Blinking; Central Nervous System | 2003 |
Effects of stimulant medications on the EEG of children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Arousal; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System St | 2002 |
Treatment effects of methylphenidate on behavioral adjustment in children with mental retardation and ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cross-Over | 2003 |
The effects of stimulant therapy, EEG biofeedback, and parenting style on the primary symptoms of attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Behavior; Biofeedback, Psychology; | 2002 |
The impact of late-afternoon stimulant dosing for children with ADHD on parent and parent-child domains.
Topics: Adult; Affect; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Chi | 2003 |
[Clinical and experimental study on treatment of childhood hyperkinetic syndrome with yizhidan].
Topics: Adrenergic Agents; Animals; Attention Deficit Disorder with Hyperactivity; Brain; Child; Dopamine; D | 2001 |
Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies.
Topics: Administration, Oral; Adolescent; Attention Deficit Disorder with Hyperactivity; Capsules; Central N | 2003 |
[Assessment on effect of treatment for childhood hyperkinetic syndrome by combined therapy of yizhi mixture and ritalin].
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2002 |
[Clinical study on treatment of children attention deficit hyperactivity disorder by jiangqian granule].
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Drug Therap | 2002 |
Efficacy of methylphenidate in patients with cerebral palsy and attention-deficit hyperactivity disorder (ADHD).
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cerebr | 2002 |
The effect of methylphenidate on three forms of response inhibition in boys with AD/HD.
Topics: Attention; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hype | 2003 |
Methylphenidate improves Stroop naming speed, but not response interference, in children with attention deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Color Perce | 2002 |
The acute effect of methylphenidate on cerebral blood flow in boys with attention-deficit/hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Blood Flow Velocity; Cerebrovascular Circulation; Chi | 2003 |
Management of attention deficit/hyperactivity disorder--use of an effective paradigm.
Topics: Attention Deficit Disorder with Hyperactivity; Biofeedback, Psychology; Child; Cognition; Combined M | 2002 |
ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2003 |
Use of methylphenidate for attention-deficit hyperactivity disorder in patients with epilepsy or electroencephalographic abnormalities.
Topics: Adolescent; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Central Nervous System S | 2003 |
Neurofeedback treatment for attention-deficit/hyperactivity disorder in children: a comparison with methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Biofeedback, Psychology; Central Nervous System Stimu | 2003 |
Selective inhibition in children with attention-deficit hyperactivity disorder off and on stimulant medication.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cross-Over | 2003 |
Motor timing deficits in community and clinical boys with hyperactive behavior: the effect of methylphenidate on motor timing.
Topics: Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulan | 2003 |
Methylphenidate down-regulates the dopamine receptor and transporter system in children with attention deficit hyperkinetic disorder (ADHD).
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Dopamine Pl | 2003 |
Melatonin for treatment of sleeping disorders in children with attention deficit/hyperactivity disorder: a preliminary open label study.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Depressants; Central Nervous S | 2003 |
Combination pharmacotherapy in children and adolescents with bipolar disorder.
Topics: Adolescent; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Attention Deficit Disorde | 2003 |
Methylphenidate treatment in children with borderline IQ and mental retardation: analysis of three aggregated studies.
Topics: Adolescent; Adolescent Behavior; Attention Deficit Disorder with Hyperactivity; Central Nervous Syst | 2003 |
Rate dependency revisited: understanding the effects of methylphenidate in children with attention deficit hyperactivity disorder.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2003 |
A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children.
Topics: Adolescent; Aggression; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disor | 2003 |
Functional effects of the DAT1 polymorphism on EEG measures in ADHD.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2003 |
Comparative efficacy of two once daily methylphenidate formulations (Ritalin LA and Concerta) and placebo in children with attention deficit hyperactivity disorder across the school day.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Cross-Over Studies; Dopamine Uptake Inhibitors | 2003 |
Selegiline in the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial.
Topics: Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Double | 2003 |
Effects of ethnicity on treatment attendance, stimulant response/dose, and 14-month outcome in ADHD.
Topics: Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; | 2003 |
Effects of stimulant medications on children with attention-deficit/hyperactivity disorder and excessive beta activity in their EEG.
Topics: Attention Deficit Disorder with Hyperactivity; Beta Rhythm; Brain Mapping; Case-Control Studies; Cen | 2003 |
Bioavailability of modified-release methylphenidate: influence of high-fat breakfast when administered intact and when capsule content sprinkled on applesauce.
Topics: Administration, Oral; Adolescent; Adult; Area Under Curve; Attention Deficit Disorder with Hyperacti | 2003 |
Effects of methylphenidate, desipramine, and L-dopa on attention and inhibition in children with Attention Deficit Hyperactivity Disorder.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Child; Choice Behavior; Desipramine; Dopam | 2003 |
The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2003 |
Three-month treatment course of methylphenidate increases plasma levels of dehydroepiandrosterone (DHEA) and dehydroepiandrosterone-sulfate (DHEA-S) in attention deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Dehydroepia | 2003 |
A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2003 |
A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2003 |
A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2003 |
A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2003 |
A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2003 |
A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2003 |
A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2003 |
A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2003 |
A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2003 |
Sequential evaluation of behavioral treatments and methylphenidate dosage for children with attention deficit hyperactivity disorder.
Topics: Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; | 2003 |
Does stimulant treatment place children at risk for adult substance abuse? A controlled, prospective follow-up study.
Topics: Adolescent; Adult; Age Factors; Attention Deficit Disorder with Hyperactivity; Central Nervous Syste | 2003 |
Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2003 |
Methylphenidate treatment for attention-deficit/hyperactivity disorder in children and adolescents with velocardiofacial syndrome: an open-label study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2003 |
Methylphenidate improves response inhibition in adults with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Central Nerv | 2003 |
Rapid improvement in academic grades following methylphenidate treatment in attention-deficit hyperactivity disorder.
Topics: Administration, Oral; Attention Deficit Disorder with Hyperactivity; Child; Cognition; Cultural Char | 2004 |
Attention-deficit/hyperactivity disorder: cognitive evoked potential (P300) topography predicts treatment response to methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cognition; | 2004 |
Differential effects of methylphenidate on attentional functions in children with attention-deficit/hyperactivity disorder.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2004 |
[Memory functions in children with attention deficit/hyperactivity disorder--the effects of methylphenidate on them].
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Int | 2004 |
Effect of methylphenidate on time perception in children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2004 |
Methylphenidate improves working memory and set-shifting in AD/HD: relationships to baseline memory capacity.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimula | 2004 |
A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).
Topics: Attention Deficit Disorder with Hyperactivity; Capsules; Central Nervous System Stimulants; Child; C | 2004 |
Sources of auditory selective attention and the effects of methylphenidate in children with attention-deficit/hyperactivity disorder.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Auditory Cortex; Child; Contingent Negativ | 2004 |
Stimulant treatment of adult attention-deficit/hyperactivity disorder.
Topics: Adult; Amphetamine; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants | 2004 |
Efficacy of theophylline compared to methylphenidate for the treatment of attention-deficit hyperactivity disorder in children and adolescents: a pilot double-blind randomized trial.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2004 |
Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial [ISRCTN64132371].
Topics: Ambulatory Care; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Double-Blin | 2004 |
A prospective study of stimulant response in preschool children: insights from ROC analyses.
Topics: Amphetamines; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Chil | 2004 |
Methylphenidate improves visual-spatial memory in children with attention-deficit/hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cross-Over | 2004 |
Methylphenidate improves visual-spatial memory in children with attention-deficit/hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cross-Over | 2004 |
Methylphenidate improves visual-spatial memory in children with attention-deficit/hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cross-Over | 2004 |
Methylphenidate improves visual-spatial memory in children with attention-deficit/hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cross-Over | 2004 |
Impact of methylphenidate delivery profiles on driving performance of adolescents with attention-deficit/hyperactivity disorder: a pilot study.
Topics: Adolescent; Adult; Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Automobile D | 2004 |
An open-label pilot study of methylphenidate in the treatment of cocaine dependent patients with adult attention deficit/hyperactivity disorder.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cocaine-Rel | 2004 |
Stimulant treatment over five years: adherence, effectiveness, and adverse effects.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Pres | 2004 |
Objective measurement of hyperactivity, impulsivity, and inattention in children with hyperkinetic disorders before and after treatment with methylphenidate.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2004 |
Methylphenidate restores visual memory, but not working memory function in attention deficit-hyperkinetic disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Dose-Response Relationship, Drug; | 2004 |
Effects of methylphenidate on attention deficits after traumatic brain injury: a multidimensional, randomized, controlled trial.
Topics: Adult; Arousal; Attention; Attention Deficit Disorder with Hyperactivity; Brain Injuries; Central Ne | 2004 |
Effects of methylphenidate on attention deficits after traumatic brain injury: a multidimensional, randomized, controlled trial.
Topics: Adult; Arousal; Attention; Attention Deficit Disorder with Hyperactivity; Brain Injuries; Central Ne | 2004 |
Effects of methylphenidate on attention deficits after traumatic brain injury: a multidimensional, randomized, controlled trial.
Topics: Adult; Arousal; Attention; Attention Deficit Disorder with Hyperactivity; Brain Injuries; Central Ne | 2004 |
Effects of methylphenidate on attention deficits after traumatic brain injury: a multidimensional, randomized, controlled trial.
Topics: Adult; Arousal; Attention; Attention Deficit Disorder with Hyperactivity; Brain Injuries; Central Ne | 2004 |
Treatment effects of methylphenidate on cognitive functioning in children with mental retardation and ADHD.
Topics: Analysis of Variance; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous Syst | 2004 |
Effects of methylphenidate treatment in children with mental retardation and ADHD: individual variation in medication response.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior; Central Nervous System Stimulants; Child; C | 2004 |
Age-dependent neuropsychological deficits and effects of methylphenidate in children with attention-deficit/hyperactivity disorder: a comparison of pre- and grade-school children.
Topics: Age Factors; Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Child; Child, Pres | 2004 |
[The use of methylphenidate in children: analysis of prescription usage based in routine data of the statutory health insurance bodies concerning drug prescriptions].
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2004 |
Design and rationale of controlled study of long-term methylphenidate and multimodal psychosocial treatment in children with ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Drug Admini | 2004 |
Academic achievement and emotional status of children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment.
Topics: Affect; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Com | 2004 |
Symptomatic improvement in children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Diagnostic | 2004 |
Social functioning in children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Combined Mo | 2004 |
Children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment: impact on parental practices.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Combined Mo | 2004 |
Assessing methylphenidate preference in ADHD patients using a choice procedure.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2004 |
The effect of methylphenidate on oppositional defiant disorder comorbid with attention deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyp | 2004 |
Emergence of tics in children with ADHD: impact of once-daily OROS methylphenidate therapy.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2004 |
Weekend holidays during methylphenidate use in ADHD children: a randomized clinical trial.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2004 |
Methylphenidate for pervasive developmental disorders: safety and efficacy of acute single dose test and ongoing therapy: an open-pilot study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Autistic Disorder; Central Nervous System | 2004 |
Novel strategy for the analysis of CPT data provides new insight into the effects of methylphenidate on attentional states in children with ADHD.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2004 |
Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ.
Topics: Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorde | 2004 |
Comparative efficacy of once-a-day extended-release methylphenidate, two-times-daily immediate-release methylphenidate, and placebo in a laboratory school setting.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2004 |
Effectiveness of an adaptive multimodal treatment in children with Attention-Deficit Hyperactivity Disorder -- global outcome.
Topics: Adaptation, Psychological; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central | 2004 |
Neurocognitive effects of methylphenidate in adult attention-deficit/hyperactivity disorder.
Topics: Adult; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2005 |
Actigraphic monitoring during sleep of children with ADHD on methylphenidate and placebo.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cross-Over | 2004 |
Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Circadian R | 2004 |
A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder.
Topics: Administration, Oral; Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2004 |
Comparative pharmacodynamics and plasma concentrations of d-threo-methylphenidate hydrochloride after single doses of d-threo-methylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in a double-blind, placebo-controlled, crossover labora
Topics: Administration, Oral; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulan | 2004 |
The effects of methylphenidate on neural systems of attention in attention deficit hyperactivity disorder.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Basal Ganglia; Central Nervous | 2004 |
Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cross-Over | 2004 |
[Does a morning dose of Methylphenidate Retard reduce hyperkinetic symptoms in the afternoon?].
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Biological Availability; Child; Chronothe | 2004 |
Short-term efficacy of methylphenidate: a randomized, double-blind, placebo-controlled trial among survivors of childhood cancer.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Brain Neoplasms; Central Nervous System S | 2004 |
Handwriting and attention in children and adults with attention deficit hyperactivity disorder.
Topics: Adult; Attention; Attention Deficit Disorder with Hyperactivity; Automatism; Central Nervous System | 2004 |
Sustained-release methylphenidate: new preparations. New pharmaceutical forms: a slight advantage for a small number of children.
Topics: Attention Deficit Disorder with Hyperactivity; Capsules; Central Nervous System Stimulants; Child; C | 2004 |
Selegiline in comparison with methylphenidate in attention deficit hyperactivity disorder children and adolescents in a double-blind, randomized clinical trial.
Topics: Adolescent; Anorexia Nervosa; Attention Deficit Disorder with Hyperactivity; Child; Double-Blind Met | 2004 |
A double-blind, placebo-controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2004 |
Open-label study of dexmethylphenidate hydrochloride in children and adolescents with attention deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Dexmethylph | 2004 |
Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder.
Topics: Adult; Amphetamines; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Blood Pre | 2005 |
[Treatment effects of parent management training for ADHD].
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child Behav | 2005 |
Pharmacotherapy of adult ADHD.
Topics: Adolescent; Adult; Age Factors; Amphetamine; Antidepressive Agents; Atomoxetine Hydrochloride; Atten | 2005 |
Stimulant medication effects in a summer treatment program among young children with attention-deficit/hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Pres | 2005 |
A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Demography; | 2005 |
Effects of methylphenidate on quantitative EEG of boys with attention-deficit hyperactivity disorder in continuous performance test.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Electroence | 2005 |
Height, weight, IGF-I, IGFBP-3 and thyroid functions in prepubertal children with attention deficit hyperactivity disorder: effect of methylphenidate treatment.
Topics: Attention Deficit Disorder with Hyperactivity; Body Height; Body Weight; Case-Control Studies; Centr | 2005 |
The acute effect of methylphenidate in Brazilian male children and adolescents with ADHD: a randomized clinical trial.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Brazil; Central Nervous System Stimulants | 2004 |
Using n-of-1 trials as a clinical tool to improve prescribing.
Topics: Acetaminophen; Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Attention Deficit Disorder with Hy | 2005 |
Dopamine transporter genotype and methylphenidate dose response in children with ADHD.
Topics: 3' Untranslated Regions; Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous | 2005 |
Sequential pharmacotherapy for children with comorbid attention-deficit/hyperactivity and anxiety disorders.
Topics: Adolescent; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System | 2005 |
Delta plots in the study of individual differences: new tools reveal response inhibition deficits in AD/Hd that are eliminated by methylphenidate treatment.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2005 |
Effects of two doses of methylphenidate on simulator driving performance in adults with attention deficit hyperactivity disorder.
Topics: Adolescent; Adult; Aged; Attention Deficit Disorder with Hyperactivity; Automobile Driving; Central | 2005 |
A dose-ranging study of a methylphenidate transdermal system in children with ADHD.
Topics: Administration, Cutaneous; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2005 |
Clinical evaluation of subjective and objective changes in motor activity and attention in children with attention-deficit/hyperactivity disorder in a double-blind methylphenidate trial.
Topics: Analysis of Variance; Attention; Attention Deficit Disorder with Hyperactivity; Child; Cross-Over St | 2005 |
Effects of methylphenidate on EEG coherence in attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; | 2005 |
The effect of methylphenidate on response inhibition and the event-related potential of children with attention deficit/hyperactivity disorder.
Topics: Adolescent; Age Factors; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimu | 2005 |
Immediate effects of methylphenidate on cognitive attention skills of children with attention-deficit-hyperactivity disorder.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Central Nervous Syst | 2005 |
Responses to methylphenidate in adolescent AD/HD: evidence from concurrently recorded autonomic (EDA) and central (EEG and ERP) measures.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2005 |
Transdermal methylphenidate, behavioral, and combined treatment for children with ADHD.
Topics: Administration, Cutaneous; Attention Deficit Disorder with Hyperactivity; Behavior; Behavior Therapy | 2005 |
Varieties of attention-deficit/hyperactivity disorder-related intra-individual variability.
Topics: Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Central Nervous System Stimulan | 2005 |
Executive functions and methylphenidate response in subtypes of attention-deficit/hyperactivity disorder.
Topics: Adolescent; Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2005 |
Does methylphenidate improve inhibition and other cognitive abilities in adults with childhood-onset ADHD?
Topics: Adult; Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Central Nervous System S | 2005 |
Dose-related effect of methylphenidate on stopping and changing in children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimula | 2006 |
Methylphenidate in children with attention-deficit hyperactivity disorder (ADHD): experience from a Sri Lankan Tertiary Children's Hospital.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Pres | 2005 |
Evaluation of pharmacological treatment of impulsivity in children with attention deficit hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2005 |
Comparison of risperidone and methylphenidate for reducing ADHD symptoms in children and adolescents with moderate mental retardation.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2005 |
Comparison of the inhibitory and excitatory effects of ADHD medications methylphenidate and atomoxetine on motor cortex.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hype | 2006 |
Age and medication effects on rhythmic responses in ADHD: possible oscillatory mechanisms?
Topics: Age Factors; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cereb | 2006 |
Influence of striatal dopamine transporter availability on the response to methylphenidate in adult patients with ADHD.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Dopamine Pl | 2005 |
Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo.
Topics: Adult; Algorithms; Analgesics, Opioid; Antidepressive Agents, Second-Generation; Attention Deficit D | 2006 |
Methylphenidate effects in attention deficit/hyperactivity disorder: electrodermal and ERP measures during a continuous performance task.
Topics: Adolescent; Arousal; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulant | 2005 |
ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Drug Admini | 2005 |
Efficacy of two long-acting methylphenidate formulations in children with attention- deficit/hyperactivity disorder in a laboratory classroom setting.
Topics: Area Under Curve; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2005 |
Performance and private speech of children with attention-deficit/hyperactivity disorder while taking the Tower of Hanoi test: effects of depth of search, diagnostic subtype, and methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Double-Blin | 2005 |
Normal attention orienting but abnormal stimulus alerting and conflict effect in combined subtype of ADHD.
Topics: Adolescent; Adult; Analysis of Variance; Attention; Attention Deficit Disorder with Hyperactivity; C | 2005 |
Symptom control in children and adolescents with attention-deficit/hyperactivity disorder on switching from immediate-release MPH to OROS MPH Results of a 3-week open-label study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2005 |
12-month efficacy and safety of OROS MPH in children and adolescents with attention-deficit/hyperactivity disorder switched from MPH.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2005 |
Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: a double-blind, randomized, cross-over trial.
Topics: Amphetamine; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Blood Pressure Monitorin | 2006 |
A pilot study of methylphenidate preference assessment in children diagnosed with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Double-Blind Method; Female; Human | 2005 |
Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2005 |
Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2005 |
Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2005 |
Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2005 |
Cytogenetic effects in children treated with methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Pres | 2005 |
Relationship between response to methylphenidate treatment in children with ADHD and psychopathology in their families.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cross-Over | 2006 |
Multicenter, randomized, open-label study of OROS methylphenidate versus atomoxetine: treatment outcomes in African-American children with ADHD.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2005 |
A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cross-Over | 2005 |
The effect of conscious control on handwriting in children with attention deficit hyperactivity disorder.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Automatism; Biomechanical Phenomena; Central N | 2005 |
A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Cardiovascular System; Central Nervous System | 2006 |
Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder.
Topics: Administration, Oral; Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2006 |
Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder.
Topics: Administration, Oral; Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2006 |
Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder.
Topics: Administration, Oral; Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2006 |
Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder.
Topics: Administration, Oral; Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2006 |
Emotional task-dependent low-frequency fluctuations and methylphenidate: Wavelet scaling analysis of 1/f-type fluctuations in fMRI of the cerebellar vermis.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cerebellum; | 2006 |
A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Chemistry, Pharmaceutical; Child; Delayed-Action Prep | 2006 |
A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD.
Topics: Administration, Cutaneous; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2006 |
[The effectiveness of body-oriented methods of therapy in the treatment of attention-deficit hyperactivity disorder (ADHD): results of a controlled pilot study].
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Combined Mo | 2006 |
Efficacy of methylphenidate in children with attention-deficit hyperactivity disorder and learning disabilities: a randomized crossover trial.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cross-Over | 2006 |
The reinforcing effects of nicotine and stimulant medication in the everyday lives of adult smokers with ADHD: A preliminary examination.
Topics: Administration, Cutaneous; Adult; Attention Deficit Disorder with Hyperactivity; Carbon Monoxide; Ce | 2006 |
Effectiveness and safety of methylphenidate in adult attention deficit hyperactivity disorder in patients with epilepsy: an open treatment trial.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2006 |
Effects of methylphenidate on multiple components of attention in children with attention deficit hyperactivity disorder.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2006 |
Stimulant treatment over 5 years: effects on growth.
Topics: Attention Deficit Disorder with Hyperactivity; Body Height; Central Nervous System Stimulants; Child | 2006 |
Effects of long-term methylphenidate treatment: a pilot follow-up clinical and SPECT study.
Topics: Attention Deficit Disorder with Hyperactivity; Blood Flow Velocity; Brain Mapping; Central Nervous S | 2006 |
An open-label trial of OROS methylphenidate in adults with late-onset ADHD.
Topics: Adolescent; Adult; Age Factors; Age of Onset; Aged; Attention Deficit Disorder with Hyperactivity; C | 2006 |
Methylphenidate improves aspects of executive function in African American children with ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior; Black People; Child; Delayed-Action Prepara | 2006 |
Assessing medication effects in the MTA study using neuropsychological outcomes.
Topics: Amphetamine; Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Central Nervous Sy | 2006 |
Assessing medication effects in the MTA study using neuropsychological outcomes.
Topics: Amphetamine; Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Central Nervous Sy | 2006 |
Assessing medication effects in the MTA study using neuropsychological outcomes.
Topics: Amphetamine; Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Central Nervous Sy | 2006 |
Assessing medication effects in the MTA study using neuropsychological outcomes.
Topics: Amphetamine; Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Central Nervous Sy | 2006 |
An n-of-1 trial service in clinical practice: testing the effectiveness of stimulants for attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2006 |
Dopamine transporter genotype influences the physiological response to medication in ADHD.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with | 2006 |
Efficacy and duration of effect of extended-release dexmethylphenidate versus placebo in schoolchildren with attention-deficit/hyperactivity disorder.
Topics: Aptitude Tests; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Ch | 2006 |
Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Anorexia; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulan | 2006 |
Comparison of the clinical efficacy of twice-daily Ritalin and once-daily Equasym XL with placebo in children with Attention Deficit/Hyperactivity Disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Double-Blind Method; Drug Administration Sched | 2006 |
ADHD medication use in a population-based sample of twins.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2006 |
Effects of methylphenidate on subtypes of attention-deficit/hyperactivity disorder.
Topics: Aggression; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimula | 2006 |
Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2006 |
Sleep and COMT polymorphism in ADHD children: preliminary actigraphic data.
Topics: Attention Deficit Disorder with Hyperactivity; Catechol O-Methyltransferase; Central Nervous System | 2006 |
Treatment-related changes in objectively measured parenting behaviors in the multimodal treatment study of children with attention-deficit/hyperactivity disorder.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimu | 2006 |
Attention-deficit/hyperactivity disorder: use of cognitive evoked potential (P300) to predict treatment response.
Topics: Acoustic Stimulation; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Dis | 2006 |
Methylphenidate-induced improvements of various measures of attention in adults with attention deficit hyperactivity disorder.
Topics: Adult; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2006 |
Absence of association with DAT1 polymorphism and response to methylphenidate in a sample of adults with ADHD.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; DNA Primers; Dopamine Plasma Membrane Transpor | 2006 |
[Switching from a short-acting to a long-acting methylphenidate preparation: a multicentre, open study in children with ADHD].
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimula | 2006 |
Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2007 |
Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
Topics: Accidents, Traffic; Adolescent; Adult; Amphetamine; Attention Deficit Disorder with Hyperactivity; A | 2006 |
Methylphenidate blood levels and therapeutic response in children with attention-deficit hyperactivity disorder: I. Effects of different dosing regimens.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2006 |
An open-label, randomized, active-controlled equivalent trial of osmotic release oral system methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan.
Topics: Administration, Oral; Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Central | 2006 |
Does brief, clinically based, intensive multimodal behavior therapy enhance the effects of methylphenidate in children with ADHD?
Topics: Adrenergic Uptake Inhibitors; Adult; Attention Deficit Disorder with Hyperactivity; Behavior Therapy | 2007 |
Meta-analysis of aggression or hostility events in randomized, controlled clinical trials of atomoxetine for ADHD.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Aged; Aggression; Atomoxetine Hydrochloride; Attention Def | 2007 |
Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child, Preschool; | 2006 |
Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child, Preschool; | 2006 |
Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child, Preschool; | 2006 |
Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child, Preschool; | 2006 |
Stimulant-related reductions of growth rates in the PATS.
Topics: Attention Deficit Disorder with Hyperactivity; Body Size; Body Weight; Central Nervous System Agents | 2006 |
Rationale, design, and methods of the Preschool ADHD Treatment Study (PATS).
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Pres | 2006 |
Pharmacogenetics of methylphenidate response in preschoolers with ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child, Preschool; | 2006 |
Safety and tolerability of methylphenidate in preschool children with ADHD.
Topics: Anorexia; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child, P | 2006 |
Methylphenidate controlled-delivery capsules (EquasymXL, Metadate CD): a review of its use in the treatment of children and adolescents with attention-deficit hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Capsules; Central Nervous System Stimulan | 2006 |
Efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Arousal; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous Syste | 2007 |
Effect of extended release stimulant-based medications on neuropsychological functioning among adolescents with Attention-Deficit/Hyperactivity Disorder.
Topics: Adolescent; Adult; Amphetamines; Attention; Attention Deficit Disorder with Hyperactivity; Central N | 2006 |
Acute neuropsychological effects of methylphenidate in stimulant drug-naïve boys with ADHD II--broader executive and non-executive domains.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimula | 2006 |
Concurrent cannabis use during treatment for comorbid ADHD and cocaine dependence: effects on outcome.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2006 |
Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Delayed-Act | 2007 |
Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder.
Topics: Administration, Oral; Adult; Attention Deficit Disorder with Hyperactivity; Cardiovascular System; C | 2006 |
Methylphenidate improves reading performance in children with attention deficit hyperactivity disorder and comorbid dyslexia: an unblinded clinical trial.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2007 |
No significant association between response to methylphenidate and genes of the dopaminergic and serotonergic systems in a sample of Brazilian children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Brazil; Central Nervous System Stimulants | 2007 |
Self-handicapping prior to academic-oriented tasks in children with attention deficit/hyperactivity disorder (ADHD): medication effects and comparisons with controls.
Topics: Adolescent; Aptitude; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorde | 2007 |
Effects of atomoxetine and methylphenidate on sleep in children with ADHD.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with | 2006 |
Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2007 |
Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Ambulatory Care; Attention; Attention Deficit Disorder with Hyperactivity; Brazil; Centr | 2007 |
A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder.
Topics: Administration, Oral; Adult; Affective Symptoms; Attention Deficit and Disruptive Behavior Disorders | 2007 |
A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD).
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with | 2007 |
Efficacy of a novel biphasic controlled-release methylphenidate formula in adults with attention-deficit/hyperactivity disorder: results of a double-blind, placebo-controlled crossover study.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2007 |
Preliminary evidence of beneficial effects of methylphenidate on listening comprehension in children with attention-deficit/hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Comprehensi | 2007 |
Measurement of the subjective effects of methylphenidate in 11- to 15-year-old children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Arousal; Attention Deficit Disorder with Hyperactivity; Attitude to Health; Central Nerv | 2007 |
Single-dose pharmacokinetics of multilayer-release methylphenidate and immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder.
Topics: Area Under Curve; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2007 |
Gait in attention deficit hyperactivity disorder : effects of methylphenidate and dual tasking.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Central | 2007 |
The effectiveness of an experimental treatment when compared to care as usual depends on the type of care as usual.
Topics: Adolescent; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyp | 2007 |
Task demands interact with the single and combined effects of medication and contingencies on children with ADHD.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2007 |
Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: a placebo-controlled pilot study.
Topics: Aggression; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2007 |
Pharmacokinetics of methylphenidate in preschoolers with attention-deficit/hyperactivity disorder.
Topics: Age Factors; Area Under Curve; Attention Deficit Disorder with Hyperactivity; Biological Availabilit | 2007 |
An analysis of patient adherence to treatment during a 1-year, open-label study of OROS methylphenidate in children with ADHD.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2007 |
Sex differences in the response of children with ADHD to once-daily formulations of methylphenidate.
Topics: Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulan | 2007 |
Hyperactive night and day? Actigraphy studies in adult ADHD: a baseline comparison and the effect of methylphenidate.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Circadian R | 2007 |
The neuropsychological effects of chronic methylphenidate on drug-naive boys with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Association Learning; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2007 |
[Factors affecting therapeutic effect of ADHD treated by optimal dose of methylphenidate].
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Drug Administration Schedule; Fema | 2007 |
[Changes of the alpha competitive structure after administration of single dose methylphenidate in different subtypes of attention deficit hyperactivity disorder boys].
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Electroencephalography; Humans; Ma | 2007 |
[Effect of extended-release methylphenidate on the ecological executive function for attention deficit hyperactivity disorder].
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Delayed-Action Preparations; Execu | 2007 |
[A pilot study on effect of methylphenidate on balance function of children with attention deficit hyperactivity disorder].
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Child; Cross-Sectio | 2007 |
Effects of major depressive disorder and attention-deficit/hyperactivity disorder on the outcome of treatment for cocaine dependence.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cocaine-Rel | 2008 |
Immediate-release methylphenidate for ADHD in children with comorbid chronic multiple tic disorder.
Topics: Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulan | 2007 |
A novel multidomain computerized cognitive assessment for attention-deficit hyperactivity disorder: evidence for widespread and circumscribed cognitive deficits.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2007 |
Quetiapine addition in methylphenidate treatment-resistant adolescents with comorbid ADHD, conduct/oppositional-defiant disorder, and aggression: a prospective, open-label study.
Topics: Adolescent; Aggression; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Central | 2007 |
Electrophysiological effects of stimulant treatment on inhibitory control in children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cerebr | 2007 |
Is age-at-onset criterion relevant for the response to methylphenidate in attention-deficit/hyperactivity disorder?
Topics: Adolescent; Adult; Age of Onset; Attention Deficit Disorder with Hyperactivity; Central Nervous Syst | 2007 |
Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Amphetamine; Analysis of Variance; Atomoxetine Hydrochlori | 2007 |
Long-term changes in management following n-of-1 trials of stimulants in attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2007 |
Performance on the continuous performance test in children with ADHD is associated with sleep efficiency.
Topics: Arousal; Attention; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder | 2007 |
Long-term effects of methylphenidate transdermal delivery system treatment of ADHD on growth.
Topics: Administration, Cutaneous; Attention Deficit Disorder with Hyperactivity; Body Mass Index; Child; Fe | 2007 |
Effects of methylphenidate on working memory components: influence of measurement.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2007 |
ADHD- and medication-related brain activation effects in concordantly affected parent-child dyads with ADHD.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; Chil | 2007 |
Methylphenidate-induced changes in cerebral hemodynamics measured by functional near-infrared spectroscopy.
Topics: Arousal; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants | 2007 |
Restoration of disturbed intracortical motor inhibition and facilitation in attention deficit hyperactivity disorder children by methylphenidate.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Central Nervous Sys | 2007 |
Modafinil as a treatment for Attention-Deficit/Hyperactivity Disorder in children and adolescents: a double blind, randomized clinical trial.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Child; Diagnostic a | 2008 |
Long-acting methylphenidate has an effect on aggressive behavior in children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Aggression; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimul | 2007 |
Switching from methylphenidate immediate release to MPH-SODAS in attention-deficit/hyperactivity disorder.
Topics: Administration, Oral; Adult; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit | 2008 |
Treatment of attention deficit hyperactivity disorder in children. Predictors of treatment outcome.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; | 2008 |
Methylphenidate improves deficient error evaluation in children with ADHD: an event-related brain potential study.
Topics: Attention Deficit Disorder with Hyperactivity; Brain; Brain Mapping; Central Nervous System Stimulan | 2007 |
Effects of stimulant medications on the EEG of girls with Attention-Deficit/Hyperactivity Disorder.
Topics: Action Potentials; Alpha Rhythm; Arousal; Attention Deficit Disorder with Hyperactivity; Central Ner | 2007 |
Medications do not necessarily normalize cognition in ADHD patients.
Topics: Adrenergic Uptake Inhibitors; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder wit | 2008 |
Response to methylphenidate in adults with ADHD is associated with a polymorphism in SLC6A3 (DAT1).
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cross-Over | 2008 |
Clinical presentation of attention-deficit/hyperactivity disorder in preschool children: the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS).
Topics: Anxiety Disorders; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder w | 2007 |
Methylphenidate effects on functional outcomes in the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS).
Topics: Affect; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child Beha | 2007 |
Comorbidity moderates response to methylphenidate in the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS).
Topics: Age Factors; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hy | 2007 |
Once-daily multilayer-release methylphenidate in a double-blind, crossover comparison to immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2007 |
Exercise responses in boys with attention deficit/hyperactivity disorder: effects of stimulant medication.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Exercise; H | 2008 |
Methylphenidate in the treatment of children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Central Nervous System | 2007 |
Event-related wave activity in the EEG provides new marker of ADHD.
Topics: Acoustic Stimulation; Adolescent; Analysis of Variance; Attention Deficit Disorder with Hyperactivit | 2008 |
Acute impact of immediate release methylphenidate administered three times a day on sleep in children with attention-deficit/hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Biological Availability; Brain; Central Nervous Syste | 2008 |
Anxiety, methylphenidate response, and working memory in children with ADHD.
Topics: Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2008 |
Open-label use of placebos in the treatment of ADHD: a pilot study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2008 |
Open-label use of placebos in the treatment of ADHD: a pilot study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2008 |
Open-label use of placebos in the treatment of ADHD: a pilot study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2008 |
Open-label use of placebos in the treatment of ADHD: a pilot study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2008 |
Children's and parents' perspectives on open-label use of placebos in the treatment of ADHD.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cros | 2008 |
Critical influences affecting response to various treatments in young children with ADHD: a case series.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Pres | 2008 |
Dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cross-Over | 2008 |
Functional magnetic resonance imaging of methylphenidate and placebo in attention-deficit/hyperactivity disorder during the multi-source interference task.
Topics: Administration, Oral; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System S | 2008 |
Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis.
Topics: Adrenergic alpha-Agonists; Attention Deficit Disorder with Hyperactivity; Bradycardia; Central Nervo | 2008 |
Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes.
Topics: Adrenergic alpha-Agonists; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2008 |
Impaired transcallosally mediated motor inhibition in adults with attention-deficit/hyperactivity disorder is modulated by methylphenidate.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Central Nervous System S | 2008 |
Adrenergic alpha2A receptor gene and response to methylphenidate in attention-deficit/hyperactivity disorder-predominantly inattentive type.
Topics: Adolescent; Alleles; Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Central Ne | 2008 |
The effects of methylphenidate on word decoding accuracy in boys with attention-deficit/hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cross-Over | 2008 |
A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
Topics: Administration, Oral; Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nerv | 2008 |
Acute effects of methylphenidate on neuropsychological parameters in adults with ADHD: possible relevance for therapy.
Topics: Adult; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2008 |
Misinterpreting emotional expressions in attention-deficit/hyperactivity disorder: evidence for a neural marker and stimulant effects.
Topics: Adolescent; Anxiety; Attention Deficit Disorder with Hyperactivity; Brain Mapping; Case-Control Stud | 2008 |
Rebound effects with long-acting amphetamine or methylphenidate stimulant medication preparations among adolescent male drivers with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adult; Amphetamine; Attention Deficit Disorder with Hyperactivity; Automobile Driving; C | 2008 |
Cognitive and behavioral effects of multilayer-release methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2008 |
Diminished serotonergic functioning in hostile children with ADHD: tryptophan depletion increases behavioural inhibition.
Topics: Aggression; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2008 |
A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder.
Topics: Administration, Cutaneous; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2008 |
A randomized crossover clinical study showing that methylphenidate-SODAS improves attention-deficit/hyperactivity disorder symptoms in adolescents with substance use disorder.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2008 |
Increased NAA and reduced choline levels in the anterior cingulum following chronic methylphenidate. A spectroscopic test-retest study in adult ADHD.
Topics: Adult; Aspartic Acid; Attention Deficit Disorder with Hyperactivity; Brain; Choline; Dopamine Uptake | 2008 |
Effects of methylphenidate on quality of life in children with both developmental coordination disorder and ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Comorbidity | 2008 |
Treatment of children with attention-deficit/hyperactivity disorder: results of a randomized, multicenter, double-blind, crossover study of extended-release dexmethylphenidate and D,L-methylphenidate and placebo in a laboratory classroom setting.
Topics: Area Under Curve; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2008 |
Sleep in adults with attention deficit hyperactivity disorder (ADHD) before and during treatment with methylphenidate: a controlled polysomnographic study.
Topics: Adult; Arousal; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Fe | 2008 |
Effects of once-daily oral and transdermal methylphenidate on sleep behavior of children with ADHD.
Topics: Administration, Cutaneous; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2009 |
Varying the wear time of the methylphenidate transdermal system in children with attention-deficit/hyperactivity disorder.
Topics: Administration, Cutaneous; Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Cen | 2008 |
Executive functioning in children with attention-deficit/hyperactivity disorder: combined type with and without a stimulant medication history.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2008 |
Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study.
Topics: Adrenergic Uptake Inhibitors; Adult; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disor | 2008 |
An evaluation of stimulant medication on the reinforcing effects of play.
Topics: Amphetamines; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous Syste | 2008 |
Methylphenidate in children with oppositional defiant disorder and both comorbid chronic multiple tic disorder and ADHD.
Topics: Age Factors; Aggression; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Diso | 2008 |
Efficacy of ACTH 4-9 analog, methylphenidate, and placebo on attention deficit disorder with hyperkinesis.
Topics: Adrenocorticotropic Hormone; Attention Deficit Disorder with Hyperactivity; Child; Double-Blind Meth | 1984 |
Controversial issues of the pharmacotherapy of the hyperactive child.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 1981 |
The persistence of stimulant effects in chronically treated children: further evidence of an inverse relationship between drug effects and placebo levels of response.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 1984 |
Stimulant medications in adults with attention deficit disorder.
Topics: Adolescent; Adult; Amitriptyline; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 1984 |
Visual evoked potential changes induced by methylphenidate in hyperactive children: dose/response effects.
Topics: Attention Deficit Disorder with Hyperactivity; Dose-Response Relationship, Drug; Electroencephalogra | 1983 |
Effects of two doses of methylphenidate on cross-situational and borderline hyperactive children's evoked potentials.
Topics: Attention Deficit Disorder with Hyperactivity; Brain; Child; Discrimination, Psychological; Evoked P | 1983 |
Cerebrospinal fluid homovanillic acid and 5-hydroxy-indoleacetic acid in adults with attention deficit disorder, residual type.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Clinical Trials as Topic; Double-Blind Method; | 1984 |
A comparative study of the efficacy of ACTH4-9 analog, methylphenidate, and placebo on attention deficit disorder with hyperkinesis.
Topics: Adrenocorticotropic Hormone; Arousal; Attention; Attention Deficit Disorder with Hyperactivity; Chil | 1983 |
Double-blind assessment of stimulant medication for attention deficit disorder: a model for clinical application.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Clinical Trials | 1983 |
The visual ERP predicts clinical response to methylphenidate in hyperactive children.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Clinical Trials as Topic; Double-B | 1984 |
Sustained-release methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Clinical Trials as Topic; Delayed-Action Prepa | 1984 |
Attention deficit disorder and the effect of methylphenidate on attention, behavioral, and cardiovascular functioning.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Cardiovascular System; Chi | 1984 |
Methylphenidate effects on symptoms of attention deficit disorder in adults.
Topics: Adolescent; Adult; Age Factors; Attention Deficit Disorder with Hyperactivity; Child; Clinical Trial | 1984 |
Cognitive-behavioral and pharmacologic interventions for hyperactive boys: comparative and combined effects.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Cognition; Combi | 1984 |
Effects of age and Ritalin dosage on the mother-child interactions of hyperactive children.
Topics: Adult; Age Factors; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Dose-Res | 1984 |
Effects of reward and methylphenidate on heart rate response morphology of augmenting and reducing children.
Topics: Attention Deficit Disorder with Hyperactivity; Auditory Perception; Electroencephalography; Evoked P | 1984 |
State-dependent and main effects of methylphenidate and pemoline on paired-associate learning and spelling in hyperactive children.
Topics: Association Learning; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Female | 1984 |
Effects of two doses of methylphenidate on verbal information processing in hyperactive children.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Child; Dose-Response Relationship, Drug; D | 1984 |
Effects of methylphenidate (Ritalin) on information processing in hyperactive children.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Child; Cognition; Female; Huma | 1984 |
Self-control in hyperactive boys in anger-inducing situations: effects of cognitive-behavioral training and of methylphenidate.
Topics: Adolescent; Anger; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Cognition | 1984 |
Ineffectiveness of imipramine in children who fail to respond to methylphenidate.
Topics: Aggression; Attention; Attention Deficit Disorder with Hyperactivity; Child; Clinical Trials as Topi | 1980 |
Learning in hyperactive children: are there stimulant-related and state-dependent effects?
Topics: Attention Deficit Disorder with Hyperactivity; Child; Cognition; Double-Blind Method; Female; Humans | 1981 |
Methylphenidate oral dose plasma concentrations and behavioral response in children.
Topics: Administration, Oral; Attention; Attention Deficit Disorder with Hyperactivity; Child; Dose-Response | 1982 |
State-dependent learning in children receiving methylphenidate.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Humans; Mental Recall; Methylpheni | 1982 |
Growth of hyperactive children on maintenance regimen of methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Body Height; Body Weight; Child; Child Development; D | 1983 |
Methylphenidate hydrochloride given with or before breakfast: I. Behavioral, cognitive, and electrophysiologic effects.
Topics: Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Child; Child Behavior; Cognitio | 1983 |
Methylphenidate hydrochloride given with or before breakfast: II. Effects on plasma concentration of methylphenidate and ritalinic acid.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Biological Availability; Child; Double-Bl | 1983 |
Methylphenidate effects on cognitive style and reaction time in four groups of children.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Child; Cognition Disorders; Dose-Response | 1982 |
An open clinical trial of L-dopa and carbidopa in adults with minimal brain dysfunction.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Carbidopa; Clinical Trials as Topic; Drug Comb | 1980 |
Double-blind trials with stimulants for hyperactivity.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Clinical Trials as Topic; Double-Blind Method; | 1980 |
Teacher response to the methylphenidate (ritalin) versus placebo status of hyperactive boys in the classroom.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Attitude; Child; Clinical Trials as Topic; | 1981 |
Responses to methylphenidate and varied doses of caffeine in children with attention deficit disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Caffeine; Child; Clinical Trials as Topic; Dose-Respo | 1981 |
ADD: not limited to children?
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Clinical Trials as Topic; Double-B | 1982 |
Double-blind administration of methylphenidate to mentally retarded children with attention deficit disorder; a preliminary study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Child Behavior; Child, Preschool; | 1982 |
Methylphenidate increases selectivity of visual scanning in children referred for hyperactivity.
Topics: Association Learning; Attention; Attention Deficit Disorder with Hyperactivity; Child; Double-Blind | 1982 |
Effect of methylphenidate on thought processing time in children.
Topics: Achievement; Attention; Attention Deficit Disorder with Hyperactivity; Child; Choice Behavior; Cogni | 1982 |
Side effects of dexedrine in hyperactive children: operationalization and quantification in a short-term trial.
Topics: Anorexia; Attention Deficit Disorder with Hyperactivity; Body Weight; Child; Dextroamphetamine; Dose | 1982 |
Methylphenidate compared with behavioral self-control in attention deficit disorder: preliminary report.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Humans; Individua | 1981 |
Medication effects in the classroom: three naturalistic indicators.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Double-Blind Method; Handwriting; Humans; Inte | 1981 |
Medication compliance in hyperactive children.
Topics: Attention Deficit Disorder with Hyperactivity; Blood Pressure; Child; Dextroamphetamine; Humans; Mal | 1981 |
Comparison of sustained-release and standard methylphenidate in the treatment of minimal brain dysfunction.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Delayed-Action Preparations; Doubl | 1980 |
Pemoline, methylphenidate, and placebo in children with minimal brain dysfunction.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Double-Blind Method; Female; Humans; Male; Met | 1980 |
Effects of methylphenidate on selective and sustained attention in hyperactive, reading-disabled, and presumably attention-disordered boys.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Child; Double-Blind Method; Dyslexia; Facu | 1980 |
Methylphenidate effects on a laboratory aggression measure in children with ADHD.
Topics: Aggression; Attention Deficit Disorder with Hyperactivity; Child; Dose-Response Relationship, Drug; | 1995 |
Methylphenidate and ADHD: influence of age, IQ and neurodevelopmental status.
Topics: Adolescent; Age Factors; Ambulatory Care; Attention Deficit Disorder with Hyperactivity; Child; Chil | 1994 |
Cerebrospinal fluid monoamine metabolites in boys with attention-deficit hyperactivity disorder.
Topics: Aggression; Attention; Attention Deficit Disorder with Hyperactivity; Child; Dextroamphetamine; Doub | 1994 |
School observations of children with attention-deficit hyperactivity disorder and comorbid tic disorder: effects of methylphenidate treatment.
Topics: Aggression; Attention Deficit Disorder with Hyperactivity; Child; Comorbidity; Dose-Response Relatio | 1995 |
Effects of late-afternoon methylphenidate administration on behavior and sleep in attention-deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child Behavior; Child, Preschool; Cross-Over S | 1995 |
Methylphenidate and cognitive flexibility: dissociated dose effects in hyperactive children.
Topics: Arousal; Attention; Attention Deficit Disorder with Hyperactivity; Child; Discrimination Learning; D | 1995 |
Do high doses of stimulants impair flexible thinking in attention-deficit hyperactivity disorder?
Topics: Attention Deficit Disorder with Hyperactivity; Child; Cross-Over Studies; Dose-Response Relationship | 1995 |
Differential effects of methylphenidate on working memory in ADHD children with and without comorbid anxiety.
Topics: Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Child; Comorbidity; Dose-Response | 1995 |
Effects of methylphenidate on reward strength in boys with attention-deficit hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Cross-Over Studies; Dose-Response | 1995 |
Consumer satisfaction with involvement in drug research: a social validity study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Clinical Trials | 1995 |
Sustained attention, activation and MPH in ADHD: a research note.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Child; Cross-Over Studies; Double-Blind Me | 1995 |
Prediction of clinical response to methylphenidate in children with attention-deficit hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Cross-Over Studies; Discriminant A | 1995 |
Differential effects of methylphenidate and self-reinforcement on attention-deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Combined Modality Therapy; D | 1995 |
Effect of dextroamphetamine and methylphenidate on calcium and magnesium concentration in hyperactive boys.
Topics: Attention Deficit Disorder with Hyperactivity; Body Weight; Calcium; Child; Circadian Rhythm; Dextro | 1994 |
A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder.
Topics: Adolescent; Adult; Age Factors; Ambulatory Care; Anxiety Disorders; Attention Deficit Disorder with | 1995 |
Efficacy of methylphenidate for attention-deficit hyperactivity disorder in children with tic disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Comorbidity; Dose-Response Relationship, Drug; | 1995 |
Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Bupropion; Child; Cross-Over Studies; Dos | 1995 |
Methylphenidate influences on both early and late ERP waves of ADHD children in a continuous performance test.
Topics: Adolescent; Arousal; Attention; Attention Deficit Disorder with Hyperactivity; Cerebral Cortex; Chil | 1994 |
Observations and ratings of tics in school settings.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Dose-Response Relationship, Drug; Female; Huma | 1994 |
Attention deficit disorder in children: three clinical variants.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Child; Child Behavior Disorder | 1994 |
Methylphenidate and information processing. Part 1: Differentiation between responders and nonresponders; Part 2: Efficacy in responders.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Child; Cross-Over Studies; Double-Blind Me | 1994 |
Acute challenge ERP as a prognostic of stimulant therapy outcome in attention-deficit hyperactivity disorder.
Topics: Acoustic Stimulation; Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Evoked Poten | 1995 |
Neurophysiological effects of stimulants.
Topics: Attention Deficit Disorder with Hyperactivity; Auditory Perceptual Disorders; Child; Double-Blind Me | 1995 |
The case of the uncertain prescriber.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Double-Blind Method; Humans; Male; Methylpheni | 1995 |
Efficacy of methylphenidate and behavioral intervention on classroom behavior in children with ADHD and mental retardation.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Child, Preschool | 1994 |
Prediction of response to methylphenidate among children with ADHD and mental retardation.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Dose-Response Relationship, Drug; Double-Blind | 1994 |
Clonidine therapy for comorbid attention deficit hyperactivity disorder and conduct disorder: preliminary findings in a children's inpatient unit.
Topics: Attention Deficit Disorder with Hyperactivity; Blood Pressure; Child; Child Behavior Disorders; Chil | 1994 |
N of 1 study: methylphenidate in a patient with borderline personality disorder and attention deficit hyperactivity disorder.
Topics: Adult; Attention; Attention Deficit Disorder with Hyperactivity; Borderline Personality Disorder; Do | 1994 |
Clinical and cognitive effects of methylphenidate on children with attention deficit disorder as a function of aggression/oppositionality and age.
Topics: Aggression; Arousal; Attention; Attention Deficit Disorder with Hyperactivity; Child; Child, Prescho | 1994 |
Malleability of social impressions of hyperactive children.
Topics: Aggression; Attention Deficit Disorder with Hyperactivity; Child; Humans; Male; Methylphenidate; Per | 1993 |
Methods of evaluating methylphenidate in children with attention deficit hyperactivity disorder: acceptability, satisfaction, and compliance.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Child; Consumer Behavior; Female; Humans; | 1993 |
Thyroid function and attention-deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Dextroamphetamine; Double-Blind Method; Euthyr | 1994 |
Reliability of global impressions for assessing methylphenidate effects in children with attention-deficit hyperactivity disorder.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Double-Blind Meth | 1993 |
The utility of curriculum-based measurement for evaluating the effects of methylphenidate on academic performance.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Child; Dose-Response Relations | 1994 |
Fenfluramine and methylphenidate in children with mental retardation and attention deficit hyperactivity disorder: laboratory effects.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Cogni | 1993 |
Effects of methylphenidate on sleep in children with attention-deficient hyperactivity disorder. An activity monitor study.
Topics: Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Child; Double-Blind Method; Fem | 1993 |
Changes in event-related potentials with stimulant medication in children with attention deficit hyperactivity disorder.
Topics: Arousal; Attention; Attention Deficit Disorder with Hyperactivity; Brain Mapping; Cerebral Cortex; C | 1993 |
Separate and combined effects of methylphenidate and behavior modification on boys with attention deficit-hyperactivity disorder in the classroom.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Child, Preschool; Combined M | 1993 |
Fenfluramine and methylphenidate in children with mental retardation and ADHD: clinical and side effects.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Double-Blind Met | 1993 |
Classroom academic performance: improvement with both methylphenidate and dextroamphetamine in ADHD boys.
Topics: Achievement; Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Dextroamphetamine; Do | 1993 |
Drug and placebo side effects in methylphenidate-placebo trial for attention deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Double-Blind Method; Female; Humans; Male; Met | 1993 |
Side effects of methylphenidate and desipramine alone and in combination in children.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Comorbidity; Depressive Disorder; | 1993 |
Visual event related potentials after methylphenidate and sodium valproate in children with attention deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Electroencephalography; Evoked Potentials, Vis | 1993 |
Does methylphenidate normalize the classroom performance of children with attention deficit disorder?
Topics: Achievement; Attention Deficit Disorder with Hyperactivity; Child; Double-Blind Method; Female; Huma | 1993 |
Methylphenidate and desipramine in hospitalized children: I. Separate and combined effects on cognitive function.
Topics: Arousal; Attention; Attention Deficit Disorder with Hyperactivity; Child; Depressive Disorder; Desip | 1993 |
A preliminary study of the relationship between central auditory processing disorder and attention deficit disorder.
Topics: Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Auditory Diseases, Central; Chi | 1993 |
Placebo-controlled evaluation of Ritalin side effects.
Topics: Adolescent; Appetite; Attention Deficit Disorder with Hyperactivity; Child; Child Behavior; Child, P | 1993 |
Effects of methylphenidate on impulsive responding in children with attention-deficit hyperactivity disorder.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Child; Discrimination Learning | 1993 |
Spatial orienting and focused attention in attention deficit hyperactivity disorder.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 1995 |
[Attention deficit disorder: treatment with methylphenidate].
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 1996 |
What they want and what they get: the social goals of boys with ADHD and comparison boys.
Topics: Aggression; Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 1996 |
Pindolol and methylphenidate in children with attention-deficit hyperactivity disorder. Clinical efficacy and side-effects.
Topics: Adolescent; Adrenergic beta-Antagonists; Attention Deficit Disorder with Hyperactivity; Central Nerv | 1996 |
Cerebrospinal fluid homovanillic acid predicts behavioral response to stimulants in 45 boys with attention deficit/hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior; Biogenic Monoamines; Central Nervous System | 1996 |
Does haloperidol block methylphenidate? Motivation or attention?
Topics: Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Child; Dopamine Agents; Dopamin | 1996 |
Methylphenidate and attentional training. Comparative effects on behavior and neurocognitive performance in twin girls with attention-deficit/hyperactivity disorder.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System S | 1996 |
Medication treatment strategies in the MTA Study: relevance to clinicians and researchers.
Topics: Adolescent; Algorithms; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Ner | 1996 |
Methylphenidate dosing: twice daily versus three times daily.
Topics: Attention Deficit Disorder with Hyperactivity; Capsules; Central Nervous System Stimulants; Child; C | 1996 |
Separate and combined effects of methylphenidate and a behavioral intervention on disruptive behavior in children with mental retardation.
Topics: Aggression; Attention; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Child | 1996 |
Methylphenidate vs dexamphetamine: a clinical audit.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Consumer Be | 1996 |
Methylphenidate slows reactions of children with attention deficit disorder during and after an error.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Double-Blin | 1996 |
Zinc deficiency in attention-deficit hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 1996 |
Epilepsy and attention deficit hyperactivity disorder: is methylphenidate safe and effective?
Topics: Adolescent; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Child; Cross-Over Studie | 1997 |
Brief report: response to methylphenidate in two children with Williams syndrome.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 1997 |
Covert visual spatial attention in boys with attention deficit hyperactivity disorder: lateral effects, methylphenidate response and results for parents.
Topics: Adoption; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulant | 1997 |
Effects of methylphenidate on event-related potentials and performance of attention-deficit hyperactivity disorder children in auditory and visual selective attention tasks.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimula | 1997 |
Fenfluramine and methylphenidate in children with mental retardation and borderline IQ: clinical effects.
Topics: Adolescent; Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 1997 |
Titrating methylphenidate in children with attention-deficit/hyperactivity disorder: is body mass predictive of clinical response?
Topics: Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Body Mass Index; Body Weight; C | 1997 |
Effects of methylphenidate on attention and nonverbal learning in children with attention-deficit hyperactivity disorder.
Topics: Analysis of Variance; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous Syst | 1997 |
Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose.
Topics: Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulan | 1997 |
Children with ADHD and tic disorder and their classmates: behavioral normalization with methylphenidate.
Topics: Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulan | 1997 |
A preliminary analysis of interactive effects between common classroom contingencies and methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; | 1997 |
A rapid method for evaluating the necessity for both a behavioral intervention and methylphenidate.
Topics: Aggression; Attention; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nerv | 1997 |
Effects of methylphenidate in children with attention deficit hyperactivity disorder: a comparison of event-related potentials between medication responders and non-responders.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Double-Blind Method; Electroenceph | 1997 |
Behavioral, situational, and temporal effects of treatment of ADHD with methylphenidate.
Topics: Affect; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Chi | 1997 |
Treatment of children with Williams syndrome with methylphenidate.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 1997 |
Double-blind versus open evaluations of stimulant drug response in children with attention-deficit hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 1996 |
Methylphenidate slows right hemisphere processing in children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System | 1996 |
Effects of methylphenidate and expectancy of ADHD children's performance, self-evaluations, persistence, and attributions on a cognitive task.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cognition; | 1997 |
Does oligoantigenic diet influence hyperactive/conduct-disordered children--a controlled trial.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child Behav | 1997 |
Sense of time in children with ADHD: effects of duration, distraction, and stimulant medication.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 1997 |
Electrophysiological indices of information processing in methylphenidate responders.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior; Central Nervous System Stimulants; Child; E | 1997 |
National Institute of Mental Health Collaborative Multimodal Treatment Study of Children with ADHD (the MTA). Design challenges and choices.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Clinical Protocols; Combined | 1997 |
Long-term follow-up of children with mental retardation/borderline intellectual functioning and ADHD.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 1997 |
Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial.
Topics: Adolescent; Appetite; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulan | 1997 |
The effect of methylphenidate on the cognitive and personality functioning of ADHD children.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 1997 |
Effects of methylphenidate on preschool children with ADHD: cognitive and behavioral functions.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child Behav | 1997 |
Effects of methylphenidate and behavioral contingencies on sustained attention in attention-deficit hyperactivity disorder: a test of the reward dysfunction hypothesis.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 1997 |
Methylphenidate versus dexamphetamine in children with attention deficit hyperactivity disorder: A double-blind, crossover trial.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 1997 |
Clinical efficacy of methylphenidate in conduct disorder with and without attention deficit hyperactivity disorder.
Topics: Adolescent; Aggression; Attention Deficit Disorder with Hyperactivity; Child; Comorbidity; Conduct D | 1997 |
Epilepsy and attention deficit hyperactivity disorder: is methylphenidate safe and effective?
Topics: Adolescent; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Child; Cross-Over Studie | 1997 |
An evaluation of methylphenidate as a potential establishing operation for some common classroom reinforcers.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; | 1997 |
Comprehensive school-based behavioral assessment of the effects of methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child Behav | 1997 |
Equivalent effects of stimulant treatment for attention-deficit hyperactivity disorder during childhood and adolescence.
Topics: Achievement; Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimu | 1998 |
Reliability and validity of the SKAMP rating scale in a laboratory school setting.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Dopamine Uptake Inhibitors; Female; Humans; Ma | 1998 |
Objective and subjective measures of the pharmacodynamic effects of Adderall in the treatment of children with ADHD in a controlled laboratory classroom setting.
Topics: Adolescent; Amphetamines; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 1998 |
Methylphenidate effects on EEG, behavior, and performance in boys with ADHD.
Topics: Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Behavior; Central Nervous Syste | 1998 |
Analog classroom assessment of Adderall in children with ADHD.
Topics: Adolescent; Amphetamines; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 1998 |
Dosage effects of methylphenidate on the social behavior of adolescents diagnosed with attention-deficit hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 1998 |
[Use of drugs in attention deficit hyperactivity disorders].
Topics: Analysis of Variance; Antidepressive Agents, Tricyclic; Attention Deficit Disorder with Hyperactivit | 1997 |
Child and parent perceptions of stimulant medication treatment in attention deficit hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Attitude to Health; Central Nervous Syste | 1998 |
Short-term side effects of stimulant medication are increased in preschool children with attention-deficit/hyperactivity disorder: a double-blind placebo-controlled study.
Topics: Affect; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 1998 |
Effectiveness of methylphenidate in Native American children with fetal alcohol syndrome and attention deficit/hyperactivity disorder: a controlled pilot study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 1998 |
Methylphenidate does not modify the impact of response frequency or stimulus sequence on performance and event-related potentials of children with attention deficit hyperactivity disorder.
Topics: Arousal; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants | 1998 |
Effects of methylphenidate on aggressive urban children with attention deficit hyperactivity disorder.
Topics: Aggression; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 1998 |
Psychopharmacologic treatment of acquired attention disorders in children with brain injury.
Topics: Adolescent; Adult; Attention; Attention Deficit Disorder with Hyperactivity; Brain Injuries; Central | 1998 |
Discriminative and participant-rated effects of methylphenidate in children diagnosed with attention deficit hyperactivity disorder (ADHD).
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 1998 |
ADHD in girls: clinical comparability of a research sample.
Topics: Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Child; Cross-Over Studies; Dext | 1999 |
Characteristics of patients with schizophrenia successive to childhood attention deficit hyperactivity disorder (ADHD).
Topics: Adolescent; Adult; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Central Nerv | 1998 |
Effects of methylphenidate on complex cognitive processing in attention-deficit hyperactivity disorder.
Topics: Adolescent; Age Factors; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimu | 1999 |
Clinical assessment of psychopharmacological treatment of preschoolers with ADHD.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child, | 1998 |
Stimulant medication withdrawal during long-term therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 1999 |
A comparison of ritalin and adderall: efficacy and time-course in children with attention-deficit/hyperactivity disorder.
Topics: Amphetamines; Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; | 1999 |
The effect of methylphenidate and clonidine on response inhibition and state regulation in children with ADHD.
Topics: Arousal; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants | 1999 |
Long-term methylphenidate therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Chronic Dis | 1999 |
Predicting methylphenidate response in children with ADHD: theoretical, empirical, and conceptual models.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cross-Over | 1999 |
Response to methylphenidate in children with ADHD and comorbid anxiety.
Topics: Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 1999 |
Further analysis of the separate and interactive effects of methylphenidate and common classroom contingencies.
Topics: Achievement; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child | 1999 |
Response to methylphenidate in boys with attention-deficit hyperactivity disorder.
Topics: Analysis of Variance; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous Syst | 1999 |
Methylphenidate versus dextroamphetamine in ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cross-Over | 1999 |
Methylphenidate and behavior modification in children with ADHD and comorbid ODD or CD: main and incremental effects across settings.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System | 1999 |
EEG correlates of methylphenidate response among children with ADHD: a preliminary report.
Topics: Arousal; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Co | 1999 |
Efficacy of methylphenidate among preschool children with developmental disabilities and ADHD.
Topics: Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Child Behavior Disorders; Child | 1999 |
Differential effectiveness of methylphenidate and Adderall in school-age youths with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Amphetamines; Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Centr | 1999 |
Effect of methylphenidate on attention in children with attention deficit hyperactivity disorder (ADHD): ERP evidence.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Child; Cross-Over Studies; Double-Blind Me | 1999 |
Population pharmacokinetics of methylphenidate in children with attention-deficit hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Body Weight; Central Nervous System Stimu | 1999 |
Do typical clinical doses of methylphenidate cause tics in children treated for attention-deficit hyperactivity disorder?
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Double-Blin | 1999 |
Neurofeedback combined with training in metacognitive strategies: effectiveness in students with ADD.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Biofeedback, Psychology; Body Temp | 1998 |
Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children.
Topics: Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulan | 1999 |
Evaluation of individual subjects in the analog classroom setting: I. Examples of graphical and statistical procedures for within-subject ranking of responses to different delivery patterns of methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cross-Over | 1998 |
Methylphenidate effects on global and complex measures of EEG.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cross-Over | 1999 |
A comparison of morning-only and morning/late afternoon Adderall to morning-only, twice-daily, and three times-daily methylphenidate in children with attention-deficit/hyperactivity disorder.
Topics: Amphetamines; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Chil | 1999 |
A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD.
Topics: Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous | 1999 |
A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD.
Topics: Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous | 1999 |
A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD.
Topics: Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous | 1999 |
A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD.
Topics: Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous | 1999 |
Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: the Multimodal Treatment Study of children with Attention-deficit/hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; | 1999 |
Double-blind methylphenidate trials: practical, useful, and highly endorsed by families.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Chi-Square Distrib | 1999 |
Parental knowledge of attention-deficit hyperactivity disorder and opinions of treatment options: impact on enrollment and adherence to a 12-month treatment trial.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Attitude to Health; Behavior Therapy; Central | 1999 |
A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder.
Topics: Adolescent; Adrenergic alpha-Agonists; Aggression; Attention Deficit Disorder with Hyperactivity; Ce | 2000 |
Functional deficits in basal ganglia of children with attention-deficit/hyperactivity disorder shown with functional magnetic resonance imaging relaxometry.
Topics: Attention Deficit Disorder with Hyperactivity; Brain; Case-Control Studies; Central Nervous System S | 2000 |
Effect of stimulant medication on driving performance of young adults with attention-deficit hyperactivity disorder: a preliminary double-blind placebo controlled trial.
Topics: Accidents, Traffic; Adult; Attention Deficit Disorder with Hyperactivity; Attitude; Automobile Drivi | 2000 |
A double-blind, placebo-controlled study of Adderall and methylphenidate in the treatment of attention-deficit/hyperactivity disorder.
Topics: Algorithms; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2000 |
Attentional capacity, a probe ERP study: differences between children with attention-deficit hyperactivity disorder and normal control children and effects of methylphenidate.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimula | 2000 |
Naming speed performance and stimulant effects indicate effortful, semantic processing deficits in attention-deficit/hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Central Nervous System Stimulan | 2000 |
The EEG consistency index as a measure of ADHD and responsiveness to medication.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cognit | 2000 |
Psychostimulant augmentation during treatment with selective serotonin reuptake inhibitors in men with paraphilias and paraphilia-related disorders: a case series.
Topics: Adult; Ambulatory Care; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimul | 2000 |
Medium-term outcomes are comparable with short-term outcomes in children with attention deficit hyperactivity disorder treated with stimulant medication.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2000 |
Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Autistic Disorder; Central Nervous System Stimulants; | 2000 |
Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Autistic Disorder; Central Nervous System Stimulants; | 2000 |
Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Autistic Disorder; Central Nervous System Stimulants; | 2000 |
Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Autistic Disorder; Central Nervous System Stimulants; | 2000 |
Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Autistic Disorder; Central Nervous System Stimulants; | 2000 |
Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Autistic Disorder; Central Nervous System Stimulants; | 2000 |
Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Autistic Disorder; Central Nervous System Stimulants; | 2000 |
Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Autistic Disorder; Central Nervous System Stimulants; | 2000 |
Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Autistic Disorder; Central Nervous System Stimulants; | 2000 |
Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Comorbidity | 2001 |
Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial.
Topics: Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulan | 2001 |
Effects of methylphenidate on sensitivity to reinforcement in children diagnosed with attention deficit hyperactivity disorder: an application of the matching law.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Mal | 2000 |
Testing the ability of children with attention deficit hyperactivity disorder to accurately report the effects of medication on their behavior.
Topics: Achievement; Attention Deficit Disorder with Hyperactivity; Attitude to Health; Central Nervous Syst | 2000 |
Findings from the NIMH Multimodal Treatment Study of ADHD (MTA): implications and applications for primary care providers.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; | 2001 |
The influence of a token economy and methylphenidate on attentive and disruptive behavior during sports with ADHD-diagnosed children.
Topics: Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; | 2001 |
Psychostimulants in preschool children with attention-deficit/hyperactivity disorder: clinical evidence from a developmental disorders institution.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child, Preschool; | 2001 |
Short-term cardiovascular effects of methylphenidate and adderall.
Topics: Adolescent; Amphetamines; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Central Ner | 2001 |
Effects of methylphenidate (Ritalin) on auditory performance in children with attention and auditory processing disorders.
Topics: Attention Deficit Disorder with Hyperactivity; Audiometry, Pure-Tone; Central Nervous System Stimula | 2000 |
Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings.
Topics: Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Cross- | 2001 |
Changes of the brain electrical fields during the continuous performance test in attention-deficit hyperactivity disorder-boys depending on methylphenidate medication.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; Elec | 2001 |
Dose-response effects of methylphenidate on ecologically valid measures of academic performance and classroom behavior in adolescents with ADHD.
Topics: Adolescent; Adolescent Behavior; Attention Deficit Disorder with Hyperactivity; Central Nervous Syst | 2001 |
Effects of chronic nicotine and methylphenidate in adults with attention deficit/hyperactivity disorder.
Topics: Adult; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2001 |
Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder.
Topics: Appetite; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; D | 2001 |
Methylphenidate selectively improves story retelling in children with attention deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cognition; | 2001 |
Treatment for hyperactive children: homeopathy and methylphenidate compared in a family setting.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2001 |
Marker gene polymorphisms in hyperkinetic disorder--predictors of clinical response to treatment with methylphenidate?
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Carrier Proteins; Central Nervous System | 2001 |
Effects of methylphenidate and expectancy on performance, self-evaluations, persistence, and attributions on a social task in boys with ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cross-Over | 2001 |
Developmental aspects of psychostimulant treatment in children and adolescents with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Amphetamines; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2001 |
The effect of stimulants on nocturnal motor activity and sleep quality in adults with ADHD: an open-label case-control study.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Central Nervous System S | 2001 |
[Clinical comparative observation on duodongning and Ritalin in treating child hyperkinetic syndrome].
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Pres | 1999 |
Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults.
Topics: Adrenergic Agents; Adult; Attention Deficit Disorder with Hyperactivity; Bupropion; Dopamine Uptake | 2001 |
Treatment of ADHD in children with tics: a randomized controlled trial.
Topics: Adolescent; Adrenergic alpha-Agonists; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2002 |
A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2002 |
Bupropion treatment for cocaine abuse and adult attention-deficit/hyperactivity disorder.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Bupropion; Cocaine-Related Disorders; Comorbid | 2002 |
Methylphenidate bioavailability in adults when an extended-release multiparticulate formulation is administered sprinkled on food or as an intact capsule.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Biological Availability; Central Nervous Syste | 2002 |
Effects of methylphenidate and expectancy on children with ADHD: behavior, academic performance, and attributions in a summer treatment program and regular classroom settings.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child Behavior Disorders; Cross-Over Studies; | 2002 |
Treatment of ADHD in neurofibromatosis type 1.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Behavior; Central Nervous System Stimulant | 2002 |
Anxiety and depression symptoms and response to methylphenidate in children with attention-deficit hyperactivity disorder and tic disorder.
Topics: Adolescent; Analysis of Variance; Anxiety; Attention Deficit Disorder with Hyperactivity; Central Ne | 2002 |
Attention-Deficit/Hyperactivity Disorder and methylphenidate: a dose-response analysis and parent-child comparison of somatic complaints.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cross-Over | 2002 |
Effects of methylphenidate on saccadic responses in patients with ADHD.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; | 2002 |
Children with ADHD and motor dysfunction compared with children with ADHD only.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cross-Over | 2002 |
Methylphenidate vs dextroamphetamine vs caffeine in minimal brain dysfunction: controlled comparison by placebo washout design with Bayes' analysis.
Topics: Attention Deficit Disorder with Hyperactivity; Caffeine; Child; Child, Preschool; Clinical Trials as | 1978 |
Time-response analysis of the effect of stimulant medication on the learning ability of children referred for hyperactivity.
Topics: Association Learning; Attention Deficit Disorder with Hyperactivity; Child; Clinical Trials as Topic | 1978 |
Effects of methylphenidate on underachieving children.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child Behavior; Clinical Trials as Topic; Fema | 1976 |
Diagnosis and treatment of minimal brain dysfunction in adults: a preliminary report.
Topics: Adult; Alcoholism; Antisocial Personality Disorder; Anxiety; Attention Deficit Disorder with Hyperac | 1976 |
Individual responses to methylphenidate and caffeine in children with minimal brain dysfunction.
Topics: Attention Deficit Disorder with Hyperactivity; Caffeine; Child; Citrates; Clinical Trials as Topic; | 1975 |
The effects of methylphenidate on the handwriting of children with minimal brain dysfunction.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child Behavior; Cognition; Follow-Up Studies; | 1977 |
Deanol and methylphenidate in minimal brain dysfunction.
Topics: Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Child; Clinical Trials as Topic | 1975 |
Methylphenidate and caffeine in the treatment of children with minimal brain dysfunction.
Topics: Administration, Oral; Attention Deficit Disorder with Hyperactivity; Caffeine; Child; Clinical Trial | 1975 |
Caffeine versus methylphenidate and d-amphetamine in minimal brain dysfunction: a double-blind comparison.
Topics: Amphetamine; Attention Deficit Disorder with Hyperactivity; Caffeine; Child; Child, Preschool; Clini | 1975 |
Food additives and hyperactivity.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Clinical Trials as Topic; Feeding Behavior; Fo | 1975 |
Caffeine in the treatment of children with minimal brain dysfunction or hyperkinetic syndrome.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Caffeine; Child; Child, Preschool; Clinic | 1975 |
A comparison of dextro-amphetamine and racemic-amphetamine in the treatment of the hyperkinetic syndrome or minimal brain dysfunction.
Topics: Adolescent; Age Factors; Amphetamine; Attention Deficit Disorder with Hyperactivity; Child; Child, P | 1976 |
Pemoline (Cylert) for minimal brain dysfunction.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Clinical Trials as Topic; Dextroamphetamine; D | 1976 |
Methylphenidate and cognitive perseveration in hyperactive children.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Child; Cognition; Concept Formation; Discr | 1992 |
Enantioselective pharmacokinetics and pharmacodynamics of dl-threo-methylphenidate in children with attention deficit hyperactivity disorder.
Topics: Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Child; Double-Blind Method; Hum | 1992 |
Prosocial behavior in hyperactive boys: effects of stimulant medication and comparison with normal boys.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Double-Blind Method; Humans; Leadership; Male; | 1992 |
Methylphenidate response in aggressive and nonaggressive ADHD children: distinctions on laboratory measures of symptoms.
Topics: Aggression; Attention; Attention Deficit Disorder with Hyperactivity; Child; Female; Humans; Male; M | 1992 |
Effects of sustained-release and standard preparations of methylphenidate on attention deficit disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Delayed-Action Preparations; Dose-Response Rel | 1992 |
The effects of methylphenidate and lithium on attention and activity level.
Topics: Arousal; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Child; Drug Therapy, Combi | 1992 |
ADHD children's responses to stimulant medication and two intensities of a behavioral intervention.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Combined Modality Therapy; D | 1992 |
Stimulant medication and reading performance: follow-up on sustained dose in ADHD boys with and without conduct disorders.
Topics: Achievement; Attention Deficit Disorder with Hyperactivity; Child; Dose-Response Relationship, Drug; | 1992 |
Effects and noneffects of methylphenidate in children with mental retardation and ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Dose-Response Relationship, Drug; Double-Blind | 1992 |
Methylphenidate in hyperactive boys with comorbid tic disorder: II. Short-term behavioral effects in school settings.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child Behavior Disorders; Comorbidity; Dose-Re | 1992 |
Covert antisocial behavior in boys with attention-deficit hyperactivity disorder: external validation and effects of methylphenidate.
Topics: Antisocial Personality Disorder; Attention; Attention Deficit Disorder with Hyperactivity; Child; Co | 1992 |
Methylphenidate and attributions in boys with attention-deficit hyperactivity disorder.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Child; Double-Blind Method; Humans; Intern | 1992 |
Methylphenidate protocol: feasibility in a pediatric practice.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Double-Blind Method; Humans; Methy | 1991 |
Effects of methylphenidate on the persistence of ADHD boys following failure experiences.
Topics: Achievement; Attention; Attention Deficit Disorder with Hyperactivity; Child; Double-Blind Method; H | 1991 |
Psychostimulant effects on academic and behavioral measures for ADHD junior high school students in a lecture format classroom.
Topics: Achievement; Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Dose-Response Rel | 1991 |
Prediction of clinical response in children taking methylphenidate.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Discrimination Le | 1991 |
Methylphenidate speeds evaluation processes of attention deficit disorder adolescents during a continuous performance test.
Topics: Adolescent; Arousal; Attention; Attention Deficit Disorder with Hyperactivity; Cerebral Cortex; Dose | 1991 |
Methylphenidate and thioridazine in the treatment of intellectually subaverage children: effects on cognitive-motor performance.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Doubl | 1991 |
The go-no go test in attention deficit disorder is sensitive to methylphenidate.
Topics: Adolescent; Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Child; Double-Blind | 1991 |
Attention deficit disorder and specific reading disability: separate but often overlapping disorders.
Topics: Arousal; Attention; Attention Deficit Disorder with Hyperactivity; Child; Dose-Response Relationship | 1991 |
Attention deficit disorder with and without hyperactivity: clinical response to three dose levels of methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child Behavior Disorders; Drug Evaluation; Fac | 1991 |
Additive effects of psychostimulants, parent training, and self-control therapy with ADHD children.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Combined Modality Therapy; D | 1991 |
Adverse side effects of methylphenidate among mentally retarded children with ADHD.
Topics: Anxiety; Attention Deficit Disorder with Hyperactivity; Child; Child Behavior; Double-Blind Method; | 1991 |
Clinical effects of methylphenidate and thioridazine in intellectually subaverage children.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Child; Child Behavior Disorder | 1991 |
Methylphenidate and dextroamphetamine treatments of hyperactivity: are there true nonresponders?
Topics: Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Child; Day Care, Medical; Dextr | 1991 |
The adolescent outcome of hyperactive children diagnosed by research criteria--III. Mother-child interactions, family conflicts and maternal psychopathology.
Topics: Achievement; Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Child of Impaired Par | 1991 |
Methylphenidate-induced changes in ADDH information processors.
Topics: Arousal; Attention; Attention Deficit Disorder with Hyperactivity; Child; Double-Blind Method; Educa | 1991 |
Differential effects of stimulant medication on reading performance of boys with hyperactivity with and without conduct disorder.
Topics: Achievement; Attention Deficit Disorder with Hyperactivity; Child; Dose-Response Relationship, Drug; | 1991 |
Fenfluramine and mental retardation.
Topics: Attention Deficit Disorder with Hyperactivity; Double-Blind Method; Encopresis; Enuresis; Fenflurami | 1991 |
A dose-response analysis of the effects of methylphenidate on the peer interactions and simulated classroom performance of ADD children with and without conduct problems.
Topics: Achievement; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Cooperative Beh | 1991 |
A divided attention analysis of the effects of methylphenidate on the arithmetic performance of children with attention-deficit hyperactivity disorder.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Child; Double-Blind Method; Humans; Male; | 1991 |
Bupropion treatment of attention-deficit hyperactivity disorder in adults.
Topics: Adult; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Bupropion; Clinical Tri | 1990 |
Efficacy of methylphenidate among mentally retarded children with attention deficit hyperactivity disorder.
Topics: Analysis of Variance; Attention; Attention Deficit Disorder with Hyperactivity; Child; Child Behavio | 1990 |
Stimulant drug treatment of hyperactivity: biochemical correlates.
Topics: 3,4-Dihydroxyphenylacetic Acid; Attention Deficit Disorder with Hyperactivity; Child; Dextroamphetam | 1990 |
Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Dose-Response Relationship, Drug; | 1990 |
Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: a comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Child Behavior; Delayed-Action Pre | 1990 |
Social judgment processes in hyperactive boys: effects of methylphenidate and comparisons with normal peers.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Clinical Trials as Topic; Double-Blind Method; | 1990 |
Motor/vocal tics and compulsive behaviors on stimulant drugs: is there a common vulnerability?
Topics: Attention Deficit Disorder with Hyperactivity; Child; Compulsive Behavior; Dextroamphetamine; Double | 1990 |
Clinical effects of a controlled trial of methylphenidate on adolescents with attention deficit disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Double-Blind Method; Female; Humans; Male | 1990 |
Methylphenidate in aggressive-hyperactive boys: I. Effects on peer aggression in public school settings.
Topics: Aggression; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Dose-Response Re | 1990 |
Effects of methylphenidate on adolescents with aggressive conduct disorder and ADDH: a preliminary report.
Topics: Adolescent; Aggression; Attention Deficit Disorder with Hyperactivity; Double-Blind Method; Humans; | 1990 |
Effects of methylphenidate on processing negativities in patients with attention-deficit hyperactivity disorder.
Topics: Arousal; Attention; Attention Deficit Disorder with Hyperactivity; Cerebral Cortex; Child; Double-Bl | 1990 |
Growth hormone and prolactin response to methylphenidate in children with attention deficit disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child Behavior; Double-Blind Method; Growth Ho | 1990 |
Methylphenidate and baseball playing in ADHD children: who's on first?
Topics: Attention Deficit Disorder with Hyperactivity; Baseball; Child; Humans; Male; Methylphenidate | 1990 |
Attention deficit hyperactivity disorder and methylphenidate: the relationship between gross body weight and drug response in children.
Topics: Attention Deficit Disorder with Hyperactivity; Body Weight; Child; Humans; Methylphenidate | 1989 |
Attention deficit disorder with hyperactivity and methylphenidate: the effects of dose and mastery level on children's learning performance.
Topics: Association Learning; Attention Deficit Disorder with Hyperactivity; Child; Dose-Response Relationsh | 1989 |
Differential psychopharmacology of methylphenidate and the neuropsychology of childhood hyperactivity.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Clinical Trials as Topic; Dose-Res | 1989 |
The effects of methylphenidate on learning in children with ADDH: the stimulus equivalence paradigm.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Child; Clinical Trials as Topic; Concept F | 1989 |
Hyperactive girls and boys: stimulant drug effects on mother-child interactions.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Clinical Trials as Topic; Do | 1989 |
Self-paced learning in children with attention deficit disorder with hyperactivity.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Child; Clinical Trials as Topic; Double-Bl | 1989 |
Active drug placebo trial of methylphenidate--a clinical service for children with an attention deficit disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Clinical Trials as Topic; Double-Blind Method; | 1989 |
Attention-deficit hyperactivity disordered boys' evaluations of and attributions for task performance on medication versus placebo.
Topics: Achievement; Attention Deficit Disorder with Hyperactivity; Child; Clinical Trials as Topic; Double- | 1989 |
Methylphenidate in children with seizures and attention-deficit disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Clinical Trials as Topic; Double-Blind Method; | 1989 |
Treatment of ADDH in mentally retarded children: a preliminary study.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Clinical Trials as Topic; Co | 1989 |
Comparative effects of methylphenidate on ADD girls and ADD boys.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Dose-Response Relationship, | 1989 |
Anger control in response to verbal provocation: effects of stimulant medication for boys with ADHD.
Topics: Aggression; Anger; Arousal; Attention Deficit Disorder with Hyperactivity; Child; Humans; Male; Meth | 1989 |
Effects of methylphenidate on inhibitory control in hyperactive children.
Topics: Arousal; Attention; Attention Deficit Disorder with Hyperactivity; Child; Compulsive Behavior; Discr | 1989 |
Externalizing behavior disorders, situational generality, and the type A behavior pattern.
Topics: Aggression; Arousal; Attention Deficit Disorder with Hyperactivity; Child; Clinical Trials as Topic; | 1989 |
Effects of methylphenidate on cardiovascular responses in attention deficit hyperactivity disordered adolescents.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Black People; Blood Pressure; Child; Dose | 1989 |
Methylphenidate treatment of attention-deficit hyperactivity disorder in boys with Tourette's syndrome.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Dose-Response Relationship, Drug; Humans; Male | 1989 |
Does stimulant medication improve the peer status of hyperactive children?
Topics: Attention Deficit Disorder with Hyperactivity; Child; Cohort Studies; Dose-Response Relationship, Dr | 1989 |
Dose-response effects of methylphenidate on academic performance and overt behavior in hyperactive children.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child Behavior; Dose-Response Relationship, Dr | 1989 |
Aggressive, prosocial, and nonsocial behavior in hyperactive boys: dose effects of methylphenidate in naturalistic settings.
Topics: Aggression; Attention Deficit Disorder with Hyperactivity; Child; Cooperative Behavior; Dose-Respons | 1989 |
Effect of anxiety on cognition, behavior, and stimulant response in ADHD.
Topics: Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Child; Child Behavior Disorders; D | 1989 |
Does methylphenidate constrict cognitive functioning?
Topics: Arousal; Attention Deficit Disorder with Hyperactivity; Child; Cognition; Female; Humans; Male; Meth | 1989 |
The action of stimulant medication in attention deficit disorder with hyperactivity: dopaminergic, noradrenergic, or both?
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Drug Therapy, Combination; H | 1988 |
Hyperactive children treated with stimulants. Is cognitive training a useful adjunct?
Topics: Achievement; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System | 1985 |
Self-esteem in children medically managed for attention deficit disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child Behavior; Double-Blind Method; Female; F | 1989 |
Methylphenidate v. placebo--a randomised double-blind crossover study in children with the attention deficit disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Clinical Trials as Topic; Double-Blind Method; | 1988 |
Methylphenidate and growth in hyperactive children. A controlled withdrawal study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Body Height; Body Weight; Child; Child De | 1988 |
Hyperactive boys almost grown up. III. Methylphenidate effects on ultimate height.
Topics: Attention Deficit Disorder with Hyperactivity; Body Height; Child; Child Development; Child, Prescho | 1988 |
Effects of methylphenidate on attention-deficit hyperactivity disorder with and without aggressive/noncompliant features.
Topics: Aggression; Attention Deficit Disorder with Hyperactivity; Child; Child Behavior Disorders; Clinical | 1988 |
Dosage effects and individual responsivity to methylphenidate in attention deficit disorder.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Child; Clinical Trials as Topic; Dose-Resp | 1988 |
Methylphenidate and memory: dissociated effects in hyperactive children.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Clinical Trials as Topic; Dose-Response Relati | 1986 |
The effects of methylphenidate on levels of processing and laterality in children with attention deficit disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Discrimination Learning; Dominance | 1988 |
ADDH and methylphenidate responders: effects on behavior controlled by complex reinforcement schedules.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Conditioning, Operant; Dose-Response Relations | 1988 |
An individual double-blind crossover trial for assessing methylphenidate response in children with attention deficit disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Child Behavior; Clinical Trials as | 1988 |
Attention deficit disorder and methylphenidate: a multi-step analysis of dose-response effects on children's cardiovascular functioning.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Clinical Trials as Topic; Dose-Response Relati | 1988 |
Effects of methylphenidate on adolescents with a childhood history of attention deficit disorder: I. Clinical findings.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Clinical Trials as Topic; Double-Blind Me | 1987 |
Effects of methylphenidate on adolescents with a childhood history of attention deficit disorder: II. Information processing.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Clinical Trials as Topic; Conc | 1987 |
Multiple microcomputers for data entry and analysis.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Clinical Trials as Topic; Computers; Humans; I | 1987 |
A controlled trial of methylphenidate in black adolescents. Attentional, behavioral, and physiological effects.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Black or African American; Dru | 1988 |
Dose-response effects of chronic methylphenidate administration on late event-related potentials in attention deficit disorder.
Topics: Adolescent; Age Factors; Attention Deficit Disorder with Hyperactivity; Child; Dose-Response Relatio | 1988 |
Short term effects of methylphenidate on the cognitive, learning and academic performance of children with attention deficit disorder in the laboratory and the classroom.
Topics: Achievement; Attention Deficit Disorder with Hyperactivity; Child; Clinical Trials as Topic; Cogniti | 1986 |
Methylphenidate and cognitive therapy in children with attention deficit disorder: a double-blind trial.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Clinical Trials | 1986 |
Comparing classroom and clinic measures of attention deficit disorder: differential, idiosyncratic, and dose-response effects of methylphenidate.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Child; Clinical Trials as Topic; Dose-Resp | 1986 |
Methylphenidate: rate-dependent effects on hyperactivity.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Clinical Trials as Topic; Dose-Res | 1986 |
The therapeutic effect of clonidine in attention deficit disorder with hyperactivity: a comparison with placebo and methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Clinical Trials as Topic; Clonidine; Double-Bl | 1986 |
Responders, nonresponders, and placebo responders among children with attention deficit disorder. Importance of a blinded placebo evaluation.
Topics: Analysis of Variance; Attention; Attention Deficit Disorder with Hyperactivity; Child; Clinical Tria | 1986 |
Assessing and treating attention deficit disorder in adolescents. The clinical application of a single-case research design.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Clinical Trials as Topic; Double-Blind Me | 1986 |
Relationship between stimulant effect, electroencephalogram, and clinical neurological findings in hyperactive children.
Topics: Arousal; Attention Deficit Disorder with Hyperactivity; Child; Clinical Trials as Topic; Double-Blin | 1986 |
Promethazine treatment of children with Attention Deficit Disorder with Hyperactivity--ineffective and unpleasant.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Clinical Trials as Topic; Fe | 1986 |
Hyperactivity and methylphenidate: rate-dependent effects on attention.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Child; Child Behavior; Clinical Trials as | 1986 |
Classroom social interactions of attention deficit disorder with hyperactivity children as a function of stimulant medication.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Clinical Trials as Topic; Dose-Response Relati | 1987 |
Which boys respond to stimulant medication? A controlled trial of methylphenidate in boys with disruptive behaviour.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Child; Child Behavior Disorders; Clinical | 1987 |
[Attention in hyperkinetic children: a signal detection analysis of the effect of methylphenidate].
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Child; Clinical Trials as Topic; Dose-Resp | 1987 |
Methylphenidate salivary levels in children.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Child; Humans; Male; Methylphenidate; Middle A | 1987 |
Peer perceptions of hyperactivity and medication effects.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Attitude; Child; Humans; Male; Methylphen | 1987 |
Sustained release and standard methylphenidate effects on cognitive and social behavior in children with attention deficit disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Cognition; Delayed-Action Preparations; Double | 1987 |
Vicissitudes of follow-up studies: differential effects of parent training and stimulant medication with hyperactives.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Follow-Up Studies; Humans; Methylphenidate; Pa | 1986 |
Methylphenidate and cognitive therapy with ADD children: a methodological reconsideration.
Topics: Achievement; Adolescent; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Chi | 1986 |
A controlled study of methylphenidate in the treatment of attention deficit disorder, residual type, in adults.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Borderline Personality Disorder; Clinical Tria | 1985 |
Methylphenidate in hyperactive children: differential effects of dose on academic, learning, and social behavior.
Topics: Achievement; Attention Deficit Disorder with Hyperactivity; Child; Clinical Trials as Topic; Dose-Re | 1985 |
Methylphenidate and children with attention deficit disorder. Dose effects on classroom academic and social behavior.
Topics: Achievement; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Clinical Trials | 1985 |
Developmental changes in the mother-child interactions of hyperactive boys: effects of two dose levels of Ritalin.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Child; Child Development; Child, Preschool; Cl | 1985 |
Methylphenidate: rate-dependent drug effects in hyperactive boys.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Conditioning, Operant; Humans; Male; Methylphe | 1985 |
Components of attention, methylphenidate dosage, and blood levels in children with attention deficit disorder.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Child; Child Behavior; Double- | 1986 |
Adherence to methylphenidate therapy in a pediatric population: a preliminary investigation.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Humans; Methylphenidate; Patient Compliance | 1985 |
Rate-dependency and hyperactivity: methylphenidate effects on operant responding.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Combined Modality Therapy; Conditioning, Opera | 1985 |
Attention deficit disorder with hyperactivity: differential effects of methylphenidate on impulsivity.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child Behavior; Dose-Response Relationship, Dr | 1985 |
Sleep amphetamine effects in MBDS and normal subjects.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Clinical Trials as Topic; Dextroamphetamine; D | 1974 |
Symposium: behavior modification by drugs. II. Psychological effects of stimulant drugs in children with minimal brain dysfunction.
Topics: Achievement; Attention Deficit Disorder with Hyperactivity; Bender-Gestalt Test; Brain Damage, Chron | 1972 |
EEG aspects in the diagnosis and treatment of minimal brain dysfunction.
Topics: Acoustic Stimulation; Attention Deficit Disorder with Hyperactivity; Brain; Cerebral Cortex; Child; | 1973 |
Anticipatory heart rate deceleration and reaction time in children with and without referral for learning disability.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Child; Child Development; Clinical Trials | 1973 |
2067 other studies available for methylphenidate and ADDH
| Article | Year |
|---|---|
Long-acting Methylphenidate Induced Transient Orofacial Dyskinesia and Upper Extremity Choreoathetosis: A Case Report.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2021 |
Azstarys (serdexmethylphenidate/dexmethylphenidate) for ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Double-Blin | 2021 |
Physical exercise and catecholamine reuptake inhibitors affect orienting behavior and social interaction in a rat model of attention-deficit/hyperactivity disorder.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Catecholamines; Central Nervous System Stimu | 2021 |
Methylphenidate Improves Autonomic Functioning among Youth with Attention-Deficit/Hyperactivity Disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2022 |
CDH2 mutation affecting N-cadherin function causes attention-deficit hyperactivity disorder in humans and mice.
Topics: Animals; Antigens, CD; Attention Deficit Disorder with Hyperactivity; Cadherins; Child; Dopamine; Ge | 2021 |
Sex differences in methylphenidate-induced dopamine increases in ventral striatum.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Corpus Striatum; D | 2022 |
The effect of methylphenidate and mixed amphetamine salts on cognitive reflection: a field study.
Topics: Amphetamine; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cogni | 2022 |
Internet parent-child interaction therapy (I-PCIT) in medically ill child: A case report.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child, Preschool; Combined Modality | 2021 |
Editorial: Evidence Concerning Dose-Dependent Effects of Stimulants on Neurocognitive Function in Children With Attention-Deficit/Hyperactivity Disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cognition; | 2022 |
Haloperidol and methylphenidate alter motor behavior and responses to conditioned fear of Carioca Low-conditioned Freezing rats.
Topics: Animals; Anxiety; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Conditioning, Psy | 2021 |
Co-treatment with low doses of buspirone prevents rewarding effects of methylphenidate and upregulates expression of 5-HT1A receptor mRNA in the nucleus accumbens.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Buspirone; Central Nervous System Stimulants | 2022 |
Nationwide Rate of Adult ADHD Diagnosis and Pharmacotherapy from 2015 to 2018.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Inc | 2021 |
The adverse association between stimulant use for attention deficit hyperactivity disorder (ADHD) and semen parameters.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Male; Meth | 2022 |
Assessment of the lamina cribrosa in attention-deficit hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2021 |
Psychiatric Comorbidities in 1p36 Deletion Syndrome and Their Treatment-A Case Report.
Topics: Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; | 2021 |
Boys with attention-deficit/hyperactivity disorder perform wider and fewer finger tapping than typically developing boys - Peer comparisons and the effects of methylphenidate from an exploratory perspective.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Mal | 2022 |
Viloxazine: A new miracle drug for attention deficit hyperactivity disorder (ADHD) or just another non-stimulant?
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Methylphen | 2022 |
Missing trials from regulatory document of methylphenidate for adults with attention-deficit/hyperactivity disorder: Response to Boesen et al.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Humans; Methylphenidate; Psychiatric Status Ra | 2022 |
A Case Study on EEG Analysis: Embedding Entropy Estimations Indicate the Decreased Neuro-Cortical Complexity Levels Mediated by Methylphenidate Treatment in Children with ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Electroence | 2022 |
Clinical trials were missing from regulatory documents of extended-release methylphenidate for ADHD in adults: A case study of public documents: author's reply.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Delayed-Action Preparations; Humans; Methylphe | 2022 |
The impact of methylphenidate treatment on the functional and structural properties of the left ventricle: A medium-term prospective study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2022 |
Plasma concentrations of methylphenidate enantiomers in adults with ADHD and substance use disorder, with focus on high doses and relationship to carboxylesterase activity.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Carboxylic Ester Hydrolases; Central Nervous S | 2022 |
Acute Tolerability of Methylphenidate in Treatment-Naïve Children with ADHD: An Analysis of Naturalistically Collected Data from Clinical Practice.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2022 |
Moderators and Other Predictors of Methylphenidate Response in Children and Adolescents with ADHD.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimula | 2022 |
Clinical characteristics of children and adolescents with ADHD with or without methylphenidate prescription at their first diagnostic assessment.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2022 |
Brainmarker-I Differentially Predicts Remission to Various Attention-Deficit/Hyperactivity Disorder Treatments: A Discovery, Transfer, and Blinded Validation Study.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Humans; Male; Methylphenid | 2023 |
Growth Hormone and Thyroid Function in Children With Attention Deficit Hyperactivity Disorder Undergoing Drug Therapy.
Topics: Attention Deficit Disorder with Hyperactivity; Body Weight; Central Nervous System Stimulants; Child | 2022 |
Methylphenidate significantly improves neurocognitive impairments in children with ADHD.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2022 |
Predictors of Stimulant Medication Continuity in Children with Attention-Deficit/Hyperactivity Disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Clinical Tr | 2022 |
[Trend in medicines use for attention deficit hyperactivity disorder in children and adolescents (2010-2019).]
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2022 |
Early and Objective Evaluation of the Therapeutic Effects of ADHD Medication through Movement Analysis Using Video Recording Pixel Subtraction.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Female; Humans; Male; Methylphenidate; Surveys | 2022 |
ASD with ADHD vs. ASD and ADHD alone: a study of the QbTest performance and single-dose methylphenidate responding in children and adolescents.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Central Nervous | 2022 |
Influence of
Topics: Attention Deficit Disorder with Hyperactivity; Catechol O-Methyltransferase; Child; Female; Fetal Al | 2022 |
Methylphenidate as a causal test of translational and basic neural coding hypotheses.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Macaca mulatta; Methylphenidate; Neurons; Vi | 2022 |
Multimodal treatment efficacy differs in dependence of core symptom profiles in adult Attention-Deficit/Hyperactivity Disorder: An analysis of the randomized controlled COMPAS trial.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Combined Mo | 2022 |
Ritalin as a causal perturbation.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Brain; Humans; Methylphenidate | 2022 |
Does methylphenidate treatment affect functional and structural ocular parameters in patients with attention deficit hyperactivity disorder? - A prospective, one year follow-up study.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Dopamine; Follow-Up Studies; Humans; Methylphe | 2022 |
Effects of Methylphenidate on the Dopamine Transporter and Beyond.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; Do | 2022 |
Shared and Unique Effects of Long-Term Administration of Methylphenidate and Atomoxetine on Degree Centrality in Medication-Naïve Children With Attention-Deficit/Hyperactive Disorder.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivi | 2022 |
The Effects of Drug Treatments for ADHD in Measures of Cognitive Performance.
Topics: Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous S | 2022 |
A comparison of mood, quality of life and executive function among narcolepsy type 1 patients with or without ADHD symptoms in China.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2022 |
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Methylphen | 2022 |
Effects of a single-dose methylphenidate challenge on resting-state functional connectivity in stimulant-treatment naive children and adults with ADHD.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; Chil | 2022 |
A Simulation Study of the Comparative Performance of Partial Area under the Curve (pAUC) and Partial Area under the Effect Curve (pAUEC) Metrics in Crossover Versus Replicated Crossover Bioequivalence Studies for Concerta and Ritalin LA.
Topics: Area Under Curve; Attention Deficit Disorder with Hyperactivity; Benchmarking; Central Nervous Syste | 2022 |
Methylphenidate Restores Behavioral and Neuroplasticity Impairments in the Prenatal Nicotine Exposure Mouse Model of ADHD: Evidence for Involvement of AMPA Receptor Subunit Composition and Synaptic Spine Morphology in the Hippocampus.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Disease Models, Animal; Female; Hippocampus; | 2022 |
Trends in use of attention deficit hyperactivity disorder medication among children and adolescents in Scandinavia in 2010-2020.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2023 |
[Effect of Rehmanniae Radix Praeparata on energy metabolism in prefrontal cortex of rats with attention deficit hyperactivity disorder based on "static Yin and dynamic Yang" theory].
Topics: Adenosine Monophosphate; Adenosine Triphosphatases; Adenosine Triphosphate; Animals; Attention Defic | 2022 |
Seasonality and ADHD: Summer time is associated with less symptoms of inattention among children and adolescents with ADHD.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2022 |
Time-dependent affective disturbances in abstinent patients with methylphenidate use disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans | 2022 |
General practice database on mortality in adults on methylphenidate: cohort study.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Cohort Studies; Female; General Pr | 2022 |
Pre-clinical evidence that methylphenidate increases motivation and/or reward preference to search for high value rewards.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Male; Met | 2023 |
Poisonings with ADHD medication in children under the age of 5 years in Australia: a retrospective study, 2004-2019.
Topics: Attention Deficit Disorder with Hyperactivity; Australia; Central Nervous System Stimulants; Child; | 2022 |
The Pharmacogenetic Impact on the Pharmacokinetics of ADHD Medications.
Topics: Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Cytochrome P | 2022 |
Psychostimulants Modafinil, Atomoxetine and Guanfacine Impair Bone Cell Differentiation and MSC Migration.
Topics: Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cell Differentiatio | 2022 |
Comparative cardiovascular side effects of medications for attention-deficit/hyperactivity disorder in children, adolescents and adults: protocol for a systematic review and network meta-analysis.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2022 |
Post-treatment symptomatic improvement of the eastern Indian ADHD probands is influenced by
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cytochrome P-450 CYP2D6; G | 2023 |
Ignore the glitch but mind the switch: Positive effects of methylphenidate on cognition in attention deficit hyperactivity disorder are related to prediction gain.
Topics: Attention Deficit Disorder with Hyperactivity; Dopamine; Humans; Methylphenidate | 2022 |
Combined Chronic Oral Methylphenidate and Fluoxetine Treatment During Adolescence: Effects on Behavior.
Topics: Animals; Anxiety; Attention Deficit Disorder with Hyperactivity; Fluoxetine; Methylphenidate; Rats; | 2023 |
Comment on: "A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention Deficit/Hyperactivity Disorder".
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Capsules; Central Nervous System Stimulants; D | 2022 |
The Prevalence and Treatment of ADHD in Spain: A Retrospective Cohort Analysis.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Fema | 2023 |
Improvement of attention deficit/hyperactivity disorder (ADHD) in three adult men during testosterone treatment: a case series.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Mal | 2022 |
Improvement of attention deficit/hyperactivity disorder (ADHD) in three adult men during testosterone treatment: a case series.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Mal | 2022 |
Improvement of attention deficit/hyperactivity disorder (ADHD) in three adult men during testosterone treatment: a case series.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Mal | 2022 |
Improvement of attention deficit/hyperactivity disorder (ADHD) in three adult men during testosterone treatment: a case series.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Mal | 2022 |
Improvement of attention deficit/hyperactivity disorder (ADHD) in three adult men during testosterone treatment: a case series.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Mal | 2022 |
Improvement of attention deficit/hyperactivity disorder (ADHD) in three adult men during testosterone treatment: a case series.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Mal | 2022 |
Improvement of attention deficit/hyperactivity disorder (ADHD) in three adult men during testosterone treatment: a case series.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Mal | 2022 |
Improvement of attention deficit/hyperactivity disorder (ADHD) in three adult men during testosterone treatment: a case series.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Mal | 2022 |
Improvement of attention deficit/hyperactivity disorder (ADHD) in three adult men during testosterone treatment: a case series.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Mal | 2022 |
Novel non-stimulants rescue hyperactive phenotype in an adgrl3.1 mutant zebrafish model of ADHD.
Topics: Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous S | 2023 |
Novel non-stimulants rescue hyperactive phenotype in an adgrl3.1 mutant zebrafish model of ADHD.
Topics: Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous S | 2023 |
Novel non-stimulants rescue hyperactive phenotype in an adgrl3.1 mutant zebrafish model of ADHD.
Topics: Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous S | 2023 |
Novel non-stimulants rescue hyperactive phenotype in an adgrl3.1 mutant zebrafish model of ADHD.
Topics: Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous S | 2023 |
Novel non-stimulants rescue hyperactive phenotype in an adgrl3.1 mutant zebrafish model of ADHD.
Topics: Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous S | 2023 |
Novel non-stimulants rescue hyperactive phenotype in an adgrl3.1 mutant zebrafish model of ADHD.
Topics: Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous S | 2023 |
Novel non-stimulants rescue hyperactive phenotype in an adgrl3.1 mutant zebrafish model of ADHD.
Topics: Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous S | 2023 |
Novel non-stimulants rescue hyperactive phenotype in an adgrl3.1 mutant zebrafish model of ADHD.
Topics: Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous S | 2023 |
Novel non-stimulants rescue hyperactive phenotype in an adgrl3.1 mutant zebrafish model of ADHD.
Topics: Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous S | 2023 |
Theory of visual attention (TVA) applied to rats performing the 5-choice serial reaction time task: differential effects of dopaminergic and noradrenergic manipulations.
Topics: Amphetamine; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cent | 2023 |
Theory of visual attention (TVA) applied to rats performing the 5-choice serial reaction time task: differential effects of dopaminergic and noradrenergic manipulations.
Topics: Amphetamine; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cent | 2023 |
Theory of visual attention (TVA) applied to rats performing the 5-choice serial reaction time task: differential effects of dopaminergic and noradrenergic manipulations.
Topics: Amphetamine; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cent | 2023 |
Theory of visual attention (TVA) applied to rats performing the 5-choice serial reaction time task: differential effects of dopaminergic and noradrenergic manipulations.
Topics: Amphetamine; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cent | 2023 |
Theory of visual attention (TVA) applied to rats performing the 5-choice serial reaction time task: differential effects of dopaminergic and noradrenergic manipulations.
Topics: Amphetamine; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cent | 2023 |
Theory of visual attention (TVA) applied to rats performing the 5-choice serial reaction time task: differential effects of dopaminergic and noradrenergic manipulations.
Topics: Amphetamine; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cent | 2023 |
Theory of visual attention (TVA) applied to rats performing the 5-choice serial reaction time task: differential effects of dopaminergic and noradrenergic manipulations.
Topics: Amphetamine; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cent | 2023 |
Theory of visual attention (TVA) applied to rats performing the 5-choice serial reaction time task: differential effects of dopaminergic and noradrenergic manipulations.
Topics: Amphetamine; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cent | 2023 |
Theory of visual attention (TVA) applied to rats performing the 5-choice serial reaction time task: differential effects of dopaminergic and noradrenergic manipulations.
Topics: Amphetamine; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cent | 2023 |
Prevalence trends and individual patterns of ADHD medication use in pregnancy in Norway and Sweden, 2010-2019.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2023 |
Prevalence trends and individual patterns of ADHD medication use in pregnancy in Norway and Sweden, 2010-2019.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2023 |
Prevalence trends and individual patterns of ADHD medication use in pregnancy in Norway and Sweden, 2010-2019.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2023 |
Prevalence trends and individual patterns of ADHD medication use in pregnancy in Norway and Sweden, 2010-2019.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2023 |
Attitudes and practices in the management of attention deficit hyperactivity disorder among Brazilian pediatric neurologists who responded to a national survey: a cross-sectional study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Attitude; Brazil; Central Nervous System | 2022 |
[ADHD medication to improve academic performance?]
Topics: Academic Performance; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulan | 2023 |
Fronto-Cerebellar Neurometabolite Alterations After Methylphenidate in Children and Adolescents With ADHD: A Proton Magnetic Resonance Spectroscopy Study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; | 2023 |
The Relationship Between Eating-Attitudes and Clinical Characteristics, Agouti-Related Peptide, and Other Biochemical Markers in Adult-Attention Deficit Hyperactivity Disorder.
Topics: Adult; Agouti-Related Protein; Attention Deficit Disorder with Hyperactivity; Attitude; Biomarkers; | 2023 |
Dose titration of osmotic release oral system methylphenidate in children and adolescents with attention-deficit hyperactivity disorder: a retrospective cohort study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2023 |
Characteristics and outcomes of cases with methylphenidate abuse, dependence or withdrawal: an analysis of spontaneous reports in EudraVigilance.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Comorbidity | 2023 |
Effects of methylphenidate on impulsive choice and delay aversion in Lewis rats.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Choice Behavior; Impulsive Behavior; Methylp | 2023 |
Transdermal dextroamphetamine (Xelstrym) for ADHD.
Topics: Administration, Cutaneous; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2023 |
In utero exposure to ADHD medication and long-term offspring outcomes.
Topics: Adult; Amphetamines; Attention Deficit Disorder with Hyperactivity; Child, Preschool; Clonidine; Coh | 2023 |
Time-varying SUVr reflects the dynamics of dopamine increases during methylphenidate challenges in humans.
Topics: Attention Deficit Disorder with Hyperactivity; Brain; Dopamine; Dopamine Antagonists; Humans; Methyl | 2023 |
Effect of atomoxetine on ADHD-pain hypersensitization comorbidity in 6-OHDA lesioned mice.
Topics: Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hy | 2023 |
Safety outcomes of selective serotonin reuptake inhibitors in adolescent attention-deficit/hyperactivity disorder with comorbid depression:
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cohort | 2023 |
Long-term changes in serum levels of lipoproteins in children and adolescents with attention-deficit/hyperactivity disorder (ADHD).
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2023 |
Methylphenidate Promotes Premature Growth Plate Closure: In Vitro Evidence.
Topics: Attention Deficit Disorder with Hyperactivity; Cells, Cultured; Central Nervous System Stimulants; G | 2023 |
Perspectives of French adolescents with ADHD and child and adolescent psychiatrists regarding methylphenidate use.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2023 |
An exploratory analysis of the performance of methylphenidate regimens based on a PKPD model of dopamine and norepinephrine transporter occupancy.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Dopamine; Humans; | 2023 |
Prescribing patterns for attention deficit hyperactivity disorder among children and adolescents in Taiwan from 2004 to 2017.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with | 2023 |
Alice in Wonderland Syndrome as a potential side-effect in Attention Deficit Hyperactivity Disorder patients undergoing Methylphenidate treatment.
Topics: Alice in Wonderland Syndrome; Attention Deficit Disorder with Hyperactivity; Drug-Related Side Effec | 2023 |
Sudden Increases in U.S. Stimulant Prescribing: Alarming or Not?
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Methylphen | 2023 |
The Burden of Attention-Deficit/Hyperactivity Disorder in Adults: A Real-World Linked Data Study.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Met | 2023 |
Long-term safety of methylphenidate in children with ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Met | 2023 |
Long-term safety of methylphenidate in children and adolescents with ADHD: 2-year outcomes of the Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE) study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2023 |
Exploration of electroencephalogram response to MPH treatment in ADHD patients.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Electroencephalogr | 2023 |
Pharmacologic Management of Cognitive Disengagement Syndrome (CDS) and Implications for Attention-Deficit/Hyperactivity Disorder (ADHD) Treatment: Emerging Treatments and Recommendations for Future Research.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2023 |
Effect of methylphenidate on the onset of puberty and reproductive organ development in rats.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Body Weight; Central Nervous System Stimulan | 2023 |
Real-World Efficacy and Safety of Extended-Release Methylphenidate (PRC-063) in the Treatment of ADHD in Pediatric and Adult Subjects: Results of a Phase IV Multicenter Comparison With Lisdexamfetamine Dimesylate.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Dext | 2023 |
The Effect of Methylphenidate Treatment on Olfactory Function in Children and Adolescents With ADHD.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Cross-Sectional Studies; Humans; M | 2023 |
[Psychostimulants: An Overview].
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Lisdexamfe | 2023 |
Efficacy of clonidine in the treatment of children with tic disorder co-morbid with attention deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Clonidine; | 2023 |
Salience and hedonic experience as predictors of central stimulant treatment response in ADHD - A resting state fMRI study.
Topics: Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; Humans; Mag | 2023 |
Epidemiology, Treatment Patterns, Comorbidities, and Concomitant Medication in Patients with ADHD in Sweden: A Registry-Based Study (2018-2021).
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cros | 2023 |
[Methylphenidate-induced psychosis in a young adult with newly diagnosed ADHD: A case report].
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Iceland; M | 2023 |
l-Arginine/nitric oxide pathway and oxidative stress in adults with ADHD: Effects of methylphenidate treatment.
Topics: Adult; Arginine; Attention Deficit Disorder with Hyperactivity; Child; Creatinine; Humans; Methylphe | 2023 |
Concomitant Drug Use among Opioid-Dependent Patients with and without Attention Deficit Hyperactivity Disorder: Does Methylphenidate Merit a Trial?
Topics: Amphetamine; Analgesics, Opioid; Attention Deficit Disorder with Hyperactivity; Central Nervous Syst | 2023 |
The Adverse Effects and Nonmedical Use of Methylphenidate Before and After the Outbreak of COVID-19: Machine Learning Analysis.
Topics: Attention Deficit Disorder with Hyperactivity; Bayes Theorem; Central Nervous System Stimulants; COV | 2023 |
Ketogenic diet ameliorates attention deficit hyperactivity disorder in rats via regulating gut microbiota.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Diet, Ket | 2023 |
Evaluation and Management of Attention-Deficit/ Hyperactivity Disorder (ADHD) in Children and Adolescents.
Topics: Adolescent; Amphetamine; Attention; Attention Deficit Disorder with Hyperactivity; Child; Employment | 2023 |
Complex Attention-Deficit/Hyperactivity Disorder in a Bilingual Child with Down Syndrome and Intellectual Disability.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Cesarean Section; Child; Down Syndrome; Female | 2023 |
WHO Model Lists of Essential Medicines: methylphenidate for ADHD in children and adolescents.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Humans; Methylphenidate; World Hea | 2023 |
Effects of adolescent methylphenidate administration on methamphetamine conditioned place preference in an animal model of attention-deficit/hyperactivity disorder: Examination of potential sex differences.
Topics: Adolescent; Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulant | 2023 |
Conflict of interest and risk of bias in systematic reviews on methylphenidate for attention-deficit hyperactivity disorder: a cross-sectional study.
Topics: Attention Deficit Disorder with Hyperactivity; Bias; Conflict of Interest; Cross-Sectional Studies; | 2023 |
Poor response to methylphenidate is associated with a smaller dorsal attentive network in adult Attention-Deficit/Hyperactivity Disorder (ADHD).
Topics: Adult; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2023 |
Methylphenidate exposure in juvenile period elicits locomotion changes and anxiolytic-like behavior in adulthood: Evidence using zebrafish as a translational model.
Topics: Animals; Anti-Anxiety Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous System | 2024 |
Dichotomous effect of methylphenidate on microglia and astrocytes: Insights from in vitro and animal studies.
Topics: Adolescent; Animals; Astrocytes; Attention Deficit Disorder with Hyperactivity; Central Nervous Syst | 2023 |
Medical Cannabis Legalization: No Contribution to Rising Stimulant Rates in the USA.
Topics: Adult; Amphetamine; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants | 2023 |
Differences between centers in functional outcome of patients with ADHD after 1 year from the time of diagnosis.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Combined Modality | 2023 |
Glutamate receptor genetic variants affected peripheral glutamatergic transmission and treatment induced improvement of Indian ADHD probands.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Genotype; Glutamic Acid; Humans; Methylphenida | 2023 |
Methylphenidate-associated chest pain in a child.
Topics: Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Central Nervous System Stim | 2023 |
Role of homeostatic feedback mechanisms in modulating methylphenidate actions on phasic dopamine signaling in the striatum of awake behaving rats.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Dopamine; Homeostasis; Mal | 2019 |
Methylphenidate and stuttering.
Topics: Adolescent; Adverse Drug Reaction Reporting Systems; Attention Deficit Disorder with Hyperactivity; | 2019 |
Success Rates at an Air Force Pilot Academy and Its Relation to Methylphenidate Use.
Topics: Academic Success; Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous | 2019 |
The countervailing forces behind France's low Ritalin consumption.
Topics: Attention Deficit Disorder with Hyperactivity; Dopamine Uptake Inhibitors; Drug Industry; France; Hu | 2019 |
"Eat, pray, love. Ritalin": A qualitative investigation into the perceived barriers and enablers to parents of children with ADHD undertaking a mindful parenting intervention.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Child; Female; Focus Groups; Humans; Love; Mal | 2019 |
Brief and extended abstinence from chronic oral methylphenidate treatment produces reversible behavioral and physiological effects.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Body Weight; Central Nervo | 2020 |
Is There Long-Term Benefit From Stimulant Treatment for ADHD?
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Methylphen | 2019 |
Debate: Are Stimulant Medications for Attention-Deficit/Hyperactivity Disorder Effective in the Long Term? (For).
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2019 |
Debate: Are Stimulant Medications for Attention-Deficit/Hyperactivity Disorder Effective in the Long Term? (Against).
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2019 |
Differential Posttreatment Outcomes of Methylphenidate for Smoking Cessation for Individuals With ADHD.
Topics: Administration, Oral; Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nerv | 2019 |
Effect of catalpol on behavior and neurodevelopment in an ADHD rat model.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Central Nervous System Sti | 2019 |
A Prescription Trend Analysis of Methylphenidate: Relation to Study Reports on Efficacy.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2020 |
Methylphenidate does not affect convergent and divergent creative processes in healthy adults.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Creativity; | 2020 |
Effects of medications on ventricular repolarization in children with attention deficit hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Electrocardiography; Female; Human | 2020 |
Effective Stimulant Dosing in Attention-Deficit/Hyperactivity Disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Methylphen | 2019 |
Effective Stimulant Dosing in Attention-Deficit/Hyperactivity Disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Methylphen | 2019 |
Effective Stimulant Dosing in Attention-Deficit/Hyperactivity Disorder-Reply.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Methylphen | 2019 |
Methylphenidate modifies reward cue responses in adults with ADHD: An fMRI study.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Conditioning, Classical; | 2020 |
Prediction of sleep side effects following methylphenidate treatment in ADHD youth.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Female | 2020 |
Integrative proteomics and pharmacogenomics analysis of methylphenidate treatment response.
Topics: Adult; Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Fe | 2019 |
Annual variation in attentional response after methylphenidate treatment.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2020 |
ADHD medication and the inverted U-shaped curve: A pharmacological study in female mice performing the rodent Continuous Performance Test (rCPT).
Topics: Amphetamine; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cent | 2020 |
Is brain arousal regulation a predictor of response to psychostimulant therapy in adult ADHD patients?
Topics: Adult; Arousal; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Ce | 2020 |
Very early-onset of RBD with ADHD: a case report study.
Topics: Adult; Age of Onset; Attention Deficit Disorder with Hyperactivity; Brain Stem; Dopamine Uptake Inhi | 2020 |
Not Really "The Same Thing".
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child Behav | 2020 |
Atomoxetine Reestablishes Long Term Potentiation in a Mouse Model of Attention Deficit/Hyperactivity Disorder.
Topics: Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hy | 2020 |
Disparate regulatory status of methylphenidate for adults with ADHD across Europe.
Topics: Adult; Age Factors; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants | 2020 |
Metabolomics study of the prefrontal cortex in a rat model of attention deficit hyperactivity disorder reveals the association between cholesterol metabolism disorder and hyperactive behavior.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Biomarkers; Central Nervou | 2020 |
Patterns of long-term ADHD medication use in Australian children.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Australia; Cen | 2020 |
Ventral striatum supports Methylphenidate therapeutic effects on impulsive choices expressed in temporal discounting task.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Delay Discounting; Dopamine Plasma Membrane | 2020 |
[New-onset trichotillomania during treatment with stimulant drugs. About two pediatric clinical cases].
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Lis | 2020 |
The effects of methylphenidate on stress fractures in patients' ages 10-29: a national database study.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2020 |
Association of methylphenidate use and traditional and cyberbullying in adolescents with ADHD.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Bullying; Central Nervous System Stimulan | 2020 |
RLS with PLMS in a child with hemolytic anemia caused by pyruvate kinase deficiency.
Topics: Anemia, Hemolytic; Anemia, Hemolytic, Congenital Nonspherocytic; Attention Deficit Disorder with Hyp | 2020 |
An Open-Label Trial of Methylphenidate Treating Sluggish Cognitive Tempo, Inattention, and Hyperactivity/Impulsivity Symptoms Among 6- to 12-Year-Old ADHD Children: What Are the Predictors of Treatment Response at Home and School?
Topics: Aged; Attention Deficit Disorder with Hyperactivity; Child; Cognition; Humans; Impulsive Behavior; M | 2021 |
ADHD Diagnosis and Drug Use Estimates in France: A Case for Using Health Care Insurance Data.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Delivery of | 2021 |
Methylphenidate affects task-switching and neural signaling in non-human primates.
Topics: Animals; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants | 2020 |
Use of methylphenidate in attention-deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Decision Making; H | 2020 |
Combining neuropsychological tests to improve the assessment of arithmetic difficulties in children with ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Brazil; Central Nervous System Stimulants; Child; Hum | 2020 |
[Progression of symptoms in children with attention deficit and hyperactivity disorder in treatment with methylphenidate].
Topics: Attention Deficit Disorder with Hyperactivity; Child; Disease Progression; Dopamine Uptake Inhibitor | 2020 |
Individualizing the dosage of Methylphenidate in children with attention deficit hyperactivity disorder.
Topics: Algorithms; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2020 |
Accommodative response in children with attention deficit hyperactivity disorder (ADHD): the influence of accommodation stimulus and medication.
Topics: Accommodation, Ocular; Attention Deficit Disorder with Hyperactivity; Child; Dopamine Uptake Inhibit | 2020 |
Allergic Reaction to Medication After Years of Taking It: What To Do Next?
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Drug Hypers | 2020 |
Effects of methylphenidate on the lower urinary tract in patients with attention deficit hyperactivity disorder and without voiding dysfunction.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Methylphen | 2020 |
Dose Adjustment of Stimulants for Children with Attention-Deficit/Hyperactivity Disorder: A Retrospective Chart Review of the Impact of Exceeding Recommended Doses.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2020 |
Trends in attention-deficit and hyperactivity disorder (ADHD) medications among children and young adults in Ireland: a repeated cross-sectional study from 2005 to 2015.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic | 2020 |
Pharmacotherapy With Attention-Deficit Disorder.
Topics: Adolescent; Adult; Amphetamines; Attention Deficit Disorder with Hyperactivity; Brief Psychiatric Ra | 2020 |
Sleep habits of children diagnosed with attention/ deficit/ hyperactivity disorder and effects of treatment on sleep related parameters.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention; Attention Deficit Disorder with Hyperactivity; Cen | 2020 |
Different effects of methylphenidate and atomoxetine on the behavior and brain transcriptome of zebrafish.
Topics: Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Behavior Rating S | 2020 |
The effects of medication on intraocular pressure in children with attention deficit hyperactivity disorder: A prospective study.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivi | 2020 |
Emotional dysregulation and callous unemotional traits as possible predictors of short-term response to methylphenidate monotherapy in drug-naïve youth with ADHD.
Topics: Adolescent; Antisocial Personality Disorder; Attention Deficit Disorder with Hyperactivity; Central | 2020 |
A novel approach to intra-individual performance variability in ADHD.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Child; Cross-Sectio | 2021 |
Differential effects of alprazolam against methylphenidate-induced neurobehavioral alterations.
Topics: Alprazolam; Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulant | 2020 |
Assessment of changes in the macula and optic nerve head using optical coherence tomography in patients with attention deficit hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2020 |
Seizure risk, methylphenidate, and ADHD: reassuring news.
Topics: Attention Deficit Disorder with Hyperactivity; Epilepsy; Humans; Methylphenidate; Seizures | 2020 |
Association between methylphenidate treatment and risk of seizure: a population-based, self-controlled case-series study.
Topics: Adolescent; Age Distribution; Attention Deficit Disorder with Hyperactivity; Central Nervous System | 2020 |
Response and Side Effects Using Stimulant Medication in Older Adults With ADHD: An Observational Archive Study.
Topics: Aged; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Electronic H | 2021 |
Maternal Sociodemographic Factors Are Associated with Methylphenidate Initiation in Children in the Netherlands: A Population-Based Study.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2021 |
Methylphenidate has mild hyperglycemic and hypokalemia effects and increases leukocyte and neutrophil counts.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2020 |
Incidence of Neutropenia with Valproate, Antipsychotics, and ADHD Medication Combination Treatment in Children and Adolescents.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Child; Female; Huma | 2020 |
Methylphenidate and the risk of burn injury among children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Burns; Central Nervous System Stimulants; | 2020 |
Methylphenidate and the Risk of New-Onset Seizures.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Methylphen | 2020 |
Methylphenidate challenge test in adults with attention deficit/hyperactivity disorder (ADHD): Clinical effects and their predictors.
Topics: Adolescent; Adult; Age Factors; Aged; Attention Deficit Disorder with Hyperactivity; Central Nervous | 2020 |
The 10-year trend in drug prescriptions for attention-deficit/hyperactivity disorder (ADHD) in Germany.
Topics: Adolescent; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central | 2021 |
The ball search field task in the evaluation of methylphenidate treatment of children with attention deficit / hyperactivity disorder.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2020 |
Diagnosis and management of an inappropriate sinus tachycardia in adolescence based upon a Holter ECG: A retrospective analysis of 479 patients.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Electrocardiography, Ambulatory; Fatty Ac | 2020 |
Frontal Cortical Monoamine Release, Attention, and Working Memory in a Perinatal Nicotine Exposure Mouse Model Following Kappa Opioid Receptor Antagonism.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Biogenic Monoamines; Disease Models, Animal; | 2021 |
Methylphenidate treatment of adult ADHD patients improves the degree of ADHD severity under routine conditions.
Topics: Activities of Daily Living; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous Sy | 2020 |
Medication utilization among adult patients with attention-deficit/hyperactivity disorder after reimbursement criteria change.
Topics: Adolescent; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Drug Pr | 2020 |
[Risk of psychosis with treatment for ADHD].
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2020 |
Methylphenidate Ameliorates Worsening Distractibility Symptoms of Misophonia in an Adolescent Male.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cognit | 2020 |
Methylphenidate-Induced Persistent Hiccups in a Child With ADHD Relieved by Add-On Risperidone.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Hiccup; Hum | 2020 |
Editorial: Two Centimeters More or Less. How Much Does It Matter to an Adolescent or a Young Adult With Attention-Deficit/Hyperactivity Disorder?
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2020 |
Is contrast sensitivity a physiological marker in attention-deficit hyperactivity disorder?
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2020 |
Impact of methylphenidate on sleep problems in adults with ADHD: a pilot polysomnography study.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Met | 2021 |
Insights from pre-treatment attrition & dropouts in an effectiveness trial of methylphenidate in children.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Humans; Methylphenidate; Patient Dropouts | 2020 |
Adult attention deficit/hyperactivity disorder in the ambulatory care setting: Erratum.
Topics: Ambulatory Care; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bupropion | 2020 |
Potential disturbance of methylphenidate of gonadal hormones or pubescent development in patients with attention-deficit/hyperactivity disorder: A twelve-month follow-up study.
Topics: Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Central Nervous System Stimulan | 2021 |
Case report: diagnosis and treatment of attention deficit hyperactivity disorder and autism spectrum disorder in patients diagnosed with oculocutaneous albinism.
Topics: Adolescent; Albinism, Oculocutaneous; Attention Deficit Disorder with Hyperactivity; Autism Spectrum | 2020 |
Students' stimulant use for cognitive enhancement: A deliberate choice rather than an emotional response to a given situation.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cognition; | 2021 |
Attention deficit hyperactivity disorder and gastrointestinal morbidity in a large cohort of young adults.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Gastrointestinal Tract; Humans; Is | 2020 |
Topics: Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Humans; Mania; Methylphenidate; Moo | 2020 |
[The effects of pharmacological treatment with stimulants on circadian activity patterns in children with attention deficit hyperactivity disorder].
Topics: Actigraphy; Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimul | 2020 |
Sedation After a Trial of Mixed Amphetamine Salts in a Boy with Attention-Deficit/Hyperactivity Disorder.
Topics: Amphetamine; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Child; Humans; | 2020 |
Drug holidays may not affect processing speed while they may reduce beneficial effects on resistance to interference among children with treated with methylphenidate: a single-center, prospective study.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Met | 2021 |
Medications for attention-deficit/hyperactivity disorder in individuals with or without coexisting autism spectrum disorder: analysis of data from the Swedish prescribed drug register.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Attention Deficit Disorder with Hyperactivity; Autism Sp | 2020 |
Commentary: Identifying individualized predictions of response in ADHD pharmacotherapy - a commentary on Rodrigues et al. (2020).
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; | 2021 |
Methylphenidate and TBI in ADHD and co-occurring epilepsy and mental disorders: a self-controlled case series study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Brain Injuries, Traumatic; Central Nervou | 2022 |
Shifting uncertainty intolerance: methylphenidate and attention-deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Impulsive | 2021 |
Regional brain volume predicts response to methylphenidate treatment in individuals with ADHD.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stim | 2021 |
Does methylphenidate use affect sperm parameters in patients undergoing infertility investigation? A retrospective analysis of 9769 semen samples.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Humans; Infertility, Male; Male; M | 2021 |
Risk factors for low adherence to methylphenidate treatment in pediatric patients with attention-deficit/hyperactivity disorder.
Topics: Administration, Oral; Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2021 |
Factors Affecting Delayed Initiation and Continuation of Medication Use for Attention-Deficit/Hyperactivity Disorder: A Nationwide Study.
Topics: Adolescent; Age Factors; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimu | 2021 |
Methylphenidate Treatment Adherence and Persistence in Children in the Netherlands.
Topics: Age Factors; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child | 2021 |
An evaluation of the effect of methylphenidate on working memory, time perception, and choice impulsivity in children with ADHD.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2022 |
Drug prescription for attention deficit hyperactivity disorder drugs in pediatric outpatients: A retrospective survey of Japanese administrative data (2012-2018).
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2021 |
Treatment of attention deficit/hyperactivity disorder in children with CHD.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2021 |
Cognitive mechanisms of methylphenidate in ADHD: Do improvements in sustained attention mediate behavioral improvements in the natural environment?
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cognition; | 2021 |
Retrospective review of use of adjunctive psychostimulants in patients with schizophrenia.
Topics: Adjuvants, Pharmaceutic; Attention; Attention Deficit Disorder with Hyperactivity; Canada; Central N | 2021 |
Increased Alopecia Areata Risk in Children with Attention-Deficit/Hyperactivity Disorder and the Impact of Methylphenidate Use: A Nationwide Population-Based Cohort Study.
Topics: Alopecia Areata; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; C | 2021 |
Acute myocardial infarction due to spontaneous coronary artery dissection in a 6-year-old boy with ADHD on the third day of treatment with methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Coronary Ve | 2022 |
Association of psychiatric comorbidities with the risk of transport accidents in ADHD and MPH.
Topics: Accidents, Traffic; Adolescent; Attention Deficit and Disruptive Behavior Disorders; Attention Defic | 2021 |
Synergistic efficacy and diminished adverse effect profile of composite treatment of several ADHD medications.
Topics: Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hy | 2021 |
Paternal exposure to a common pharmaceutical (Ritalin) has transgenerational effects on the behaviour of Trinidadian guppies.
Topics: Animals; Anxiety; Attention Deficit Disorder with Hyperactivity; Cocaine; Epigenomics; Exploratory B | 2021 |
Fetal methylphenidate exposure induced ADHD-like phenotypes and decreased Drd2 and Slc6a3 expression levels in mouse offspring.
Topics: Animals; Animals, Newborn; Attention Deficit Disorder with Hyperactivity; Dopamine Plasma Membrane T | 2021 |
Structural brain network topology underpinning ADHD and response to methylphenidate treatment.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Brain; Brain Mapping; Central Nervous Sys | 2021 |
Effects of methylphenidate on sensory and sensorimotor gating of initially psychostimulant-naïve adult ADHD patients.
Topics: Acoustic Stimulation; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System S | 2021 |
The US Food and Drug Administration's authorisation of Purdue's controlled-release methylphenidate for adult ADHD: comments on the regulatory practice.
Topics: Attention Deficit Disorder with Hyperactivity; Drug and Narcotic Control; Humans; Methylphenidate; U | 2021 |
Can parents believe websites' information about methylphenidate's side effects?
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Consumer Health In | 2021 |
Prediction of treatment dosage and duration from free-text prescriptions: an application to ADHD medications in the Swedish prescribed drug register.
Topics: Attention Deficit Disorder with Hyperactivity; Drug Prescriptions; Humans; Methylphenidate; Sweden; | 2021 |
Unprovoked Dystonic Reaction in a Child Taking Long-Term Methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Benztropine; Central Nervous System Stimulants; Child | 2022 |
Successful Ziprasidone Treatment for Resistant Attention-Deficit/Hyperactivity Disorder and Provisional Motor Tic Disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Comorbidity; Humans; Methylphenidate; Piperazines; Th | 2022 |
Efficacy and safety of methylphenidate on attention deficit hyperactivity disorder in children with Down syndrome.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Down Syndro | 2021 |
Long-Term Treatment With Extended-Release Methylphenidate Treatment in Children Aged 4 to <6 Years.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Pres | 2022 |
α2-Adrenergic Agonists or Stimulants for Preschool-Age Children With Attention-Deficit/Hyperactivity Disorder.
Topics: Adrenergic alpha-2 Receptor Agonists; Attention Deficit Disorder with Hyperactivity; Central Nervous | 2021 |
Update on methylphenidate and dexmethylphenidate formulations for children with attention-deficit/hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Delayed-Act | 2021 |
Acute intranasal dopamine application counteracts the reversal learning deficit of spontaneously hypertensive rats in an attentional set-shifting task.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Disease Models, Animal; Dopamine; Methylphen | 2021 |
The importance of achieving long-term treatment effects in ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Methylphen | 2021 |
Usefulness of Near-Infrared Spectroscopy (NIRS) for evaluating drug effects and improvements in medication adherence in children with Attention Deficit Hyperactivity Disorder (ADHD).
Topics: Attention Deficit Disorder with Hyperactivity; Child; Humans; Male; Medication Adherence; Methylphen | 2021 |
Functional MHCI deficiency induces ADHD-like symptoms with increased dopamine D1 receptor expression.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Dopamine; Genes, MHC Class I; Humans; Methyl | 2021 |
Editorial: On the Safety of Long-term Methylphenidate Treatment of Attention-Deficit/Hyperactivity Disorder in Early Childhood.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child, Preschool; | 2022 |
Risk of Respiratory Infectious Diseases and the Role of Methylphenidate in Children with Attention-Deficit/Hyperactivity Disorder: A Population-Based Cohort Study.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cohort Stud | 2021 |
Current use of attention-deficit hyperactivity disorder (ADHD) medications and clinical characteristics of child and adolescent psychiatric outpatients prescribed multiple ADHD medications in Japan.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Female; Guanfacine; | 2021 |
A Longitudinal Study of Resting-State Connectivity and Response to Psychostimulant Treatment in ADHD.
Topics: Adolescent; Amphetamine; Attention Deficit Disorder with Hyperactivity; Brain; Case-Control Studies; | 2021 |
Methylphenidate ameliorates the homeostatic balance between levels of kynurenines in ADHD children.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Kyn | 2021 |
Medications for attention-deficit/hyperactivity disorder in Japan: A retrospective cohort study of label compliance.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2021 |
Methylphenidate and atomoxetine treatment negatively affect physical growth indexes of school-age children and adolescents with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with | 2021 |
Effects of methylphenidate on mismatch negativity and P3a amplitude of initially psychostimulant-naïve, adult ADHD patients.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Cognition; Electroencephalography; Humans; Met | 2023 |
ADHD Masquerading as Cautopyreiophagia Exacerbated by Risperidone and Improved With Methylphenidate in a Preschooler.
Topics: Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulan | 2021 |
The association between symptom severity and theory of mind impairment in children with attention deficit/hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Empathy; Hu | 2021 |
Treatment with Methylphenidate for Attention Deficit Hyperactivity Disorder (ADHD) and the Risk of All-Cause Poisoning in Children and Adolescents: A Self-Controlled Case Series Study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2021 |
A Case of Persistent Relapsing Regression With Infantile Speech Responding to Methylphenidate Therapy.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Methylphen | 2021 |
Changes in medical use of central nervous system stimulants among US adults, 2013 and 2018: a cross-sectional study.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cross-Secti | 2021 |
Secular trends and regional variations in pharmacotherapy of attention-deficit/hyperactivity disorder (ADHD) among children and adolescents in Germany.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2021 |
ADHD and Drug Holidays: Effects on Anthropometric Changes during Methylpenidate Treatment.
Topics: Adolescent; Adolescent Development; Attention Deficit Disorder with Hyperactivity; Central Nervous S | 2021 |
Long-term effects of stimulant exposure on cerebral blood flow response to methylphenidate and behavior in attention-deficit hyperactivity disorder.
Topics: Adult; Affect; Age Factors; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous Sy | 2018 |
Effect of Biperiden Treatment in Acute Orofacial and Extremity Dyskinesia With Methylphenidate Therapy.
Topics: Attention Deficit Disorder with Hyperactivity; Biperiden; Central Nervous System Stimulants; Child; | 2018 |
ADHD in Germany: Trends in Diagnosis and Pharmacotherapy.
Topics: Adolescent; Adult; Aged; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimu | 2017 |
Methylphenidate use and school performance among primary school children: a descriptive study.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Educational | 2017 |
The Clinical Characteristics of ADHD Diagnosed in Adolescents in Comparison With Younger Children.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2020 |
Model-Based Approach for Optimizing Study Design and Clinical Drug Performances of Extended-Release Formulations of Methylphenidate for the Treatment of ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Delayed-Act | 2017 |
Age-related pharmacotherapy of attention deficit hyperactivity disorder in Slovenia in children and adolescents: A population-based study.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2017 |
Lens opacities in children using methylphenidate hydrochloride.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Cataract; Central Nervous System Stimulan | 2017 |
The Possible Effect of Methylphenidate Treatment on Empathy in Children Diagnosed with Attention-Deficit/Hyperactivity Disorder, Both With and Without Comorbid Oppositional Defiant Disorder.
Topics: Adolescent; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyp | 2017 |
Processing speed can monitor stimulant-medication effects in adults with attention deficit disorder with hyperactivity.
Topics: Adolescent; Adult; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System | 2017 |
Treatment effect of methylphenidate on intrinsic functional brain network in medication-naïve ADHD children: A multivariate analysis.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Brain; Brain Mapping; Central Nervous Sys | 2018 |
Evaluation of sleep organization in patients with attention deficit hyperactivity disorder (ADHD) and ADHD as a comorbidity of epilepsy.
Topics: Actigraphy; Adolescent; Attention Deficit Disorder with Hyperactivity; Brazil; Central Nervous Syste | 2017 |
The risk of injury in adults with attention-deficit hyperactivity disorder: A nationwide, matched-cohort, population-based study in Taiwan.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Female; Hum | 2017 |
Exocytosis-related genes and response to methylphenidate treatment in adults with ADHD.
Topics: Adult; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperact | 2018 |
First-Dose Methylphenidate-Induced Changes in Brain Functional Connectivity Are Correlated With 3-Month Attention-Deficit/Hyperactivity Disorder Symptom Response.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Connectome; | 2017 |
Seasonality of Methylphenidate Administration among Children in Israel.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2016 |
Attention-deficit/hyperactivity disorder: the impact of methylphenidate on working memory, inhibition capacity and mental flexibility.
Topics: Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Central Nervous System Stimulan | 2017 |
Trichotillomania in Attention-Deficit/Hyperactivity Disorder Under Methylphenidate Treatment.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Delayed-Act | 2017 |
Methylphenidate poisoning: relatively mild symptoms even after high-dose exposure.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2017 |
Theory of Mind and Empathy in Children With ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Empathy; Hu | 2019 |
[ECG before administration of Ritalin
Topics: Attention Deficit Disorder with Hyperactivity; Cardiovascular Diseases; Electrocardiography; Humans; | 2017 |
Patient and provider characteristics related with prescribing of ADHD medication: Nationwide health insurance claims database study in Korea.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with | 2018 |
Individual Variability and Medications to Treat Attention-Deficit/Hyperactivity Disorder: The World According to the Caudate.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2017 |
Methylphenidate disintegration from oral formulations for intravenous use by experienced substance users.
Topics: Administration, Intravenous; Administration, Oral; Adult; Attention Deficit Disorder with Hyperactiv | 2017 |
Efficacy of Stimulants Beyond Treatment of Core Symptoms of Attention-Deficit/Hyperactivity Disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Methylphen | 2017 |
The Effect of Methylphenidate on the Microstructure of Schedule-Induced Polydipsia in an animal model of ADHD.
Topics: Analysis of Variance; Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System | 2017 |
The Effect of Attention-Deficit/Hyperactivity Disorder and Methylphenidate Treatment on the Adult Auditory Temporal Order Judgment Threshold.
Topics: Acoustic Stimulation; Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Auditory Per | 2017 |
Narcolepsy-cataplexy and psychosis: a case study.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compound | 2017 |
The Cochrane Collaboration withdraws a review on methylphenidate for adults with attention deficit hyperactivity disorder.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Clinical Tr | 2017 |
Stimulant medication to treat attention-deficit/hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Decision Ma | 2017 |
Serum brain-derived neurotrophic factor levels in treatment-naïve boys with attention-deficit/hyperactivity disorder treated with methylphenidate: an 8-week, observational pretest-posttest study.
Topics: Attention Deficit Disorder with Hyperactivity; Brain-Derived Neurotrophic Factor; Central Nervous Sy | 2018 |
Excessive and Frequent Menstrual Bleeding With Methylphenidate in an Adolescent Girl With Attention-Deficit Hyperactivity Disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Female | 2017 |
Age-dependent, lasting effects of methylphenidate on the GABAergic system of ADHD patients.
Topics: Adult; Age Factors; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System | 2017 |
Blockade of α2-adrenergic receptors in prelimbic cortex: impact on cocaine self-administration in adult spontaneously hypertensive rats following adolescent atomoxetine treatment.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic Uptake Inhibitors; Age Factors; Animals; Atomoxe | 2017 |
Methylphenidate and Atomoxetine-Responsive Prefrontal Cortical Genetic Overlaps in "Impulsive" SHR/NCrl and Wistar Rats.
Topics: Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Choice Behavior; | 2017 |
Effectiveness of Psychotherapy in Adult ADHD: What Do Patients Think? Results of the COMPAS Study.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Met | 2019 |
Association of Risk of Suicide Attempts With Methylphenidate Treatment.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2017 |
Recent Trends in the Prescribing of ADHD Medications in Canadian Primary Care.
Topics: Adolescent; Adult; Aged; Attention Deficit Disorder with Hyperactivity; Canada; Central Nervous Syst | 2020 |
Calling for More Research of Medication Effects in Bipolar Disorder: Response to Ketter and Dell'Osso.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Methylphen | 2017 |
Commentary on the Risk of Treatment-Emergent Mania With Methylphenidate in Bipolar Disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Central Nervous System Stimulants; | 2017 |
[EPIDEMIOLOGY OF RITALIN PRESCRIPTION IN 6-18 YEARS OLD ISRAELI CHILDREN - TIME TO CHANGE POLICY].
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2017 |
Attentional Lapses in Attention-Deficit/Hyperactivity Disorder: Blank Rather Than Wandering Thoughts.
Topics: Adult; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2017 |
Influence of Written Informed Consent for Methylphenidate on Medicine Persistence Rates in Children with Attention-Deficit Hyperactivity Disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2017 |
Weight, Height, and Body Mass Index in Patients with Attention-Deficit/Hyperactivity Disorder Treated with Methylphenidate.
Topics: Adolescent; Age Factors; Attention Deficit Disorder with Hyperactivity; Body Height; Body Mass Index | 2017 |
[Effect of methylphenidate on c-Fos expression in parvalbumin interneurons of juvenile rat frontal cortex].
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Cerebral Cortex; Dopamine; Frontal Lobe; Int | 2017 |
Pharmacotherapy of Attention Deficit Hyperactivity Disorder Symptom Profile in ASD.
Topics: Aripiprazole; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autism Spect | 2017 |
Dosage of methylphenidate and traumatic brain injury in ADHD: a population-based study in Taiwan.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Brain Injuries, Traumatic; Central Nervou | 2018 |
Assessing risk of bias in randomized controlled trials of methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Bias; Central Nervous System Stimulants; | 2018 |
Pharmacogenetics of methylphenidate in childhood attention-deficit/hyperactivity disorder: long-term effects.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2017 |
Attention-Deficit/Hyperactivity Disorder Medication Use in Adolescents: The Patient's Perspective.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cross- | 2017 |
Effect of methylphenidate on visual responses in the superior colliculus in the anaesthetised rat: Role of cortical activation.
Topics: Amphetamine; Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulan | 2017 |
Methylphenidate doses in Attention Deficit/Hyperactivity Disorder and comorbid substance use disorders.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2017 |
The effect of methylphenidate treatment on suspiciousness in children with ADHD alone or comorbid with ODD.
Topics: Adolescent; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyp | 2018 |
Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Delaye | 2017 |
Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Delaye | 2017 |
Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Delaye | 2017 |
Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Delaye | 2017 |
Clinical factors associated with decision to recommend methylphenidate treatment for children with ADHD in France.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2018 |
Differences in Adverse Event Reporting Rates of Therapeutic Failure Between Two Once-daily Extended-release Methylphenidate Medications in Canada: Analysis of Spontaneous Adverse Event Reporting Databases.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Attention Deficit Disorder with Hyperactivity; Canad | 2017 |
ADHD, Smoking Withdrawal, and Inhibitory Control: Results of a Neuroimaging Study with Methylphenidate Challenge.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Female; Hum | 2018 |
Deficiency of tumor suppressor NDRG2 leads to attention deficit and hyperactive behavior.
Topics: Adaptor Proteins, Signal Transducing; Animals; Astrocytes; Attention Deficit Disorder with Hyperacti | 2017 |
Methylphenidate: Gender trends in adult and pediatric populations over a 7year period.
Topics: Adolescent; Adult; Age Factors; Aged; Attention Deficit Disorder with Hyperactivity; Central Nervous | 2017 |
Impact of developmental exposure to methylphenidate on rat brain's immune privilege and behavior: Control versus ADHD model.
Topics: Animals; Anxiety; Attention; Attention Deficit Disorder with Hyperactivity; Blood-Brain Barrier; Bra | 2018 |
[Upward trend in the use of psychostimulants by adults].
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2017 |
Placental Complications Associated With Psychostimulant Use in Pregnancy.
Topics: Abruptio Placentae; Adrenergic Uptake Inhibitors; Adult; Amphetamine; Atomoxetine Hydrochloride; Att | 2017 |
Suicide risk reduction in youths with attention-deficit/hyperactivity disorder prescribed methylphenidate: A Taiwan nationwide population-based cohort study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cohort | 2018 |
Cotempla XR-ODT--another long-acting methylphenidate for ADHD.
Topics: Administration, Oral; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulan | 2017 |
Time and psychostimulants: Opposing long-term structural effects in the adult ADHD brain. A longitudinal MR study.
Topics: Adult; Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous S | 2017 |
Nasal Bleeding Probably Associated with Methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Delayed-Act | 2017 |
Six-year outcome in subjects diagnosed with attention-deficit/hyperactivity disorder as adults.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cross-Secti | 2018 |
[Response With Methylphenidate to ADHD-Like Symptoms in Pervasive Developmental Disorder: Does CES-1 Enzyme Gene Polymorphism Have a Role?]
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Carboxylic Ester Hydrolases; Central Nerv | 2017 |
Shati/Nat8l knockout mice show behavioral deficits ameliorated by atomoxetine and methylphenidate.
Topics: Acetyltransferases; Amphetamine-Related Disorders; Animals; Aspartic Acid; Atomoxetine Hydrochloride | 2018 |
[Does methylphenidate cause liver damage? An analysis of ad hoc reports to the "Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM)"].
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Attention Deficit Disorder with Hyperact | 2018 |
Association Between Methylphenidate and Amphetamine Use in Pregnancy and Risk of Congenital Malformations: A Cohort Study From the International Pregnancy Safety Study Consortium.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Amphetamine; Attention Deficit Disorder with Hyperac | 2018 |
Diagnosing and treating ADHD in adults.
Topics: Adult; Aged; Aged, 80 and over; Attention Deficit Disorder with Hyperactivity; Central Nervous Syste | 2018 |
Drug treatment of ADHD - tenuous scientific basis.
Topics: Adolescent; Amphetamines; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2018 |
Resolution of methylphenidate osmotic release oral system-induced hair loss in two siblings after dose escalation.
Topics: Administration, Oral; Alopecia; Attention Deficit Disorder with Hyperactivity; Central Nervous Syste | 2017 |
Integrative genomic analysis of methylphenidate response in attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2018 |
Chronic Methylphenidate Alters Tonic and Phasic Glutamate Signaling in the Frontal Cortex of a Freely-Moving Rat Model of ADHD.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Disease M | 2019 |
Decreased resting gamma activity in adult attention deficit/hyperactivity disorder.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Brain; Case-Control Studies; Elect | 2019 |
Attention deficit hyperactivity disorder pharmacotherapy in Slovenian adults: a population-based study.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disord | 2018 |
Comment: Has the relationship between ADHD medications and seizures been settled?
Topics: Attention Deficit Disorder with Hyperactivity; Cognition; Double-Blind Method; Epilepsy; Humans; Met | 2018 |
Methylphenidate selectively modulates one sub-component of the no-go P3 in pediatric ADHD medication responders.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2018 |
Infant Exposure to Methylphenidate and Duloxetine During Lactation.
Topics: Adult; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Breast Feeding; Depress | 2018 |
Risk of suicide attempts in adolescents and young adults with attention-deficit hyperactivity disorder: a nationwide longitudinal study.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disord | 2018 |
International Consensus Statement on Screening, Diagnosis and Treatment of Substance Use Disorder Patients with Comorbid Attention Deficit/Hyperactivity Disorder.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Comorbidity | 2018 |
Patterns and profiles of methylphenidate use both in children and adults.
Topics: Adolescent; Adult; Age Factors; Attention Deficit Disorder with Hyperactivity; Central Nervous Syste | 2018 |
[All you need to know about methylphenidate (and dared not ask)].
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2018 |
Perinatal Outcomes of Women Diagnosed with Attention-Deficit/Hyperactivity Disorder: An Australian Population-Based Cohort Study.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Australia; Central Nervous System | 2018 |
Semi-Automated Biomarker Discovery from Pharmacodynamic Effects on EEG in ADHD Rodent Models.
Topics: Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Biomarkers; Disea | 2018 |
Optimization of Methylphenidate Extended-Release Chewable Tablet Dose in Children with ADHD: Open-Label Dose Optimization in a Laboratory Classroom Study.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Delayed-Act | 2018 |
Amphetamine, but not methylphenidate, increases ethanol intake in adolescent male, but not in female, rats.
Topics: Alcohol Drinking; Amphetamine; Animals; Attention Deficit Disorder with Hyperactivity; Central Nervo | 2018 |
Genetic imaging study with [Tc-
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Brain; Brain Mapping; Central Nervous Sys | 2018 |
Relative Bioavailability of Methylphenidate Extended-release Chewable Tablets Chewed Versus Swallowed Whole.
Topics: Administration, Oral; Adult; Area Under Curve; Attention Deficit Disorder with Hyperactivity; Biolog | 2018 |
Improvements in Irritability with Open-Label Methylphenidate Treatment in Youth with Comorbid Attention Deficit/Hyperactivity Disorder and Disruptive Mood Dysregulation Disorder.
Topics: Adolescent; Affective Symptoms; Attention Deficit and Disruptive Behavior Disorders; Attention Defic | 2018 |
Psychostimulants: Influence on Body Mass Index and Height in a Pediatric Population with Attention-Deficit/Hyperactivity Disorder?
Topics: Attention Deficit Disorder with Hyperactivity; Body Height; Body Mass Index; Central Nervous System | 2018 |
Pediatric ADHD Medication Exposures Reported to US Poison Control Centers.
Topics: Adolescent; Age Distribution; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder wit | 2018 |
Prevalence, incidence and persistence of ADHD drug use in Japan.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with | 2019 |
The Effect of Previous Methylphenidate Use on Incidence of Stress Fractures in Military Recruits: A Retrospective Cohort.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Female | 2018 |
[Health-related quality of life in cases of attention deficit hyperactivity disorder with and without pharmacological treatment].
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Central Nervous Sys | 2019 |
Effects of Interaction Between DRD4 Methylation and Prenatal Maternal Stress on Methylphenidate-Induced Changes in Continuous Performance Test Performance in Youth with Attention-Deficit/Hyperactivity Disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Female; Gen | 2018 |
Successful Add-on Vortioxetine for an Adolescent With Attention-Deficit/Hyperactivity Disorder.
Topics: Adolescent; Anti-Anxiety Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous Syst | 2018 |
Resolution of Anxiety Symptoms in Response to Stimulants in a Patient With Attention-Deficit/Hyperactivity Disorder and Generalized Anxiety Disorder.
Topics: Adult; Amphetamine; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2018 |
Long-Term Tolerability and Safety of Pharmacological Treatment of Adult Attention-Deficit/Hyperactivity Disorder: A 6-Year Prospective Naturalistic Study.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Female; Hum | 2018 |
Rapid quantitative analysis of methylphenidate and ritalinic acid in oral fluid by liquid chromatography triple quadrupole mass spectrometry (LC-QqQ-MS).
Topics: Attention Deficit Disorder with Hyperactivity; Child, Preschool; Chromatography, Liquid; Drug Stabil | 2018 |
[In process].
Topics: Arrhythmias, Cardiac; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulan | 2017 |
What stops practitioners discussing medication breaks in children and adolescents with ADHD? Identifying barriers through theory-driven qualitative research.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2018 |
The Jury Is Still Out on the Benefits and Harms of Methylphenidate for Children and Adolescents With Attention-Deficit/Hyperactivity Disorder.
Topics: Adolescent; Adolescent Behavior; Adolescent Development; Age Factors; Attention Deficit Disorder wit | 2018 |
Neurocognitive assessment of children with neurodevelopmental disorders: Preliminary findings.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cognition; | 2018 |
Attention deficit hyperactivity disorder in genetically-determined intellectual disability.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Follow-Up S | 2019 |
Relationship Between Symptomatic and Functional Improvement and Remission in a Treatment Response to Stimulant Trial.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2018 |
How to Dose Attention-Deficit/Hyperactivity Disorder Medications Without a Grain of Salt.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Female; Hum | 2018 |
Relationship Between Aggravation of Seizures and Methylphenidate Treatment in Subjects with Attention-Deficit/Hyperactivity Disorder and Epilepsy.
Topics: Adolescent; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Central Nervous System S | 2018 |
[Supervised off-label prescribing of methylphenidate in adult ADHD].
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Drug Prescr | 2019 |
Physician Training and Qualification to Educate Patients on Attention-Deficit/Hyperactivity Disorder Stimulant Diversion and Misuse.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2018 |
Delay Aversion and Executive Functioning in Adults With Attention-Deficit/Hyperactivity Disorder: Before and After Stimulant Treatment.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cognition; | 2018 |
Lower risk of fractures under methylphenidate treatment for ADHD: A dose-response effect.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2018 |
Overexpression of the Thyroid Hormone-Responsive (THRSP) Gene in the Striatum Leads to the Development of Inattentive-like Phenotype in Mice.
Topics: Animals; Attention; Attention Deficit Disorder with Hyperactivity; Corpus Striatum; Dopamine; Dopami | 2018 |
Weekday-only chronic oral methylphenidate self-administration in male rats: Reversibility of the behavioral and physiological effects.
Topics: Administration, Oral; Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Cent | 2019 |
Reward-enhancing effect of methylphenidate is abolished in dopamine transporter knockout mice: A model of attention-deficit/hyperactivity disorder.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Dopamine | 2018 |
[Children's and adolescents' perception of their quality of life in cases of attention deficit hyperactivity disorder with and without pharmacological treatment and in controls].
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Attitude to Health; Case-Control Studies; | 2018 |
Childhood narcolepsy and autism spectrum disorders: four case reports.
Topics: Age of Onset; Antidepressive Agents; Anxiety Disorders; Asperger Syndrome; Attention Deficit Disorde | 2018 |
Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Asia; Atomoxetine Hydrochloride; Attention Deficit | 2018 |
Effects of dual tasking and methylphenidate on gait in children with attention deficit hyperactivity disorder.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Central | 2018 |
Lower risk of stress fractures in young adults with ADHD under chronic treatment with methylphenidate.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Female; Fractures, Stress; Humans; Male; | 2019 |
Methylphenidate use in males with Duchenne muscular dystrophy and a comorbid attention-deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cognition; | 2019 |
Effects of long-term methylphenidate use on growth and blood pressure: results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS).
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Body Height; Body Mass In | 2018 |
The Decrease in Human Endogenous Retrovirus-H Activity Runs in Parallel with Improvement in ADHD Symptoms in Patients Undergoing Methylphenidate Therapy.
Topics: Attention Deficit Disorder with Hyperactivity; Endogenous Retroviruses; Humans; Methylphenidate | 2018 |
[ADHD and Ritalin: neuronarratives in a virtual community of Facebook Social Network].
Topics: Adolescent; Anxiety; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulant | 2018 |
Associations between Attention-Deficit Hyperactivity Disorder (ADHD) Treatment and Patient Nutritional Status and Height.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Body Height; Body Mass Index; Brazil; Cen | 2018 |
A comparative study on the neurophysiological mechanisms underlying effects of methylphenidate and neurofeedback on inhibitory control in attention deficit hyperactivity disorder.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2018 |
QuilliChew extended-release chewable tablets for the treatment of ADHD in patients ages 6 years old and above.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2018 |
[Biological Mechanisms of ADHD].
Topics: Attention Deficit Disorder with Hyperactivity; Basal Ganglia; Brain; Dopamine Plasma Membrane Transp | 2018 |
Methylphenidate promotes the interaction between motor cortex facilitation and attention in healthy adults: A combined study using event-related potentials and transcranial magnetic stimulation.
Topics: Adolescent; Adult; Analysis of Variance; Attention; Attention Deficit Disorder with Hyperactivity; C | 2018 |
Long-term challenge of methylphenidate changes the neuronal population and membrane property of dopaminergic neuron in rats.
Topics: Action Potentials; Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System St | 2019 |
Treatment of Comorbid Adult Attention-deficit/Hyperactivity Disorder and Generalized Anxiety Disorder: 2 Case Reports.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2018 |
Production Effect in Adults With ADHD With and Without Methylphenidate (MPH): Vocalization Improves Verbal Learning.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Female; Hum | 2019 |
Methylphenidate-induced "Moving Ear Syndrome" in a child with ADHD responding favorably to add-on propranolol.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Dyskinesia, | 2019 |
Tardive Oculogyric Crisis With Low-Dose Antipsychotic in an Adolescent: A Case Report.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2018 |
Methylphenidate Alters Functional Connectivity of Default Mode Network in Drug-Naive Male Adults With ADHD.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Brain; Brain Mapping; Gyrus Cinguli; Humans; M | 2020 |
Updated 2018 NICE guideline on pharmacological treatments for people with ADHD: a critical look.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2019 |
Methylphenidate-Induced Nocturnal Bruxism Alleviated by Adjunctive Clonidine.
Topics: Analgesics; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2019 |
Exfoliative Skin Reactions with Methylphenidate and Desensitization Procedures in Two Cases.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Pres | 2019 |
High pretreatment cognitive impulsivity predicts response of oppositional symptoms to methylphenidate in patients with attention-deficit hyperactivity disorder/oppositional defiant disorder.
Topics: Adolescent; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyp | 2019 |
Effect of ADHD medication in male C57BL/6J mice performing the rodent Continuous Performance Test.
Topics: Amphetamine; Animals; Atomoxetine Hydrochloride; Attention; Attention Deficit Disorder with Hyperact | 2019 |
A General Framework for Assessing In vitro/In vivo Correlation as a Tool for Maximizing the Benefit-Risk Ratio of a Treatment Using a Convolution-Based Modeling Approach.
Topics: Algorithms; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cross- | 2019 |
Incidence and risk of attention-deficit hyperactivity disorder in children with amblyopia: A nationwide cohort study.
Topics: Adrenergic Uptake Inhibitors; Amblyopia; Atomoxetine Hydrochloride; Attention Deficit Disorder with | 2019 |
Differential effects of ADHD medications on impulsive action in the mouse 5-choice serial reaction time task.
Topics: Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Attention; Attention Deficit Disor | 2019 |
Subjective and objective assessments of sleep problems in children with attention deficit/hyperactivity disorder and the effects of methylphenidate treatment.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Behavior; Child; Child, Preschool; Female | 2018 |
A Quantitative Comparison Approach for Methylphenidate Drug Regimens in Attention-Deficit/Hyperactivity Disorder Treatment.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Delayed-Act | 2019 |
[ADHD across the lifespan - The need for guidelines for assessment and treatment of neurodevelopmental disorders in an aging population].
Topics: Aged; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Male | 2019 |
Developmental nicotine exposure precipitates multigenerational maternal transmission of nicotine preference and ADHD-like behavioral, rhythmometric, neuropharmacological, and epigenetic anomalies in adolescent mice.
Topics: Adolescent; Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Corpus Striatu | 2019 |
Individual Variability in Reaction Time and Prediction of Clinical Response to Methylphenidate in Adult ADHD: A Prospective Open Label Study Using Conners' Continuous Performance Test II.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cognition; | 2021 |
Methylphenidate administration reverts attentional inflexibility in adolescent rats submitted to a model of neonatal hypoxia-ischemia: Predictive validity for ADHD study.
Topics: Animals; Animals, Newborn; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous | 2019 |
[Treatment of attention-deficit/hyperactivity disorder in clinical practice. A retrospective study].
Topics: Adolescent; Adrenergic Uptake Inhibitors; Age Distribution; Atomoxetine Hydrochloride; Attention Def | 2019 |
Methylphenidate associated vitiligo in a child: A case report.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Mal | 2019 |
Beta band oscillatory deficits during working memory encoding in adolescents with attention-deficit hyperactive disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Beta Rhythm; Brain; Central Nervous Syste | 2019 |
Methylphenidate effects on processing speed in a clinical sample of adults with ADHD and substance use disorder: a pilot study.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2019 |
Psychosis with Methylphenidate or Amphetamine in Patients with ADHD.
Topics: Adolescent; Adult; Amphetamine; Attention Deficit Disorder with Hyperactivity; Central Nervous Syste | 2019 |
Psychosis during Attention Deficit-Hyperactivity Disorder Treatment with Stimulants.
Topics: Amphetamine; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Human | 2019 |
Electroencephalography Functional Networks Reveal Global Effects of Methylphenidate in Youth with Attention Deficit/Hyperactivity Disorder.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Brain; Child; Electroencephalo | 2019 |
From the Editor-in-Chief's Desk.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Methylphen | 2019 |
Corneal Edema Associated With Systemic Dopaminergic Agents.
Topics: Adult; Aged; Attention Deficit Disorder with Hyperactivity; Corneal Edema; Diterpenes; Dopamine; Dop | 2019 |
Examining the heterogeneity of treatment patterns in attention deficit hyperactivity disorder among children and adolescents in the Texas Medicaid population: modeling suboptimal treatment response.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2019 |
Normalization of increased retinal background noise after ADHD treatment: A neuronal correlate.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Electroreti | 2020 |
Drug Prescriptions for Children With ADHD in Japan: A Study Based on Health Insurance Claims Data Between 2005 and 2015.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2020 |
The Modulation of Neural Noise Underlies the Effectiveness of Methylphenidate Treatment in Attention-Deficit/Hyperactivity Disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cerebral Cortex; C | 2019 |
Non-Medical Use of Prescription Stimulants for Treatment of Attention Disorders by University Students: Characteristics and Associations.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cognition D | 2019 |
A Maximum Dose for Methylphenidate-How Much Is Too Much?
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Dose-Response Rela | 2019 |
Effects of methylphenidate on the ERP amplitude in youth with ADHD: A double-blind placebo-controlled cross-over EEG study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2019 |
Methylphenidate Treatment Initiated During Childhood Is Continued in Adulthood in Half of the Study Population.
Topics: Adolescent; Age Factors; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimu | 2019 |
Methylphenidate and the risk of psychosis in adolescents and young adults: a population-based cohort study.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Cohort Studies; Female; Humans; In | 2019 |
ADHD medication treatment and risk of psychosis.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cohort | 2019 |
Methylphenidate increases willingness to perform effort in adults with ADHD.
Topics: Adult; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2019 |
Glutaminergic signaling in the caudate nucleus is required for behavioral sensitization to methylphenidate.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Caudate Nucleus; Central N | 2019 |
Debate: Are Stimulant Medications for Attention-Deficit/Hyperactivity Disorder Effective in the Long Term?
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2019 |
Bereitschaftspotential and lateralized readiness potential in children with attention deficit hyperactivity disorder: altered motor system activation and effects of methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; Child; Cont | 2019 |
Predictive Value of Slow and Fast EEG Oscillations for Methylphenidate Response in ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Beta Rhythm; Brain; Child; Cognition; Electroencephal | 2019 |
Consumption of methylphenidate and atomoxetine in the private healthcare sector in South Africa: a longitudinal study.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2019 |
Basic processes as foundations of cognitive impairment in adult ADHD.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cognitive D | 2019 |
Ventricular arrhythmias in children with attention deficit disorder--a symptom of autonomic imbalance?
Topics: Accelerated Idioventricular Rhythm; Adolescent; Attention Deficit Disorder with Hyperactivity; Auton | 2014 |
Methylphenidate Reduces State Anxiety During a Continuous Performance Test That Distinguishes Adult ADHD Patients From Controls.
Topics: Adult; Analysis of Variance; Anxiety; Anxiety Disorders; Attention; Attention Deficit Disorder with | 2017 |
Four-year outcome in psychopharmacologically treated adults with attention-deficit/hyperactivity disorder: a questionnaire survey.
Topics: Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2013 |
ADHD is undertreated in Brazil.
Topics: Attention Deficit Disorder with Hyperactivity; Brazil; Central Nervous System Stimulants; Humans; Me | 2012 |
Management of adult attention deficit hyperactivity disorder in UK primary care: a survey of general practitioners.
Topics: Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2013 |
Management of ADHD in children across Europe: patient demographics, physician characteristics and treatment patterns.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System | 2013 |
What influences clinicians' decisions about ADHD medication? Initial data from the Influences on Prescribing for ADHD Questionnaire (IPAQ).
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Decision Ma | 2013 |
Actigraphic evaluation for patients with attention deficit/hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Dopamine Uptake Inhibitors; Female; Humans; Male; Met | 2013 |
Neurotrophin 3 genotype and emotional adverse effects of osmotic-release oral system methylphenidate (OROS-MPH) in children with attention-deficit/hyperactivity disorder.
Topics: Asian People; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Chil | 2014 |
Emotion recognition in children and adolescents with attention-deficit/hyperactivity disorder (ADHD).
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Central Nervous Sys | 2013 |
Response to the letter "Actigraphic evaluation for patients with attention deficit/hyperactivity disorder".
Topics: Attention Deficit Disorder with Hyperactivity; Dopamine Uptake Inhibitors; Female; Humans; Male; Met | 2013 |
Surveillance of diversion and nonmedical use of extended-release prescription amphetamine and oral methylphenidate in the United States.
Topics: Adolescent; Adult; Amphetamine; Amphetamine-Related Disorders; Attention Deficit Disorder with Hyper | 2013 |
Good news: methylphenidate for ADHD in epilepsy.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Epilepsy; Female; | 2013 |
More attention to ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Dopamine Up | 2013 |
Caregiver survey of pharmacotherapy to treat attention deficit/hyperactivity disorder in individuals with Williams syndrome.
Topics: Adolescent; Amphetamines; Aortic Stenosis, Subvalvular; Attention Deficit Disorder with Hyperactivit | 2013 |
Potential trends in Attention Deficit Hyperactivity Disorder (ADHD) drug use on a college campus: wastewater analysis of amphetamine and ritalinic acid.
Topics: Adolescent; Adult; Amphetamines; Attention Deficit Disorder with Hyperactivity; Central Nervous Syst | 2013 |
An inventory of European data sources for the long-term safety evaluation of methylphenidate.
Topics: Adolescent; Adverse Drug Reaction Reporting Systems; Attention Deficit Disorder with Hyperactivity; | 2013 |
Neurocognitive effects of methylphenidate on ADHD children with different DAT genotypes: a longitudinal open label trial.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2013 |
Acute Effects of MPH on the Parent-Teen Interactions of Adolescents With ADHD.
Topics: Adolescent; Affect; Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Central Ner | 2017 |
Methylphenidate and atomoxetine for treatment of nocturnal enuresis in a child with attention-deficit hyperactivity disorder.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2013 |
Processing of continuously provided punishment and reward in children with ADHD and the modulating effects of stimulant medication: an ERP study.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Central Nervous Syst | 2013 |
The association between medication for attention-deficit/hyperactivity disorder and cancer.
Topics: Adolescent; Amphetamines; Antidepressive Agents; Antipsychotic Agents; Attention Deficit Disorder wi | 2013 |
Influence of methylphenidate on motor performance and attention in children with developmental coordination disorder and attention deficit hyperactive disorder.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2013 |
Descriptive comparison of drug treatment-persistent, -nonpersistent, and nondrug treatment patients with newly diagnosed attention deficit/hyperactivity disorder in Germany.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2013 |
The role of Homer 1a in increasing locomotor activity and non-selective attention, and impairing learning and memory abilities.
Topics: Animals; Attention; Attention Deficit Disorder with Hyperactivity; Carrier Proteins; Genetic Vectors | 2013 |
Adolescence methylphenidate treatment in a rodent model of attention deficit/hyperactivity disorder: dopamine transporter function and cellular distribution in adulthood.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Disease M | 2013 |
Methylphenidate vs atomoxetine: personalized medicine in attention- deficit/hyperactivity disorder.
Topics: Adrenergic Uptake Inhibitors; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous | 2013 |
Methylphenidate improves some but not all measures of attention, as measured by the TEA-Ch in medication-naïve children with ADHD.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Central | 2014 |
Assessment of cognitive domains during treatment with OROS methylphenidate in adolescents with ADHD.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimula | 2014 |
Motor regulation problems and pain in adults diagnosed with ADHD.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Data Interp | 2013 |
[Influential factors for methylphenidate treatment compliance in children with attention deficit hyperactivity disorder].
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2013 |
Commentary: Filling out the evidence base for treatment of attention-deficit hyperactivity disorder symptoms in children with intellectual and developmental disability: conclusions for clinicians--a response to Simonoff et al. (2013).
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Female; Humans; In | 2013 |
Commentary: RCT of optimal dose methylphenidate in children and adolescents with severe ADHD and ID--a reply to Arnold (2013).
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Female; Humans; In | 2013 |
Long-term stimulant treatment affects brain dopamine transporter level in patients with attention deficit hyperactive disorder.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Caudate Nucleus; Central | 2013 |
Attention-deficit/hyperactivity disorder, physical health, and lifestyle in older adults.
Topics: Aged; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; D | 2013 |
Epilepsy in a large cohort of children diagnosed with attention deficit/hyperactivity disorders (ADHD).
Topics: Adolescent; Age of Onset; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Central Ne | 2013 |
The impact of methylphenidate on seizure frequency and severity in children with attention-deficit-hyperactivity disorder and difficult-to-treat epilepsies.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Epilepsy; Female; | 2013 |
Low dopamine transporter occupancy by methylphenidate as a possible reason for reduced treatment effectiveness in ADHD patients with cocaine dependence.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stim | 2013 |
Methylphenidate and venlafaxine attenuate locomotion in spontaneously hypertensive rats, an animal model of attention-deficit/hyperactivity disorder, through α2-adrenoceptor activation.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antidepressive Agents, Second-Generation; Attentio | 2013 |
Stimulants improve theory of mind in children with attention deficit/hyperactivity disorder.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2014 |
A non-interventional study of extended-release methylphenidate in the routine treatment of adolescents with ADHD: effectiveness, safety and adherence to treatment.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Delayed-Action Preparations; Human | 2013 |
[ADHD register: post-marketing evaluation of the benefit-risk profile of drugs and promotion of the appropriateness].
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with | 2013 |
[Not Available].
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Female; Humans; Male; Methylphenida | 2013 |
Methylphenidate and continuous spike and wave during sleep in a child with attention deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Female; Hum | 2013 |
[Dietary patterns in patients with attention deficit hyperactivity disorder].
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Delayed-Act | 2014 |
Effects of stimulants and atomoxetine on cortisol levels in children with ADHD.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with | 2013 |
Positive effects of methylphenidate on hyperactivity are moderated by monoaminergic gene variants in children with autism spectrum disorders.
Topics: Attention Deficit Disorder with Hyperactivity; Biogenic Monoamines; Central Nervous System Stimulant | 2014 |
Barriers to seeking help among children with attention deficit hyperactivity disorder in Taiwan.
Topics: Age Factors; Attention Deficit Disorder with Hyperactivity; Caregivers; Central Nervous System Stimu | 2014 |
Nonmedical use of prescription ADHD stimulant medications among adults in a substance abuse treatment population: early findings from the NAVIPPRO surveillance system.
Topics: Adolescent; Adult; Amphetamine-Related Disorders; Attention Deficit Disorder with Hyperactivity; Cen | 2015 |
Santos et al. reply.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Epilepsy; Female; | 2013 |
Changes in plasma Brain-derived neurotrophic factor (BDNF) levels induced by methylphenidate in children with Attention deficit-hyperactivity disorder (ADHD).
Topics: Attention Deficit Disorder with Hyperactivity; Brain-Derived Neurotrophic Factor; Central Nervous Sy | 2013 |
Lobeline Effects on Cognitive Performance in Adult ADHD.
Topics: Adult; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2018 |
Parents' Perspectives About Factors Influencing Adherence to Pharmacotherapy for ADHD.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Attitude to Health; Central Nervous System Sti | 2017 |
Methylphenidate reduces ADHD symptoms in children with severe ADHD and intellectual disability.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Female; Humans; In | 2013 |
Response to Damkier.
Topics: Attention Deficit Disorder with Hyperactivity; Female; Humans; Methylphenidate; Pregnancy | 2014 |
Methylphenidate and pregnancy.
Topics: Attention Deficit Disorder with Hyperactivity; Female; Humans; Methylphenidate; Pregnancy | 2014 |
An observational study of response heterogeneity in children with attention deficit hyperactivity disorder following treatment switch to modified-release methylphenidate.
Topics: Adolescent; Age Factors; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimu | 2013 |
Five-fold increase in national prevalence rates of attention-deficit/hyperactivity disorder medications for children and adolescents with autism spectrum disorder, attention-deficit/hyperactivity disorder, and other psychiatric disorders: a Danish registe
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2013 |
Attention-deficit/hyperactivity disorder drugs and growth: an Italian prospective observational study.
Topics: Adolescent; Adolescent Development; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attenti | 2013 |
White-matter connectivity and methylphenidate-induced changes in attentional performance according to α2A-adrenergic receptor gene polymorphisms in Korean children with attention-deficit hyperactivity disorder.
Topics: Adolescent; Anisotropy; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimul | 2013 |
No association between catechol-O-methyltransferase (COMT) genotype and attention deficit hyperactivity disorder (ADHD) in Japanese children.
Topics: Adolescent; Asian People; Attention Deficit Disorder with Hyperactivity; Catechol O-Methyltransferas | 2014 |
Daily Symptom Profiles of Children With ADHD Treated With Modified-Release Methylphenidate.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2017 |
Switching from immediate release to sustained release methylphenidate in the treatment of children and adolescents with attention deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2013 |
Toward systems neuroscience of shared and distinct neural effects of medications used to treat attention-deficit/hyperactivity disorder.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Brain; Humans; Male; Methy | 2013 |
ADHD, stimulant treatment in childhood and subsequent substance abuse in adulthood - a naturalistic long-term follow-up study.
Topics: Adolescent; Adult; Age Factors; Alcoholism; Attention Deficit Disorder with Hyperactivity; Central N | 2014 |
The possible effect of methylphenidate on kleptomania in a school-age girl with attention-deficit/hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Disruptive, | 2014 |
Prescribing methylphenidate for moderate ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Drug Prescriptions | 2013 |
More and better should be done to guarantee evidence-based management of ADHD in children across Europe.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Female; Humans; Ma | 2014 |
Effect of OROS methylphenidate on encopresis in children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyp | 2014 |
Author's reply to Timimi.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Drug Prescriptions | 2013 |
Over-prescribing methylphenidate won't be cured by autism-style assessments.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Drug Prescriptions | 2013 |
Reply to L. Reale et al. "More and better should be done to guarantee evidence-based management of ADHD in children across Europe".
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Female; Humans; Ma | 2014 |
Effectiveness of methylphenidate in the treatment of encopresis whether or not attention-deficit/hyperactivity disorder symptoms are present.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Encopresis; | 2013 |
Abuse of methylphenidate in Germany: data from spontaneous reports of adverse drug reactions.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Amphetamine-Related Disorders; Attention | 2014 |
Long-term effects of stimulants on neurocognitive performance of Taiwanese children with attention-deficit/hyperactivity disorder.
Topics: Asian People; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimu | 2013 |
[Cardiovascular risks and management during Attention Deficit Hyperactivity Disorder treatment with methylphenidate].
Topics: Attention Deficit Disorder with Hyperactivity; Blood Pressure; Central Nervous System Stimulants; Ch | 2014 |
Substance use disorders in association with attention-deficit/hyperactivity disorder, co-morbid mental disorders, and medication in a nationwide sample.
Topics: Adolescent; Adult; Antidepressive Agents; Antipsychotic Agents; Attention Deficit Disorder with Hype | 2014 |
Attention-deficit hyperactivity disorder (ADHD) as a pyridoxine-dependent condition: urinary diagnostic biomarkers.
Topics: Attention Deficit Disorder with Hyperactivity; Biomarkers; Chromatography, High Pressure Liquid; Hum | 2014 |
Long-term effects of ADHD medication on adult height: results from the NESARC.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Body Height; Central Nervous Syste | 2013 |
Not just another antipsychotic-for-conduct-problems trial.
Topics: Aggression; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2014 |
Effects of switching to once-daily modified-release methylphenidate from previous treatment with other psychostimulants in children and adolescents with ADHD: an observational study with clinician, parent, and teacher evaluations.
Topics: Adolescent; Adolescent Behavior; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervo | 2014 |
From the editor-in-chief's desk.
Topics: Attention Deficit Disorder with Hyperactivity; Humans; Methylphenidate | 2013 |
Methylphenidate side effect profile is influenced by genetic variation in the attention-deficit/hyperactivity disorder-associated CES1 gene.
Topics: Adolescent; Appetite; Attention Deficit Disorder with Hyperactivity; Carboxylic Ester Hydrolases; Ce | 2013 |
Autonomic hypoactivity in boys with attention-deficit/hyperactivity disorder and the influence of methylphenidate.
Topics: Adolescent; Arousal; Attention Deficit Disorder with Hyperactivity; Autonomic Nervous System; Centra | 2014 |
Parental quality of life and depressive mood following methylphenidate treatment of children with attention-deficit hyperactivity disorder.
Topics: Adolescent; Adult; Affect; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2014 |
Effects of Methylphenidate on Default-Mode Network/Task-Positive Network Synchronization in Children With ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Brain; Case-Control Studies; Child; Female; Humans; M | 2017 |
A dose-ranging study of behavioral and pharmacological treatment in social settings for children with ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; | 2014 |
Methylphenidate treatment in children with attention deficit hyperactivity disorder and comorbid social phobia.
Topics: Adolescent; Adolescent Behavior; Attention Deficit Disorder with Hyperactivity; Central Nervous Syst | 2014 |
Determination of amphetamine and methylphenidate in exhaled breath of patients undergoing attention-deficit/hyperactivity disorder treatment.
Topics: Adult; Amphetamine; Attention Deficit Disorder with Hyperactivity; Chromatography, Liquid; Exhalatio | 2014 |
Psychiatric Comorbidity at the Time of Diagnosis in Adults With ADHD: The CAT Study.
Topics: Adult; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Comorbidity; Cross-Sectiona | 2016 |
Prognostic factors that increase the risk for reduced white matter volumes and deficits in attention and learning for survivors of childhood cancers.
Topics: Age Factors; Antineoplastic Agents; Attention; Attention Deficit Disorder with Hyperactivity; Brain; | 2014 |
Medication: the smart-pill oversell.
Topics: Achievement; Antisocial Personality Disorder; Attention; Attention Deficit Disorder with Hyperactivi | 2014 |
Commentary on Konstenius et al. (2014): on medication development for stimulant addiction.
Topics: Amphetamine-Related Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System | 2014 |
Transgenerational transmission of hyperactivity in a mouse model of ADHD.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Disease M | 2014 |
ADHD Medication Trends in Turkey: 2009-2013.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivi | 2017 |
Aberrant CaMKII activity in the medial prefrontal cortex is associated with cognitive dysfunction in ADHD model rats.
Topics: Animals; Attention; Attention Deficit Disorder with Hyperactivity; CA1 Region, Hippocampal; Calcium- | 2014 |
[Effect of parent training in combination with methylphenidate treatment on family relationships for children with attention deficit/hyperactivity disorder].
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2014 |
Severity but not comorbidities predicts response to methylphenidate in adults with attention-deficit/hyperactivity disorder: results from a naturalistic study.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Comorbidity | 2014 |
The effect of methylphenidate on very low frequency electroencephalography oscillations in adult ADHD.
Topics: Adolescent; Adult; Aged; Attention; Attention Deficit Disorder with Hyperactivity; Brain; Case-Contr | 2014 |
Differential responses of two related neurosteroids to methylphenidate based on ADHD subtype and the presence of depressive symptomatology.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Biomarkers; Central Nervous Sy | 2014 |
[Drug therapy for AD/HD investigation of usefulness of extended-release methylphenidate and atomoxetine from the viewpoint of persistency rate].
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child D | 2014 |
Impact of executive functions on school and peer functions in youths with ADHD.
Topics: Adolescent; Age Factors; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Centra | 2014 |
Impact of executive functions on school and peer functions in youths with ADHD.
Topics: Adolescent; Age Factors; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Centra | 2014 |
Impact of executive functions on school and peer functions in youths with ADHD.
Topics: Adolescent; Age Factors; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Centra | 2014 |
Impact of executive functions on school and peer functions in youths with ADHD.
Topics: Adolescent; Age Factors; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Centra | 2014 |
Dopamine transporter occupancy by methylphenidate and impulsivity in adult ADHD.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Dopamine Plasma Membrane Transport Proteins; D | 2014 |
Prefrontal grey and white matter neurometabolite changes after atomoxetine and methylphenidate in children with attention deficit/hyperactivity disorder: a (1)H magnetic resonance spectroscopy study.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Aspartic Acid; Atomoxetine Hydrochloride; Attention; Atten | 2014 |
A nationwide study of attention-deficit/hyperactivity disorder drug use among adults in Iceland 2003-2012.
Topics: Adult; Age Factors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Centra | 2014 |
Effect of visual attention on postural control in children with attention-deficit/hyperactivity disorder.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Central Nervous Syst | 2014 |
[Priapism - side effect of methylphenidate].
Topics: Adverse Drug Reaction Reporting Systems; Attention Deficit Disorder with Hyperactivity; Central Nerv | 2014 |
Predictors of pharmacological treatment outcomes with atomoxetine or methylphenidate in patients with attention-deficit/hyperactivity disorder from China, Egypt, Lebanon, Russian Federation, Taiwan, and United Arab Emirates.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; China; Egypt; | 2014 |
[ADHD: Methylphenidate for epileptics?].
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Epilepsy; Female; | 2013 |
Managing ADHD and disruptive behaviour disorders with combination psychostimulant and antipsychotic treatment.
Topics: Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Attention Def | 2014 |
Attention-Deficit/Hyperactivity Disorder-like Phenotype in a Mouse Model with Impaired Actin Dynamics.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cofilin 1 | 2015 |
Methylphenidate-risperidone combination in child psychiatry: A retrospective analysis of 44 cases.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Child Psychiatry; Conduct Disorder | 2014 |
Cocaine-seeking behavior in a genetic model of attention-deficit/hyperactivity disorder following adolescent methylphenidate or atomoxetine treatments.
Topics: Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous S | 2014 |
Children's relative age in class and use of medication for ADHD: a Danish Nationwide Study.
Topics: Age Factors; Attention Deficit Disorder with Hyperactivity; Child; Denmark; Female; Humans; Male; Me | 2014 |
The metabotropic glutamate receptor subtype 7 rs3792452 polymorphism is associated with the response to methylphenidate in children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Asian People; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Centr | 2014 |
Altered strategy in short-term memory for pictures in children with attention-deficit/hyperactivity disorder: a near-infrared spectroscopy study.
Topics: Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Central Nervous System Stimulan | 2014 |
Genetic and pharmacological modulation of the steroid sulfatase axis improves response control; comparison with drugs used in ADHD.
Topics: Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hy | 2014 |
The impact of discontinuing methylphenidate on weight and eating behavior.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Body Mass Index; Central Nervous System S | 2015 |
Methylphenidate treatment causes oxidative stress and alters energetic metabolism in an animal model of attention-deficit hyperactivity disorder.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; Di | 2014 |
ADHD subjects fail to suppress eye blinks and microsaccades while anticipating visual stimuli but recover with medication.
Topics: Adult; Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Blinking; Central Nervou | 2014 |
Efficacy, Safety, and Tolerability of a Novel Methylphenidate Extended-Release Oral Suspension (MEROS) in ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cross-Over | 2017 |
Effect of methylphenidate on neurocognitive test battery: an evaluation according to the diagnostic and statistical manual of mental disorders, fourth edition, subtypes.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2014 |
Pay attention to impulsivity: modelling low attentive and high impulsive subtypes of adult ADHD in the 5-choice continuous performance task (5C-CPT) in female rats.
Topics: Analysis of Variance; Animals; Atomoxetine Hydrochloride; Attention; Attention Deficit Disorder with | 2014 |
Prefrontal cortical and striatal transcriptional responses to the reinforcing effect of repeated methylphenidate treatment in the spontaneously hypertensive rat, animal model of attention-deficit/hyperactivity disorder (ADHD).
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Central Nervous System Sti | 2014 |
Comparing stimulant effects in youth with ADHD symptoms and epilepsy.
Topics: Adolescent; Amphetamine; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimu | 2014 |
Treating enuresis in a patient with ADHD: application of a novel behavioural modification therapy.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; | 2014 |
Reinforcement enhances vigilance among children with ADHD: comparisons to typically developing children and to the effects of methylphenidate.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2015 |
Drug treatment for attention-deficit/hyperactivity disorder and suicidal behaviour: register based study.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Amphetamine; Atomoxetine Hydrochloride; Attention D | 2014 |
A 36 month naturalistic retrospective study of clinic-treated youth with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2014 |
[Prescription of methylphenidate for children: importance of recommendations to limit misuse].
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Dopamine Uptake | 2014 |
[The influence of attention-deficit hyperactivity disorder on quality of life: case reports].
Topics: Adolescent; Adult; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System | 2014 |
Medical treatment of children and youths with attention-deficit/hyperactivity disorder (ADHD): a Norwegian Prescription Registry Based Study.
Topics: Adolescent; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; C | 2014 |
Medication persistence in Turkish children and adolescents with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Age Factors; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimu | 2014 |
Thyrotoropin receptor knockout changes monoaminergic neuronal system and produces methylphenidate-sensitive emotional and cognitive dysfunction.
Topics: Affective Symptoms; Animals; Attention Deficit Disorder with Hyperactivity; Biogenic Monoamines; Cog | 2014 |
Effects of methylphenidate on acute Math performance in children with ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Female; Humans; Ma | 2014 |
Methylphenidate misuse in adult patients and the impact of therapeutic use.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Data Interp | 2015 |
Use of extended-release methylphenidate (concerta) in treatment of cocaine dependence in a patient presenting with attention deficit hyperactivity disorder.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cocaine-Rel | 2014 |
Comparison of pregnancy and lactation labeling for attention-deficit hyperactivity disorder drugs marketed in Australia, the USA, Denmark, and the UK.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Australia; Benzhydryl Comp | 2014 |
Cognitive Testing to Identify Children With ADHD Who Do and Do Not Respond to Methylphenidate.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimula | 2017 |
The effects of stimulant medications for ADHD.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Canada; Central Nervous System Stimulants | 2014 |
Individual and combined effects of physical exercise and methylphenidate on orienting behavior and social interaction in spontaneously hypertensive rats.
Topics: Analysis of Variance; Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System | 2014 |
The spontaneously hypertensive rat/Izm (SHR/Izm) shows attention deficit/hyperactivity disorder-like behaviors but without impulsive behavior: therapeutic implications of low-dose methylphenidate.
Topics: Analysis of Variance; Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System | 2014 |
A preliminary study on methylphenidate-regulated gene expression in lymphoblastoid cells of ADHD patients.
Topics: Adult; Ataxin-1; Attention Deficit Disorder with Hyperactivity; Basic Helix-Loop-Helix Transcription | 2015 |
Individual differences in novelty-seeking behavior in spontaneously hypertensive rats: Enhanced sensitivity to the reinforcing effect of methylphenidate in the high novelty-preferring subpopulation.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Condition | 2015 |
Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: results from a population-based study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2014 |
Academy of Medicine-Ministry of Health clinical practice guidelines: attention deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Caregivers; Child; Evidence-Based Medicine; Humans; M | 2014 |
COMT genotype affects brain white matter pathways in attention-deficit/hyperactivity disorder.
Topics: Anisotropy; Attention Deficit Disorder with Hyperactivity; Brain; Brain Mapping; Catechol O-Methyltr | 2015 |
Early discontinuation of attention-deficit/hyperactivity disorder drug treatment: a Danish nationwide drug utilization study.
Topics: Adolescent; Adult; Age Factors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperacti | 2015 |
[Pharmacological management of attention deficit hyperactivity disorder with methylphenidate and atomoxetine within a context of epilepsy].
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2014 |
Drug Holidays From ADHD Medication: International Experience Over the Past Four Decades.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2015 |
The impact of stimulants on cognition and the brain in attention-deficit/hyperactivity disorder: what does age have to do with it?
Topics: Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; Cognition D | 2014 |
Functional dysconnectivity of corticostriatal circuitry and differential response to methylphenidate in youth with attention-deficit/hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Brain Mapping; Central Nervous System Stimulants; Cer | 2015 |
Nationwide rate of attention-deficit hyperactivity disorder diagnosis and pharmacotherapy in Korea in 2008-2011.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2014 |
Effect of methylphenidate on height and weight in Korean children and adolescents with attention-deficit/hyperactivity disorder: a retrospective chart review.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Body Height; Body Weight; Central Nervous | 2014 |
Impact of a restrictive drug access program on the risk of cardiovascular encounters in children exposed to ADHD medications.
Topics: Adolescent; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; | 2014 |
Treatment receipt and outcomes from a clinic employing the attention-deficit/hyperactivity disorder treatment guideline of the children's medication algorithm project.
Topics: Adolescent; Algorithms; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hype | 2014 |
Effectiveness and safety of a long-acting, once-daily, two-phase release formulation of methylphenidate (Ritalin ® LA) in school children under daily practice conditions.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Delayed-Action Preparations; Dose-Response Rel | 2015 |
The Israel Survey of Mental Health among Adolescents: prevalence of attention-deficit/hyperactivity disorder, comorbidity, methylphenidate use, and help-seeking patterns.
Topics: Adolescent; Adolescent Behavior; Adolescent Development; Arabs; Attention Deficit Disorder with Hype | 2014 |
Prevalence, Patient Characteristics, and Pharmacological Treatment of Children, Adolescents, and Adults Diagnosed With ADHD in Sweden.
Topics: Adolescent; Adult; Age Distribution; Anxiety Disorders; Attention Deficit Disorder with Hyperactivit | 2018 |
Plasma Methylphenidate Levels in Youths With Attention Deficit Hyperactivity Disorder Treated With OROS Formulation.
Topics: Administration, Oral; Adolescent; Aripiprazole; Attention Deficit Disorder with Hyperactivity; Centr | 2015 |
Drug holiday utilisation in ADHD-diagnosed children and adolescents in South Africa.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2014 |
Combined stimulant and antipsychotic treatment in adolescents with attention-deficit/hyperactivity disorder: a cross-sectional observational structural MRI study.
Topics: Administration, Oral; Adolescent; Antipsychotic Agents; Attention; Attention Deficit Disorder with H | 2015 |
Treatment compliance or medication adherence in children and adolescents on ADHD medication in clinical practice: results from the COMPLY observational study.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with | 2015 |
Effects of clonidine and methylphenidate on motor activity in Fmr1 knockout mice.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Attention Deficit Disorder with Hyperactivity; Centra | 2015 |
Normalisation of frontal theta activity following methylphenidate treatment in adult attention-deficit/hyperactivity disorder.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cues; Elect | 2015 |
Attention deficit/hyperactivity disorder and medication with stimulants in young children: a DTI study.
Topics: Anisotropy; Attention Deficit Disorder with Hyperactivity; Brain; Case-Control Studies; Central Nerv | 2015 |
Effectiveness of one-year pharmacological treatment of adult attention-deficit/hyperactivity disorder (ADHD): an open-label prospective study of time in treatment, dose, side-effects and comorbidity.
Topics: Adrenergic Uptake Inhibitors; Adult; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disor | 2014 |
Acoustic noise improves motor learning in spontaneously hypertensive rats, a rat model of attention deficit hyperactivity disorder.
Topics: Acoustic Stimulation; Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System | 2015 |
Variability of kinematic graphomotor fluency in adults with ADHD.
Topics: Adolescent; Adult; Amphetamines; Attention Deficit Disorder with Hyperactivity; Automation; Biomecha | 2014 |
Detection of auto-antibodies to DAT in the serum: interactions with DAT genotype and psycho-stimulant therapy for ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Autoantibodies; Central Nervous System Stimulants; Ch | 2015 |
Methylphenidate and the risk of trauma.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Emergency Service, Hospital; Femal | 2015 |
Quetiapine-induced myocarditis presenting as acute STEMI.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; C | 2015 |
Differences in methylphenidate abuse rates among methadone maintenance treatment patients in two clinics.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Benzodiazepines; Central Nervous System Stimul | 2015 |
Acute focal dystonic reaction after acute methylphenidate treatment in an adolescent patient.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Dyston | 2015 |
Persistence and remission of ADHD during adulthood: a 7-year clinical follow-up study.
Topics: Adolescent; Adult; Aged; Attention Deficit Disorder with Hyperactivity; Brazil; Central Nervous Syst | 2015 |
Addition of methylphenidate to intensive dialectical behaviour therapy for patients suffering from comorbid borderline personality disorder and ADHD: a naturalistic study.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Borderline Personality Disor | 2015 |
Methylphenidate treatment beyond adolescence maintains increased cocaine self-administration in the spontaneously hypertensive rat model of attention deficit/hyperactivity disorder.
Topics: Age Factors; Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulan | 2015 |
Attention deficit/hyperactivity disorder and interictal epileptiform discharges: it is safe to use methylphenidate?
Topics: Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimul | 2015 |
Effect of methylphenidate treatment during adolescence on norepinephrine transporter function in orbitofrontal cortex in a rat model of attention deficit hyperactivity disorder.
Topics: Age Factors; Analysis of Variance; Animals; Attention Deficit Disorder with Hyperactivity; Central N | 2015 |
[Evolution of stress in families of children with attention deficit hyperactivity disorder].
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Family Health; Humans; Methylpheni | 2015 |
Injury prevention by medication among children with attention-deficit/hyperactivity disorder: a case-only study.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with | 2015 |
[Reconsider the diagnosis and treatment approach for ADHD].
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with | 2015 |
Probabilistic Markov Model Estimating Cost Effectiveness of Methylphenidate Osmotic-Release Oral System Versus Immediate-Release Methylphenidate in Children and Adolescents: Which Information is Needed?
Topics: Administration, Oral; Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2015 |
An observational study of pharmacological treatment in primary care of children with ADHD in the United kingdom.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2015 |
Differences in abuse potential of ADHD drugs measured by contrasting poison centre and therapeutic use data.
Topics: Adolescent; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central | 2015 |
The effect of methylphenidate on sustained attention among adolescents with attention-deficit hyperactivity disorder.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimula | 2015 |
Trends in attention-deficit/hyperactivity disorder drug consumption in children and adolescents in Slovenia from 2001 to 2012: a drug use study from a national perspective.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2015 |
Improvement of learning and increase in dopamine level in the frontal cortex by methylphenidate in mice lacking dopamine transporter.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Avoidance Learning; Corpus Striatum; Dopamin | 2015 |
The clinical profile of children with ADHD that require OROS-methylphenidate combined with shorter-acting formulations.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2015 |
Assessment and treatment of attention-deficit/hyperactivity disorder: part 2.
Topics: Adolescent; Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Atte | 2015 |
Immediate-release methylphenidate for the treatment of ADHD in adults.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Methylphen | 2015 |
High Familial Correlation in Methylphenidate Response and Side Effect Profile.
Topics: Adolescent; Adult; Appetite; Attention Deficit Disorder with Hyperactivity; Central Nervous System S | 2019 |
[Children's relative age in class and medication for attention-deficit/hyperactivity disorder. A population-based study in a health department in Spain].
Topics: Age Factors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervo | 2015 |
Effects of long-term methylphenidate treatment in adolescent and adult rats on hippocampal shape, functional connectivity and adult neurogenesis.
Topics: Administration, Oral; Aging; Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous | 2015 |
Methylphenidate mediated change in prosody is specific to the performance of a cognitive task in female adult ADHD patients.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cognition; | 2015 |
[Hyperkinetic disorders in childhood and adolescence- an analysis of KinderAGATE 2009-2012].
Topics: Adolescent; Age Factors; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Centra | 2015 |
Extended-release Methylphenidate Treatment and Outcomes in Comorbid Social Anxiety Disorder and Attention-deficit/Hyperactivity Disorder: 2 Case Reports.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Delayed-Act | 2015 |
Regulatory action and moderate decrease in methylphenidate use among ADHD diagnosed patients aged five and under in Korea.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2015 |
ADHD-associated dopamine transporter, latrophilin and neurofibromin share a dopamine-related locomotor signature in Drosophila.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Disease Models, Animal; Dopamine; Dopamine P | 2016 |
Low-dose Methylphenidate Monotherapy for Features of Attention-Deficit/Hyperactivity Disorder Secondary to Hereditary Cerebellar Ataxia.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cerebe | 2015 |
Methylphenidate facilitates hypnotizability in adults with ADHD: a naturalistic cohort study.
Topics: Adult; Attention; Attention Deficit Disorder with Hyperactivity; Cohort Studies; Combined Modality T | 2015 |
Reinforcement and Stimulant Medication Ameliorate Deficient Response Inhibition in Children with Attention-Deficit/Hyperactivity Disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Delay Disco | 2016 |
LPHN3 and attention-deficit/hyperactivity disorder: a susceptibility and pharmacogenetic study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Central Nervous Sys | 2015 |
[Two times daily to manage daily life].
Topics: Activities of Daily Living; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous Sy | 2015 |
ADHD-like behavior in a patient with hypothalamic hamartoma.
Topics: Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; Child; Hama | 2016 |
Population pharmacokinetics of methylphenidate hydrochloride extended-release multiple-layer beads in pediatric subjects with attention deficit hyperactivity disorder.
Topics: Adolescent; Adult; Age Factors; Attention Deficit Disorder with Hyperactivity; Central Nervous Syste | 2015 |
Neurological adverse effects of methylphenidate may be misdiagnosed as meningoencephalitis.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Diagnostic | 2015 |
Attention Deficit Hyperactivity Disorder and oxidative stress: A short term follow up study.
Topics: Adolescent; Antioxidants; Aryldialkylphosphatase; Attention Deficit Disorder with Hyperactivity; Bio | 2015 |
Visual Hallucinations with Methylphenidate and Acetaminophen in Combination.
Topics: Acetaminophen; Antipyretics; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit | 2015 |
OROS-Methylphenidate-Induced Raynaud's Phenomenon: A Dose-Related Side Effect.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Dose-R | 2015 |
Combined methylphenidate and atomoxetine pharmacotherapy in attention deficit hyperactivity disorder.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2015 |
The effects of methylphenidate on refraction and anterior segment parameters in children with attention deficit hyperactivity disorder.
Topics: Accommodation, Ocular; Adolescent; Anterior Chamber; Attention Deficit Disorder with Hyperactivity; | 2015 |
The Effect of Medical Treatment of Attention Deficit Hyperactivity Disorder (ADHD) on Foster Care Caseloads: Evidence from Danish Registry Data.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Denmark; Fe | 2015 |
Medication for ADHD and accidental injury.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Medication | 2015 |
Effect of drugs on the risk of injuries in children with attention deficit hyperactivity disorder: a prospective cohort study.
Topics: Accidents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous | 2015 |
Changes of Heart Rate Variability during Methylphenidate Treatment in Attention-Deficit Hyperactivity Disorder Children: A 12-Week Prospective Study.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Autonomic Nervous System; Biom | 2015 |
Association of adult attention deficit hyperactivity disorder subtypes and response to methylphenidate HCL treatment: A magnetic resonance spectroscopy study.
Topics: Adolescent; Adult; Aspartic Acid; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2015 |
Anxiety and Depressed Mood Decline Following Smoking Abstinence in Adult Smokers with Attention Deficit Hyperactivity Disorder.
Topics: Adult; Anxiety; Attention Deficit Disorder with Hyperactivity; Combined Modality Therapy; Counseling | 2015 |
Long-Term Treatment Outcome in Adult Male Prisoners With Attention-Deficit/Hyperactivity Disorder: Three-Year Naturalistic Follow-Up of a 52-Week Methylphenidate Trial.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Delayed-Act | 2015 |
Impaired neural reward processing in children and adolescents with reactive attachment disorder: A pilot study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Brain; Child; Child Abuse; Dopamine Uptak | 2015 |
JHSB Policy Brief. Does Medical Treatment of Children's Behavioral Problems Lower Foster Care Rates?
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Denmark; Fo | 2015 |
Effects of methylphenidate on appetite and growth in children diagnosed with attention deficit and hyperactivity disorder.
Topics: Adolescent; Appetite; Attention Deficit Disorder with Hyperactivity; Biomarkers; Body Height; Body W | 2016 |
Psychostimulant prescribing trends in a paediatric population in Ireland: a national cohort study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2015 |
Pharmacological cognitive enhancement: treatment of neuropsychiatric disorders and lifestyle use by healthy people.
Topics: Alzheimer Disease; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Cholinestera | 2015 |
Attention-deficit/hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia spectrum disorders: A nationwide population-based study in Taiwan.
Topics: Adolescent; Age of Onset; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2015 |
The billion dollar business of being smart.
Topics: Amphetamine; Attention Deficit Disorder with Hyperactivity; Caffeine; Central Nervous System Stimula | 2015 |
Cost-utility analysis of methylphenidate treatment for children and adolescents with ADHD in Brazil.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Brazil; Central Nervous System Stimulants | 2016 |
Relationship between soluble intercellular adhesion molecules and attention-deficit/hyperactivity disorder.
Topics: Antigens, CD; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Cell Adhesion Mol | 2015 |
Pilot study of the efficacy of empowering patients through coaching as a complementary therapy in attention deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Combined Mo | 2016 |
Increase in Menstrual Cycle Length Induced by Extended-Release Methylphenidate in an Adolescent with Attention-Deficit/Hyperactivity Disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Delaye | 2016 |
Attenuation of methylphenidate-induced tolerance on cognition by buspirone co-administration.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Avoidance Learning; Buspirone; Central Nervo | 2015 |
Differential therapeutic effects of 12-week treatment of atomoxetine and methylphenidate on drug-naïve children with attention deficit/hyperactivity disorder: A counting Stroop functional MRI study.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Analysis of Variance; Atomoxetine Hydrochloride; Attention | 2015 |
Developing a Risk Score to Guide Individualized Treatment Selection in Attention Deficit/Hyperactivity Disorder.
Topics: Administration, Oral; Adolescent; Adolescent Behavior; Attention Deficit Disorder with Hyperactivity | 2015 |
Attention-deficit hyperactivity disorder, its treatment with medication and the probability of developing a depressive disorder: A nationwide population-based study in Taiwan.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Comorbidity; Depres | 2016 |
Methylphenidate: pulmonary hypertension and heart valve disease.
Topics: Age Factors; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Heart | 2015 |
Stuttering Associated With the Use of Short-Acting Oral Methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Mal | 2015 |
Does collateral retrospective information about childhood attention-deficit/hyperactivity disorder symptoms assist in the diagnosis of attention-deficit/hyperactivity disorder in adults? Findings from a large clinical sample.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Brazil; Central Nervous System Sti | 2016 |
Not All Generic Concerta Is Created Equal: Comparison of OROS Versus Non-OROS for the Treatment of ADHD.
Topics: Administration, Oral; Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2016 |
Blink rate and blink timing in children with ADHD and the influence of stimulant medication.
Topics: Analysis of Variance; Attention; Attention Deficit Disorder with Hyperactivity; Blinking; Central Ne | 2017 |
Long Withdrawal of Methylphenidate Induces a Differential Response of the Dopaminergic System and Increases Sensitivity to Cocaine in the Prefrontal Cortex of Spontaneously Hypertensive Rats.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Biological Transport; Central Nervous System | 2015 |
Successful treatment of an adult with symptomatic attention deficit, hyperactivity, and impulsivity after temporal lobe resection: case report.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Female; Hum | 2016 |
Functional Imaging Changes in the Medial Prefrontal Cortex in Adult ADHD.
Topics: Adult; Attention; Attention Deficit Disorder with Hyperactivity; Brain Diseases; Brain Mapping; Cent | 2018 |
Attention-deficit hyperactivity disorder, its pharmacotherapy, and the risk of developing bipolar disorder: A nationwide population-based study in Taiwan.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bipolar Disord | 2016 |
Management and Treatment of Attention-Deficit/Hyperactivity Disorder on College Campuses.
Topics: Adult; Amphetamines; Attention Deficit Disorder with Hyperactivity; Counseling; Female; Humans; Lisd | 2015 |
Aberrant regulation of synchronous network activity by the attention-deficit/hyperactivity disorder-associated human dopamine D4 receptor variant D4.7 in the prefrontal cortex.
Topics: Action Potentials; Animals; Attention Deficit Disorder with Hyperactivity; Dopamine Uptake Inhibitor | 2016 |
Stimulant medication effects on growth and bone age in children with attention-deficit/hyperactivity disorder: a prospective cohort study.
Topics: Absorptiometry, Photon; Adiposity; Age Factors; Anthropometry; Attention Deficit Disorder with Hyper | 2016 |
Impact of negative media publicity on attention-deficit/hyperactivity disorder medication in Taiwan.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2016 |
Stimulant use following the publicity of cardiovascular safety and the introduction of patient medication guides.
Topics: Amphetamines; Attention Deficit Disorder with Hyperactivity; Cardiovascular Diseases; Central Nervou | 2016 |
Methylphenidate for ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Methylphen | 2015 |
Sixty seconds on . . . ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Drug Admini | 2015 |
Use of prescription stimulant for Attention Deficit Hyperactivity Disorder in Aboriginal children and adolescents: a linked data cohort study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2015 |
Adolescent methylphenidate treatment differentially alters adult impulsivity and hyperactivity in the Spontaneously Hypertensive Rat model of ADHD.
Topics: Aging; Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Di | 2016 |
Exploratory analysis of early treatment discontinuation and clinical outcomes of patients with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention; Attention Deficit Disorder with Hyperactivity; Cen | 2017 |
Effects of methylphenidate on body index and physical fitness in Korean children with attention deficit hyperactivity disorder.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Body Mass Index; Central Nervous System St | 2016 |
Is adjunctive pharmacotherapy in attention-deficit/hyperactivity disorder cost-effective in Canada: a cost-effectiveness assessment of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant for the treatment of ADHD.
Topics: Amphetamine; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child | 2016 |
ADHD and medication.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Humans; Methylphenidate; United Kingdom | 2016 |
Pharmacogenetics of methylphenidate response and tolerability in attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Chi-Sq | 2017 |
EEG Brain Wave Activity at Rest and during Evoked Attention in Children with Attention-Deficit/Hyperactivity Disorder and Effects of Methylphenidate.
Topics: Adolescent; Alpha Rhythm; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous | 2016 |
Methylphenidate for attention-deficit/hyperactivity disorder: Too much of a good thing?
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Female; Humans; Ma | 2016 |
Risk of Injury According to Attention Deficit Hyperactivity Disorder, Comorbid Mental Illness, and Medication Therapy.
Topics: Adolescent; Adult; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperacti | 2016 |
Meds are no panacea for children who might have ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Exercise; H | 2016 |
Report of a 14-Year-Old Boy Whose Testosterone Level Decreased After Starting on Methylphenidate.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans | 2016 |
Seasonal Patterns of Medications for Treating Attention-Deficit/Hyperactivity Disorder: Comparison of Methylphenidate and Atomoxetine.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2016 |
Switch in Therapy from Methylphenidate to Atomoxetine in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: An Analysis of Patient Records.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with | 2016 |
Attention deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; History, 20 | 2016 |
Cytogenetic Effects of Chronic Methylphenidate Treatment and Chronic Social Stress in Adults with Attention-Deficit/Hyperactivity Disorder.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Cells, Cultured; Central Nervous S | 2016 |
ADHD and psychostimulants - overdiagnosis and overprescription.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Drug Overdose; Fem | 2016 |
ADHD medication overdose and misuse: the NSW Poisons Information Centre experience, 2004-2014.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2016 |
Partial validation of a French version of the ADHD-rating scale IV on a French population of children with ADHD and epilepsy. Factorial structure, reliability, and responsiveness.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2016 |
The impact of a model-based clinical regional registry for attention-deficit hyperactivity disorder.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child, | 2017 |
Reports of Perceived Adverse Events of Stimulant Medication on Cognition, Motivation, and Mood: Qualitative Investigation and the Generation of Items for the Medication and Cognition Rating Scale.
Topics: Adolescent; Adult; Affect; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2016 |
Quality of Life of Adult Patients With Attention-Deficit/Hyperactivity Disorder Taking Methylphenidate.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Met | 2016 |
Quality of Life of Adult Patients With Attention-Deficit/Hyperactivity Disorder Taking Methylphenidate-Reply.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Met | 2016 |
Effects of Methylphenidate on Sleep Functioning in Children with Attention-Deficit/Hyperactivity Disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Female; Hum | 2016 |
How the School Nurse Can Help Improve the Effectiveness of ADHD Medication.
Topics: Amphetamines; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Chil | 2016 |
Is the evidence base of methylphenidate for children and adolescents with attention-deficit/hyperactivity disorder flawed?
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimula | 2016 |
Intrinsic Brain Connectivity Following Long-Term Treatment with Methylphenidate in Children with Attention-Deficit/Hyperactivity Disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; Child; Func | 2016 |
Factors Associated With Adherence to Methylphenidate Treatment in Adult Patients With Attention-Deficit/Hyperactivity Disorder and Substance Use Disorders.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2016 |
Naturalistic Pharmacotherapy Compliance among Pediatric Patients with Attention Deficit/Hyperactivity Disorder: a Study Based on Three-Year Nationwide Data.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2016 |
Factors predicting treatment adherence in patients with adult attention-deficit/hyperactivity disorder: a preliminary study.
Topics: Adolescent; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central | 2016 |
Methylphenidate for attention-deficit/hyperactivity disorder: The longest debate.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Met | 2016 |
Combined pharmacotherapy-multimodal psychotherapy in children with Disruptive Behavior Disorders.
Topics: Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Attention Def | 2016 |
A candidate gene investigation of methylphenidate response in adult attention-deficit/hyperactivity disorder patients: results from a naturalistic study.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Female; Gen | 2016 |
Perseveration by NK1R-/- ('knockout') mice is blunted by doses of methylphenidate that affect neither other aspects of their cognitive performance nor the behaviour of wild-type mice in the 5-Choice Continuous Performance Test.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Central Nervous System Sti | 2016 |
Relationship between the DAT1 gene and the effects of methylphenidate administration in adult attention deficit hyperactivity disorder: a magnetic resonance spectroscopy study.
Topics: Administration, Oral; Adolescent; Adult; Alleles; Aspartic Acid; Attention Deficit Disorder with Hyp | 2016 |
Treatment of Attention-Deficit/Hyperactivity Disorder in Preschool-Age Children: Child and Adolescent Psychiatrists' Adherence to Clinical Practice Guidelines.
Topics: Adolescent; Adolescent Psychiatry; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; | 2016 |
Methylphenidate HCL for the treatment of ADHD in children and adolescents.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2016 |
Methylphenidate Overdose Causing Secondary Polydipsia and Severe Hyponatremia in an 8-Year-Old Boy.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Hyp | 2017 |
Prospective observational study protocol to investigate long-term adverse effects of methylphenidate in children and adolescents with ADHD: the Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE) study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2016 |
Prospective observational study protocol to investigate long-term adverse effects of methylphenidate in children and adolescents with ADHD: the Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE) study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2016 |
Prospective observational study protocol to investigate long-term adverse effects of methylphenidate in children and adolescents with ADHD: the Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE) study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2016 |
Prospective observational study protocol to investigate long-term adverse effects of methylphenidate in children and adolescents with ADHD: the Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE) study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2016 |
The evidence base of methylphenidate for children and adolescents with attention-deficit hyperactivity disorder is in fact flawed.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2016 |
Response to: The evidence base of methylphenidate for children and adolescents with attention-deficit/hyperactivity disorder is in fact flawed.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2016 |
Quantifying the Benefits and Risks of Methylphenidate as Treatment for Childhood Attention-Deficit/Hyperactivity Disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Female; Humans; Ma | 2016 |
Methylphenidate for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Female; Humans; Ma | 2016 |
QuilliChew ER--extended-release chewable methylphenidate tablets.
Topics: Administration, Oral; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulan | 2016 |
Methylphenidate for Treating ADHD: A Naturalistic Clinical Study of Methylphenidate Blood Concentrations in Children and Adults With Optimized Dosage.
Topics: Adolescent; Adult; Aged; Attention Deficit Disorder with Hyperactivity; Body Weight; Central Nervous | 2017 |
ADHD in childhood epilepsy: Clinical determinants of severity and of the response to methylphenidate.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2016 |
The cardiovascular safety of methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Cardiovascular Diseases; Central Nervous System Stimu | 2016 |
Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Cardiovascular Diseases; Case-Control Stu | 2016 |
Trust, but verify. The errors and misinterpretations in the Cochrane analysis by O. J. Storebo and colleagues on the efficacy and safety of methylphenidate for the treatment of children and adolescents with ADHD.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2016 |
Latest trends in ADHD drug prescribing patterns in children in the UK: prevalence, incidence and persistence.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2016 |
Early life stress induces attention-deficit hyperactivity disorder (ADHD)-like behavioral and brain metabolic dysfunctions: functional imaging of methylphenidate treatment in a novel rodent model.
Topics: Animals; Attention; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Brain; Disease | 2017 |
Association between medication prescription for atopic diseases and attention-deficit/hyperactivity disorder.
Topics: Anti-Allergic Agents; Asthma; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; C | 2016 |
Methylphenidate toxicity after Roux-en-Y gastric bypass.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Diabetes Me | 2016 |
Trends in Stimulant Medication Use in Commercially Insured Youths and Adults, 2010-2014.
Topics: Adolescent; Adult; Amphetamines; Attention Deficit Disorder with Hyperactivity; Central Nervous Syst | 2016 |
Relationship between the SNAP-25 gene and the effects of methylphenidate on the anterior cingulate cortex of patients with adult attention deficit hyperactivity disorder: a magnetic resonance spectroscopy study.
Topics: Adult; Aspartic Acid; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulan | 2016 |
Preventative treatment in an animal model of ADHD: Behavioral and biochemical effects of methylphenidate and its interactions with ovarian hormones in female rats.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cocaine; | 2016 |
Prevalence rates of youths diagnosed with and medicated for ADHD in a nationwide survey in Taiwan from 2000 to 2011.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with | 2017 |
Prevalence of sleep disorders and their relationship with core symptoms of inattention and hyperactivity in children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2016 |
Effects of high-frequency repetitive transcranial magnetic stimulation (rTMS) on spontaneously hypertensive rats, an animal model of attention-deficit/hyperactivity disorder.
Topics: Animals; Animals, Newborn; Attention Deficit Disorder with Hyperactivity; Brain-Derived Neurotrophic | 2016 |
Medication Persistence, Duration of Treatment, and Treatment-switching Patterns Among Canadian Patients Taking Once-daily Extended-release Methylphenidate Medications for Attention-Deficit/Hyperactivity Disorder: A Population-based Retrospective Cohort St
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Canada; Central Nervous System Stimulants | 2016 |
Differences in Utilization Patterns among Medications in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: a 36-Month Retrospective Study Using the Korean Health Insurance Review and Assessment Claims Database.
Topics: Administration, Oral; Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperac | 2016 |
Initiation and Persistence of Pharmacotherapy for Youths with Attention Deficit Hyperactivity Disorder in Taiwan.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2016 |
Differential impact of a multimodal versus pharmacological therapy on the core symptoms of attention deficit/hyperactivity disorder in childhood.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Combined Mo | 2016 |
Spontaneous coronary artery dissection in a patient on methylphenidate for attention deficit hyperactivity disorder.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Coronary Angiography; Coronary Vessel Anomalie | 2016 |
Development of a refill pattern method to measure polypharmacy in administrative claims databases.
Topics: Adolescent; Algorithms; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Ch | 2016 |
A Cost-Utility Analysis of Lisdexamfetamine Versus Atomoxetine in the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Inadequate Response to Methylphenidate.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2016 |
Focusing the Neuroscience and Societal Implications of Cognitive Enhancers.
Topics: Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Cognition; Cognition Disorders; | 2017 |
Differential effects of methylphenidate and atomoxetine on intrinsic brain activity in children with attention deficit hyperactivity disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with | 2016 |
Use of drugs for ADHD among adults-a multinational study among 15.8 million adults in the Nordic countries.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Amphetamine; Atomoxetine Hydrochloride; Attention D | 2016 |
Methylphenidate for Attention-Deficit/Hyperactivity Disorder.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; | 2016 |
Methylphenidate for Attention-Deficit/Hyperactivity Disorder-Reply.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; | 2016 |
Effects of methylphenidate on the impairment of spontaneous alternation behavior in mice intermittently deprived of REM sleep.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Disease Models, Animal; Hippocampus; Male; M | 2016 |
Imitations and Transformations: On Side Effects of the ADHD Epidemic.
Topics: Adult; Anthropology, Medical; Attention Deficit Disorder with Hyperactivity; Central Nervous System | 2017 |
Hyperfocusing as a dimension of adult attention deficit hyperactivity disorder.
Topics: Adolescent; Adult; Attention; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; C | 2016 |
Methylphenidate in the treatment of an adolescent female with obsessive-compulsive disorder and attention deficit hyperactivity disorder: a case report.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Comorb | 2017 |
Neurological soft signs are associated with attentional dysfunction in children with attention deficit hyperactivity disorder.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Child; F | 2016 |
A Comparison of Effectiveness of Parent Behavioral Management Training and Methylphenidate on Reduction of Symptomsof Attention Deficit Hyperactivity Disorder.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimu | 2016 |
First evidence of HERV-H transcriptional activity reduction after methylphenidate treatment in a young boy with ADHD.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Endoge | 2016 |
Prevalence of medically treated children with ADHD and type 1 diabetes in Germany - Analysis of two representative databases.
Topics: Adolescent; Age Factors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; C | 2016 |
Medication Effects on EEG Biomarkers in Attention-Deficit/Hyperactivity Disorder.
Topics: Adolescent; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Biomarkers; Brain | 2017 |
BDNF concentrations and daily fluctuations differ among ADHD children and respond differently to methylphenidate with no relationship with depressive symptomatology.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Biomarkers; Brain-Derived Neurotrophic Fa | 2017 |
Acute effects of methylphenidate on impulsivity and attentional behavior among adolescents comorbid for ADHD and conduct disorder.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimula | 2016 |
Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in Germany.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with | 2017 |
Chondrocyte proliferation, viability and differentiation is declined following administration of methylphenidate utilized for the treatment of attention-deficit/hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Cell Differentiation; Cell Proliferation; Cells, Cult | 2017 |
Beliefs regarding medication and side effects influence treatment adherence in adolescents with attention deficit hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cross- | 2017 |
Long term pharmacotherapy by methylfenidate or atomoxetine DAT 1 10/10 ADHD children in correlation with results of the imaging methods.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with | 2016 |
Dyskinesia in Treatment-Naive and Stimulant-Treated Children With ADHD.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2020 |
Prescribing patterns for attention deficit hyperactivity disorder medications among children and adolescents in Korea, 2007-2011.
Topics: Adolescent; Age Distribution; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivi | 2016 |
Attention Deficit Disorder and Allergic Rhinitis: Are They Related?
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Biomarkers; Child; Comorbidity; Dopamine | 2016 |
Short-term efficacy and tolerability of methylphenidate in children with traumatic brain injury and attention problems.
Topics: Attention Deficit Disorder with Hyperactivity; Brain Injuries, Traumatic; Central Nervous System Sti | 2017 |
Methylphenidate for ADHD in children and adolescents: throwing the baby out with the bathwater.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Humans; Methylphenidate; Parents; | 2016 |
Evidence on methylphenidate in children and adolescents with ADHD is in fact of 'very low quality'.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Data Collection; Humans; Judgment; | 2016 |
The use of modified-release methylphenidate in the treatment of attention-deficit/hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Delayed-Action Pre | 2017 |
The age-dependent effects of a single-dose methylphenidate challenge on cerebral perfusion in patients with attention-deficit/hyperactivity disorder.
Topics: Adult; Age Factors; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants | 2017 |
Oculomotor Abnormalities in Children with Attention-Deficit/Hyperactivity Disorder Are Improved by Methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Female; Fix | 2017 |
Dopaminergic modulation of default mode network brain functional connectivity in attention deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Brain; Child; Cognition; Connectome; Dopamine Uptake | 2016 |
Duloxetine Alleviates Stimulant Dysphoria, Helps With Enuresis, and Complements Cognitive Response in an Adolescent With Attention-Deficit/Hyperactivity Disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cognit | 2016 |
Basics of meta-analysis: I
Topics: Algorithms; Attention Deficit Disorder with Hyperactivity; Attitude; Cognition; Effect Modifier, Epi | 2017 |
Comparative efficacy and tolerability of pharmacological interventions for attention-deficit/hyperactivity disorder in children, adolescents and adults: protocol for a systematic review and network meta-analysis.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Adult; Attention Deficit Disorder with Hyperactivi | 2017 |
Effects of amphetamine and methylphenidate on attentional performance and impulsivity in the mouse 5-Choice Serial Reaction Time Task.
Topics: Amphetamine; Animals; Attention; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Ce | 2017 |
Cyclic Alternating Pattern Associated with Catathrenia and Bruxism in a 10-Year-Old Patient.
Topics: Attention Deficit Disorder with Hyperactivity; Bruxism; Central Nervous System Stimulants; Child; El | 2017 |
Effects of methylphenidate on attention in Wistar rats treated with the neurotoxin N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP4).
Topics: Animals; Attention; Attention Deficit Disorder with Hyperactivity; Benzylamines; Central Nervous Sys | 2017 |
An Evaluation Approach for the Performance of Dosing Regimens in Attention-Deficit/Hyperactivity Disorder Treatment.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2017 |
Effects of methylphenidate treatment on the cerebellum in adult attention-deficit hyperactivity disorder: a magnetic resonance spectroscopy study.
Topics: Adolescent; Adult; Aspartic Acid; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2017 |
What are the benefits of methylphenidate as a treatment for children and adolescents with attention-deficit/hyperactivity disorder?
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Bias; Central Nervous System Stimulants; | 2017 |
Disrupted Glutamatergic Transmission in Prefrontal Cortex Contributes to Behavioral Abnormality in an Animal Model of ADHD.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Disease M | 2017 |
A prenatal nicotine exposure mouse model of methylphenidate responsive ADHD-associated cognitive phenotypes.
Topics: Age Factors; Analysis of Variance; Animals; Animals, Newborn; Attention Deficit Disorder with Hypera | 2017 |
Hemodynamic profile and behavioral characteristics during induction of anesthesia in pediatric patients with attention deficit hyperactivity disorder.
Topics: Adolescent; Amphetamine; Anesthesia; Anti-Anxiety Agents; Anxiety; Attention Deficit Disorder with H | 2017 |
Attention Deficit Hyperactivity Disorder Symptoms and Low Educational Achievement: Evidence Supporting A Causal Hypothesis.
Topics: Academic Success; Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System | 2017 |
Effect of Methylphenidate on Emotional Dysregulation in Children With Attention-Deficit/Hyperactivity Disorder + Oppositional Defiant Disorder/Conduct Disorder.
Topics: Adolescent; Affective Symptoms; Attention Deficit Disorder with Hyperactivity; Child; Comorbidity; C | 2017 |
Attention-deficit/hyperactivity disorder and enuresis: a study about effectiveness of treatment with methylphenidate or desmopressin in a pediatric population.
Topics: Adolescent; Antidiuretic Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous Syst | 2019 |
Topics: Age Factors; Animals; Attention Deficit Disorder with Hyperactivity; Brain; Brain Chemistry; Central | 2017 |
The effect of methylphenidate-OROS
Topics: Administration, Oral; Adolescent; Adolescent Behavior; Age Factors; Attention Deficit Disorder with | 2017 |
Family-based association study of DRD4 gene in methylphenidate-responded Attention Deficit/Hyperactivity Disorder.
Topics: Adolescent; Asian People; Attention Deficit Disorder with Hyperactivity; Child; Exons; Family; Femal | 2017 |
The association between methylphenidate treatment and the risk for fracture among young ADHD patients: A nationwide population-based study in Taiwan.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Female; Fracture | 2017 |
Is There an Effect of Methylphenidate on Thrombocytopenia?
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans | 2017 |
Improving decision making in the treatment of ADHD.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with | 2008 |
AD(H)D.
Topics: Adolescent; Age Factors; Attention Deficit Disorder with Hyperactivity; Australia; Central Nervous S | 2008 |
ADHD, methylphenidate and driving: does some legislation endanger public health?
Topics: Attention Deficit Disorder with Hyperactivity; Automobile Driving; Central Nervous System Stimulants | 2008 |
A young man with acute dilated cardiomyopathy associated with methylphenidate.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Cardiomyopathy, Dilated; Central Nervous | 2008 |
Pharmacogenetics of methylphenidate response in attention deficit/hyperactivity disorder: association with the dopamine transporter gene (SLC6A3).
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Chi-Sq | 2008 |
Pharmacotherapy of ADHD in adults.
Topics: Adrenergic Uptake Inhibitors; Adult; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Diso | 2008 |
Clinical and molecular-genetic markers of ADHD in children.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Biomarkers; Central Nervous Sy | 2008 |
Cognition-enhancing doses of methylphenidate preferentially increase prefrontal cortex neuronal responsiveness.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Catecholamines; Central Nervous System Stimu | 2008 |
Juvenile methylphenidate modulates reward-related behaviors and cerebral blood flow by decreasing cortical D3 receptors.
Topics: Age Factors; Aging; Animals; Attention Deficit Disorder with Hyperactivity; Avoidance Learning; Beha | 2008 |
Suffer the restless children: the evolution of ADHD and paediatric stimulant use, 1900-80.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; History, 20 | 2007 |
Abuse of medications employed for the treatment of ADHD: results from a large-scale community survey.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Data C | 2008 |
[Comment on the European guidelines for use of delayed action drugs for treatment of hyperkinetic disorders].
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2008 |
Methylphenidate-associated enuresis in attention deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Mal | 2008 |
Juvenile Huntington disease exacerbated by methylphenidate: case report.
Topics: Age of Onset; Attention Deficit Disorder with Hyperactivity; Child; DNA Repeat Expansion; Dopamine U | 2008 |
Methylphenidate does not increase ethanol consumption in a rat model for attention-deficit hyperactivity disorder-the spontaneously hypertensive rat.
Topics: Alcohol Drinking; Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2008 |
Effect of long-acting OROS methylphenidate on routine driving in young adults with attention-deficit/hyperactivity disorder.
Topics: Accidents, Traffic; Adult; Attention Deficit Disorder with Hyperactivity; Automobile Driving; Centra | 2008 |
Children's self-reports on perceived effects on taking stimulant medication for ADHD.
Topics: Achievement; Adolescent; Aggression; Amphetamine; Attention Deficit Disorder with Hyperactivity; Att | 2009 |
Atomoxetine-associated hemospermia: a case report.
Topics: Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2008 |
Association of the catechol-O-methyltransferase polymorphism with methylphenidate response in a classroom setting in children with attention-deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Catechol O-Methyltransferase; Central Nervous System | 2008 |
Massive variation in Ritalin prescribing.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2008 |
Response to Brasić (2007): psychomotor study of children with ADHD.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Child; Dextroamphetamine; Humans; Lower Ex | 2008 |
Successful child psychotherapy of attention deficit/hyperactive disorder: an agitated depression explanation.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Communicati | 2008 |
[The impact of attention deficit/hyperactivity disorder (ADHD) in mothers on the treatment of their ADHD children--review and summary of the study protocol of a randomized controlled multi-centre trial on parent training].
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Chil | 2008 |
Psychostimulant treatment and the developing cortex in attention deficit hyperactivity disorder.
Topics: Adolescent; Amphetamines; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2009 |
The impact of individual and methodological factors in the variability of response to methylphenidate in ADHD pharmacogenetic studies from four different continents.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2008 |
Diagnosis and management of attention-deficit/hyperactivity disorder in children, young people, and adults: summary of NICE guidance.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disord | 2008 |
Genome-wide association study of response to methylphenidate in 187 children with attention-deficit/hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Chi-Square Distrib | 2008 |
Attention-deficit/hyperactivity disorder: a personal perspective.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System | 2008 |
Treating adult ADHD with stimulants.
Topics: Adult; Amphetamine; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants | 2008 |
Impact of withdrawal of Ritalin LA in the Western Cape.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Delayed-Action Pre | 2008 |
Bruxism arising during monotherapy with methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Follow-Up S | 2008 |
Cardiac arrest with pulseless electrical activity associated with methylphenidate in an adolescent with a normal baseline echocardiogram.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Cardiopulmonary Resuscitation; Central Ne | 2008 |
Tactile and visual hallucinations in a child with methylphenidate and fluoxetine combination.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Dopamine Up | 2008 |
Insomnia, night terror, and depression related to clonidine in attention-deficit/hyperactivity disorder.
Topics: Adrenergic alpha-Agonists; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2008 |
No elevated genomic damage in children and adolescents with attention deficit/hyperactivity disorder after methylphenidate therapy.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Central Nervous Sys | 2009 |
Recent NIMH clinical trials and implications for practice.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System | 2008 |
[Joint position of the Guideline Group of the European Network for Hyperkintetic Disorders (EUNETHYDIS) and the German Central ADHD Network for ECG Recording on methylphenidate prescriptions].
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Death, Sudd | 2008 |
Methylphenidate in attention deficit hyperactivity disorder and bipolar disorder.
Topics: Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Central Nervous Sy | 2008 |
Cerebral DARPP-32 expression after methylphenidate administration in young and adult rats.
Topics: Aging; Animals; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimula | 2009 |
[A plea for more boredom: ADHD in young children from the medical and psychotherapy viewpoint].
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Boredom; Central Nervous System Stimulant | 2008 |
Effective methylphenidate treatment of an adult Aspergers Syndrome and a comorbid ADHD: a clinical investigation with fMRI.
Topics: Adult; Asperger Syndrome; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous Syst | 2009 |
Early postnatal exposure to methylphenidate alters stress reactivity and increases hippocampal ectopic granule cells in adult rats.
Topics: Analysis of Variance; Animals; Animals, Newborn; Attention Deficit Disorder with Hyperactivity; Beha | 2009 |
[The effects of methylphenidate on various components of visual attention in children with attention-deficit hyperactivity disorder].
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2008 |
Adolescent and adult male spontaneous hyperactive rats (SHR) respond differently to acute and chronic methylphenidate (Ritalin).
Topics: Aging; Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Brain; Brain Chemis | 2009 |
Methylphenidate improves response inhibition but not reflection-impulsivity in children with attention deficit hyperactivity disorder (ADHD).
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child Behav | 2009 |
Excessive talking triggered by methylphenidate in a boy with ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child, Preschool; | 2009 |
Development of 5-HT transporter density and long-term effects of methylphenidate in an animal model of ADHD.
Topics: Age Factors; Animals; Attention Deficit Disorder with Hyperactivity; Carrier Proteins; Central Nervo | 2009 |
[Retrospective analysis of pervasive developmental disorder patients initially diagnosed with attention deficit/hyperactivity disorder].
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child Development Disorders, Pervasive; Child, | 2009 |
CREM mutations and ADHD symptoms.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Cyclic AMP Response Element Modulator; Human | 2009 |
Recognizing parents' symptoms, obesity, and bipolar depression.
Topics: Adolescent; Age Factors; Antimanic Agents; Attention Deficit Disorder with Hyperactivity; Bipolar Di | 2008 |
NK1 (TACR1) receptor gene 'knockout' mouse phenotype predicts genetic association with ADHD.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Base Sequence; Case-Control Studies; Corpus | 2010 |
Stimulant dosing for children with ADHD: a medical claims analysis.
Topics: Amphetamine; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child | 2009 |
Attention-deficit hyperactivity disorder: treatment discontinuation in adolescents and young adults.
Topics: Adolescent; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cohort | 2009 |
[Mechanism for the efficacy of methylphenidate on attention deficit/hyperactivity disorder and related clinical evidence].
Topics: Attention Deficit Disorder with Hyperactivity; Child; Dopamine Uptake Inhibitors; Evidence-Based Med | 2008 |
[Drug dependence and methylphenidate].
Topics: Attention Deficit Disorder with Hyperactivity; Dopamine Uptake Inhibitors; Humans; Methylphenidate; | 2008 |
[Dyslexia: a disease, a disorder or something else?].
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Dyslexia; G | 2009 |
[Non-verbal learning disorders: a clinical study and pharmacological treatment].
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2009 |
[Attention deficit hyperactivity disorder in adults].
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disord | 2009 |
[Malnutrition in children with DAMP?].
Topics: Appetite; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; H | 2009 |
Uncanny scripts: understanding pharmaceutical emplotment in the aboriginal context.
Topics: Adolescent; Adult; Anthropology, Cultural; Attention Deficit Disorder with Hyperactivity; Central Ne | 2009 |
A case of acute cardiomyopathy and pericarditis associated with methylphenidate.
Topics: Acute Disease; Adolescent; Angina Pectoris; Attention Deficit Disorder with Hyperactivity; Cardiomyo | 2009 |
Methylphenidate, interstimulus interval, and reaction time performance of children with attention deficit/hyperactivity disorder: a pilot study.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimula | 2009 |
Focalin XR for ADHD.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2009 |
Adenosine receptor antagonists improve short-term object-recognition ability of spontaneously hypertensive rats: a rodent model of attention-deficit hyperactivity disorder.
Topics: Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Animals; Attention Deficit Dis | 2009 |
MAOA is associated with methylphenidate improvement of oppositional symptoms in boys with attention deficit hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Humans; Male; Methylphenidate; Mon | 2009 |
Opening the white boxes: the licensing documentation of efficacy and safety of psychotropic medicines for children.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Citalopra | 2009 |
A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with | 2009 |
Response to methylphenidate in children and adolescents with ADHD: does comorbid anxiety disorders matters?
Topics: Adolescent; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Brain; Causality; Cent | 2009 |
The open-label treatment of attention-deficit/hyperactivity disorder in 4- and 5-year-old children with beaded methylphenidate.
Topics: Anorexia; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child, P | 2009 |
Attention deficit hyperactivity disorder erroneously diagnosed and treated as bipolar disorder.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Benzod | 2009 |
[Without treatment the crash threatens].
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivi | 2009 |
[Follow-up of ADHD patients. Adults "fidget" differently].
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Diagnosis, | 2009 |
Predicting response of ADHD symptoms to methylphenidate treatment based on comorbid anxiety.
Topics: Adolescent; Analysis of Variance; Anxiety; Attention Deficit Disorder with Hyperactivity; Child; Chi | 2010 |
DRL performance of spontaneously hypertensive rats: dissociation of timing and inhibition of responses.
Topics: Analysis of Variance; Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Cent | 2009 |
Self concept, action control and ADHD symptoms under methylphenidate treatment in adults with ADHD.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Female; Hum | 2009 |
Absence of cytogenetic effects in children and adults with attention-deficit/hyperactivity disorder treated with methylphenidate.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2009 |
Sleep problems and disorders among adolescents with persistent and subthreshold attention-deficit/hyperactivity disorders.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2009 |
Methylphenidate induction of complex visual hallucinations.
Topics: Adolescent; Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulant | 2009 |
Visual fields in children with attention-deficit/hyperactivity disorder before and after treatment with stimulants.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Met | 2010 |
Dopamine transporter genotype and stimulant side effect factors in youth diagnosed with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2009 |
Methylphenidate has positive hypocholesterolemic and hypotriglyceridemic effects: new data.
Topics: Adolescent; Adult; Apolipoproteins; Attention Deficit Disorder with Hyperactivity; Child; Cholestero | 2009 |
Cardiovascular effects of methylphenidate.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Central Nervous System St | 2009 |
Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD.
Topics: Adolescent; Amphetamine; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Central Nerv | 2009 |
[Methylphenidate. A drug for attention deficit disorders to be used with precaution].
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Methylphen | 2009 |
An 8-year follow-up study of profiles and predictors of methylphenidate use in a nationwide sample of boys.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child Behav | 2009 |
Association between attention-deficit/hyperactivity disorder and sleep impairment in adulthood: evidence from a large controlled study.
Topics: Adolescent; Adult; Age of Onset; Attention Deficit Disorder with Hyperactivity; Comorbidity; Diagnos | 2009 |
Flow cytometric detection of Pig-A mutant red blood cells using an erythroid-specific antibody: application of the method for evaluating the in vivo genotoxicity of methylphenidate in adolescent rats.
Topics: Alkylating Agents; Animals; Antibodies, Monoclonal; Attention Deficit Disorder with Hyperactivity; C | 2010 |
Stimulant use linked to sudden death in children without heart problems.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Central Nervous Sys | 2009 |
Possible association between attention deficit hyperactivity disorder and attempted suicide in adolescents - a pilot study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Comorb | 2010 |
Do sluggish cognitive tempo symptoms predict response to methylphenidate in patients with attention-deficit/hyperactivity disorder-inattentive type?
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Cogni | 2009 |
A report of two cases of sexual side effects with OROS methylphenidate.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Delayed-Action Preparations; Dose- | 2009 |
Prefrontal cortex Homer expression in an animal model of attention-deficit/hyperactivity disorder.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Blotting, Western; Carrier Proteins; Central | 2009 |
Effects of stimulant medication under varied motivational operations.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Choice Behavior; Delayed-Action Preparatio | 2009 |
Carboxylesterase 1 gene polymorphism and methylphenidate response in ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Carboxylesterase; Carboxylic Ester Hydrolases; Centra | 2009 |
[The assessment of Attention Deficit Hyperactivity Disorder (ADHD) by teacher ratings - validity and reliability of the FBB-HKS].
Topics: Adolescent; Affective Symptoms; Attention Deficit Disorder with Hyperactivity; Central Nervous Syste | 2009 |
A washout period needed before switching from a neuroleptic to an amphetamine.
Topics: Adolescent; Amphetamines; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Child | 2009 |
Drug therapies for attentional disorders alter the signal-to-noise ratio in the superior colliculus.
Topics: Action Potentials; Animals; Artifacts; Attention; Attention Deficit Disorder with Hyperactivity; Cen | 2009 |
Taking the stress out of individualizing ADHD drug therapy.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; | 2009 |
Atomoxetine may improve methylphenidates' efficacy in treatment of ADHD?
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivi | 2009 |
Maternal ratings of attention problems in ADHD: evidence for the existence of a continuum.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cross-Secti | 2009 |
Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with | 2009 |
Increased glutamate-stimulated release of dopamine in substantia nigra of a rat model for attention-deficit/hyperactivity disorder--lack of effect of methylphenidate.
Topics: Action Potentials; Animals; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Diseas | 2009 |
Age-related changes in motor subtle signs among girls and boys with ADHD.
Topics: Age Factors; Amphetamines; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2009 |
Food intake and serum levels of iron in children and adolescents with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Anemia, Iron-Deficiency; Attention Deficit Disorder with Hyperactivity; Biomarkers; Braz | 2010 |
Outcomes after accidental pediatric ingestions of (dextro)amphetamine and methylphenidate.
Topics: Accidents; Amphetamine; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimul | 2009 |
A candidate gene analysis of methylphenidate response in attention-deficit/hyperactivity disorder.
Topics: Achievement; Adolescent; Arousal; Attention Deficit Disorder with Hyperactivity; Catechol O-Methyltr | 2009 |
Dexmethylphenidate for attention deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Dexmethylphenidate | 2009 |
OROS methylphenidate-induced skin eruptions.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Delayed-Action Pre | 2009 |
Amygdala reduction in patients with ADHD compared with major depression and healthy volunteers.
Topics: Amygdala; Attention Deficit Disorder with Hyperactivity; Brain; Cross-Sectional Studies; Depressive | 2010 |
Variability of response time as a predictor of methylphenidate treatment response in korean children with attention deficit hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Female; Humans; Korea; Male; Methy | 2009 |
Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)--a pharmacoepidemiological and qualitative study.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with | 2009 |
Attention Deficit Hyperactivity Disorder: coping or curing?
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System | 2009 |
[Attention deficit disorder in childhood].
Topics: Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; Child; Huma | 2009 |
Reasons for pretreatment attrition and dropout from methylphenidate in adults with attention-deficit/hyperactivity disorder: the role of comorbidities.
Topics: Age Factors; Attention Deficit Disorder with Hyperactivity; Comorbidity; Humans; Methylphenidate; Pa | 2009 |
Effects of motivation and medication on electrophysiological markers of response inhibition in children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2010 |
Switching from oral extended-release methylphenidate to the methylphenidate transdermal system: continued attention-deficit/hyperactivity disorder symptom control and tolerability after abrupt conversion.
Topics: Administration, Oral; Attention Deficit Disorder with Hyperactivity; Child; Delayed-Action Preparati | 2010 |
[Clinical assessment of the effect of switch from immediate-release to extended-release methylphenidate in 181 patients with isolated attention deficit/hyperactivity disorder (AD/HD) or AD/HD associated with pervasive developmental disorder].
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Child Development Disorders, Perva | 2009 |
Distinctive linguistic styles in children with ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Female; Hum | 2009 |
ADHD and growth: anthropometric changes in medicated and non-medicated ADHD boys.
Topics: Adolescent; Anthropometry; Attention Deficit Disorder with Hyperactivity; Body Height; Body Weight; | 2009 |
Central stimulants in the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adolescents. A naturalistic study of the prescription in Sweden, 1977-2007.
Topics: Adolescent; Adverse Drug Reaction Reporting Systems; Amphetamine; Attention Deficit Disorder with Hy | 2009 |
Effect of methylphenidate on the quality of life in children with epilepsy and attention deficit hyperactivity disorder: and open-label study using an osmotic-controlled release oral delivery system.
Topics: Administration, Oral; Adolescent; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Ce | 2009 |
General anesthesia in a juvenile with attention-deficit hyperactivity disorder accompanied by long-term use of methylphenidate (Concerta).
Topics: Anesthesia, General; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulant | 2009 |
Functional analysis of intron 8 and 3' UTR variable number of tandem repeats of SLC6A3: differential activity of intron 8 variants.
Topics: 3' Untranslated Regions; Alleles; Attention Deficit Disorder with Hyperactivity; Cell Culture Techni | 2010 |
Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy.
Topics: Administration, Oral; Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperac | 2010 |
Sleep and daytime sleepiness in methylphenidate medicated and un-medicated children with attention-deficit/hyperactivity disorder (ADHD).
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2009 |
Predictive factors for persistent use and compliance of immediate-release methylphenidate: a 36-month naturalistic study.
Topics: Adolescent; Age Factors; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Dru | 2009 |
Adverse reactions to methylphenidate treatment for attention-deficit/hyperactivity disorder: structure and associations with clinical characteristics and symptom control.
Topics: Appetite; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; D | 2009 |
Measuring methylphenidate response in attention-deficit/hyperactvity disorder: how are laboratory classroom-based measures related to parent ratings?
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Delayed-Act | 2009 |
Response to methylphenidate is not influenced by DAT1 polymorphisms in a sample of Brazilian adult patients with ADHD.
Topics: 3' Untranslated Regions; Adult; Attention Deficit Disorder with Hyperactivity; Brazil; Dopamine Plas | 2010 |
[Antipsychotic agents and stimulants: a judicious combination?].
Topics: Adult; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Benzodiazepines; Central | 2010 |
Aripiprazole induced acute dystonia after discontinuation of a stimulant medication.
Topics: Acute Disease; Antipsychotic Agents; Aripiprazole; Attention Deficit Disorder with Hyperactivity; Bi | 2010 |
Clinical and cognitive response to extended-release methylphenidate (Medikinet) in attention deficit/hyperactivity disorder: efficacy evaluation.
Topics: Adolescent; Age Factors; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimu | 2009 |
Identification of selected therapeutic agents as inhibitors of carboxylesterase 1: potential sources of metabolic drug interactions.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Attention Deficit Disorder with Hyperactivity; Carboxyl | 2010 |
Forebrain overexpression of CK1delta leads to down-regulation of dopamine receptors and altered locomotor activity reminiscent of ADHD.
Topics: Amphetamine; Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Casein Kinase | 2010 |
Prepuberal subchronic methylphenidate and atomoxetine induce different long-term effects on adult behaviour and forebrain dopamine, norepinephrine and serotonin in Naples high-excitability rats.
Topics: Adrenergic Uptake Inhibitors; Aging; Animals; Atomoxetine Hydrochloride; Attention; Attention Defici | 2010 |
Oral megadose methylphenidate ingestion for suicide attempt.
Topics: Administration, Oral; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulan | 2009 |
Plasma methylphenidate concentrations in youths treated with high-dose osmotic release oral system formulation.
Topics: Administration, Oral; Adolescent; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Cen | 2010 |
Trends in incidence and characteristics of children, adolescents, and adults initiating immediate- or extended-release methylphenidate or atomoxetine in the Netherlands during 2001-2006.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Age Factors; Atomoxetine Hydrochloride; Attention D | 2010 |
Methods of recruiting adolescents with psychiatric and substance use disorders for a clinical trial.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Clinical Trials as Topic; Cognitive Behav | 2009 |
Packages of care for attention-deficit hyperactivity disorder in low- and middle-income countries.
Topics: Attention Deficit Disorder with Hyperactivity; Developing Countries; Dopamine Uptake Inhibitors; Hea | 2010 |
Chronic Ritalin use and cancer.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Chromosome Aberrat | 2010 |
[Management of children, adolescents and adults with attention deficit/hyperactivity disorder (ADHD) in Germany. Position of the central adhd network for 2009 special expert assessment by the medical expert on evaluation of development in public health].
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2010 |
[Bipolar disorders as co-morbidity in childhood and adolescence--underdiagnosed or overinterpreted? Therapy of a 14-year-old boy with hyperkinetic conduct disorder and hypomania].
Topics: Adolescent; Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; A | 2010 |
Methylphenidate normalizes elevated dopamine transporter densities in an animal model of the attention-deficit/hyperactivity disorder combined type, but not to the same extent in one of the attention-deficit/hyperactivity disorder inattentive type.
Topics: Animals; Attention; Attention Deficit Disorder with Hyperactivity; Corpus Striatum; Dopamine Plasma | 2010 |
Motor function and methylphenidate effect in children with attention deficit hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2010 |
Unraveling the nature of hyperactivity in children with attention-deficit/hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Central Nervous System Stimulan | 2010 |
BBC programme gave distorted facts about ADHD study.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Met | 2010 |
The discrepancy in attention deficit hyperactivity disorder (ADHD) medications diffusion: 1994-2003--a global pharmaceutical data analysis.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Cent | 2010 |
Methylphenidate effect in children with ADHD can be measured by an ecologically valid continuous performance test embedded in virtual reality.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2010 |
[The utility of a continuous performance test embedded in virtual reality in measuring the effectiveness of MPH treatment in boys with ADHD].
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2010 |
Peripheral vasculopathy associated with psychostimulant treatment in children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Amphetamine; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimu | 2010 |
Efficacy of a methylphenidate transdermal system versus t.i.d. methylphenidate in a laboratory setting.
Topics: Administration, Cutaneous; Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Cent | 2011 |
Personality disorder in ADHD Part 1: Assessment of personality disorder in adult ADHD using data from a clinical trial of OROS methylphenidate.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Comorbidity | 2010 |
Personality disorders in ADHD Part 2: The effect of symptoms of personality disorder on response to treatment with OROS methylphenidate in adults with ADHD.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Comorbidity | 2010 |
Personality disorders in ADHD Part 3: Personality disorder, social adjustment, and their relation to dimensions of adult ADHD.
Topics: Adult; Affective Symptoms; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2010 |
Atomoxetine. Attention-deficit/hyperactivity disorder: no better than methylphenidate.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with | 2010 |
EEG coherence in children with attention-deficit/hyperactivity disorder: differences between good and poor responders to methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; Child; Elec | 2010 |
Prevalence of methylphenidate prescription among school-aged children in a Swiss population: increase in the number of prescriptions in the Swiss Canton of Vaud, from 2002 to 2005, and changes in patient demographics.
Topics: Adolescent; Age Factors; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimu | 2010 |
Differential effects of methylphenidate on problem solving in adults with ADHD.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Female; Hum | 2011 |
The effect of chronic methylphenidate administration on presynaptic dopaminergic parameters in a rat model for ADHD.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Binding Sites; Brain; Central Nervous System | 2010 |
Young adults with ADHD: an analysis of their service needs on transfer to adult services.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Contin | 2010 |
Pica in a child with attention deficit hyperactivity disorder and successful treatment with methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Dopamine Uptake Inhibitors; Humans; Male; Meth | 2010 |
Childhood methylphenidate treatment of ADHD and response to affective stimuli.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Basal Ganglia; Child; Emotions; Gyrus Cinguli; | 2011 |
Pulmonary arterial hypertension in an adolescent treated with methylphenidate.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans | 2010 |
Chronic caffeine treatment during prepubertal period confers long-term cognitive benefits in adult spontaneously hypertensive rats (SHR), an animal model of attention deficit hyperactivity disorder (ADHD).
Topics: Analysis of Variance; Animals; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Caffei | 2010 |
Evaluation of light/dark cycle in anxiety- and depressive-like behaviors after regular treatment with methylphenidate hydrochloride in rats of different ages.
Topics: Age Factors; Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety Disorders; Attention Defic | 2011 |
[Methylphenidate and sleep: Results of a multicentre study on a population of children with attention deficit hyperactivity disorder].
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2010 |
A naturalistic 10-year prospective study of height and weight in children with attention-deficit hyperactivity disorder grown up: sex and treatment effects.
Topics: Adolescent; Age Factors; Aging; Attention Deficit Disorder with Hyperactivity; Body Height; Body Wei | 2010 |
Cardiovascular safety of ADHD medications: rationale for and design of an investigator-initiated observational study.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit | 2010 |
Newly approved once-daily formulations of medications for the treatment of Attention Deficit (Hyperactivity) Disorder (ADHD) in children and adolescents.
Topics: Administration, Cutaneous; Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hy | 2010 |
Dopamine D4 receptors modulate brain metabolic activity in the prefrontal cortex and cerebellum at rest and in response to methylphenidate.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Cerebellum; Child; Dopamine Uptake Inhibitor | 2010 |
[Hallucinations caused by the introduction of methylphenidate at low doses].
Topics: Attention Deficit Disorder with Hyperactivity; Child; Dopamine Uptake Inhibitors; Female; Hallucinat | 2010 |
Correlating family nurse practitioners' perspectives of adult ADD/ADHD with employed pharmacotherapy: a pilot study.
Topics: Adult; Age Factors; Aged; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Atti | 2010 |
Association among SNAP-25 gene DdeI and MnlI polymorphisms and hemodynamic changes during methylphenidate use: a functional near-infrared spectroscopy study.
Topics: Adolescent; Adult; Alleles; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous Sy | 2011 |
Sub-chronic exposure to atomoxetine up-regulates BDNF expression and signalling in the brain of adolescent spontaneously hypertensive rats: comparison with methylphenidate.
Topics: Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hy | 2010 |
Cardiovascular safety of stimulant medications for pediatric attention-deficit hyperactivity disorder.
Topics: Adolescent; Adult; Amphetamines; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Card | 2010 |
[Ritalin for better or worse[Editorial]].
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Methylphen | 2010 |
Reduced striatal dopamine underlies the attention system dysfunction in neurofibromatosis-1 mutant mice.
Topics: Animals; Attention; Attention Deficit Disorder with Hyperactivity; Brain; Child; Corpus Striatum; Do | 2010 |
Increased dental trauma in children with attention deficit hyperactivity disorder treated with methylphenidate--a pilot study.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cephalometry; Chil | 2010 |
Attention-deficit/hyperactivity phenotype in mice lacking the cyclin-dependent kinase 5 cofactor p35.
Topics: Animals; Atrophy; Attention Deficit Disorder with Hyperactivity; Brain; Disease Models, Animal; Dopa | 2010 |
Personalized medicine and pharmacogenomics in child psychiatry.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Female; Genetic As | 2009 |
Pharmacogenomics of methylphenidate response: making progress.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Female; Genetic As | 2009 |
Methylphenidate and atomoxetine enhance prefrontal function through α2-adrenergic and dopamine D1 receptors.
Topics: Adrenergic Uptake Inhibitors; Animals; Appetitive Behavior; Atomoxetine Hydrochloride; Attention Def | 2010 |
A simple allele-specific polymerase chain reaction method to detect the Gly143Glu polymorphism in the human carboxylesterase 1 gene: importance of genotyping for pharmacogenetic treatment.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alleles; Amino Acid Substitution; Antiviral Agents; Atte | 2010 |
A 12-month prospective, observational study of treatment regimen and quality of life associated with ADHD in central and eastern europe and eastern Asia.
Topics: Adolescent; Asia, Eastern; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2012 |
Treatment stabilization in children and adolescents with attention-deficit/hyperactivity disorder: data from the Netherlands.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with | 2010 |
Lack of association between response of OROS-methylphenidate and norepinephrine transporter (SLC6A2) polymorphism in Korean ADHD.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Female; Gen | 2011 |
Oral megadose methylphenidate ingestion for suicide attempt.
Topics: Administration, Oral; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulan | 2010 |
Effects of osmotic-release methylphenidate in attention-deficit/hyperactivity disorder as measured by event-related potentials.
Topics: Acoustic Stimulation; Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2010 |
Response requirement and increases in accuracy produced by stimulant drugs in a 5-choice serial reaction-time task in rats.
Topics: Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous S | 2011 |
Possible association of norepinephrine transporter -3081(A/T) polymorphism with methylphenidate response in attention deficit hyperactivity disorder.
Topics: Adolescent; Alleles; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulant | 2010 |
Body mass index of children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Body Mass Index; Central Nervous System S | 2011 |
The changing prevalence of attention-deficit/hyperactivity disorder and methylphenidate prescriptions: a study of data from a random sample of insurees of the AOK Health Insurance Company in the German State of Hesse, 2000-2007.
Topics: Adolescent; Age Factors; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimu | 2010 |
Research on cytogenetic risk of ADHD treatments in children.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Chromosome Aberrations; Humans; Methylphenidat | 2010 |
Iron status in toddlerhood predicts sensitivity to psychostimulants in children.
Topics: Anemia, Iron-Deficiency; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Centra | 2012 |
Task-related default mode network modulation and inhibitory control in ADHD: effects of motivation and methylphenidate.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System | 2011 |
Parent and teacher ratings of attention during a year-long methylphenidate trial in children treated for cancer.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2011 |
Adrenergic α2A receptor gene is not associated with methylphenidate response in adults with ADHD.
Topics: Adult; Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Central Nervous System S | 2011 |
Noise benefit in prepulse inhibition of the acoustic startle reflex.
Topics: Acoustic Stimulation; Analysis of Variance; Animals; Attention Deficit Disorder with Hyperactivity; | 2011 |
[Severe factual errors in Tidsskriftet].
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Conflict of Intere | 2010 |
Maximum-corrected and chance-corrected measures of effect size for the Mantel-Haenszel test.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Methylphen | 2010 |
Norepinephrine transporter gene (SLC6A2) is involved with methylphenidate response in Korean children with attention deficit hyperactivity disorder.
Topics: Alleles; Asian People; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimula | 2011 |
Effects of atomoxetine, desipramine, d-amphetamine and methylphenidate on impulsivity in juvenile rats, measured in a T-maze procedure.
Topics: Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hy | 2011 |
The possible effect of methylphenidate on secondary encopresis in children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2011 |
Methylphenidate treatment in adolescent rats with an attention deficit/hyperactivity disorder phenotype: cocaine addiction vulnerability and dopamine transporter function.
Topics: Age Factors; Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Addictive; Cocaine-Re | 2011 |
Methylphenidate self-administration and conditioned place preference in an animal model of attention-deficit hyperactivity disorder: the spontaneously hypertensive rat.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Central Nervous System Sti | 2011 |
Autonomic correlates at rest and during evoked attention in children with attention-deficit/hyperactivity disorder and effects of methylphenidate.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Autonomic Nervous System; Cent | 2011 |
Effect of methylphenidate on intelligence quotient scores in Chinese children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Asian People; Attention Deficit Disorder with Hyperactivity; Child; Cognition; Female; H | 2011 |
The end of drugging children: toward the genealogy of the ADHD subject.
Topics: Amphetamines; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Chil | 2011 |
Successful methylphenidate treatment of early onset extreme obesity in a child with a melanocortin-4 receptor gene mutation and attention deficit/hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Child, Preschool; Humans; Male; Methylphenidate; Muta | 2011 |
Methylphenidate normalizes emotional processing in adult patients with attention-deficit/hyperactivity disorder: preliminary findings.
Topics: Acoustic Stimulation; Adult; Analysis of Variance; Arousal; Attention; Attention Deficit Disorder wi | 2011 |
The efficiency of behavior rating scales to assess inattentive-overactive and oppositional-defiant behaviors: applying generalizability theory to streamline assessment.
Topics: Adolescent; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyp | 2011 |
Correspondence (letter to the editor): Is the treatment the problem?
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2010 |
Correspondence (letter to the editor): What about the dam break upstream?
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2010 |
Correspondence (letter to the editor): Uncritical prescription.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2010 |
Less discontinuation of ADHD drug use since the availability of long-acting ADHD medication in children, adolescents and adults under the age of 45 years in the Netherlands.
Topics: Adolescent; Adult; Age Factors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperacti | 2010 |
The history of attention deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Diagnostic and Sta | 2010 |
Reward processing in male adults with childhood ADHD--a comparison between drug-naïve and methylphenidate-treated subjects.
Topics: Adult; Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Basal Ganglia; Brain; Ca | 2011 |
Parental reporting of adverse drug reactions associated with attention-deficit hyperactivity disorder (ADHD) medications in children attending specialist paediatric clinics in the UK.
Topics: Adolescent; Adverse Drug Reaction Reporting Systems; Attention Deficit Disorder with Hyperactivity; | 2011 |
Impairment of neuropsychological behaviors in ganglioside GM3-knockout mice.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Emotions; Female; G(M3) Ga | 2011 |
The nonmedical use of prescription stimulants among dental and dental hygiene students.
Topics: Adolescent; Adult; Amphetamines; Attention; Attention Deficit Disorder with Hyperactivity; Attitude | 2011 |
Nurse-delivered and doctor-delivered care in an attention deficit hyperactivity disorder follow-up clinic: a comparative study using propensity score matching.
Topics: Ambulatory Care; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; C | 2011 |
Methylphenidate does not improve interference control during a working memory task in young patients with attention-deficit hyperactivity disorder.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Brain; Brain Mapping; Central | 2011 |
Combining carbamazepine, neuroleptics and acetylcholinesterase inhibitors with methylphenidate only reduces adverse side effects, but is less effective than a combination with atomoxetine.
Topics: Aggression; Antipsychotic Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperac | 2011 |
[Infantile psychosis secondary to methylphenidate].
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Mal | 2011 |
Clinical response to methylphenidate in a patient with self-induced photosensitive epilepsy.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Epilepsy, R | 2011 |
A pilot study: differential effects of methylphenidate-OROS on working memory and attention functions in children with attention-deficit/hyperactivity disorder with and without behavioural comorbidities.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Child; Child Behavior Disorders; Comorbidi | 2011 |
Commentary: the only way is down. Augmented deactivation of the default mode network by increased catecholamine transmission--a general mechanism? Reflections on Liddle et al. (2011).
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Female; | 2011 |
Effect of methylphenidate on motivation in children with attention-deficit/hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Met | 2011 |
Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with | 2011 |
Patterns of methylphenidate use and assessment of its abuse and diversion in two French administrative areas using a proxy of deviant behaviour determined from a reimbursement database: main trends from 2005 to 2008.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Attention Deficit Disorder with Hyperactivity; Central N | 2011 |
Methylphenidate treatment and dyskinesia in children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimula | 2011 |
Treatment of ADHD in patients unresponsive to methylphenidate.
Topics: Amphetamines; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous Syste | 2011 |
Pharmacologic treatment of attention-deficit/hyperactivity disorder in children: incidence, prevalence, and treatment patterns in the Netherlands.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with | 2011 |
GIT1 is associated with ADHD in humans and ADHD-like behaviors in mice.
Topics: Adaptor Proteins, Signal Transducing; Amphetamine; Animals; Attention Deficit Disorder with Hyperact | 2011 |
Characteristics of college students with attention-deficit hyperactivity disorder symptoms who misuse their medications.
Topics: Amphetamines; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Como | 2011 |
Methylphenidate-induced visual hallucinations.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Hallucinati | 2011 |
Do phenotypic characteristics, parental psychopathology, family functioning, and environmental stressors have a role in the response to methylphenidate in children with attention-deficit/hyperactivity disorder? A naturalistic study from a developing count
Topics: Adolescent; Adult; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder w | 2011 |
Oral health status, salivary flow rate and salivary quality in children, adolescents and young adults with ADHD.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2011 |
The preschool ADHD Treatment Study (PATS) as the culmination of twenty years of clinical trials in pediatric psychopharmacology.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child, Pres | 2011 |
Stimulant adherence and academic performance in urban youth with attention-deficit/hyperactivity disorder.
Topics: Achievement; Adolescent; Amphetamine; Anxiety Disorders; Attention Deficit and Disruptive Behavior D | 2011 |
Effect of osmotic-release oral system methylphenidate on different domains of attention and executive functioning in children with attention-deficit-hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Drug Delive | 2011 |
Catechol-O-methyltransferase valine158methionine polymorphism moderates methylphenidate effects on oppositional symptoms in boys with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adolescent Behavior; Alleles; Attention Deficit Disorder with Hyperactivity; Catechol O- | 2011 |
Methylphenidate and fluphenazine, but not amphetamine, differentially affect impulsive choice in spontaneously hypertensive, Wistar-Kyoto and Sprague-Dawley rats.
Topics: Amphetamine; Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulan | 2011 |
A cooperative interaction between LPHN3 and 11q doubles the risk for ADHD.
Topics: Aspartic Acid; Attention Deficit Disorder with Hyperactivity; Brain; Case-Control Studies; Choline; | 2012 |
Norepinephrine transporter -3081(A/T) and alpha-2A-adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS-methylphenidate treatment.
Topics: Attention Deficit Disorder with Hyperactivity; Blood Pressure; Cardiovascular Diseases; Child; Delay | 2012 |
Co-existence of ADHD, autoimmune hypothyroidism and pituitary macroadenoma presenting in a behaviour clinic: a case report and brief review of the literature.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Autoimmune Diseases; Community Mental Hea | 2011 |
Stimulant medication in pre-school children in New South Wales.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child, Preschool; | 2011 |
Differential effects of predictors on methylphenidate initiation and discontinuation among young people with newly diagnosed attention-deficit/hyperactivity disorder.
Topics: Adolescent; Age Factors; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimu | 2011 |
Effects of methylphenidate on olfaction and frontal and temporal brain oxygenation in children with ADHD.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Brain; Case-Control Studies; Child; Dopam | 2011 |
[Attention deficit disorder: multidisciplinary observational study over 1 year].
Topics: Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2011 |
Methylphenidate delivery mechanisms for the treatment of children with attention deficit hyperactivity disorder: heterogeneity in parent preferences.
Topics: Administration, Cutaneous; Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central | 2011 |
The what, where, and when of catechol-O-methyltransferase.
Topics: Attention Deficit Disorder with Hyperactivity; Brain; Catechol O-Methyltransferase; Central Nervous | 2011 |
Adults with ADHD: ignored and under-treated.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Met | 2011 |
Acute generalized exanthematous pustulosis induced by methylphenidate: a new adverse effect.
Topics: Acute Generalized Exanthematous Pustulosis; Adrenal Cortex Hormones; Anti-Inflammatory Agents; Atten | 2011 |
[Nutrition and attention deficit hyperactivity disorder: developmental follow-up of the anthropometric variables of a group of patients receiving treatment with osmotic controlled-release methylphenidate].
Topics: Adolescent; Anthropometry; Attention Deficit Disorder with Hyperactivity; Body Height; Body Mass Ind | 2011 |
An adolescent with kleptomania and attention-deficit/hyperactivity disorder treated with methylphenidate.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Comorb | 2011 |
Is there potential for the treatment of children with ADHD beyond psychostimulants?
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Pres | 2011 |
Unilateral gynecomastia in a prepubertal boy.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Gynecomasti | 2012 |
Cue effects on methylphenidate self-administration in rats.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Central Nervous System Sti | 2011 |
What contributes to patient and parent satisfaction with medication in the treatment of children with ADHD? A report on the development of a new rating scale.
Topics: Administration, Oral; Adolescent; Adolescent Behavior; Attention Deficit Disorder with Hyperactivity | 2011 |
Assessment of daily profiles of ADHD and ODD symptoms, and symptomatology related to ADHD medication, by parent and teacher ratings.
Topics: Activities of Daily Living; Administration, Oral; Adolescent; Adult; Attention Deficit Disorder with | 2011 |
An observational study of once-daily modified-release methylphenidate in ADHD: the effect of previous treatment on ADHD symptoms, other externalising symptoms and quality-of-life outcomes.
Topics: Activities of Daily Living; Administration, Oral; Adolescent; Adolescent Behavior; Attention Deficit | 2011 |
Relationship between quality of life and psychopathological profile: data from an observational study in children with ADHD.
Topics: Activities of Daily Living; Administration, Oral; Adolescent; Adolescent Behavior; Attention Deficit | 2011 |
An observational study of once-daily modified-release methylphenidate in ADHD: quality of life, satisfaction with treatment and adherence.
Topics: Activities of Daily Living; Administration, Oral; Adolescent; Attention Deficit Disorder with Hypera | 2011 |
An observational study of once-daily modified-release methylphenidate in ADHD: effectiveness on symptoms and impairment, and safety.
Topics: Administration, Oral; Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2011 |
Editorial: Observational studies in ADHD: the effects of switching to modified-release methylphenidate preparations on clinical outcomes and adherence.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2011 |
Experimental strategies for investigating psychostimulant drug actions and prefrontal cortical function in ADHD and related attention disorders.
Topics: Adolescent; Adult; Attention; Attention Deficit Disorder with Hyperactivity; Behavior; Brain; Catech | 2011 |
Treadmill exercise and methylphenidate ameliorate symptoms of attention deficit/hyperactivity disorder through enhancing dopamine synthesis and brain-derived neurotrophic factor expression in spontaneous hypertensive rats.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Brain-Derived Neurotrophic Factor; Central N | 2011 |
PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.
Topics: Animals; Attention; Attention Deficit Disorder with Hyperactivity; Carbon Radioisotopes; Corpus Stri | 2011 |
Methylphenidate: growth retardation.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2011 |
ADHD medication use, adherence, persistence and cost among Texas Medicaid children.
Topics: Adolescent; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; C | 2011 |
Treatment outcomes with methylphenidate formulations among patients with ADHD: retrospective claims analysis of a managed care population.
Topics: Adolescent; Aged; Attention Deficit Disorder with Hyperactivity; Child; Delayed-Action Preparations; | 2011 |
Ingestion of stimulant medications does not alter bispectral index or clinical depth of anesthesia at 1 MAC sevoflurane in children.
Topics: Adolescent; Ambulatory Surgical Procedures; Anesthesia, Inhalation; Anesthetics, Inhalation; Attenti | 2012 |
Strain differences in self-administration of methylphenidate and sucrose pellets in a rat model of attention-deficit hyperactivity disorder.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Central Nervous System Sti | 2011 |
Methylphenidate transdermal system in preschool children with attention-deficit/hyperactivity disorder.
Topics: Administration, Cutaneous; Attention Deficit Disorder with Hyperactivity; Child, Preschool; Humans; | 2011 |
Long-term effects of short-acting methylphenidate on growth rates of children with attention deficit hyperactivity disorder at Queen Sirikit National Institute of Child Health.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Body Height; Body Weight; Central Nervous | 2011 |
Phenotypic psychiatric characterization of children with Williams syndrome and response of those with ADHD to methylphenidate treatment.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Central Nervous Sys | 2012 |
Methylphenidate treatment in the spontaneously hypertensive rat: influence on methylphenidate self-administration and reinstatement in comparison with Wistar rats.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Central Nervous System Sti | 2012 |
Prospective, naturalistic study of open-label OROS methylphenidate treatment in Chinese school-aged children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Delayed-Action Preparations; Femal | 2011 |
Clinically-oriented monitoring of acute effects of methylphenidate on cerebral hemodynamics in ADHD children using fNIRS.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimula | 2012 |
AQT cognitive speed and processing efficiency differentiate adults with and without ADHD: a preliminary study.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2011 |
Late potentials in the signal-averaged electrocardiogram in pre-pubertal children with ADHD, before and after methylphenidate treatment.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2012 |
[Intellectual abilities in adolescents with former ADHD diagnoses - relationships to current ADHD symptoms, comorbid symptoms, and medication history: results of an 8.5-year follow-up of the Cologne Adaptive Multimodal Treatment Study (CAMT)].
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System | 2012 |
The change of the cortisol levels in children with ADHD treated by methylphenidate or atomoxetine.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivi | 2012 |
Treatment practices in Tourette syndrome: the European perspective.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Anxiety; Aripiprazole; Atomoxetine Hydrochloride | 2012 |
Effects of osmotic-release methylphenidate on height and weight in children with attention-deficit hyperactivity disorder (ADHD) following up to four years of treatment.
Topics: Anthropometry; Attention Deficit Disorder with Hyperactivity; Body Height; Body Mass Index; Body Wei | 2012 |
Validation of the AQT color-form additive model for screening and monitoring pharmacological treatment of ADHD.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Association Learning; Atomoxetine Hydrochloride; At | 2013 |
Successful treatment of severe disruptive disorder featuring symptoms of the Klüver-Bucy Syndrome following a massive right temporal-parietal hemorrhage.
Topics: Adrenergic alpha-Agonists; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Di | 2013 |
Differential effects of methylphenidate and atomoxetine on attentional processes in children with ADHD: an event-related potential study using the Attention Network Test.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention; Attention Deficit Disorder with | 2012 |
[ADD psychosis: treatment with antipsychotics and methylphenidate?].
Topics: Adult; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous System S | 2012 |
Attention-deficit/hyperactivity disorder in childhood epilepsy: a neuropsychological and functional imaging study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Brain; Brain Mapping; Central Nervous Sys | 2012 |
Trends in the consumption of attention deficit hyperactivity disorder medications in Castilla y León (Spain): changes in the consumption pattern following the introduction of extended release methylphenidate.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2012 |
The use of dopaminergic and stimulant drugs for the treatment of depression.
Topics: Amphetamines; Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hype | 2012 |
Stimulants and cardiovascular events in youth with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Amphetamines; Angina Pectoris; Arrhythmias, Cardiac; Attention Deficit Disorder with Hyp | 2012 |
Safe and effective methylphenidate therapy in a pediatric patient with glaucoma.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Contraindic | 2012 |
ADHD pharmacotherapy: rates of stimulant use and cardiovascular risk.
Topics: Attention Deficit Disorder with Hyperactivity; Blood Pressure; Central Nervous System Stimulants; De | 2012 |
Altered cortical morphology in sensorimotor processing regions in adolescents and adults with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adult; Age Factors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperacti | 2012 |
[Atomoxetine in ADHD: caution].
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivi | 2011 |
Prevalence of prescribed attention-deficit hyperactivity disorder medications and diagnosis among Canadian preschoolers and school-age children: 1994-2007.
Topics: Age Factors; Attention Deficit Disorder with Hyperactivity; Canada; Central Nervous System Stimulant | 2012 |
Effects of methylphenidate on attentional set-shifting in a genetic model of attention-deficit/hyperactivity disorder.
Topics: Animals; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants | 2012 |
Status epilepticus associated with the administration of long-acting methylphenidate in a 7-year-old girl.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Delayed-Act | 2012 |
[Methylphenidate induced ST elevation acute myocardial infarction].
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Coronary Vasospasm | 2012 |
Regional brain perfusion before and after treatment with methylphenidate may be associated with the G1287A polymorphism of the norepinephrine transporter gene in children with attention-deficit/hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; Child; Fema | 2012 |
Differential behavioral responses of the spontaneously hypertensive rat to methylphenidate and methamphetamine: lack of a rewarding effect of repeated methylphenidate treatment.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Central Nervous System Sti | 2012 |
The rCBF brain mapping in adolescent ADHD comorbid developmental coordination disorder and its changes after MPH challenging.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Brain; Brain Mapping; Central Nervous Sys | 2012 |
[Response to 'ADD psychosis: treatment with antipsychotics and methylphenidate?'].
Topics: Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulan | 2012 |
Brain region differences in regulation of Akt and GSK3 by chronic stimulant administration in mice.
Topics: Amphetamine; Animals; Arrestins; Attention Deficit Disorder with Hyperactivity; beta-Arrestins; Brai | 2012 |
The use of medication against attention deficit hyperactivity disorder in Denmark: a drug use study from a national perspective.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2012 |
Encouraging news about ADHD drugs and heart risk in adults.
Topics: Adult; Attention; Attention Deficit Disorder with Hyperactivity; Cardiovascular Diseases; Central Ne | 2012 |
Improving working memory in children with attention-deficit/hyperactivity disorder: the separate and combined effects of incentives and stimulant medication.
Topics: Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulan | 2012 |
[Update on Current Care guidelines: ADHD (attention-deficit/hyperactivity disorder, children and adolescents)].
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with | 2012 |
Psychosis induced by the interaction between disulfiram and methylphenidate may be dose dependent.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Cocaine-Related Disorders; Disulfiram; Dopamin | 2012 |
Depressive symptoms as a side effect of the sustained release form of methylphenidate in a 7-year-old boy with attention-deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Delayed-Act | 2012 |
The ADHD-susceptibility gene lphn3.1 modulates dopaminergic neuron formation and locomotor activity during zebrafish development.
Topics: Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Diencephalon; Dis | 2012 |
No beneficial effects of adding parent training to methylphenidate treatment for ADHD + ODD/CD children: a 1-year prospective follow-up study.
Topics: Adolescent; Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Child; Conduct Diso | 2014 |
Quality of life of methylphenidate treatment-responsive adolescents with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2012 |
Identifying patient subgroups who benefit most from a treatment: using administrative claims data to uncover treatment heterogeneity.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Compar | 2012 |
Methylphenidate-induced erections in a prepubertal child.
Topics: Age Factors; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child | 2013 |
Isolation rearing as a preclinical model of attention/deficit-hyperactivity disorder.
Topics: Age Factors; Analysis of Variance; Animals; Animals, Newborn; Attention Deficit Disorder with Hypera | 2012 |
Chemical leukoderma after the application of a transdermal methylphenidate patch.
Topics: Administration, Cutaneous; Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2012 |
Diacylglycerol kinase β knockout mice exhibit attention-deficit behavior and an abnormal response on methylphenidate-induced hyperactivity.
Topics: Akathisia, Drug-Induced; Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2012 |
Possible effect of norepinephrine transporter polymorphisms on methylphenidate-induced changes in neuropsychological function in attention-deficit hyperactivity disorder.
Topics: Adolescent; Alleles; Attention; Attention Deficit Disorder with Hyperactivity; Child; Female; Gene F | 2012 |
Distinct age-dependent effects of methylphenidate on developing and adult prefrontal neurons.
Topics: Age Factors; Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulan | 2012 |
Association of a carboxylesterase 1 polymorphism with appetite reduction in children and adolescents with attention-deficit/hyperactivity disorder treated with methylphenidate.
Topics: Adolescent; Alleles; Appetite; Attention Deficit Disorder with Hyperactivity; Carboxylic Ester Hydro | 2013 |
Trends of outpatient prescription drug utilization in US children, 2002-2010.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Ambulatory Care; Anti-Bacterial Agents; Attenti | 2012 |
The epidemiology of pharmacologically treated attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults in UK primary care.
Topics: Adolescent; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central | 2012 |
The early history of the neuroscience of attention-deficit/hyperactivity disorder.
Topics: Amphetamine; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child | 2012 |
A population-based study of stimulant drug treatment of ADHD and academic progress in children.
Topics: Achievement; Age Factors; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hy | 2012 |
Confounding diagnoses in the neurodevelopmental disabilities population: a child with hearing loss, absence epilepsy, and attention-deficit hyperactivity disorder (ADHD).
Topics: Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Audiometry, Pure-Tone; Central Nervo | 2013 |
Prenatal nicotine exposure mouse model showing hyperactivity, reduced cingulate cortex volume, reduced dopamine turnover, and responsiveness to oral methylphenidate treatment.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Disease Models, Animal; Dopamine; Female; Gy | 2012 |
Methylphenidate-induced acute orofacial and extremity dyskinesia.
Topics: Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; C | 2013 |
Long-term relationship between methylphenidate and tobacco consumption and nicotine craving in adults with ADHD in a prospective cohort study.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2013 |
Do ADHD children with and without child behavior checklist-dysregulation profile have different clinical characteristics, cognitive features, and treatment outcomes?
Topics: Aggression; Attention Deficit Disorder with Hyperactivity; Checklist; Child; Child Behavior; Cogniti | 2015 |
Effects of ADHD therapeutic agents, methylphenidate and atomoxetine, on hippocampal neurogenesis in the adolescent mouse dentate gyrus.
Topics: Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Brain-Derived Neu | 2012 |
Refining psychiatric phenotypes for response to treatment: contribution of LPHN3 in ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Cross-Over Studies; Dopamine Uptake Inhibitors | 2012 |
Age-specific prevalence, incidence of new diagnoses, and drug treatment of attention-deficit/hyperactivity disorder in Germany.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Age Factors; Atomoxetine Hydrochloride; Attention Deficit | 2012 |
[The medical treatment of attention deficit hyperactivity disorder (ADHD) with amphetamines in children and adolescents].
Topics: Adolescent; Adult; Amphetamines; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervo | 2012 |
Overlapping Prescriptions of Stimulants for Children and Adolescents With Attention-Deficit Hyperactivity Disorder.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2012 |
Predictive factors for more than 3 years' duration of central stimulant treatment in adult attention-deficit/hyperactivity disorder: a retrospective, naturalistic study.
Topics: Adult; Age Factors; Antisocial Personality Disorder; Attention Deficit Disorder with Hyperactivity; | 2012 |
Is there a relationship between hyperactivity/inattention symptoms and poor oral health? Results from the GINIplus and LISAplus study.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Cohort Studies; Den | 2013 |
Not robots: children's perspectives on authenticity, moral agency and stimulant drug treatments.
Topics: Adolescent; Adolescent Behavior; Amphetamines; Attention Deficit Disorder with Hyperactivity; Centra | 2013 |
Evaluation of the Duration of Action and Comparative Effectiveness of Lisdexamfetamine Dimesylate and Behavioral Treatment in Youth With ADHD in a Quasi-Naturalistic Setting.
Topics: Adolescent; Apathy; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous | 2015 |
A comparative study of the effects of ABT-418 and methylphenidate on spatial memory in an animal model of ADHD.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Disease M | 2012 |
Prescriptions for ADHD medication, 2004-08.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Age Factors; Attention Deficit Disorder with Hypera | 2012 |
Use of partial AUC (PAUC) to evaluate bioequivalence--a case study with complex absorption: methylphenidate.
Topics: Area Under Curve; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2013 |
Several concerns arise when the results are interpreted.
Topics: Amantadine; Attention Deficit Disorder with Hyperactivity; Dopamine Agents; Dopamine Uptake Inhibito | 2011 |
[Methylphenidate in the treatment of children with attention-deficit hyperactivity disorder: monitoring in biological matrices].
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Dopamine Uptake Inhibitors; Drug M | 2013 |
Physical exercise and catecholamine reuptake inhibitors affect orienting behavior and social interaction in a rat model of attention-deficit/hyperactivity disorder.
Topics: Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Attention; Attention Deficit Disor | 2012 |
Dopaminergic and noradrenergic gene polymorphisms and response to methylphenidate in korean children with attention-deficit/hyperactivity disorder: is there an interaction?
Topics: Asian People; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Chil | 2012 |
Methylphenidate effects on blood serotonin and melatonin levels may help to synchronise biological rhythms in children with ADHD.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Body Height; Body Mass Index; Body Weight | 2013 |
Psychopharmacology for the clinician: management of comorbid Tourette syndrome and attention-deficit/hyperactivity disorder: are psychostimulants an option?
Topics: Adrenergic alpha-2 Receptor Agonists; Attention Deficit Disorder with Hyperactivity; Central Nervous | 2012 |
Management strategies for attention-deficit/hyperactivity disorder: a regional deliberation on the evidence.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Pres | 2012 |
Social isolation induces deficit of latent learning performance in mice: a putative animal model of attention deficit/hyperactivity disorder.
Topics: Aggression; Animals; Attention; Attention Deficit Disorder with Hyperactivity; Caffeine; Central Ner | 2013 |
Comparison of prescription drug costs in the United States and the United Kingdom, part 3: methylphenidate.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2012 |
No significant association between genetic variants in 7 candidate genes and response to methylphenidate treatment in adult patients with ADHD.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Female; Gen | 2012 |
Long-term neurocognitive effects of methylphenidate in patients with attention deficit hyperactivity disorder, even at drug-free status.
Topics: Adolescent; Age Factors; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimu | 2012 |
Variations in Physician Attitudes Regarding ADHD and Their Association With Prescribing Practices.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Attitude of Health Personnel; Central Ner | 2015 |
Stimulant treatment and injury among children with attention deficit hyperactivity disorder: an application of the self-controlled case series study design.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2013 |
Stimulant drugs trigger transient volumetric changes in the human ventral striatum.
Topics: Adult; Age Factors; Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Basal Gangl | 2014 |
Comprehensive phenotype/genotype analyses of the norepinephrine transporter gene (SLC6A2) in ADHD: relation to maternal smoking during pregnancy.
Topics: Alleles; Attention Deficit Disorder with Hyperactivity; Child; Child Behavior; Cognition; Double-Bli | 2012 |
Methylphenidate: abuse and addiction.
Topics: Adolescent; Adult; Age Factors; Attention Deficit Disorder with Hyperactivity; Central Nervous Syste | 2012 |
Persistence of pharmacological treatment into adulthood, in UK primary care, for ADHD patients who started treatment in childhood or adolescence.
Topics: Adolescent; Adult; Age Factors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperacti | 2012 |
The Trend in Morning Levels of Salivary Cortisol in Children With ADHD During 6 Months of Methylphenidate Treatment.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Female; Hum | 2017 |
Safety of attention-deficit/hyperactivity disorder medications in children: an intensive pharmacosurveillance monitoring study.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adverse Drug Reaction Reporting Systems; Atomoxetine Hydro | 2012 |
Drug treatment patterns of attention-deficit/hyperactivity disorder in children and adolescents in Germany: results from a large population-based cohort study.
Topics: Adolescent; Age Factors; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimu | 2012 |
Nonmedical Use and Diversion of ADHD Stimulants Among U.S. Adults Ages 18-49: A National Internet Survey.
Topics: Adult; Amphetamines; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulant | 2015 |
Methylphenidate therapy, headaches and caffeine consumption.
Topics: Attention Deficit Disorder with Hyperactivity; Female; Humans; Male; Methylphenidate | 2013 |
Increased locomotor activity and non-selective attention and impaired learning ability in SD rats after lentiviral vector-mediated RNA interference of Homer 1a in the brain.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Brain; Carrier Proteins; G | 2013 |
Cognitive styles in hyperactive children and the effect of methylphenidate.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 1971 |
Comorbidities in ADHD children treated with methylphenidate: a database study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Cardiovascular Diseases; Case-Control Stu | 2013 |
Methylphenidate and the response to growth hormone treatment in short children born small for gestational age.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Body Height; Central Nervous System Stimu | 2012 |
AAP releases guideline on diagnosis, evaluation, and treatment of ADHD.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System | 2013 |
Pharmacologic intervention for attention-deficit hyperactivity disorder in preschoolers : is it justified?
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; | 2013 |
Growth and pubertal development of adolescent boys on stimulant medication for attention deficit hyperactivity disorder.
Topics: Adolescent; Adolescent Development; Age Factors; Attention Deficit Disorder with Hyperactivity; Body | 2013 |
A university physician's duty to nonpatient students.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Drug and Narcotic | 2012 |
Cardiovascular measures in children and adolescents with attention-deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with | 2012 |
Parental perceived benefits of OROS-methylphenidate treatment for the child with attention-deficit/hyperactivity disorder and for parents themselves.
Topics: Adult; Asian People; Attention; Attention Deficit Disorder with Hyperactivity; Caregivers; Central N | 2013 |
Performance on a strategy set shifting task during adolescence in a genetic model of attention deficit/hyperactivity disorder: methylphenidate vs. atomoxetine treatments.
Topics: Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hy | 2013 |
Quillivant XR--an extended release oral suspension of methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Clinical Trials as | 2013 |
Impaired cliff avoidance reaction in dopamine transporter knockout mice.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Avoidance Learning; Behavior, Animal; Diseas | 2013 |
Attempted abuse of concerta.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Delayed-Action Preparations; Diagnosis, D | 2002 |
Influence of stimulants on electrodermal studies in Fragile X syndrome.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2002 |
[Hyperkinetic syndrome and dyslexia. Medical help for the hyperactive child].
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Dyslexia; H | 2002 |
EEG differences between good and poor responders to methylphenidate in boys with the inattentive type of attention-deficit/hyperactivity disorder.
Topics: Adolescent; Alpha Rhythm; Arousal; Attention Deficit Disorder with Hyperactivity; Beta Rhythm; Centr | 2002 |
Toward optimal health: the experts discuss attention deficit disorder.
Topics: Adult; Age Factors; Attention Deficit Disorder with Hyperactivity; Child; Female; Humans; Incidence; | 2002 |
Dopamine transporter gene and response to methylphenidate in attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Brazil; Central Nervous System Stimulants | 2002 |
Increased urine phenylethylamine after methylphenidate treatment in children with ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Autistic Disorder; Biomarkers; Central Nervous System | 2002 |
Subchronic methylphenidate administration has no effect on locomotion, emotional behavior, or water maze learning in prepubertal mice.
Topics: Affect; Animals; Attention Deficit Disorder with Hyperactivity; Body Weight; Central Nervous System | 2002 |
[Apropos the National Board and Welfare's report on ADDH: some views on the treatment with central nervous system stimulants].
Topics: Adolescent; Adult; Amphetamine; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervou | 2002 |
ADHD guidelines address frequent childhood condition.
Topics: Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nerv | 2001 |
Isolated orofacial dyskinesia: a methylphenidate-induced movement disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Dose-Respon | 2002 |
Methylphenidate produces a false-positive urine amphetamine screen.
Topics: Amphetamines; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Chil | 2002 |
A slow start to the new millennium. Zyvox, Concerta and Mifeprex headline the year.
Topics: Abortifacient Agents, Steroidal; Acetamides; Anti-Infective Agents; Attention Deficit Disorder with | 2000 |
An unlikely vice: Ritalin.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; | 2001 |
Bupropion-methylphenidate combination and grand mal seizures.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Bupropion; Depressive Disorder; Dose-Resp | 2002 |
Elevated striatal dopamine transporter in a drug naive patient with Tourette syndrome and attention deficit/ hyperactivity disorder: positive effect of methylphenidate.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Corpus Stri | 2002 |
Megadose intranasal methylphenidate (ritalin) abuse in adult attention deficit hyperactivity disorder.
Topics: Administration, Intranasal; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous Sy | 2002 |
[The course of behaviour changes in children with attention deficit and hyperactivity after drug treatment].
Topics: Attention Deficit Disorder with Hyperactivity; Behavior; Central Nervous System Stimulants; Child; F | 2002 |
[Phonological processing in children with attention deficit hyperactivity disorder: is methylphenidate effective?].
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Pres | 2002 |
Ritalin is okay for kids with both ADHD and Tourette's syndrome, study says.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Clinical Tr | 2002 |
Effects of methylphenidate discontinuation on cerebral blood flow in prepubescent boys with attention deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Brain; Cerebrovascular Circulation; Child; Humans; Ma | 2002 |
Proceed, with caution: SPECT cerebral blood flow studies of children and adolescents with attention deficit hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Brain; Cerebrovascular Circulation; Child | 2002 |
Is ritalin the answer?
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Family; Hum | 2002 |
[Waived EEG diagnosis before administration and during drug therapy with methylphenidate: dangerous or justifiable?].
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cerebr | 2002 |
A postmarketing clinical experience study of Metadate CD.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Capsules; Central Nervous System Stimulan | 2002 |
Comments on effect of food on early drug exposure from extended-release stimulants: results from the Concerta, Adderall XR food evaluation study.
Topics: Absorption; Administration, Oral; Adult; Amphetamines; Area Under Curve; Attention Deficit Disorder | 2002 |
Dexamphetamine for obsessive-compulsive disorder.
Topics: Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2003 |
Stimulant treatment of bulimia nervosa with and without attention-deficit disorder: three case reports.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Bulimia; Central Nervous System Stimulants; De | 2003 |
[Stimulant drugs in neurofibromatosis type 1 and attention deficit disorder].
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2002 |
Methylphenidate and intracortical excitability: opposite effects in healthy subjects and attention-deficit hyperactivity disorder.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cerebral Co | 2003 |
A feasibility study of the children's medication algorithm project (CMAP) algorithm for the treatment of ADHD.
Topics: Adolescent; Algorithms; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimul | 2003 |
[Off-label use: the case of methylphenidate (Ritalin)].
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Drug Labeli | 2002 |
Dopamine transporter gene, response to methylphenidate and cerebral blood flow in attention-deficit/hyperactivity disorder: a pilot study.
Topics: Attention Deficit Disorder with Hyperactivity; Cerebrovascular Circulation; Child; Dopamine Plasma M | 2003 |
Glutamatergic changes with treatment in attention deficit hyperactivity disorder: a preliminary case series.
Topics: Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cen | 2002 |
Updates on attention deficit hyperactivity disorder, child abuse and neglect, and sudden infant death syndrome.
Topics: Adrenergic Uptake Inhibitors; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder wi | 2003 |
Slowing of growth in height and weight on stimulants: a characteristic pattern.
Topics: Adolescent; Age Distribution; Attention Deficit Disorder with Hyperactivity; Body Height; Body Weigh | 2003 |
[AD/HD (attention deficit and hyperactivity syndrome) and methylphenidate].
Topics: Attention Deficit Disorder with Hyperactivity; Child; Drug Approval; Humans; Methylphenidate; Nation | 2003 |
Mechanism of action of methylphenidate: insights from PET imaging studies.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Basal Ganglia; Brain; Brain Mappin | 2002 |
Is there stimulant sensitivity in children?
Topics: Adolescent; Adult; Animals; Arousal; Attention Deficit Disorder with Hyperactivity; Central Nervous | 2002 |
The use of a laboratory school protocol to evaluate concepts about efficacy and side effects of new formulations of stimulant medications.
Topics: Amphetamines; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Chil | 2002 |
Methylphenidate in treatment of adults with Attention-Deficit/Hyperactivity Disorder.
Topics: Adolescent; Adult; Age Factors; Attention Deficit Disorder with Hyperactivity; Central Nervous Syste | 2002 |
A positron emission tomography study of methylphenidate in adults with ADHD: alterations in resting blood flow and predicting treatment response.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Blood Flow Velocity; Brain; Cerebrovascular Ci | 2003 |
Childhood is not what it used to be: the rise of Ritalin has more to do with shifting social values than advances in neuropharmacology.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Control; Child; Humans; Methylphenidate; Soc | 2002 |
Upping the Ritalin: fiction.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Child; Diagnostic Errors; Female; Humans; Male | 2003 |
Who manages the care of students with Attention Deficit Hyperactivity Disorder (ADHD) in higher education?
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2003 |
Current practice in the management of Attention Deficit Disorder with Hyperactivity (ADHD).
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child Healt | 2003 |
High-dose methylphenidate treatment of attention deficit hyperactivity disorder in a preschooler.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child Behavior; Ch | 2003 |
Electrophysiological investigation of the effectiveness of methylphenidate in children with and without ADHD.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; | 2003 |
Prilosec, nexium and stereoisomers.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Drug Interactions; | 2003 |
[The costs of drugs against ADDH should be reduced].
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cost Contro | 2003 |
Daily methylphenidate use slows the growth of children: a community based study.
Topics: Attention Deficit Disorder with Hyperactivity; Body Height; Central Nervous System Stimulants; Child | 2003 |
Response to methylphenidate in children with attention deficit hyperactivity disorder and manic symptoms in the multimodal treatment study of children with attention deficit hyperactivity disorder titration trial.
Topics: Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Chi-Square Distribution; Child; Dru | 2003 |
Methylphenidate and the cytochrome P450 system.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cytoch | 2003 |
Efficacy or effectiveness: which comes first, the cure or the treatment?
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans | 2003 |
Association of the 480 bp DAT1 allele with methylphenidate response in a sample of Irish children with ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Dopamine Pl | 2003 |
[EEG diagnosis before beginning and during drug treatment of hyperkinetic children and adolescents].
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cerebr | 2003 |
Outcome-based comparison of Ritalin versus food-supplement treated children with AD/HD.
Topics: Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulan | 2003 |
Prevalence of and change in the prescription of methylphenidate in Israel over a 2-year period.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2003 |
Temporal judgments, hemispheric equivalence, and interhemispheric transfer in adolescents with attention deficit hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cerebr | 2004 |
Attention deficit hyperactivity disorder, combined type: better executive function performance with longer-term psychostimulant medication.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cognition D | 2003 |
Children in clinical research: a conflict of moral values.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Behavior Control; Biomedical Research; Ch | 2003 |
Inappropriate prescription of methylphenidate.
Topics: Amphetamine-Related Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System | 2003 |
Attention patterns in children with attention deficit disorder with or without hyperactivity.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Child; Female; Humans; Male; M | 2003 |
What are the long-term effects of methylphenidate treatment?
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Brain; Cognition Disorders; Disease Models, | 2003 |
Methylphenidate-induced plasticity: what should we be looking for?
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; Di | 2003 |
Paediatric methylphenidate (Ritalin) restrictive conditions of prescription in France.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Drug and Na | 2004 |
The dopamine D4 receptor is essential for hyperactivity and impaired behavioral inhibition in a mouse model of attention deficit/hyperactivity disorder.
Topics: Amphetamine; Animals; Animals, Outbred Strains; Attention Deficit Disorder with Hyperactivity; Behav | 2004 |
Effects of once-daily osmotic-release methylphenidate on blood pressure and heart rate in children with attention-deficit/hyperactivity disorder: results from a one-year follow-up study.
Topics: Administration, Oral; Adolescent; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Chi | 2004 |
[New therapeutic options in the treatment of attention deficit/hyperactivity disorder].
Topics: Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bra | 2004 |
Incidence and prevalence of drug-treated attention deficit disorder among boys in the UK.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2004 |
[Analysis of methylphenidate's efficacy using the abbreviated version Conners' questionnaire in attention deficit hyperactivity disorder].
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Diagnostic | 2004 |
Sleep disorders and daytime sleepiness in children with attention-deficit/hyperactive disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Disorders o | 2004 |
Acetyl-L-carnitine reduces impulsive behaviour in adolescent rats.
Topics: Acetylcarnitine; Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Brain Che | 2004 |
An update on attention deficit disorder.
Topics: Adult; Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Ch | 2004 |
Doing their jobs: mothering with Ritalin in a culture of mother-blame.
Topics: Adaptation, Psychological; Anger; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2004 |
Evidence that methylphenidate enhances the saliency of a mathematical task by increasing dopamine in the human brain.
Topics: Adult; Attention; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimu | 2004 |
Amphetamine-induced chorea in attention deficit-hyperactivity disorder.
Topics: Adult; Amphetamines; Attention Deficit Disorder with Hyperactivity; Chorea; Humans; Male; Methylphen | 2004 |
Empirical, ethical, and political perspectives on the use of methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Control; Child; Child Welfare; Humans; Methy | 1999 |
The impact of the Food and Drug Administration Modernization Act on the recruitment of children for research.
Topics: Adolescent; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Benzodiazepines; C | 2003 |
Italian attention-deficit/hyperactivity disorder registry.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; | 2004 |
Association of norepinephrine transporter gene with methylphenidate response.
Topics: Adolescent; Alleles; Asian People; Attention Deficit Disorder with Hyperactivity; Central Nervous Sy | 2004 |
European clinical guidelines for hyperkinetic disorder -- first upgrade.
Topics: Alleles; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Ch | 2004 |
Hallucinations during methylphenidate therapy.
Topics: Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; | 2004 |
Human subjects research. Pediatric study of ADHD drug draws high-level public review.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; | 2004 |
Prevalence and characteristics of adolescents patients with co-occurring ADHD and substance dependence.
Topics: Adolescent; Adolescent Behavior; Attention Deficit Disorder with Hyperactivity; Central Nervous Syst | 2004 |
Effect of methylphenidate on auditory event related potential in boys with attention deficit hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Central Nervous Sys | 2004 |
Profiles, co-morbidity and their relationship to treatment of 191 children with AD/HD and their families.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2004 |
An analysis of the significant variation in psychostimulant use across the U.S.
Topics: Adolescent; Amphetamines; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Centr | 2005 |
Trends in the prescribing of stimulant medication for the treatment of Attention Deficit Hyperactivity Disorder in adults in New South Wales.
Topics: Adolescent; Adult; Age Distribution; Attention Deficit Disorder with Hyperactivity; Central Nervous | 2004 |
Flawed attention-deficit/hyperactivity disorder medication comparison.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Delayed-Act | 2004 |
Regional cerebral blood flow in children with attention deficit hyperactivity disorder: comparison before and after methylphenidate treatment.
Topics: Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; Cerebrovasc | 2005 |
A post hoc analysis of d-threo-methylphenidate hydrochloride (focalin) versus d,l-threo-methylphenidate hydrochloride (ritalin).
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Clinical Tr | 2004 |
[Methylphenidate. A possibility for rare hyperactive children].
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Dopamine Ag | 2004 |
Evaluation of the reinforcing effects of monoamine reuptake inhibitors under a concurrent schedule of food and i.v. drug delivery in rhesus monkeys.
Topics: Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hy | 2005 |
[Attention deficit hyperactivity syndrome (ADHS) in Germany].
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System | 2004 |
Prevalence and correlates of illicit methylphenidate use among 8th, 10th, and 12th grade students in the United States, 2001.
Topics: Adolescent; Adolescent Behavior; Attention Deficit Disorder with Hyperactivity; Attitude to Health; | 2004 |
Methylphenidate an effective treatment for ADHD?
Topics: Adrenergic alpha-Agonists; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Auti | 2004 |
A process for developing community consensus regarding the diagnosis and management of attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2005 |
Children's persistence with methylphenidate therapy: a population-based study.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; British Columbia; Central Nervous | 2004 |
[Caffeine, cannabis and cocaine: from automedication to 'automutilation' in adults with ADHD].
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Caffeine; Central Nervous System Stimulants; C | 2004 |
Methylphenidate: prescribing patterns in a South African primary care patient population.
Topics: Adolescent; Age Factors; Attention Deficit Disorder with Hyperactivity; Chemistry, Pharmaceutical; C | 2005 |
Stimulant drug action in attention deficit hyperactivity disorder (ADHD): inference of neurophysiological mechanisms via quantitative modelling.
Topics: Adolescent; Arousal; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System St | 2005 |
Dopamine receptor 4 (DRD4) 7-repeat allele predicts methylphenidate dose response in children with attention deficit hyperactivity disorder: a pharmacogenetic study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2004 |
Effect of methylphenidate formulation for attention deficit hyperactivity disorder on patterns and outcomes of treatment.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Databases, | 2004 |
The parent's perspective.
Topics: Adolescent; Anecdotes as Topic; Attention Deficit Disorder with Hyperactivity; Central Nervous Syste | 2005 |
Multiple comparisons in drug efficacy studies: scientific or marketing principles?
Topics: Adult; Arthritis; Attention Deficit Disorder with Hyperactivity; Celecoxib; Child; Clinical Trials a | 2004 |
Review of new compounds available in Australia for the treatment of attention-deficit hyperactivity disorder.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Australia; Bio | 2004 |
Psychostimulant treatment of adults with mental retardation and attention-deficit hyperactivity disorder.
Topics: Adult; Amphetamine; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants | 2004 |
Treating adolescent girls and women with ADHD: gender-specific issues.
Topics: Adolescent; Adult; Age Factors; Amphetamine; Anxiety Disorders; Attention Deficit Disorder with Hype | 2005 |
[The value of cognitive evoked potentials in assessing the effectiveness of methylphenidate treatment in children with attention deficit hyperactivity disorder].
Topics: Attention Deficit Disorder with Hyperactivity; Humans; Methylphenidate | 2005 |
[Attention deficit hyperactivity disorder therapy update: extended-release methylphenidate].
Topics: Attention Deficit Disorder with Hyperactivity; Methylphenidate | 2005 |
Mental illness and addiction issue brief: psychotropic medication and children: year end report-2004.
Topics: Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimula | 2004 |
[Long-acting methylphenidate. An alternative medical therapy for adult patients with attention deficit hyperactivity disorder].
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Female; Hum | 2005 |
The treatment of attention deficit disorder: new evidence.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Combined Mo | 2005 |
Methylphenidate-evoked changes in striatal dopamine correlate with inattention and impulsivity in adolescents with attention deficit hyperactivity disorder.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimula | 2005 |
Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2005 |
Individual change in methylphenidate use in a national sample of children aged 2 to 11 years.
Topics: Age Factors; Attention Deficit Disorder with Hyperactivity; Canada; Central Nervous System Stimulant | 2005 |
The difference between steroids and Ritalin is...
Topics: Attention Deficit Disorder with Hyperactivity; Baseball; Biomedical Enhancement; Doping in Sports; H | 2005 |
What is a clinically important level of improvement in symptoms of attention-deficit/hyperactivity disorder?
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2005 |
Functional MRI in attention-deficit hyperactivity disorder: evidence for hypofrontality.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Basal Ganglia; Case-Control Studies; Cent | 2005 |
Calibration of ADHD assessments across studies: a meta-analysis tool.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Bayes Theorem; Central Nervous Sys | 2005 |
Stimulant-atypical antipsychotic interaction and acute dystonia.
Topics: Adolescent; Aggression; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Bipolar | 2005 |
The answerable question and a hierarchy of evidence.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2005 |
Effects of combined treatment on Turkish children diagnosed with attention-deficit/hyperactivity disorder: a preliminary report.
Topics: Adolescent; Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Child; Conduct Diso | 2005 |
Methylphenidate differentially regulates c-fos and fosB expression in the developing rat striatum.
Topics: Age Factors; Aging; Animals; Animals, Newborn; Attention Deficit Disorder with Hyperactivity; Centra | 2005 |
Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder.
Topics: Adolescent; Age Factors; Attention Deficit Disorder with Hyperactivity; California; Case Management; | 2005 |
Exploring clinician uncertainty in the diagnosis and treatment of attention deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Attitude of Health Personnel; Central Nervous System | 2005 |
Effects of stimulant medication on cognitive performance of children with ADHD.
Topics: Administration, Oral; Amphetamines; Attention Deficit Disorder with Hyperactivity; Case-Control Stud | 2005 |
Hyperactivity, impaired learning on a vigilance task, and a differential response to methylphenidate in the TRbetaPV knock-in mouse.
Topics: Alleles; Animals; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System S | 2005 |
Reversible ischaemic neurological deficit associated with short-term methylphenidate medication.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Isc | 2006 |
Assessment of adherence measures with different stimulants among children and adolescents.
Topics: Adolescent; Amphetamines; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2005 |
Real impairments, real treatments.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Control; Central Nervous System Stimulants; | 2005 |
'Real' ethics for 'real' boys: context and narrative in bioethics.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Control; Bioethics; Central Nervous System S | 2005 |
ADHD, values, and the self.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Decision Ma | 2005 |
Splitting the self: the not-so-subtle consequences of medicating boys for ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Control; Central Nervous System Stimulants; | 2005 |
Will the "real boy" please behave: dosing dilemmas for parents of boys with ADHD.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Behavior Control; Biomedical Enhancement; | 2005 |
Beyond "real boys" and back to parental obligations.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Control; Central Nervous System Stimulants; | 2005 |
Dosing dilemmas: are you rich and white or poor and black?
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Black or African American; Central Nervou | 2005 |
Beyond creativity: ADHD drug therapy as a moral damper on a child's future success.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Control; Central Nervous System Stimulants; | 2005 |
Comments on 'Cytogenetic effects in children treated with methylphenidate' by El-Zein et al.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Chromosome | 2005 |
The influence of methylphenidate on the power spectrum of ADHD children - an MEG study.
Topics: Alpha Rhythm; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimu | 2005 |
No support for association between the dopamine transporter (DAT1) gene and ADHD.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2005 |
Methylphenidate: use in daily practice.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2005 |
Stimulant medication in 47,XYY syndrome: a report of two cases.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cognition D | 2005 |
[Better health care for children and adolescents with attention deficit hyperactivity disorder].
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Behavior; Central Nervous System Stimulan | 2005 |
[Increasing trend in prescription of methylphenidate in general practices in the north-east of The Netherlands, 1998-2003].
Topics: Adolescent; Adult; Age Factors; Attention Deficit Disorder with Hyperactivity; Central Nervous Syste | 2005 |
Association between dopamine transporter (DAT1) genotype, left-sided inattention, and an enhanced response to methylphenidate in attention-deficit hyperactivity disorder.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimula | 2005 |
Judgments of the fairness of using performance enhancing drugs.
Topics: Analysis of Variance; Attention; Attention Deficit Disorder with Hyperactivity; Attitude; Biomedical | 2005 |
Global and regional gray matter reductions in ADHD: a voxel-based morphometric study.
Topics: Adolescent; Atrophy; Attention Deficit Disorder with Hyperactivity; Brain; Brain Mapping; Central Ne | 2005 |
[Who is the hyperactive child?].
Topics: Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulan | 2005 |
Cost-effectiveness of ADHD treatments: findings from the multimodal treatment study of children with ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; | 2005 |
Cost-effectiveness of ADHD treatments: findings from the multimodal treatment study of children with ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; | 2005 |
Cost-effectiveness of ADHD treatments: findings from the multimodal treatment study of children with ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; | 2005 |
Cost-effectiveness of ADHD treatments: findings from the multimodal treatment study of children with ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; | 2005 |
Dopamine transporter in attention-deficit hyperactivity disorder normalizes after cessation of methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Dopamine Agents; Humans; Male; Methylphenidate | 2005 |
High sibling correlation on methylphenidate response but no association with DAT1-10R homozygosity in Dutch sibpairs with ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Comorbidity; Dopamine Agents; Dopamine Plasma | 2005 |
Successful desensitization of methylphenidate-induced rash.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Desensitiza | 2005 |
Different adaptations in ventral tegmental area dopamine neurons in control and ethanol exposed rats after methylphenidate treatment.
Topics: Action Potentials; Animals; Animals, Newborn; Apomorphine; Attention Deficit Disorder with Hyperacti | 2006 |
Response to cocaine, alone and in combination with methylphenidate, in cocaine abusers with ADHD.
Topics: Administration, Oral; Adrenergic Agents; Adult; Attention Deficit Disorder with Hyperactivity; Choic | 2006 |
[Medical treatments of hyperactive child: about the new pharmaceutical forms of methylphenidate marketed in France].
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Delayed-Act | 2006 |
Differential behavioral and neurochemical effects of cocaine after early exposure to methylphenidate in an animal model of attention deficit hyperactivity disorder.
Topics: Age Factors; Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Central Nervo | 2006 |
[Influence of methylphenidate on growth of school age children with attention deficit hyperactivity disorder].
Topics: Attention Deficit Disorder with Hyperactivity; Body Height; Body Weight; Case-Control Studies; Centr | 2005 |
[How safe are ADHD drugs?].
Topics: Administration, Oral; Adolescent; Adverse Drug Reaction Reporting Systems; Attention Deficit Disorde | 2005 |
Patients with attention-deficit/hyperactivity disorder without observed apneic episodes in sleep or daytime sleepiness have normal sleep on polysomnography.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2005 |
Response to comments on 'Cytogenetic effects in children treated with methylphenidate' by El-Zein et al.
Topics: Attention Deficit Disorder with Hyperactivity; Carcinogens; Central Nervous System Stimulants; Child | 2006 |
Methylphenidate transdermal system.
Topics: Administration, Cutaneous; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2005 |
Latent inhibition and asymmetrical visual-spatial attention in children with ADHD.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2005 |
The neurology of attention deficit/hyperactivity disorder.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stim | 2005 |
[How to treat ADHD/DAMP? Is there a conclusive answer? A critical survey of the MTA trial?].
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; | 2005 |
Australia: the N of 1 trial, an underappreciated research method.
Topics: Acetaminophen; Aged; Attention Deficit Disorder with Hyperactivity; Australia; Child; Child, Prescho | 2006 |
An open trial of adjunctive donepezil in attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adult; Amphetamines; Antimanic Agents; Attention Deficit Disorder with Hyperactivity; Ch | 2005 |
Performance on a visual sustained attention and discrimination task is associated with urinary excretion of norepineprhine metabolite in children with attention-deficit/hyperactivity disorder (AD/HD).
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2006 |
Management of attention deficit hyperactivity disorder: a parental perspective.
Topics: Attention Deficit Disorder with Hyperactivity; Attitude to Health; Australia; Behavior Therapy; Cent | 2005 |
Clonidine-induced gynecomastia and hyperprolactinemia in a 6-year-old child.
Topics: Age Factors; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Child; Clonidine; Comor | 2005 |
Cerebral vasculitis following oral methylphenidate intake in an adult: a case report.
Topics: Acute Disease; Adult; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System S | 2006 |
Effect of methylphenidate formulation on treatment patterns and use of emergency room services.
Topics: Adolescent; Adult; Aged; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimu | 2006 |
A comparison of methylphenidate formulations in the treatment of ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Chemistry, Pharmaceutical; Child; Humans; Methylpheni | 2006 |
The effects of self-management in general education classrooms on the organizational skills of adolescents with ADHD.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Combined Modality Thera | 2006 |
Fine motor skills and effects of methylphenidate in children with attention-deficit-hyperactivity disorder and developmental coordination disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Female; Fun | 2006 |
Can central auditory processing tests resist supramodal influences?
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cogn | 2005 |
Correlates of methylphenidate use in Canadian children: a cross-sectional study.
Topics: Attention Deficit Disorder with Hyperactivity; Canada; Central Nervous System Stimulants; Child; Chi | 2006 |
The prevalence of ADHD in children with enuresis: comparison between a tertiary and non-tertiary care sample.
Topics: Academic Medical Centers; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2006 |
Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: results from a population-based study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2006 |
Stimulant medications: how to minimize their reinforcing effects?
Topics: Attention Deficit Disorder with Hyperactivity; Behavior, Addictive; Brain; Central Nervous System St | 2006 |
Effect of methylphenidate on Stroop Color-Word task performance in children with attention deficit hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2006 |
Visual function and ocular features in children and adolescents with attention deficit hyperactivity disorder, with and without treatment with stimulants.
Topics: Adolescent; Amphetamine; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimu | 2007 |
[Effect of subtype and psychiatric comorbidities on methylphenidate treatment in adults with attention-deficit hyperactivity disorder].
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2007 |
Changes in medications administered in schools.
Topics: Adolescent; Adult; Amphetamines; Attention Deficit Disorder with Hyperactivity; Central Nervous Syst | 2006 |
Spontaneously hypertensive rats do not predict symptoms of attention-deficit hyperactivity disorder.
Topics: Age Factors; Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Central Nervo | 2006 |
Recent trends in stimulant medication use among U.S. children.
Topics: Adolescent; Age Distribution; Age Factors; Amphetamines; Attention Deficit Disorder with Hyperactivi | 2006 |
Transgenic mice expressing a human mutant beta1 thyroid receptor are hyperactive, impulsive, and inattentive.
Topics: Age Factors; Analysis of Variance; Animals; Attention; Attention Deficit Disorder with Hyperactivity | 2006 |
[Benefit of the extended-release methylphenidate formulations: a comparative study in childhood].
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Chemistry, Pharmaceutical; Child; Delayed | 2006 |
ADHD and insomnia.
Topics: Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimula | 2006 |
Dexmethylphenidate extended release: in attention-deficit hyperactivity disorder.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2006 |
Comparative effects of methylphenidate and mixed salts amphetamine on height and weight in children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adverse Drug Reaction Reporting Systems; Amphetamines; Attention Deficit Disorder with H | 2006 |
Does prolonged therapy with a long-acting stimulant suppress growth in children with ADHD?
Topics: Attention Deficit Disorder with Hyperactivity; Body Height; Body Mass Index; Body Weight; Central Ne | 2006 |
Less is more: inpatient management of a child with complex pharmacotherapy.
Topics: Aggression; Amphetamines; Attention Deficit Disorder with Hyperactivity; Child; Clonidine; Depressio | 2006 |
Deficits in diagnosis, treatment and continuity of care in African-American children and adolescents with ADHD.
Topics: Adolescent; Amphetamines; Attention Deficit Disorder with Hyperactivity; Attitude to Health; Black o | 2006 |
Methylphenidate abuse in Texas, 1998-2004.
Topics: Adolescent; Adolescent Behavior; Adult; Age Factors; Attention Deficit Disorder with Hyperactivity; | 2006 |
ADHD drugs and cardiovascular risk.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Drug | 2006 |
Determinants of adherence to methylphenidate and the impact of poor adherence on maternal and family measures.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2006 |
Concomitant use of atomoxetine and OROS-methylphenidate in a 10-year-old child suffering from attention-deficit/hyperactivity disorder with comorbid bipolar disorder and Tourette syndrome.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivi | 2006 |
Transdermal methylphenidate (Daytrana) for ADHD.
Topics: Administration, Cutaneous; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2006 |
Methylphenidate transdermal system in attention-deficit hyperactivity disorder in children: A viewpoint by Raul R. Silva.
Topics: Administration, Cutaneous; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2006 |
[Diagnosis and treatment of the attention-deficit/hyperactivity syndrome (ADHS) in adults with drug addiction in in-patient and out-patient setting].
Topics: Adult; Alcoholism; Ambulatory Care; Attention Deficit Disorder with Hyperactivity; Borderline Person | 2006 |
Modulation of transcallosally mediated motor inhibition in children with attention deficit hyperactivity disorder (ADHD) by medication with methylphenidate (MPH).
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Corpus Callosum; Dopamine Agonists | 2006 |
Psychotic and manic-like symptoms during stimulant treatment of attention deficit hyperactivity disorder.
Topics: Adolescent; Age Factors; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Central Ne | 2006 |
Adolescents with attention deficit and hyperactivity disorder/learning disability and their proneness to accidents.
Topics: Accident Proneness; Accidents; Adolescent; Attention Deficit Disorder with Hyperactivity; Central Ne | 2006 |
Methylphenidate is not clastogenic in cultured human lymphocytes and in the mouse bone-marrow micronucleus test.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Cell Culture Techniques; Cells, Cultured; Ce | 2006 |
Academic achievement in children with ADHD.
Topics: Affect; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Edu | 2006 |
The latest drugs on the FDA's radar.
Topics: Amphetamine; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Contr | 2006 |
The relationship between regional cerebral blood flow and response to methylphenidate in children with attention-deficit hyperactivity disorder: comparison between non-responders to methylphenidate and responders.
Topics: Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; Cerebrovasc | 2007 |
An ADHD 6-year-old child ultrarapid metabolizer for CYP2D6.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Pres | 2006 |
Neurocognitive development of visuocognitive motor behavior revealed by event-related potentials in cued continuous performance test.
Topics: Adolescent; Adult; Age Factors; Attention; Attention Deficit Disorder with Hyperactivity; Central Ne | 2006 |
Value of 99mTc-TRODAT-1 SPECT to predict clinical response to methylphenidate treatment in adults with attention deficit hyperactivity disorder.
Topics: Adult; Age Factors; Attention Deficit Disorder with Hyperactivity; Brain; Dopamine Plasma Membrane T | 2006 |
Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study.
Topics: Adolescent; Adolescent Behavior; Aggression; Attention; Attention Deficit Disorder with Hyperactivit | 2006 |
Dopamine transporter density and behavioral response to methylphenidate in a hyperlocomotor rat model.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Bromodeoxyuridine; Disease | 2006 |
[Medication for ADHD and the risk of cardiovascular mortality].
Topics: Amphetamine; Arrhythmias, Cardiac; Attention Deficit Disorder with Hyperactivity; Cardiovascular Dis | 2006 |
A novel method for oral stimulant administration in the neonate rat and similar species.
Topics: Administration, Oral; Animals; Animals, Newborn; Animals, Suckling; Attention Deficit Disorder with | 2007 |
Parents report on stimulant-treated children in the Netherlands: initiation of treatment and follow-up care.
Topics: Adolescent; Aftercare; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimula | 2006 |
A new way to deliver psychiatric meds.
Topics: Administration, Cutaneous; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2006 |
Introduction: new developments in the treatment of attention-deficit/hyperactivity disorder.
Topics: Administration, Cutaneous; Adolescent; Adrenergic alpha-Agonists; Adult; Attention Deficit Disorder | 2006 |
Combination pharmacotherapy for adult ADHD.
Topics: Adolescent; Adult; Antidepressive Agents, Tricyclic; Attention Deficit Disorder with Hyperactivity; | 2006 |
Naturalistic long-term use of methylphenidate in bipolar disorder.
Topics: Adolescent; Adult; Antidepressive Agents; Antipsychotic Agents; Attention; Attention Deficit Disorde | 2006 |
Re: Characteristics of methylphenidate in a university student sample.
Topics: Administration, Intranasal; Attention Deficit Disorder with Hyperactivity; Central Nervous System St | 2006 |
Dimensional analysis of ADHD subtypes in rats.
Topics: Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hy | 2007 |
Dopamine transporter 3'-UTR VNTR genotype and ADHD: a pharmaco-behavioural genetic study with methylphenidate.
Topics: 3' Untranslated Regions; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimu | 2007 |
[Dualism of AD(H)D and the problem of surmounting it].
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2006 |
A prospective open trial of guanfacine in children with pervasive developmental disorders.
Topics: Adolescent; Adrenergic alpha-Agonists; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2006 |
A prospective open trial of guanfacine in children with pervasive developmental disorders.
Topics: Adolescent; Adrenergic alpha-Agonists; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2006 |
A prospective open trial of guanfacine in children with pervasive developmental disorders.
Topics: Adolescent; Adrenergic alpha-Agonists; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2006 |
A prospective open trial of guanfacine in children with pervasive developmental disorders.
Topics: Adolescent; Adrenergic alpha-Agonists; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2006 |
A prospective open trial of guanfacine in children with pervasive developmental disorders.
Topics: Adolescent; Adrenergic alpha-Agonists; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2006 |
A prospective open trial of guanfacine in children with pervasive developmental disorders.
Topics: Adolescent; Adrenergic alpha-Agonists; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2006 |
A prospective open trial of guanfacine in children with pervasive developmental disorders.
Topics: Adolescent; Adrenergic alpha-Agonists; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2006 |
A prospective open trial of guanfacine in children with pervasive developmental disorders.
Topics: Adolescent; Adrenergic alpha-Agonists; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2006 |
A prospective open trial of guanfacine in children with pervasive developmental disorders.
Topics: Adolescent; Adrenergic alpha-Agonists; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2006 |
Association of 4-repeat allele of the dopamine D4 receptor gene exon III polymorphism and response to methylphenidate treatment in Korean ADHD children.
Topics: Alleles; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; DN | 2007 |
Preschool meds: the first clinical trial examining the effects of generic Ritalin on 3- to 5-year-old subjects raises questions not only about the safety of the drug but also about the ethics of testing on ever younger brains.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Control; Central Nervous System Stimulants; | 2002 |
Use of double-blind placebo-controlled N-of-1 trials among stimulant-treated youths in The Netherlands: a descriptive study.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2007 |
Pharmacological management of a youth with ADHD and a seizure disorder.
Topics: Adrenergic Uptake Inhibitors; Anticonvulsants; Atomoxetine Hydrochloride; Attention Deficit Disorder | 2006 |
[Ethical aspects of pharmacological cognition enhancement and the use of psychostimulants by children and young persons].
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Behavior Control; Biomedical Enhancement; | 2006 |
Attention-deficit/hyperactivity disorder with obstructive sleep apnea: a treatment outcome study.
Topics: Adenoidectomy; Adenoids; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimu | 2007 |
Prevalence of methylphenidate use among Israeli children: 1998-2004.
Topics: Adolescent; Age Factors; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Dru | 2006 |
Methylphenidate (Ritalin)-associated cataract and glaucoma.
Topics: Attention Deficit Disorder with Hyperactivity; Cataract; Child; Glaucoma; Humans; Male; Methylphenid | 2006 |
ADHD update: new data on the risks of medication.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hype | 2006 |
[Attention deficit with hyperactivity].
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Dopamine Agents; Fami | 2006 |
The incidence of methylphenidate use by Canadian children: what is the impact of socioeconomic status and urban or rural residence?
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2006 |
Cmap ADHD and comorbid aggression algorithm.
Topics: Aggression; Algorithms; Attention Deficit Disorder with Hyperactivity; Biomedical Research; Bipolar | 2007 |
Methylphenidate and atomoxetine increase histamine release in rat prefrontal cortex.
Topics: Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Histamine Release | 2007 |
Stimulant-drug therapy for attention-deficit disorder (with or without hyperactivity) and sudden cardiac death.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Death, Sudd | 2007 |
Reboxetine use in the treatment of attention-deficit/hyperactivity disorder.
Topics: Adolescent; Antidepressive Agents; Antidepressive Agents, Tricyclic; Attention Deficit Disorder with | 2006 |
Methylphenidate and hypertension.
Topics: Adolescent; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyp | 2006 |
St. John's wort may diminish methylphenidate's efficacy in treating patients suffering from attention deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Drug Interactions; Humans; Hypericum; Methylphenidate | 2007 |
Differential effects of modafinil and methylphenidate on stop-signal reaction time task performance in the rat, and interactions with the dopamine receptor antagonist cis-flupenthixol.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Benzhydryl Compounds; Cent | 2007 |
[Comment on a letter regarding the article "Dualism of AD(H)D"].
Topics: Attention Deficit Disorder with Hyperactivity; Child; Editorial Policies; Germany; Humans; Methylphe | 2007 |
Effect of long-term treatment with stimulant medication on growth?
Topics: Attention Deficit Disorder with Hyperactivity; Body Height; Body Weight; Central Nervous System Stim | 2007 |
Risperidone-to-methylphenidate switch reaction in children: three cases.
Topics: Adolescent; Akathisia, Drug-Induced; Antipsychotic Agents; Attention Deficit and Disruptive Behavior | 2007 |
Striatal creatine and glutamate/glutamine in attention-deficit/hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Choline; Co | 2007 |
Intervention strategies in children with cochlear implants having attention deficit hyperactivity disorder.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Auditory Threshold; Brain Diseases; Centra | 2007 |
Methylphenidate reduces impulsive behaviour in juvenile Wistar rats, but not in adult Wistar, SHR and WKY rats.
Topics: Age Factors; Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Central Nervo | 2007 |
[Effects of methylphenidate in auditory processing evaluation of children and adolescents with attention deficit hyperactivity disorder].
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Auditory Perception; Auditory Threshold; | 2007 |
Self-regulation of visual attention and facial expression of emotions in ADHD children.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimula | 2007 |
Pharmacotherapy of aggression in a 9-year-old with ADHD.
Topics: Aggression; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2007 |
Patterns of psychostimulant prescribing to children with ADHD in Western Australia: variations in age, gender, medication type and dose prescribed.
Topics: Adolescent; Age Factors; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimu | 2007 |
Acute effects of methylphenidate on performance during the Test of Variables of Attention in children with attention deficit/hyperactivity disorder.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimula | 2007 |
Comments on efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder.
Topics: Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; | 2007 |
Fundamental movement skills and children with attention-deficit hyperactivity disorder: peer comparisons and stimulant effects.
Topics: Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Central Nervous System Stimulan | 2007 |
From attention-deficit/hyperactivity disorder to medical stimulant use to the diversion of prescribed stimulants to non-medical stimulant use: connecting the dots.
Topics: Adolescent; Amphetamines; Attention Deficit Disorder with Hyperactivity; Canada; Central Nervous Sys | 2007 |
Polypharmacy and EPS in a child; a case report.
Topics: Attention Deficit Disorder with Hyperactivity; Benztropine; Bipolar Disorder; Child; Comorbidity; Do | 2007 |
Clinical implications of ethical concepts: moral self-understandings in children taking methylphenidate for ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Attitude to Health; Central Nervous System Stimulants | 2007 |
Whither authenticity: ADHD, medication, and Striving for the'good life'--a commentary on Singh.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Empirical R | 2007 |
Prevalence of methylphenidate use among Canadian children following parental divorce.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Canada; Central Nervous System Stimulants; Chi | 2007 |
Novice drivers with attention-deficit hyperactivity disorder.
Topics: Accidents, Traffic; Adolescent; Attention Deficit Disorder with Hyperactivity; Automobile Driving; C | 2007 |
Hematologic and blood biochemistry monitoring during methylphenidate treatment in children with attention-deficit/hyperactivity disorder: 2-year, open-label study results.
Topics: Attention Deficit Disorder with Hyperactivity; Blood Cells; Blood Chemical Analysis; Central Nervous | 2007 |
The neurobiology of attention-deficit/hyperactivity disorder.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivi | 2007 |
[Effect of methylphenidate on executive function for children with attention deficit hyperactivity disorder].
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Child; Executive Fu | 2007 |
Excessive masturbation and hypersexual behavior associated with methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Dopamine Up | 2007 |
[Methylphenidate prescriptions in the city of Cologne: overrepresentation of privately insured patients. Results of an analysis based on prescription data].
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Cities; Drug Pre | 2007 |
ADHD remains clinical challenge: data indicate need for closer follow-up of treated children.
Topics: Arkansas; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; D | 2007 |
Does methylphenidate cause a cytogenetic effect in children with attention deficit hyperactivity disorder?
Topics: Attention Deficit Disorder with Hyperactivity; Child; DNA Damage; Female; Germany; Humans; Male; Met | 2007 |
Seizure risk in patients with attention-deficit-hyperactivity disorder treated with atomoxetine.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with | 2007 |
Methylphenidate-induced orofacial and extremity dyskinesia.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Dyskinesia, | 2007 |
The use of health care services and psychotropic medication in a community sample of 9-year-old schoolchildren with ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child Healt | 2007 |
Methylphenidate and somatic hallucinations.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Hallucinati | 2007 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Depressed dopamine activity in caudate and preliminary evidence of limbic involvement in adults with attention-deficit/hyperactivity disorder.
Topics: Adult; Attention; Attention Deficit Disorder with Hyperactivity; Carbon Radioisotopes; Caudate Nucle | 2007 |
Modifiers of long-term school outcomes for children with attention-deficit/hyperactivity disorder: does treatment with stimulant medication make a difference? Results from a population-based study.
Topics: Achievement; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child | 2007 |
A pilot investigation of teachers' perceptions of psychotropic drug use in schools.
Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; At | 2007 |
Case report: "Purely" psychiatric presentation of multiple sclerosis in an adolescent boy.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Diagno | 2007 |
Treatment of adult ADHD and comorbid disorders.
Topics: Adult; Amphetamines; Antidepressive Agents, Tricyclic; Atomoxetine Hydrochloride; Attention Deficit | 2006 |
Pharmacology of adult ADHD with stimulants.
Topics: Adult; Amphetamines; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulant | 2007 |
Effects of methylphenidate in ADHD adults on target evaluation processing reflected by event-related potentials.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Choice Beha | 2007 |
[Methylphenidate in adults with attention-deficit/hyperactivity disorder].
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2007 |
Effects of methylphenidate and bupropion on DHEA-S and cortisol plasma levels in attention-deficit hyperactivity disorder.
Topics: Antidepressive Agents, Second-Generation; Attention Deficit Disorder with Hyperactivity; Biomarkers; | 2008 |
Development and validation of the outburst monitoring scale for children and adolescents.
Topics: Adolescent; Aggression; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Central | 2007 |
[After the researchers have left the field].
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Met | 2007 |
[Sociodemographic and clinical factors associated with compliance to methylphenidate treatment in children with attention deficit hyperactivity disorder].
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2007 |
Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Delayed-Act | 2007 |
Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies.
Topics: Adrenergic Uptake Inhibitors; Adult; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Diso | 2007 |
Continuity in methylphenidate treatment of adults with attention-deficit/hyperactivity disorder.
Topics: Adult; Age Factors; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants | 2007 |
Pleasure and discipline in the uses of Ritalin.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Methylphen | 2008 |
[Hyperactivity and prescription of Ritalin in the canton of Vaud (Switzerland), 2002].
Topics: Adolescent; Adult; Age Factors; Attention Deficit Disorder with Hyperactivity; Catchment Area, Healt | 2007 |
Methylphenidate use and divorce.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Divo | 2007 |
[Prescribing of stimulants for ADHD in Nordland County].
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Amphetamine; Atomoxetine Hydrochloride; Attention D | 2007 |
Administration of oral methylphenidate during adolescence prevents suppressive development of dopamine projections into prefrontal cortex and amygdala after an early pharmacological challenge in gerbils.
Topics: Administration, Oral; Aging; Amygdala; Animals; Attention Deficit Disorder with Hyperactivity; Centr | 2007 |
Acute dyskinesia on starting methylphenidate after risperidone withdrawal.
Topics: Acute Disease; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous | 2007 |
Patterns and predictors of medication compliance, diversion, and misuse in adult prescribed methylphenidate users.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Comorbidity | 2007 |
Sleep disturbances and ADHD medications.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2007 |
Nicotine as a conditioned stimulus: impact of attention-deficit/hyperactivity disorder medications.
Topics: Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; | 2007 |
Early stress and chronic methylphenidate cross-sensitize dopaminergic responses in the adolescent medial prefrontal cortex and nucleus accumbens.
Topics: Aging; Animals; Attention Deficit Disorder with Hyperactivity; Disease Models, Animal; Dopamine; Dop | 2007 |
Critical assessment of the methylphenidate transdermal system.
Topics: Adhesiveness; Administration, Cutaneous; Adolescent; Attention Deficit Disorder with Hyperactivity; | 2007 |
Treatment strategies for a case of severe ADHD.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cognitive B | 2007 |
Scientists examine benefits, risks of treating preschoolers with ADHD drugs.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child, Pr | 2007 |
Association of dopamine, serotonin, and nicotinic gene polymorphisms with methylphenidate response in ADHD.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; DNA Mutational Analysis; Dopamine | 2008 |
Interactions of attention-deficit/hyperactivity disorder therapeutic agents with the efflux transporter P-glycoprotein.
Topics: Adenosine Triphosphate; Amphetamine; Animals; Atomoxetine Hydrochloride; ATP Binding Cassette Transp | 2008 |
[Quantitative effect of treatment with methylphenidate on EEG--a pilot study].
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cerebr | 2007 |
The nonmedical use of prescription ADHD medications: results from a national Internet panel.
Topics: Adolescent; Adult; Alcoholism; Amphetamine-Related Disorders; Appetite Depressants; Attention Defici | 2007 |
A case of disulfiram-methylphenidate interaction: implications for treatment.
Topics: Adult; Alcoholism; Attention Deficit Disorder with Hyperactivity; Disulfiram; Dopamine beta-Hydroxyl | 2007 |
Effectiveness of methylphenidate in the 10-month continuation phase of the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS).
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child, Preschool; | 2007 |
Parent versus teacher ratings of attention-deficit/hyperactivity disorder symptoms in the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS).
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child Behavior; Ch | 2007 |
Association of Parkinson's disease with symptoms of attention deficit hyperactivity disorder in childhood.
Topics: Adult; Aged; Aged, 80 and over; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; | 2007 |
Asymmetry of basal ganglia in children with attention deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Basal Ganglia; Case-Control Studies; Caudate Nucleus; | 2007 |
Health-related quality of life in methylphenidate-treated children with attention-deficit-hyperactivity disorder: results from a Taiwanese sample.
Topics: Adolescent; Age Factors; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimu | 2007 |
Acute myocardial infarction related to methylphenidate for adult attention deficit disorder.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Coronary Va | 2010 |
Prevalence and patterns of methylphenidate use in French children and adolescents.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2008 |
Long-term effects of methylphenidate on neural networks associated with executive attention in children with ADHD: results from a longitudinal functional MRI study.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Brain; Child; Cognition; Cues; Drug Admini | 2007 |
School-based administration of ADHD drugs decline, along with diversion, theft, and misuse.
Topics: Amphetamine; Amphetamine-Related Disorders; Attention Deficit Disorder with Hyperactivity; Attitude | 2007 |
Methylphenidate and chromosome damage.
Topics: Adolescent; Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulant | 2008 |
[The use of methylphenidate in children with ADHD].
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2007 |
[Use of methylphenidate among children in Iceland 1989-2006].
Topics: Adolescent; Age Distribution; Attention Deficit Disorder with Hyperactivity; Central Nervous System | 2007 |
Objective versus subjective assessment of methylphenidate response.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2008 |
Heterogeneity in the pharmacodynamics of two long-acting methylphenidate formulations for children with attention deficit/hyperactivity disorder. A growth mixture modelling analysis.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cross-Over | 2008 |
Is NICE infallible? A qualitative study of its assessment of treatments for attention-deficit/hyperactivity disorder (ADHD).
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cost-Benefit Analysis; Dex | 2008 |
[Medication-induced mandibular luxation in a seven-year-old patient].
Topics: Attention Deficit Disorder with Hyperactivity; Child; Dopamine Uptake Inhibitors; Dystonia; Humans; | 2008 |
Emotional expression in children treated with ADHD medication: development of a new measure.
Topics: Affect; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Exp | 2008 |
Long-acting methylphenidate-OROS in youths with attention-deficit hyperactivity disorder suboptimally controlled with immediate-release methylphenidate: a study of cost effectiveness in The Netherlands.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2008 |
Behavioral responses to methylphenidate and apomorphine in rats exposed neonatally to bisphenol-A.
Topics: Animals; Animals, Newborn; Apomorphine; Attention Deficit Disorder with Hyperactivity; Behavior, Ani | 2007 |
Driving-related risks and impact of methylphenidate treatment on driving in adults with attention-deficit/hyperactivity disorder (ADHD).
Topics: Accidents, Traffic; Adult; Attention Deficit Disorder with Hyperactivity; Automobile Driving; Case-C | 2008 |
Methylphenidate and nicotine focus responding to an informative discrete CS over successive sessions of appetitive conditioning.
Topics: Animals; Appetite; Attention Deficit Disorder with Hyperactivity; Conditioning, Psychological; Dextr | 2008 |
Association between tryptophan hydroxylase 2, performance on a continuance performance test and response to methylphenidate in ADHD participants.
Topics: Adolescent; Alleles; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulant | 2008 |
Catechol-O-methyltransferase Val158Met polymorphism is associated with methylphenidate response in ADHD children.
Topics: Alleles; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Catechol O-Methyltrans | 2008 |
Supraventricular tachycardia in an adolescent with attention-deficit/hyperactivity disorder (ADHD).
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Catheter Ablation; Central Nervous System | 2008 |
Knowledge of pharmacists regarding ritalin and ADHD and their attitude towards the use of ritalin to treat ADHD.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Education, Pharmacy; Education, Ph | 2008 |
Preschool attention deficit disorder. New studies show that both drugs and parent training can be effective.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; | 2007 |
Drugging unruly children is a method of social control.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Humans; Methylphenidate; Social Control, Forma | 2008 |
Association between treatment with central nervous system stimulants and Raynaud's syndrome in children: a retrospective case-control study of rheumatology patients.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Central Nerv | 2008 |
In the long run, skills are as good as pills for attention deficit hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System | 2008 |
No increase in long-term risk for nicotine use disorders after treatment with methylphenidate in children with attention-deficit/hyperactivity disorder (ADHD): evidence from a non-randomised retrospective study.
Topics: Age Factors; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child | 2008 |
Cardiac arrest during induction of anaesthesia in a child on long-term amphetamine therapy.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Heart Arres | 2008 |
Methylphenidate DAT binding in adolescents with Attention-Deficit/ Hyperactivity Disorder comorbid with Substance Use Disorder--a single photon emission computed tomography with [Tc(99m)]TRODAT-1 study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Chemistry, Pharmaceutical; Data Interpret | 2008 |
Dissociation in response to methylphenidate on response variability in a group of medication naïve children with ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Data Interp | 2008 |
Methylphenidate disrupts social play behavior in adolescent rats.
Topics: Adrenergic Antagonists; Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Attention | 2008 |
Lymphomatoid drug reaction secondary to methylphenidate hydrochloride.
Topics: Adult; Antigens, CD; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulant | 2008 |
Attention-deficit/hyperactivity disorder: advances in diagnostic and therapeutic approaches.
Topics: Adolescent; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyp | 2008 |
National survey of adherence, efficacy, and side effects of methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan.
Topics: Adolescent; Age of Onset; Attention Deficit Disorder with Hyperactivity; Catchment Area, Health; Cen | 2008 |
National survey of adherence, efficacy, and side effects of methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan.
Topics: Adolescent; Age of Onset; Attention Deficit Disorder with Hyperactivity; Catchment Area, Health; Cen | 2008 |
National survey of adherence, efficacy, and side effects of methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan.
Topics: Adolescent; Age of Onset; Attention Deficit Disorder with Hyperactivity; Catchment Area, Health; Cen | 2008 |
National survey of adherence, efficacy, and side effects of methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan.
Topics: Adolescent; Age of Onset; Attention Deficit Disorder with Hyperactivity; Catchment Area, Health; Cen | 2008 |
The Life Participation Scale for Attention-Deficit/Hyperactivity Disorder--Child Version: psychometric properties of an adaptive change instrument.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with | 2007 |
Stimulant dosing in the community treatment of adult attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2008 |
Photophobia and methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Mal | 2008 |
Behavioural characterisation of rats exposed neonatally to bisphenol-A: responses to a novel environment and to methylphenidate challenge in a putative model of attention-deficit hyperactivity disorder.
Topics: Animals; Animals, Newborn; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Benzhydr | 2008 |
Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood.
Topics: Adolescent; Adult; Age Factors; Attention Deficit Disorder with Hyperactivity; Central Nervous Syste | 2008 |
Advancing the spontaneous hypertensive rat model of attention deficit/hyperactivity disorder.
Topics: Animals; Association Learning; Attention; Attention Deficit Disorder with Hyperactivity; Central Ner | 2008 |
Case of a 67-year-old woman diagnosed with ADHD successfully treated with methylphenidate.
Topics: Aged; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Diagnostic a | 2008 |
Dopaminergic dysfunction in attention deficit hyperactivity disorder (ADHD), differences between pharmacologically treated and never treated young adults: a 3,4-dihdroxy-6-[18F]fluorophenyl-l-alanine PET study.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2008 |
Methylphenidate and dextroamphetamine-induced peripheral vasculopathy.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Dext | 2008 |
A bibliometric study of international scientific productivity in attention-deficit hyperactivity disorder covering the period 1980-2005.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Bibliometrics; Brazil; Central Nervous Sy | 2008 |
Methylphenidate in the treatment of female adolescents with cooccurrence of attention deficit/hyperactivity disorder and borderline personality disorder: a preliminary open-label trial.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Borderline Personality Disorder; C | 2008 |
Attitudes toward attention-deficit hyperactivity disorder (ADHD) treatment: parents' and children's perspectives.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Attitude to Health; Bias; Caregivers; Cen | 2008 |
The effects of methylphenidate on decision making in attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2008 |
[Drug-induced psychosis after intake of a modified--release formulation of methylphenidate].
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Diagnosis, Differential; Dose-Response Re | 2009 |
Stimulant medications precipitate Tourette's syndrome.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Dextroamphe | 1982 |
[Stimulant therapy in children].
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Dextroamphe | 1982 |
Arousal, temporal and spatial uncertainty and drug effects.
Topics: Adult; Alcohol Drinking; Amphetamine; Antipsychotic Agents; Arousal; Attention; Attention Deficit Di | 1983 |
Pharmacokinetics of benzodiazepines and psychostimulants in children.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Attention Deficit Disorder with Hyperactivity; Biotransforma | 1983 |
How much stimulant medication is appropriate for hyperactive school children?
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Lea | 1984 |
Combination of neuroleptic and stimulant treatment in attention deficit disorder with hyperactivity.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Drug Therapy, Combination; F | 1984 |
Effect of methylphenidate on young adult's vigilance and event-related potentials.
Topics: Adult; Arousal; Attention; Attention Deficit Disorder with Hyperactivity; Brain; Electroencephalogra | 1981 |
Strategies for study of the neurochemistry of attention deficit disorder in children.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Clonidine; Dopamine beta-Hydroxylase; Growth H | 1982 |
Treatment of attention deficit and borderline personality disorders with psychostimulants: case report.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Borderline Personality Disorder; Delayed-Actio | 1984 |
Possible change in noradrenergic receptor sensitivity following methylphenidate treatment: growth hormone and MHPG response to clonidine challenge in children with attention deficit disorder and hyperactivity.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Child Behavior; Clonidine; Drug In | 1984 |
Hyperactivity, drugs and attention deficit.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Femal | 1984 |
Slow-release methylphenidate: problems when children chew tablets.
Topics: Abdomen; Anorexia; Attention Deficit Disorder with Hyperactivity; Child; Delayed-Action Preparations | 1984 |
Effects of methylphenidate on reading in children with attention deficit disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Dose-Response Relationship, Drug; | 1984 |
Side effects of dextroamphetamine and methylphenidate in hyperactive children--a brief review.
Topics: Anorexia; Attention Deficit Disorder with Hyperactivity; Body Weight; Child; Dextroamphetamine; Grow | 1984 |
Hyperactivity.
Topics: Amphetamines; Attention Deficit Disorder with Hyperactivity; Child; Diagnosis, Differential; Humans; | 1984 |
Hyperactivity--by any other name.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Dextroamp | 1983 |
Auditory ERP augmentation-reduction and methylphenidate dosage needs in attention and reading disordered children.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Double-Blind Method; Dyslexia; Evoked Potentia | 1983 |
Age, stimulant drug, and practice effects on P3 latency and concurrent reaction time.
Topics: Age Factors; Attention Deficit Disorder with Hyperactivity; Cerebral Cortex; Child; Dose-Response Re | 1984 |
The impact of phonemic processing instruction on the reading achievement of reading-disabled children.
Topics: Achievement; Attention Deficit Disorder with Hyperactivity; Child; Dyslexia; Female; Humans; Male; M | 1984 |
Use of stimulants for alcoholic patients with attention deficit disorder.
Topics: Adult; Alcoholism; Attention Deficit Disorder with Hyperactivity; Humans; Male; Methylphenidate | 1983 |
The effects of stimulant drugs on curiosity behaviors of hyperactive boys.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Exploratory Behavior; Humans; Male; Methylphen | 1983 |
Enuresis: a new look at stimulant therapy.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Dose-Response Relationship, Drug; Enuresis; Fe | 1983 |
Methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Delayed-Action Preparations; Humans; Methylphe | 1983 |
Hyperactive children's event-related potentials fail to support underarousal and maturational-lag theories.
Topics: Age Factors; Alpha Rhythm; Arousal; Attention Deficit Disorder with Hyperactivity; Beta Rhythm; Brai | 1983 |
Stimulant medication and the hyperactive adolescent: myths and facts.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Dextroamphetamine; Dose-Respon | 1983 |
Mother-child interaction in hyperactive and normal kindergarten-aged children and the effect of treatment.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Child, Preschool; Female; Fo | 1983 |
Prolactin, growth hormone and growth responses in boys with attention deficit disorder and hyperactivity treated with methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Body Height; Body Weight; Child; Growth Hormone; Huma | 1984 |
Substituting stimulants in treating behavior disorders.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Dyskinesia, Drug-Induced; Humans; Male; Methyl | 1984 |
The effect of stimulant medication on academic performance, in the context of multimodal treatment, in attention deficit disorders with hyperactivity: two case reports.
Topics: Achievement; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Dextroamphetami | 1984 |
Computer analyzed EEG in methylphenidate-responsive hyperactive children.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Computers; Electroencephalography; Female; Hum | 1984 |
Schedule-induced behavior in hyperactive children.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Female; Humans; Male; Methylphenidate; Motor A | 1984 |
Neurochemical correlates of attention deficit disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Dextroamphetamine; Dopamine; Humans; Methoxyhy | 1984 |
Hyperactivity and the attention deficit disorders: expanding frontiers.
Topics: Aggression; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Cognition; Cogni | 1984 |
Diagnosis and management of attention deficit disorder: a pediatric perspective.
Topics: Amphetamines; Attention; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Dia | 1984 |
Young adult outcome of hyperactive children who received long-term stimulant treatment.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Child; Employment; Follow-Up Studies; Humans; | 1984 |
Urinary 3-methoxy-4-hydroxyphenylglycol sulfate excretion in seventy-three schoolchildren with minimal brain dysfunction syndrome.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Drugs, Chinese Herbal; Female; Glycols; Humans | 1984 |
[Psychotropic drugs for children].
Topics: Amitriptyline; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Benzodiazepines; Ce | 1981 |
Potential risk of prolonged administration of stimulant medication for hyperactive children.
Topics: Attention Deficit Disorder with Hyperactivity; Blood Pressure; Child; Eosinophilia; Hematocrit; Huma | 1980 |
Drug alterations of punished responding after chlordiazepoxide: possible screen for agents useful in minimal brain dysfunction.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Bupropion; Chlordiazepoxide; Conditioning, O | 1981 |
The paradoxical effect of central nervous system stimulants on hyperactivity: a paradox unexplained by the rate-dependent effect.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Behavior; Behavior, Animal; Child; Columbida | 1982 |
The speech of hyperactive children and their mothers: comparison with normal children and stimulant drug effects.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Humans; Male; Methylphenidate; Mother-Child Re | 1983 |
Therapeutic response of a schizophrenic boy to a methylphenidate-chlorpromazine combination.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Chlorpromazine; Drug Therapy, Combination; Hum | 1983 |
Tricyclic antidepressant and methylphenidate treatment of attention deficit disorder in children.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Clomipramine; Desipramine; D | 1983 |
Effects of methylphenidate in adolescents with attention deficit disorder.
Topics: Adolescent; Age Factors; Attention Deficit Disorder with Hyperactivity; Double-Blind Method; Female; | 1983 |
The Personality Inventory for Children and response to methylphenidate: preliminary evidence for predictive utility.
Topics: Adolescent; Anxiety; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Female; | 1983 |
Sleep architecture and REM sleep measures in prepubertal children with attention deficit disorder with hyperactivity.
Topics: Arousal; Attention Deficit Disorder with Hyperactivity; Child; Electroencephalography; Humans; Male; | 1983 |
Stimulant medications precipitate Tourette's syndrome.
Topics: Acute Disease; Amphetamines; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; | 1982 |
The effect of attentional effort on visual evoked potential N1 latency.
Topics: Adolescent; Arousal; Attention; Attention Deficit Disorder with Hyperactivity; Child; Dose-Response | 1982 |
The physician's role in learning disability.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Child; Environment; Female; Humans; Learning D | 1982 |
Perceptions and attitudes of hyperactive children and their mothers regarding treatment with methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Attitude to Health; Child; Female; Humans; Internal-E | 1982 |
Interpreting results on optimal doses of methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child Behavior; Humans; Methylphenidate | 1982 |
Adults and adolescents with attention deficit disorder: clinical and behavioral responses to psychostimulants.
Topics: Adolescent; Adult; Attention; Attention Deficit Disorder with Hyperactivity; Humans; Male; Methylphe | 1982 |
Psychopharmacology of attention deficit disorder: pharmacokinetic, neuroendocrine, and behavioral measures following acute and chronic treatment with methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Growth Hormone; Humans; Kinetics; Male; Methyl | 1982 |
The hyperkinetic child: current status.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Child; Dextroamphetamine; Dose-Response Re | 1982 |
Clinical studies of methylphenidate serum levels in children and adults.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Child; Humans; Methylphenidate | 1982 |
Learning ability and methylphenidate (Ritalin) plasma concentration in hyperkinetic children. A preliminary investigation.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Humans; Male; Methylphenidate; Ver | 1982 |
Dosage effects of methylphenidate on paired associate learning: positive/negative placebo responders.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Dose-Response Relationship, | 1982 |
A 30-month follow-up of hyperactive children.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Family; Female; Follow-Up St | 1982 |
Factors associated with children's adherence to stimulant medication.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Female; Humans; Male; Methyl | 1982 |
Ritalin vs. response cost in the control of hyperactive children: a within-subject comparison.
Topics: Achievement; Attention; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Huma | 1982 |
The hyperactive child.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Counseling; Dextroamphetamin | 1982 |
Effect of methylphenidate hydrochloride on stature of hyperactive children.
Topics: Attention Deficit Disorder with Hyperactivity; Body Height; Child; Dose-Response Relationship, Drug; | 1982 |
The effect of stimulant medication in childhood-onset pervasive developmental disorder--a case report.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child Development Disorders, Pervasive; Humans | 1982 |
A dose-response and time-action analysis of autonomic and behavioral effects of methylphenidate in attention deficit disorder with hyperactivity.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Dose-Response Relationship, | 1982 |
Optimal dosages of methylphenidate for improving the learning and behavior of hyperactive children.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Child; Child Behavior; Female; Humans; Lea | 1981 |
Evaluation of the relative effectiveness of methylphenidate and cognitive behavior modification in the treatment of kindergarten-aged hyperactive children.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child, Preschool; Cognition; Cues; | 1981 |
Differential effects of parent training and stimulant medication with hyperactives: A progress report.
Topics: Achievement; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Child, Preschoo | 1981 |
Plasma free and total tryptophan, blood serotonin, and the hyperactivity syndrome: no evidence for the serotonin deficiency hypothesis.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Double-Blind Method; Female; Humans; Hydrocort | 1981 |
"Hyperactivity" : still a maze of questions.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Humans; Methylphe | 1980 |
Saccades of hyperactive and normal boys during ocular pursuit.
Topics: Adaptation, Physiological; Attention; Attention Deficit Disorder with Hyperactivity; Child; Child, P | 1981 |
Tryptophan metabolism in children with attentional deficit disorder.
Topics: Adolescent; Adult; Attention; Attention Deficit Disorder with Hyperactivity; Blood Platelets; Child; | 1981 |
Attention-deficit disorder: monitored data-based assessment and treatment.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Female; Humans; | 1981 |
Response of hyperactivity and attention deficit to methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Humans; Male; Methylphenidate | 1981 |
Normalizing effects of methylphenidate on hyperactive children's vigilance performance and evoked potentials.
Topics: Adolescent; Age Factors; Attention; Attention Deficit Disorder with Hyperactivity; Child; Child, Pre | 1981 |
The use of psychopharmacology to study reciprocal influences in parent-child interaction.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Child; Diazepam; Double-Blind Method; Humans; | 1981 |
A four-year follow-up study of the effects of methylphenidate on the behavior and academic achievement of hyperactive children.
Topics: Achievement; Adolescent; Attention Deficit Disorder with Hyperactivity; Behavior; Child; Female; Fol | 1981 |
Hyperkinesis comes of age: what do we know and where should we go?
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Diagnosis, Differ | 1980 |
[Hypermotoric syndrome in childhood].
Topics: Attention Deficit Disorder with Hyperactivity; Child; Environment; Female; Humans; Hyperkinesis; Mal | 1980 |
Growth disturbances in hyperkinetic children.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Dextroamphetamine; Growth Disorders; Humans; H | 1980 |
Classroom observation code for hyperactive children: a replication of validity.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Diagnosis, Differential; Hum | 1980 |
Visual-motor tracking by hyperkinetic children.
Topics: Age Factors; Attention Deficit Disorder with Hyperactivity; Child; Dextroamphetamine; Humans; Male; | 1980 |
The influence of methylphenidate on spontaneous autonomic activity and behavior in children diagnosed as hyperactive.
Topics: Attention Deficit Disorder with Hyperactivity; Autonomic Nervous System; Child; Female; Heart Rate; | 1981 |
Risperidone in childhood schizophrenia.
Topics: Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Child; Drug Therapy, Combinatio | 1995 |
Pediatricians' knowledge and attitudes concerning diagnosis and treatment of attention deficit and hyperactivity disorders. A national survey approach.
Topics: Adult; Aged; Amphetamines; Antidepressive Agents, Tricyclic; Attention Deficit Disorder with Hyperac | 1995 |
The acceptability of interventions for attention-deficit hyperactivity disorder among elementary and middle school teachers.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; | 1995 |
World wide use of psychotropic drugs in child and adolescent psychiatric disorders.
Topics: Adolescent; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Canada; Child; Chi | 1995 |
Generic bioequivalence.
Topics: Attention Deficit Disorder with Hyperactivity; Child, Preschool; Dose-Response Relationship, Drug; D | 1995 |
Syndrome triad in children and adolescents.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Circadian Rhythm; Comorbidity; Female; Humans; | 1995 |
More frequent diagnosis of attention deficit-hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Humans; Methylphenidate; Prevalence; United St | 1995 |
Adverse effects of chewing methylphenidate.
Topics: Administration, Oral; Attention Deficit Disorder with Hyperactivity; Child; Humans; Male; Masticatio | 1995 |
Combined methylphenidate and imipramine complication.
Topics: Aggression; Anemia; Attention Deficit Disorder with Hyperactivity; Blood Cells; Child; Drug Synergis | 1995 |
The use of methylphenidate in Michigan.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Child Welfare; Child, Preschool; D | 1995 |
Attention-deficit disorder. Born to be hyperactive?
Topics: Adult; Aged; Attention Deficit Disorder with Hyperactivity; Child; Diagnosis, Differential; Educatio | 1995 |
Neurometric subgroups in attentional and affective disorders and their association with pharmacotherapeutic outcome.
Topics: Adolescent; Adult; Anticonvulsants; Antidepressive Agents; Attention Deficit Disorder with Hyperacti | 1995 |
Combined pharmacotherapy: an emerging trend in pediatric psychopharmacology.
Topics: Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Benzodiazepines; Child Psychiatry; | 1995 |
Case study: maternal residual attention deficit disorder associated with failure to thrive in a two-month-old infant.
Topics: Attention Deficit Disorder with Hyperactivity; Failure to Thrive; Humans; Infant; Male; Maternal Wel | 1995 |
Predicting outcome in a multimodal day treatment program for children with severe behaviour problems.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Child Behavior Disorders; Child, P | 1994 |
Chronology of the management of a child who has ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Drug Administration Schedule; Humans; Male; Me | 1995 |
Controls on ADHD drug should be reduced.
Topics: Attention Deficit Disorder with Hyperactivity; Drug and Narcotic Control; Humans; Methylphenidate | 1994 |
Tics and dyskinesias associated with stimulant treatment in attention-deficit hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Chronic Disease; | 1994 |
Depression and hopelessness in children with disruptive behaviour disorders.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Child Behavior Disorders; Co | 1994 |
Attention deficit hyperactivity disorder in adults: diagnosis, treatment, and prognosis.
Topics: Adult; Antidepressive Agents, Tricyclic; Attention Deficit Disorder with Hyperactivity; Clonidine; D | 1994 |
[Diagnosis and drug treatment in hyperactive children].
Topics: Adolescent; Antidepressive Agents, Tricyclic; Attention Deficit Disorder with Hyperactivity; Child; | 1994 |
Clonidine for stimulant-related sleep problems.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Clonidine; Dextroamphetamine; Drug Therapy, Co | 1994 |
Paroxysmal kinesigenic dystonia after methylphenidate administration.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Carbamazepine; Dystonia; Humans; Male; Me | 1994 |
Cerebral glucose metabolism in adults with attention deficit hyperactivity disorder after chronic stimulant treatment.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Brain; Deoxyglucos | 1994 |
Evaluating and managing attention deficit disorder in children who are deaf or hard of hearing.
Topics: Achievement; Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Counseling; Deafness; | 1993 |
Cognitive and neuropsychological characteristics of attention deficit hyperactivity disorder children receiving stimulant medications.
Topics: Adolescent; Arousal; Attention; Attention Deficit Disorder with Hyperactivity; Child; Cognition Diso | 1993 |
Mismatch negativity in hyperactive children: effects of methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Evoked Potentials, Auditory; Humans; Methylphe | 1993 |
Perceptions of methylphenidate effects on hyperactive children's peer interactions.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Child; Female; Humans; Male; Methy | 1993 |
[Therapy of hyperkinetic syndrome is many-sided. Interview by Dr. med. Fritz Schnitger].
Topics: Attention Deficit Disorder with Hyperactivity; Child; Combined Modality Therapy; Food Hypersensitivi | 1993 |
A comparison of day treatment and outpatient treatment for children with disruptive behaviour problems.
Topics: Ambulatory Care; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Child Behav | 1993 |
Aims and methodological problems in multimodal treatment studies.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Child Behavior Disorders; Cognitiv | 1993 |
Methylphenidate protocol: feasibility in a pediatric practice.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Clinical Protocols; Double-Blind Method; Feedb | 1993 |
The use of antidepressants in the treatment of children with behaviour disorders.
Topics: Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Child; Child Behavior Disorder | 1993 |
Attention deficit hyperactivity disorder, creativity, and the effects of methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Child; Creativity; Humans; Impu | 1993 |
Effects of acute stimulant medication on cerebral metabolism in adults with hyperactivity.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Behavior; Brain; Dextroamphetamine; Female; Hu | 1993 |
Drug therapy in attention-deficit hyperactivity disorder.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Agents; Chi | 1996 |
Medication for attention-deficit hyperactivity disorder: balancing art and science.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Agents; Depression | 1996 |
Behavioural disorders are overdiagnosed in US.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Pres | 1996 |
Adult attention deficit disorder in the United Kingdom.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Humans; Male; Methylphenidate; Prisoners; Unit | 1996 |
The use of methylphenidate in Michigan.
Topics: Adrenergic Uptake Inhibitors; Attention Deficit Disorder with Hyperactivity; Child; Diagnosis, Diffe | 1996 |
Need for bedtime dose of ritalin.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Drug Admini | 1996 |
Paying attention. The controversy over ADHD and the drug Ritalin is obscuring a real look at the disorder and its underpinnings.
Topics: Attention Deficit Disorder with Hyperactivity; Brain; Female; Humans; Magnetic Resonance Imaging; Ma | 1996 |
ADD and soft signs.
Topics: Attention Deficit Disorder with Hyperactivity; Brain Damage, Chronic; Central Nervous System Stimula | 1996 |
Cognitive event-related potentials in populations at risk for substance abuse.
Topics: Aggression; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 1996 |
Intervention strategies for students with ADHD: creating a holistic approach.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cognitive Behavior | 1996 |
Predictors of weight loss in children with attention deficit hyperactivity disorder treated with stimulant medication.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Body Height; Body Mass Index; Central Ner | 1996 |
Parent acceptability and feasibility of ADHD interventions: assessment, correlates, and predictive validity.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Attitude to Health; Behavior Therapy; Chi | 1996 |
Methylphenidate euphoria.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Euphoria; H | 1996 |
Growth deficits in ADHD children revisited: evidence for disorder-associated growth delays?
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Body Height; Body Weight; Central Nervous | 1996 |
Behavioral and pharmacological studies on the validation of a new animal model for attention deficit hyperactivity disorder.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Disease Models, Animal; Ma | 1996 |
Increased methylphenidate usage for attention deficit disorder in the 1990s.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Drug Utilization | 1996 |
Clonidine for treatment of attention-deficit/hyperactivity disorder.
Topics: Adrenergic alpha-Agonists; Attention Deficit Disorder with Hyperactivity; Central Nervous System; Ce | 1996 |
Combined treatment with moclobemide and methylphenidate for comorbid major depression and adult attention-deficit/hyperactivity disorder.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Benzamides; Comorbidity; Depressive Disorder; | 1996 |
Use of growth hormone for non-growth hormone deficient children.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Drug Utiliz | 1996 |
Attention deficit hyperactivity disorder: a disease or a symptom complex?
Topics: Anticonvulsants; Attention; Attention Deficit Disorder with Hyperactivity; Child; Child Behavior Dis | 1997 |
Attention deficit continues to attract research attention.
Topics: Attention Deficit Disorder with Hyperactivity; Humans; Methylphenidate | 1996 |
Use of methylphenidate in a patient with glaucoma and attention-deficit hyperactivity disorder: a clinical dilemma.
Topics: Attention Deficit Disorder with Hyperactivity; Contraindications; Glaucoma, Open-Angle; Humans; Intr | 1997 |
Unexpected interaction of methylphenidate (Ritalin) with anaesthetic agents.
Topics: Anesthetics, Dissociative; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 1997 |
Efficacy of methylphenidate in bulimia nervosa comorbid with attention-deficit hyperactivity disorder: a case report.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Bulimia; Central Nervous System Stimulants; Co | 1997 |
Attention deficit hyperactivity disorder: a disease or a symptom complex?
Topics: Anticonvulsants; Attention; Attention Deficit Disorder with Hyperactivity; Child; Child Behavior Dis | 1997 |
Methylphenidate patterns among Medicaid youths.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 1997 |
Pemoline and hepatotoxicity.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Chemical and Drug Induced Liver Injury; Drug T | 1997 |
Medication for children with attention disorders.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Met | 1997 |
Lack of effect of methylphenidate on serum growth hormone (GH), GH-binding protein, and insulin-like growth factor I.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Carrier Proteins; Child; Growth Hormone; | 1997 |
[Attention deficit hyperactivity disorder, facilitating alcohol and drug abuse in an adult].
Topics: Adult; Alcoholism; Attention Deficit Disorder with Hyperactivity; Cannabis; Central Nervous System S | 1997 |
ADHD: the role of the family physician.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Cognitive Behavioral Therapy | 1997 |
Open-label treatment of comorbid depression and attentional disorders with co-administration of serotonin reuptake inhibitors and psychostimulants in children, adolescents, and adults: a case series.
Topics: 1-Naphthylamine; Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Chemotherapy, Adj | 1996 |
Methylphenidate and the immune system.
Topics: Adolescent; Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulant | 1997 |
Medication-induced seizures.
Topics: 1-Naphthylamine; Adolescent; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; C | 1997 |
The case of the missing methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Drug Utilization; Female; Humans; Male; Methyl | 1997 |
Does methylphenidate influence cognitive performance?
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Pres | 1997 |
[Therapy program for children with hyperkinetic and oppositional problem behavior--organization and single case evaluation].
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; | 1996 |
Methylphenidate-induced obsessive-compulsiveness.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Mal | 1998 |
Debate is needed over who provides drug treatment in attention deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Attitude of Health Personnel; Central Nervous System | 1998 |
The management of patients with attention-deficit hyperactivity disorder by family practitioners.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; | 1998 |
Stimulant use and trichotillomania.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 1998 |
Differences in plasma concentrations of the D- and L-threo methylphenidate enantiomers in responding and non-responding children with attention-deficit hyperactivity disorder.
Topics: Analysis of Variance; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous Syst | 1998 |
Intranasal abuse of prescribed methylphenidate.
Topics: Administration, Intranasal; Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervo | 1998 |
Stimulant use and the potential for abuse in Wisconsin as reported by school administrators and longitudinally followed children.
Topics: Administrative Personnel; Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Attitude | 1998 |
Methylphenidate in the United States, 1990 through 1995.
Topics: Attention Deficit Disorder with Hyperactivity; Drug Utilization; Humans; Methylphenidate; United Sta | 1998 |
Methylphenidate treatment for cocaine abusers with adult attention-deficit/hyperactivity disorder: a pilot study.
Topics: Adult; Ambulatory Care; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Cocaine; Co | 1998 |
Response to growth hormone in attention deficit hyperactivity disorder: effects of methylphenidate and pemoline therapy.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Female; Gro | 1998 |
Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate.
Topics: Administration, Oral; Adult; Animals; Attention Deficit Disorder with Hyperactivity; Brain; Brain Ch | 1998 |
Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate.
Topics: Administration, Oral; Adult; Animals; Attention Deficit Disorder with Hyperactivity; Brain; Brain Ch | 1998 |
Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate.
Topics: Administration, Oral; Adult; Animals; Attention Deficit Disorder with Hyperactivity; Brain; Brain Ch | 1998 |
Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate.
Topics: Administration, Oral; Adult; Animals; Attention Deficit Disorder with Hyperactivity; Brain; Brain Ch | 1998 |
Selective effects of methylphenidate in attention deficit hyperactivity disorder: a functional magnetic resonance study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Brain Mapping; Central Nervous System Sti | 1998 |
Effects of stimulant medication on the lateralisation of line bisection judgements of children with attention deficit hyperactivity disorder.
Topics: Analysis of Variance; Attention; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervo | 1999 |
US panel calls for research into effects of Ritalin.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Methylphen | 1998 |
How stimulant drugs may calm hyperactivity.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Brain; Carrier Proteins; C | 1999 |
Carbamazepine and methylphenidate in ADHD.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Carbamazepine; Drug Administration Schedu | 1999 |
Components of attention in children with complex partial seizures with and without ADHD.
Topics: Adolescent; Anticonvulsants; Attention; Attention Deficit Disorder with Hyperactivity; Child; Comorb | 1999 |
Zeroing in on attention deficit disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; Child; Huma | 1999 |
[Central nervous system stimulants in AD/HD in adults].
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Met | 1999 |
Doing Ritalin right. Sure, it works--but there are big flaws in the way it's being given.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child Welfare; Dopamine Uptake Inhibitors; Hum | 1998 |
No news is bad news?
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Met | 1999 |
An adolescent who abruptly stops his medication for attention-deficit hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans | 1999 |
Intractable obsessive-compulsive disorder: comorbidity with unrecognized adult attention-deficit hyperactivity disorder?
Topics: Adult; Age Factors; Attention Deficit Disorder with Hyperactivity; Comorbidity; Humans; Male; Methyl | 1999 |
Treatment of attention-deficit/hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child Behav | 1999 |
Combining methylphenidate and clonidine: a clinically sound medication option.
Topics: Adolescent; Adverse Drug Reaction Reporting Systems; Aggression; Antihypertensive Agents; Attention | 1999 |
The age of Ritalin.
Topics: Adolescent; Adrenergic Agents; Attention Deficit Disorder with Hyperactivity; Child; Consensus Devel | 1998 |
Thinking differently. Brain scans give new hope for diagnosing ADHD.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Blood Flow Velocity; Brain; Child; Humans | 1998 |
A 55-year-old man with attention-deficit/hyperactivity disorder, 1 year later.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Male; Meth | 1999 |
Hypoglycemia and propranolol in pediatric behavioral disorders.
Topics: Adrenergic beta-Antagonists; Attention Deficit Disorder with Hyperactivity; Central Nervous System S | 1999 |
Attention-deficit-hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cultural Character | 1999 |
Prevalence of Tourette syndrome.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Methylphen | 1999 |
Methylphenidate role in Tourette syndrome prevalence.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Met | 1999 |
Executive function and attention deficit hyperactivity disorder: stimulant medication and better executive function performance in children.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 1999 |
Are stimulants overprescribed? Treatment of ADHD in four U.S. communities.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 1999 |
Neurogenetic determinism and the new euphenics. Child and adolescent psychiatrists use methylphenidate because it makes children better.
Topics: Adolescent Psychiatry; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimula | 1999 |
Stimulant medications decrease energy expenditure and physical activity in children with attention-deficit/hyperactivity disorder.
Topics: Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Calorimetry; Case-Control Studi | 1999 |
Perceptual and response interference in children with attention-deficit hyperactivity disorder, and the effects of methylphenidate.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Central | 1999 |
Practical guidelines for the treatment of substance abusers with adult attention-deficit hyperactivity disorder.
Topics: Adult; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous System | 1999 |
Sensitivity to reward frequency in boys with attention deficit hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 1999 |
Attention deficit hyperactivity disorder.
Topics: Amphetamines; Attention Deficit Disorder with Hyperactivity; Child; Child Behavior; Child, Preschool | 1999 |
Liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry enantiomeric separation of dl-threo-methylphenidate, (Ritalin) using a macrocyclic antibiotic as the chiral selector.
Topics: Atmospheric Pressure; Attention Deficit Disorder with Hyperactivity; Child; Chromatography, Liquid; | 1999 |
Childhood inattention-overactivity, aggression, and stimulant medication history as predictors of young adult outcomes.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Foll | 1999 |
Do stimulants improve self-esteem in children with ADHD and peer problems?
Topics: Analysis of Variance; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorde | 1999 |
Psychotic side effects of psychostimulants: a 5-year review.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Pres | 1999 |
Treating comorbid ADHD, major depression, and panic.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Clonazepam; | 1999 |
Methylphenidate (Ritalin) use and abuse.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 1999 |
Development of clinical services for attention-deficit/hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; | 1999 |
The difference between efficacy and effectiveness research in studying attention-deficit/hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Met | 1999 |
Clonidine and methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Clonidine; | 1999 |
Association of the dopamine transporter gene (DAT1) with poor methylphenidate response.
Topics: Alleles; Attention Deficit Disorder with Hyperactivity; Black People; Carrier Proteins; Central Nerv | 1999 |
Non-selective attention in a rat model of hyperactivity and attention deficit: subchronic methylphenydate and nitric oxide synthesis inhibitor treatment.
Topics: Animals; Attention; Attention Deficit Disorder with Hyperactivity; Disease Models, Animal; Dopamine | 2000 |
Remodeling of neural networks in the anterior forebrain of an animal model of hyperactivity and attention deficits as monitored by molecular imaging probes.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Autoradiography; Calcium-Calmodulin-Dependen | 2000 |
Long-acting stimulants for the treatment of attention-deficit disorder in cocaine-dependent adults.
Topics: Adult; Algorithms; Amphetamines; Antidepressive Agents, Second-Generation; Attention Deficit Disorde | 2000 |
Is ritalin underused?
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Met | 2000 |
Psychostimulant clinical response in fetal alcohol syndrome.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2000 |
Trends in the prescribing of psychotropic medications to preschoolers.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Control; Central Nervous System Stimulants; | 2000 |
Psychotropic drug use in very young children.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Control; Central Nervous System Stimulants; | 2000 |
Study supports medication for ADHD.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; Chil | 2000 |
What the multimodal treatment study of children with attention deficit/hyperactivity disorder did and did not say about the use of methylphenidate for attention deficits.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; | 2000 |
"Model" behavior.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Carrier Proteins; Central Nervous System Sti | 2000 |
Ritalin use in BC.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; British Columbia; Child; Drug Prescriptio | 2000 |
Fluoxetine-related death in a child with cytochrome P-450 2D6 genetic deficiency.
Topics: Antipruritics; Attention Deficit Disorder with Hyperactivity; Child; Cytochrome P-450 CYP2D6; Dopami | 2000 |
Adverse response to methylphenidate in combination with valproic acid.
Topics: Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Bruxism; Central Nervous System Stim | 2000 |
Psychostimulants and psychiatrists: the Trent Adult Psychiatry Psychostimulant Survey.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Attitude of Health Personnel; Cent | 2000 |
A follow-up pilot study of objective measures in children with attention deficit hyperactivity disorder.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Child; Dextroamphetamine; Fema | 2000 |
Central auditory processing disorder and ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Audiometry; Auditory Perceptual Disorders; Central Ne | 2000 |
Serotonin and the therapeutic effects of ritalin.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Brain; Carrier Proteins; Central Nervous Sys | 2000 |
Deficient intracortical inhibition in drug-naive children with attention-deficit hyperactivity disorder is enhanced by methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Drug Utiliz | 2000 |
[Studies of evoked potentials in children with the syndrome of attention deficit and hyperactivity].
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Event-Relat | 1999 |
[The evaluation of the effects of pharmacological treatment of children with attention deficit hyperactivity disorder].
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Pres | 1999 |
USA to improve care of children with ADHD.
Topics: Adolescent; Adrenergic Agents; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; | 2000 |
Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Carrier Proteins; Corpus Striatum; Dopamine Pl | 2000 |
Liquid-liquid extraction using 96-well plate format in conjunction with liquid chromatography/tandem mass spectrometry for quantitative determination of methylphenidate (Ritalin) in human plasma.
Topics: Attention Deficit Disorder with Hyperactivity; Calibration; Chromatography, Liquid; Humans; Mass Spe | 2000 |
Your patients are on drugs.
Topics: Adolescent; Adolescent Behavior; Attention Deficit Disorder with Hyperactivity; Central Nervous Syst | 2000 |
Drugged-out toddlers. A new study documents an alarming increase in behavior-altering medication for preschoolers.
Topics: Age Factors; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous S | 2000 |
Does my child need Ritalin? Stimulants are still the most effective treatment for ADHD. The challenge is to use them wisely.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Humans; Methylphenidate | 2000 |
Mothers' and children's perceptions of medication for children with attention-deficit hyperactivity disorder.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Attitude to Health; Central Nervou | 2000 |
The reliability, validity, and unique contributions of self-report by adolescents receiving treatment for attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Caregivers; Central Nervous System Stimul | 2000 |
A procedure to teach self-control to children with attention deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child, Preschool; | 2000 |
Association and linkage of DRD4 and DRD5 with attention deficit hyperactivity disorder (ADHD) in a sample of Turkish children.
Topics: Alleles; Attention Deficit Disorder with Hyperactivity; Child; Dopamine Uptake Inhibitors; Family He | 2000 |
Bone mineral density and turnover in children with attention-deficit hyperactivity disorder receiving methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Body Height; Bone Density; Central Nervous System Sti | 2000 |
Role of Ritalin in preschoolers.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child, Preschool; | 2000 |
Epidemiology. Duke study faults overuse of stimulants for children.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Drug Utiliz | 2000 |
Stimulant treatment in Maryland public schools.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2000 |
A new long-acting methylphenidate (Concerta).
Topics: Attention Deficit Disorder with Hyperactivity; Child; Clinical Trials as Topic; Delayed-Action Prepa | 2000 |
US parents sue psychiatrists for promoting Ritalin.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Control; Child; Conflict of Interest; Dopami | 2000 |
Sleep and alertness in children with ADHD.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Chil | 2000 |
Methylphenidate affects striatal dopamine differently in an animal model for attention-deficit/hyperactivity disorder--the spontaneously hypertensive rat.
Topics: Acetylcholine; Animals; Attention Deficit Disorder with Hyperactivity; Disease Models, Animal; Dopam | 2000 |
Stimulant treatment in young boys with symptoms suggesting childhood mania: a report from a longitudinal study.
Topics: Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Central Nervous System Stimulants; | 2000 |
ADHD, Ritalin, and big brother.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Female; Hum | 2000 |
Parents accuse APA of Ritalin conspiracy?
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Methylphen | 2000 |
[Attention deficit disorder with hyperactivity in children: diagnosis and therapeutic management].
Topics: Adolescent; Adrenergic alpha-Agonists; Antidepressive Agents; Attention Deficit Disorder with Hypera | 2000 |
Attention deficit hyperactivity disorder: binding of [99mTc]TRODAT-1 to the dopamine transporter before and after methylphenidate treatment.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Brain; Carrier Proteins; Caudate Nucleus; Corp | 2000 |
[Attention deficit-hyperactivity disorder (ADHD); etiology, diagnosis and treatment].
Topics: Age Factors; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child | 2000 |
Amelioration of specific working memory deficits by methylphenidate in a case of adult attention deficit/hyperactivity disorder.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Huma | 2000 |
The ritalin wars continue.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Conflict of | 2000 |
Characterization of methylphenidate exposures reported to a regional poison control center.
Topics: Adolescent; Adult; Age Distribution; Attention Deficit Disorder with Hyperactivity; Child; Child, Pr | 2000 |
The multimodal treatment study of children with attention deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Combined Mo | 2000 |
Student perceptions of methylphenidate abuse at a public liberal arts college.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Attitude to Health; Data Collection; Female; H | 2000 |
No more 'afternoon nasties'. A new rival of Ritalin keeps kids out of the nurse's office.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Delayed-Action Preparations; Femal | 2000 |
Pushing pills on kids? Lawyers claim a conspiracy to oversell Ritalin.
Topics: Attention Deficit Disorder with Hyperactivity; California; Central Nervous System Stimulants; Child; | 2000 |
Clinical trials. Planned Ritalin trial for tots heads into uncharted waters.
Topics: Attention Deficit Disorder with Hyperactivity; Bioethics; Central Nervous System Stimulants; Child; | 2000 |
Ritalin tests for preschoolers.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Pres | 2000 |
Update on investigation of Ritalin conspiracy.
Topics: Attention Deficit Disorder with Hyperactivity; Attitude to Health; Central Nervous System Stimulants | 2001 |
Frontal lobe disinhibition, Rett syndrome and attention deficit hyperactivity disorder.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2001 |
NICE issues new guidelines on Ritalin.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Met | 2000 |
Benefit of long-term stimulants on driving in adults with ADHD.
Topics: Adolescent; Adult; Age Factors; Attention Deficit Disorder with Hyperactivity; Automobile Driving; C | 2001 |
Ritalin: mom's little helper. A disorder long linked to sons migrates up the family tree.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Child; Female; Genetic Predisposition to Disea | 2001 |
Obsessive-compulsive symptoms secondary to methylphenidate treatment.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Dose-Response Relationship, Drug; Female; Huma | 2001 |
Questioning the treatment for ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Control; Brain; Central Nervous System Stimu | 2001 |
Drugs used in the treatment of attention-deficit/hyperactivity disorder affect postsynaptic firing rate and oscillation without preferential dopamine autoreceptor action.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Autoreceptors; Catecholamines; Central Nervo | 2001 |
[Problem in methylphenidate use for the treatment of attention deficit hyperactivity disorder in Japan].
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Drug Approval; Drug Utilizat | 2001 |
Evidence and belief in attention deficit hyperactivity disorder. Reintroduction of methylphenidate in Italy needs careful monitoring.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Italy; Leg | 2001 |
Stimulant therapy and seizure risk in children with ADHD.
Topics: Adolescent; Adult; Amphetamines; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Bra | 2001 |
Methylphenidate increased regional cerebral blood flow in subjects with attention deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cerebr | 2001 |
Tailored psychosocial treatments for ADHD: the search for a good fit.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; | 2001 |
Psychosocial treatment issues in the MTA: a reply to Greene and Ablon.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Combined Mo | 2001 |
Comprehensive versus matched psychosocial treatment in the MTA study: conceptual and empirical issues.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Combined Mo | 2001 |
ADHD treatment in the 21st century: pushing the envelope.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Combined Mo | 2001 |
Can methylphenidate facilitate sleep in children with attention deficit hyperactivity disorder?
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Met | 2001 |
Retrospective comparison of Adderall and methylphenidate in the treatment of attention deficit hyperactivity disorder.
Topics: Amphetamines; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Chil | 2001 |
[Prescription of central nervous system stimulants].
Topics: Adolescent; Adult; Age Factors; Attention Deficit Disorder with Hyperactivity; Central Nervous Syste | 2001 |
An adolescent who abruptly stops his medication for attention-deficit hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Denial, Psychological; Follow-Up S | 2001 |
Why we really do need Ritalin.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Biological Evolution; Child; Child Behavio | 1998 |
Explosive outbursts associated with methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Pres | 2001 |
The development of selective attention in children with attention deficit hyperactivity disorder.
Topics: Age Factors; Attention; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Central | 2001 |
[Neuropsychological follow-up of attention deficit/hyperactive disorder in adulthood before and after treatment with methylphenidate].
Topics: Adult; Attention; Attention Deficit Disorder with Hyperactivity; Follow-Up Studies; Humans; Male; Me | 2001 |
Efficacy of Adderall and methylphenidate in attention deficit hyperactivity disorder: a reanalysis using drug-placebo and drug-drug response curve methodology.
Topics: Algorithms; Amphetamines; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stim | 2001 |
Pharmacokinetic interactions between cyclosporine and bupropion or methylphenidate.
Topics: Antidepressive Agents, Second-Generation; Attention Deficit Disorder with Hyperactivity; Bupropion; | 2001 |
Myoclonus during prolonged treatment with sertraline in an adolescent patient.
Topics: Adolescent; Anticonvulsants; Antidepressive Agents, Second-Generation; Attention Deficit Disorder wi | 2001 |
[Is Ritalin prescribed insufficiently to hyperactive children in Nordland?].
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Drug Prescr | 2001 |
Correlations between motor persistence and plasma levels in methylphenidate-treated boys with ADHD.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2001 |
Commentary on Greene and Ablon: What does the MTA study tell us about effective psychosocial treatment for ADHD?
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cognitive B | 2001 |
Concerns about Ritalin.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child Behavior; Ch | 2001 |
The effect of child characteristics on teachers' acceptability of classroom-based behavioral strategies and psychostimulant medication for the treatment of ADHD.
Topics: Adolescent; Adolescent Behavior; Attention Deficit Disorder with Hyperactivity; Attitude; Central Ne | 2001 |
Moderators and mediators of long-term adherence to stimulant treatment in children with ADHD.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2001 |
[Functioning, comorbidity and treatment of 141 adults with attention deficit hyperactivity disorder (ADHD) at a psychiatric outpatient department].
Topics: Adrenergic alpha-Agonists; Adult; Age Factors; Attention Deficit Disorder with Hyperactivity; Centra | 2001 |
Pharmaceuticals: conspiracy to increase ritalin profits alleged.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Conflict of | 2001 |
Effects of methylphenidate on kinematic aspects of handwriting in hyperactive boys.
Topics: Attention Deficit Disorder with Hyperactivity; Biomechanical Phenomena; Central Nervous System Stimu | 2001 |
Methylphenidate (OROS formulation).
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Child; Clinical Trials as Topic; Dopamine Upta | 2001 |
A retrospective study of children's perceptions of participation as clinical research subjects in a minimal risk study.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Attitude to Health; Child; Clinica | 2001 |
New Ritalin ad blitz makes parents jumpy.
Topics: Advertising; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child | 2001 |
[Drug treatment of school children with attention deficit and hyperactivity disorder].
Topics: Adolescent; Amphetamine; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimu | 2001 |
Treatment of attention deficit hyperactivity disorder in children.
Topics: Attention Deficit Disorder with Hyperactivity; Attitude of Health Personnel; Central Nervous System | 2001 |
Another long-acting methylphenidate (Metadate CD).
Topics: Anorexia; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Clinical Trials as | 2001 |
Gabapentin and methylphenidate treatment of a preadolescent with attention deficit hyperactivity disorder and bipolar disorder.
Topics: Acetates; Amines; Antimanic Agents; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; | 2001 |
Boom in Ritalin sales raises ethical issues.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Behavior; Behavior Control; Child; Health; Hum | 1996 |
Methylphenidate ER tablet lodging in esophagus.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Delayed-Action Preparations; Esophagus; F | 2001 |
Methylphenidate effects on task-switching performance in attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Child; Decision Making; Female | 2001 |
Is increased D2 receptor availability associated with response to stimulant medication in ADHD.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Caudate Nucleus; Central Nervous System S | 2001 |
Cognitive factors in anorexia nervosa: a case history.
Topics: Adolescent; Anorexia Nervosa; Attention Deficit Disorder with Hyperactivity; Central Nervous System | 2001 |
Prescription of methylphenidate to children and youth, 1990-1996.
Topics: Adolescent; Age Factors; Attention Deficit Disorder with Hyperactivity; British Columbia; Central Ne | 2001 |
Effectiveness of attention-deficit/hyperactivity treatment and diagnosis methods tested.
Topics: Adult; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous System | 2000 |
Pharmacotherapies for attention-deficit/hyperactivity disorder: expected-cost analysis.
Topics: Amphetamines; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Chil | 2001 |
Treatment of ADHD when tolerance to methylphenidate develops.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Dextroamphetamine; Dose-Response R | 2002 |
ADHD and addiction.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Cocaine-Related Disorders; Dopamine Uptake I | 2002 |
Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications.
Topics: Administration, Oral; Adult; Age Factors; Attention Deficit Disorder with Hyperactivity; Behavior; B | 2002 |
Methylphenidate use for attention deficit hyperactivity disorder in northern Israel--a controversial issue.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2001 |
Failed attempts at intranasal abuse of Concerta.
Topics: Administration, Intranasal; Adolescent; Attention Deficit Disorder with Hyperactivity; Euphoria; Fem | 2002 |
Building a program of outcomes research: personal reflections.
Topics: Adrenergic Agents; Attention Deficit Disorder with Hyperactivity; Brain Injuries; Female; Humans; Ma | 2001 |
Is attention deficit hyperactivity disorder increasing among girls in the US? Trends in diagnosis and the prescribing of stimulants.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2002 |
Methylphenidate to treat ADHD is not contraindicated in children with tics.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Female | 2002 |
Effects of histamine H(3) receptor ligands GT-2331 and ciproxifan in a repeated acquisition avoidance response in the spontaneously hypertensive rat pup.
Topics: Animals; Anti-Anxiety Agents; Arousal; Attention Deficit Disorder with Hyperactivity; Avoidance Lear | 2002 |
EEG differences between good and poor responders to methylphenidate and dexamphetamine in children with attention-deficit/hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; Child; Dext | 2002 |
Methylphenidate isomer approved by FDA.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2002 |
Does extended medication with amphetamine or methylphenidate reduce growth in hyperactive children?
Topics: Adolescent; Amphetamine; Attention Deficit Disorder with Hyperactivity; Body Height; Body Weight; Ce | 2002 |
Lessons from three year olds.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child, Preschool; | 2002 |
Reduced salivary cortisol in children with comorbid Attention deficit hyperactivity disorder and oppositional defiant disorder.
Topics: Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; | 2002 |
[Central stimulants in the treatment of children with ADHD: unknown long-term effect and uncertain pharmacological documentation].
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Pres | 2002 |
The effects of delayed rewards, tokens, and stimulant medication on sportsmanlike behavior with ADHD-diagnosed children.
Topics: Amphetamines; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Child, Prescho | 2002 |
Behavioural and pharmacological relevance of stroke-prone spontaneously hypertensive rats as an animal model of a developmental disorder.
Topics: Animals; Arousal; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2002 |
Gaze pursuit and arm control of adolescent males diagnosed with attention deficit hyperactivity disorder (ADHD) and normal controls: evidence of a dissociation in processing visual information of short and long duration.
Topics: Adolescent; Analysis of Variance; Arm; Attention Deficit Disorder with Hyperactivity; Case-Control S | 2002 |
Dexmethylphenidate (Focalin) for ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Dexmethylphenidate | 2002 |
Methylphenidate-related growth impairment.
Topics: Attention Deficit Disorder with Hyperactivity; Body Height; Central Nervous System Stimulants; Child | 2002 |
[A reply concerning scientologists and ADHD: Scientific evidence and indications for treatment with methylphenidate].
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Conflict of Intere | 2002 |
Treatment of attention-deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Humans; Methylphenidate | 2002 |
Who is using the drugs I prescribe?
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child Abuse | 2002 |
Use of medication by young people with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Australia; Central | 2002 |
Prevalence of methylphenidate use and change over a two-year period: a nationwide study of 2- to 11-year-old Canadian children.
Topics: Age Factors; Attention Deficit Disorder with Hyperactivity; Canada; Central Nervous System Stimulant | 2002 |
Methylphenidate-evoked potentiation of extracellular dopamine in the brain of adolescents with premature birth: correlation with attentional deficit.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Brain; Carbon Radioisotopes; Dopamine; Do | 2002 |
A review of psychophysiological research with hyperkinetic children.
Topics: Amphetamines; Attention Deficit Disorder with Hyperactivity; Autonomic Nervous System; Blood Pressur | 1978 |
Growth of hyperkinetic children taking methylphenidate, dextroamphetamine, or imipramine/desipramine.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Desipramine; Dextroamphetamine; Growth; Humans | 1978 |
The use of methylphenidate and imipramine in Gilles de la Tourette's disease in children.
Topics: Acute Disease; Attention Deficit Disorder with Hyperactivity; Catecholamines; Child; Humans; Imipram | 1977 |
MBD children--variability in developmental patterns or growth inhibitory effect of stimulants?
Topics: Adolescent; Amphetamines; Attention Deficit Disorder with Hyperactivity; Body Height; Body Weight; C | 1979 |
Family practice grand rounds. Hyperactivity: a symptom, not a disease entity.
Topics: Anxiety; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Epilepsy, Absence; | 1977 |
A four-fold model for subgrouping the hyperkinetic/MBD syndrome.
Topics: Adolescent; Aggression; Attention Deficit Disorder with Hyperactivity; Child; Humans; Hyperkinesis; | 1979 |
Clinical experience with methylphenidate.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Cerebral Palsy; Child; Child, Preschool; | 1979 |
The hyperactive child syndrome.
Topics: Age Factors; Attention Deficit Disorder with Hyperactivity; Child; Child Behavior Disorders; Child, | 1979 |
Methylphenidate in 6-hydroxydopamine-treated developing rat pups. Effects on activity and maze performance.
Topics: Age Factors; Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Brain Chemist | 1978 |
Methylphenidate-induced chorea: case report and pharmacologic implications.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Brain; Child; Child, Preschool; Chorea; Dopa | 1978 |
Effect of methylphenidate on academic progress.
Topics: Attention Deficit Disorder with Hyperactivity; Dyslexia; Handwriting; Humans; Methylphenidate | 1978 |
Pupillary and heart rate reactivity in children with minimal brain dysfunction.
Topics: Adolescent; Arousal; Attention Deficit Disorder with Hyperactivity; Child; Dextroamphetamine; Female | 1978 |
Treatment of minimal brain dysfunction in a young adult.
Topics: Adolescent; Adult; Age Factors; Attention Deficit Disorder with Hyperactivity; Child; Dose-Response | 1978 |
Hyperkinetic/aggressive boys in treatment: predictors of clinical response to methylphenidate.
Topics: Age Factors; Aggression; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Fem | 1978 |
Adult minimal brain dysfunction and schizophrenia: a case report.
Topics: Administration, Oral; Adult; Attention Deficit Disorder with Hyperactivity; Diagnosis, Differential; | 1978 |
Growth of hyperactive children treated with methylphenidate.
Topics: Age Factors; Attention Deficit Disorder with Hyperactivity; Body Height; Body Weight; Child; Child, | 1978 |
Depression and psychotic regression following prolonged methylphenidate use and withdrawal: case report.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Depression; Humans; Male; Methylphenidate; Psy | 1979 |
[The so-called "persistent infantile pattern of attentiveness" in minimal brain dysfunction children. Essay of a human ethologic interpretation with its consequences in therapy (author's transl].
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Educa | 1977 |
[Special schooling, education counseling psychotherapy and pharmacotherapy in children with minimal brain damage].
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Counseling; Educ | 1977 |
Hyperactivity among white middle-class children. Psychogenic and other causes.
Topics: Adolescent; Affective Symptoms; Aggression; Amphetamines; Anxiety; Attention Deficit Disorder with H | 1977 |
A possible subgroup of the schizophrenic syndrome and implications for treatment.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Diazepam; Dominance, Cerebral; Dys | 1976 |
Growth of hyperkinetic children taking methylphenidate, dextroamphetamine, or imipramine/desipramine.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Dextroamphetamin | 1976 |
The identification and treatment of adult brain dysfunction.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Dextroamphetamine; Female; Humans; Imipramine; | 1976 |
The hyperactive child.
Topics: Achievement; Age Factors; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Cr | 1976 |
Comprehensive management of the hyperkinetic child.
Topics: Adolescent; Amphetamines; Anxiety; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; | 1976 |
Tics following methylphenidate administration. A report of 20 cases.
Topics: Acute Disease; Adolescent; Age Factors; Attention Deficit Disorder with Hyperactivity; Child; Female | 1976 |
Minimal brain dysfunction, stimulant drugs, and autonomic nervous system activity.
Topics: Acoustic Stimulation; Arousal; Attention Deficit Disorder with Hyperactivity; Autonomic Nervous Syst | 1975 |
Childhood chemotherapy and later drug abuse and growth curve: a follow-up study of 30 adolescents.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Body Height; Cannabis; Child; Child Behav | 1975 |
[Methylphenidat (Ritalin) as a psychotropic drug in children with minimal brain dysfunction and epilepsy].
Topics: Age Factors; Attention Deficit Disorder with Hyperactivity; Diagnosis, Differential; Drug Evaluation | 1975 |
Letter: The hyperactive child.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Humans; Hyperkinesis; Methylphenidate | 1975 |
Letter: Growth of hyperactive children.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Growth; Humans; Hyperkinesis; Methylphenidate; | 1975 |
Letter: Methylphenidate reaction.
Topics: Ataxia; Attention Deficit Disorder with Hyperactivity; Child; Humans; Male; Methylphenidate; Movemen | 1975 |
Hyperactivity in children.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child Reactive Disorders; Dextroamphetamine; D | 1975 |
Minimal brain dysfunction: A note of caution in management.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Humans; Learning Disabilities; Methylphenidate | 1975 |
Using cerebral stimulants to treat minimal brain dysfunction.
Topics: Attention Deficit Disorder with Hyperactivity; Attitude of Health Personnel; Child; Humans; Hyperkin | 1975 |
The learning-disabled or hyperactive child: diagnosis and treatment.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child Behavior Disorders; Dextroamphetamine; H | 1975 |
Methylphenidate: a review.
Topics: Attention Deficit Disorder with Hyperactivity; Humans; Hyperkinesis; Methylphenidate; Substance-Rela | 1976 |
Minimal brain dysfunction/specific learning disability: a clinical approach for the primary physician.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child Behavior Disorders; Dextroamphetamine; F | 1976 |
The spontaneously hypertensive rat (SHR) as an animal model of childhood hyperactivity (ADHD): changed reactivity to reinforcers and to psychomotor stimulants.
Topics: Analysis of Variance; Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System | 1992 |
Methylphenidate in hyperactive boys with comorbid tic disorder. I. Clinic evaluations.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Behavior; Child; Humans; Male; Methylphen | 1992 |
Are too many children being treated with methylphenidate?
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; British Columbia; Child; Cross-Sec | 1992 |
Hyperactivity and attention deficit disorder syndromes in China.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; China; Combined Modality The | 1992 |
Fixed drug eruption of the scrotum due to methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Drug Eruptions; Genital Diseases, Male; Humans | 1992 |
Aggression in boys with attention deficit-hyperactivity disorder: methylphenidate effects on naturalistically observed aggression, response to provocation, and social information processing.
Topics: Aggression; Attention Deficit Disorder with Hyperactivity; Child; Child Behavior Disorders; Cognitio | 1992 |
ADHD and research methodology.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Bias; Data Interpretation, Statistical; H | 1992 |
Growth deficits in children treated with desipramine: a controlled study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Body Height; Body Weight; Child; Desipram | 1992 |
Pharmacodynamics of pemoline in attention deficit disorder with hyperactivity.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Child; Dose-Response Relationship, Drug; H | 1992 |
An examination of the "dosage" effects of both behavior therapy and methylphenidate on the classroom performance of two ADHD children.
Topics: Achievement; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Combined Modali | 1992 |
A comparison of medicated and nonmedicated attention-deficit disordered hyperactive boys.
Topics: Achievement; Adolescent; Affect; Age Factors; Attention Deficit Disorder with Hyperactivity; Child; | 1992 |
Single and combined effects of methylphenidate and behavior therapy on the classroom performance of children with attention-deficit hyperactivity disorder.
Topics: Achievement; Attention; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Comb | 1992 |
Effects of two treatment techniques on delay and vigilance tasks with attention deficit hyperactive disorder (ADHD) children.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Cognitive Behavio | 1992 |
[Hyperkinetic disorders with attention deficit. Diagnostic and therapeutic approach].
Topics: Attention Deficit Disorder with Hyperactivity; Child; Dextroamphetamine; Drug Administration Schedul | 1991 |
Dramatic favorable responses of children with learning disabilities or dyslexia and attention deficit disorder to antimotion sickness medications: four case reports.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cyclizine; | 1991 |
Mental retardation and ADHD!
Topics: Attention Deficit Disorder with Hyperactivity; Child; Humans; Intellectual Disability; Methylphenida | 1992 |
Methylphenidate and interpersonal relationships of children with attention deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Female; Humans; Interpersonal Relations; Male; | 1991 |
Effects of background anger, provocation, and methylphenidate on emotional arousal and aggressive responding in attention-deficit hyperactivity disordered boys with and without concurrent aggressiveness.
Topics: Adult; Aggression; Analysis of Variance; Anger; Arousal; Attention Deficit Disorder with Hyperactivi | 1991 |
Methylphenidate use in Michigan.
Topics: Attention Deficit Disorder with Hyperactivity; Drug Utilization; Humans; Methylphenidate; Michigan | 1991 |
Effects of methylphenidate on the auditory processing abilities of children with attention deficit-hyperactivity disorder.
Topics: Adolescent; Analysis of Variance; Attention; Attention Deficit Disorder with Hyperactivity; Auditory | 1991 |
Effects of high methylphenidate doses on the cognitive performance of hyperactive children.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Cognition; Humans; Methylphenidate; Psychologi | 1991 |
[Methylphenidate--current prescribing rate].
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Attitude of Health Personnel; Child; Cros | 1991 |
Extensive and enantioselective presystemic metabolism of dl-threo-methylphenidate in humans.
Topics: Administration, Oral; Adult; Attention Deficit Disorder with Hyperactivity; Biological Availability; | 1991 |
Social impact of stimulant treatment for hyperactive children.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Dextroamphetamine; Humans; Interpersonal Relat | 1991 |
Social acceptability of methylphenidate and behavior modification for treating attention deficit hyperactivity disorder.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Attitude; Behavior Therapy; Child; Female; Hum | 1991 |
[Discussion comment on the contribution by E. Schulz and H. Remschmidt: Stimulant therapy of hyperkinetic syndrome in childhood and adolescence].
Topics: Attention Deficit Disorder with Hyperactivity; Child; Dose-Response Relationship, Drug; Humans; Meth | 1991 |
[A study of 10 children. Positive effects of central nervous system stimulants in hyperactivity and attention disorder].
Topics: Attention Deficit Disorder with Hyperactivity; Child; Female; Humans; Male; Methylphenidate | 1991 |
Intranasal abuse of prescribed methylphenidate by an alcohol and drug abusing adolescent with ADHD.
Topics: Administration, Intranasal; Adolescent; Alcoholism; Arousal; Attention Deficit Disorder with Hyperac | 1991 |
Combination of treatments for attention deficit hyperactivity disorder in adults.
Topics: Adult; Age Factors; Attention Deficit Disorder with Hyperactivity; Drug Therapy, Combination; Humans | 1991 |
Stimulant medication and attention deficit-hyperactivity disorder. The child's perspective.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Health Knowledge, Attitudes, Pract | 1991 |
Stimulants and school performance.
Topics: Achievement; Attention Deficit Disorder with Hyperactivity; Child; Dyslexia; Humans; Methylphenidate | 1991 |
Use of methylphenidate for attention deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Drug Administration Schedule; Humans; Methylph | 1991 |
Use of methylphenidate for attention deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Humans; Methylphenidate | 1990 |
Use of methylphenidate for attention deficit hyperactivity disorder.
Topics: Activities of Daily Living; Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Family | 1990 |
Relative efficacy of ritalin and biofeedback treatments in the management of hyperactivity.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Biofeedback, Psychology; Child; Combined | 1990 |
The spontaneously hypertensive rat as an animal model of attention-deficit hyperactivity disorder: effects of methylphenidate on exploratory behavior.
Topics: Animals; Arousal; Attention Deficit Disorder with Hyperactivity; Disease Models, Animal; Dose-Respon | 1990 |
Effects of methylphenidate on early adolescent growth.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Body Height; Body Weight; Female; Growth; | 1990 |
Use of methylphenidate for attention deficit hyperactivity disorder. Mental Health Committee, Canadian Paediatric Society.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Drug Evaluation; Humans; Methylphe | 1990 |
Primary disorder of vigilance: a novel explanation of inattentiveness, daydreaming, boredom, restlessness, and sleepiness.
Topics: Arousal; Attention; Attention Deficit Disorder with Hyperactivity; Boredom; Child; Child Behavior Di | 1990 |
Stimulant medication use by primary care physicians in the treatment of attention deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Drug Utilization; Humans; Methylphenidate; Par | 1990 |
Pemoline and urinary excretion of catecholamines and indoleamines in children with attention deficit disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Dextroamphetamine; Humans; Hydroxyindoleacetic | 1986 |
The concurrent use of lithium and methylphenidate in a child.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child Behavior Disorders; Drug Therapy, Combin | 1989 |
Stimulant medication and short attention span: a clinical approach.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Child; Dextroamphetamine; Dose-Response Re | 1989 |
Stimulants, urinary catecholamines, and indoleamines in hyperactivity. A comparison of methylphenidate and dextroamphetamine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Attention Deficit Disorder with Hyperactivity; Catecholamines; Child | 1985 |
Absence of tolerance to the behavioral effects of methylphenidate in hyperactive and inattentive children.
Topics: Attention Deficit Disorder with Hyperactivity; Body Constitution; Child; Drug Tolerance; Female; Hum | 1989 |
Methylphenidate plasma concentrations in chronically and acutely treated latency-age children.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior; Child; Humans; Male; Methylphenidate | 1989 |
The use of stimulant medication with children.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Child; Dextroamphetamine; Dose-Response Re | 1989 |
Enantioselective aspects of the disposition of dl-threo-methylphenidate after the administration of a sustained-release formulation to children with attention deficit-hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Delayed-Action Preparations; Femal | 1989 |
Teaching parents to conduct behavioral relaxation training with their hyperactive children.
Topics: Arousal; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Combined Modality T | 1989 |
Attention disorder in children: is the literature purged? Was it ever tainted?
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Child; Crime; Fraud; Humans; Intellectual Disa | 1989 |
Tryptophan antagonism of stimulant-induced tics.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Drug Therapy, Combination; Humans; Male; Methy | 1989 |
[Ritalin: a stimulating drug in the treatment of children with minimal brain dysfunction (MBD)].
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Combined Modality Therapy; F | 1989 |
Assessing response to methylphenidate for attention deficit disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Clinical Trials as Topic; Double-Blind Method; | 1989 |
Comparative effects of methylphenidate on attention-deficit hyperactivity disorder with and without aggressive/noncompliant features.
Topics: Aggression; Attention Deficit Disorder with Hyperactivity; Child; Female; Humans; Male; Methylphenid | 1989 |
Striatal dysfunction in attention deficit and hyperkinetic disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Brain; Cerebrovascular Circulation; Child; Corpus Str | 1989 |
Sustained release methylphenidate: pharmacokinetic studies in ADDH males.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Delayed-Action Preparations; Human | 1989 |
Does haloperidol block methylphenidate?
Topics: Attention Deficit Disorder with Hyperactivity; Child; Drug Therapy, Combination; Haloperidol; Humans | 1989 |
Parent, teacher, child. A trilateral approach to attention deficit disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Child Behavior; Female; Humans; Male; Methylphenidate | 1989 |
The response of aggressive and nonaggressive ADHD children to two doses of methylphenidate.
Topics: Adolescent; Aggression; Attention Deficit Disorder with Hyperactivity; Child; Double-Blind Method; F | 1989 |
Imipramine binding to platelets of children with attention deficit disorder with hyperactivity.
Topics: Attention Deficit Disorder with Hyperactivity; Blood Platelets; Carrier Proteins; Child; Humans; Imi | 1988 |
Attention deficit disorder: evaluation and treatment.
Topics: Age Factors; Anorexia; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Body Height; | 1985 |
The use of imipramine in Tourette's syndrome and attention deficit disorder: case report.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Dextroamphe | 1985 |
Effects of methylphenidate on whirler mice: an animal model for hyperkinesis.
Topics: Administration, Oral; Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System | 1985 |
Neuropharmacology of methylphenidate and a neural substrate for childhood hyperactivity.
Topics: Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Brain; Child; Half-Life; Humans | 1985 |
Neuroleptic-induced tics in two hyperactive children.
Topics: Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Child; Dextroamphetamine; Halop | 1986 |
The relationship between stimulant medication and tics.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Dextroamphe | 1988 |
A survey of medication treatment for hyperactive/inattentive students.
Topics: Adolescent; Age Factors; Attention Deficit Disorder with Hyperactivity; Baltimore; Central Nervous S | 1988 |
The effects of background illumination and stimulant medication on smooth pursuit eye movements of hyperactive children.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Child; Dose-Response Relationship, Drug; E | 1989 |
Methylphenidate in children with the attention deficit disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Humans; Methylphenidate | 1989 |
Medication vs behavior management.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Humans; Methylphenidate; Pro | 1989 |
Activation, arousal, and neuropsychological rehabilitation.
Topics: Adult; Afferent Pathways; Arousal; Attention Deficit Disorder with Hyperactivity; Cerebral Cortex; C | 1987 |
Effects of acute and chronic methylphenidate administration on beta-endorphin, growth hormone, prolactin and cortisol in children with attention deficit disorder and hyperactivity.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Endorphins; Female; Growth Hormone; Humans; Hy | 1987 |
Tourette's syndrome in Monroe County school children.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Behavior; Child; Child, Preschool; Clonid | 1988 |
Methylphenidate side effects.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Delusions; Humans; Methylphenidate | 1988 |
Medicating children with attention deficit disorder.
Topics: Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Child; Child Psychiatry; Human | 1988 |
Prenatal methylazoxymethanol treatment potentiates d-amphetamine- and methylphenidate-induced motor activity in male and female rats.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Azo Compounds; Dextroamphetamine; Disease Mo | 1988 |
Psychostimulant rebound in attention deficit disordered boys.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Humans; Male; Methylphenidate; Parents | 1988 |
The use of methylphenidate in autism.
Topics: Attention Deficit Disorder with Hyperactivity; Autistic Disorder; Child; Humans; Intellectual Disabi | 1988 |
Cognitive training in academically deficient ADDH boys receiving stimulant medication.
Topics: Achievement; Attention Deficit Disorder with Hyperactivity; Child; Combined Modality Therapy; Follow | 1988 |
Effects of methylphenidate hydrochloride on the subjective reporting of mood in children with attention deficit disorder.
Topics: Adult; Affect; Age Factors; Attention Deficit Disorder with Hyperactivity; Child; Female; Humans; Ma | 1988 |
The effect of methylphenidate on urinary catecholamine excretion in hyperactivity: a partial replication.
Topics: 3,4-Dihydroxyphenylacetic Acid; Attention Deficit Disorder with Hyperactivity; Catecholamines; Child | 1988 |
Treatment compliance in ADD.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Humans; Methylphenidate; Patient Compliance | 1988 |
Attention deficit disorder and methylphenidate: a multilevel analysis of dose-response effects on children's impulsivity across settings.
Topics: Achievement; Attention Deficit Disorder with Hyperactivity; Child; Dose-Response Relationship, Drug; | 1988 |
Effects of methylphenidate dosage in hyperactive reading-disabled children: II. Reading achievement.
Topics: Achievement; Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Dose-Response Relatio | 1988 |
Methylphenidate-induced delusional disorder in a child with attention deficit disorder with hyperactivity.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Delusions; Humans; Male; Methylphenidate | 1988 |
Electrodermal lability predicts presentation rate effects and stimulant drug effects on paired associate learning in hyperactive children.
Topics: Association Learning; Attention Deficit Disorder with Hyperactivity; Child; Double-Blind Method; Gal | 1988 |
The Ritalin controversy: what's made this drug's opponents hyperactive?
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Humans; Methylphenidate | 1988 |
Methylphenidate treatment of hyperactive autistic children.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Autistic Disorder; Child; Child, Preschoo | 1988 |
Methylphenidate revisited.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Child; Drug Administration Schedul | 1988 |
Use of imipramine for attention deficit disorder in a borderline patient.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Borderline Personality Disorder; Humans; Imipr | 1988 |
The effects of methylphenidate on the interactions of preschool ADHD children with their mothers.
Topics: Attention Deficit Disorder with Hyperactivity; Child, Preschool; Cooperative Behavior; Dose-Response | 1988 |
Automatic and effortful processing in attention deficit/hyperactivity disorder.
Topics: Arousal; Attention; Attention Deficit Disorder with Hyperactivity; Child; Dextroamphetamine; Humans; | 1988 |
Family abuse of methylphenidate.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Family; Female; Humans; Male; Meth | 1988 |
Efficacy of behavior management versus methylphenidate in a hyperactive child: the role of dynamics.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Combined Modality | 1988 |
Tourette's syndrome.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Diagnosis, Differential; Humans; Male; Methylp | 1987 |
Blood levels and tolerance to stimulants in ADDH children.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Cognition; Drug Tolerance; H | 1986 |
Natural social behaviors in hyperactive children: dose effects of methylphenidate.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Dose-Response Relationship, Drug; | 1987 |
Stereoselective disposition of methylphenidate in children with attention-deficit disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Chromatography, Gas; Humans; Kinet | 1987 |
Therapeutic interventions to prevent delinquency in hyperactive boys.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Child; Combined Modality Therapy; | 1987 |
Tricyclic antidepressants in the treatment of children with attention deficit disorder.
Topics: Antidepressive Agents, Tricyclic; Attention; Attention Deficit Disorder with Hyperactivity; Child; H | 1987 |
Diminished effectiveness of methylphenidate on cognitive tasks in attention deficit disorder with hyperactivity.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Cognition; Double-Blind Method; Hu | 1987 |
Effect of methylphenidate on skin conductance in hyperactive children and its relationship to urinary peptides.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Autistic Disorder; Child; Child, Preschoo | 1987 |
Is there dose-dependent tolerance associated with chronic methylphenidate therapy in hyperactive children: oral dose and plasma considerations.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Dose-Response Relationship, Drug; Drug Toleran | 1987 |
Treatment effects of oral and transdermal clonidine in relation to methylphenidate: an open pilot study in ADD-H.
Topics: Administration, Cutaneous; Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Clonidi | 1987 |
Pediatricians' reported practices in the assessment and treatment of attention deficit disorders.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Dextroamphetamine; Humans; Manuals as Topic; M | 1987 |
An objective measure of methylphenidate response: clinical use of the MCA.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Child; Computers; Female; Huma | 1987 |
Compliance with pharmacological and cognitive treatments for attention deficit disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Cognition; Femal | 1987 |
Changes in family function and relationships in children who respond to methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Humans; Male; Methylphenidate; Parent-Child Re | 1987 |
American Academy of Pediatrics Committee on Children with Disabilities, Committee on Drugs: Medication for children with an attention deficit disorder.
Topics: Antidepressive Agents, Tricyclic; Attention Deficit Disorder with Hyperactivity; Child; Dextroamphet | 1987 |
Cortical atrophy in young adults with a history of hyperactivity in childhood.
Topics: Adult; Atrophy; Attention Deficit Disorder with Hyperactivity; Brain; Brain Diseases; Cerebral Corte | 1986 |
A neuropathic substrate for stimulant drug effects in hyperactive children.
Topics: Antisocial Personality Disorder; Arousal; Attention Deficit Disorder with Hyperactivity; Child; Corp | 1986 |
Type A behavior in normal and hyperactive children: multisource evidence of overlapping constructs.
Topics: Achievement; Adolescent; Aggression; Arousal; Attention Deficit Disorder with Hyperactivity; Child; | 1986 |
Attention deficit disorder in adolescents.
Topics: Adolescent; Arousal; Attention Deficit Disorder with Hyperactivity; Combined Modality Therapy; Dextr | 1986 |
Hyperactivity and methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Humans; Methylphenidate | 1986 |
Hyperactivity, drugs and attention to features in a story.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Child; Humans; Memory; Mental Recall; Meth | 1986 |
Methylphenidate-induced mania in a prepubertal child.
Topics: Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Child; Child Behavior Disorders; Hu | 1986 |
Effects of continuous and partial reinforcement and methylphenidate on learning in children with attention deficit disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Combined Modality Therapy; Female; Humans; Mal | 1986 |
Different patterns of local brain energy metabolism associated with high and low doses of methylphenidate. Relevance to its action in hyperactive children.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Autoradiography; Brain; Deoxyglucose; Extrap | 1987 |
Pharmacological treatment of attention deficit disorder, residual type (ADD,RT, "minimal brain dysfunction," "hyperactivity") in adults.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Humans; Methylphenidate; Pargyline; Pemoline; | 1985 |
Dysthymia and attention deficit disorder in adults.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Child; Depressive Disorder; Humans; Methylphen | 1986 |
Behavioral effects of low-dose methylphenidate in childhood attention deficit disorder: implications for a mechanism of stimulant drug action.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Dose-Response Relationship, Drug; Double-Blind | 1986 |
Clinical management of children with hyperactivity. A shift in diagnostic and therapeutic emphasis.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child Behavior; Child Development; Humans; Med | 1986 |
Prediction of methylphenidate (Ritalin) responsiveness through sensory integrative testing.
Topics: Arousal; Attention Deficit Disorder with Hyperactivity; Child; Humans; Male; Methylphenidate; Nystag | 1986 |
The normalizing effects of methylphenidate on the classroom behavior of ADDH children.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Child; Child Behavior; Cooperative Behavio | 1985 |
Methylphenidate and cognitive therapy: a comparison of treatment approaches with hyperactive boys.
Topics: Achievement; Attention; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Cogn | 1985 |
Adolescents and ritalin.
Topics: Adolescent; Age Factors; Attention Deficit Disorder with Hyperactivity; Child; Humans; Methylphenida | 1985 |
State-dependent learning in hyperactive children receiving methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Female; Humans; Learning; Male; Methylphenidat | 1985 |
Evaluating drug effectiveness in an office setting for children with attention deficit disorders.
Topics: Ambulatory Care; Attention Deficit Disorder with Hyperactivity; Child; Humans; Male; Methylphenidate | 1985 |
[Urinary 3-methoxy-4-hydroxyphenylglycol sulfate in school children with minimal brain dysfunction syndrome].
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Female; Glycols; Humans; Mal | 1985 |
Separating psychological factors from brain trauma in treating a hyperactive child.
Topics: Adaptation, Psychological; Affective Symptoms; Attention Deficit Disorder with Hyperactivity; Brain | 1985 |
Ten years of experience with 1,000 hyperactive children in a private practice.
Topics: Amphetamine; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Body Height; Body Weig | 1985 |
Attention deficit disorder children with or without hyperactivity. Which behaviors are helped by stimulants?
Topics: Aggression; Attention; Attention Deficit Disorder with Hyperactivity; Child; Child Behavior; Female; | 1985 |
Methylphenidate and idiopathic thrombocytopenic purpura--is there an association?
Topics: Attention Deficit Disorder with Hyperactivity; Child; Female; Humans; Methylphenidate; Purpura, Thro | 1985 |
Psychostimulant plasma concentration and learning performance.
Topics: Administration, Oral; Attention Deficit Disorder with Hyperactivity; Dextroamphetamine; Female; Huma | 1985 |
Catecholamine metabolism in the attention deficit disorder: implications for the use of amino acid precursor therapy.
Topics: Attention Deficit Disorder with Hyperactivity; Catecholamines; Dopamine; Humans; Levodopa; Methylphe | 1985 |
A developmental dose-response analysis of the effects of methylphenidate on the peer interactions of attention deficit disordered boys.
Topics: Age Factors; Attention Deficit Disorder with Hyperactivity; Child; Child Development; Child, Prescho | 1985 |
Attention deficit disorders in adults.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Brain Stem; Evoked Potentials; Female; Follow- | 1985 |
Methylphenidate treatment of cocaine abusers without attention deficit disorder: a negative report.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Cocaine; Humans; Male; Methylphenidate; Substa | 1985 |
The role of methylphenidate and dextroamphetamine in hyperactivity in children.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Developmental Disabilities; Dextroamphetamine; | 1971 |
The adolescent with a learning problem. The need for insight.
Topics: Adolescent; Age Factors; Attention Deficit Disorder with Hyperactivity; Community Mental Health Serv | 1973 |
Drugs in management of minimal brain dysfunction.
Topics: Amphetamine; Anticonvulsants; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; | 1973 |
Methylphenidate in children with minimal brain dysfunction: effects on attention span, visual-motor skills, and behavior.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Behavior; Child; Female; Humans; Male; Met | 1974 |
[Minimal brain dysfunction].
Topics: Attention Deficit Disorder with Hyperactivity; Child; Dextroamphetamine; Female; Humans; Male; Methy | 1974 |
Letter: Need for medication in minimal brain dysfunction.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Dextroamphetamine; Humans; Methylphenidate; Ph | 1974 |
Pathophysiology of the hyperactive child syndrome.
Topics: Animals; Arousal; Attention Deficit Disorder with Hyperactivity; Auditory Perception; Brain; Child; | 1974 |
Four types of hyperkinesis.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Child Abuse; Child Behavior | 1974 |
Symposium: behavior modification by drugs. 3. The clinical use of stimulant drugs in children.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Dextroamphetamine; Feeding and Eat | 1972 |
Methylphenidate for adolescents with minimal brain dysfunction.
Topics: Adolescent; Aging; Attention Deficit Disorder with Hyperactivity; Electroencephalography; Evaluation | 1973 |
Psychological assessment of children with minimal brain dysfunction.
Topics: Achievement; Analysis of Variance; Attention; Attention Deficit Disorder with Hyperactivity; Auditor | 1973 |
Amphetamine-type drugs for hyperactive children.
Topics: Appetite; Attention Deficit Disorder with Hyperactivity; Body Weight; Brain; Child; Dextroamphetamin | 1972 |
Oral medications for minimal brain dysfunction in children.
Topics: Administration, Oral; Age Factors; Attention Deficit Disorder with Hyperactivity; Child; Child Behav | 1973 |
The hyperactive child syndrome.
Topics: Age Factors; Amphetamine; Attention Deficit Disorder with Hyperactivity; Child Behavior Disorders; C | 1973 |
The hyperactive child.
Topics: Age Factors; Amphetamine; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Di | 1973 |
A long-term comparison of two treatment regimens for minimal brain dysfunction. Drug therapy versus combined therapy.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Counseling; Dextroamphetamin | 1973 |
[The minimal brain dysfunction syndrome].
Topics: Affective Symptoms; Amphetamine; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Chi | 1973 |
EEG issues in children with minimal brain dysfunction.
Topics: Acoustic Stimulation; Attention Deficit Disorder with Hyperactivity; Child; Diagnosis, Differential; | 1973 |
Minimal brain dysfunctions in children.
Topics: Amphetamine; Attention; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Comm | 1974 |
Usefulness of methylphenidate.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Brain Damage, Chronic; Child; Child Behav | 1972 |
Recognizing minimal cerebral dysfunction in the infant and toddler. Some clinical clues and thoughts on management.
Topics: Attention Deficit Disorder with Hyperactivity; Brain Damage, Chronic; Child, Preschool; Humans; Hype | 1972 |
Mood-altering drugs and hyperkinetic children.
Topics: Attention Deficit Disorder with Hyperactivity; Brain Damage, Chronic; Child; Child Behavior Disorder | 1972 |
Hyperactivity in children: types, diagosis, drug therapy, approaches to management.
Topics: Amphetamine; Anxiety; Attention; Attention Deficit Disorder with Hyperactivity; Brain Damage, Chroni | 1972 |
Minimal brain dysfunction and methylphenidate.
Topics: Advertising; Attention Deficit Disorder with Hyperactivity; Brain Damage, Chronic; Brain Diseases; C | 1971 |
Methylphenidate and minimal brain dysfunction.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Brain Damage, Chronic; Child; Child Behav | 1971 |
Methylphenidate problems.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Drug and Narcotic Control; Humans; Methylpheni | 1971 |
[Minimal cerebral dysfunction. Apropos of the treatment of 90 cases].
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Drug Evaluation; Humans; Inf | 1971 |